<SEC-DOCUMENT>0001159036-23-000012.txt : 20230221
<SEC-HEADER>0001159036-23-000012.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230221162738
ACCESSION NUMBER:		0001159036-23-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		23648606

	BUSINESS ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HALOZYME THERAPEUTICS INC
		DATE OF NAME CHANGE:	20040312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>halo-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e,d:732e51618ba84e17b469190f5cc138c6--><html xmlns:halo="http://www.halozyme.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>halo-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8xLTEtMS0xLTc0Mzkw_28c6115e-6ed0-41bd-a18f-ad76eb678d6b">0001159036</ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8yLTEtMS0xLTc0Mzkw_e535d3b9-c1a5-4d4b-af3a-2eb27b614432">false</ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8zLTEtMS0xLTc0Mzkw_947832ce-ddd3-444f-8fce-4c92c62fa4b7">2022</ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF80LTEtMS0xLTc0Mzkw_41215f0d-42ab-4a22-8f7d-e3750030384c">FY</ix:nonNumeric><ix:nonNumeric contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8">http://www.halozyme.com/20221231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d">http://www.halozyme.com/20221231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk1OQ_f58b5d2c-2f99-454c-b819-957e5d1ad0df">P7Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ibb2a521823a94cd4a32245c29e206a17_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzAtMS0xLTEtNzQzOTA_616895c8-a73a-4bef-a0dd-c72d2fa4ce88">25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3bbc2ed39e364802b20b15e694472966_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzEtMS0xLTEtNzQzOTA_63d70a6f-18ac-44f9-98b6-e53f429e3830">2.08</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7acdf8fbc6a64af7bd0d8bed1ab7c3df_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzItMS0xLTEtNzQzOTA_124d781a-7042-4ef1-90ae-08fef44cd78a">25</ix:nonFraction><ix:nonNumeric contextRef="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzgzNg_6d31b2bd-233b-4e57-aa4d-35605e28c115">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzOTc_69d1271f-c244-47f4-82d2-6cf455ace36c">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="halo-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e409ee707b430fa8ecc2238eb488b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia117119a079043f09f5bfce4b51e42fe_I20230214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if0faa2d5cad4416b986007776707121f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i528d79391acd4adabf0eb110ab4c0d71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cddd407fea442d591705c36d0c6b738_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e37d51271604aea8b4052a4f33ab467_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658b6d0704704e0b8064188c8e0a801d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afa1af705a047488d2ed7629419da96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8be6b96e36e440009875fac05281e167_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db3fb4810984f62a4337b6b494f3743_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9749fc8e01b42f3bc4d2a62a57108c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99205eb539fe44e688694e9c32636419_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c116ced97cc4fe5b21319832ce43f61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f04615dfbd45e198c13ee612a4296b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53b6dc71630413f9a2aeceedcc0e052_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee6817d503e4a18b7eb816904b0aebe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa017f03308949e29662213e518d9cb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed2278944d84aca8963978003d797f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185f758e56d34e259efb04a87b79e6fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb480a816cd4772ba95677abf4d9f15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c457ab9e1fd454291cd030cc56319d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ffb5ed70da4329a8be32a8e3f59679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3a0d1278564dac88cdb6a4890dbeb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bfa39e1da314354bf34589788f5d3f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47eab477396949258aac7c749bf0936c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa88a5eb896493187880ac27c0e4dae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5286105d8e646a890ecc12d4b237245_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6665e5678736405d8d250f39ff73c605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ddf1b282954e588fac184cee2096f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03f2e05bd964f27b59d8e973985f611_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0f4252003945d1b7cf619e91241e33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="collaborator"><xbrli:measure>halo:collaborator</xbrli:measure></xbrli:unit><xbrli:context id="i60c9f6a3aea6447bb885f06a67eeffbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>halo:product</xbrli:measure></xbrli:unit><xbrli:context id="ia03e264b59b746d98f5b7e2c7a6418fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb48210945840e8bf77e3e377c72c8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a632685f724b3dbe494cea07cd7170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:RocheandBaxaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4d74a6abc13a425a8418a3669d66efc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:RocheandBaxaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f9c44c518d2425ea72beec31a2cfebc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0043cfac8af6431f80518ace0a62f8c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib244486e83334e049f9f415b79e745f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c942b53e0e34ec598f5d722217d08af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4a9fcdff314021b35297f8bb703b1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b260f831be1449294bba3c541338639_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea80ef23e3af4bc4be5f2356bb7d3fd5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2b61270d2f40c6863815f87fb3703c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36466ed48de4b458fea7a53fde94578_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01dfe5b9a34240f480cb63ff4e1b02c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4698a330a0b744d6b6d168b99f00f6e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce4eddf7dff4d1f9f2c4573eb5f3534_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64016d8d05444060803595ff46f871b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fb9df557854a4aadba56811dda6704_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac11f44bfb95456296f38ba52920a3c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7de7cf8a78e4bf89bff3256afe84223_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica047ad710284104a38c9d206a018d0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae824ce4a274eccaa7296d3a60e81c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if724606c27844c38bcc67de0fd811b33_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db9f9565034499aa800a640e58be214_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161c82ffd29845e4a51dc871f1f5be81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2c71a5430c427b9f25c98b1682de64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b127d42f404009be3f5197ca82946e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe33da92d9bb4158bc8a5df544e374a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97526871a974553b87645589cdb1f48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie834c01de6184c509a71caad06bb9266_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe8666679dc4bae993f8d56771a1678_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514044e6ba7547189405fbf239f8caea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b5b3910fab4729b3312f22278dd16b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad21366e94841b6b92a3ed6b8d2c8c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27889e318d8545478c0d04d0e999f6a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb93b74a42f341839f733106bc085ac3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6d5252a77b41629cc0e5e24355f1dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd51566fb48417294740b3e09f08d33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e016f17e20404aa3c14094fdf86c28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>halo:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8e0bb6ebfa47f385eb8b8a3556d019_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5cf73d12df4c3bbe1f1cedfe244210_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d619669e18b442786311ba013af06b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78cce61194d43d69a49bc5e102059f3_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardsVestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0189c904b3b4a0381ae6dda4687bd18_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardUnvestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4843830e52a4d92a52b5a09eac1bca4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c84478a64df453893c7636f8f759caa_D20220524-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ac13fbf17f4f2e89a956199a4d633c_D20220524-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id94bd204eed14a56b841b0ecdc83ef00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46732f52d6ca44279534ffa554f17160_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2cc80566cd460e9bc994220806e7aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5224a272d9e145089365401ed07c3c98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35353e8145c94fd192b2662112671742_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cab7782001e401d90fa7549f89275f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>halo:security</xbrli:measure></xbrli:unit><xbrli:context id="i26f722a27dd74b5a9adc18b420c72150_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e4382062e1f4fcfa9e54b30b7e489a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i043b1eced14f4b38ba17b9e0e8ab15b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1deac62ace9c4a888e48f6d9be99dc47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0bddbb8047a491eb63c197e05eb5ca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b8615d6e094174ae8446257115cc1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bcd41a7e814a89918feebb95c129d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib382d0872eaf4b9bbec1ce9d6cceaaab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb83fc6f4b8a45c282238332c7a95841_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5560b65f4f134a1a914172192531d861_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d7d10d24c84281aed5c4277d167461_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c4df731a4f4a4f8fec1bae60a10484_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295651e13dfb4e4cb45f942c4b96e6f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i615de6d5889a4f7d9b1e1d3352937654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7b7b97519c44cdb7226898a6b54701_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eb9ad4bee4649d78ef3bbf1a1aea014_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id61a0f73d0f4425b9a935315a9005c6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9ffaaa4bdf4e638aa15b0e3a30d7a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7ded3a1a584de3b69284715edd8be3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9996ff38f74a49bde5979244e15762_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54544bbec51b460cbeee6e64fdecbc48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950980fb07fe4ca48b48af65c8b224d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3553503311549e6857ea8d049b691a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53f54adb1e5481b8288c131402733b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1c66ed8e4d4b888d17e06a9f8a1c64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f0a156c29745f4a1204a53f9dce5d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877577fc197a449885cec3a196905eba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadbcfda7fe5a4065a2147788d3d2fc7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee689853b26446da4160f945de64c92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f39c15bffce464ca04a0703850470a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78115efa8e2a4a209a2d9ea8a508c0a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib225da12484b414eaf886beb6791a1b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8074c437f714421b84dc5a2ed6b754ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7988ef80a8a4481095a9cd1737928a5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i712a0cd86d3144a297233b33d9781be8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732cceb6359a4dd8865fb5bfa8aeddc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14a2f85de0e485aa57a080d39183883_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e565d32284c4425b05dd65037f38a6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f73c68191284413968a1e7705daeae2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07f947ffcad43d1a6fdf23e3ea0bfce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eaf51e78af04c08b9c64c703cd9221e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8112a093b0c7415eac739e594b629a96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4880129e17ee45a6a5ecb048862fed65_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb52ba56d5ce40bbbf9715e825b909b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597a7d3db45a491e997fe35aa9195b3c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9e40e7d2f244e7b9f66aabd6640852_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75bae0cb0a8a47fb8fcca30b77f6d60e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6fd44e583748d3937db0246f9e5e4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f2f770cb08e46b1a34f5576b2a08663_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0700499fc900499a90faac950d6d4b98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023f24dd6ed643a38263bb9cabdf7718_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b10c333e5154705818149064609c145_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1416bdf7345c4bbabccb8d19a9cf5196_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fcd05c589b426dac58da8abe28d615_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice50c8c082a44a54a348b09d6dad8248_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4ba887d67549afa576d9763e0d4017_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85e98d198d2439aa49f4b9aba5ac485_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i616018ae8ce340d4a55a54fe3fc0c272_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aaaf000b7794cc1afa3317b68317e08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b67aab8964449fb89bd5540b396933d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:A2017RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a90a57424684701b78e04f25324c4d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69070eb1e6084fa48dccbf68b4d6f8d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OtherCollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cbad069681845ec855aab295e5acbce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4592615a3c74e559071621a0a01a228_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b33c1eddff241b7b992cad79cd90321_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5103cb702ff64758983fc79a04fae1aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21db3970f77426c9be0b7002d0bc269_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358cffcf78784467b140596c17157c72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c68a9508eb404082e43ef1e4a75c24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia230ccd2446e49578990a8e709b8b5cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i026e429b3e77423ca0b1a2eddcd26847_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6d68430cff43a0ae03fd967d945fa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1892e4c1066a4e5ca9ecbf598525a0af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida924054054447ada0707db648939f23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f2f3a242d74ae0839b985994afacfe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092e2002b6d245c29ce295a98666505c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1746187612e2471bb184a56028b058f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653f9955b2014441a9bd9524de9a0b9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24180acc66b4c2788f9aa46657e38d0_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>halo:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="businessday"><xbrli:measure>halo:businessDay</xbrli:measure></xbrli:unit><xbrli:context id="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb78064361704a2b8da472621b690b46_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37a3aaaa88549e188282c778e953fba_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie370140c043940ccaecdf292abc511eb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f827aac2a7f4d6ba5ee22c890a4ad04_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade1f569835e40b9a1f4b38283707214_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb55488282dd4b958067934ecba25817_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1520c9eee1f745169c91ccff5d6b28d5_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1c2507713c4df99577b5f739d6ca30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331533d9ad814e1893350fa816c1bff2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fe4bb4bcec457485790bf0cbd54177_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dda495c5d645e186db199b0df8597d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc071eb48f04102a50c800a5c43ac33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3193ab8c85db49f3a4a9823da38d8dc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c657f7c7aa4b2cb4c74f3daa87f921_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bfd4954a6f40fa97c846c2ec979f5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6640df7e0ae2463c8b79ef848a1764c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f407711aaf64227803041f2eee55522_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fda7522287d46afb55413abf54c3425_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide89d55cf7d0475f89869db8cc5fdbe8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4625c024584b4d8d8743379dc7d92c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703c64067ee4482fa9fb83302bac63af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b58f9782c2498893a72173de677682_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dbbe44f2ba045c184c92f9829993116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09d99918fc743c484565395961829c3_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4742da9fb4d0482b803c94968d340b74_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59247bc7b3264b0e86653efe7c50ef9a_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea8d2ab91694fe48abae65438654fbd_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689f2de5af2642238ab9ec7684b8feaa_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8462f2e104247cfb928c19b4f5a2e9b_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaeded4049949cc8d23c4b49d1bfbee_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThirdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6503f2b3881e494aad8c2e128e68f23e_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65af036188ba41eb9fe14b30fb6f1f23_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad72bf7f121e428cab4063032f673cf8_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8764e1163d9d4b42a29fc48e21d37b26_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if262c47c59524111aa76f3840681c866_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2000d717e3b8448690bbc1088fd76ea0_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f1c68d52374db68ae5953d4cd57bf9_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbde07f8da7e4c42b763a251cf0afea0_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6dbdd6695e246f4ad6f672de1aadaa2_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c06e4fe9e8a43a382f8063e6334c895_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492b1e853ac0430faf0bcfe39c9d177f_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d39948aab61416789923cae1ff3c69e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6347633a08434f869706fa2b2f074866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:AmendedAndRestated2021StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01989d60674a45c6ab5875f437acf6a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:OutstandingAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d039d4e0614847a563288bd41158dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdeb7c5afc384d8ba911a737f1419fb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc18d66d2f8f44a4b0473fbc86ab01c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id935d90decb947c3a71099b77bbdac41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec84c34382b44c1e86f9926be1ce3983_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdcc06b9a17743358ff945dd4bed0581_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id969cad6a23d405695239ec30d807f30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bcc82bb2f64c658849f7c71cab48e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e361b0a7e3429099a5544603eb7191_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69087abdb2354c6392a5a633290514cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8de33c335a241468926b3ab8403600b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4a09f254e64faa9bec7e186cb4016f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae176b036399446d884c8a71d329328e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808656e5b1f84f9e8f223c40572ea0cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd57b3450df84c0c9a4020d97056c443_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d72a210e204519967ca7ede33dc391_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cb9a7240414e81abe47db83af3899f_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0d2c8d2d884311ac502e7ea910dc91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744eaed75e9d41b98136429882bab1e4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf745bbf6d154e1899189c7bcad6fc6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949d937237ca46f89a339135fe399f09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec91f8bf02b4770a0909a40dcb95e52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f8ea5c34ea42f0b18170ff0ca21581_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26cfa0230994968ac1d99e765d751b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fa634e741e4e6c976c685332948c76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb2a521823a94cd4a32245c29e206a17_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:CliffVestingFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbc2ed39e364802b20b15e694472966_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:MonthlyVestingAfterOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acdf8fbc6a64af7bd0d8bed1ab7c3df_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:PercentageVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f301c76e72f45fc8bd78b64ae95e300_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813698ed62b94b59be1b62617f5dd7cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bca0917c34b4c89a31b6213fad20334_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2a39ae6cf344228e691d7fec6bd39c_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f9407bb50f40638225cd8fe3f7988f_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7953193d06b84f52adffe498a800882d_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c1972749fa94302ad6f4164caadc9fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9826afc8d63f4d5ca646159f99d34e57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a9b9adaae647398fdba511e9ef1777_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b9ab30830f4339a4ee873a5fc79362_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fdc2cdaf2a4fa09d8fe1a529c0e500_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie346c01929994c85883bfeb74a94e8e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6362e86b7647058ad2270b025883b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">halo:OfficeAndResearchFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ia95727628f324bdb89c986083075e8bf_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">halo:OfficeAndResearchFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d046463d2847239062ac90d2a20ea2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i605fb0614d614a189301d7b5aade275c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17b587fd04b4b8eb4297c5113c4d2f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:OtherStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182a0e0c521c4a8e849c93a64dc49a7c_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887f9a04206a45138521ae3e2d97845c_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7aa8bd02d7448e5943ae4e632674862_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d54b5d7bf64043bb0258fe6d02efc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c7ed8f55754813819fbae73df620ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46db7bf283d452193c503c22cecc2a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i732e51618ba84e17b469190f5cc138c6_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcz_3039f082-efea-448c-8c46-e62ba4c15d89">10-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6ZTgxNTBmNjAxZGVhNGJjMGEwZmIyMTA3NDY4YjJiZGEvdGFibGVyYW5nZTplODE1MGY2MDFkZWE0YmMwYTBmYjIxMDc0NjhiMmJkYV8wLTAtMS0xLTc0Mzkw_7f39f248-0a13-4020-8516-c0824bee77fc">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8xMTY_7eaed370-9f1d-468e-8c96-9ba467b5eb21"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8xMTY_c3892bcb-f581-454b-ae35-8ab9b084f3d7">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NWU1MjBjNWY3MGJhNDQ1NTk3YTE5N2JmNmIxMjJjZDgvdGFibGVyYW5nZTo1ZTUyMGM1ZjcwYmE0NDU1OTdhMTk3YmY2YjEyMmNkOF8wLTAtMS0xLTc0Mzkw_78f611b7-b20b-4cdf-a17f-7a0b005f4600">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY4_5ace5fa1-fd3d-4f88-abfc-76ad0de4058f">001-32335</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><img src="halo-20221231_g1.jpg" alt="halo-20221231_g1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY5_1c19f32a-0569-49e1-90c5-1c247a6f0d4c">HALOZYME THERAPEUTICS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exact name of registrant as specified in its charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8wLTAtMS0xLTc0Mzkw_a9f6ecf9-937f-4539-9b4b-6e1111276700">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8wLTItMS0xLTc0Mzkw_12644291-c215-4ced-85a2-ff213d278c6e">88-0488686</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8zLTAtMS0xLTc0Mzkw_5b05c6e6-2593-4574-9e4f-b7ceaba8af1d">12390 El Camino Real</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8zLTItMS0xLTc0Mzkw_8e8c48d9-662f-45ac-bd20-bc390819aea4">92130</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl80LTAtMS0xLTc0Mzkw_868f0ba3-14c8-4ff5-a43d-8091cc114ecf">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl81LTAtMS0xLTc0Mzkw_175bd6bb-a43f-4677-bcd6-bfcefb1011bc">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcw_847e41bd-d898-4fa2-9b66-96d0e93d12cb">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc0_4b1558bc-efb0-4a63-85af-afea7f87cae0">794-8889</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered under Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.694%"><tr><td style="width:1.0%"></td><td style="width:40.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTAtMS0xLTc0Mzkw_b05df7d9-61e0-4add-b522-fcdf6ed07e1e">Common Stock, $0.001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTEtMS0xLTc0Mzkw_268ca402-2cc8-4eb2-bf0f-5646053e7653">HALO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTItMS0xLTc0Mzkw_06bb8112-91f9-4bbb-9e88-e503c37a7481">The NASDAQ Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered under Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc1_bd9c31a9-460a-4527-a216-a77d4a755572">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcx_2e005afd-4bbb-403a-a8c8-549146d74fa8">No</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcy_0e29ec34-4273-4ddb-8649-bab6098d44d6">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc2_477c2d3c-256d-4fe1-80aa-c4ddf9422d2d">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:17.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8wLTAtMS0xLTc0Mzkw_0ef607d1-d028-423d-87cb-11b074ff40bf">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8xLTQtMS0xLTc0Mzkw_4d89ee9b-03cd-43ad-a893-05bb8ed9d01c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8xLTUtMS0xLTc0Mzkw_525bea12-5a7b-4876-9293-c9cf3a2f3e86">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY1_d41450ca-c7c6-4d6e-a18b-20e34c7eeab3">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744;</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY2_659a0e1f-0c27-4d04-9469-e1d0490d1471">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June&#160;30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i75e409ee707b430fa8ecc2238eb488b2_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8yNDg2_981a5fd0-935b-46e4-94d2-239462a4724b">5.1</ix:nonFraction> billion based on the closing price on the NASDAQ Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant.&#160;This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="ia117119a079043f09f5bfce4b51e42fe_I20230214" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMDA5_24d4463a-57f1-45d9-8293-0ca694e15c65">135,366,862</ix:nonFraction> as of February&#160;14, 2023.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_7"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_1422">Summary of Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_1422">3</a></span></div></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_10">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_13">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_13">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_16">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_16">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_19">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_22">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_22">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_25">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_25">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_28">43</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_31">PART II</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_34">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_34">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_37">(Reserved)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_37">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_40">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_43">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_43">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_46">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_49">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_49">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_52">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_52">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_55">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_55">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_58">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_58">63</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_61">PART III</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_64">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_64">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_67">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_67">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_70">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_73">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_73">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_76">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_76">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_79">PART IV</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_82">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_82">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_85">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_85">68</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_88">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_88">69</a></span></div></td></tr></table></div><div id="i732e51618ba84e17b469190f5cc138c6_1422"></div><div><span><br/></span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks and uncertainties, including those described in the section labeled &#8220;Risk Factors&#8221; in &#8220;Part I, Item 2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report. These risks include the following:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our partnered or proprietary products and product candidates could be associated with adverse events or product recalls.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our contract manufacturers or vendors are unable or unwilling for any reason to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or other proprietary or partnered products and product candidates, our and our partners&#8217; product development or commercialization efforts could be delayed or suspended and our business results of operations and our collaborations could be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to perform necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hylenex and our partners&#8217; ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business strategy is focused on growth of our ENHANZE technology, our auto-injector technology, our commercial products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and as a result there is a risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our ENHANZE technology or by acquiring new technologies may require the use of additional resources, result in increased expense and ultimately may not be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected or delayed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or harm our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our future business and operations.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions resulting from pandemics or similar public health crises could cause a disruption of the development of our and our partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause repayment obligations to accelerate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If proprietary or partnered product candidates are approved for commercialization but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have insufficient insurance coverage.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, , our business, financial condition, and results of operations may be adversely affected or delayed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future acquisitions could disrupt our business and impact our financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is subject to significant volatility.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because some of our and our partners&#8217; products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of certain development and commercialization of our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny. If patent laws or the interpretation of patent laws change, our business may be adversely impacted because we may lose the ability to enforce our intellectual property rights against competitors who develop and commercialize products based on our discoveries.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third-party reimbursement and customer contracts are not available, our proprietary and our partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners&#8217; products, resulting in less revenue to us.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition and rapid technological change that could result in the development of products by others that are competitive with our proprietary and partnered products, including those under development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to attract, hire and retain key personnel our business could be negatively affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the &#8220;safe harbor&#8221; provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.  All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;opportunity,&#8221; &#8220;project&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters such as the development or regulatory approval of new partner products, enhancements of existing products or technologies, timing and success of the launch of new products by us and our partners, third party performance under key collaboration agreements, the ability to successfully integrate Antares Pharma, Inc. into our business, the ability of our bulk drug and device part manufacturers to provide adequate supply for our partners, revenue, expense, cash burn levels and our ability to make timely repayments of debt, anticipated amounts and timing of share repurchases, anticipated profitability and expected trends and other statements regarding our plans and matters that are not historical are forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., Antares Pharma Inc., and Antares Pharma Inc.&#8217;s wholly-owned subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. References to &#8220;Notes&#8221; refer to the Notes to Consolidated Financial Statements included herein (refer to Part II, Item 8).</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_13"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15.02pt">Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving&#160;the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our first commercially approved product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver.&#160;Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;),  Takeda Pharmaceuticals International AG and Baxalta US Inc (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC)(&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co, Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme, to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal offices and research facilities are located at 12390 El Camino Real, San Diego, CA 92130. Our telephone number is (858)&#160;794-8889 and our e-mail address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">info@halozyme.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.halozyme.com. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K. Our periodic and current reports that we filed with the SEC are available on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.halozyme.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, free of charge, as soon as reasonably practicable after we have electronically filed such material with, or furnished them to, the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technology</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids, potentially reducing treatment burden. For example, rHuPH20 has been used to convert drugs that must be delivered intravenously into SC injections or to reduce the number of SC injections needed for effective therapy. When ENHANZE technology is applied subcutaneously, the rHuPH20 acts locally and transiently, with a tissue half-life of less than 30 minutes.&#160;HA at the local site reconstitutes its normal density within two days and, therefore, the effect of rHuPH20 on the architecture of the SC space is temporary. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares, our technology also includes pressure-assisted auto-injector technology. The pressure-assisted auto-injector technology is a form of parenteral drug delivery that continues to gain acceptance and demand among the medical and patient community. Encompassing a variety of sizes and designs, our technology operates by using pressure to force the drug, in solution or suspension, through the skin and deposits the drug into the SC or intramuscular tissue. We have designed disposable, pressure-assisted auto-injector devices to address acute and chronic medical needs, such as rheumatoid arthritis and psoriasis, allergic reactions, migraine headaches, testosterone deficiency and maternal health. Our current platforms include the VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> QuickShot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disposable pressure-assisted auto-injection systems, the Vai&#8482; auto-injector and disposable pen injection systems. Our auto-injectors offer a does capacity ranging from 0.5 mL to 2.25 mL. They are designed for speed and patient comfort and accommodate for highly viscous drug products. They are customizable for fill volumes and needle lengths to meet our partners&#8217; needs for reliability requirements, including for emergency use applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leader in converting IV biologics to SC delivery and extending the dosing interval of SC drugs, using our commercially-validated ENHANZE technology. Our ENHANZE technology also has the potential for SC delivery of small molecules, including those developed as long-acting injectables and other therapies that might benefit from larger dose/larger volume SC delivery. We collaborate with leading pharmaceutical and biotechnology companies to help them develop products that combine our ENHANZE technology with their proprietary compounds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our partners, such as larger injection volumes administered rapidly, extended dosing intervals, and reduced treatment burden and healthcare costs. In addition, ENHANZE has been demonstrated to enable the combination of two therapeutic antibodies in a single injection, as well as the development of new co-formulation intellectual property. We leverage our strategic, technical, regulatory and alliance management skills in support of our partners' efforts to develop new subcutaneously delivered products. We currently have twelve collaborations with five currently approved products and additional product candidates in development using our ENHANZE technology. We intend to work with our existing partners to expand our collaborations to add new targets and develop targets and product candidates under the terms of the operative collaboration agreements. We will also continue our efforts to enter into new collaborations to derive additional revenue from our proprietary technology. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also support leading pharmaceutical companies by assisting in the development of, and supplying, auto-injector devices and auto-injector drug combination products. We leverage our engineering, regulatory and manufacturing skills to support our partners&#8217; plans. We intend to extend the range of auto-injectors available to current and new partners, initiating development of a high volume auto-injector, and further extend the number of partners by gaining more partners for the current auto-injectors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Product Candidates</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our marketed proprietary products and product candidates under development and our marketed partnered products and product candidates under development with our partners:</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:22.5pt"><img src="halo-20221231_g2.jpg" alt="halo-20221231_g2.jpg" style="height:828px;margin-bottom:5pt;vertical-align:text-bottom;width:625px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:22.5pt"><img src="halo-20221231_g3.jpg" alt="halo-20221231_g3.jpg" style="height:825px;margin-bottom:5pt;vertical-align:text-bottom;width:625px"/></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Products and Product Candidates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex Recombinant (hyaluronidase human injection)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell Hylenex recombinant which is a formulation of rHuPH20 that facilitates SC administration for achieving hydration, increases the dispersion and absorption of other injected drugs and, in SC urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XYOSTED (testosterone enanthate) Injection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell in the U.S. our proprietary product XYOSTED injection for SC administration of testosterone replacement therapy (&#8220;TRT&#8221;) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadism).  XYOSTED is the only FDA-approved SC testosterone enanthate product for once-weekly, at-home self-administration and is approved and marketed in three dosage strengths, 50 mg, 75 mg and 100 mg. Safety and efficacy of XYOSTED in males less than 18 years old have not been established.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOCDURNA (desmopressin acetate) Sublingual Tablets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell NOCDURNA in the U.S., which is the first and only sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (&#8220;NP&#8221;) in adults who awaken at least two times per night to urinate. In the NOCDURNA clinical trials, NP was defined as night-time urine production exceeding one-third of the 24-hour urine production. NOCDURNA is a sublingual tablet, marketed in two dosage strengths, that dissolves quickly under the tongue without water and has been shown in clinical studies to reduce nighttime urination by nearly one-half (in patients who average three nighttime bathroom visits.) We license NOCDURNA from Ferring. In October 2022, we sent a notice to Ferring that we are terminating the NOCDURNA license agreement with an effective termination date in October 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TLANDO (testosterone undecanoate) Oral Formulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO is a twice daily oral formulation of testosterone indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO was granted FDA approval in March 2022. In June 2022, we announced the commercial launch of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety and efficacy of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in males less than 18 years old have not been established.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATRS - 1902</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing program to develop a proprietary drug device combination product for the endocrinology market, for patients who require additional supplemental hydrocortisone, identified as ATRS-1902. The development program uses a novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue. The IND application includes the protocol for an initial clinical study to compare the pharmacokinetic profile of our novel formulation of hydrocortisone versus Solu-Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is an anti-inflammatory glucocorticoid and is the current standard of care for the management of acute adrenal crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FDA accepted our IND for ATRS-1902 enabling us to initiate our Phase 1 clinical study. The Phase 1 clinical study, designed to evaluate the safety, tolerability and pharmacokinetics (&#8220;PK&#8221;) of a liquid stable formulation of hydrocortisone, was initiated in September 2021. The study was a cross-over design to establish the PK profile of ATRS-1902 (100 mg) compared to Solu-Cortef (100 mg), the reference-listed drug, in 32 healthy adults. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced the positive results from the Phase 1 clinical study and were granted Fast Track designation by the FDA. The positive results supported the advancement of our ATRS-1902 development program to a pivotal study for the treatment of acute adrenal insufficiency using our Vai novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Products</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to twelve Roche target compounds (the Roche Collaboration). Under this agreement, Roche elected a total of eight targets, two of which are exclusive. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, Roche launched a SC formulation of Herceptin (trastuzumab) (Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) in Europe for the treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard IV form. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC for the treatment of patients with HER2-positive breast cancer. In February 2019, we announced that Roche received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Herceptin SC under the brand name Herceptin Hylecta&#8482; (trastuzumab and hyaluronidase-oysk). In April 2019, Roche made Herceptin Hylecta available in the U.S. In October 2022, Roche Pharmaceuticals China announced the approval of Herceptin in China for the treatment of patients with early-stage and metastatic HER2-positive breast cancer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pertuzumab) and Herceptin for SC injection (Phesgo&#8482;) utilizing ENHANZE technology for the treatment of patients with HER2-positive breast cancer. In December 2020, the European Commission (&#8220;EC&#8221;) also approved Phesgo for the treatment of patients with early and metastatic HER2-positive breast cancer. In July 2022, Roche submitted the Initial Marketing Application (&#8220;IMA&#8221;) for the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pertuzumab) and Herceptin for SC injection (Phesgo) to Center for Drug Evaluation (&#8220;CDE&#8221;) in China.  In September 2022, Chugai Pharmaceutical Co., Ltd. (a Member of the Roche Group) announced the submission of a new NDA in Japan for fixed-dose SC combination of pertuzumab and trastuzumab (same monoclonal antibodies as in Perjeta and Herceptin) with ENHANZE. This application is based on data from two clinical studies including the results from the global Phase 3 FeDeriCa study in patients with HER2-positive breast cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Roche launched MabThera&#174; SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour IV infusion. In May 2016, Roche announced that the European Medicines Agency (&#8220;EMA&#8221;) approved Mabthera SC to treat patients with chronic lymphocytic leukemia (&#8220;CLL&#8221;). In June 2017, the FDA approved Genentech&#8217;s RITUXAN HYCELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination of rituximab using ENHANZE technology (approved and marketed under the MabThera SC brand in countries outside the U.S. and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health Canada approved a combination of rituximab and rHuPH20 (approved and marketed under the brand name RITUXAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) for patients with CLL. In November 2022, Roche submitted the IMA for Mabthera SC to CDE in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we entered into an agreement with Roche to develop and commercialize one additional exclusive target using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized. Roche subsequently returned the rights for the first exclusive target. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer for TECENTRIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab) using ENHANZE technology. In December 2020, Roche initiated a Phase 3 study in patients with non-small cell lung cancer (NSCLC) for TECENTRIQ using ENHANZE technology. In August 2022, Roche announced that the Phase 3 study met its co-primary endpoints, showing non-inferior levels of Tecentriq  in the blood (pharmacokinetics), when injected subcutaneously, compared with IV infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic NSCLC for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In November 2022, Roche submitted a Biologics License Application (&#8220;BLA&#8221;) to the FDA and a Marketing Authorization Application (&#8220;MAA&#8221;) to the EMA for SC formulation of Tecentriq (atezolizumab) with ENHANZE across all approved indications of IV Tecentriq. In January 2023, FDA accepted the BLA for the SC formulation of Tecentriq with the official PDUFA goal date of September 15, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ocrelizumab) with ENHANZE technology in subjects with multiple sclerosis. In April 2022, Roche initiated a Phase 3 study evaluating OCREVUS with ENHANZE technology in subjects with multiple sclerosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Roche nominated a new undisclosed exclusive target to be studied using ENHANZE technology. In November 2021, Roche initiated a Phase 1 study with the undisclosed target and ENHANZE.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2007, we and Takeda entered into a collaboration and license agreement under which Takeda obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (the Takeda Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the EC granted Takeda marketing authorization in all European Union (&#8220;EU&#8221;) Member States for the use of HYQVIA (solution for SC use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Takeda launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first SC immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, Takeda announced that HYQVIA received a marketing authorization from the EC for a pediatric indication, which was launched in Europe to treat primary and certain secondary immunodeficiencies. In September 2020, Takeda announced that the EMA approved a label update for HYQVIA broadening its use and making it the first and only facilitated SC immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (SID).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Takeda initiated a Phase 1 single-dose, single-center, open-label, three-arm study to assess the tolerability and safety of immune globulin SC (human), 20% solution with ENHANZE (TAK-881) at various infusion rates in healthy adult subjects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Takeda announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA, for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and Takeda confirmed its intention to submit regulatory applications in the United States and European Union in its fiscal year 2022. In July 2022, Takeda filed a supplemental Biologics License Application (sBLA) for the potential expanded use of HYQVIA for pediatric indication for primary immunodeficiency. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics in primary care and specialty care indications. Pfizer has elected five targets and has returned two targets. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an exclusive basis. Janssen has initiated several Phase 3 studies, Phase 2 studies and Phase 1 studies of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab), directed at CD38, using ENHANZE technology in patients with amyloidosis, smoldering myeloma and multiple myeloma. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, Janssen&#8217;s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA study evaluating SC DARZALEX in comparison to IV DARZALEX in patients with relapsed or refractory multiple myeloma. DARZALEX SC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (utilizing ENHANZE technology) was found to be non-inferior to DARZALEX IV with regard the co-primary endpoints of Overall Response Rate and Maximum Trough concentration. In May 2020, we announced that Janssen received US FDA approval and launched the commercial sale of DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX FASPRO can be administered over three to five minutes, significantly less time than DARZALEX IV which requires multi-hour infusions. In June 2020, we announced that Janssen received European marketing authorization and launched the commercial sale of DARZALEX SC utilizing ENHANZE in the EU. Subsequent to these approvals, Janssen received several additional regulatory approvals for additional indications and patient populations in US, EU, Japan and China.  Beginning with the US, in January 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant. In January 2021, Janssen received accelerated approval from the FDA for DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed AL amyloidosis (not recommended for the treatment of patients with AL amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials). In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D-Pd) for patients with multiple myeloma after first or subsequent relapse. In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with D-Pd for patients with multiple myeloma after first or subsequent relapse. In November 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with Kyprolis&#174; (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. In the EU, in June 2021, we announced that Janssen received marketing authorization from the EC for DARZALEX SC in two new indications, in combination with D-VCd in newly diagnosed adult patients with AL amyloidosis and in combination with D-Pd in adult patients with relapsed or refractory multiple myeloma. In Japan in March 2021, Janssen announced approval from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for the SC formulation of DARZALEX (known as DARZQURO) in Japan for the treatment of multiple myeloma, and in May 2021 Janssen commenced commercial sale in Japan. In August 2021, Janssen received approval of DARZQURO for systemic AL amyloidosis in Japan. In China in October 2021, Janssen&#8217;s DARZALEX FASPRO was approved by the China National Medical Products Administration (NMPA) for the treatment of primary light chain amyloidosis, in combination with D-VCd in newly diagnosed patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen elected EGFR and cMET as a bispecific antibody (amivantamab) target on an exclusive basis, which is being studied in solid tumors. In November 2020, Janssen initiated a Phase 1 study of amivantamab and ENHANZE. In September 2022, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with epidermal growth factor receptor (EGFR)-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3). In November 2022, Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients with advanced or metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (PALOMA-2).  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2021, Janssen elected the target HIV reverse transcriptase limited to non-nucleoside reverse transcriptase inhibitors. In December 2021, Janssen initiated a Phase 1 clinical trial combining rilpivirine and ENHANZE. Janssen and ViiV are exploring the possibility of an ultra-long acting version of CABENUVA using ENHANZE.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. AbbVie elected one target on an exclusive basis, TNF alpha, for which it has discontinued development and returned the target.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics. Lilly currently has the right to select up to three targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS had the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS products directed at up to eleven targets. Targets may be selected on an exclusive basis or non-exclusive basis. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select 3 additional targets by November 2024. In October 2019, BMS initiated a Phase 1 study of relatlimab, an anti-LAG 3 antibody, in combination with nivolumab using ENHANZE technology. In May 2021, BMS initiated a Phase 3 of nivolumab using ENHANZE technology, for patients with advanced or metastatic clear cell renal cell carcinoma (CheckMate-67T), leveraging data and insights from Phase 1/2 CA209-8KX study in patients with solid tumors. In June 2022, BMS nominated a new undisclosed target. In August 2022, BMS initiated a Phase 3 trial to compare the drug levels of nivolumab with ENHANZE administered subcutaneously vs IV administration in participants with melanoma following complete resection (CheckMate-6GE). BMS plans to initiate a Phase 3 trial in early 2023 to demonstrate the drug exposure levels of nivolumab and relatlimab fixed-dose combination with ENHANZE is not inferior than intravenous administration in participants with previously untreated metastatic or unresectable melanoma (RELATIVITY-127).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion&#8217;s portfolio of products directed at up to four exclusive targets and has access to utilize ENHANZE with up to three exclusive targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">argenx Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we and argenx entered into an agreement for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases in Multifocal Motor Neuropathy (MMN). In October 2020, we and argenx entered into an agreement to expand the collaboration relationship. Under the newly announced expansion, argenx gained the ability to exclusively access our ENHANZE technology for three additional targets for a total of up to six targets under the existing and newly expanded collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using ENHANZE technology. In December 2019, argenx reported that based on data from the phase 1 study and internal company analysis, a one minute injection administered every 2 weeks may be possible. In December 2020, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with immune thrombocytopenia (ITP), an immune disorder in which the blood does not clot normally. In January 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology in pemphigus vulgaris and foliaceus (PV), a rare autoimmune disease that causes painful blisters on the skin and mucous membranes.  In February 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and initiated a Phase 3 study of ARGX-113 using ENHANZE technology in myasthenia gravis (MG), an autoimmune disorder of the musculoskeletal system caused by IgG autoantibodies. In December 2021, argenx announced the FDA approval of efgartigimod (VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of generalized myasthenia gravis for the IV dosing regimen.  In March 2022, argenx announced that data from argenx&#8217;s phase 3 ADAPT-SC study evaluating SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART (efgartigimod alfa-fcab) IV formulation in gMG patients. In June 2022, argenx initiated a study, BALLAD, evaluating Efgartigimod with ENHANZE in bullous pemphigoid. In September 2022, argenx announced the submission of a BLA to the US FDA for SC efgartigimod for the treatment of adults with gMG. In November 2022, argenx announced the acceptance of the BLA application for SC efgartigimod in gMG with a priority review and a Prescription Drug User Free Act (&#8220;PDUFA&#8221;) date of March 20, 2023. In January 2023, argenx announced the review time was extended by the FDA to June 20, 2023 to allow the FDA sufficient time to review. Argenx has also submitted a marketing authorization application to the European Medicines Agency for SC efgartigimod for the treatment of adults with gMG with an anticipated regulatory approval decision in the fourth quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we and Horizon entered into a global collaboration and license agreement that gives Horizon exclusive access to ENHANZE technology for SC formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE to develop a SC formulation of TEPEZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teprotumumab-trbw), indicated for the treatment of thyroid eye disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients. In March 2021, Horizon completed dosing in a Phase 1 study exploring the SC formulation of TEPEZZA. The trial was a small, single-dose Phase 1 pharmacokinetic trial which included evaluation of ENHANZE technology for a SC formulation. In March 2022, Horizon announced the completion of a Phase 1 trial for the TEPEZZA SC program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ViiV Healthcare Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a global collaboration and license agreement with ViiV. The license gives ViiV exclusive access to our ENHANZE technology for four specific small and large molecule targets for the treatment and prevention of HIV. These targets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors (NRTI) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs), capsid inhibitors and broadly neutralising monoclonal antibodies (bNAbs), that bind to the gp120 CD4 binding site. In December 2021, ViiV initiated enrollment of a Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE. In February 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a broadly neutralizing antibody, administered subcutaneously with ENHANZE technology. In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE technology. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chugai Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.  The license gives Chugai exclusive access to ENHANZE drug delivery technology for an undisclosed target. Chugai intends to explore the potential use of ENHANZE for a Chugai drug candidate. In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIH CRADA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we announced a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the National Institute of Allergy and Infectious Diseases&#8217; Vaccine Research Center (VRC), part of National Institute of Health (NIH), </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enabling the VRC&#8217;s use of ENHANZE technology to develop SC formulations of  VRC07-523LS and N6LS broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment. In April 2021, we were notified that the first patient was dosed with N6LS and rHuPH20 in VRC 609 Phase 1 dose-escalation  study to evaluate safety, tolerability, and pharmacokinetics of N6LS using ENHANZE technology. In October 2022, the VRC 609 Phase 1 study was completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAPRISA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration with the Centre for the AIDS Programme of Research in South Africa (CAPRISA), a non-profit company, to evaluate safety, tolerability and pharmacokinetics of a human monoclonal antibody (CAP256V2LS) in HIV-negative and HIV-positive women in South Africa. In October 2020, we were notified that the first patient was dosed with CAP256V2LS and rHuPH20 in CAPRISA 012B Phase 1 dose-escalation study to evaluate safety, tolerability, and pharmacokinetics of CAP256V2LS alone and in combination with VRC07-523LS using ENHANZE technology. In January 2021, we were notified the first patient was dosed with CAP256V2LS and rHuPH20 in combination with VRC07-523LS and rHuPH20 in CAPRISA 012B Phase 1 study. VRC07-523LS broadly neutralizing antibody was supplied by the NIH/VRC under a research collaboration with CAPRISA. In June 2022, we received final study reports for CAPRISA 012B Phase 1 study and concluded our collaboration with CAPRISA.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device and Other Drug Product Collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva License, Development and Supply Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. Pursuant to the agreement, Teva is obligated to purchase all of its delivery device requirements from us. We received an upfront cash payment and a milestone payment upon FDA product approval. We also receive a negotiated purchase price for each device sold, as well as royalties on Teva&#8217;s commercial sales of the product. The agreement will continue until the expiration of the last to expire patent that is filed no later than 12 months after FDA approval. We have multiple patents that have been granted by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) that cover this product, the latest of which will expire in 2033. We have and plan to continue to file patent applications covering this product. We are the exclusive supplier of the device, which we developed, for Teva&#8217;s generic Epinephrine Injection USP products, indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. Teva&#8217;s Epinephrine Injection, utilizing our patented VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and EpiPen Jr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and therefore, subject to state law, substitutable at the pharmacy. We supply the device and Teva is responsible for the drug, assembly and packaging, distribution and commercialization of the finished product, for which we also receive royalties on Teva&#8217;s net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2007, we entered into a license, development and supply agreement with Teva under which we developed and will supply a disposable pen injector for two therapeutic products: exenatide and teriparatide. Under the agreement, we received an upfront payment and development milestones, and are entitled to receive royalties on net product sales by Teva in territories where commercialized. On February 25, 2022, Teva notified us that it was terminating the exenatide program and related agreement due to a lack of commercial viability. The termination was effective August 23, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the multi-dose pen, which we developed, used in Teva&#8217;s generic teriparatide injection product. In 2020, Teva launched Teriparatide Injection, the generic version of Eli Lilly&#8217;s branded product Forsteo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> featuring our multi-dose pen platform, for commercial sale in several countries outside of the U.S. Under an exclusive development, license and supply agreement with Teva, we are responsible for the manufacturing and supply of the multi-dose pen used in Teva&#8217;s generic teriparatide product and Teva is responsible for the sale and distribution of the product. We are compensated for devices sold to Teva and we are entitled to receive royalties on net product sales by Teva in the territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, we entered into a license, supply and distribution agreement with Teva for an auto-injector product containing sumatriptan for the treatment of migraines.  Teva is responsible for the manufacture, supply, commercialization and distribution of the drug, and Halozyme is responsible for the manufacture and supply of the device and assembly and packaging of the finished product. We are compensated at cost for product shipment to Teva and Teva distributes the product in the U.S. Teva also received an option for distribution rights in other territories. In addition, net profits are shared equally between Halozyme and Teva. The term of the agreement continues seven years from commercial launch, which was in June 2016, with automatic one-year renewals unless terminated sooner by either party in accordance with the terms of the agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covis Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, we entered into a development and license agreement with Covis, to develop and supply a SC auto-injector system for use with Makena, a progestin drug (hydroxyprogesterone caproate) indicated to reduce the risk of preterm birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past. Under the agreement, we were granted an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks. Covis is responsible for the clinical development and preparation, </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission and maintenance of all regulatory applications, and is responsible for the manufacture and supply of the drug to be used in the product, and to market, distribute and sell the product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into a manufacturing agreement with Covis for the exclusive supply of the device, a variation of our VIBEX QuickShot SC auto-injector developed by us, and fully assembled and packaged final finished product of the Makena SC auto-injector. We receive a contracted price per unit on each product manufactured and royalties based on net sales of products commencing on product launch in a particular country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2020, Covis received notice that the FDA proposed to withdraw approval of Makena (hydroxyprogesterone caproate injection). Covis requested a public hearing in an effort to maintain patient access to Makena as a treatment option to reduce pre-term birth. In October 2022 the hearing resulted in the FDA Advisory Committee recommending that Makena should not remain on the market.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a development agreement with Pfizer to jointly develop a combination drug device rescue pen utilizing the QuickShot auto-injector and an undisclosed Pfizer drug. We are continuing to evaluate the next steps for this program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a global agreement with Idorsia to develop a novel, drug-device product containing selatogrel. A new chemical entity selatogrel is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia will pay for the development of the combination product and will be responsible for applying for and obtaining global regulatory approvals for the product. The parties intend to enter into a separate commercial license and supply agreement pursuant to which Antares will provide fully assembled and labelled product to Idorsia at cost plus mark-up. Idorsia will then be responsible for global commercialization of the product, pending FDA or foreign approval. Halozyme will be entitled to receive royalties on net sales of the commercial product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ferring Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into an exclusive license and commercial supply agreement with Ferring for the marketed product NOCDURNA (desmopressin acetate) in the U.S. Under the terms of the license agreement, we paid Ferring an upfront payment of $5.0 million upon execution and paid an additional $2.5 million on October 1, 2021. Ferring is eligible for tiered royalties and additional commercial milestone payments potentially totaling up to $17.5 million based on our net sales of NOCDURNA in the U.S. In October 2022, we sent a notice to Ferring that we are terminating the NOCDURNA license agreement with an effective termination date in October 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lipocine Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an exclusive license agreement with Lipocine for the product TLANDO (testosterone undecanoate) in the U.S. In June 2022, we announced the commercial launch of TLANDO. Under the terms of the license agreement, we paid Lipocine an upfront payment of $11.0 million. Lipocine is eligible for additional milestone payments up to $10.0 million and tiered royalty and commercial milestones based on net sales of TLANDO in the U.S. We will be responsible for the manufacturing and commercialization of TLANDO. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Otter Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a supply agreement with Otter to manufacture the VIBEX auto-injection system device, designed and developed to incorporate a pre-filled syringe for delivery of methotrexate, assemble, package, label and supply the final OTREXUP product and related samples to Otter at cost plus mark-up. Otter is responsible for manufacturing, formulation and testing of methotrexate and the corresponding pre-filled syringe for assembly with the device manufactured by us, along with the commercialization and distribution of OTREXUP. OTREXUP is a SC methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto-injector, indicated for adults with severe active rheumatoid arthritis (&#8220;RA&#8221;), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Further, we entered into a license agreement with Otter in which we granted Otter a worldwide, exclusive, fully paid-up license to certain patents relating to OTREXUP that may also relate to our other products for Otter to commercialize and otherwise exploit OTREXUP in the field as defined in the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of the collaboration agreements, refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies - Revenues under Collaborative Agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Intellectual Proprietary Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other intellectual proprietary rights are essential to our business. Our success will depend in part on our ability to obtain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights of third parties. Our strategy is to actively pursue patent protection in the U.S. and certain foreign jurisdictions for technology that we believe to be proprietary to us and that offers us a potential competitive advantage. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Halozyme Patent Portfolio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Halozyme patent portfolio includes patents in the U.S., Europe and other countries in the world and we also have numerous pending patent applications. In general, patents have a term of 20 years from the application filing date or earlier claimed priority date. Our issued patents will expire between 2023 and 2039. We continue to file and prosecute patent applications to strengthen and grow our patent portfolio pertaining to our recombinant human hyaluronidase and other drugs and drug delivery devices, which cover primarily compositions of matter, formulations, methods of use and devices. We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024, which we believe cover the products and product candidates under our existing collaborations and Hylenex recombinant. In addition, we have, under prosecution throughout the world, multiple patent applications that relate specifically to individual product candidates under development, the expiration of which can only be definitely determined upon maturation into our issued patents. We believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proprietary Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely on trade secrets, proprietary know-how, regulatory exclusivities and continuing technological innovation to protect our products and technologies. We protect our trade secrets, proprietary know-how and innovation, in part, by maintaining physical security of our sites and electronic security of our information technology systems and utilizing confidentiality and proprietary information agreements. Our policy is to require our employees, directors, consultants, advisors, partners, outside scientific partners and sponsored researchers, other advisors and other individuals and entities to execute confidentiality agreements upon the start of employment, consulting or other contractual relationships with us. These agreements provide that all confidential information developed or made known to the individual or entity during the course of the relationship is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees and some other parties, the agreements provide that all discoveries and inventions conceived by the individual will be our exclusive property. In certain instances, partners with which we have entered into development agreements may have rights to certain technology developed in connection with such agreements. Despite the use of these agreements and our efforts to protect our intellectual property, there is a risk of unauthorized use or disclosure of information. Furthermore, our trade secrets may otherwise become known to, or underlying technology may be independently developed by, our competitors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also file trademark applications to protect the names of our products and product candidates. These applications may not mature to registration and may be challenged by third parties. We are pursuing trademark protection in a number of different countries around the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs associated with the product development, quality and regulatory work required to maintain the ENHANZE platform, expenses associated with testing of new auto-injectors, activities and support for our partners in their development and manufacturing of product candidates performed on behalf of our partners, compensation and other expenses for research and development personnel, supplies and materials, facility costs and amortization and depreciation. We charge all research and development expenses to operations as they are incurred. Prior to our November 2019 restructuring, our research and development activities were primarily focused on the development of PEGPH20.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have our own manufacturing facility for our product and our partners&#8217; products and product candidates, or the capability to package our products. We have engaged third parties to manufacture bulk rHuPH20 and Hylenex.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent Indiana LLC (Catalent) to produce supplies of bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under current Good Manufacturing Practices (cGMP) for clinical and commercial uses. Catalent currently produces bulk rHuPH20 for use in Hylenex and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products. We rely on their ability to successfully manufacture these batches according to product specifications. It is important for our business for Catalent and Avid to (i)&#160;retain their status as cGMP-approved manufacturing facilities; (ii) successfully scale up bulk rHuPH20 production; and/or (iii)&#160;manufacture the bulk rHuPH20 required by us and our partners for use in our proprietary and collaboration products and product candidates. In addition to supply obligations, Avid and Catalent will also provide support for data and information used in the chemistry, manufacturing and controls sections for FDA and other regulatory filings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a commercial manufacturing and supply agreement with Patheon Manufacturing Services, LLC (Patheon) under which Patheon will provide the final fill and finishing steps in the production process of Hylenex recombinant. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use third parties to manufacture our auto-injector technology products and product candidates, including the products and related components we supply to our partners. For our products and product candidates, we verify that they are manufactured in accordance with FDA&#8217;s cGMPs for drug products and FDA&#8217;s current Quality System Regulations (&#8220;QSRs&#8221;) for medical devices and equivalent provisions in the EU and elsewhere, which are required as part of the overall obligations necessary, in the EU for instance, to obtain a CE-mark. We enter into quality agreements with our third-party manufacturers which require compliance with cGMPs, QSRs and foreign equivalents, to the extent applicable. We use third-party service providers to assemble and package our products and product candidates under our direction. We monitor and evaluate manufacturers and suppliers to assess compliance with regulatory requirements and our internal quality standards and benchmarks. We perform quality reviews of manufacturing for all of our product candidates and products, and quality releases for all of our product candidates and products that we sponsor or commercialize.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party manufacturers to manufacture and supply certain components, drugs, final assembly and finished product. Below is a summary of our key production, manufacturing, assembly and packaging arrangements with third-party manufacturers for products commercialized by us and our partners:</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phillips-Medisize Corporation (&#8220;Phillips&#8221;), an international outsource provider of design and manufacturing services, produces commercial quantities of components of our QuickShot auto-injector device for XYOSTED, our QuickShot auto-injector device for the Makena product with Covis, and our VIBEX epinephrine auto-injector product with Teva.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ComDel Innovation, Inc. (&#8220;ComDel&#8221;), a domestic provider of integrated solutions for product development, tooling, and manufacturing, produces commercial quantities of components for the VIBEX sumatriptan auto-injector product and for the teriparatide pen product with Teva.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jabil Healthcare, an international manufacturing development company produces commercial quantities of components of our VIBEX auto-injector device for the OTREXUP product for Otter and the VIBEX epinephrine auto-injector product with Teva.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fresenius Kabi supplies commercial quantities of pre-filled syringes of testosterone for XYOSTED.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sharp Corporation (&#8220;Sharp&#8221;), an international contract packaging company, assembles and packages XYOSTED, Sumatriptan Injection USP and the Makena auto-injector products, and the OTREXUP auto-injector product for Otter.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer supplies the active pharmaceutical ingredient (&#8220;API&#8221;) for TLANDO.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NextPharma, an international pharmaceutical manufacturing company, supplies the bulk capsule product for TLANDO.</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PCI Pharma Services (&#8220;PCI&#8221;), an international contract packaging company, bottles and packages TLANDO.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales, Marketing and Distribution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for, and support utilization of,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hylenex recombinant and one that supports the promotion of our testosterone products XYOSTED and TLANDO. Our commercial activities also include marketing and related services and commercial support services such as commercial operations, managed markets and commercial analytics. We also employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services to assist with our commercial activities.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell XYOSTED, TLANDO and Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell Hylenex to hospitals and XYOSTED and TLANDO to other end-user customers. We engage Integrated Commercialization Solutions (ICS), a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and distribution of Hylenex recombinant to our customers in the United States. We also contract with numerous wholesale distributors, including Cardinal, McKesson Corporation (&#8220;McKesson&#8221;) and AmerisourceBergen Corporation to distribute our other proprietary products (including XYOSTED and TLANDO) to retail pharmacies as well as the Veterans Administration and other governmental agencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to shipping and distribution services, these distributors and third-party logistics provider, Cardinal Health 105, Inc., also known as Specialty Pharmaceutical Services (&#8220;Cardinal&#8221;) provide us with other key services related to logistics, warehousing, returns and inventory management, sales reports, contract administration and chargebacks processing and accounts receivable management. We also use a division of Cardinal for sample administration. In addition, we utilize these third parties to perform various other services for us relating to regulatory monitoring, including call center management, adverse event reporting, safety database management and other product maintenance services. In exchange for these services, we pay fees to certain distributors based on a percentage of wholesale acquisition cost. We have also contracted with several specialty pharmacies to support fulfillment of certain prescriptions. In addition, we use third parties to perform various other services for us relating to regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary therapeutics. We face competition from a number of sources, some of which may target the same indications as our product or product candidates, including large pharmaceutical companies, smaller pharmaceutical companies, biotechnology companies, academic institutions, government agencies and private and public research institutions, many of which have greater financial resources, drug development experience, sales and marketing capabilities, including larger, well established sales forces, manufacturing capabilities, experience in obtaining regulatory approvals for product candidates and other resources than us. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE technology may face increasing competition from alternate approaches and/or emerging technologies to deliver medicines SC. In addition, our partners face competition in the commercialization of the product candidates for which the partners seek marketing approval from the FDA and other regulatory authorities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hylenex recombinant is currently the only FDA approved recombinant human hyaluronidase on the market. The competitors for Hylenex recombinant include, but are not limited to, Bausch Health Companies, Inc.&#8217;s product, Vitrase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.&#8217;s product, Amphadase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a bovine (bull) hyaluronidase.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XYOSTED and TLANDO</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there are several different formulations for TRT including intramuscular injection, transdermal patches and gels, oral formulations and nasal gels. Competition in the U.S. testosterone replacement market includes transdermal solutions such as AbbVie&#8217;s Androgel&#174; 1% and 1.62%, Perrigo&#8217;s generic Androgel&#174; Topical Gel, 1.62%, Eli Lilly&#8217;s Axiron&#174;, Endo&#8217;s Testim&#174; and Fortesta&#174; (and the authorized generic) and Allergan plc&#8217;s (&#8220;Allergan&#8221;) Androderm&#174;. Other forms of TRT include injectables such as Endo&#8217;s Aveed&#174;, Pfizer&#8217;s Depo&#174;-Testosterone, and several generic oil testosterone products sold by Actavis, Sandoz, Viatris Inc., Teva and others, as well as Testopel&#174; pellets by Endo and JATENZO&#174;, an oral formulation, by Tolmar, and Kyzatrex, an oral formulation by Marius Pharmaceuticals.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a wide range of competitors depending upon the branded or generic marketplace, the therapeutic product category, and the product type, including dosage strengths and route of administration. Our competitors include established specialty pharmaceutical companies, major brand name and generic manufacturers of pharmaceuticals such as Teva, Viatris, Eli Lilly and Endo, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. Our competitors also include third party contract medical device design and development companies such as Scandinavian Health Ltd., Ypsomed AG, West Pharmaceutical and Owen Mumford Ltd. Many of our competitors have greater financial and other resources than we have, such as more commercial resources, larger research and development staffs and more extensive marketing and manufacturing organizations. Smaller or early stage emerging companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory agencies in foreign countries regulate the manufacture and sale of the pharmaceutical products that we or our partners have developed or that our partners currently are developing. The FDA has established guidelines and safety standards that are applicable to the laboratory and preclinical evaluation and clinical investigation of therapeutic products and stringent regulations that govern the manufacture and sale of these products. The process of obtaining regulatory approval for a new therapeutic product usually requires a significant amount of time and substantial resources. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory obligations continue post-approval and include the reporting of adverse events when a drug is utilized in the broader patient population. Promotion and marketing of drugs is also strictly regulated, with penalties imposed for violations of FDA regulations, the Lanham Act and other federal and state laws, including the federal anti-kickback statute.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to continue to seek, through our partners, approval to market products and product candidates in foreign countries, which may have regulatory processes that differ materially from those of the FDA. Our partners may rely upon independent consultants to seek and gain approvals to market our proposed products in foreign countries or may rely on other pharmaceutical or biotechnology companies to license our proposed products. We cannot guarantee that approvals to market any of our partners&#8217; products can be obtained in any country. Approval to market a product in any one foreign country does not necessarily indicate that approval can be obtained in other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of drug products. In addition, FDA regulations and guidance may be revised or reinterpreted by the agency or reviewing courts in ways that may significantly affect our business and development of our partners&#8217; product candidates and any products that we may commercialize. It is impossible to predict whether additional legislative changes will be enacted, or FDA regulations, guidance or interpretations changed, or what the impact of any such changes may be. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about our Executive Officers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information concerning our executive officers, including their names, ages and certain biographical information can be found in Part III, Item&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors, Executive Officers and Corporate Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This information is incorporated by reference into Part I of this report.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The experience, expertise and dedication of our employees drive the progress and accomplishments of Halozyme. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;14, 2023, we had 393 full-time employees. None of our employees are unionized and we believe our employee relations to be good. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognizing the value of our employees and the contributions they make in achieving our business objectives and overall success, we focus on creating and providing an inclusive and safe work environment where employees are respected and rewarded for their contributions, work together as one team, have opportunities to grow and develop their careers, and support the communities in which we work. We also believe this approach to human capital management is essential to attracting and retaining employees in the highly competitive biotechnology and pharmaceutical labor market. To achieve this supportive working environment, our human capital management efforts focus on:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Values and Ethics:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation of our human capital management strategy is contained in our corporate values statement and our Code of Conduct and Ethics (the &#8220;Code of Conduct&#8221;), both of which provide uniform guidance to all our employees regarding expectations for proper workplace behavior. Our corporate values emphasize respecting and valuing fellow team members and acting with integrity and honesty to uphold the highest ethical standards. We believe these values provide an environment in which all employees can feel proud and motivated to contribute their valued talents to achieving corporate goals and objectives.  Our values also emphasize empowering employees and personal accountability as a means to fulfill our commitments to patients, partners, shareholders and each other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors adopted and regularly reviews the Code of Conduct, which applies to all of our employees, officers and directors. Adherence to the Code of Conduct helps ensure that all employees can feel a part of an organization that emphasizes adherence to laws and policies covering the industry in which we work. Our Code of Conduct also emphasizes each employee&#8217;s accountability for making decisions and taking actions in a highly ethical manner with a focus on honesty, fairness and integrity and treating all fellow employees in a respectful and inclusive manner. We have established a reporting hotline that enables employees to file anonymous reports of any suspected violations of the Code of Conduct. We believe that providing an ethical environment in which to work is vital to our efforts to attract, retain and develop our employees.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to build and maintain a diverse team of employees that is passionate about and committed to having a positive impact on the lives of patients and their families. We value and celebrate the unique talents, backgrounds and perspectives each employee contributes to achieving our mission and corporate objectives. In support of this philosophy, we adopted the Biotechnology Innovation Organization&#8217;s principles on workforce development, diversity and inclusion. Our diverse and inclusive culture is key to attract, develop and retain our talent pool within the globally competitive biotechnology industry. Our dedication to these principles has resulted in a diverse and inclusive employee base consisting of 45% female and 31% non-white/Caucasian employees as of February&#160;14, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an equal opportunity employer, we strive to attract and connect with diverse talent who best match our core values and who will be successful and thrive at Halozyme. Our recruiting team partners with hiring managers and we select diverse interview panels to help provide insight at every stage of the process to identify the best possible candidate &#8211; whether internal or external &#8211; to fill open roles in the company. We evaluate our recruitment and retention efforts based on a variety of metrics, including offer acceptance rate, time-to-hire, turnover and diversity of our employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Professional Development for Employees at All Levels:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are firmly committed to employee development as an essential driver of our future growth and overall success of Halozyme. We understand that high performing employees are always seeking a challenge and reaching for ways to broaden, deepen and develop their skills and grow professionally. To support our employees, we conduct an individual development plan process to give employees the opportunity and accountability to document their career goals and discuss the actions necessary to achieve those goals. We have two internal training programs: our senior leader development program is focused on advancing business acumen and leadership skills and our learning and development curriculum for the entire organization is focused on personal, professional, team and leadership development opportunities and grounded in our established leadership attributes which identify the knowledge, skills, abilities and behaviors that contribute to individual and organizational performance. In addition, everyone attends or participates in compliance, harassment prevention, and safety training and we offer education assistance for college and university courses, training seminars and educational conference attendance opportunities to all employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To monitor progress, we review our succession plan for key senior management positions as part of our annual talent review and identify development opportunities to help ensure potential successor readiness.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Engagement:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building trust and a high performing culture is a top priority for Halozyme. We achieve this by providing a platform for employees to give feedback, collaborate on solutions, and discuss how to make changes to help improve our experience at work. Over the years, we have regularly conducted employee engagement surveys to better understand what we do well and where there are opportunities for improvement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the insights gained from past surveys, we have focused on strengthening cross-functional teamwork including how teams communicate and how we hold each other accountable. Examples of specific actions we have taken in response to employee survey feedback include all-employee training on cross-functional teamwork and a learning series to equip employees to give and receive constructive feedback.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold frequent all-employee meetings that serve as an open forum to share progress on strategy and corporate goals as well as potential at-risk areas, celebrate achievements, and share best practices and learnings. Beginning in 2020 and continuing into 2023 we have increased the frequency of our all-employee meetings from monthly to semi-monthly while transitioning from work-from-home to a hybrid workplace to keep employees well-informed, connected and to provide them with a setting to ask questions and discuss solutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management tracks and assesses retention and attrition and interviews departing employees in order to identify any addressable trends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation &amp; Benefits:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation and benefits programs, with oversight from the Compensation Committee of our Board of Directors, are designed to attract, retain and reward employees through competitive salaries, annual bonus eligibility, long-term incentive awards, Employee Stock Purchase Plan, a 401(k) Plan, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and employee assistance programs. Each year we conduct surveys to benchmark our salaries and benefits and confirm we are satisfied with the competitiveness of our total compensation offering. We also provide a variety of peer-to-peer and corporate recognition programs to celebrate and recognize our employees for their hard work and contributions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Health and Safety:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to promoting the health and safety of our employees because we believe it fosters employee productivity and job performance. We have developed and implemented annual workplace safety training which is intended to remind our employees of workplace safety procedures that may be useful in the event of emergency situations and to assist our employees in helping to prevent workplace accidents. We have a Safety Operations Team which meets on a quarterly basis to review workplace safety and adherence to safety policies. This team reports safety metrics and results of ongoing initiatives to the CEO semi-annually and the Board annually. Further, our Code of Conduct emphasizes our commitment to preventing unlawful employment discrimination and workplace harassment including mandatory, on-going sexual harassment training and provides a mechanism for reporting any violations of this policy.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our response to COVID-19:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we take the health and safety of our employees, their families and our local communities very seriously, we continued case monitoring, contact tracing and notifications as required, diagnostic testing and enhanced safety protocols to ensure business continuity and risk of transmission is minimized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Citizenship:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in supporting the community in which we work and provide our employees multiple opportunities to contribute to the community, including providing company-wide community service days/volunteerism supporting:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient advocacy/healthcare;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health disparities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">STEM education;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Humanitarian services (e.g., food drives, home builds, meal services);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Environment (e.g., lagoon cleanup events, park restoration); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Children in underserved communities (e.g. school supply drives, holiday adopt-a-family).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:34.8pt">Risk Factors</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval from the FDA or equivalent health authorities is necessary to design, develop, test, manufacture and market pharmaceutical products and medical devices in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our partnered or proprietary product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our partners may provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such  filings and approvals may not occur when we or our partners expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our partnered or proprietary product candidates for failure to collect sufficient clinical or animal safety data and require additional clinical or animal safety studies which may cause lengthy delays and increased costs to our or our partners&#8217; development programs. Any such issues associated with rHuPH20 could have an adverse impact on future development of our partners&#8217; products which include rHuPH20, future sales of Hylenex recombinant, or our ability to maintain our existing ENHANZE collaborations or enter into new ENHANZE collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. </span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information relating to the approval of product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our partners must maintain our regulatory approvals. If we or any of our partners are unsuccessful in maintaining the required regulatory approvals, our revenues would be adversely affected.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our partnered or proprietary and the products and product candidates could be associated with adverse events or product recalls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, our partnered or proprietary products and product candidates could be associated with adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent to very common) or product recalls. Adverse events associated with the use of our partnered or proprietary products or product candidates may be observed at any time, including in clinical trials or when a product is commercialized, and any such adverse events may negatively affect our or our partners&#8217; ability to obtain or maintain regulatory approval or market such products and product candidates. Adverse events such as toxicity or other safety issues associated with the use of our partnered or proprietary products and product candidates could require us or our partners to perform additional studies or halt development or commercialization of these products and product candidates or expose us to product liability lawsuits which will harm our business. For example, we experienced a clinical hold on patient enrollment and dosing in our phase 2 study of PEGPH20 in patients with PDA (a discontinued program), which was not resolved until we implemented steps to address an observed possible difference in TE event rates between the arms of the study. We or our partners may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical products or product candidates which we have not planned or anticipated. There can be no assurance that we or our partners will resolve any issues related to any product or product candidate adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a product fails to conform to its specifications or comply with the applicable laws or regulations, we or our partners may be required to or may decide to voluntarily recall the product or regulatory authorities may request or require that we recall a product even if there is no immediate potential harm to a patient. Any recall of our products or their components that we supply to our partners could materially adversely affect our business by rendering us unable to sell those products or components for some time and by adversely affecting our reputation. Recalls are costly and take time and effort to administer. Even if a recall only initially relates to a single product, product batch, or a portion of a batch, recalls may later be expanded to additional products or batches or we or our partners may incur additional costs and need to dedicate additional efforts to investigate and rule out the potential for additional impacted products or batches. Moreover, if any of our partners recall a product due to an issue with a product or component that we supplied, they may claim that we are responsible for such issue and may seek to recover the costs related to such recall or be entitled to certain contractual remedies from us. Recalls may further result in decreased demand for our partnered or proprietary products, could cause our partners or distributors to return products to us for which we may be required to provide refunds or replacement products, or could result in product shortages. Recalls may also require regulatory reporting and prompt regulators to conduct additional inspections of our or our partners&#8217; or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractors&#8217; facilities, which could result in findings of noncompliance and regulatory enforcement actions. A recall could also result in product liability claims by individuals and third-party payers. In addition, product liability claims or other safety issues could result in an investigation of the safety or efficacy of our products, our manufacturing processes and facilities, or our marketing programs conducted by the FDA or the authorities of the EU member states and other jurisdictions. Such investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations on the indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action by the FDA, the EMA or the competent authorities of the EU member states could lead to product liability lawsuits as well.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our contract manufacturers or vendors are unable to or unwilling for any reason to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or our other proprietary or partnered products and product candidates, our and our partners&#8217; product development and commercialization efforts could be delayed or stopped and our business results of operations and our collaborations could be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of third parties in our supply chain for the supply and manufacture of our partnered and proprietary products and the availability of such products depends upon our ability to procure the raw materials, components, packaging materials and finished products from these third parties, several of which are currently our single source for the materials necessary for certain of our products. We have entered into supply agreements with numerous third-party suppliers.  For example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent  Indiana LLC (Catalent) to produce bulk rHuPH20.&#160;These manufacturers each produce bulk rHuPH20 under cGMP for use in Hylenex recombinant, and for use in partnered products and product candidates. We rely on their ability to successfully manufacture bulk rHuPH20 according to product specifications. In addition to supply obligations, our contract manufacturers will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We also rely on vendors to supply us with raw materials to produce reagents and other materials for bioanalytical assays used to support our partners&#8217; clinical trials. We also have a commercial manufacturing and supply agreement with Patheon under which Patheon provides the final fill and finishing steps in the production process of Hylenex recombinant. If any of our contract manufacturers or vendors: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up production to meet corporate or regulatory authority quality standards; (iii) is unable to procure the labor, raw materials, reagents or components necessary to produce our proprietary products, including bulk rHuPH20 and Hylenex recombinant our bioanalytical assays or our partnered products or (iv) fails to manufacture and supply our partnered and proprietary products, including bulk rHuPH20 in the quantity and quality required by us or our partners for use in Hylenex and partnered products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties&#8217; or other third party manufacturers&#8217; business or financial condition could adversely affect their abilities or willingness to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable or unwilling to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by any of our contract manufacturers. Any delays, interruptions or other problems regarding the ability or willingness of our contract manufacturers to supply bulk rHuPH20 or the ability or willingness of other third-party manufacturers, to supply other raw materials or ingredients necessary to produce our other proprietary or partnered products on a timely basis could: (i) cause the delay of our partners&#8217; clinical trials or otherwise delay or prevent the regulatory approval of our partners&#8217; product candidates; (ii) delay or prevent the effective commercialization of proprietary or partnered products and product candidates; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our partners. Such delays could damage our relationship with our partners, and they could have a material adverse effect on royalties and thus our business and financial condition. Additionally, we rely on third parties to manufacture, prepare, fill, finish, package, store and ship our proprietary and partnered products and product candidates on our behalf. If the third parties we identify fail to perform their obligations, the progress of partners&#8217; clinical trials could be delayed or even suspended and the commercialization of our partnered or proprietary products could be delayed or prevented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Minnetonka, Minnesota facility supports our administrative functions, product development and quality operations and is intended to eventually provide additional manufacturing and warehousing capabilities in the future.  If we begin manufacturing and producing commercial products in the future, we will be subject to relevant risks comparable to those of our third-party manufacturers. For example, we may not be able to begin product manufacturing and production due to a number of different reasons including, but not limited to, an ability to obtain necessary supplies and materials, labor and expertise.  To the extent we rely on our ability to manufacture and ship any of our proprietary and partnered products, our inability to do so could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to perform necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the product, we have retained third-party service providers to perform a variety of functions related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products, key aspects of which are out of our direct control. We place substantial reliance on these providers as well as other third-party providers that perform services for us, including, depending on the product, entrusting our inventories of products to their care and handling. We also may rely on third parties to administer our drug price reporting and rebate payments and contracting obligations under federal programs. Despite our reliance on third parties, we have responsibilities for compliance with the applicable legal and program requirements. By example, in certain states, we are required to hold licenses to distribute our products in these states and must comply with the associated state laws. Moreover, if these third-party service providers fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us or encounter physical damage or a natural disaster at their facilities, our ability to deliver products to meet commercial demand would be significantly impaired. In addition, we may use third parties to perform various other services for us relating to regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If our employees or any third-party service providers fail to comply with applicable laws and regulations, we and/or they may face regulatory or False Claims Act enforcement actions. Moreover, if the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we and/or they could be subject to regulatory sanctions. We do not currently have the internal capacity to perform these important commercial functions, and we may not be able to maintain commercial arrangements for these services on reasonable terms.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if&#160;a key collaboration agreement, is terminated for any reason, our business could suffer.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are heavily dependent on our partners to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits, including revenues from milestones, royalties and product sales from these collaborations. Our partners may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions may not be visible to us immediately and could negatively impact our ability to forecast and our ability to achieve the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could negatively impact our operations. In addition, the termination of a key collaboration agreement by one or more of our partners could have a material adverse impact on our ability to enter into additional collaboration agreements with new partners on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and may lead us to reevaluate the applications and value of our technology.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex and our partners&#8217; ENHANZE products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rHuPH20 is a key technological component of Hylenex and our ENHANZE technology and most of our ENHANZE partnered products and product candidates, including the current and future products and product candidates under our ENHANZE collaborations. We derive a substantial portion of our revenues from our ENHANZE collaborations. Therefore, if  there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for HYQVIA as well as in a former partner&#8217;s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former partner&#8217;s program will have a significant impact on our proprietary product and our partners&#8217; product and product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our Hylenex commercialization activities, the development or commercialization activities of our ENHANZE partners, or deter our entry into additional ENHANZE collaborations with third parties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business strategy is focused on growth of our ENHANZE technology, our auto-injector technology, our commercial products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and as a result there is a risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our ENHANZE technology or by acquiring new technologies may require the use of additional resources, result in increased expense and ultimately may not be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the fourth quarter of 2019, we decided to focus our resources on our ENHANZE technology and our commercial product, Hylenex. By focusing primarily on these areas, we increase the potential impact on us if one of those partner programs does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. We may also expand our strategic focus by seeking new therapeutics applications of our technology or by acquiring new technologies which may require the use of additional resources, increased expense and would require the attention of senior management. For example, in May 2022, we acquired Antares as a means to diversify the sources of our revenues. There can be no assurance that our investment in Antares or any such future investment of resources in new technologies will ultimately result in additional approved proprietary or partnered products or commercial success of new therapeutic applications of our technology.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected or delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, our partners may obtain different results in subsequent trials or studies that fail to show the desired levels of dose safety and efficacy, or we or our partners may not obtain applicable regulatory approval for our products for a variety of other reasons. Preclinical, nonclinical, and clinical trials for proprietary or partnered product candidates could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the course of clinical studies, the final data from later Phase 3 studies may differ from data observed in early phase clinical trials, and clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our partners&#8217; product candidates;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical and nonclinical test results may reveal inferior pharmacokinetics, adverse events or unexpected safety issues associated with the use of our partners&#8217; product candidates;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require that we or our partners change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive; </span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may reject our and our partners&#8217; trial data or disagree with their interpretations of either clinical trial data or applicable regulations;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies including conditions to assure safe use programs and we or a partner may decide to not pursue regulatory approval for a such a product;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our partners, our contract manufacturers or our raw material suppliers;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our or our partners&#8217; contract research organization, or CRO, to properly perform the clinical trial in accordance with the written protocol, our contractual obligations with them or applicable regulatory requirements; </span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our partners, our contract manufacturers or our raw material suppliers; </span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proprietary or partnered product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a proprietary or partnered product candidate is not approved in a timely fashion or approval is not obtained on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, financial condition and results of operation and we would become more dependent on the development of other proprietary or partnered product candidates and/or our ability to successfully acquire other technologies. There can be no assurances that we or our any partnered product candidate will receive regulatory approval in a timely manner, or at all. There can be no assurance that partners will be able to gain clarity as to the FDA&#8217;s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit an opportunity will be limited or may not be possible.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that certain proprietary or partnered products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or harm our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Takeda is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a partner, or any applicable third party service provider of a partner, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the partnered product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of partnered product candidates; and/or (ii) delay or prevent the effective commercialization of partnered products. Such delays could have a material adverse effect on our business and financial condition. We also rely on our partners to commercialize and distribute their products and if they are unsuccessful in commercializing their products, the resulting royalty revenue we would receive may be lower than expected.   </span></div><div style="margin-top:4pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could harm our business.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any approved products, along with the manufacturing processes, post-approval clinical data requirements, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our partners and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Further, because some of our proprietary and partnered products and product candidates are drug/device combination products, we and our partners will have to comply with extensive regulatory requirements than would otherwise be required for products that are not combination products. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our partners and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, substantially dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay our or our partners&#8217; clinical trials or otherwise inhibit our or  partners&#8217; ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our partners and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements may result in adverse regulatory actions including but not limited to, any of the following:</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our partners&#8217; products or manufacturing processes;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of our or our partners&#8217; products from the market;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory recall;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of any of our partners&#8217; ongoing clinical trials;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our or our partners&#8217; products;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; or</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our stock price and future business and operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we completed the acquisition of Antares. Our integration of the Antares business into our operations will be a complex and time-consuming process that may not be successful. The primary areas of focus for successfully combining the business of Antares with our operations may include, among others: retaining and integrating key employees, integrating information, communications and other systems, and managing the growth of the combined company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully integrate the business of Antares into our operations, we may not realize the anticipated benefits. We acquired Antares with the expectation that the acquisition will result in various benefits for the combined company, including providing an opportunity for increased revenues through growth of device revenue and commercial products and development of a new high volume auto-injector. Increased competition, unresolvable technical issues and/or deterioration in business conditions may limit our ability to grow this business. As such, we may not be able to realize the benefits anticipated in connection with the acquisition.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business interruptions resulting from pandemics or similar public health crises could cause a disruption of the development of our and our partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business and results of operations by, among other things, disrupting the development of our and our partnered product candidates and commercialization of our and our partnered approved products, causing disruptions in the operations of our third-party contract manufacturing organizations upon whom we rely for the production and supply of our proprietary products, including Hylenex and the bulk rHuPH20 we supply to our partners, and causing other disruptions to our operations.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the COVID-19 pandemic led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which future pandemics impact our operations and/or those of our partners will depend on future developments, which are highly uncertain and unpredictable, including the duration or recurrence of outbreaks, potential future government actions, new information that will emerge concerning the severity and impact of that pandemic and the actions to contain the pandemic or address its impact in the short and long term, among others.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business disruptions associated with a global pandemic could impact the business, product development priorities and operations of our partners, including potential delays in manufacturing their product candidates or approved products. For example, clinical trial conduct may be impacted in geographies affected by a pandemic. The progress or completion of these clinical trials could be adversely impacted by the pandemic. Additionally, interruption or delays in the operations of the FDA, the EMA and other similar foreign regulatory agencies, or changes in regulatory priorities to focus on the pandemic, may affect required regulatory review, inspection, clearance and approval timelines. Disruptions such as these could result in delays in the development programs of our partnered products or impede the commercial efforts for approved products, resulting in potential reductions or delays in our revenues from partner royalty or milestone payments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on many third parties to source active pharmaceutical ingredient and drug products, manufacture and assemble our devices, distribute finished products and provide various logistics activities in order to manufacture and sell our partnered and proprietary products.  For example, we rely on third-party manufacturers to manufacture the bulk rHuPH20 that we supply to our partners for their commercial products and product candidates, as well as our commercial product Hylenex. If any such third party manufacturer is adversely impacted by a pandemic and related consequences, including staffing shortages, production slowdowns and disruptions in delivery systems, availability of raw materials, reagents or components or if they divert resources or manufacturing capacity to accommodate the development of coronavirus treatments or vaccines, our supply chain may be disrupted, limiting our ability to sell Hylenex or supply bulk rHuPH20 to our partners. Any such disruptions to the operations of the third parties upon whom we rely to manufacture and sell our partnered and proprietary products could result in reductions or delays in our revenues.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital in the future to fund our operations for general corporate purposes if we do not achieve the level of revenues we expected. Our current cash reserves and expected revenues may not be sufficient for us to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i)&#160;new collaborative agreements;  (ii)&#160;expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v)&#160;monetizing assets; and/or (vi) the public offering of securities.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to raise additional capital in the future, it may not be available on favorable financing terms within the time required, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic business initiatives. If we raise additional capital through a public offering of securities or equity, a substantial number of additional shares of our common stock may be issued, which will dilute the ownership interest of our current investors and may negatively affect our stock price.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause repayment obligations to accelerate.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of our consolidated indebtedness, net of debt discount, as of&#160;December&#160;31, 2022&#160;was $1,506.1 million, which includes $13.5 million in aggregate principal amount of the 2024 Convertible Notes and $805.0 million in aggregate principal amount of the 2027 Convertible Notes and $720.0 million in aggregate principal of the 2028 Convertible Notes, net of unamortized debt discount of $0.1 million,  $14.4 million and $17.9 million for the 2024 Convertible Notes, 2027 Convertible Notes and 2028 Convertible Notes, respectively.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness may:</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make it difficult for us to satisfy our financial obligations, including making scheduled principal and interest payments on our indebtedness;</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions, share repurchases or other general business purposes;</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to use a portion of our cash flow from operations to make debt service payments;</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility to plan for, or react to, changes in our business and industry;</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our less leveraged competitors; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to the impact of adverse economic and industry conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our 2022 Credit Agreement includes certain affirmative and negative covenants, that, among other things, may restrict our ability to: create liens on assets; incur additional indebtedness; make investments; make acquisitions and other fundamental changes; and sell and dispose of property or assets. The 2022 Credit Agreement also includes financial covenants requiring us to maintain, measured as of the end of each fiscal quarter, a maximum consolidated net leverage ratio of 4.75 to 1.00 initially, which declines to 4.00 to 1.00 over the term of the loan facility, and a minimum consolidated interest coverage ratio of 3.00 to 1.00. The 2022 Credit Agreement also contains customary representations and warranties and events of default.  Complying with the covenants contained in the 2022 Credit Agreement could make it more difficult for us to execute our business strategy.  Further, in the event of default by us under the 2022 Credit Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the 2022 Credit Agreement which would harm our financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our existing or any future debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. It will also depend on financial, business or other factors affecting our operations, many of which are beyond our control. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund operations, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligations, an event of default may occur under any of our debt instruments which could result in an acceleration of such debt upon which we may be required to repay all the amounts outstanding under some or all of our debt instruments.  Such an acceleration of our debt obligations could harm our financial condition. From time to time, we may seek to retire or repurchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Any such repurchases or exchanges would be on such terms and at such prices as we determine, and will depend on current market conditions, our liquidity needs, any restrictions in our contracts and other factors. The amounts involved in such transactions could be material.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their notes, we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. Even if holders of the Convertible Notes do not elect to convert their notes, we are required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability when the conditional conversion feature is triggered, which results in a material reduction of our net working capital. For example, as of December&#160;31, 2022, the conditional conversion feature was triggered and our 2024 Convertible Notes are classified as a current liability. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of our Convertible Notes, to the extent we deliver shares upon conversion, will dilute the ownership interests of existing stockholders. Any sales in the public market of the Convertible Notes or our common stock issuable upon conversion of the Convertible Notes could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If proprietary or partnered product candidates are approved for commercialization but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming that existing or future proprietary or partnered product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these newly-approved products, including, among others:</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which the use of these products is restricted by the approved product label;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price of these products relative to other therapies for the same or similar treatments;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which reimbursement for these products and related treatments will be available from third party payers including government insurance programs and private insurers;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic or biosimilar competitors to these products; </span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our partners to fund sales and marketing efforts; and</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of the sales and marketing efforts of our partners.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these proprietary or partnered products do not gain or maintain market acceptance or experience reduced sales resulting in commercial performance below that which was expected or projected, the revenues we expect to receive from these products will be diminished which could harm our ability to fund future operations, including conduct acquisitions, execute our planned share repurchases, or affect our ability to use funds for other general corporate purposes and cause our business to suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our proprietary or partnered product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.&#160;&#160; </span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain and maintain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties.&#160;We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024, which we believe cover the products and product candidates under our existing collaborations, and Hylenex.&#160;Although we believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases, upon expiration of our patents other pharmaceutical companies may (if they do not infringe our other patents) seek to compete with us by developing, manufacturing and selling biosimilars to the active drug ingredient in our ENHANZE technology used by our partners in combination with their products.&#160;Any such loss of patent protection or proprietary rights could lead to a reduction or loss of revenues, incentivize one or more of our key ENHANZE partners to terminate their relationship with us and impact our ability to enter into new collaboration and license agreements.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have sufficient insurance coverage.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture, testing, marketing and sale of pharmaceutical products and medical devices involves the risk of product liability claims by consumers and other third parties. Product liability claims may be brought by individuals seeking relief for themselves, or by groups seeking to represent a class of injured patients.  Further, third-party payers, either individually or as a putative class, may bring actions seeking to recover monies spent on one of our products. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the insurance coverage may not be sufficient and could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our partnered product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third-party pharmaceutical product will give rise to liability claims against us. Product liability claims can also result in additional regulatory consequences including, but not limited to, investigations and regulatory enforcement actions, as well as recalls, revocation or approvals, or labeling, marketing or promotional restrictions or changes.  Product liability claims could also harm our reputation and the reputation of our products, adversely affecting our ability to market our products successfully.  In addition, defending a product liability lawsuit is expensive and can divert the attention of our key employees from operating our business.  Such claims can also impact our ability to initiate or complete clinical trials.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partners do not achieve projected development, clinical, or regulatory  goals in the timeframes  publicly announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, , our business, financial condition , and results of operations may be adversely affected or delayed.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our and our collaborators&#8217; control. If scientific, regulatory, strategic or other factors cause a collaboration partner to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management&#8217;s attention from our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates. </span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions could disrupt our business and impact our financial condition.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to augment and extend our revenue   we acquired Antares in May 2022 and we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to issue additional convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain acquisitions may impact our relationship with existing or potential partners who are competitive with the acquired business, products or technologies;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel of an acquired company may decide not to work for us.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any future acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability between different tax jurisdictions, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on September 30, 2021, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. This resulted in substantially and disproportionately increasing our reported net income and our earnings per share compared to our operating results for 2021. Historical and future comparisons to these amounts are not, and will not be, indicative of actual profitability trends for our business. Starting in 2022, we recorded income tax expense at an estimated tax rate that approximate statutory tax rates, resulting a reduction in our net income and net income per share.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is subject to significant volatility.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended December&#160;31, 2022 were $59.46 and $31.36, respectively. In addition to the other risks and uncertainties described elsewhere in this Annual Report on Form 10-K and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the presence of competitive products to those being developed by our partners;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure (actual or perceived) of our partners to devote attention or resources to the development or commercialization of partnered products or product candidates licensed to such partner;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a dispute regarding our failure, or the failure of one of our partners, to comply with the terms of a collaboration agreement; </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the termination, for any reason, of any of our collaboration agreements;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resignation, or other departure, of members of management or our Board of Directors;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the healthcare industry;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pandemics or other global crises;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the financial markets;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost associated with obtaining regulatory approval for any of our proprietary or partnered product candidates;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure, for any reason, to secure or defend our intellectual property position;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or delay of applicable regulatory bodies to approve our proprietary or partnered product candidates;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of safety or tolerability issues associated with our proprietary or partnered products or product candidates;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our or our partners&#8217; clinical trials to meet efficacy endpoints;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions or delays in the conduct of  our or our partners&#8217; clinical trials or securing of regulatory approvals;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory action with respect to our proprietary or partnered products and product candidates such as loss of regulatory approval to commercialize such products, clinical holds, imposition of onerous requirements for approval or product recalls;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to generate product revenues anticipated by investors;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product collaboration candidate; </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of additional debt and/or equity securities by us;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to obtain financing on acceptable terms or at all; </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a restructuring of our operations;</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to execute our share repurchase program in the time and manner we expect due to market, business, legal or other considerations; or </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a conversion of the Convertible Notes into shares of our common stock.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a &#8220;Well-Known Seasoned Issuer&#8221; and may file automatic shelf registration statements at any time with the SEC. Sales of substantial amounts of shares of our common stock or other securities under any future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult. First, our Board of Directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation, does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions in our charter documents may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in connection with our Convertible Notes issuances, we have entered into indentures, dated as of November&#160;18, 2019, of March 1, 2021 and August 18, 2022 (the&#8220;Indentures&#8221;) with The Bank of New York Mellon Trust Company, N.A., as trustee. Certain provisions in the Indentures could make it more difficult or more expensive for a third party to acquire us.  For example, if a takeover would constitute a fundamental change, holders of the Convertible Notes will have the right to require us to repurchase their Convertible Notes in cash.  In addition, if a takeover constitutes a make-whole fundamental change, we may be required to increase the conversion rate for holders who convert their Convertible Notes in connection with such takeover. In addition, a change of control constitutes an event of default under our 2022 Credit Agreement.  Such event of default could result in the administrative agent or the lender parties thereto declaring the unpaid principal, all accrued and unpaid interest, and all other amounts owing or payable under the 2022 Credit Agreement to be immediately due and payable.  In either case, and in other cases, our obligations under the Convertible Notes and the Indentures could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical and medical device companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products and our partners&#8217; products and product candidates. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our or our partners&#8217; products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that our partners&#8217; change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive to our partners. For example, the approval of the HYQVIA BLA was delayed by the FDA until we and our partner provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was ultimately approved by the FDA, the FDA or other foreign regulatory agency may, at any time, halt our and our partners&#8217; development and commercialization activities due to safety concerns. In addition, even if our proprietary or partnered products are approved, regulatory agencies may also take post-approval action limiting or revoking our or our partners&#8217; ability to sell these products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our proprietary or our partnered products and therefore harm our financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of these regulations, in addition to our partners, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers&#8217; and manufacturers&#8217; processes, are in compliance with cGMP and other FDA regulations. If our partners, we, or our contract suppliers and manufacturers, fail these inspections, our partners may not be able to commercialize their products in a timely manner without incurring significant additional costs, or at all.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our and our partners&#8217; products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our and our partners&#8217; products and product candidates are considered to be drug/device combination products by the FDA, consisting of a drug product and a drug delivery device. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of the product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our and our partners&#8217; products and product candidates, the primary mode of action is typically attributable to the drug component of the products, which means that the Center of Drug Evaluation and Research has primary jurisdiction over the products&#8217; premarket development and review. These products and product candidates will be and have been subject to the FDA drug approval process and will not require a separate FDA clearance or approval for the device component. Even though these products and product candidates will not require a separate FDA clearance or approval, both the drug and device centers within the FDA will review the marketing application for safety, the efficacy of both the drug and device component, including the design and reliability of the injector, and a number of other different areas, such as to ensure that the drug labeling adequately discloses all relevant information and risks, and to confirm that the instructions for use are accurate and easy to use. These reviews could increase the time needed for review completion of a successful application and may require additional studies, such as usage studies, to establish the validity of the instructions for use. Such reviews and requirements may extend the time necessary for the approval of drug-device combinations. In the case of combination product candidates for which we or our partners are seeking approval via the ANDA pathway, it is also possible that the agency may decide that the unique nature of combination products leads it to question the claims of bioequivalence and/or same labeling, resulting in the need to refile the application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This may result in delays in product approval and may cause us or our partners to incur additional costs associated with testing, including clinical trials. Approval via the 505(b)(2) pathway may also result in additional selling expenses and a decrease in market acceptance due to the lack of substitutability by pharmacies or formularies. In addition, approval under the 505(b)(2) or ANDA regulatory pathway is not a guarantee of an exclusive position for the approved product in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, although precedent and guidance exist for the approval of such combination products, the FDA could change what it requires or how it reviews submissions. Changes in review processes or the requirement for the study of combination products could delay anticipated launch dates or be cost prohibitive. Such delay or failure to launch these products or devices could adversely affect our revenues and future profitability. If our or our partners&#8217; combination product candidates are approved, we, our partners, and any of our respective contractors will be required to comply with FDA regulatory requirements related to both drugs and devices. For instance, drug/device combination products must comply with both the drug cGMPs and device QSRs. Depending on whether the drug and device components are at the same facility, however, the FDA regulations provide a streamlined method to comply with both sets of requirements. The FDA has specifically promulgated guidance on injectors, which discuss the FDA&#8217;s requirements with respect to marketing application and post-market injector design controls and reliability analyses. Additionally, drug/device combination products will be subject to additional FDA and constituent part reporting requirements. Compliance with these requirements will require additional effort and monetary expenditure.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act (FCPA), false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency (or &#8220;sunshine&#8221;) laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of products outside the U.S. will also likely subject us to the FCPA and foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of certain development and commercialization of our products.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:</span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to obtain patent protection for our products and technologies;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and</span></div><div style="margin-top:4pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks to protect the names of our products (e.g. Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys&#8217; fees and costs, for past infringement if it is ultimately determined that our products infringe a third party&#8217;s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management&#8217;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain other jurisdictions, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses, that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved or cleared by the FDA or other foreign regulatory agencies. However, physicians and other healthcare practitioners may prescribe drug products and use medical devices for off-label or unapproved uses, and such uses are common across some medical specialties. Although the FDA does not regulate a physician&#8217;s choice of medications, treatments or product uses, the Federal Food, Drug and Cosmetic Act and FDA regulations significantly restrict permissible communications on the subject of off-label uses of drug products and medical devices by pharmaceutical and medical device companies. As the sponsors of FDA approved products, we and our partners will not only be responsible for the actions of the companies but also can be held liable for the actions of employees and contractors, requiring that all employees and contractors engaging in regulated functions, such as product promotion, be adequately trained and monitored, which requires time and monetary expenditures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that a company has improperly promoted a product &#8220;off label&#8221; or otherwise not in accordance with the agency&#8217;s promotional requirements, the FDA may issue a warning letter or seek other enforcement action to limit or restrict certain promotional activities or materials or seek to have product withdrawn from the market or seize product, among other enforcement requirements. In addition, a company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil fines, criminal fines and penalties, civil damages and exclusion from federal funded healthcare programs such as Medicare and Medicaid and/or government contracting, consent decrees and corporate integrity agreements, as well as potential liability under the federal FCA and applicable state false claims acts. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by such conduct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in addition to the regulatory restrictions on off-label promotion, there are other FDA restrictions on and requirements concerning product promotion and advertising, such as requirements that such communications be truthful and non-misleading and adequately supported. The FDA also has requirements concerning the distribution of drug samples. The FDA and other authorities may take the position that we are not in compliance with promotional, advertising, and marketing requirements, and, if such non-compliance is proven, we may be subject to significant liability, including but not limited to administrative, civil and criminal penalties and fines, in addition to regulatory enforcement actions.  </span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are controlled substances and accordingly, we, and our contractors, distributors, prescribers, and dispensers must comply with Federal controlled substances laws and regulations, enforced by the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;), as well as state-controlled substances laws and regulations enforced by state authorities. These requirements include, but are not limited to, registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, and other requirements. These requirements are enforced by the DEA through periodic inspections. Not only must continuous controlled substance registration be maintained, but compliance with the applicable controlled substance requirements will require significant efforts and expenditures, which could also inhibit successful commercialization. These compliance requirements also add complexity to the distribution, prescribing and dispensing of certain of our products that may also impact commercialization, including the establishment of anti-diversion procedures. If we and our contractors, distributors, prescribers, and dispensers do not comply with the applicable controlled substance requirements, we or they may be subject to administrative, civil or criminal enforcement, including civil penalties, refusals to renew necessary registrations, revocation of registrations, criminal proceedings, or consent decrees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny. if patent laws or the interpretation of patent laws change, our business may be adversely impacted because we may lose the ability to enforce our intellectual property rights against competitors develop and commercialize products based on our discoveries.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from &#8220;first to invent&#8221; to &#8220;first to file,&#8221; implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.</span></div><div style="margin-top:6pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party reimbursement and customer contracts are not available, our proprietary and partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; ability to earn sufficient returns on proprietary and partnered products will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third-party payers may not establish adequate levels of reimbursement for the products that we and our partners commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners&#8217; products, resulting in less revenue to us.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our proprietary or partnered products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third-party payers increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003 and the Affordable Care Act of 2010 (ACA), could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our product and our partners&#8217; ability to sell their products.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our business may be impacted by changes in federal reimbursement policy resulting from executive actions, federal regulations, or federal demonstration projects.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal administration and/or agencies, such as the Centers for Medicare &amp; Medicaid Services, or CMS, have announced a number of demonstration projects, recommendations and proposals to implement various elements described in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug pricing blueprint. CMS, the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. For example, in November 2020, former President Trump announced the interim final rule to implement the Most Favored Nations drug pricing model seeking to tie Medicare payment rates to an international index price. This final rule was subsequently rescinded by CMS. Additionally, a number of Congressional committees have also held hearings and evaluated proposed legislation on drug pricing and payment policy which may affect our business. For example, in July 2019, the Senate Finance Committee advanced a bill that in part would penalize pharmaceutical manufacturers for increasing drug list prices covered by Medicare Part B and Part D, faster than the rate of inflation, and cap out-of-pocket expenses for Medicare Part D beneficiaries. Several other proposals have been introduced that, if enacted and implemented, could affect access to and sales of our and our partners&#8217; products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription medication from Canada or other countries. For example, in August 2022, &#8220;The Inflation Reduction Act of 2022&#8221; was enacted which will, among other things, allow and require the federal government to negotiate prices for some drugs covered under Medicare Part B and Part D, require drug companies to pay rebates to Medicare if prices rise faster than inflation for drugs used by Medicare beneficiaries and cap out-of-pocket spending for individuals enrolled in Medicare Part D.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this dynamic environment, we are unable to predict which or how many federal policy, legislative or regulatory changes may ultimately be enacted. To the extent federal government initiatives decrease or modify the coverage or reimbursement available for our or our partners&#8217; products, limit or impact our decisions regarding the pricing of biopharmaceutical products or otherwise reduce the use of our or our partners&#8217; U.S. products, such actions could have a material adverse effect on our business and results of operations. </span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, individual states are considering proposed legislation and have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, private payers in the US, including insurers, pharmacy benefit managers (PBMs), integrated healthcare delivery systems, and group purchasing organizations, are continuously seeking ways to reduce drug costs.  Many payers have developed and continue to develop ways to shift a greater portion of drug costs to patients through, for example, limited benefit plan designs, high deductible plans and higher co-pay or coinsurance obligations. Consolidation in the payer space has also resulted in a few large PBMs and insurers which place greater pressure on pricing and utilization negotiations for our and our partners&#8217; products in the U.S., increasing the need for higher discounts and rebates and limiting patient access and utilization.  Ultimately, additional discounts, rebates and other price reductions, fees, coverage and plan changes, or exclusions imposed by these private payers on our and our partners&#8217; products could have an adverse event on product sales, our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. CMS recently has issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from government pricing calculations to avoid payment of increased Medicaid rebates. In recent years, other pharmaceutical manufacturers have been named in class action lawsuits challenging the legality of their co-pay programs under a variety of federal and state laws. Our co-pay coupon programs could become the target of similar lawsuits or insurer actions. It is possible that the outcome of litigation against other manufacturers, changes in insurer policies regarding co-pay coupons, and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these programs.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. Government price reporting regulations are complex and may require a manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition and rapid technological change that could result in the development of products by others that are competitive with our proprietary and partnered products, including those under development.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary and partnered products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. The competitors for Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant include, but are not limited to, Bausch Health Companies, Inc.&#8217;s FDA-approved product, Vitrase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.&#8217;s product, Amphadase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a bovine (bull) hyaluronidase. For our ENHANZE technology, such competitors may include major </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and partnered products and product candidates or that could render our and our partners&#8217; products, technologies and product candidates obsolete or noncompetitive.</span></div><div style="margin-top:4pt;text-align:justify"><span><br/></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to attract, hire and retain key personnel our business could be negatively affected.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the performance of key employees with relevant experience. We depend substantially on our ability to hire, train, motivate and retain high quality personnel. If we are unable to identify, hire and retain qualified personnel, our ability to support current and future alliances with strategic partners could be adversely impacted. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we were to lose key personnel, we may lose some portion of our institutional knowledge and technical know-how, potentially causing a disruption or delay in one or more of our partnered development programs until adequate replacement personnel could be hired and trained. In addition, we do not have key person life insurance policies on the lives of any of our employees which would help cover the cost of associated with the loss of key employees.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including laboratories, offices and other research facilities, are headquartered in San Diego, California. We have additional facilities in Ewing, New Jersey and Minnetonka, Minnesota. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, pandemics, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, tornadoes, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our partners, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors&#8217; insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our partners&#8217; research and development programs.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information technology storage and access systems and are devoting resources to protect against such intrusion. Cyberattacks could render us or our partners unable to utilize key systems or access important data needed to operate our business.&#160;The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners&#8217; information technology storage and access systems could result in the breakdown or other service interruption, or the disruption of our ability to use such systems or disclosure or dissemination of  proprietary and confidential information that is electronically stored, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials or personal information belonging to us, our staff, our patients, customers and/or other business partners which could result in a material adverse impact on our business, operating results and financial condition. We continue to invest in monitoring, and other security and data recovery measures to protect our critical and sensitive data and systems. However, these may not be adequate to prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of our systems. In addition, our cybersecurity insurance may not be sufficient to cover us against liability related to any such breaches. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results, financial condition and reputation.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_19"></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.36pt">Unresolved Staff Comments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt">Properties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and research facilities are currently located in San Diego, California. In addition, we have an office in Ewing, New Jersey. We also lease a building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. As of December&#160;31, 2022, we leased an aggregate of approximately 194,000 square feet of space. We believe our facilities are adequate for our current and near-term needs.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_25"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position. </span></div><div id="i732e51618ba84e17b469190f5cc138c6_28"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_31"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i732e51618ba84e17b469190f5cc138c6_34"></div><div style="margin-top:14pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#8220;HALO.&#8221; As of February&#160;14, 2023, we had approximately 69,016 stockholders of record and beneficial owners of our common stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock. We currently intend to retain available cash for funding operations, stock repurchases and other capital initiatives; therefore, we do not expect to pay any dividends on our common stock in the foreseeable future. Any future determination to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Equity Securities by the Issuer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we announced that the Board of Directors authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock over a three-year period. The shares were purchased through open market transactions and through an Accelerated Share Repurchase (ASR) agreement. During 2021, we repurchased 4.6 million shares of common stock for $200.0&#160;million at an average price of $43.02 under the program. We completed the program in October 2021 having repurchased a total of 22.3 million shares for $550.0 million at an average price per share of $24.72. We retired the repurchased shares and they resumed the status of authorized and unissued shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board of Directors authorized our second share repurchase program, to repurchase up to $750.0 million of our outstanding common stock over a three-year period. In August 2022, we entered into an ASR agreement with Bank of America to repurchase $109.8&#160;million of our common stock. At inception, pursuant to the agreement, we paid $109.8&#160;million to Bank of America and took an initial delivery of 2.0&#160;million shares. In December 2022, we finalized the transaction and received an additional 0.4&#160;million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares. Under this program, through December&#160;31, 2022, we repurchased 8.4 million shares of common stock for $350.0 million at an average price of $41.69.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph and Cumulative Total Return</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notwithstanding any statement to the contrary in any of our previous or future filings with the SEC, the following information relating to the price performance of our common stock shall not be deemed to be &#8220;filed&#8221; with the SEC or to be &#8220;soliciting material&#8221; under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and it shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares Halozyme Therapeutics, Inc.&#8217;s cumulative five-year total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph tracks the performance of a $100 investment in our common stock and in each of the indexes (with the reinvestment of all dividends) from December&#160;31, 2017 to December 31, 2022. The historical stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:6pt;text-align:center"><img src="halo-20221231_g4.jpg" alt="halo-20221231_g4.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:37.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$72</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$88</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$211</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$198</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$281</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$133</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$192</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$235</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Biotechnology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$114</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130</span></td></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_37"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt">(Reserved)</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_40"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt"> Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical information, the following discussion contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to risks described in the Part I, Item&#160;1A, Risks Factors, and elsewhere in this Annual Report. References to &#8220;Notes&#8221; are Notes included in our Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving&#160;the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids.&#160;We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the  patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc.  (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC)(&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme, to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 and recent key events are as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, Roche announced that the Phase 3 IMscin001 study evaluating a subcutaneous formulation of Tecentriq&#174; (atezolizumab) with ENHANZE met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with IV infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic non-small cell lung cancer for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In November 2022, Roche submitted a BLA to the FDA and a MAA to the EMA for SC atezolizumab with ENHANZE across all approved indications of IV Tecentriq. In January 2023, the FDA accepted the BLA with a PDUFA goal date of September 15, 2023.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2022, Roche submitted an Initial Market Application (IMA) for Mabthera SC to the Center for Drug Evaluation (CDE) in China.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2022, Roche Pharmaceuticals China announced the approval of Herceptin SC (trastuzumab injection subcutaneous with ENHANZE) in China for the treatment of patients with early-stage and metastatic HER2-positive breast cancer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2022, Roche submitted an IMA for the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pertuzumab) and Herceptin for subcutaneous injection (Phesgo&#8482;) to the CDE in China.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, Roche initiated a phase 3 study evaluating OCREVUS (ocrelizumab) with ENHANZE in subjects with multiple sclerosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">argenx</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">In November 2022, argenx announced the acceptance of the BLA for SC efgartigimod for the treatment of adults with generalized myasthenia gravis (gMG). In January 2023, argenx announced that FDA extended the PDUFA date to June 20, 2023.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2022, argenx announced the submission of a Marketing Authorization Application to the EMA for SC efgartigimod for the treatment of adults with gMG.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, argenx initiated a phase 2 study evaluating efgartigimod with ENHANZE in subjects with bullous pemphigoid.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, argenx announced that data from argenx&#8217;s phase 3 ADAPT-SC study evaluating SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of gMG achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (efgartigimod alfa-fcab) intravenous IV formulation in gMG patients. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chugai</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, Chugai Pharmaceutical Co., Ltd. (a Member of the Roche Group) announced the submission of a NDA in Japan for the fixed-dose SC combination of pertuzumab and trastuzumab (same monoclonal antibodies as in Perjeta and Herceptin) with ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of a targeted antibody administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.  The license gives Chugai exclusive access to ENHANZE drug delivery technology for an undisclosed target. Under the terms of the agreement, we received an upfront payment of $25 million and Chugai is obligated to make future payments of up to $160 million, in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones. We will also be entitled to receive royalties on sales of commercialized medicines using our ENHANZE technology.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2022, Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients with advanced or metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (PALOMA-2).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ViiV</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study in subjects with HIV to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a broadly neutralizing antibody, administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022, Takeda achieved a sales milestone for HYQVIA, triggering a payment of $10 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2022, Takeda filed a sBLA for the potential expanded use of HYQVIA for pediatric indication for primary immunodeficiency.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2022, Takeda announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Immunoglobulin infusion 10% (Human) with rHuPH20), for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and Takeda confirmed its intention to submit regulatory applications in the United States and European Union in its fiscal year 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BMS plans to initiate a Phase 3 trial in early 2023 to demonstrate the drug exposure level of nivolumab and relatlimab fixed-dose combination with ENHANZE is not inferior to IV administration in participants with previously untreated metastatic or unresectable melanoma (Relativity-127).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, BMS initiated a Phase 3 trial to compare the drug levels of nivolumab with ENHANZE administered subcutaneously versus IV administration in participants with melanoma following complete resection (CheckMate-6GE).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, BMS nominated an undisclosed target resulting in a $5 million payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2023, we elected to redeem on March 17, 2023 all of our remaining outstanding 1.25% convertible senior notes due 2024. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we completed the sale of $720.0 million aggregate principal amount of the 2028 Convertible Senior Note. We used a portion of the net proceeds to facilitate an induced conversion of a portion of the 2024 Convertible Senior Notes. In connection with the induced conversion, we paid the holders $77.6 million in cash and issued 1.51 million shares.  We also used a portion of the net proceeds to repay the $250.0 million term loan facility due 2026 and the $120.0 million revolving credit facility.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we entered into an amendment to our credit agreement that increased the size of our revolving credit facility from $350 million to $575 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the third quarter of 2022, we accelerated $100 million share repurchase from 2023 into 2022. We repurchased 2.1 million shares of common stock in open market purchases for $90.2 million at an average price per share of $43.09 and entered into an ASR agreement to repurchase $109.8 million of our common stock for which we took an initial delivery 2.0 million shares. In December 2022, we finalized the ASR transaction and received an additional 0.4&#160;million shares for a total of 2.4 million shares at an average price per share of $45.62. During 2022, we repurchased a total of 4.5 million shares for $200.0 million at an average price per share of $44.44. As of December 31, 2022, we repurchased a total of 8.4 million shares for $350.0 million at an average price per share of $41.69 under our $750 million 3-year share repurchase plan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we completed an $150 million ASR that was initiated in December of 2021, resulting in the total repurchase of 3.9 million shares at a price of $38.51 per share.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we announced the commercial launch of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, we completed the acquisition of Antares resulting in an expansion of our commercial portfolio of proprietary and partnered products and the potential for future growth through new agreements. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement that provided for a $350 million revolving credit facility and a $250 million term loan facility. The proceeds from a $120 million draw on the revolving credit facility and the $250 million term facility were used to fund a portion of the Antares acquisition, refinance Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, we entered into an agreement for assignment and assumption of a lease with Seismic Software, Inc. pursuant to which effective January 1, 2023 we assumed Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately 73,238 square feet of space in office and research facilities. The premises are intended to serve as our new headquarters which we occupied on January 1, 2023.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December 31, 2022 and 2021 </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalty revenue was $360.5 million in 2022 compared to $203.9 million in 2021. The increase was mainly driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche in all geographies and contribution from new device royalty revenue as a result of the Antares acquisition, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche. We expect royalty revenue to continue to grow as a result of our 2020 ENHANZE partner product launches, offsetting the ongoing impact from biosimilars related to our mature ENHANZE partner products.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product sales, net were as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:48.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total product sales, net increased by $86.8 million in 2022 compared to 2021, primarily due to contribution from our proprietary and device partnered products as the result of the Antares acquisition. We expect that sales of proprietary products will grow in future years as we work to expand market share in the TRT market. We expect that product sales of bulk rHuPH20 and device partnered products will fluctuate in future periods based on the needs of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues Under Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues under collaborative agreements were as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:48.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Upfront license fees, license fees for the election of additional targets, event-based payments, license maintenance fees and amortization of deferred upfront and other license fees:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,575)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees decreased by $35.0 million in 2022, compared to 2021 primarily due to the timing of milestones driven by partner activities. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our partners&#8217; ability to meet various clinical and regulatory milestones set forth in such agreements and our ability to obtain new collaborative agreements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of our proprietary and device partnered products and bulk rHuPH20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales were $139.3 million in 2022 compared to $81.4 million in 2021. The increase of $57.9 million in cost of product sales was mainly due to an increase in sales in our proprietary, partnered products as a result of the Antares acquisition and amortization of inventory step-up associated with purchase accounting for the Antares acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amortization of intangibles expense was $43.1 million for 2022. The amortization of intangibles expense is due to the acquisition of Antares in May 2022, in which we acquired intangible assets that are amortized over their useful lives.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, preclinical and regulatory activities related to our ENHANZE collaborations and our development platform. Research and development expenses were $66.6 million in 2022 compared to $35.7 million in 2021. The increase of $30.9 million is primarily due to planned investments in ENHANZE and an increase in compensation expense related to the ongoing combined larger workforce as a result of the Antares acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative (SG&amp;A) expenses consist primarily of salaries and related costs for personnel in executive, selling and administrative functions as well as professional fees for legal and accounting, business development, commercial operations support for proprietary products and alliance management and marketing support for our collaborations. SG&amp;A expenses were $143.5 million in 2022 compared to $50.3 million in 2021. The increase of $93.2 million, was primarily due to one-time Antares Pharma acquisition costs and an increase in compensation expense related to the ongoing combined larger workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $16.9 million in 2022 compared to $7.5 million in 2021. The increase of $9.4 million was primarily due an increase in interest expense related to the 2022 term loans, the revolving credit facility and the 2028 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income tax expense was $46.8 million in 2022 compared to income tax benefit of $154.2 million in 2021. The increase in income tax expense is due to the recording of our first year of income tax expense in the current year whereas in the prior year period there was an income tax benefit due to the release of the valuation allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December 31, 2021 and 2020</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to changes in financial condition and the results of operations for fiscal year 2021 compared to fiscal year 2020, refer to Part II - Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, which was filed with the SEC on February&#160;22, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $362.8 million. We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i)&#160;new collaborative agreements; (ii)&#160;expansions or revisions to existing collaborative relationships; (iii)&#160;private financings; (iv)&#160;other equity or debt financings; (v) monetizing assets; and/or (vi)&#160;the public offering of securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, draw on our existing line of credit, offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital to raise funds for additional working capital, capital  expenditures, share repurchases, acquisitions or for other general corporate purposes. Our material cash requirements include the following contractual and other obligations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt consists of convertible notes. The aggregate principal amount of our convertible notes is $1,538.5 million, with $13.5 million classified as short term. Future interest payments associated with our convertible notes total $48.9 million, with $9.3 million payable within 12 months.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease arrangements related to our office and research facilities and certain autos under non-cancelable operating leases. As of December&#160;31, 2022, we have lease payment obligations of $47.0 million, with $7.8 million payable within 12 months.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third-party manufacturing obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracted with third-party manufacturers for the supply of bulk rHuPH20, fill/finish of Hylenex recombinant, other proprietary products and partnered products. Under these agreements, we are required to purchase certain quantities each year during the terms of the agreements. Contractual obligations for purchases of goods or services include agreements that are enforceable and legally binding to us and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts disclosed here were limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee. As of December&#160;31, 2022, we had third-party manufacturing obligations of $97.8 million, payable within 12 months.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other purchase obligations and commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations represent an estimate of all open purchase orders and contractual obligations in the ordinary course of business for which we have not received the goods or services. We also have commitments which represents minimum royalty payments to be paid in accordance with the TLANDO exclusive license agreement with Lipocine. As of December&#160;31, 2022, we had other purchase obligations and other commitments of $48.7 million, with $44.2 million payable within 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected timing of payments of the obligations above is estimated based on information we have as of December&#160;31, 2022. Timing of payments and actual amounts paid may be different, depending on the time of receipt of goods or services, or changes to agreed-upon amounts for some obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital uses and requirements and anticipated sources of funds to satisfy these requirements depend on numerous forward-looking factors. These factors may&#160;include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of investments in our ENHANZE platform and auto-injector technology including development of new versions of rHuPH20 and auto-injector devices;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to develop and validate additional manufacturing processes of rHuPH20, auto-injectors, and testosterone replacement therapies;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to expand the number of collaboration partner products developed and launched by partners including costs to scale-up manufacturing;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of royalties and milestones from our partners;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaborative, licensing and other arrangements that we may&#160;establish; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license new products, technologies or businesses and invest in development.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations was $240.1 million in 2022 compared to $299.4 million in 2021. The $59.3 million decrease in cash provided by operations was mainly due to an increase in transaction expenses associated with the Antares acquisition and an increase in working capital spend, partially offset by an increase in royalties revenue for 2022 compared to the prior year.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $487.0 million in 2022 compared to net cash used in investing activities of $406.3 million in 2021. The increase in cash used in investing activities was primarily due to the acquisition of Antares, partially offset by an increase in cash from the sale of marketable securities and the sale of assets in 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $362.4 million in 2022, compared to net cash provided by financing activities of $77.9 million in 2021, mainly due to $702.0 million cash received from the 2028 Convertible Notes offering and $291.6 million decrease related to the 2024 Convertible Notes induced conversion, a $150.1 million decrease in repurchase of common stock and a $1.5 million increase in net proceeds from the issuance of common stock under equity incentive plans, partially offset by, $784.9 million cash received from the 2027 Convertible Notes offering in the prior year and a $69.1 million payment for the Capped Call Transactions during the current year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our Board of Directors approved a $550 million share repurchase program, pursuant to which we could repurchase our issued and outstanding shares of common stock from time to time. We completed the share repurchase program in October 2021 and retired the repurchased shares. In December 2021, we announced our second share repurchase program, to repurchase up to $750.0 million of our outstanding common stock over a three-year period. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within the notes to the consolidated financial statements for additional information regarding our share repurchases.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Long-Term Debt</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th  and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the 5 consecutive business days immediately after any 5 consecutive trading day period (such 5 consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2028 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of December&#160;31, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#8217; fee of $12.7 million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3 million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Operations for the twelve months ended December&#160;31, 2022. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which is included in other income (expense) of the consolidated statements of income. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment of $13.5 million to effect the redemption in March 2023.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250 million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term Facility were used to fund a portion of the Antares acquisition, refinance Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increases the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the revolving credit facility are otherwise unchanged. Concurrently with the entry into the Amendment, the Company repaid the entire outstanding term loan facility and repaid all outstanding loans under the revolving credit facility under the Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, the revolving credit facility was undrawn.   </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Our significant accounting policies are outlined in Note 2 to the Consolidated Financial Statements included in the Form 10-K. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Methodology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Judgment and Uncertainties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Effect if Actual Results Differ From Assumptions</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For collaborative agreements, we are entitled to receive event-based payments subject to the collaboration partner's achievement of specified development and regulatory milestones. We recognize revenue when it is deemed probable that these milestones will be achieved, which could be in a period prior to its actual occurrence. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones, and if necessary, adjust our estimate of the overall transaction price.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue is recognized when we determine it is probable a milestone will be achieved. This assessment is based on our past experience with our collaboration partners, market insight and partner communication. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A revenue reversal will be required in the event it is determined that achievement of a milestone, previously deemed probable, will not occur. This reversal may be material. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For collaborative agreements, royalty revenue is recognized in the period the underlying sales occur, but we do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The amount of royalty revenue recognized for the quarter is estimated using our knowledge of past royalty payments, market insight and an estimate made by our collaboration partners provided in a preliminary report.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A final royalty report and associated royalty payment is received approximately 60 days after quarter-end. If necessary, a true-up is recorded at that time if there is a difference from the initial estimated royalty revenue recorded. To date, the true-up entries have not been material.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For collaborative arrangements, when necessary, we perform an allocation of the upfront amount based on relative stand-alone selling prices (SSP) of licenses for individual targets. We determine<br/>license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The inputs used in the valuation model to determine SSP are based on estimates utilizing market data and information provided by our collaboration partners. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.112%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share-Based Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Methodology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Judgment and Uncertainties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Effect if Actual Results Differ From Assumptions</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We maintain a Stock Incentive Plan, which provides for share-based payment awards, including stock options, restricted stock and performance awards. We determine the fair value of our stock option awards at the date of grant using a Black-Scholes model. We determine the fair value of our restricted stock awards at the date of grant using the closing market value of our common stock on the date of grant. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option-pricing models and generally accepted valuation techniques require management to make assumptions and to apply judgment to determine the fair value of our awards. These assumptions and judgments include estimating the future volatility of our stock price, expected dividend yield and future employee stock option exercise behaviors. Changes in these assumptions can materially affect the fair value estimate. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our performance awards require management to make assumptions regarding the likelihood of achieving long-term Company goals.<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not currently believe there is a reasonable likelihood that there will be a material change in estimates or assumptions we use to determine stock-based compensation expense. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to changes in share-based compensation expense that could be material. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If actual results are not consistent with the assumptions used, the share-based compensation expense reported in our financial statements may not be representative of the actual economic cost of the share-based compensation. A 10% change in our share-based compensation expense for the year ended December&#160;31, 2022 would have affected pre-tax earnings by approximately $2.4&#160;million in 2022. </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business Combinations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Antares acquisition, as disclosed in Note 3, the acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, under the acquisition method of accounting we recognized the identifiable assets acquired and the liabilities assumed at their fair values as of the date of acquisition. We measured the goodwill as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date fair values of the identifiable assets acquired and liabilities assumed.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant estimates and assumptions used in estimating the fair value of acquired technology and other identifiable intangible assets include future cash flows that we expect to generate from the acquired assets.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, we could record impairment charges. In addition, we have estimated the economic lives of certain acquired assets and these lives are used to calculate amortization expense. If our estimates of the economic lives change, amortization expenses could be accelerated or slowed.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A contingent liability with a value of $15.7&#160;million was assumed related to TLANDO. The fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. We remeasure the fair value of the contingent liability on a quarterly basis.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The inputs used in the Monte Carlo simulation include significant estimates and assumptions which include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If there is a change in the inputs and assumptions used to fair value the contingent liability, that could have a material impact on our consolidated balance sheet and statements of income.</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill and Intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We estimate the fair value of acquired intangible assets that have finite useful lives whenever an event or change in circumstances indicates that the carrying value of the asset may not be recoverable. We test for potential impairment of goodwill and other intangible assets that have indefinite useful lives annually in the second fiscal quarter or whenever indicators of impairment arise.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant estimates and assumptions used in estimating the fair value of the intangible assets.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A change in any of the estimates and assumptions used may result an impairment charge in our consolidated statement of income.</span></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any, on us.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_43"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.3pt">Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our cash equivalents and marketable securities consisted of investments in money market funds, asset-backed securities, U.S. Treasury securities, corporate debt securities, agency bonds and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of December&#160;31, 2022, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_46"></div><div style="margin-top:14pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt">Financial Statements and Supplementary Data</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are annexed to this report beginning on page F-1.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_49"></div><div style="margin-top:14pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.52pt">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_52"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.3pt">Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we completed the acquisition of Antares. Under guidelines established by the SEC, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. In conducting our evaluation of the effectiveness of our internal control over financial reporting, we excluded the internal control activities of Antares from our evaluation for the period ended December&#160;31, 2022. We are in the process of integrating Antares into our system of internal control over financial reporting. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted above, there have been no significant changes in our internal control over financial reporting that occurred during the period ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) and Rule&#160;15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the financial results of Antares in the consolidated financial statements from the date of acquisition. Antares represented approximately 9% of total assets as of December&#160;31, 2022 and 17% of total revenues, for the year ended December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022.  In conducting its assessment of the effectiveness of our internal control over financial reporting, our management excluded the internal control activities of Antares from its evaluation for the period ended December 31, 2022. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)&#160;in Internal Control-Integrated Framework (2013 framework) (the COSO criteria). Based on our assessment, management concluded that, as of December&#160;31, 2022, our internal control over financial reporting is effective based on the COSO criteria. The independent registered public accounting firm that audited the consolidated financial statements that are included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. The report appears below.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Halozyme Therapeutics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Halozyme Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Management&#8217;s Report On Internal Control Over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Antares Pharma, Inc., which is included in the 2022 consolidated financial statements of the Company and constituted 9% of total assets as of December&#160;31, 2022 and 17% of total revenues, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Antares Pharma, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2022 and 2021,  the related consolidated statements of income, comprehensive income, cash flows, and stockholders&#8217; equity for each of the three years in the period ended December&#160;31, 2022, and the related notes and the financial statement schedule listed in the Index at Item 15(a) and our report dated February&#160;21, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/&#160;&#160;&#160;&#160;Ernst&#160;&amp; Young LLP</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023 </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_55"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.86pt">Other Information</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i732e51618ba84e17b469190f5cc138c6_61"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i732e51618ba84e17b469190f5cc138c6_64"></div><div style="margin-top:14pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding directors is incorporated by reference to our definitive Proxy Statement (the Proxy Statement) to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting of Stockholders under the heading &#8220;Election of Directors.&#8221; The information required by this item regarding our code of ethics is incorporated by reference to the information under the caption &#8220;Code of Conduct and Ethics and Corporate Governance Guidelines&#8221; to be contained in the Proxy Statement. The information required by this item regarding our audit committee is incorporated by reference to the information under the caption &#8220;Board Meetings and Committees&#8212;Audit Committee&#8221; to be contained in the Proxy Statement. The information required by this item regarding material changes, if any, to the process by which stockholders may recommend nominees to our board of directors is incorporated by reference to the information under the caption &#8220;Board Meetings and Committees&#8212;Nominating and Governance Committee&#8221; to be contained in the Proxy Statement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Helen I. Torley, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M.B. Ch. B., M.R.C.P. (60), President, Chief Executive Officer and Director. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme&#8217;s Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis&#174;, Prolia&#174;, Sensipar&#174;, and Miacalcin&#174;. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar&#174; and Stivarga&#174; and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five years, Dr. Torley served on the board of directors of Quest Diagnostics Incorporated, a diagnostic information services company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nicole LaBrosse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (40), Senior Vice President, Chief Financial Officer. Ms. LaBrosse has served as the Senior Vice President, Chief Financial Officer since February 2022 and has over 19 years of public accounting and corporate finance experience. She previously served as the Company&#8217;s Vice President, Finance and Accounting from January 2020 to February 2022 and as the Company&#8217;s Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017, she was the Company&#8217;s Senior Director, Financial Reporting. Prior to joining the Company, Ms. LaBrosse was an auditor with PricewaterhouseCoopers, LLP from 2004 to 2015. She received a certified public accounting license after receiving a B.S. degree in corporate finance and accounting and her M.S. degree in accounting from Bentley College.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mark Snyder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (56), Senior Vice President, General Counsel, Chief Compliance Officer and Secretary.  Mr. Snyder joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary.  Mr. Snyder has over 30 years of experience in legal and business management roles.  Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President &amp; Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016.  Before Qualcomm, </span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross &amp; McIntosh.  Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Business.  He received his J.D. from Boston College Law School.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael J. LaBarre</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (59), Senior Vice President, Chief Technical Officer.  Dr. LaBarre joined Halozyme in June 2008 as Vice President, Product Development and has served in various officer positions most recently as Senior Vice President, Chief Technical Officer since January 2020.  Prior to joining Halozyme, Dr. LaBarre served as Vice President, Product Development at Paramount BioSciences, a pharmaceutical company, from April 2006 to June 2008. Prior to that he served as Director, Analytical and Protein Biochemistry, Discovery Research at Biogen Idec, a pharmaceutical company, from December 2003 to April 2006.  He also served in various research and development roles at IDEC Pharmaceuticals Corporation, a pharmaceutical company, from November 1995 to December 2003 most recently as Director, Analytical and Formulation Sciences, R&amp;D.  Prior to joining IDEC, Dr. LaBarre held research and development positions at various pharmaceutical companies from July 1992 to November 1995. Dr. LaBarre received his Ph.D. in Chemistry from the University of Arizona and his B.S. in Chemistry from Southampton College of Long Island University.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_67"></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Executive Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the information under the captions &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation and Related Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  to be contained in the Proxy Statement.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_70"></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as set forth below, the information required by this item is incorporated by reference to the information under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; to be contained in the Proxy Statement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our compensation plans under which our equity securities are authorized for issuance as of December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares&#160;<br/>to&#160;be Issued upon<br/>Exercise of<br/>Outstanding Options,<br/>Restricted&#160;Stock<br/>Units and Performance Stock Units<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of&#160;Outstanding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of Shares<br/>Remaining Available <br/>for Future Issuance<br/>under Equity<br/>Compensation<br/>Plans (Excluding<br/>Shares Reflected <br/>in Column (a))<br/>(c)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,550,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,413,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,550,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,413,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________________</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Represents stock options, restricted stock units, and performance stock units under the Amended and Restated 2021 Stock Plan. This includes 2,650,103 shares available for future purchase under our ESPP plan.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">This amount does not include performance stock units as there is no exercise price for such units.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_73"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the information under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Corporate Governance - Director Independence&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be contained in the Proxy Statement.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_76"></div><div style="margin-top:14pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Principal Accounting Fees and Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the information under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Accounting Fees and Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; to be contained in the Proxy Statement.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_79"></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i732e51618ba84e17b469190f5cc138c6_82"></div><div style="-sec-extract:summary;margin-top:14pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-top:9pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.84pt">Documents filed as part of this report.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:91.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm ID <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl84Mi9mcmFnOmFmNTZkOTVkNjU0NjQ3NGFiZDhiMzg2M2Q4MzgxNzE5L3RhYmxlOjA1MjZlNWNiODJjMzRkODQ4OWFkNDZiZGQ3MGZiOGQ2L3RhYmxlcmFuZ2U6MDUyNmU1Y2I4MmMzNGQ4NDg5YWQ0NmJkZDcwZmI4ZDZfMS0wLTEtMS03NDM5MC90ZXh0cmVnaW9uOjQ3NDc5NDY5YTEwZDQxMWI5MzdhOTRkZDE4OTA1YjRmXzYz_06dd525a-6e80-4e3c-86b9-0c00a091f65e">42</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_91">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets at December&#160;31, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_94">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income for Each of the Years Ended December&#160;31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_100">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income for Each of the Years Ended December&#160;31, 2022,<br/>&#160;&#160;&#160;&#160;&#160;2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_103">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for Each of the Years Ended December&#160;31, 2022, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_106">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for Each of the Years Ended December&#160; 31, 2022,<br/>&#160;&#160;&#160;&#160;&#160;2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_109">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to the Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_112">10</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;List of all Financial Statement schedules.</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statement schedule of Halozyme Therapeutics, Inc. is filed as part of this Annual Report on Form 10-K and should be read in conjunction with the consolidated financial statements of Halozyme Therapeutics, Inc. </span></div><div style="margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:91.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule II: Valuation and Qualifying Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i732e51618ba84e17b469190f5cc138c6_169">45</a></span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or notes thereto. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;List of Exhibits required by Item&#160;601 of Regulation&#160;S-K. See part (b)&#160;below.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.28pt">Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">Amended and Restated Certification of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/3/2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">Bylaws, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312519294791/d826183dex41.htm">Indenture, dated November 18, 2019, between The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/18/2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312519294791/d826183dex42.htm">Form of Note, dated November 18, 2019, between the Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/18/2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Indenture, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee and registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/18/2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Form of Note, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant (included within Exhibit 4.5)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/18/2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/ex45descriptionofsecurities.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex101.htm">Form of Capped Call Confirmation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/18/2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522158531/d326486dex101.htm">Credit Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors, Bank of America N.A. and each of those additional Lenders that are a party to such agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/24/2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522158531/d326486dex102.htm">Security Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors and Bank of America N.A </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/24/2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/d384340dex101.htm">Amendment No. 1 to the Credit Agreement </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/19/2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903622000038/ex101agreementforassignmen.htm">Agreement for Assignment and Assumption of Lease, Del Mar Corporate Centre I Office Lease and First Amendment to Office Lease</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/10/2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1016169/000156459019024598/atrs-ex101_6.htm">Lease Agreement, dated July 1, 2019, by and between Antares Pharma, Inc. and Whitewater Properties I, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/5/2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903622000059/ex104halozymetherapeuticsi.htm">Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex102-halozymetherapeutics.htm">Halozyme Therapeutics, Inc. 2021 Stock Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex103-stockplanxoptionagre.htm">Form of Stock Option Agreement (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr></table></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex104-stockplanxrsuagreeme.htm">Form of Restricted Stock Units Agreement for Officers (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex105stockplan-rsuagreemen.htm">Form of Restricted Stock Units Agreement (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex106-2021stockplanxrsaagr.htm">Form of Restricted Stock Award Agreement (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex107-2021stockplanxformof.htm">Form of Performance Stock Units (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000026/ex108-2021_stockxplanxxxdi.htm">Form of Directors Restricted Stock Units Agreement (2021 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903616000106/haloproxy2016.htm#sa10bb5633675425dac4a2a8982c813d5">Halozyme Therapeutics, Inc. 2011 Stock Plan (as amended through May 2, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/6/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000129993311001376/exhibit2.htm">Form of Stock Option Agreement (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000129993311001376/exhibit3.htm">Form of Stock Option Agreement for Executive Officers (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903615000079/ex102formofrsuagreement.htm">Form of Restricted Stock Units Agreement for Officers (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903615000079/ex103rsaagreement.htm">Form of Restricted Stock Award Agreement for Officers (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903615000092/ex102formofstockoptionagre.htm">Form of Stock Option Agreement (2011 Stock Plan -grants made on or after 11/4/2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903615000092/ex104formofrsuagreement.htm">Form of Restricted Stock Units Agreement (2011 Stock Plan - grants made on or after 11/4/2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903617000014/ex10222011stockplan-rsuagr.htm">Form of Restricted Stock Units Agreement (2011 Plan - grants made on or after 2/22/2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000093639207000962/a36672exv99w1.htm">Form of Indemnity Agreement for Directors and Executive Officers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/20/2007</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903620000037/ex101halozymepsuawarda.htm">Form of PSU Agreement (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/ex1026formofpsuawardagreem.htm">Form of PSU Agreement (2011 Stock Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/23/2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903622000059/ex103-severancepolicy.htm">Severance Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903615000092/ex101formofamendedandresta.htm">Form of Amended and Restated Change In Control Agreement with Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903616000106/haloproxy2016.htm#sc0339c9ee6c74a658fb4a9f534714b33">Halozyme Therapeutics, Inc. Executive Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF-14A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/23/2016</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903616000106/haloproxy2016.htm#sc0339c9ee6c74a658fb4a9f534714b33">Halozyme Therapeutics, Inc. Non Qualified Deferred Compensation Plan Adoption Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/ex1039directorsdeferredequ.htm">Halozyme Therapeutics, Inc Directors Deferred Equity Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex211subsidiaries2022.htm">Subsidiaries of Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231auditorconsent2022.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31110k2022.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31210k2022.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3210k2022.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Presentation Linkbase</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan or arrangement.</span></td></tr></table></div><div style="margin-top:9pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.41pt">Financial Statement Schedules.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;15(a) 2 above.</span></div><div id="i732e51618ba84e17b469190f5cc138c6_85"></div><div style="margin-top:14pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Form 10-K Summary</span></div><div style="margin-top:6pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_88"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:4.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme Therapeutics, Inc.,<br/>a Delaware corporation</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Know all persons by these presents, that each person whose signature appears below constitutes and appoints Helen I. Torley and Nicole LaBrosse, and each of them, as his/her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him/her and in his/her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his/her substitute or substituted, may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President&#160;and&#160;Chief&#160;Executive&#160;Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(Principal&#160;Executive&#160;Officer),&#160;Director</span></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;Nicole LaBrosse</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice&#160;President and&#160;Chief&#160;Financial&#160;Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nicole LaBrosse</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal&#160;Financial&#160;and&#160;Accounting&#160;Officer)</span></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jeffrey W. Henderson</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jeffrey W. Henderson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Connie L. Matsui</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Connie L. Matsui</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/   Jean-Pierre Bizzari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Jean-Pierre Bizzari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Bernadette Connaughton</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bernadette Connaughton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;James M. Daly</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;James M. Daly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Barbara Duncan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Barbara Duncan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Matthew L. Posard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Matthew L. Posard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;Moni Miyashita</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;     Moni Miyashita</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_91"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Halozyme Therapeutics, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, cash flows and stockholders&#8217; equity for each of&#160;the three years in the period ended December&#160;31, 2022, and the related notes and the financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB),&#160;the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;21, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of these critical audit matters do not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating these critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:35.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Determination of Overall Transaction Price for Collaboration Agreements<br/></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December&#160;31, 2022 the Company has eleven collaboration agreements.  As discussed in Notes 2 and 5 of the financial statements, amounts are included in the transaction price when management determines that it is probable that the amount will not result in a significant reversal of revenue in the future. During 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if0faa2d5cad4416b986007776707121f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RhYmxlOjk2MzJjNDgwZGI1NTQwODhiOTYxYTFhNjI3ZGMxYTUyL3RhYmxlcmFuZ2U6OTYzMmM0ODBkYjU1NDA4OGI5NjFhMWE2MjdkYzFhNTJfMi0yLTEtMS03NDM5MC90ZXh0cmVnaW9uOmViMzFlOTI2NTE1ZDRjZjJiNWZiZDE1OGExZTc2MmQ2XzM0OA_a35f0aea-824f-4c7d-b6db-97af468f7940">59.0</ix:nonFraction> million of variable consideration in the transaction price under their collaboration arrangements.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing management&#8217;s conclusions related to determining the probability of achievement of milestones is complex and highly judgmental as a result of the uncertainties given the progression of developing and commercializing the combined targets is completed by the collaboration partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s process to routinely evaluate the probability of achievement of milestones and any related constraint for each collaboration, in addition to the controls over the completeness and accuracy of determining the population of agreements and potential milestone payments.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the milestone amounts included, or excluded, from the transaction price, we performed audit procedures that included, among others, observing the meetings of the Company&#8217;s accounting and alliance managers discussing the status of each collaboration agreement. For each milestone, we examined evidence including correspondence with the collaboration partner and evaluated management&#8217;s conclusions on the probabilities of achievement. We reviewed supporting documentation to corroborate that milestones were included in the transaction price when determined to be probable of achievement. We reviewed the collaboration agreements and related amendments to validate the completeness of the list of targets and potential milestone payments that management considered in their analysis. We performed a lookback analysis to validate the company&#8217;s accuracy of determining the probability of achieving these milestones.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/><br/><br/></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation of intangible assets acquired in connection with the Antares Pharma, Inc. acquisition<br/>&#160;&#160;&#160;&#160;<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As disclosed in Note 3 of the consolidated financial statements, the Company completed the acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;) on May 24, 2022 for total consideration of approximately $1,045.7 million. The transaction was accounted for as a business combination. The Company recorded intangible assets of $589.8 million, which includes in-process research and development (&#8220;IPR&amp;D&#8221;) of $48.7 million.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the Company&#8217;s accounting for its acquisition of Antares was complex due to the significant estimation uncertainty in determining the fair value of the intangible assets. A significant emphasis is placed on the appropriateness of the estimate considerations used by management to determine the fair value of the acquired intangible assets due to sensitivity of the respective fair values to the underlying assumptions. The Company used an income approach to measure the intangible assets. The significant assumptions used to estimate the value of the intangible assets included discount rates and revenue growth rates. These significant assumptions related to the intangible assets are forward looking and could be affected by future economic and market conditions.<br/></span></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:35.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company's process for determining the fair value of intangible assets acquired in connection with the Antares acquisition. This included controls over management&#8217;s development of the above-described assumptions used in the valuation models applied.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company&#8217;s use of the income approach and testing the significant assumptions used in the valuation model, as described above. We evaluated the completeness and accuracy of underlying data used in supporting the assumptions and estimates. We evaluated the reasonableness of projected revenue growth used within the valuations against analyst expectations, industry trends, and other market information. In addition, we involved valuation specialists to assist in assessing the significant assumptions and methodologies used by the Company.<br/></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RleHRyZWdpb246ZTg2MTExNjA4MjAyNGY3MGFkMmY4ZWM3NzMxN2VhNzJfMzgyOA_c3c8cc93-8cb7-4be3-b702-76746396deed">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2006.</span></div><div style="margin-top:14pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RleHRyZWdpb246ZTg2MTExNjA4MjAyNGY3MGFkMmY4ZWM3NzMxN2VhNzJfMzgzMA_4e09691a-bde9-4e6c-ac38-8a993a013daa">San Diego, California</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023 </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMy0yLTEtMS03NDM5MA_181dbfb6-a9e9-44cb-bbcd-cd44c9159966">234,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMy00LTEtMS03NDM5MA_c36bc1bb-7cd2-4769-8aa4-78a5efef11ba">118,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNC0yLTEtMS03NDM5MA_183ed636-f38a-4e91-b2e5-02d01081e7f6">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNC00LTEtMS03NDM5MA_46577cd9-a795-499f-be75-44ded45e5a4e">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNS0yLTEtMS03NDM5MA_11f345d9-4422-4abb-8451-648233675f11">231,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNS00LTEtMS03NDM5MA_6a3474db-b864-48e9-bc65-af605eaa6e10">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNi0yLTEtMS03NDM5MA_4d18f8f1-f73f-4a7e-8922-a0f39b1d603f">100,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNi00LTEtMS03NDM5MA_962fcf97-b485-4cb2-a640-79eb1751bb55">53,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNy0yLTEtMS03NDM5MA_ddac6b8f-0baa-420c-817a-3d5d79fc9e19">45,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNy00LTEtMS03NDM5MA_99bb485b-9013-4ea4-bc91-e941411ea3d3">40,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOC0yLTEtMS03NDM5MA_533a81e3-6228-47af-9570-2fee5d78b5cf">739,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOC00LTEtMS03NDM5MA_08fe6d72-3da3-4115-b560-8ee3dd6cec45">926,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOS0yLTEtMS03NDM5MA_aaab9fb0-9942-4793-a70e-6072dd13c39e">75,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOS00LTEtMS03NDM5MA_109cf565-a0ca-4f26-99ce-4ba2474d6649">8,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTAtMi0xLTEtNzQzOTA_33b942e6-b8c9-40ab-a167-dc7d69a85e0b">26,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTAtNC0xLTEtNzQzOTA_26dfbeaa-ea8b-4324-8bac-3f5b79b8c0d2">13,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtMi0xLTEtNzY4MzY_8ad3e54a-03cb-4973-942d-398445d87ca7">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtNC0xLTEtNzY4NDA_74fbe102-f74a-45ed-b66a-796756e15d24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItMi0xLTEtNzY4NDQ_dd85f5d2-f186-4591-b4c4-f3b079f86a67">546,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItNC0xLTEtNzY4NDg_c15d0ed4-34b3-4601-b977-3abe52414903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtMi0xLTEtNzQzOTA_d1a39fad-32f2-4183-abb8-c8e8806ae8ce">44,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtNC0xLTEtNzQzOTA_23bacede-bf7f-4eac-ac1f-944360293da6">155,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItMi0xLTEtNzQzOTA_5aab020c-86a3-4097-9101-e37c073dd56a">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItNC0xLTEtNzQzOTA_de845456-e1ca-4817-9a89-6ea58e850bd1">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTMtMi0xLTEtNzQzOTA_defaa3fa-4737-4150-8c4c-cd8a3a5ad02f">1,841,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTMtNC0xLTEtNzQzOTA_fb22da81-1189-4d65-b093-edef36a2fa9d">1,104,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTctMi0xLTEtNzQzOTA_533b12a0-5f11-463d-8d11-51c0d4e87cd8">17,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTctNC0xLTEtNzQzOTA_e77c80d9-2dbb-4a3e-84f5-3e0eab4f647e">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTgtMi0xLTEtNzQzOTA_340d532b-9679-4727-a433-8341dcb97734">96,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTgtNC0xLTEtNzQzOTA_e111b956-411b-45aa-85f0-d10be76aba12">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTktMi0xLTEtNzQzOTA_10587122-0fac-49e8-bac9-324ef3b6514e">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTktNC0xLTEtNzQzOTA_7b6237ee-6701-4e2a-8a18-ea45aed96dc6">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjAtMi0xLTEtNzQzOTA_60fcd98e-fb6f-4982-a31c-eb9cbc936eda">13,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjAtNC0xLTEtNzQzOTA_88f30245-f625-4447-88a6-6568321c0c3b">89,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjEtMi0xLTEtNzQzOTA_cb76e6a0-f890-4ead-9b8b-234fda5b49be">130,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjEtNC0xLTEtNzQzOTA_333b72e9-ddf4-4514-85ff-fec77f12a29e">117,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjItMi0xLTEtNzQzOTA_9654e333-7bc9-49f1-b578-93e8280f76d6">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjItNC0xLTEtNzQzOTA_2a4b4aa2-e753-4b27-bfeb-bb8891658877">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjMtMi0xLTEtNzQzOTA_8736d116-f1ad-49da-b896-dfbe52a7896b">1,492,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjMtNC0xLTEtNzQzOTA_b09bffae-4b98-4b40-b4ec-f40c14766b8c">787,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjQtMi0xLTEtNzQzOTA_fdb9d7e5-80ce-40f4-92e2-8c68b23f054d">30,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjQtNC0xLTEtNzQzOTA_7b89acf0-f265-4515-8ee0-4f0c92e58959">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMi0xLTEtODY5MDk_3cae766c-f545-4b36-a6a7-68de5b53dfeb">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctNC0xLTEtODY5MTQ_63f56b2c-e5a4-4755-acf9-923a09030f62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjUtMi0xLTEtNzQzOTA_9bf93c2b-350b-43d3-8eab-7c615f2f0a5d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjUtNC0xLTEtNzQzOTA_726a3816-4054-4c86-b22d-c049ef06f390"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8yMg_307f3c94-3982-485c-b40a-9c6166eec83f"><ix:nonFraction unitRef="usdPerShare" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8yMg_c497ac7d-82a3-4a77-a97e-40ce3a28df96">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8zNg_94cbf721-c694-4bfe-be28-03a875c5f877"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8zNg_c53025d5-a24a-46f3-b25b-fbf76a1d1323">20,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_31124b5e-5321-4ff7-af46-860973f6dcba"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_701f6031-ffa8-4816-8022-2672f2e4686e"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_ab756c43-2b9f-4161-9e23-bd3614b42d0a"><ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_bf6b48b9-e3db-4ff1-979f-2caadb5f2bdf">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;issued and outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMi0xLTEtNzQzOTA_0a90b709-ab05-4e48-84d1-a8ee87fbf25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctNC0xLTEtNzQzOTA_562b5ea1-0dbb-4fcc-8523-c77b669757cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8xOQ_996531a4-7e04-42d5-b187-ddc159b979ca"><ix:nonFraction unitRef="usdPerShare" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8xOQ_ef4b20fc-eeaa-4e7f-9fee-1c8057311ff9">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8zMw_384bce4e-d729-4ed2-90d7-3ef9a38b4728"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8zMw_7e861bc9-0006-4218-a169-ad5289014493">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV81NQ_56c453fe-a82b-4f02-9d4f-d26d35ad1281"><ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV81NQ_eb3ce5ce-d3f3-4229-bba9-13096dab3f8d">135,154</ix:nonFraction></ix:nonFraction> and </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV82Nw_7cd60df6-6a14-4652-a7e8-c9f4b808dd3c"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV82Nw_9ecbcd2b-7757-4bca-8959-6e255d65263b">137,498</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMi0xLTEtNzQzOTA_edc52c73-4219-4d38-9b6e-f05ccd43e7ae">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtNC0xLTEtNzQzOTA_48b58c8b-0246-436d-b5df-7b2da8cabfcd">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjktMi0xLTEtNzQzOTA_9d9dab43-a56d-4a46-9647-ca9761d97e11">27,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjktNC0xLTEtNzQzOTA_e61ae07b-c026-4131-8fef-259bec2c3665">256,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzAtMi0xLTEtNzQzOTA_b4ea27d6-27b9-485e-8826-b60a231f111c">922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzAtNC0xLTEtNzQzOTA_8383f539-9071-4b7f-879a-bc8206fd861f">620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (Accumulated deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzEtMi0xLTEtNzQzOTA_30be9517-d122-4958-b772-850dfc262ca7">143,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzEtNC0xLTEtNzQzOTA_eef3c2e9-c0cf-4d63-a207-5da9fecc602a">58,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzItMi0xLTEtNzQzOTA_8568c4bd-5052-4056-8234-93a59f6fdbfa">169,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzItNC0xLTEtNzQzOTA_2e28b2b7-a19d-469d-a1c1-95ec94300ca7">196,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzMtMi0xLTEtNzQzOTA_ab52509b-d9ad-41ad-a61d-786ffc827423">1,841,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzMtNC0xLTEtNzQzOTA_16098ea0-8596-44df-9d32-4364c3e6cbf4">1,104,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtMi0xLTEtNzQzOTA_f9ebb5a0-26b2-4bc1-88fb-37a1d5d40db2">360,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtNC0xLTEtNzQzOTA_519de520-b7e0-4a04-ab99-847e49b9c1c3">203,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtNi0xLTEtNzQzOTA_a811c11f-4248-465f-bfa4-9174dfef170f">88,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtMi0xLTEtNzQzOTA_9f5706fc-be28-44fe-a7a9-65c544c50a9e">191,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtNC0xLTEtNzQzOTA_073e7e48-d773-4798-b05f-2360125cd06c">104,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtNi0xLTEtNzQzOTA_601b8964-8cd4-4f40-9802-08a7b0551810">55,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtMi0xLTEtNzQzOTA_ba626d84-a40f-4c0d-8528-ea980b47127e">108,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtNC0xLTEtNzQzOTA_36ae2c29-53a9-48d0-b84f-99dcf0f99210">135,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtNi0xLTEtNzQzOTA_a6f8e8db-150a-4fb7-a861-cbd94bc21ca7">123,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtMi0xLTEtNzQzOTA_de2cbc55-43af-4569-b720-00638e5c67d7">660,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtNC0xLTEtNzQzOTA_45f528d0-ff54-4731-b11b-f2fc15a12015">443,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtNi0xLTEtNzQzOTA_a4a678ae-1cff-4340-a621-9e9e3c373d80">267,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtMi0xLTEtNzQzOTA_cabfe48f-2aa6-4498-808a-43b9a0ebd4e5">139,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtNC0xLTEtNzQzOTA_ed5115da-09a8-4770-b620-c6a87541b412">81,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtNi0xLTEtNzQzOTA_2ea0d77e-3d6f-4ff3-8ce1-5789d6e73eec">43,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktMi0xLTEtNzY4NjI_d8b1d1d2-47d3-46c7-932a-2232e4a9818a">43,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNC0xLTEtNzY4NzI_b63fcc55-de43-4a59-8289-d8019732925a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNi0xLTEtNzY4NzY_f59a0f34-ba74-4df1-af71-4e035d71506b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktMi0xLTEtNzQzOTA_ac3ec183-ecdb-471d-97c6-585fc761e225">66,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNC0xLTEtNzQzOTA_9317833a-3977-4367-b3cf-c011513a2a20">35,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNi0xLTEtNzQzOTA_a51e77a9-0f8d-4986-b4ee-7ae07258b765">34,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTItMS0xLTc0Mzkw_d1b8a53e-2b25-4548-bf00-e1a39ef5e547">143,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTQtMS0xLTc0Mzkw_bdcc3658-2025-4172-b654-75e8bfa322e2">50,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTYtMS0xLTc0Mzkw_1737ed17-2f28-4f47-ac38-85033d068e1b">45,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTItMS0xLTc0Mzkw_499de6b4-4e7a-4cdc-9431-a4158e31822a">392,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTQtMS0xLTc0Mzkw_363fc5ec-e1fe-4304-b387-68902fd177d6">167,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTYtMS0xLTc0Mzkw_7be2228a-7ed1-4cc3-ab86-73e8df342bba">123,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTItMS0xLTc0Mzkw_f4551fbf-a648-4e10-8e3f-0de0d80ab028">267,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTQtMS0xLTc0Mzkw_ed4554d5-4bae-4134-a497-3a917f2631fb">275,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTYtMS0xLTc0Mzkw_a217b5ea-15e7-4ed5-b389-ad78f6a9fb33">144,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTItMS0xLTc0Mzkw_a9da85b3-79fe-464c-a38e-b9a1cad42d38">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTQtMS0xLTc0Mzkw_b2cc8265-45f1-4136-8870-099d08a43e09">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTYtMS0xLTc0Mzkw_b3963e39-0000-4a30-9bc8-a83280e3e6e2">5,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement expense related to convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTItMS0xLTc0Mzkw_48ec0d53-97c4-4169-8055-7ac2c16a4578">2,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTQtMS0xLTc0Mzkw_b25017f5-3c1e-4ef5-8001-185c1bbe6061">20,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTYtMS0xLTc0Mzkw_9dc434a9-ecab-4116-90bb-e2e42fa32605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTItMS0xLTc0Mzkw_be50dc35-9ba4-436f-a11b-45969541b406">16,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTQtMS0xLTc0Mzkw_9f10e8b0-7690-42b3-90a0-4bed02e74cb3">7,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTYtMS0xLTc0Mzkw_80132c04-5ebf-4364-af8d-8affdb4378e2">20,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTItMS0xLTc0Mzkw_6f76cc98-4df1-4009-aa56-a0b23d35557b">248,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTQtMS0xLTc0Mzkw_9db9460a-4322-4982-9bfc-70b8cad900a3">248,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTYtMS0xLTc0Mzkw_893f5b2f-a833-405c-a7be-0eb60fb84e24">129,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTItMS0xLTc0Mzkw_e20e5b70-f29f-43d8-b7c4-06004e8e8882">46,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTQtMS0xLTc0Mzkw_a0780544-573f-4cb4-8b6c-f6007d9dd940">154,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTYtMS0xLTc0Mzkw_a640f14f-90de-4e3e-b6d2-074e64df7228">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTItMS0xLTc0Mzkw_96f0c3aa-5c12-4f25-8a6d-7e953e1fb2f2">202,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTQtMS0xLTc0Mzkw_7e055fc6-a221-4fb5-81d1-f6527016c7fd">402,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTYtMS0xLTc0Mzkw_85c586ac-332a-441c-9326-5aad2eab2861">129,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTItMS0xLTc0Mzkw_5ea474a3-4935-409f-b1f6-0c23528ff704">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTQtMS0xLTc0Mzkw_56f1e55e-92db-4580-a49b-a8162671c9e3">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTYtMS0xLTc0Mzkw_28d865af-ab4a-4652-bafa-35d9d6a9e59e">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTItMS0xLTc0Mzkw_1f7e6d42-1220-4c3f-a723-65bddbead965">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTQtMS0xLTc0Mzkw_90df12ad-38ef-4119-be81-f951e22ece70">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTYtMS0xLTc0Mzkw_5eb74c41-2581-408f-b2c4-7a744ae4cfb7">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTItMS0xLTc0Mzkw_3076df54-8ef5-4524-9d7e-f6c57fbf9dfe">136,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTQtMS0xLTc0Mzkw_ba9ced94-83bc-49c5-9009-ad4e10599866">140,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTYtMS0xLTc0Mzkw_298d4fd9-3775-4a46-9f66-7affba1ac200">136,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTItMS0xLTc0Mzkw_74b905ce-f502-4fa1-8b55-93de403f236c">140,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTQtMS0xLTc0Mzkw_94bb954b-67ff-48db-95b6-866bfd1e0e93">146,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTYtMS0xLTc0Mzkw_c30ec5df-84e0-4b73-8e45-88775ac98820">141,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_103"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItMi0xLTEtNzQzOTA_d47a8eb9-7523-40e8-aa3f-4971ec57c4bf">202,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItNC0xLTEtNzQzOTA_60be4c5b-6178-4b18-9f60-bc8026e75c51">402,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItNi0xLTEtNzQzOTA_347f3216-c688-4900-b9d7-1ca9ed2c1afd">129,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtMi0xLTEtNzQzOTA_3e0c6bce-d898-4978-a133-7e947ca76ce0">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtNC0xLTEtNzQzOTA_039c9754-b31b-423a-a1ce-9cdd66ee9943">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtNi0xLTEtNzQzOTA_438cc356-f4a1-46bc-a044-3561dde959e4">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtMi0xLTEtNzQzOTA_d157fe0a-0a2a-449c-8dbe-bdb5e69c2b1e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtNC0xLTEtNzQzOTA_59fa7019-d860-4e25-8ab1-38c04c337bd7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtNi0xLTEtNzQzOTA_c0f80336-b932-4725-8c3a-59a39a855d0b">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on foreign currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtMi0xLTEtNzQzOTA_080b16f7-f5e4-4aaf-856b-f4aecbe4b98f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtNC0xLTEtNzQzOTA_e65c5a9e-a9d2-483c-95eb-17138f9210af">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtNi0xLTEtNzQzOTA_b46b55f4-5a2a-4edc-9246-9f3f735f83d4">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctMi0xLTEtNzQzOTA_735aed52-6500-45d7-b3c6-682d277d58f4">201,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctNC0xLTEtNzQzOTA_983fd84f-bc66-4eaf-8430-d75a642cf15c">402,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctNi0xLTEtNzQzOTA_719ff727-cac1-47e5-a7fd-dea1f55762a6">128,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtMi0xLTEtNzQzOTA_42f5ebf3-6fc0-4f51-8ef4-0e4267cbf0c5">202,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtNC0xLTEtNzQzOTA_7bf5bc56-f203-4d2c-abdf-1366d821a929">402,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtNi0xLTEtNzQzOTA_d3adb040-6081-49b7-bb7b-3ee7cccb81cd">129,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtMi0xLTEtNzQzOTA_7d235115-9957-440c-902d-ac5b9ad2c954">24,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtNC0xLTEtNzQzOTA_5ba6d948-ac7b-441f-9b17-432e6ef29459">20,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtNi0xLTEtNzQzOTA_ab2a02c6-5a1c-4ec9-8c25-23dc2b6f346b">17,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtMi0xLTEtNzQzOTA_c7c61460-2c4e-48ac-82d0-993672e1890d">6,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtNC0xLTEtNzQzOTA_acd892d3-cfb7-4391-8db4-ec8cd16affc7">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtNi0xLTEtNzQzOTA_76f7e2b5-7812-401e-8285-e97b4a6fa342">3,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctMi0xLTEtNzY5MDA_3eea5411-bb42-4951-9bc1-de5cacecd8af">43,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNC0xLTEtNzY5MDY_1741ea51-9805-4678-9e4b-b97f9f99af0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNi0xLTEtNzY5MTI_9d32dafb-0eb8-40d9-8ecc-f20977165c79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctMi0xLTEtNzQzOTA_94eeef79-b224-489e-9e40-063274644846">7,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNC0xLTEtNzQzOTA_585668e1-ccde-475a-a909-0e7e308f760a">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNi0xLTEtNzQzOTA_6df86f6a-fdcb-4fd6-bba2-bc658b99aab8">14,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Amortization of (accretion of discounts) premiums on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktMi0xLTEtNzQzOTA_0c4bc317-47b6-42cb-bb52-d574c025ebd2">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktNC0xLTEtNzQzOTA_53b64d99-ba80-4076-a0d7-da4ad5d9b99f">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktNi0xLTEtNzQzOTA_828a1e72-bb24-48a2-b4bb-e53172affa00">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Realized loss on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTItMS0xLTg4MDA5_5761c0c8-e0e9-457f-b31b-e0afc06ce4f7">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTQtMS0xLTg4MDEz_e3b40dd5-65d4-416d-9d48-3b4231c4d917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTYtMS0xLTg4MDE3_31220cd1-2546-42c7-97aa-c72be04879cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Loss (gain) on disposal of equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTItMS0xLTc0Mzkw_e39a5423-9a25-45d6-a666-581322c2c00f">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTQtMS0xLTc0Mzkw_460c9289-4926-4b0b-8e1c-7cae63a719a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTYtMS0xLTc0Mzkw_0fadeb90-e63d-4fc0-b0c4-dfa5c6bac988">772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Deferral of unearned revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTItMS0xLTc0Mzkw_5130b374-2d1c-4e71-a5e1-9274372d5819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTQtMS0xLTc0Mzkw_1844b6de-e940-4df6-b845-9f644a2d0d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTYtMS0xLTc0Mzkw_a942900d-4764-49a1-9120-a50190ba391f">4,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Recognition of deferred revenue </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTItMS0xLTc0Mzkw_87d71244-5ef2-4848-a4e8-a9ff3b9a4682">2,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTQtMS0xLTc0Mzkw_48cae35b-907f-4be6-bcad-040294a66227">1,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTYtMS0xLTc0Mzkw_d2d8f1f7-ed4f-4066-812e-64151dc88a9b">4,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Lease payments deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTItMS0xLTc0Mzkw_6aa07ac4-8fa0-4f88-959d-ae3c36c7808e">903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTQtMS0xLTc0Mzkw_70667c77-0429-4c80-92e5-53e12bdb5b55">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="halo:DeferredRentPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTYtMS0xLTc0Mzkw_6bb966d9-a9c6-4e47-967c-9f4519b34c02">1,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Loss on impairment of right-of-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTItMS0xLTc0Mzkw_1f25b14c-b6d2-45df-8255-7f38ea2ac542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTQtMS0xLTc0Mzkw_c6302169-1ca9-4015-913b-021e4ba73740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTYtMS0xLTc0Mzkw_257390fd-4222-48e5-9876-2068f0582d51">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Induced conversion expense related to convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTItMS0xLTc0Mzkw_91a296ab-cc7d-45e1-b76c-6fb887d5509e">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTQtMS0xLTc0Mzkw_73987c3d-7589-4010-94a4-326dc81f65af">20,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTYtMS0xLTc0Mzkw_8d2abd63-de83-4376-aeba-f1e01f666a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Deferred income taxes (including benefit from valuation allowance release)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTItMS0xLTc0Mzkw_65dd5155-e1bb-49c0-baea-7a06f17f316a">40,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTQtMS0xLTc0Mzkw_eb96da9c-c628-4a75-9da6-6d90a66bc50a">155,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTYtMS0xLTc0Mzkw_6d175cbf-60c5-4b98-99f8-cd52e378ab2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTItMS0xLTc0Mzkw_ade32cf0-821c-46e0-8c09-ed7e8c1ccc66">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTQtMS0xLTc0Mzkw_96181b95-b950-464f-929e-608da54d5c8b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTYtMS0xLTc0Mzkw_93ba43dc-1293-45ea-b21d-d7e434db9e57">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTItMS0xLTc0Mzkw_65e655bc-5d13-4dd8-8b48-87985da39704">83,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTQtMS0xLTc0Mzkw_a6bc8359-d787-49dc-b4ae-d8544e7cbb99">6,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTYtMS0xLTc0Mzkw_21294b13-6c01-4ce2-8c78-634672ff383b">38,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTItMS0xLTc0Mzkw_c6339382-a96c-474e-8db8-01565c677545">17,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTQtMS0xLTc0Mzkw_439a2f5b-ffa5-4962-bb35-52007ac0ac23">7,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTYtMS0xLTc0Mzkw_c1a6d217-8329-41a5-a976-5f98475ea86a">31,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTItMS0xLTc0Mzkw_16e1413a-cbf4-4d44-b235-f4255c2638f0">9,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTQtMS0xLTc0Mzkw_2918daec-ce03-4aa5-98e6-00a7fbf0aad2">11,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTYtMS0xLTc0Mzkw_05b8063d-3dd3-4c63-bacd-39e32b9de6fa">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTItMS0xLTc0Mzkw_ae7bdb64-e27c-4f52-b6f6-ef6504adb15d">24,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTQtMS0xLTc0Mzkw_d59bd880-024b-4ecc-8e95-9fa8e9f57569">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTYtMS0xLTc0Mzkw_987ec089-c006-4466-b879-11e529a7f945">41,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Net cash  provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTItMS0xLTc0Mzkw_531789fd-177b-4b44-9c09-30c5e482771c">240,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTQtMS0xLTc0Mzkw_b992558e-2828-4566-8a12-9cc672e33b9a">299,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTYtMS0xLTc0Mzkw_5f6994f6-0f78-4247-9e54-9f24f28a7a0e">55,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTItMS0xLTc0Mzkw_98897996-c70f-4b8a-b11f-edb250c6de77">255,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTQtMS0xLTc0Mzkw_9bda6867-ae0b-40fb-82d3-0427e536406f">652,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTYtMS0xLTc0Mzkw_6bbae1ff-9dbf-473f-8622-76d53fa095a0">226,185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTItMS0xLTc0Mzkw_3276e6d8-07e6-45a1-9bd2-15886e024d2b">746,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTQtMS0xLTc0Mzkw_d2dea306-1637-4f67-8481-fceba6f275de">247,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTYtMS0xLTc0Mzkw_84bcb6b0-d918-43c9-9e43-0fa7ee7fe5b9">305,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Acquisitions of business, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTItMS0xLTc2OTI2_aa126c95-6988-4fb8-b7a3-0f32cf10e21f">999,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTQtMS0xLTc2OTMw_244feffb-c953-4ff1-ae09-19a6a3c89994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTYtMS0xLTc2OTM0_e8c05ebd-4598-4fa8-89b9-f68a3debda8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTItMS0xLTc0Mzkw_df83708b-9a1f-4ed0-aaf4-d4d064fe9ff3">4,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTQtMS0xLTc0Mzkw_bff5d5fa-2e16-4b0a-bc0f-90d86c4ec87f">1,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTYtMS0xLTc0Mzkw_00b72011-14f9-4a12-aaba-af2bc360d451">2,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTItMS0xLTc0Mzkw_c16b0ece-8ba8-4155-9f1a-64d1faf9f7b8">26,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTQtMS0xLTc0Mzkw_856debca-7cec-4c16-beeb-1a17445d7f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTYtMS0xLTc0Mzkw_5d9b4b4b-6a15-4a5d-8d61-629d639de513">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Net cash (used in) provided by  investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTItMS0xLTc0Mzkw_e716790d-a920-47e9-aca5-ef58db3626ca">487,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTQtMS0xLTc0Mzkw_3dd44252-8f1b-42ca-9e4c-69df8fe33832">406,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTYtMS0xLTc0Mzkw_f9e1cbbd-a09b-4e16-a4f2-021bcd1ee1dd">78,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTItMS0xLTc2OTcw_d03c5f2a-a543-4462-b4d9-828d6106b07a">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTQtMS0xLTc2OTc4_fb3afc26-61d7-49f4-a706-dcbbb01c710e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTYtMS0xLTc2OTgz_b97b431a-db66-4e55-a0b8-a9e4b49bd841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTItMS0xLTc2OTcw_6e149abe-30c0-47db-aaa1-2a36bdc5252f">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTQtMS0xLTc2OTc4_84a8ed51-2c56-4a84-9c6d-38ff2d3988e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTYtMS0xLTc2OTgz_81424a0b-ef27-45a7-9639-7991c70de6f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from revolving credit facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTItMS0xLTc2OTcw_fe60a0a0-d3af-4502-9e83-26ee7d55a1b2">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTQtMS0xLTc2OTc4_cdcd42ce-5a40-4af4-85e9-458bd792c256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTYtMS0xLTc2OTgz_cbce0e6c-7b41-486e-a86d-f1239f8a163e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Repayment of revolving credit facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTItMS0xLTc2OTcw_fb2d6334-6341-4d61-b414-df8ae1270258">120,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTQtMS0xLTc2OTc4_332b82d4-a687-45d3-946e-b1a58e84585b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTYtMS0xLTc2OTgz_1bb40fa6-f4d6-4531-b7ae-9fe0215fb592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from issuance of 2027 Convertible Notes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTItMS0xLTc0Mzkw_f6bbdf7b-d87d-4432-becf-40a681847534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTQtMS0xLTc0Mzkw_b929485f-04d3-4ba7-8a5e-d77783370664">784,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTYtMS0xLTc0Mzkw_cede7f3b-fd53-4d57-b9be-3707cdbbcbd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTItMS0xLTc0Mzkw_01b9bcc2-de22-4c0d-8fea-40542e59093e">77,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTQtMS0xLTc0Mzkw_60617d4c-77eb-4577-87bd-060f632769bb">369,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTYtMS0xLTc0Mzkw_1bd7ea81-1bd0-403d-afa9-871c4a785825">19,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from issuance of 2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTItMS0xLTc2OTc0_a05e9fa1-32a6-4939-aa54-1fc6c3f89c65">702,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTQtMS0xLTc2OTkx_72a57861-8571-4d64-9bc8-4ce497df643c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTYtMS0xLTc2OTk2_66f79e47-17b2-4806-8c4c-92546cd29279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Purchase of capped call</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="halo:PurchaseOfCappedCall" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTItMS0xLTc2OTc0_0791ef14-6572-4255-8e19-bd3f72cae461">69,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="halo:PurchaseOfCappedCall" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTQtMS0xLTc2OTkx_204785bd-397b-4e99-9be8-3eb2c58a4ea2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="halo:PurchaseOfCappedCall" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTYtMS0xLTc2OTk2_60c70162-9ea3-4982-93dd-8858d7b508de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Payment of debt issuance cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTItMS0xLTc0Mzkw_08d5d031-9ac2-42af-9b50-8680347e61db">7,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTQtMS0xLTc0Mzkw_b5b8cd95-a634-4906-a00d-7e8ac2e4eae5">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTYtMS0xLTc0Mzkw_4161a0a5-813a-4aa9-95fa-05453aac667b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTItMS0xLTc0Mzkw_dc54b3ff-a8ba-4df0-b863-0b077ca74b7b">200,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTQtMS0xLTc0Mzkw_e9d786dc-102b-44d0-96c3-f634926a2986">350,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTYtMS0xLTc0Mzkw_504b8563-56b6-4e8a-835f-86977ca08aaa">150,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTItMS0xLTc0Mzkw_5a4d298f-2512-4e5b-9e75-68835bf2574c">14,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTQtMS0xLTc0Mzkw_08630b10-4ea5-4850-b7b9-d204c947e88d">12,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTYtMS0xLTc0Mzkw_a5e3c07d-f24b-4088-bdf8-d84a58268d69">63,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTItMS0xLTc0Mzkw_8c123702-7174-45b8-b205-a0e4e1ecc7a0">362,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTQtMS0xLTc0Mzkw_16d344d0-ca1f-4aab-b0b1-b3b2a8b3bba9">77,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTYtMS0xLTc0Mzkw_64eea650-a8a5-44f6-adbb-0116fe331f95">106,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTItMS0xLTc0Mzkw_65c5f9ea-da2d-4cd1-a034-93aea2063a9a">115,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTQtMS0xLTc0Mzkw_f267f751-1e10-455a-b356-378370dd8bc8">28,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTYtMS0xLTc0Mzkw_4a82a8f9-8943-4196-8faa-0635e58d535a">27,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTItMS0xLTc0Mzkw_aec1aa5f-5f01-4ce0-bf57-312859992bd7">119,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTQtMS0xLTc0Mzkw_bf385dd4-1b87-43e6-8447-f4adb1315f75">148,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTYtMS0xLTc0Mzkw_4d4098f1-322a-4d57-9d89-a98be0823960">120,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTItMS0xLTc0Mzkw_9da26be3-f10f-4959-94c0-c912042208be">234,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTQtMS0xLTc0Mzkw_3c3f4393-466b-4c50-acd6-068561746e43">119,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTYtMS0xLTc0Mzkw_7e7434e1-88dc-4755-8b0f-27d6fbaed56f">148,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTItMS0xLTc0Mzkw_8eceea71-c9ee-4823-a8ab-188f65528838">6,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTQtMS0xLTc0Mzkw_d020018c-6796-4512-b219-ee890f55dbcb">3,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTYtMS0xLTc0Mzkw_e23fd59a-c00d-4b06-b134-927b94081c2e">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Income taxes paid (received), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTItMS0xLTc0Mzkw_ec617a10-26b6-4ca8-9553-6561533a894a">16,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTQtMS0xLTc0Mzkw_cfd27d88-968c-4ec4-a82f-6a77a9cadd18">375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTYtMS0xLTc0Mzkw_c03c70cc-a874-4382-930f-08583bd06df4">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTItMS0xLTc0Mzkw_20ff97ea-9d4a-47c9-8b19-bc84638225e4">6,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTQtMS0xLTc0Mzkw_5d0511fb-7006-45cc-83f7-91fd53f9b4d7">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTYtMS0xLTc0Mzkw_71aae187-d9d6-4db3-8ff1-86871fe0a20f">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTItMS0xLTc0Mzkw_9eb84721-3aab-4293-b345-d82c9c7c4fc6">34,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTQtMS0xLTc0Mzkw_fc0afc53-2528-4daa-aa98-23e558cb3ed5">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTYtMS0xLTc0Mzkw_0b396591-f81a-4f8c-9547-8a2768540ae9">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">Common stock issued for induced conversion related to convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTItMS0xLTc0Mzkw_b0f46168-2df2-4e22-9b1e-00333f8ad59c">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTQtMS0xLTc0Mzkw_501a86eb-c2df-4a78-be1d-14994def0513">7,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTYtMS0xLTc0Mzkw_bef8481c-9ac3-464b-a828-6d4f76b7ac0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_109"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:31.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.584%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BALANCE AT DECEMBER 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i658b6d0704704e0b8064188c8e0a801d_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMi0xLTEtNzQzOTA_85238cde-6de5-4bad-8916-9cc0cd0414ae">136,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658b6d0704704e0b8064188c8e0a801d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItNC0xLTEtNzQzOTA_cfc3696e-3161-42ad-8c1e-844355274a8e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afa1af705a047488d2ed7629419da96_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItNi0xLTEtNzQzOTA_d6b0596f-4fb2-4c3c-ab6c-71e922a50630">695,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be6b96e36e440009875fac05281e167_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItOC0xLTEtNzQzOTA_ddeb55ca-c893-478b-b559-dd56b2a63045">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7db3fb4810984f62a4337b6b494f3743_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMTAtMS0xLTc0Mzkw_b1c03e57-86fb-4c38-ba76-039105b7b00e">603,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMTItMS0xLTc0Mzkw_c775e75f-1270-4358-bdf2-a8f8032bc6c7">91,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzQtNi0xLTEtNzQzOTA_85ca7cae-4b02-4745-9ffa-35ea7f842358">17,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzQtMTItMS0xLTc0Mzkw_96a4faf7-8fd9-46bd-9082-ba4e63772e96">17,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtMi0xLTEtNzQzOTA_8a37a70d-656c-420a-a560-9a642c00971e">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtNC0xLTEtNzQzOTA_b31cbcc9-2076-468c-8e7d-16a288225a80">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtNi0xLTEtNzQzOTA_739131a3-f866-4eda-a1b8-b18324a390a1">63,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtMTItMS0xLTc0Mzkw_96044f1d-f108-4366-86bd-896a5ecb2f08">63,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock awards, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzctMi0xLTEtNzQzOTA_90326c3a-922f-47e3-a4fe-fea3845379f5">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtMi0xLTEtNzQzOTA_b2659564-bef2-49ff-af1a-9f42c29fa714">7,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtNC0xLTEtNzQzOTA_f975eb4f-b033-4afb-b8fd-73cc150bc0e7">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtNi0xLTEtNzQzOTA_fb9bda6a-c4c0-4ef6-8a2c-722634d2018d">150,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtMTItMS0xLTc0Mzkw_8554d68f-36af-4be5-82ea-001518eafd38">150,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzktNi0xLTEtNzQzOTA_b84b0a52-784f-4dc2-a37a-a8c6bc31bfb4">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzktMTItMS0xLTc0Mzkw_2e1bddcd-9af0-4b2f-bc83-9ab6f01f13ca">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9749fc8e01b42f3bc4d2a62a57108c5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEwLTgtMS0xLTc0Mzkw_59a3fed4-260e-4022-b533-f05286161837">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEwLTEyLTEtMS03NDM5MA_3de2ba28-9537-4cde-8b24-2eaed8f91295">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net lncome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzExLTEwLTEtMS03NDM5MA_1e245937-ab76-4c40-8f4d-db595f62f8cd">129,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzExLTEyLTEtMS03NDM5MA_4223148b-1f35-44fa-ac2b-f27319413816">129,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BALANCE AT DECEMBER 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99205eb539fe44e688694e9c32636419_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTItMS0xLTc0Mzkw_fece5f31-8da2-4063-86ac-74738205d6bd">135,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99205eb539fe44e688694e9c32636419_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTQtMS0xLTc0Mzkw_6cc37b37-06ae-43b3-a581-c8e295e6431a">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c116ced97cc4fe5b21319832ce43f61_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTYtMS0xLTc0Mzkw_dc7bff86-da75-41a5-b9ce-309465c24e70">625,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f04615dfbd45e198c13ee612a4296b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTgtMS0xLTc0Mzkw_62380bb1-5d6f-4064-b5f5-614a595345e4">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie53b6dc71630413f9a2aeceedcc0e052_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTEwLTEtMS03NDM5MA_cc05262b-7bf0-41a1-85a7-f5b939e7e7ea">474,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTEyLTEtMS03NDM5MA_5604ccc6-6eaf-43c9-8333-267187a26c07">151,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative adjustment from adoption of ASU 2020-06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee6817d503e4a18b7eb816904b0aebe_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTYtMS0xLTc3MDYw_42d90888-0e2a-4922-90f3-89aed6290766">65,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa017f03308949e29662213e518d9cb3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTEwLTEtMS03NzA2NA_f4c209d9-958b-4185-b9d9-c0a829222217">12,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaed2278944d84aca8963978003d797f3_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEzLTEyLTEtMS04NTI3NA_58ad16c6-aa06-44d7-9bab-db0fc5533914">52,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTYtMS0xLTc0Mzkw_7bf82bf6-eaf6-46aa-bc64-4e5d1e38f39f">20,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTEyLTEtMS03NDM5MA_0db9fc45-867c-4cea-9704-6a406befe3eb">20,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for the induced conversion related to convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTItMS0xLTc3MDcx_3a9528e9-2c6b-4727-b3e5-bcf1fff5bb06">9,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTQtMS0xLTc3MDgy_73bb399e-d0fb-455f-a58d-eb3eae8631ad">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTYtMS0xLTc3MDg2_77e1c285-b5b3-4432-9c41-8269239001ff">13,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTEyLTEtMS04MzE4Nw_5dcb3cdb-6744-43db-be94-4da70fc60900">13,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTItMS0xLTc0Mzkw_fbedc20b-e88f-496d-b6b1-4b06680a7c67">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTQtMS0xLTc0Mzkw_2823904d-b920-4ced-b32b-31ec668e5697">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTYtMS0xLTc0Mzkw_85b88e70-459a-4490-a217-f7377efc2eb2">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTEyLTEtMS03NDM5MA_61564cea-c0e5-4287-b6bb-c40e394a4d40">12,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTItMS0xLTc0Mzkw_b848a224-8b52-49f4-b58e-4d20305a553b">8,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTQtMS0xLTc0Mzkw_73592b2c-efe9-4bfd-a076-b2cb8eaa23fb">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTYtMS0xLTc0Mzkw_8a18a440-7868-4a8f-90a1-cdf64468da94">350,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTEyLTEtMS03NDM5MA_5fd31c0d-050a-4cdc-936b-aae6f1328caf">350,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185f758e56d34e259efb04a87b79e6fd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE5LTgtMS0xLTc0Mzkw_15360597-fe81-4d86-90f4-ba99ad284cb3">642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE5LTEyLTEtMS03NDM5MA_2db08823-1bd9-419c-b43f-10d33b5bd4f5">642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb480a816cd4772ba95677abf4d9f15_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIwLTEwLTEtMS03NDM5MA_24fd6654-3390-4047-bd3c-c6eb05b4b24b">402,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIwLTEyLTEtMS03NDM5MA_1527a884-8a02-4ced-8d08-0017bb71a04b">402,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BALANCE AT DECEMBER 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c457ab9e1fd454291cd030cc56319d8_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTItMS0xLTc0Mzkw_30427e81-38ef-4bb5-aa80-08a2eb3d5fa5">137,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c457ab9e1fd454291cd030cc56319d8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTQtMS0xLTc0Mzkw_3e7d7137-8c2d-4818-96ad-1e247af925c8">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ffb5ed70da4329a8be32a8e3f59679_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTYtMS0xLTc0Mzkw_210b5dc1-aac6-4e4d-8810-007000dedee3">256,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3a0d1278564dac88cdb6a4890dbeb0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTgtMS0xLTc0Mzkw_12ffc752-cfdb-4e6c-a7c8-be7248bb3a9a">620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa39e1da314354bf34589788f5d3f5_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTEwLTEtMS03NDM5MA_50690b0e-7f58-4821-8921-5afb4cb0ce9e">58,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTEyLTEtMS03NDM5MA_6564f586-233b-4462-be9c-41050d3b901f">196,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIzLTYtMS0xLTc0Mzkw_1f2674f3-38b5-4982-b9e5-6796321cc495">24,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIzLTEyLTEtMS03NDM5MA_2583660c-e291-4721-a923-8597fd86ed84">24,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for the induced conversion related to convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTItMS0xLTc0Mzkw_bb88eae5-e37a-4924-9b00-acacb3d5b526">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTQtMS0xLTc0Mzkw_9a26f679-d9dd-469f-9e51-e38c4b2e72e0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTYtMS0xLTc0Mzkw_51d3859e-4982-4056-a216-ea7c71cb22f6">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTEyLTEtMS03NDM5MA_8e15ab2d-d863-4680-97f8-448f65b02145">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under the ESPP plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTItMS0xLTc0Mzkw_d8787bad-b1ea-4933-aca5-625d06656339">1,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTQtMS0xLTc0Mzkw_cff7308d-4a9c-4150-85a3-de27fe8ce08a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTYtMS0xLTc0Mzkw_9fd7e45c-af68-4c3e-be36-b1560506e01d">14,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTEyLTEtMS03NDM5MA_9451a4ae-303a-4ebc-b9c6-82a965dcf34a">14,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capped call transaction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231" decimals="-3" name="halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTYtMS0xLTg2OTM0_86bec908-a1aa-45bf-bc44-a924a0025596">69,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTEyLTEtMS05NDUyNg_d19ff79b-e3e3-47a6-92aa-1cb1fffed9c8">69,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTItMS0xLTc0Mzkw_884dc7cf-9db2-42dd-bb08-3894d6d5a643">4,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTQtMS0xLTc0Mzkw_64fe92e8-e3f7-451d-ad69-ede6ff7240ac">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTYtMS0xLTc0Mzkw_9d7c0554-baa6-4e94-9086-635e7e178e06">199,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTEyLTEtMS03NDM5MA_5d3eed11-b842-4bb5-b8d4-95b0e1b462a9">200,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa88a5eb896493187880ac27c0e4dae_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMwLTgtMS0xLTc0Mzkw_7ed3b20a-4e44-4c08-9752-961a637c6127">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMwLTEyLTEtMS03NDM5MA_be9cf10d-26b0-4882-a8f2-33ee09cd052f">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5286105d8e646a890ecc12d4b237245_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMxLTEwLTEtMS03NDM5MA_6dbabfa2-67e7-4334-a063-39b58eebd0b2">202,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMxLTEyLTEtMS03NDM5MA_7a1e0644-dc83-4345-8aa5-adcc0df7696d">202,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BALANCE AT DECEMBER 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6665e5678736405d8d250f39ff73c605_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTItMS0xLTc0Mzkw_9838ce9c-00e7-45ce-8404-58982a0a99b2">135,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6665e5678736405d8d250f39ff73c605_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTQtMS0xLTc0Mzkw_37322953-3666-48a4-bdd0-f9803aa1c313">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ddf1b282954e588fac184cee2096f3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTYtMS0xLTc0Mzkw_5c4afba6-121f-40da-b9ce-431e311f11d9">27,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if03f2e05bd964f27b59d8e973985f611_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTgtMS0xLTc0Mzkw_eb6943db-fbdb-4efa-9c87-01201640f6d1">922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0f4252003945d1b7cf619e91241e33_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTEwLTEtMS03NDM5MA_74051915-ae32-42a2-956c-e8ee9c015d04">143,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTEyLTEtMS03NDM5MA_50829b5d-dea4-4690-a209-82f754547a60">169,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:117pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_112"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i732e51618ba84e17b469190f5cc138c6_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM5MjQ_7b45fa0b-62d0-470a-a71c-3abc1d74757c" continuedAt="i9446e124381c4f2f97d9193160fef25d" escape="true">Organization and Business </ix:nonNumeric></span></div><ix:continuation id="i9446e124381c4f2f97d9193160fef25d"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving&#160;the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids.&#160;We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex, that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver.&#160;Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma (International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC)(&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from <ix:nonFraction unitRef="collaborator" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="halo:NumberOfCollaborationsRoyaltiesReceived" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyMzE_49549d09-71cc-470c-bef2-3e51d37e3e94">three</ix:nonFraction> of these collaborations, including royalties from sales of <ix:nonFraction unitRef="product" contextRef="i60c9f6a3aea6447bb885f06a67eeffbe_D20220101-20221231" decimals="INF" name="halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNDE_81354fb8-29b6-4bd5-a0c5-8b614ba92e18">one</ix:nonFraction> product from the Takeda collaboration, <ix:nonFraction unitRef="product" contextRef="ia03e264b59b746d98f5b7e2c7a6418fd_D20220101-20221231" decimals="INF" name="halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNDk_a77eb4d0-845a-4fdd-a6ef-53fe3bdc07ec">three</ix:nonFraction> products from the Roche collaboration and <ix:nonFraction unitRef="product" contextRef="i0fb48210945840e8bf77e3e377c72c8b_D20220101-20221231" decimals="INF" name="halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNTk_d76fcc2e-9de6-480e-a60d-dde37eb605b7">one</ix:nonFraction> product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries disclosed in Note 2.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_118"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTk3_53b1c6d4-2560-45ce-91af-f3da4055e27c" continuedAt="ia96f305b8a284dc7b09cbb038b6abda0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia96f305b8a284dc7b09cbb038b6abda0" continuedAt="i111a4230899f4001a85669cf43bce77a"><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTc5_8f5263c6-91c6-49c2-b9b3-bf9fa9051c12" escape="true"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDk0_055d2b49-083f-47a3-a1bd-c225d5674cd2" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of December&#160;31, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQz_a4aa5050-2ab3-4362-b25f-7ba4d32189d5" escape="true">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQ1_346a8ba8-a558-4f65-9baf-cf0bbe0b0315" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2022 and 2021, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzI4MzY_5aab020c-86a3-4097-9101-e37c073dd56a">0.5</ix:nonFraction> million was pledged as collateral for the letters of credit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDg5_7657b110-68e1-499e-b51c-4e54dd8da89c" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i111a4230899f4001a85669cf43bce77a" continuedAt="i40b13f1f06fd4a199359175ca7eb028a"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTQy_3f05ed6d-c10f-413a-b7a8-b6cb34da053f" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer&#8217;s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded <ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxMDg_222e8aaf-6104-4708-aa1e-ca0ff2ffe61f"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxMDg_a5b4d569-5fa1-4021-b05d-f479cc1739aa">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts at December 31, 2022 and 2021. Approximately <ix:nonFraction unitRef="number" contextRef="ic8a632685f724b3dbe494cea07cd7170_I20221231" decimals="2" name="halo:ConcentrationRiskPercentageInstantDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxNjQ_7e976ea8-8bd1-4dc1-ad38-f99e7b773074">52</ix:nonFraction>% of the accounts receivable balance at December&#160;31, 2022 represents amounts due from Janssen and Roche. Approximately <ix:nonFraction unitRef="number" contextRef="i4d74a6abc13a425a8418a3669d66efc8_I20211231" decimals="2" name="halo:ConcentrationRiskPercentageInstantDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcyNzg_20f5d549-2a7e-4ac6-96bc-353209fac5b9">90</ix:nonFraction>% of the accounts receivable balance at December&#160;31, 2021 represents amounts due from Janssen, Roche and Takeda. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDgw_dc04d637-0310-42ae-8d14-0e6a82040632" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:56.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f9c44c518d2425ea72beec31a2cfebc_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItMi0xLTEtNzQzOTA_f1636e92-ce43-4430-9bdf-cbd16d3d678d">20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0043cfac8af6431f80518ace0a62f8c4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItNC0xLTEtNzQzOTA_a290a0ca-40f8-4247-99fd-f5aa41de1a32">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib244486e83334e049f9f415b79e745f0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItNi0xLTEtNzQzOTA_1fd0ee28-373c-4e38-865b-49c6c0d2eaf6">35</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c942b53e0e34ec598f5d722217d08af_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtMi0xLTEtNzQzOTA_c65e9d8e-f0ca-43c8-bd06-99bb84023f84">46</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d4a9fcdff314021b35297f8bb703b1f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtNC0xLTEtNzQzOTA_e84f90d0-44d7-4573-82c1-299a21bb9014">48</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b260f831be1449294bba3c541338639_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtNi0xLTEtNzQzOTA_d6884ed5-bbb1-45b9-ab31-113950b7d269">26</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea80ef23e3af4bc4be5f2356bb7d3fd5_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtMi0xLTEtNzQzOTA_1b65de95-127a-4d8a-b931-1011591a3145">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a2b61270d2f40c6863815f87fb3703c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtNC0xLTEtNzQzOTA_36005c02-ab65-465e-9dfa-899e3b99b645">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia36466ed48de4b458fea7a53fde94578_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtNi0xLTEtNzQzOTA_012467b1-3e79-4956-9f1e-7bf8afdd8dac">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01dfe5b9a34240f480cb63ff4e1b02c2_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtMi0xLTEtNzQzOTA_88e02cf2-c24c-41c6-a43d-f4c9141fcc84">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4698a330a0b744d6b6d168b99f00f6e0_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtNC0xLTEtNzQzOTA_65484e45-49af-4bb2-9b92-e9d101f35aca">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce4eddf7dff4d1f9f2c4573eb5f3534_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtNi0xLTEtNzQzOTA_66daf3d9-7437-4611-a227-2aeec576d8c9">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:56.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64016d8d05444060803595ff46f871b5_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItMi0xLTEtNzQzOTA_c57587cc-9a25-4a18-874d-936b047de763">437,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fb9df557854a4aadba56811dda6704_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItNC0xLTEtNzQzOTA_989fccf9-63f4-49bf-b1db-743e5e42b76e">293,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac11f44bfb95456296f38ba52920a3c3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItNi0xLTEtNzQzOTA_7056c737-1cc7-4e56-b501-ecf00c7dbd24">106,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de7cf8a78e4bf89bff3256afe84223_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtMi0xLTEtNzQzOTA_a41f8cef-8ecf-4599-af82-ec7d8c9be998">166,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica047ad710284104a38c9d206a018d0a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtNC0xLTEtNzQzOTA_9823a9a4-a447-4afd-a8a8-36cdc43d72b0">134,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae824ce4a274eccaa7296d3a60e81c1_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtNi0xLTEtNzQzOTA_aea77b12-3faa-4ffa-89c2-e99c87aaa310">95,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if724606c27844c38bcc67de0fd811b33_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtMi0xLTEtNzQzOTA_d62d12f4-d8e7-41a4-96ea-01fcbdab7e3a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db9f9565034499aa800a640e58be214_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtNC0xLTEtNzQzOTA_6bcfc95b-a514-4082-8ea7-f956ab409d56">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161c82ffd29845e4a51dc871f1f5be81_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtNi0xLTEtNzQzOTA_f4957bd9-8c6d-4024-8f00-0b6de3fe86be">30,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d2c71a5430c427b9f25c98b1682de64_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtMi0xLTEtNzQzOTA_42597817-7a87-4089-966b-7e1ed62da410">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b127d42f404009be3f5197ca82946e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtNC0xLTEtNzQzOTA_66b26118-d18b-4798-a464-20fe463ced6c">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe33da92d9bb4158bc8a5df544e374a7_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtNi0xLTEtNzQzOTA_d2f424d5-752c-46e4-9cc9-3d28e5dd64e9">20,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97526871a974553b87645589cdb1f48_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtMi0xLTEtNzQzOTA_8feefe0d-e2cd-4bc0-b660-23fc97e639b3">47,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie834c01de6184c509a71caad06bb9266_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtNC0xLTEtNzQzOTA_914723e2-f128-4787-8c93-b5b1f55b72e3">11,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe8666679dc4bae993f8d56771a1678_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtNi0xLTEtNzQzOTA_16d27fcb-dd92-499b-b0d3-3309f53f426b">10,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514044e6ba7547189405fbf239f8caea_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctMi0xLTEtNzQzOTA_cf256883-34d8-4122-a2d3-b346788c7ed9">5,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b5b3910fab4729b3312f22278dd16b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctNC0xLTEtNzQzOTA_dcf5b9bb-9aa2-4c2b-b020-1b61ed7bf7ca">3,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad21366e94841b6b92a3ed6b8d2c8c0_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctNi0xLTEtNzQzOTA_10671869-ba64-4dca-9fc4-344680f4c03f">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27889e318d8545478c0d04d0e999f6a4_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtMi0xLTEtNzQzOTA_b3a61bb5-3ccb-4965-9f7f-d8aae645d26f">660,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb93b74a42f341839f733106bc085ac3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtNC0xLTEtNzQzOTA_a14c9cd9-7bc0-4018-95e2-7b6f2d28b68b">443,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6d5252a77b41629cc0e5e24355f1dd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtNi0xLTEtNzQzOTA_603df498-d213-434f-93a4-93bfe53ecf09">267,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTI2_4dc25a72-89ff-42e3-8190-a25349f80e94" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded <ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzg1NzA_8d90cc5d-a43b-4053-a934-2013e32e68c2"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzg1NzA_ffed0aae-1550-4ba6-8873-88ac4004b49f">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts at December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTky_492fddd9-9bce-4661-a33f-6bffd18797bb" continuedAt="i68dc92fb88294a92bfa2581081285899" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i40b13f1f06fd4a199359175ca7eb028a" continuedAt="if0e65280c7e1410e9411043fb803d3f7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68dc92fb88294a92bfa2581081285899">and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</ix:continuation></span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQ0_83f79d5e-3734-4464-8f1e-52e3fa3b46da" continuedAt="i5ef27175a372498480b8bff00ee59227" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from <ix:nonNumeric contextRef="icfd51566fb48417294740b3e09f08d33_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzk2NTM_6d2e546a-57fd-422c-a06c-fe2ed7aceb70">3</ix:nonNumeric> years to <ix:nonNumeric contextRef="ia2e016f17e20404aa3c14094fdf86c28_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzk2NTk_aefea1e0-d0aa-453d-92fd-c16ed3fa2ca2">12</ix:nonNumeric> years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ef27175a372498480b8bff00ee59227">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDkw_3bf08919-4646-4ac9-a012-cfcffb5a906f" continuedAt="i716c99673d38472191e5f4a9d231d6c3" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i716c99673d38472191e5f4a9d231d6c3">Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from <ix:nonNumeric contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzExMzE3_9ccab25d-9707-48fa-8cf5-76fd1a733c39">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzExMzIz_dca088eb-d835-4950-bb4e-75b627d0ac2b">ten years</ix:nonNumeric> and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDUz_d1ecbc5c-6f71-47af-b07e-d8de7d6fb694" continuedAt="id6213d1d55ea42308dbe79ea087234d7" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id6213d1d55ea42308dbe79ea087234d7">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.</ix:continuation> </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDU4_7e8761b1-5bf2-44aa-a58c-9de75d2d1161" escape="true"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM4NDgyOTA3ODA0ODk_ed76da53-d539-4614-8509-3f40bdd7cfb6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="halo:GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM4NDgyOTA3ODA0OTA_6134271b-e813-4b30-a817-b4b3c39758e8" continuedAt="i42da5e86e2fc449da166f7d6166efbd8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="if0e65280c7e1410e9411043fb803d3f7" continuedAt="id3c686d228b84978812b8df16a8650d8"><ix:continuation id="i42da5e86e2fc449da166f7d6166efbd8"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:continuation><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDYw_98a43518-1c61-491b-b336-f9a1ecd1b336" continuedAt="ibd1abebdfe5347c1a699c7ec800a6e14" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or  (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="id3c686d228b84978812b8df16a8650d8" continuedAt="iea59e34aeae94ac0bbdf0f886c8f20f0"><ix:continuation id="ibd1abebdfe5347c1a699c7ec800a6e14" continuedAt="i50a33a2ab1744da38405e2af5c754754"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="iea59e34aeae94ac0bbdf0f886c8f20f0" continuedAt="i1b73c79ac10646c58eaed9718b1a52fa"><ix:continuation id="i50a33a2ab1744da38405e2af5c754754" continuedAt="id657e7e2535b4b3486d20ca2b34ac352"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i1b73c79ac10646c58eaed9718b1a52fa" continuedAt="ida227af554f84e4b90f48c3a04f24ccc"><ix:continuation id="id657e7e2535b4b3486d20ca2b34ac352" continuedAt="id348769ef3ac4faca30a37ee54b844de"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ida227af554f84e4b90f48c3a04f24ccc" continuedAt="i0cee04cbc6ef404091a3e019a41e2b06"><ix:continuation id="id348769ef3ac4faca30a37ee54b844de" continuedAt="i938ac59e8d5646df9ed09b8112e04277"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,  TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our consolidated statements of income.</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i0cee04cbc6ef404091a3e019a41e2b06" continuedAt="i126c469a60a14720be5d05b809696aaf"><ix:continuation id="i938ac59e8d5646df9ed09b8112e04277"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDgx_40656374-27a0-4e28-bb38-2ba05b11c976" continuedAt="if48ed462b5e444eca2e1c2a87c2e86c8" escape="true">Cost of Sales</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if48ed462b5e444eca2e1c2a87c2e86c8">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</ix:continuation> </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDMw_8f097b02-4524-4a45-8cfb-afaf731434f8" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTcw_a0e109ef-d292-4fae-b3ec-0fb8f119933f" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTkw_5c28e065-3871-4cc1-8af7-95a6deeaed94" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTg1_4f30eba5-a4d4-4b2b-b17a-eb5890b6671c" continuedAt="i292092d5a56249f6be332e3149bbb777" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i292092d5a56249f6be332e3149bbb777">As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in <ix:nonFraction unitRef="segment" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM2Mjg2_e8eddb05-b6f2-4f2b-adb1-0f6696147af8">one</ix:nonFraction> operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and  (ii)&#160;product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment</ix:continuation>.</span></div></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i126c469a60a14720be5d05b809696aaf"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTkz_94d285c9-71e8-42a3-a1d5-8b5c23149ef0" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_121"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDM_10b1beed-aa44-4793-bcc7-6a4f80478127" continuedAt="i79d113326cb64d0eb289fa5aa9fa6516" escape="true">Business Combination</ix:nonNumeric></span></div><ix:continuation id="i79d113326cb64d0eb289fa5aa9fa6516" continuedAt="i930f5f38faae4a71b109739c507bf119"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $<ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjAyMg_f8c020c3-14f2-4ac8-b58c-01e76dd3ae43">1,045.7</ix:nonFraction>&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $<ix:nonFraction unitRef="usdPerShare" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="2" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA0Ng_0131515f-3cc5-41b7-ac93-375412669de5">5.60</ix:nonFraction> in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#8217; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $<ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA2Nw_69f51dd8-98d9-4942-a47e-24ed97e35093">19.7</ix:nonFraction>&#160;million and seller transaction costs paid by us on behalf of Antares of $<ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA5Ng_06570eb1-c636-41ea-a9e5-9bae2cd4f1cb">22.9</ix:nonFraction>&#160;million. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#8220;BofA&#8221;) and other lenders that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="ide8e0bb6ebfa47f385eb8b8a3556d019_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjEyNA_6cd1a311-f19e-41a7-a39f-80695742d6d2">350</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i5b5cf73d12df4c3bbe1f1cedfe244210_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjE1MQ_00f31d3c-9402-40f1-abb9-e1bf4903b135">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;, collectively with the Revolving Credit Facility, the &#8220;2022 Facility&#8221;) as described in Note 8. We recognized transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjI2Nw_6ea3a7ec-c416-43f9-be47-7e3c5f1375f1">21.9</ix:nonFraction>&#160;million in the twelve months ended December&#160;31, 2022. These costs are reported in selling, general and administrative expenses in our condensed consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Consideration</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDU_f5e88c75-2425-4f6e-8f86-268db9ef1e6d" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:87.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzAtMi0xLTEtODQ5OTU_9204a4ed-9a41-4f58-9cd3-c19f0489fac5">956,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzEtMi0xLTEtODQ5OTU_ff591229-1884-4d34-a679-688cff7391ab">45,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzItMi0xLTEtODQ5OTU_86b68553-464e-47da-8cd8-3a2b8e986461">22,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzMtMi0xLTEtODQ5OTU_dd52f06e-80da-4257-8ed2-8b5881ecd95f">19,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredBonusAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzQtMi0xLTEtODQ5OTU_699fc417-3c0b-48f3-9645-6e0015df1863">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzUtMi0xLTEtODQ5OTU_6bbbaf04-bcfb-4a1c-9c54-01c20b15130c">1,045,668</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $<ix:nonFraction unitRef="usd" contextRef="if78cce61194d43d69a49bc5e102059f3_D20220524-20220524" decimals="-5" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjI5Ng_8c0f2522-7bfb-4d78-b561-99a0fdcf5bd2">32.2</ix:nonFraction>&#160;million paid for vested equity awards as well as $<ix:nonFraction unitRef="usd" contextRef="id0189c904b3b4a0381ae6dda4687bd18_D20220524-20220524" decimals="-5" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjMyNQ_ac689e2b-3f9f-48e9-8224-1dafb6a0d168">13.6</ix:nonFraction>&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjM1Mw_b3daade6-071b-4ffb-89dc-e3142ac1b05a">8.7</ix:nonFraction>&#160;million is included in our consolidated statements of income in twelve months ended December&#160;31, 2022.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on valuations and management estimates. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the allocation of the purchase price, therefore, the fair value estimates assigned to intangible assets, goodwill and the related tax impacts of the acquisition, among other items, are subject to change as additional information is received to complete our analysis and certain tax returns are finalized. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDg_c575a054-943c-440a-8e27-da9593b1ebeb" continuedAt="i97bf594854394779875685f9454b0fdd" escape="true">As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.</ix:nonNumeric></span></div></ix:continuation><div style="height:103.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i930f5f38faae4a71b109739c507bf119" continuedAt="i4352c3e8b4b7474e9a4a9e842c165b4d"><div><ix:continuation id="i97bf594854394779875685f9454b0fdd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:50.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as initially reported)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as adjusted )</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $<ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEtMC0xLTEtNzc5NDUvdGV4dHJlZ2lvbjplYzYxZGI3MWIxYzI0YTRkYmUyMDk2MDRlMWY3ZTk3MV81NDk3NTU4MTM5NTE_6ed90206-ee12-49c2-b904-c2def953faa5">46,548</ix:nonFraction> cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEtMi0xLTEtODUwMDA_ad53d8ce-967e-4722-82b6-0eed33244124">999,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzItNi0xLTEtOTUzOTI_cd106ee3-123f-41cf-bed1-86142a6fd0cd">999,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzMtMi0xLTEtODUwMDI_9b28d3f9-21be-4669-b94c-3e69d7407214">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzQtNi0xLTEtOTUzOTI_f5e254ae-e2dc-4d64-9f75-50bf3199549b">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzQtMi0xLTEtODUwMDI_9172fdc5-563e-406e-a305-a1ef5087ab22">82,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzUtNi0xLTEtOTUzOTI_21bd31ce-862f-4feb-84a0-6d2a4654877b">82,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzUtMi0xLTEtODUwMDI_93fc0e43-ab4f-4422-857b-763d5259cfea">34,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtNC0xLTEtOTU0MDA_528f80a4-2d3e-4e9e-b78f-cb71442ca9e1">6,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtNi0xLTEtOTUzOTI_c6d98772-b019-4a69-9924-92072f331996">28,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtMi0xLTEtODUwMDI_d004608e-35e0-460d-9e02-f66856ec5772">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzctNi0xLTEtOTUzOTI_1e72ac55-464e-48ef-a3ca-6605de054e03">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzctMi0xLTEtODUwMDI_9cf64b72-0671-4125-b5d6-ba642fe7b3e6">28,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzgtNi0xLTEtOTUzOTI_5b97814d-7483-40c3-8d94-7aa481554091">28,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzgtMi0xLTEtODUwMDI_59dbf8c5-2f47-45df-b6fa-8ad9862b80c2">987,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzktNC0xLTEtOTU0MDA_f88d5736-2fab-40d2-99a2-9461edb280b1">397,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzktNi0xLTEtOTUzOTI_db362d08-4e98-4539-a4b5-5e18e1541bca">589,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEwLTItMS0xLTg1MDA0_5980040d-75fc-409a-b97a-6e62b1993061">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzExLTYtMS0xLTk1Mzky_d1c736ec-1611-4a46-8ec7-83991598be3e">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzExLTItMS0xLTg1MDA0_63f0aefe-0f6b-41c9-911f-b3e07d1e2adc">33,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTQtMS0xLTk1NDAw_d4bb60d0-4288-4565-866f-ec304f19ebdf">7,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTYtMS0xLTk1Mzky_ff48979d-815f-4cde-b0a7-8eff33b6bacb">41,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTItMS0xLTg1MDA0_fc7ba025-db68-47ea-8316-51d7c73073c8">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEzLTYtMS0xLTk1Mzky_2070084a-7ad3-4d1d-adaf-1830c74b124a">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEzLTItMS0xLTg1MDA0_01b1da5f-68be-4fdd-846f-ea8ac342aaa2">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE0LTYtMS0xLTk1Mzky_c773be7b-4483-4420-8a37-19b43c8993d4">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE0LTItMS0xLTg1MDA0_d5a621f9-04c6-4fe6-9897-73ed0cbab0b0">159,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" sign="-" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTQtMS0xLTk1NDAw_8e61584f-57c1-43d3-81e3-c2a7806e6b97">88,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTYtMS0xLTk1Mzky_1536e488-82c5-418a-90a2-a6b37d52aa18">71,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTItMS0xLTg1MDA0_9884b71a-e98a-4fc0-a463-11ee9e160b2e">135,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" sign="-" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTQtMS0xLTk1NDAw_35809ce6-0017-4da9-bce5-1b97bc26c443">114,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTYtMS0xLTk1Mzky_76175999-8da9-4925-8ee2-721db0f28739">20,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTItMS0xLTg1MDA0_8eee26d3-27fe-4124-9194-078a3403221d">799,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" sign="-" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTQtMS0xLTk1NDAw_891ab693-cbc5-4abb-85b7-c0f46fe8dfb2">209,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTYtMS0xLTk1Mzky_b42faba2-0a92-4f54-a133-0a67bd5afbfc">590,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTItMS0xLTg1MDA0_273c2e26-b65e-4f05-ac8d-95bab6c03cdb">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE4LTQtMS0xLTk1NDAw_57115ffa-0351-4617-8aac-0bf3e1ff9f5e">209,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE4LTYtMS0xLTk1Mzky_722f2c33-1558-4f4b-b408-f82343d1f888">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable unit. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A contingent liability with a preliminary value of $<ix:nonFraction unitRef="usd" contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzE2NDkyNjc0NTQ2Nzk_f47eb009-16df-429d-842b-233f9fb15db7">130.0</ix:nonFraction>&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded measurement period adjustments in fourth quarter of 2022 to decrease intangible assets as a result of revised future cash flow estimates from the initial purchase price allocation and adjustments to accrued expenses. These measurement period adjustments were made to reflect facts and circumstances that existed as of the acquisition date. We also recorded a measurement period adjustment in the fourth quarter of 2022 to reduce the acquisition-date fair value of contingent liability by $<ix:nonFraction unitRef="usd" contextRef="id4843830e52a4d92a52b5a09eac1bca4_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MjExNjI_f8e65733-9087-4b41-961b-fd2bc3528b46">114.3</ix:nonFraction>&#160;million as a result of revised future cash flow estimates. The measurement period adjustment has been recorded to reflect facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Identifiable Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#8217; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;D will be tested annually for impairment and will not be amortized. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDY_6b435435-8ccc-4fcb-9d04-cb8c22b88b63" continuedAt="i948b2c05a95c42da943bf512a6a1cd3c" escape="true"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDY_a240009b-32e3-44fc-9de5-56228b18d64d" continuedAt="i3edf72dc3a3d43f0839135ce2c1276ed" escape="true">Useful lives and preliminary values are presented in the table below.</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="height:103.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i4352c3e8b4b7474e9a4a9e842c165b4d"><div><ix:continuation id="i948b2c05a95c42da943bf512a6a1cd3c"><ix:continuation id="i3edf72dc3a3d43f0839135ce2c1276ed"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:74.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c84478a64df453893c7636f8f759caa_D20220524-20221231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzEtMi0xLTEtODUwMDY_e311293b-bae6-4568-a52b-2375301f96fb">402,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c84478a64df453893c7636f8f759caa_D20220524-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzEtNC0xLTEtODUwMDg_2e267498-b4a0-4ef7-a182-d9a37a71ced9">7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzItMi0xLTEtODUwMDY_0e6550fa-62b2-452f-9f19-5e43ea841b0b">136,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzItNC0xLTEtODUwMDg_b5898edd-52a0-4e99-8fd5-9df5db1806dc">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzMtMi0xLTEtODUwMDY_7aa4bee9-abd4-46e1-9973-4f757d1a75ed">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzMtNC0xLTEtODUwMDg_0c16b277-997a-4735-bd32-7cb6ad401212">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ac13fbf17f4f2e89a956199a4d633c_D20220524-20221231" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzQtMi0xLTEtODUwMDY_c46daf3e-b738-4138-94f0-0483f9c5bb8c">48,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzUtMi0xLTEtODUwMDY_a12627a7-e488-41ea-b625-b3462b07f2a4">589,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include Antares&#8217; results of operations from the date of acquisition on May 24, 2022 through December&#160;31, 2022. Total revenues and net loss after taxes attributable to Antares during this period and included in our consolidated financial statements for the twelve months ended December&#160;31, 2022 total $<ix:nonFraction unitRef="usd" contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjUxMg_7768de69-fad0-4da0-804a-97667b33f2a3">112.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjU0MQ_7bc9d3c9-561a-49f7-a1f5-3cbf541b5d7a">67.6</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDc_b1ca775b-6c87-4343-91d1-818f1f07ee02" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:78.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzItMi0xLTEtODUwMTM_2b6a2122-8b87-4a7c-93ec-f55e19d9f24c">712,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzItNC0xLTEtODUwMTU_4b62ba4e-aa18-4e6f-86cf-431a750fcc6e">627,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzMtMi0xLTEtODUwMTM_e480f4a0-316b-485d-906f-eb9d1e1ca472">218,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzMtNC0xLTEtODUwMTU_aa48a5fa-937d-4163-b535-167e1e47239b">295,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal year 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</span></div></ix:continuation><div style="height:103.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_124"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMTU_e2ce47d8-93ac-4cc0-9956-4510ab370a5f" continuedAt="i2bb3dba1a7ae4bd486af812a07ef309b" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="i2bb3dba1a7ae4bd486af812a07ef309b" continuedAt="i5e2ce238b433432e8bd51a6a3aa21ba6"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMzM_d01a3859-031c-4615-8ad3-64fe620d86dd" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItMi0xLTEtNzQzOTA_b56e2341-eeb6-45b2-bcc3-f5e79e35cf09">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItNC0xLTEtNzQzOTA_62438e6f-6b84-4f3c-97eb-2e5d222fe7ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItNi0xLTEtNzQzOTA_2305c7f2-1ded-495e-a36f-3a36b6449af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItOC0xLTEtNzQzOTA_2f4373c6-fe50-4727-8cb9-e20f91448e42">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtMi0xLTEtNzQzOTA_5fe28ff2-c5e4-4bb4-9b78-334d422ef736">7,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtNC0xLTEtNzQzOTA_ea6e809a-1d97-4ed9-9586-d93629a1adaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtNi0xLTEtNzQzOTA_3098513f-be4d-4c4c-b4fa-6dcd3297d563">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtOC0xLTEtNzQzOTA_23e0bcbc-45d5-4dcf-a835-2b04b901bfcf">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtMi0xLTEtNzQzOTA_26c7c89c-787f-4a81-bc79-82f22f4123c1">111,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtNC0xLTEtNzQzOTA_bc8cadab-a481-4d52-98a0-bcd1a09e0115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtNi0xLTEtNzQzOTA_77bc74d8-409d-4eaa-b365-a9280a0b2c12">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtOC0xLTEtNzQzOTA_2b5258e5-20cf-4640-afdd-3ce9bc03bf88">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46732f52d6ca44279534ffa554f17160_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtMi0xLTEtODYyMTQ_20b5b859-055e-4071-8eb2-e3824d9efe35">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46732f52d6ca44279534ffa554f17160_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNC0xLTEtODYyMjI_f1e8fdb6-1158-4128-9448-b7e62b41fe3d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46732f52d6ca44279534ffa554f17160_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNi0xLTEtODYyMzA_cee6d1c4-5c80-4d68-ab5c-d5b0248f28ea">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46732f52d6ca44279534ffa554f17160_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtOC0xLTEtOTQ1NDE_ef7d15a1-4d6a-4fb8-a603-8c8f4f646640">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtMi0xLTEtNzQzOTA_67a0e6e9-137b-4cfc-b808-27074e366ec7">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNC0xLTEtNzQzOTA_b84f1b60-e47e-4752-925c-330f4e9013ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNi0xLTEtNzQzOTA_813a84c6-5cc3-4594-8e17-6348769918f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtOC0xLTEtNzQzOTA_d96667b9-2879-4694-b47f-1be1e387eeed">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctMi0xLTEtNzQzOTA_2aeb7495-094c-4591-aa0c-04eae83b8081">129,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctNC0xLTEtNzQzOTA_dc4fb9f7-fc4c-4843-8ce0-e2bf3dd7819c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctNi0xLTEtNzQzOTA_1f0f73f3-e40c-493e-977c-b8ea97517f19">944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctOC0xLTEtNzQzOTA_5c6afcff-574f-4270-bf1d-832d1664d997">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5224a272d9e145089365401ed07c3c98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItMi0xLTEtNzQzOTA_0f108e2d-d99f-43c8-b9fb-c35dfc9020b4">32,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5224a272d9e145089365401ed07c3c98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItNC0xLTEtNzQzOTA_aa00cb01-6c8f-4f5e-9c53-23bd41a8076a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5224a272d9e145089365401ed07c3c98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItNi0xLTEtNzQzOTA_3d2c5525-32f0-46d4-9325-d8fb44ad2e01">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5224a272d9e145089365401ed07c3c98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItOC0xLTEtNzQzOTA_82f894d5-c6f0-4cda-b1a9-a8b27fcb3b13">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35353e8145c94fd192b2662112671742_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtMi0xLTEtNzQzOTA_60ee536e-85fd-4c30-8cee-b5312e6f0e7d">58,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35353e8145c94fd192b2662112671742_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtNC0xLTEtNzQzOTA_5150e635-0ca5-4519-ab8c-b96d1bb40d8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35353e8145c94fd192b2662112671742_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtNi0xLTEtNzQzOTA_574d3b01-fb38-46fa-a9fb-3ae5edcb5180">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35353e8145c94fd192b2662112671742_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtOC0xLTEtNzQzOTA_3ad610a6-2302-49f1-9abe-e6f6cf7f0486">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtMi0xLTEtNzQzOTA_2e46f26c-082d-45d0-9562-a155be08d85e">231,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtNC0xLTEtNzQzOTA_7b11f873-2bad-4301-9889-7eeb60e67066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtNi0xLTEtNzQzOTA_7fede8fb-4d3a-4736-9a64-e36da9b1a114">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtOC0xLTEtNzQzOTA_671390e7-df98-4a98-9020-0060b44d5ea3">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Government Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtMi0xLTEtNzgxNTI_9be69273-d155-47fb-a0d0-e4afb51818f9">17,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNC0xLTEtNzgxNTY_1a56b7d7-fb7b-4507-a1c8-cdb55c3d3e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNi0xLTEtNzgxNjA_cc182308-0d7a-464a-93d1-f597fd9d3e8b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtOC0xLTEtODMxOTU_5fd7f6f0-d827-4521-b032-326703c06c0b">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtMi0xLTEtNzQzOTA_34867402-06d5-4f53-a27d-da5fcaacfd66">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNC0xLTEtNzQzOTA_c3ed9e3a-8916-4e59-8f16-0a04cffb7bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNi0xLTEtNzQzOTA_21b4d99e-8478-4b4a-af98-1e9e39a3ded5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtOC0xLTEtNzQzOTA_0b4a57d5-bcb2-4f83-bca4-d25094efa36f">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtMi0xLTEtNzQzOTA_92e46b45-de7d-433a-9aeb-1af5a47a8a87">622,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtNC0xLTEtNzQzOTA_1e0ecec6-a4f0-42bc-804e-c4cdee22540d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtNi0xLTEtNzQzOTA_a34690eb-1f38-47a4-b389-e07ba3f10974">620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtOC0xLTEtNzQzOTA_7976797e-da27-48d5-be52-110a3d842c6a">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, <ix:nonFraction unitRef="security" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEyOQ_4202b5f3-03b0-4172-a3ec-717f988b6134">20</ix:nonFraction> available-for-sale marketable securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzIwMQ_3b759b89-5452-4b10-88b0-4c2d4c28c874">117.2</ix:nonFraction>&#160;million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzI0OA_f4eb9abb-2999-4fed-a0c5-780b5e4591dc">0.9</ix:nonFraction> million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of December&#160;31, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMjg_60f78136-f391-4e8d-b885-4d8cb1a42058" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:66.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzEtMi0xLTEtNzQzOTA_85a88e4b-db5f-4726-846a-67bd03a1f6f7">114,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzEtNC0xLTEtNzQzOTA_c23db440-1e50-4467-8f33-5f37af5f66a6">500,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzItMi0xLTEtNzQzOTA_dd58e9ec-76d6-4ed4-9b4b-37e514556ae4">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzItNC0xLTEtNzQzOTA_fa1d765d-8813-45a6-a7ed-f0cce49cc1ef">121,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzMtMi0xLTEtNzQzOTA_b4273f5a-ff0b-475c-b7cf-4cb5e6c3dff1">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzMtNC0xLTEtNzQzOTA_f2d6072f-05f6-44d9-bbfa-65c358932f07">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5e2ce238b433432e8bd51a6a3aa21ba6"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMzA_1b840746-530b-4e4d-97bc-ec194585ebe0" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:29.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f722a27dd74b5a9adc18b420c72150_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMi0xLTEtNzQzOTA_41cc1b4c-545f-493c-bf0d-884a7592fe78">191,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e4382062e1f4fcfa9e54b30b7e489a5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtNC0xLTEtNzQzOTA_f2606eea-c338-41b9-9409-8a954c5dcb0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i043b1eced14f4b38ba17b9e0e8ab15b0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtNi0xLTEtNzQzOTA_8398edf1-593a-404e-bae9-691a061d0d3a">191,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1deac62ace9c4a888e48f6d9be99dc47_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtOC0xLTEtNzQzOTA_5cde5dc0-7e95-4a1f-975a-7e13bc402d36">118,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bddbb8047a491eb63c197e05eb5ca4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMTAtMS0xLTc0Mzkw_db2ad7cb-91ec-4152-bc58-6e8a01b5ffa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b8615d6e094174ae8446257115cc1d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMTItMS0xLTc0Mzkw_bf683083-d7a7-445f-8529-22b6639a47f8">118,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bcd41a7e814a89918feebb95c129d1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMi0xLTEtNzQzOTA_79fd4d6d-719b-4a35-9de2-439bb3eaf9a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib382d0872eaf4b9bbec1ce9d6cceaaab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtNC0xLTEtNzQzOTA_e0c0ec3c-0c6d-4131-b88f-abbc42f2d3d4">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtNi0xLTEtNzQzOTA_efa81c1e-501c-4783-ad2a-db442117599c">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb83fc6f4b8a45c282238332c7a95841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtOC0xLTEtNzQzOTA_7a27c3eb-b0ed-46a5-ba09-3899b04c473d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5560b65f4f134a1a914172192531d861_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMTAtMS0xLTc0Mzkw_2eb64b55-a41d-438c-aeb4-1c2cd8e523bf">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5224a272d9e145089365401ed07c3c98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMTItMS0xLTc0Mzkw_614341a0-3992-43c3-8ab4-dd90941cd6f3">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d7d10d24c84281aed5c4277d167461_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMi0xLTEtNzQzOTA_3b85c7c0-e148-4b44-afb1-c0866a5090be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c4df731a4f4a4f8fec1bae60a10484_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktNC0xLTEtNzQzOTA_f5153236-de23-4adf-b962-9f15fc8e5df1">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktNi0xLTEtNzQzOTA_af10d751-3914-4288-9bb7-06523f34b38e">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295651e13dfb4e4cb45f942c4b96e6f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktOC0xLTEtNzQzOTA_18e9e971-43d3-4b06-bb33-4e68ab7f87c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615de6d5889a4f7d9b1e1d3352937654_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMTAtMS0xLTc0Mzkw_7f571c9c-163d-46df-a472-1048f54b1cc7">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35353e8145c94fd192b2662112671742_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMTItMS0xLTc0Mzkw_0ed4edab-9985-48f3-8742-15963edd8b0f">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7b7b97519c44cdb7226898a6b54701_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTItMS0xLTc0Mzkw_34266971-fc7c-4d28-80af-38ae6c44a95d">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb9ad4bee4649d78ef3bbf1a1aea014_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTQtMS0xLTc0Mzkw_546053f9-db71-47d3-86e4-945601e151fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61a0f73d0f4425b9a935315a9005c6a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTYtMS0xLTc0Mzkw_7255e293-d805-448d-b746-7014e60b9d5d">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9ffaaa4bdf4e638aa15b0e3a30d7a0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTgtMS0xLTc0Mzkw_6fd2b15e-8956-4bc5-9bae-c7ec31d15704">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ded3a1a584de3b69284715edd8be3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTEwLTEtMS03NDM5MA_dcc45ea7-7bff-4dc6-b7bf-1d97ee5e50e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9996ff38f74a49bde5979244e15762_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTEyLTEtMS03NDM5MA_fea108c2-7669-4afc-b58a-66ae2a52bfe1">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54544bbec51b460cbeee6e64fdecbc48_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTQtMS0xLTc0Mzkw_73923599-9c5d-4d6e-b2c0-4ae231811c4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950980fb07fe4ca48b48af65c8b224d9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTYtMS0xLTc0Mzkw_9d150699-fe9e-4b08-867c-76dac01da38d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3553503311549e6857ea8d049b691a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTEwLTEtMS03NDM5MA_b037a254-3db9-44fa-926c-8af251133330">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53f54adb1e5481b8288c131402733b2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTEyLTEtMS04NTMxMA_95ad9544-bc2d-4c02-b086-d0f5071fcc83">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1c66ed8e4d4b888d17e06a9f8a1c64_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTItMS0xLTg2MjQx_91e2ba2c-ae02-4561-854b-1e11a9c73c45">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f0a156c29745f4a1204a53f9dce5d3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTQtMS0xLTg2MjUx_5e0cd3ad-33ac-4431-8452-eb7badea6bd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877577fc197a449885cec3a196905eba_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTYtMS0xLTk0NTUw_55a02427-b847-4431-914a-1ff7bf9436e0">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbcfda7fe5a4065a2147788d3d2fc7c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTItMS0xLTc0Mzkw_4283a1d8-5514-416f-943f-27050334fb75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee689853b26446da4160f945de64c92_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTQtMS0xLTc0Mzkw_5a4f03a1-83f5-4ebb-ad30-9350292d564f">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f39c15bffce464ca04a0703850470a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTYtMS0xLTc0Mzkw_0b87257d-2b9b-4c59-9e56-ea4c85be828e">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78115efa8e2a4a209a2d9ea8a508c0a2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTgtMS0xLTc0Mzkw_bb9988ab-bcf0-4a72-8fcc-ca7e0c8eda1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib225da12484b414eaf886beb6791a1b2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTEwLTEtMS03NDM5MA_c6e786b6-ef9c-4f25-84c6-1ee62e1245c2">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8074c437f714421b84dc5a2ed6b754ed_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTEyLTEtMS03NDM5MA_b1e965a0-41a2-46ea-9a4f-6c053cbddbcc">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7988ef80a8a4481095a9cd1737928a5f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTItMS0xLTc0Mzkw_72f00942-2361-41f1-8dd5-c9b08a3bb254">305,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712a0cd86d3144a297233b33d9781be8_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTQtMS0xLTc0Mzkw_e823bed0-a480-48d8-8368-c74e6079823c">15,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTYtMS0xLTc0Mzkw_d907cda4-a81d-45f1-a9cc-71d743da02f9">320,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732cceb6359a4dd8865fb5bfa8aeddc9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTgtMS0xLTc0Mzkw_9fd86423-f525-492c-b2ea-7ec4ad74f638">349,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14a2f85de0e485aa57a080d39183883_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTEwLTEtMS03NDM5MA_e65268b4-48fa-49d0-8fe6-aae7f321af50">391,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTEyLTEtMS03NDM5MA_d5a57d44-41e3-459a-8779-c9b23ced04fc">740,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="i2e565d32284c4425b05dd65037f38a6b_I20211231" decimals="INF" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzk0OA_961b4647-fb14-4e5c-a717-3106e968b88f"><ix:nonFraction unitRef="usd" contextRef="i2f73c68191284413968a1e7705daeae2_I20221231" decimals="INF" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzk0OA_ebe3ebfc-3787-4d54-bef0-0033c46d3338">no</ix:nonFraction></ix:nonFraction> available for sale securities that were classified within Level 3 as of December 31, 2022 and 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contingent liability with a value of $<ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzU0OTc1NTgxNjEwMA_4c7e0e4b-f60b-440a-b707-dac7545fbed7">15.7</ix:nonFraction>&#160;million was assumed related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. We will remeasure the fair value of the contingent liability on a quarterly basis. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date is recognized in our consolidated statements of income.</span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_127"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4Mzc_12c04c1c-4a44-4b43-b235-1af4142bcbfc" continuedAt="i1a7f7421eab84860a1026a941f8864e4" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i1a7f7421eab84860a1026a941f8864e4"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4NDA_5760a95d-36e2-4291-bcd2-ff19375c73e5" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItMi0xLTEtNzQzOTA_4546fb48-73ee-4383-9bca-7a4115abbebd">360,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItNC0xLTEtNzQzOTA_482ccb13-55ef-45bc-835a-998066c30261">203,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItNi0xLTEtNzQzOTA_4250e05c-3e4e-41cb-9f79-6948db3a1e68">88,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07f947ffcad43d1a6fdf23e3ea0bfce_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtMi0xLTEtNzQzOTA_5f015124-38dd-4e7c-9df9-5f6d0a76b339">82,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eaf51e78af04c08b9c64c703cd9221e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtNC0xLTEtNzQzOTA_ed80f446-05b4-4ab7-a56f-259f4646d8ac">80,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8112a093b0c7415eac739e594b629a96_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtNi0xLTEtNzQzOTA_f5bf3c37-fdf6-4910-97e3-c4e4e98871d8">38,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4880129e17ee45a6a5ecb048862fed65_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtMi0xLTEtNzgzMTc_a5be6214-c229-428c-9c2d-36b01e26a1fc">72,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb52ba56d5ce40bbbf9715e825b909b4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtNC0xLTEtNzg0MDI_11be0f85-58d7-416a-a58d-993d344e0ac8">23,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597a7d3db45a491e997fe35aa9195b3c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtNi0xLTEtNzgzOTA_87e9774b-e72e-4925-ab8d-e4ab8173e81a">17,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Device Partnered Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9e40e7d2f244e7b9f66aabd6640852_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctMi0xLTEtNzgzMzI_f3aa467c-cded-468d-97b9-85a448cb263c">36,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75bae0cb0a8a47fb8fcca30b77f6d60e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctNC0xLTEtNzgzMzY_4e4c4ab4-7ce2-481e-b63b-6e704cc4c329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6fd44e583748d3937db0246f9e5e4f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctNi0xLTEtNzgzNDI_106fcd07-d757-41af-b8a9-920e715c1e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtMi0xLTEtNzQzOTA_da4f4601-36a6-489f-8518-3cdc28c6251f">191,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtNC0xLTEtNzQzOTA_b7ae06af-4c12-44a9-88d2-cfc2a8602569">104,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtNi0xLTEtNzQzOTA_fc839084-bfb6-49f8-9512-077cfe3627d9">55,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2f770cb08e46b1a34f5576b2a08663_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTItMS0xLTc0Mzkw_52c46979-1365-4831-a902-c91d9efa27fa">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0700499fc900499a90faac950d6d4b98_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTQtMS0xLTc0Mzkw_333e5015-d485-43be-8d1a-3d398ec77033">42,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023f24dd6ed643a38263bb9cabdf7718_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTYtMS0xLTc0Mzkw_01f794b1-2e8e-47d1-b19b-dfd04b642e60">37,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development milestones and regulatory milestone and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0faa2d5cad4416b986007776707121f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTItMS0xLTc0Mzkw_a35f0aea-824f-4c7d-b6db-97af468f7940">59,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b10c333e5154705818149064609c145_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTQtMS0xLTc0Mzkw_600dfc6f-f139-4661-b867-878fc4dac2cc">42,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1416bdf7345c4bbabccb8d19a9cf5196_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTYtMS0xLTc0Mzkw_c47714da-a3b1-4a1c-bec9-97a8f3a89215">69,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fcd05c589b426dac58da8abe28d615_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTItMS0xLTc0Mzkw_9a3f6219-9eb2-408e-a64f-0a5ec2645ea1">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice50c8c082a44a54a348b09d6dad8248_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTQtMS0xLTc0Mzkw_171009ed-2eb8-473d-a08d-d6ad0116e7ca">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4ba887d67549afa576d9763e0d4017_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTYtMS0xLTc0Mzkw_7ac55d36-80de-4b59-84c5-acf3556402ec">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85e98d198d2439aa49f4b9aba5ac485_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTItMS0xLTc0Mzkw_74cb8d2a-269d-40b0-add0-7954a2f815b1">9,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616018ae8ce340d4a55a54fe3fc0c272_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTQtMS0xLTc0Mzkw_db210134-992c-490e-9bae-a53e915e8e8b">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaaf000b7794cc1afa3317b68317e08_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTYtMS0xLTc0Mzkw_2d13fee8-ad53-41a3-af45-955e4d870d00">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTItMS0xLTc0Mzkw_efe983de-83ea-49d5-9011-40d782a92226">108,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTQtMS0xLTc0Mzkw_1525f97e-fc37-471c-b4c4-922121b77947">135,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTYtMS0xLTc0Mzkw_1f77b4a5-4256-4c0d-aac3-61152cb0c7f9">123,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTItMS0xLTc0Mzkw_62f81c8b-ece3-4a81-a5e9-280d04cc59f4">660,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTQtMS0xLTc0Mzkw_7be1b223-75df-424b-a7d8-6de357730a75">443,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTYtMS0xLTc0Mzkw_2bccc657-7867-446a-b37d-56a1fb06af3d">267,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzIxMg_46d11c31-ba1b-415c-a07b-3e87d5e07d63">429.5</ix:nonFraction> million. This amount represents royalties and sales milestone earned in the current period, as well as $<ix:nonFraction unitRef="usd" contextRef="i2b67aab8964449fb89bd5540b396933d_D20220101-20221231" decimals="-5" name="halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzMxMQ_36d71683-b9ca-4936-88f9-7e7d2fa4108d">59.0</ix:nonFraction> million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. We also recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i9a90a57424684701b78e04f25324c4d3_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzUwNg_eb68afa3-f8ef-4ccf-a810-fbfef44f61b5">2.0</ix:nonFraction> million during the year ended December&#160;31, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4MjQ_e91a886c-f25b-40e9-9940-fa78c3f83ec9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:78.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzEtMi0xLTEtNzQzOTA_1ddac736-e799-451d-bf53-06b40e075d35">186,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzEtNC0xLTEtNzQzOTA_58d5eec4-4cb3-40ee-b8c0-a7c89c502bc5">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzItMi0xLTEtNzQzOTA_495cf8b1-1d14-4187-8f0e-93b027f3414d">44,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzItNC0xLTEtNzQzOTA_6b7066b1-183d-4304-930f-7ff6cfac441c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzMtMi0xLTEtNzQzOTA_d9a88b22-423a-4830-a806-40d30d3119f3">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzMtNC0xLTEtNzQzOTA_5a222fda-370e-49ab-9904-984673c4cb2e">4,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $<ix:nonFraction unitRef="usd" contextRef="i69070eb1e6084fa48dccbf68b4d6f8d1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExMTE_3291e636-6b28-40ae-88d0-151933416d60">80.7</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="i1cbad069681845ec855aab295e5acbce_I20221231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExMjM_32435db4-723d-4b16-b72a-a5a3b8aa3e4c">75.2</ix:nonFraction> million relates to unfulfilled product purchase orders and $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExNzc_7fa525a1-f32d-4d83-bf56-441de41c4cc6">5.5</ix:nonFraction> million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzEzNDU_7fa525a1-f32d-4d83-bf56-441de41c4cc6">5.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie4592615a3c74e559071621a0a01a228_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzEzNDk_210fcdb5-34ad-4c80-bfe3-130003ebcfac">3.2</ix:nonFraction> million is expected to be used by our customers within the next <ix:nonNumeric contextRef="ie4592615a3c74e559071621a0a01a228_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE0MDg_1935b20c-7613-44ec-947d-279bb0b34b95">12</ix:nonNumeric> months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzM4NDgyOTA3MDA4OTk_9650a637-7a02-40ca-911e-868a0a9ec48c">44.1</ix:nonFraction>&#160;million as of December&#160;31, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_130"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExOTc_c7b2067b-5060-403d-b35f-a3d3ad1b7766" continuedAt="i93711b5c385d4e28b0ab5aed7ecf0186" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="i93711b5c385d4e28b0ab5aed7ecf0186" continuedAt="ie4e768eee52f4bd7a44fc890a7f44f26"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMjE_09a2cb8e-c60b-44d4-9509-c56dea78aa31" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzEtMi0xLTEtNzQzOTA_d2aa5d71-4c9e-4082-9b7c-b043a3a4c2f4">62,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzEtNC0xLTEtNzQzOTA_7250f87d-1fc7-4503-a62e-99b07d6521ab">18,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzItMi0xLTEtNzQzOTA_61723767-d297-42cb-9eb0-d60b3a9759af">18,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzItNC0xLTEtNzQzOTA_2976a900-1ea2-4bbb-9e7c-cc5c4cc54b8c">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzMtMi0xLTEtNzQzOTA_f5619f27-ac77-4704-b0ff-1aeb4e1adc4d">100,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzMtNC0xLTEtNzQzOTA_5c5911bf-957b-422b-92e3-6b590725afcc">63,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzQtMi0xLTEtNzQzOTA_c8b639df-1321-4ebe-a5ca-ce82caff5c62">6,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzQtNC0xLTEtNzQzOTA_2ee1723c-cd14-45fa-9685-f04cde78aa6d">4,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzUtMi0xLTEtNzQzOTA_495cf8b1-1d14-4187-8f0e-93b027f3414d">44,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzUtNC0xLTEtNzQzOTA_6b7066b1-183d-4304-930f-7ff6cfac441c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzYtMi0xLTEtNzQzOTA_fe05ad17-7b7b-4a34-9642-ee4e0fbc80c7">232,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzYtNC0xLTEtNzQzOTA_89cde978-cee8-40e6-a324-5b348e4451e3">92,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzctMi0xLTEtNzQzOTA_8d4ac7f2-fc43-48dc-b6ac-8ef4e40e151b">1,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzctNC0xLTEtNzQzOTA_004e0c10-f4e3-4e7f-99c1-e0c94656749b">1,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzgtMi0xLTEtNzQzOTA_9f646636-ede8-4f6c-93f5-cf38966ec874">231,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzgtNC0xLTEtNzQzOTA_59431d01-f8e7-4019-9a8f-18caa3549abf">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMjI_238342d5-ed9d-4901-8837-c6e29f4c6bf8" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzEtMi0xLTEtNzQzOTA_40b00e95-174d-4b90-8197-8bee3610acd7">13,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzEtNC0xLTEtNzQzOTA_536aa3f8-407e-4fb4-95c1-ab6ee0b1ab48">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzItMi0xLTEtNzQzOTA_db675912-8bb3-4bf8-98d0-6f93ad3c71ca">40,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzItNC0xLTEtNzQzOTA_9163b76d-284f-4693-9d7c-5819c6edc50c">17,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzMtMi0xLTEtNzQzOTA_b25e9078-41bc-48e4-b5ba-b6c9d3fab54f">45,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzMtNC0xLTEtNzQzOTA_999d6488-295e-4023-9613-10cd8fb4049e">25,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzQtMi0xLTEtNzQzOTA_bee0a077-a34b-441e-b8d3-5ebf510540ef">100,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzQtNC0xLTEtNzQzOTA_18218ae9-bec6-4b42-a236-695389c714c9">53,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNzY_5f2c8aa1-dc31-4cdc-ae01-a7eadd8f5f54" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzEtMi0xLTEtNzQzOTA_d7b9cd46-06fa-4a40-97c7-1532b51877b0">51,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzEtNC0xLTEtNzQzOTA_d7cb5c61-5af2-45c1-81f5-9353270589c7">47,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzMtMi0xLTEtNzQzOTA_3ceec5f1-fff7-405a-b958-d62ec2e88fc6">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzMtNC0xLTEtNzQzOTA_8394f522-7189-4900-b64c-4388752fde8e">3,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzQtMi0xLTEtNzQzOTA_3640b1bf-b3ed-4678-9e1c-eb017eb4363d">14,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzQtNC0xLTEtNzQzOTA_d73c1ec4-9ca0-4879-8e4d-c2b84d5c1238">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzUtMi0xLTEtNzQzOTA_af7ac967-f996-434d-a1be-a49cc9a89d6f">71,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzUtNC0xLTEtNzQzOTA_5bcc451a-0890-44ae-aeda-785989fccaa7">53,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzYtMi0xLTEtNzQzOTA_f0f5ef94-e568-4918-8f66-69211f181c02">26,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzYtNC0xLTEtNzQzOTA_3376c587-aec6-47be-8060-6e794ccdf247">13,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzctMi0xLTEtNzQzOTA_ad8d030e-bacb-41dc-879d-523162b19809">45,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzctNC0xLTEtNzQzOTA_2a928fde-214d-4df9-80dc-1903d62b6e2e">40,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ie4e768eee52f4bd7a44fc890a7f44f26"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMTc_d36430b4-625c-4d87-adbb-8613e01f1893" continuedAt="ia6f78909d3f64976bc0723862f253d60" escape="true">Property and equipment, net consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><ix:continuation id="ia6f78909d3f64976bc0723862f253d60"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b33c1eddff241b7b992cad79cd90321_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzEtMi0xLTEtNzQzOTA_a78ec63c-bd99-4a06-b6b4-612487da3d80">7,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5103cb702ff64758983fc79a04fae1aa_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzEtNC0xLTEtNzQzOTA_d481b2d2-ff55-4779-ac13-56ef831da746">7,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21db3970f77426c9be0b7002d0bc269_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzItMi0xLTEtNzQzOTA_b7445fb3-6a01-4100-a9d7-7efb85b29ca0">27,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358cffcf78784467b140596c17157c72_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzItNC0xLTEtNzQzOTA_c4a57458-7483-4756-ba85-6a873b78e83e">5,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c68a9508eb404082e43ef1e4a75c24_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzMtMi0xLTEtNzQzOTA_a2a5d844-3da2-4e59-8082-7eec7e9b0952">7,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia230ccd2446e49578990a8e709b8b5cb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzMtNC0xLTEtNzQzOTA_bd863739-ed01-4818-ae04-32013fa8c642">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026e429b3e77423ca0b1a2eddcd26847_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzQtMi0xLTEtNzQzOTA_4aaf0b2c-4293-49a1-aeff-d26842915cda">6,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6d68430cff43a0ae03fd967d945fa0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzQtNC0xLTEtNzQzOTA_e222de22-b99d-4165-8517-c443ab87d8e3">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzUtMi0xLTEtNzQzOTA_8b7a0d97-a11b-49c7-8184-f74eed8412ac">49,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzUtNC0xLTEtNzQzOTA_f1673df3-b4e4-4a30-ad8b-6eaa0eb6d9ae">19,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzYtMi0xLTEtNzQzOTA_9720be8d-79b9-49f4-8f0f-d6da8d7cd3ca">14,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzYtNC0xLTEtNzQzOTA_d4a48926-676c-4ea1-98b0-45008c678506">13,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzctMi0xLTEtNzQzOTA_9e060dd4-3c65-4480-8176-4a0404a9c082">35,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzctNC0xLTEtNzQzOTA_aa84a261-f2f5-495c-a8ac-11832800aa2d">6,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d">Right of use of assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMi0xLTEtNzQzOTA_1c1d6fb5-55d6-4e21-a8e4-3cae6e5fae42">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtNC0xLTEtNzQzOTA_b64d7123-46f2-477f-8f34-bf453bc72272">2,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzktMi0xLTEtNzQzOTA_7946445b-3fe1-4586-ae15-912c6cdbd6b2">75,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzktNC0xLTEtNzQzOTA_aeb2d788-69e2-4cb3-adcc-3ab3c723cfa3">8,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY4Ng_8488e3bc-9b0d-4a28-b4bd-f9adb1e9616a"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY4Ng_c8cad1dc-e876-4b39-a595-d0ac6f65774a">6.5</ix:nonFraction></ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY5MA_f022c007-c4c9-45dd-bb3c-a83a3a16912b">3.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzU0OTc1NTgxNTEyNg_b2145956-c92d-4e07-997e-618029e16878">3.3</ix:nonFraction> million, inclusive of ROU asset amortization of $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc0MQ_2e7301a5-e435-4aa4-a502-2ba7fb89cdad">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc0NQ_b2f40e14-0891-4951-88da-b8d9374e1876">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc1Mg_c09ef873-3fc0-4f46-bb1c-87f7e757baba">1.7</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExODE_ed6367a8-9cf7-492a-92a4-df5616624343" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzItMi0xLTEtNzQzOTA_b671cbd8-0449-44c9-b3ca-c425d533bfa3">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzItNC0xLTEtNzQzOTA_2a335f1f-56be-43de-a487-2070cd5157f8">9,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzMtMi0xLTEtNzQzOTA_f60d8db3-26fc-41da-876b-c1c2c682be94">12,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzMtNC0xLTEtNzQzOTA_2001ef1c-0af0-4e5c-b4b1-d764cd34769f">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtMi0xLTEtNzg2MDA_a06cace9-d199-4edd-85c6-a0787d9ec7f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtNC0xLTEtNzg2MDQ_573e2ccb-87d6-4477-b246-30a61cf4f5bb">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMi0xLTEtNzg2MDA_f69e6767-a968-403f-b2a4-fd9bb99e4476">30,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtNC0xLTEtNzg2MDQ_e15e29e1-d156-44a8-bb59-8a33f4c43343">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtMi0xLTEtNzQzOTA_167e03b0-e392-4d12-8de8-3a8b0079518a">29,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtNC0xLTEtNzQzOTA_36f4a89c-e0b0-42e5-8c79-bdcb828a82aa">3,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b">Lease liability</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMi0xLTEtNzQzOTA_c073f310-4f97-434c-a0a7-cf6e4fab4c23">34,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtNC0xLTEtNzQzOTA_d358bd7d-f5dc-4470-9d8c-cecf621cc397">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzYtMi0xLTEtNzQzOTA_3861f857-60c7-43ac-83fb-df521850f2a7">126,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzYtNC0xLTEtNzQzOTA_f4381c3a-8fbf-4843-8c22-1c7c8d7f300d">24,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzctMi0xLTEtNzQzOTA_b47b5db9-ea87-49a5-830d-9937de03210d">30,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzctNC0xLTEtNzQzOTA_bab86996-63e6-406f-b91b-fc7830967130">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzgtMi0xLTEtNzQzOTA_407c971c-626d-4906-a5e5-cc644a35ab3d">96,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzgtNC0xLTEtNzQzOTA_23cf7631-d131-4da6-b403-d3d8de213c60">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzkzNw_5ea3d222-ffc1-4ed5-98e9-bd5e4bf5f366">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzk0MQ_4ecf3846-239d-462e-9fac-60550f6ac9e9">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzk0OA_a2941c35-3b66-496f-b1ad-685e44ecbf0c">0.5</ix:nonFraction> million for the twelve months ended December&#160;31, 2022, 2021 and 2020, respectively. Total lease expense for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNDQ_3b632798-d5c8-466e-b867-57245a671f92">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNDk_38985484-b8f5-4aab-89cc-ffb2bd20fec2">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNTY_d662dd5c-eb42-43f4-9c51-c43bff088efd">2.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNDY_cd5883b2-d13c-45db-8972-0feff683234b">4.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNTA_3be62fc5-51ee-485b-aec6-76f18bfefce5">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNTc_7363817f-be7c-45cc-a5f1-f8beb85ce3fe">3.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_136"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDM_d314ae57-8384-4771-a767-b1a89313ff63" continuedAt="i9782e96a076f4bbe91ac2becb12716f8" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i9782e96a076f4bbe91ac2becb12716f8"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares. A Goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDkzOA_5bb0edc5-af11-4fdb-90b4-4c69b4a64f35">409.0</ix:nonFraction>&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDQ_d77cba80-0901-4c40-afc7-c7e165b77c30" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:84.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzAtMi0xLTEtODUxMjA_3901922d-a846-4a0b-9872-9cb151380c74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzEtMi0xLTEtODUxMjA_6d88dd73-b1a4-4a0b-bf16-fdf6bea605cf">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzItMi0xLTEtODUxMjA_e97b1e2a-57fd-4ce6-abcb-2fd0e8b5f981">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk1OQ_f58b5d2c-2f99-454c-b819-957e5d1ad0df">seven</span> to <ix:nonNumeric contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk3MA_9211750f-8b39-41f5-a219-0b05b8380879">ten years</ix:nonNumeric>. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDU_6dfb0689-d7a1-4eec-9c67-ced3e312ae88" continuedAt="i54425f4e5a634d119a9c6b0fd99fcf35" escape="true"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDU_96f0eade-0a68-4cd5-8b47-3993390cd3d9" continuedAt="i4eb12edd7cc747dbb7bd298d60e688df" escape="true">The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i54425f4e5a634d119a9c6b0fd99fcf35"><ix:continuation id="i4eb12edd7cc747dbb7bd298d60e688df"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:46.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1892e4c1066a4e5ca9ecbf598525a0af_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtMi0xLTEtODUxMjY_44e4f062-dbb4-4250-b600-aa744554fed6">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida924054054447ada0707db648939f23_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtNC0xLTEtODUxMjg_fdc2e711-92f4-4813-83c6-81dd0929be02">402,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida924054054447ada0707db648939f23_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtNi0xLTEtODUxMzA_15b2b81d-d8ed-44ca-b3b5-ce79e19f6872">34,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida924054054447ada0707db648939f23_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtOC0xLTEtODUxMzI_06480cde-a441-4003-ab36-87d561e92de0">367,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61f2f3a242d74ae0839b985994afacfe_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItMi0xLTEtODUxMjY_4585a527-3310-413e-b592-e015bddf4094">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092e2002b6d245c29ce295a98666505c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItNC0xLTEtODUxMjg_d9c98209-b02d-4dc7-96b0-0d428b369e23">136,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092e2002b6d245c29ce295a98666505c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItNi0xLTEtODUxMzA_f595f2b7-f1bd-42de-80d6-0562fcb51aed">8,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092e2002b6d245c29ce295a98666505c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItOC0xLTEtODUxMzI_64ce580e-aa05-4b32-b474-be6dfcc9a941">127,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1746187612e2471bb184a56028b058f5_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtMi0xLTEtODUxMjY_1899cb27-4d98-43cf-91e1-82ba1de4eec3">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtNC0xLTEtODUxMjg_4e86f7bd-fe0d-44f4-940d-571bdaa81ea9">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtNi0xLTEtODUxMzA_62e23ee4-7ca0-4280-b62b-0444cd90473d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtOC0xLTEtODUxMzI_2e454fd6-d766-44eb-985c-64f868ad987d">2,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtNC0xLTEtODUxMjg_29600986-ed4d-4e6b-b385-2923c7eedf66">541,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtNi0xLTEtODUxMzA_bcf92c3e-9c79-45ea-b755-2daaee9ca2b0">43,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtOC0xLTEtODUxMzI_e1237bc9-0fb3-433c-8066-07507796ae83">497,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzUtOC0xLTEtODUxMzI_7bfa58bf-3c2f-4ece-88bc-c12f699d10ad">48,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzYtOC0xLTEtODUxMzI_ed210064-3e50-4d70-9911-9b5487d64216">546,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDY_0167d37e-b11c-4302-aae4-b7bee97e6ce9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzEtMi0xLTEtODUxNDk_b19cc93b-bba3-4b41-9c13-f266014f0f31">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzItMi0xLTEtODUxNDk_13dc6270-f3c2-472d-a036-7ae830df834f">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzMtMi0xLTEtODUxNDk_30234fc3-5669-4aa1-9a3e-31999005422e">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzQtMi0xLTEtODUxNDk_f49d85c5-6f6e-44a9-b834-f8223f15efa8">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzUtMi0xLTEtODUxNDk_930d7fe4-41a4-4c85-893e-6476bc855a13">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzYtMi0xLTEtODUxNDk_9553e5e8-5142-493c-9343-570a5174a005">141,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzctMi0xLTEtODUxNDk_7f0b392b-c9b0-4647-99a3-a935e41a1483">497,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_139"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDkz_61d232a1-1f48-42bb-ae52-8aee60ab67e0" continuedAt="i4171523151d34b0b89d48c4ca64259b7" escape="true">Long-Term Debt, Net</ix:nonNumeric></span></div><ix:continuation id="i4171523151d34b0b89d48c4ca64259b7" continuedAt="ie9ca09c9ff89454b89613a3810352c0b"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA0MA_a62746b6-1f35-4970-ac0d-a44effac3ed3">1.00</ix:nonFraction>% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA2NA_93f41eb6-c414-4bb3-9ea2-447581f25b1c">720.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA4Ng_64109338-a653-49bb-acc8-6705e049e7f2">1.00</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDEwNw_5a7b20b2-3af1-465a-8cf9-019d1c815e0e">18.0</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDEzNw_c02fd79c-bcc9-4caa-a918-ac7e80d8d506">702.0</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE2Ng_47b2ec02-5cd9-43df-abaa-0255861d7353">1.0</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE4Ng_a2cfa316-3484-4769-bb80-2d4c354d4f23">1.00</ix:nonFraction>%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of  common stock exceeds <ix:nonFraction unitRef="number" contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE5OA_805ee6e8-f084-4381-9379-21ca799232f0">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIwNw_18480a9a-0c18-4a06-a736-d2e692f3ca40">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIxNA_a32cff64-d168-403a-b080-63f430e01862">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="businessday" contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331" decimals="INF" name="halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIyMg_ab333ca6-5ea2-4d9d-a7aa-969dc68361a2">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIyOA_27c7300d-7cc5-4a49-84d8-08d4e709f891">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIzNA_6416f21a-223c-41f1-8e4f-d378c12fc94e">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI0MA_0195e4f5-495c-49f4-8e08-3e3f6370628a">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2028 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI2NQ_8a791e9e-65e4-4af2-9f55-3377a95ea2b2">17.8517</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI5Ng_bdab0f0b-e305-46ca-ab91-ac572dc76360">56.02</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb78064361704a2b8da472621b690b46_I20220831" decimals="4" name="halo:DebtInstrumentCapCallTransactionCapPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDMyOA_b42c17bd-e9b1-494a-b1a6-ce9548caa5b4">75.4075</ix:nonFraction> per share of common stock, representing a premium of <ix:nonFraction unitRef="number" contextRef="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831" decimals="INF" name="halo:SaleOfStockPremiumOverLastReportedSalePricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM1NQ_b43d0696-d0be-4ce3-9d74-9b9785ed8d38">75</ix:nonFraction>% above the last reported sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia37a3aaaa88549e188282c778e953fba_I20220815" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM0NA_55bb62ed-d07b-4455-abb4-e54d7c0d71eb">43.09</ix:nonFraction> per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of December&#160;31, 2022, no capped calls have been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="halo:PaymentForCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM3NA_06769d75-0c93-4518-913e-861e6ea316ae">69.1</ix:nonFraction>&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the Condensed Consolidated Balance Sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzI4_1b498e78-f228-4cd6-80d0-4d082b679f6e">0.25</ix:nonFraction>% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzk4_2154fe00-d4a9-4244-bba8-83944a14f665">805.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzEzNA_b2c51a1d-939f-45ae-a0d1-8440c63869b7">0.25</ix:nonFraction>% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ie9ca09c9ff89454b89613a3810352c0b" continuedAt="iaa04a679b0c24de8ac1e93053de03d7b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQwMw_c2f37d80-143e-468b-8fd6-9dae5d1abac1">20.1</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="i2f827aac2a7f4d6ba5ee22c890a4ad04_D20210301-20210331" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQyNQ_813832c6-76a9-435c-886a-9da8469fcca9">784.9</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQ4Ng_f366c9b8-bdbe-410f-aa0d-7002eda9c43b">0.4</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzcwNg_7b6c21d9-7cdd-4800-a67f-5e0cd9425821">0.25</ix:nonFraction>%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds <ix:nonFraction unitRef="number" contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2MjI_d4bd48eb-3aaa-4770-9753-2d663250a3bd">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2NzA_0e7b5152-d033-4b17-8f76-754835da22be">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2OTc_25070eeb-b714-4765-8f06-68527c560829">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDc3_d1ee043c-0841-4e78-a66f-ae82a69b541f">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDg1_04486b50-3628-48d7-b60d-6236e9fde370">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzIxMTc_b44d4495-ebd0-4ae4-b4fa-4939c28a6cf1">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of December&#160;31, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzMxODk_eb966ad5-a0e7-46ba-8968-8d32755f1a00">12.9576</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ie370140c043940ccaecdf292abc511eb_I20210331" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzMzMjM_3359c6a6-3f2b-4847-bf58-0e82d32fe1f6">77.17</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM1NDc_5679bbb7-3278-4068-986c-4dd4ca203295">1.25</ix:nonFraction>% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM2MjA_378426b9-6762-4315-ba8f-22e6e17b1866">460.0</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM2NTY_754f1c84-a818-44ed-9483-0b762340d99e">1.25</ix:nonFraction>% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4Mjc_916421cb-4bfd-46b1-b814-373e3370d440">12.7</ix:nonFraction> million, was approximately $<ix:nonFraction unitRef="usd" contextRef="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4NDk_78e80aec-8083-49ec-8652-d02e38d8a933">447.3</ix:nonFraction> million. We also incurred debt issuance cost totaling $<ix:nonFraction unitRef="usd" contextRef="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4OTg_4dea3285-87c5-4e54-a479-75fe7dca1c0f">0.3</ix:nonFraction> million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of <ix:nonFraction unitRef="number" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQxNDQ_9e728caa-fbfe-4b0b-beb1-d109d5500437">1.25</ix:nonFraction>%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUwNjc_ac1f5bce-5c9e-44a7-b162-68f0b8a396f4">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUxMTU_0109801f-3a30-43b7-bf5d-38845bea47be">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUxNDI_36de6fa4-6c66-41a8-82b1-fc7c2cf63cba">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the <ix:nonFraction unitRef="trading_day" contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUyNzk_737b3bed-02b0-4e42-8436-039ae1869326">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUzMzA_e53fd116-2d8b-4368-b13b-f55f15ceb25d">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUzNzA_5fa9800d-cc65-4faa-aaac-e29530a9ccbf">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU1NTY_877e8dcf-1658-48d7-b921-8b1ee67b5a64">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="iaa04a679b0c24de8ac1e93053de03d7b" continuedAt="i8082d2a35d4e46e5bb70a58679004ee3"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY0MTQ_208dbab3-0c78-4d57-8dba-f6188c68a8dc">41.9208</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="iade1f569835e40b9a1f4b38283707214_I20191130" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY1NDg_cd0834f4-4584-48ca-b1f0-48b35debc8b5">23.85</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $<ix:nonFraction unitRef="usd" contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY3MDI_6c78706d-0707-4d06-8366-be25421ca36b">369.1</ix:nonFraction>&#160;million principal amount of the 2024 Convertible Notes (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY4Njc_4a60ec0a-58d3-48db-acbd-bc325384d0fb">370.2</ix:nonFraction>&#160;million in cash, which includes principal and accrued interest, and issued approximately <ix:nonFraction unitRef="shares" contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331" decimals="-4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY5NTE_44585733-7563-412d-ba8e-380e1feb8685">9.08</ix:nonFraction>&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $<ix:nonFraction unitRef="usd" contextRef="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzcxNjI_638c865d-072d-48a5-8ad3-8ade8d8f9bb3">21.0</ix:nonFraction> million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Operations for the twelve months ended December&#160;31, 2022. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTI4Ng_a352148c-3600-48cd-8929-d2e3696e0f7e">77.4</ix:nonFraction>&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTMxNQ_ba3d53de-250a-4bc1-9abd-b821da106c25">77.6</ix:nonFraction>&#160;million in cash, which includes principal and accrued interest, and issued approximately <ix:nonFraction unitRef="shares" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTM0Mw_71ef3d20-9504-4fd3-9d73-eac5dfb1e8f5">1.51</ix:nonFraction>&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTM3MA_516c0550-5d1b-4bf6-8681-fe6708823f50">2.7</ix:nonFraction>&#160;million in induced conversion expense which is included in other income (expense) of the consolidated statements of income. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1520c9eee1f745169c91ccff5d6b28d5_D20230301-20230331" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4NDgyOTA3MjIyOTM_b07f7b85-6cb5-400e-93a2-d3811b9c2809">13.5</ix:nonFraction>&#160;million to effect the redemption in March 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i8082d2a35d4e46e5bb70a58679004ee3" continuedAt="iea85d657d99e4e91a3d36ce23a8e7856"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of the Convertible Notes</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDc4_95e7b770-f706-4121-8023-65cd1f04187d" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzItMi0xLTEtNzQzOTA_3445b9b3-abd7-47c3-a010-8ba73828dabc">13,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzItNC0xLTEtNzQzOTA_fb7c3503-30e2-4836-9c33-bcb89f21c19d">90,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzMtMi0xLTEtNzQzOTA_f3af7336-7f03-47dd-8fd1-4c4485ebb9dd">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzMtNC0xLTEtNzQzOTA_2e00bf2e-8bec-41e4-945b-77ce9d0ed6ee">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dda495c5d645e186db199b0df8597d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtMi0xLTEtNzkyMDI_1a072152-37d7-42e3-bdca-6be33b27cdc4">720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtNC0xLTEtNzkxOTQ_e6660325-4fa5-4219-b9eb-7cd7183f38fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtMi0xLTEtNzQzOTA_675045ec-c9c5-4202-a81c-8ebed64b4a22">1,538,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtNC0xLTEtNzQzOTA_b20c417c-8ff4-4a09-9e72-f88daead9587">895,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzctMi0xLTEtNzQzOTA_ee6daef2-c60c-4c3c-9ef3-13b6b73af342">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzctNC0xLTEtNzQzOTA_11b8e64b-3263-4cf5-bb43-00d47f334e6e">1,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzgtMi0xLTEtNzQzOTA_745014d4-5806-4f8b-ab03-7db4d30a0e94">14,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzgtNC0xLTEtNzQzOTA_18d85f50-ec4c-4fa7-973e-da20b851fef9">17,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2dda495c5d645e186db199b0df8597d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEwLTItMS0xLTc5MjM4_7f95fc23-5fae-45c9-84a5-daeac2692a1d">17,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEwLTQtMS0xLTc5MjMw_363fbd0c-55bb-401c-b0d8-9cb2e3c43c48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzktMi0xLTEtNzQzOTA_168443e5-fcb7-4f7c-b103-6e5734f0f1f0">32,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzktNC0xLTEtNzQzOTA_647106a7-f549-495b-8f7d-a828f886d85b">19,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEyLTItMS0xLTc0Mzkw_e6b9b7c4-2c56-4d06-8d23-80ed26c612e1">13,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEyLTQtMS0xLTc0Mzkw_98cc6e1f-6343-4b38-85dd-30cfb3ca624d">89,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEzLTItMS0xLTc0Mzkw_c6311f0d-ac30-4992-b102-d36b1e64dd63">790,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEzLTQtMS0xLTc0Mzkw_6486100e-e772-4df3-aa3c-29ef3d3db286">787,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dda495c5d645e186db199b0df8597d_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE2LTItMS0xLTgzMjQ3_cdfddfb7-fc4e-46e3-9c92-29554e47116b">702,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE2LTQtMS0xLTgzMjU1_bd6c95df-5f3a-4294-ad6e-bc14c17f883f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE0LTItMS0xLTc0Mzkw_9d30c1aa-8335-45be-b032-3b97c58e0454">1,506,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE0LTQtMS0xLTc0Mzkw_ead307a2-1cf8-4e05-a0da-2fff5a7f39f2">876,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE3LTItMS0xLTc0Mzkw_c7332748-037e-4aaf-9e4c-167c8feec6bb">32,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE3LTQtMS0xLTc0Mzkw_ba5edeb1-1858-4d53-8a9b-b38eb439b51a">159,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE4LTItMS0xLTc0Mzkw_1c94d487-d91a-48cc-9d19-231aa653e23d">784,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE4LTQtMS0xLTc0Mzkw_c3a7228b-5ac0-4c31-9ba4-1ba0e2d92c33">718,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dda495c5d645e186db199b0df8597d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTItMS0xLTc5MjUx_ea377ec4-75a1-4993-a41e-5d05d69f3b24">849,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTQtMS0xLTgzMjU3_32ee4e60-f009-4ee1-9b3c-3f5c482b125b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE5LTItMS0xLTc0Mzkw_94274bf1-aafb-4c8c-b95d-c01019e75088">1,666,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE5LTQtMS0xLTc0Mzkw_6e902ce1-2418-47f4-ab3b-f383fb64650a">878,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTItMS0xLTc0Mzkw_05564cbf-b573-448e-b1b4-a19d9d81bc35">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3193ab8c85db49f3a4a9823da38d8dc6_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTQtMS0xLTc0Mzkw_24848fd6-5585-479b-bb21-d63f906a9d3a">2.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3c657f7c7aa4b2cb4c74f3daa87f921_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIzLTItMS0xLTc0Mzkw_115a8dce-1c97-42ba-8973-7883bb7a5a4d">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i79bfd4954a6f40fa97c846c2ec979f5f_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzI3LTQtMS0xLTgzMjYx_0d7f85f2-3b74-4935-948f-eaacc18ec8e9">5.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6640df7e0ae2463c8b79ef848a1764c9_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzI4LTItMS0xLTc5MjYx_1560fc6d-bfbf-437b-804d-c69ea5db6425">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="iea85d657d99e4e91a3d36ce23a8e7856" continuedAt="ic8ac7600c6214f23823de5e43ff51c30"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDg2_848cf99f-57a3-4fe5-8299-b5ce5c02fa1b" continuedAt="i4f28fb730f21490990745278cae2f985" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:71.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzMtMi0xLTEtNzQzOTA_25e791fa-a351-47fc-bfbc-1c72c7649022">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzMtNC0xLTEtNzQzOTA_e3c9703f-5534-42bb-8155-dd4301e5faeb">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzQtMi0xLTEtNzQzOTA_75b1b9c5-a887-4835-971f-bf44e2730641">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzQtNC0xLTEtNzQzOTA_dc3003c8-f78b-4f45-9280-14868e2c4cb2">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtMi0xLTEtNzkzMzg_ac87696e-094f-4317-87c5-8f4685299f6c">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtNC0xLTEtNzkzMzQ_f3c9ac4c-9788-4343-8a3f-2fbb982267ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtMi0xLTEtNzQzOTA_ef416488-bb95-48f8-9085-0134c491fb7a">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtNC0xLTEtNzQzOTA_c7dd6977-00ac-4ce1-b8bb-9fd250192a38">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzgtMi0xLTEtNzQzOTA_f7568901-3a93-4854-a220-b1cd548849db">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzgtNC0xLTEtNzQzOTA_75463287-0fe1-4a60-a6a9-2d2bbf179a80">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzktMi0xLTEtNzQzOTA_588c5536-9d6a-4379-82fe-5186c3f362be">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzktNC0xLTEtNzQzOTA_4a1194cf-2730-4688-b618-3a123a4d4cb5">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzExLTItMS0xLTc5MzU4_d2b17169-1d02-4ba4-8296-cff55a38c0dc">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzExLTQtMS0xLTc5MzUz_89f3bbbe-274b-4f39-87b1-eb7e610dbf3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEwLTItMS0xLTc0Mzkw_d4ef8ae6-6cfb-40f1-b99d-75f4d30a2a5e">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEwLTQtMS0xLTc0Mzkw_ce551230-1bb3-459e-9f9d-ada857a974ec">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEzLTItMS0xLTc0Mzkw_ffcb6154-4ed8-4640-a7fc-cae86a81ed0d">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEzLTQtMS0xLTc0Mzkw_28b91e2b-3994-413c-8e24-bc53db284528">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE0LTItMS0xLTc0Mzkw_97c75b85-640e-464a-b578-036ba7c82f01">5,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE0LTQtMS0xLTc0Mzkw_140ca618-584a-46d2-aea9-9bdc31dc5406">4,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE3LTItMS0xLTgzMjY3_a33a11b5-3470-4cb7-a72a-9754dde00441">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE3LTQtMS0xLTgzMjc0_178e2f2c-c7a9-4903-9223-920cb04f4d2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE1LTItMS0xLTc0Mzkw_845914c9-23ac-4248-8baf-7aff3b4cfe1a">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE1LTQtMS0xLTc0Mzkw_753a82cb-13f4-4943-9dba-1193a17efbd1">7,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89d55cf7d0475f89869db8cc5fdbe8_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE4LTItMS0xLTc0Mzkw_5727978c-251f-4ce3-a7fb-6cac6a239718">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e4625c024584b4d8d8743379dc7d92c_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE4LTQtMS0xLTc0Mzkw_2b8e3c08-2f07-4c1a-a574-dc274487fe0e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i703c64067ee4482fa9fb83302bac63af_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE5LTItMS0xLTc0Mzkw_6b198f92-9e03-49f5-8deb-1e4dcf31fdc1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0b58f9782c2498893a72173de677682_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzIyLTQtMS0xLTgzMjgw_b3bd4dc8-c36a-41cd-94ae-4e01687fd73b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dbbe44f2ba045c184c92f9829993116_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzIzLTItMS0xLTgzMjc2_f2ffbb22-e707-4e29-803b-c45e6bf446cc">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="ie09d99918fc743c484565395961829c3_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODMxOA_1272a142-aa8e-4005-b610-e560dbc88844">350</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i4742da9fb4d0482b803c94968d340b74_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM0NQ_d4f5ec34-f52b-425a-b2dc-707f46a148bb">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;). Proceeds from a $<ix:nonFraction unitRef="usd" contextRef="i59247bc7b3264b0e86653efe7c50ef9a_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM3Mg_3afa6f62-d433-4fa4-8953-635c84521395">120</ix:nonFraction>&#160;million draw on the Revolving Credit Facility and the $<ix:nonFraction unitRef="usd" contextRef="i8ea8d2ab91694fe48abae65438654fbd_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM5OQ_19019e94-8d12-4cb1-a381-1d8a4959fd20">250</ix:nonFraction>&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to <ix:nonFraction unitRef="number" contextRef="i689f2de5af2642238ab9ec7684b8feaa_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQxOQ_610f51e1-6ed5-4f5c-bb8d-5749f4cafc9b">2.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="if8462f2e104247cfb928c19b4f5a2e9b_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQzMg_505a90d6-b3f9-4469-b963-fd08cc3ebd09">5.00</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8aaeded4049949cc8d23c4b49d1bfbee_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ0NQ_7b0e135f-cc48-480a-8665-32289316ce12">7.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ1OQ_1bd52f8e-aa92-4511-8870-06c75184e264"><ix:nonFraction unitRef="number" contextRef="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ1OQ_21e93b6e-b3ae-4438-9f0f-c21463ad29cb">10.00</ix:nonFraction></ix:nonFraction>% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ic8ac7600c6214f23823de5e43ff51c30"><ix:continuation id="i4f28fb730f21490990745278cae2f985"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of <ix:nonFraction unitRef="number" contextRef="i6503f2b3881e494aad8c2e128e68f23e_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ3Mw_5c8b9bea-a918-4566-8c91-e918e7bbb16c">0.10</ix:nonFraction>%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus <ix:nonFraction unitRef="number" contextRef="i65af036188ba41eb9fe14b30fb6f1f23_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ4Ng_44227ea2-1b17-472e-acd5-b5d593c1c25a">0.50</ix:nonFraction>%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="iad72bf7f121e428cab4063032f673cf8_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ5OQ_de04651c-d0e1-46ea-ae19-31169ad9f52d">1.10</ix:nonFraction>%, and (4) <ix:nonFraction unitRef="number" contextRef="i8764e1163d9d4b42a29fc48e21d37b26_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUxMg_618c3f05-6728-406d-ae99-1369fb5cc764">1.00</ix:nonFraction>%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from <ix:nonFraction unitRef="number" contextRef="if262c47c59524111aa76f3840681c866_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUyNQ_8385bc31-7483-4137-899e-2fcc8db9f797">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2000d717e3b8448690bbc1088fd76ea0_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUzOA_0cb0e7f1-67b5-4faf-9031-c6180c19f20b">1.25</ix:nonFraction>% in the case of base rate loans and from <ix:nonFraction unitRef="number" contextRef="i26f1c68d52374db68ae5953d4cd57bf9_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU1MQ_e0181319-7a2d-44c2-bef0-8eb85d7105dc">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="idbde07f8da7e4c42b763a251cf0afea0_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU2NA_b82a2418-7fcd-4df9-8448-9029aceb45e7">2.25</ix:nonFraction>% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from <ix:nonFraction unitRef="number" contextRef="id6dbdd6695e246f4ad6f672de1aadaa2_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU3Nw_f921e839-8a5d-4084-b0e3-8e43c6f61eba">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8c06e4fe9e8a43a382f8063e6334c895_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU5MA_2723cbdb-9ed2-43aa-ab23-e5a0fdc35e81">0.35</ix:nonFraction>% per annum based on our consolidated net leverage ratio. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $<ix:nonFraction unitRef="usd" contextRef="ie09d99918fc743c484565395961829c3_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODYxMA_fc7d5447-92b4-4ab9-97b4-32e5e78a6681">350</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i492b1e853ac0430faf0bcfe39c9d177f_I20220831" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODYzNw_259a423f-e64b-4371-99ac-f7657b826e5a">575</ix:nonFraction>&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $<ix:nonFraction unitRef="usd" contextRef="ie09d99918fc743c484565395961829c3_I20220524" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODY2NA_1f0f47a7-da6e-4ddb-9fe1-a964e49520a4">3.6</ix:nonFraction>&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of December&#160;31, 2022, the unamortized debt issuance cost related to the revolving credit facility was $<ix:nonFraction unitRef="usd" contextRef="i3d39948aab61416789923cae1ff3c69e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODY5MQ_68205490-fd5a-485f-aa74-4f15d6bcc44a">3.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDgw_b548e943-918c-4a67-8430-6ae917a17226" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities and interest payments of long-term debt as of December&#160;31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:85.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzAtMi0xLTEtNzQzOTA_4b68052b-a075-45d1-b06a-d836a9feb988">22,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEtMi0xLTEtNzQzOTA_b9ffc44f-5647-4165-9516-5a329c2725a3">9,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzItMi0xLTEtNzQzOTA_d97c2787-d6d9-437b-9cfc-3a95a4bea107">9,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzMtMi0xLTEtNzQzOTA_9f2823a2-a059-43aa-9260-6fb0481dc986">9,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzQtMi0xLTEtNzQzOTA_ed050b2f-2437-4884-a73f-2d7bdd4faa18">812,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzUtMi0xLTEtNzQzOTA_adb2ca7f-3770-4e86-9ab6-3c89eeeb176f">724,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:LongTermDebtIncludingInterestGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzYtMi0xLTEtNzQzOTA_5ebffe69-c5e4-41d2-92eb-a40e84722990">1,587,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amount representing coupon interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:LongTermDebtInterestGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzctMi0xLTEtNzQzOTA_a6bdbcd5-9f69-409d-af3d-ebd393ca7c7c">48,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross balance of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzgtMi0xLTEtNzQzOTA_78f19b30-baff-4bd5-a9e2-4705565d7f78">1,538,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzktMi0xLTEtNzQzOTA_6fae817b-4e7f-44e1-803f-d40d586124b1">32,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEwLTItMS0xLTc0Mzkw_e666cc00-735b-4d1c-a5f0-3861a6bfba40">1,506,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzExLTItMS0xLTc0Mzkw_5f363caa-13ed-4778-a440-1fc1738e1a91">13,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion and unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEyLTItMS0xLTc0Mzkw_d15a2e88-1330-43f2-8217-16caecce754c">1,492,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_142"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMzk_7c8af158-3736-4ac1-8747-1807e0fbbce8" continuedAt="i9134197acc0c474faf599fcff4ba4727" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9134197acc0c474faf599fcff4ba4727" continuedAt="i3fdf00c83e7c4190bcdb1d13d29f4071"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently grant stock options, restricted stock awards, performance stock units and restricted stock units under the Amended and Restated 2021 Stock Plan (&#8220;2021 Stock Plan&#8221;), which was approved by the stockholders on May 5, 2021 an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides for the grant of up to <ix:nonFraction unitRef="shares" contextRef="i6347633a08434f869706fa2b2f074866_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMQ_c861d380-90bc-40c2-b444-c757ddf1c007">17.8</ix:nonFraction> million shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended December&#160;31, 2022, we granted share-based awards under the 2021 Stock Plan. At December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i01989d60674a45c6ab5875f437acf6a5_I20221231" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzczOA_b6a3b0be-5458-4f83-bfea-4112290d57b2">6,550,075</ix:nonFraction> shares were subject to outstanding awards and <ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4Xzc4Nw_688efd1e-9432-480c-a393-34031d2e57d0">14,764,481</ix:nonFraction> shares were available for future grants of share-based awards. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTA_4b28467d-ce81-4c85-8372-aab331a137a9" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity awards was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d039d4e0614847a563288bd41158dd_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItMi0xLTEtNzQzOTA_3842ae28-6bbe-4947-99a2-0c01b6211f31">9,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdeb7c5afc384d8ba911a737f1419fb9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItNC0xLTEtNzQzOTA_08f556a9-8077-4036-914f-da57a316a3ce">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc18d66d2f8f44a4b0473fbc86ab01c5_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItNi0xLTEtNzQzOTA_ad34a0a6-1d61-4625-af19-2c6cbc16951b">5,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id935d90decb947c3a71099b77bbdac41_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtMi0xLTEtNzQzOTA_70ab1d60-afe9-4442-bcf0-64df8f8fc2f7">14,494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec84c34382b44c1e86f9926be1ce3983_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtNC0xLTEtNzQzOTA_7f145e42-3ebd-4e61-b422-cc3b7d3cbde5">13,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdcc06b9a17743358ff945dd4bed0581_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtNi0xLTEtNzQzOTA_4ba8d7ad-1612-4cf4-8e1f-3aee1ddd4a7e">11,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtMi0xLTEtNzQzOTA_1ec244c8-0683-43cb-aa20-cc860c503c68">24,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtNC0xLTEtNzQzOTA_f67aaafa-4fa0-4cf5-a155-8065d576fd9e">20,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtNi0xLTEtNzQzOTA_88b65a1a-dc42-465a-bf19-ee6958eb53db">17,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTE_6d5118d9-d4eb-4824-9d46-36535d6c0ea1" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItMi0xLTEtNzQzOTA_06877995-7eb2-42fd-8a62-e8e55cb7dc6a">10,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItNC0xLTEtNzQzOTA_63f35339-3b29-4b8e-a61e-11d85813909b">10,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItNi0xLTEtNzQzOTA_6c2e37d5-3a31-4f92-8ef4-4cae440db100">8,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bcc82bb2f64c658849f7c71cab48e6_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtMi0xLTEtNzQzOTA_51194f4e-91e1-4589-830e-fff4302791dd">13,424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e361b0a7e3429099a5544603eb7191_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtNC0xLTEtNzQzOTA_1b059a9c-a253-4014-adbd-76a6440155e6">10,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69087abdb2354c6392a5a633290514cd_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtNi0xLTEtNzQzOTA_eb7e9e09-f8da-4e24-a838-83b633ea5fd7">8,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtMi0xLTEtNzQzOTA_2de17cb1-32b2-4b7a-b1d1-1ecaf981f2ed">24,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtNC0xLTEtNzQzOTA_9db80a5c-8c97-403f-b960-0ccade5bb473">20,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtNi0xLTEtNzQzOTA_83b51e13-d87a-4526-b80d-fb5399972ca6">17,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMDA_81aaccb7-2593-4877-9d9e-ad178a755147" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:70.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8de33c335a241468926b3ab8403600b_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzItMi0xLTEtNzQzOTA_065b38f5-e39a-4288-9414-0437b5e32a4d">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzItNC0xLTEtNzQzOTA_c979de26-6d96-44c9-8fb3-2f21ea2cd464">2.66</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzMtMi0xLTEtNzQzOTA_5e34d8cf-d616-4c0f-94d4-b3bd7579ce9e">26,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzMtNC0xLTEtNzQzOTA_564ff225-b6c9-4005-80ad-6625462b1e39">2.32</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzQtMi0xLTEtNzQzOTA_981945e4-daf1-4e02-af42-beea4c28171f">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzQtNC0xLTEtNzQzOTA_c0e046e5-25ca-4e47-99b1-c039d1c30162">1.91</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd57b3450df84c0c9a4020d97056c443_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzUtMi0xLTEtNzQzOTA_85cbb308-0679-4080-af9e-f6a74fb97d87">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23d72a210e204519967ca7ede33dc391_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzUtNC0xLTEtNzQzOTA_744f378b-b113-4a1c-a426-4e416f7efedf">0.45</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE1MTc_58e8537c-5ea8-44c5-a6c7-b36eb7091b4c">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least <ix:nonFraction unitRef="number" contextRef="i99cb9a7240414e81abe47db83af3899f_I20210228" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE3MTk_c7e2b162-7307-4335-8417-ac7bfcb3be71">1</ix:nonFraction>% and up to <ix:nonFraction unitRef="number" contextRef="i99cb9a7240414e81abe47db83af3899f_I20210228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE3MzI_e02f5961-34a7-4d79-b012-088dccb5217c">15</ix:nonFraction>% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $<ix:nonFraction unitRef="usd" contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228" decimals="-3" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE4NTQ_751bfbb2-8f13-4ea0-8256-d4bb37fe6661">25,000</ix:nonFraction> worth of our common stock for a calendar year. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i0f0d2c8d2d884311ac502e7ea910dc91_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE5MTQ_46e182d9-b48c-4eb7-863e-94c16f39d358">2,650,103</ix:nonFraction> shares were available for future purchase. The offering period is generally for a <ix:nonNumeric contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxNDM_5e9590be-5a24-4952-87e1-976de53bdff5">six-months</ix:nonNumeric> period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the twelve months ended December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i744eaed75e9d41b98136429882bab1e4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU0OTc1NTgyMTEwMw_be2c7f3e-ba17-4bce-bcf6-800e93d3b656">32,124</ix:nonFraction> shares were issued pursuant to the ESPP.</span></div></ix:continuation><div style="height:99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i3fdf00c83e7c4190bcdb1d13d29f4071" continuedAt="i948bd5605e274e559196a6d6ba07f309"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Options granted under the Plans must have an exercise price equal to at least <ix:nonFraction unitRef="number" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzI0NDM_ea6aa13b-c387-43a8-a1c7-f183c7c70ac7">100</ix:nonFraction>% of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of <ix:nonNumeric contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzI1NzA_c3776739-bd0c-494e-9c7b-5c6905faddaf">ten years</ix:nonNumeric> and vest at the rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMjA_9de894c7-2c78-48a3-8b01-f413360dc9fe" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option award activity as of and for the year ended December&#160;31, 2022 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:45.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Underlying<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price&#160;per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzEtMi0xLTEtNzQzOTA_3e82fe02-2d78-4897-a000-d9dc367a43a5">4,965,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzEtNC0xLTEtNzQzOTA_cdbc910e-6248-49b7-8175-b0ce6d8cef6d">20.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzItMi0xLTEtNzQzOTA_7021a696-88b8-4b4f-a370-80a3e71bae7d">1,773,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzItNC0xLTEtNzQzOTA_a8d6451d-776c-4f67-94d9-8c654f81bac5">37.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzMtMi0xLTEtNzQzOTA_a65d93de-88b9-4597-bb4a-c060203e536e">789,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzMtNC0xLTEtNzQzOTA_dd90cae5-7dab-4894-8049-efd78c7bf5fc">19.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzQtMi0xLTEtNzQzOTA_c5afc763-45b5-428a-8462-868b3f62719b">581,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzQtNC0xLTEtNzQzOTA_4e9a603d-e878-4533-aaee-4bb97ab795fa">33.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtMi0xLTEtNzQzOTA_f6aa5243-b498-4f91-9c52-0e1ac44ad3ed">5,368,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtNC0xLTEtNzQzOTA_d1965781-261f-4f8c-8dcf-a538bf296a58">24.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtNi0xLTEtNzQzOTA_ee21eaa4-2445-483c-aca2-20a02cf133ce">6.48</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtOC0xLTEtNzQzOTA_32d57543-1a5f-4a33-83d3-fd40507c0d81">171.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtMi0xLTEtNzQzOTA_bc6cfce7-109f-4152-ae6a-34f0b6532396">5,368,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtNC0xLTEtNzQzOTA_bf15b7ac-80bb-43a7-a141-d1e99bf41ce0">24.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtNi0xLTEtNzQzOTA_18f15636-a711-40f0-9b01-f99552ac9125">6.48</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtOC0xLTEtNzQzOTA_a8d73a3c-7c3e-488e-bab7-d741228cc5c0">171.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctMi0xLTEtNzQzOTA_5a385dcc-9f4b-4c5e-93de-55fd41018cd4">3,176,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctNC0xLTEtNzQzOTA_5ce518d1-23d0-464c-a9e3-30855c5d0f02">17.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctNi0xLTEtNzQzOTA_fb6b6a46-676a-416d-8992-8be2f2d39f32">4.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctOC0xLTEtNzQzOTA_8c7f0b65-efcb-473b-bef1-d353ab3b52da">126.0</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMTM_b2680287-3773-4d59-8808-b2777751ae90">14.22</ix:nonFraction> per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMjc_2331eab2-70cb-4984-a459-c19a948fea1f">18.21</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwNDQ_0ea32591-4377-461a-9c04-a1c55f832b47">20.74</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNjM_a058ebb8-6aef-4aa0-b3ce-6032e8c1f666">21.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNjc_25689326-40c0-4c26-a600-0ddec4441f13">33.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNzQ_de66576f-a3af-4986-939c-151b5519b51a">49.7</ix:nonFraction> million, respectively. Cash received from stock option exercises for the years ended December&#160;31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyNzU_0e18aae0-5a18-43e0-a167-1218165b256a">15.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyNzk_6de71b2d-a5e1-4b7f-91e0-2d2decfc2a40">16.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyODY_e12e4216-d2ff-4d91-919c-feb0025b1eef">66.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTM_93a5fbaf-ba83-4776-b14d-eec47a908253" continuedAt="if0380a12836641af846d0fe62d62c0a1" escape="true">The assumptions used in the Black-Scholes model were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><ix:continuation id="if0380a12836641af846d0fe62d62c0a1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:56.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyMmJkZjBhZDRkMDI0MDQwOGY5YjU5OWY2NTQ0YTlhMF80_054c943c-6f06-4c2b-bf5b-d0e92d6cd242">39.91</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyMmJkZjBhZDRkMDI0MDQwOGY5YjU5OWY2NTQ0YTlhMF83_52f76993-437f-4c3d-939e-6416b400f514">50.81</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf745bbf6d154e1899189c7bcad6fc6a_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNjMxOWMxZDUyNDE0ZTRlOWNlNjkxZDU5OWFlMDZlNF80_507fc7da-67bd-447b-8357-98f3d157fc13">41.01</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i949d937237ca46f89a339135fe399f09_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNjMxOWMxZDUyNDE0ZTRlOWNlNjkxZDU5OWFlMDZlNF83_1f6c1e6b-1fbb-4309-953b-26d7c05e57c8">46.45</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibec91f8bf02b4770a0909a40dcb95e52_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjo4NGM2NmY0MTljNTE0NjM2OWJjYTRhMDE4MGNmMGQyNV80_174fd7d8-4c2f-4393-8e8b-c780033bc0f8">47.57</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i81f8ea5c34ea42f0b18170ff0ca21581_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjo4NGM2NmY0MTljNTE0NjM2OWJjYTRhMDE4MGNmMGQyNV83_dcbb937c-d62d-4135-aee3-7835b6765779">51.82</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtMi0xLTEtNzQzOTA_53851a75-4a14-4e5c-9449-5838e87db346">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtNC0xLTEtNzQzOTA_b8a228c3-ac69-4890-aef4-c9d5df566975">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtNi0xLTEtNzQzOTA_f6fa26c0-d9b2-44ea-84b8-fc53457bb8a6">5.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyM2YzYTY2ZTg4MWY0NWI5OWQ4ZjM2MjUwMjEwZTg0Zl80_a3cffc41-e913-4532-af6f-d9fe68f94ada">1.37</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyM2YzYTY2ZTg4MWY0NWI5OWQ4ZjM2MjUwMjEwZTg0Zl83_b58a7ef2-9b43-483e-8f95-42deaec073ac">4.27</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNDgwN2QxODYzMzA0NDMzOTNmZDhlOGI1ZmY2ZTEzOV80_92c6c13b-01ab-4c39-a045-05131d362865">0.36</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNDgwN2QxODYzMzA0NDMzOTNmZDhlOGI1ZmY2ZTEzOV83_842eb2d0-1166-429f-8225-86e5509c33ac">1.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiYmMyNjgwOGI5M2M0OGVhOTkxZDY5YjNmYzA1NWZlOF80_c03a2a9b-34fe-4ccc-a84f-764e39a85b83">0.22</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiYmMyNjgwOGI5M2M0OGVhOTkxZDY5YjNmYzA1NWZlOF83_b057bfc3-caa9-4b8f-b110-26a5a1c66502">1.67</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtMi0xLTEtNzQzOTA_9d542880-55c6-4601-9559-b7fb57945861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtNC0xLTEtNzQzOTA_2bc2e924-cea0-46b8-a8e4-e0d66bc16ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtNi0xLTEtNzQzOTA_2340cf4d-851e-487d-878a-42114e6f37ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i948bd5605e274e559196a6d6ba07f309"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxNDI_3389530c-f0e8-48ac-af77-0d5f4c76638d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:49.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(yrs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id26cfa0230994968ac1d99e765d751b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzEtMi0xLTEtNzQzOTA_5fe74f2c-1d1a-4096-8987-2bdb171fb198">858,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id26cfa0230994968ac1d99e765d751b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzEtNC0xLTEtNzQzOTA_3889b2aa-b444-4c53-b08a-b1cf478ef09f">29.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzItMi0xLTEtNzQzOTA_b2af6158-c602-4415-b155-dd305e185abc">706,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzItNC0xLTEtNzQzOTA_9aa289cb-1988-4ae4-b86f-da63f95a5fb1">39.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzMtMi0xLTEtNzQzOTA_22abd24d-57ea-4bf9-b172-5357eaa346a7">320,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzMtNC0xLTEtNzQzOTA_4aec6d9b-c5d2-4c4e-bacb-a35c431c2193">26.68</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzQtMi0xLTEtNzQzOTA_6a595368-6723-4c0e-b961-4c6c98a93b11">204,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzQtNC0xLTEtNzQzOTA_a92b62fd-28de-489a-8ac1-efd1867ba893">35.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtMi0xLTEtNzQzOTA_a478ed01-6b47-468e-9940-6a2444b0a35d">1,039,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtNC0xLTEtNzQzOTA_433cff86-fa06-4cae-8b48-4207d7198052">35.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtNi0xLTEtNzQzOTA_6080def6-d61d-4d45-a664-d8810778dac8">1.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtOC0xLTEtNzQzOTA_c65e7b2f-f3fa-4b84-9e05-c12b6890c6c7">59.1</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NDY_2d15db81-2a73-42dc-b4ec-cbfb5fed40a2">8.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NTA_1ccde901-d99f-4ee6-8a4e-4e64361527cf">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NTc_c1ac2010-8b3b-46c9-b40b-a21624d08fe9">10.1</ix:nonFraction> million, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NDk_ea1e508c-0ed8-4a72-bd68-7d852088760a">11.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NTM_54221237-93eb-42ab-a873-0fc3c5743dff">19.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NjA_d060b7ce-aa9b-499d-8cad-42f3447dd899">14.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A PSU is a promise by us to issue a share of our common stock upon achievement of a specific performance condition.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwOTg_06e5d27f-3039-48ec-a564-ec6438300eae" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:74.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzEtMi0xLTEtNzQzOTA_dd07c96a-e046-4562-b179-6dd397381914">69,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzEtNC0xLTEtNzQzOTA_c08fc0b7-2ad8-4dc3-bce5-099deb63c915">40.66</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzItMi0xLTEtNzQzOTA_0a1ce1bc-1915-4470-a546-0d3a83e5ea42">129,773</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzItNC0xLTEtNzQzOTA_c06cf36e-e472-47fd-8a97-4f75ee98d453">41.42</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzMtMi0xLTEtNzQzOTA_c0b096ca-dcfe-411a-9d5e-1318cf9e545b">2,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzMtNC0xLTEtNzQzOTA_93c900b0-5ae6-4d3b-ab7a-2986372e394a">63.41</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzQtMi0xLTEtNzQzOTA_43a810f9-a77d-486d-9236-855abcefae1c">53,746</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzQtNC0xLTEtNzQzOTA_6a718371-06df-4469-8704-30beafc9d505">27.20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzUtMi0xLTEtNzQzOTA_ce72d61f-13a9-4a54-a8f1-06014068fbae">142,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzUtNC0xLTEtNzQzOTA_a1648be8-9006-4ad6-a597-441d5db65855">46.01</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the PSUs was based on the closing market value of our common stock on the date of grant. The fair value of PSUs vested during the years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwNzI_a780acab-6c57-437c-b938-57f42a5c5026">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id9fa634e741e4e6c976c685332948c76_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwNzk_6e20ee62-6d23-43fe-879c-f7dd941e5e42">0.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_148"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMjQ_b85770cf-d431-44fe-9f16-76a2e1f63bac" continuedAt="ib2138faa57de4f829698079f8ef3305b" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ib2138faa57de4f829698079f8ef3305b"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzgy_06cc318c-422b-4b3d-9bf3-ea80f59c2eee">789,870</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzg2_b892cbcf-7f20-4466-8d6c-361e6f1c08d9">1,179,032</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzkz_4a5f1db7-21f9-444f-9720-8e5c262e2bc2">4,705,843</ix:nonFraction> shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIxOQ_ff0ec140-9c33-414c-9df9-09d28b4859a6">15.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIyMw_1d4539cc-dcd1-41ab-864e-a12d71083de3">16.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMA_4fe6c09f-52fb-4dc3-ad59-4446de4c933a">66.2</ix:nonFraction> million, respectively. For the years ended December&#160;31, 2022, 2021 and 2020, we issued <ix:nonFraction unitRef="shares" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI4Mg_3faa253b-d748-44e2-9c49-dcd0e8a7b1f8">254,907</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI4Ng_890368d7-e94e-482d-8ae6-c2583aed8212">299,958</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI5Mw_103b52eb-e596-47a6-bcaf-55b7e7af0157">571,963</ix:nonFraction> shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU holders surrendered <ix:nonFraction unitRef="shares" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQxMA_86b4e4d6-08f1-4251-b346-1293b587c44e">68,425</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQxNA_59fc98fe-e1b1-4065-977e-5a5dae87234e">94,795</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQyMQ_6bb671c1-8a01-461c-b6d3-8aef08a8bd6e">142,905</ix:nonFraction> RSUs, respectively, to pay for minimum withholding taxes totaling approximately $<ix:nonFraction unitRef="usd" contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUwNA_6b1b6532-9779-46f1-8d24-fa03c22b9f33">4.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUwOA_7f3d3813-a948-4672-aa72-07655c7c2ba3">8.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUxNQ_e8387f18-1d3e-4692-900c-6d900c4bf97b">5.5</ix:nonFraction> million, respectively. Stock options and unvested restricted units totaling approximately <ix:nonFraction unitRef="shares" contextRef="i6f301c76e72f45fc8bd78b64ae95e300_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYwMA_0253f9e0-166b-412b-a196-743dff7cb52b">6.6</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i813698ed62b94b59be1b62617f5dd7cb_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYwNA_92555a1a-1616-4d39-b5ac-87c05e3dc2d6">5.9</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i2bca0917c34b4c89a31b6213fad20334_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYxMQ_d05048a9-0c77-40a5-b45e-0db037339d2f">6.7</ix:nonFraction> million shares of our common stock were outstanding as of December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Board of Directors authorized a capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="iec2a39ae6cf344228e691d7fec6bd39c_I20191130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzc5OA_c4834c82-6ef5-44ea-9d80-22901273442f">550.0</ix:nonFraction> million of outstanding common stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzgzNg_6d31b2bd-233b-4e57-aa4d-35605e28c115">three</span>-year period. During 2020, we repurchased <ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzg3OA_40c68a28-1ba7-46d0-a77e-77ebba422c6d">6.5</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzkwOA_6b8a6b96-886e-4fc3-a0ba-c441b25c9d97">150.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzkzNA_8668c92f-ff4b-404a-a979-84b1ea76d020">23.05</ix:nonFraction>. During 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxODI0Nw_78387462-c476-4075-882b-25339a84a062">4.6</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzk5Ng_af3eff85-fa35-4650-bd0b-d0017a91a324">200.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxODI3Mw_cece3ba7-1fbf-4b1e-ab2c-858c2053ad47">43.02</ix:nonFraction> under the program. The shares were purchased through open market transactions and through an ASR agreement. The $<ix:nonFraction unitRef="usd" contextRef="iec2a39ae6cf344228e691d7fec6bd39c_I20191130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzExMzc_6e48a9c0-4bbb-4a7b-932d-894d083e12d1">550.0</ix:nonFraction>&#160;million share repurchase program was completed in October 2021 having repurchased a total of <ix:nonFraction unitRef="shares" contextRef="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEyMjU_c92432dd-a3bc-43a7-bca3-99efa16aa8c5">22.3</ix:nonFraction>&#160;million shares at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEyNTg_a0c5bf7e-58ea-4deb-9831-ab2acb0432d2">24.72</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzNjY_bf195f7a-c5fa-4266-b076-d700c3bb51b9">750.0</ix:nonFraction>&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzOTc_69d1271f-c244-47f4-82d2-6cf455ace36c">three</span>-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $<ix:nonFraction unitRef="usd" contextRef="i62f9407bb50f40638225cd8fe3f7988f_D20211201-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE1Mjk_2af24972-4fdb-4565-bcc1-43c2c78f28ad">150.0</ix:nonFraction>&#160;million of common stock. At inception pursuant to the agreement, we paid $<ix:nonFraction unitRef="usd" contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE1OTc_bbc6bf6d-d67e-4802-87ba-880cca5756da">150.0</ix:nonFraction>&#160;million  and took initial delivery of <ix:nonFraction unitRef="shares" contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE2NDg_1486ca84-09e0-4bed-bc3f-940636b97c51">3.5</ix:nonFraction>&#160;million shares. In June 2022, we finalized the transaction and received an additional <ix:nonFraction unitRef="usd" contextRef="i7953193d06b84f52adffe498a800882d_D20220601-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNjYwMg_30937324-34a1-4605-a71b-95a819ead2fb">0.4</ix:nonFraction>&#160;million shares. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, concurrent with the sale of  2028 Convertible Notes and the 2022 Induced Conversion, we repurchased <ix:nonFraction unitRef="shares" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzE5Ng_41d42d14-22bb-48a6-a299-7a9abcd68a66">2.1</ix:nonFraction>&#160;million shares of common stock in open market purchases for $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzE2OQ_ee6022f8-804e-4458-926d-2f1f7a40be0d">90.2</ix:nonFraction>&#160;million. Also, in August 2022, we entered into an ASR agreement to repurchase $<ix:nonFraction unitRef="usd" contextRef="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzIyNA_388fa2c6-b45a-48c2-a2b5-d5b3556955a3">109.8</ix:nonFraction>&#160;million of our common stock. At inception, pursuant to the agreement, we paid $<ix:nonFraction unitRef="usd" contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzI1NQ_95468259-9e39-4e8b-bd71-57e6f18980d8">109.8</ix:nonFraction>&#160;million and took an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzI4Mw_64549627-1ec5-40a1-bd4a-b60c599455ba">2.0</ix:nonFraction>&#160;million shares.  In December 2022, we finalized the transaction and received an additional <ix:nonFraction unitRef="shares" contextRef="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzEzOA_c7665f9c-16e0-4629-8fc9-d44e3e353192">0.4</ix:nonFraction>&#160;million shares. We retired the repurchased shares and they resumed their status of authorized and unissued shares. </span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMjA_671d4717-94f1-4873-a3f8-fc1818c4b9fe" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:50.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItMi0xLTEtNzQzOTA_d47f53ce-81fe-49fd-b033-ab6fc3e70a0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItNC0xLTEtNzQzOTA_768720c0-37d7-4694-b9a0-ee499fcc8eb0">0.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItNi0xLTEtNzQzOTA_1277c105-0b59-46d1-903f-bef62241659d">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtMi0xLTEtNzQzOTA_59383df2-d2e1-45cb-bb77-63b4b898b22f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtNC0xLTEtNzQzOTA_e121d3d1-069d-4343-84c0-312e9fc413f8">0.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtNi0xLTEtNzQzOTA_1cad5d4e-59db-441d-a17a-b18f7d9577b8">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtMi0xLTEtNzQzOTA_43e82fe2-1a76-4795-9583-9c87d890281d">4,500,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtNC0xLTEtNzQzOTA_9850e034-5a1c-414a-bc3f-410e32ed27e1">44.44</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtNi0xLTEtNzQzOTA_fc6fb5e2-69f4-4c41-add8-c95fc2af667b">200,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtMi0xLTEtNzQzOTA_5a99e1c3-81c7-4273-a98e-34db6bc283ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtNC0xLTEtNzQzOTA_628ea29b-26a6-4599-8f20-0b5d94e1e421">0.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtNi0xLTEtNzQzOTA_ce8d2dea-fd3c-43c8-8b96-b03ae6b42683">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtMi0xLTEtNzQzOTA_6536d069-adab-4119-b5b4-8fadb214e461">4,500,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtNC0xLTEtNzQzOTA_9648ce9a-f7cd-4446-abc5-09619b203232">44.44</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtNi0xLTEtNzQzOTA_750bf2b7-f3fb-4ef5-a813-2fe6417a9370">200,000</ix:nonFraction></span></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Included in the total cost of shares purchased is a commission fee of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="INF" name="halo:TreasuryStockAcquiredFeeCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE5NjY_4d351685-b403-4adf-b391-43d97ba90ff1">0.02</ix:nonFraction> per share.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Included is <ix:nonFraction unitRef="shares" contextRef="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIwMDQ_d013e6a9-0e2f-4426-a55b-95dfe581e7ba">0.4</ix:nonFraction>&#160;million shares delivered in December 2022 upon completion of the ASR.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_151"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTc_c512f175-a0f5-4c21-9d90-e583645021b8" continuedAt="if9ef79db408d4c3aa2c359cec46be112" escape="true">Net Income per share</ix:nonNumeric></span></div><ix:continuation id="if9ef79db408d4c3aa2c359cec46be112"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTg_8e6890b9-e5ce-45b6-a2b4-3ae7b64261c0" continuedAt="i3a15ec2d83d64beeb44f56e69cff18df" escape="true">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):</ix:nonNumeric></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><ix:continuation id="i3a15ec2d83d64beeb44f56e69cff18df"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:64.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtMi0xLTEtNzQzOTA_d47a8eb9-7523-40e8-aa3f-4971ec57c4bf">202,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtNC0xLTEtNzQzOTA_60be4c5b-6178-4b18-9f60-bc8026e75c51">402,710</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtNi0xLTEtNzQzOTA_347f3216-c688-4900-b9d7-1ca9ed2c1afd">129,085</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtMi0xLTEtNzQzOTA_ffef96f5-5082-4888-abd0-5b6d0ddc4cba">136,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtNC0xLTEtNzQzOTA_ebf56050-deb5-4552-bd80-4762873d27fb">140,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtNi0xLTEtNzQzOTA_2791f2b4-6e44-45ce-9780-e44a7049bec5">136,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctMi0xLTEtNzQzOTA_54c196e1-a571-4577-b338-0ae3035ec51b">2,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctNC0xLTEtNzQzOTA_31ed96ba-475e-4c69-b484-f0ad6bf2d814">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctNi0xLTEtNzQzOTA_09b157f0-5380-4e38-beb3-5d0c09f6734a">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c1972749fa94302ad6f4164caadc9fe_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtMi0xLTEtNzQzOTA_06511dcb-0037-411b-83b7-ccc703507e47">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9826afc8d63f4d5ca646159f99d34e57_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtNC0xLTEtNzQzOTA_e2ae39f9-0c4a-49f3-92b0-9ba282e2cb65">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0a9b9adaae647398fdba511e9ef1777_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtNi0xLTEtNzQzOTA_4d43e9eb-fcb9-49cb-be78-5f577d8a8da6">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9b9ab30830f4339a4ee873a5fc79362_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktMi0xLTEtNzQzOTA_190b1195-604e-44d0-a87a-052f56b2c40c">1,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28fdc2cdaf2a4fa09d8fe1a529c0e500_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktNC0xLTEtNzQzOTA_a1471ce9-423d-4d3c-b5b4-d99c47945e10">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie346c01929994c85883bfeb74a94e8e9_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktNi0xLTEtNzQzOTA_8e903fb4-fca3-4d10-8ecc-ed05bc012f3e">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTItMS0xLTc0Mzkw_5e98007f-7911-4c4d-967b-53c249117d3a">140,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTQtMS0xLTc0Mzkw_b0681b73-7880-4324-bf8f-df0cf420dc53">146,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTYtMS0xLTc0Mzkw_b7d34828-411e-404c-af6a-baa01bdc049d">141,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTItMS0xLTc0Mzkw_5ea474a3-4935-409f-b1f6-0c23528ff704">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTQtMS0xLTc0Mzkw_56f1e55e-92db-4580-a49b-a8162671c9e3">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTYtMS0xLTc0Mzkw_28d865af-ab4a-4652-bafa-35d9d6a9e59e">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTItMS0xLTc0Mzkw_1f7e6d42-1220-4c3f-a723-65bddbead965">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTQtMS0xLTc0Mzkw_90df12ad-38ef-4119-be81-f951e22ece70">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTYtMS0xLTc0Mzkw_5eb74c41-2581-408f-b2c4-7a744ae4cfb7">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTk_5c2a9c9a-6af4-4305-babc-0b12c0e91534" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:65.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItMi0xLTEtNzQzOTA_f7b62039-1288-4177-af00-084a8af45898">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItNC0xLTEtNzQzOTA_97f8908f-4c18-4cda-93bc-c472f44c09b3">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItNi0xLTEtNzQzOTA_a84dd32c-5977-439d-b319-b47bfb28045e">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1). The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_154"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzI1MTg_4bac8898-579b-462d-bb2b-030f7cfc7292" continuedAt="ie6f05de2ce044513b3e5d01f97428d5b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie6f05de2ce044513b3e5d01f97428d5b"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and research facilities are located in San&#160;Diego, California. In addition, we have an office in Ewing, New Jersey. We also lease a building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. We lease an aggregate of approximately <ix:nonFraction unitRef="sqft" contextRef="i5f6362e86b7647058ad2270b025883b0_D20220101-20221231" decimals="0" name="halo:OperatingLeasesAreaLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzE4NA_44d05109-01a0-460b-ba82-411d639107bf">194,000</ix:nonFraction> square feet of space. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we assumed Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately <ix:nonFraction unitRef="sqft" contextRef="ia95727628f324bdb89c986083075e8bf_D20220301-20220331" decimals="0" name="halo:OperatingLeasesAreaLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzM4NDgyOTA3MDQ5Mjk_f1aeba6e-3e48-4c42-921a-4b53dbb53292">73,238</ix:nonFraction> square feet of space in office and research facilities which commenced on December 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY0MA_84a8cac0-140f-4b1e-bf12-756f64a31f8f">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY0NA_e7170a4a-3d24-43d2-a849-2e1f7cce4c6e">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY1MQ_375ea6eb-cdaa-4857-a95f-a61bd5e040a6">2.3</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzI1MDk_44c54801-0aeb-425b-aa9e-2d6a120c805e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate annual future minimum operating lease payments as of December&#160;31, 2022 are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:84.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzEtMi0xLTEtNzQzOTA_ba12b4a4-ad5e-43dd-926d-6a21eff7f798">7,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzItMi0xLTEtNzQzOTA_ea2d4c04-8759-4532-8629-ee367ba8bbff">6,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzMtMi0xLTEtNzQzOTA_5926d74a-329f-4737-a8c0-af75b291a516">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzQtMi0xLTEtNzQzOTA_e32b386b-5a63-4f20-b8b5-9d06eb5a784f">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzUtMi0xLTEtNzQzOTA_c40dfbcb-83ef-469a-a1fe-980523bd6518">5,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzYtMi0xLTEtODUzNzc_953e4ad0-d1e1-4201-b5de-c0d68f3dc730">17,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzYtMi0xLTEtNzQzOTA_3d39ff47-48e1-444d-a6ac-34b4d0e762c3">47,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzctMi0xLTEtNzQzOTA_f65a66b8-f77e-46ea-9ffa-ed2a741aeb28">12,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzgtMi0xLTEtNzQzOTA_12083406-1283-49f8-91a7-ae213fe65829">34,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term of our operating leases is approximately <ix:nonNumeric contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1Xzg3Nw_f2a96ed0-4d27-4165-a1e1-87c54a7a65aa">7.64</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_157"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Income Taxes</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5NDE_93d82016-87ee-44bd-a558-956c5a8c1d9e" continuedAt="i749244dc29d14d669ed02b740a08c0f9" escape="true"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MTk_92cae4eb-0119-4312-bd4e-5445c4cd85a4" escape="true"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income (loss) before income taxes summarized by region were as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:58.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItMi0xLTEtNzQzOTA_82addc02-91fc-4242-83df-4434e0053b54">248,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItNC0xLTEtNzQzOTA_0d670333-0135-4b4a-9dce-68af34e6e3da">248,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItNi0xLTEtNzQzOTA_2ae7ee56-3c8c-423a-b4da-76a45e9601c7">130,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtMi0xLTEtNzQzOTA_085a76bd-b715-41d2-925a-fb4d9b10600b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtNC0xLTEtNzQzOTA_6057014c-6c62-405c-aa87-ed3ece45b637">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtNi0xLTEtNzQzOTA_c57ba34f-4094-420e-8bfe-280607786d83">1,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtMi0xLTEtNzQzOTA_f23619ef-19a7-4d01-abd0-9215a5671e4d">248,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtNC0xLTEtNzQzOTA_b33b165c-df43-42a5-ad33-44aed6ccd237">248,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtNi0xLTEtNzQzOTA_de9347cf-f0c6-414a-b972-2711c8d4b826">129,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5Mzg_eca1d787-c676-4fd5-ae73-2f2765fcaa71" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:70.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzMtMi0xLTEtNzQzOTA_d08f9c98-c344-4847-a2e6-90f58afbf6be">32,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzMtNC0xLTEtNzQzOTA_33bd1cc1-43c2-4727-9406-9444ebdce90c">42,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzQtMi0xLTEtNzQzOTA_6ce7588c-2d24-4729-96c1-ade100ba474f">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzQtNC0xLTEtNzQzOTA_486fb87a-2c0d-4109-bfe7-bb446e29abe9">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzUtMi0xLTEtNzQzOTA_df78d31e-5eb1-4019-8259-fe2eea28a14e">96,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzUtNC0xLTEtNzQzOTA_68da0f0a-598f-4f72-bece-6eee919b9e6b">109,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzYtMi0xLTEtNzQzOTA_3cd8401c-c589-44b5-ba13-192c7e71ed7b">6,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzYtNC0xLTEtNzQzOTA_f2e5b4df-bb83-4172-850b-fbfaffd115a3">1,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzgtMi0xLTEtNzQzOTA_3c7c079e-fa6a-4129-8852-6f3e64af7ea7">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzgtNC0xLTEtNzQzOTA_d25dd7d1-494c-42ed-bc39-9fe43bcb1a73">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktMi0xLTEtODcxNDE_d9b53911-ea04-4ed2-9cd3-14be95011f65">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktNC0xLTEtODcxNDk_cf9912bc-d15b-4da1-8cbb-3987329eb396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxAssetTransactionRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTItMS0xLTg3MTQx_fec5e7cc-16e4-4ef3-bdf9-32a44c134bca">2,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:DeferredTaxAssetTransactionRelatedExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTQtMS0xLTg3MTQ5_0a921c65-b7d2-491c-a151-8e6e8c96eabe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTItMS0xLTg3MTQx_67b7f859-209c-4b09-a8ad-8e5354b7d798">18,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTQtMS0xLTg3MTQ5_f44814cd-9ee9-4844-a357-ae149c34b549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxAssetsInterestExpenseLimitation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktMi0xLTEtNzQzOTA_4a6e9b0d-1871-488d-a944-800b5c37c5e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:DeferredTaxAssetsInterestExpenseLimitation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktNC0xLTEtNzQzOTA_0233d55b-d07b-4e72-bdf5-f481220aee36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTItMS0xLTc0Mzkw_d55bee8f-89b3-4a60-9a71-095f3b20e86e">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTQtMS0xLTc0Mzkw_65e1652e-3e7a-4f91-8210-05c26f3dbbf9">3,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTItMS0xLTc0Mzkw_5b4e5ccc-52af-40ec-b9e7-c34ee334ef1f">172,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTQtMS0xLTc0Mzkw_f5eb369a-f8df-4eba-bf63-cfaa72ccfc6f">157,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEyLTItMS0xLTc0Mzkw_977f38d4-bc1a-4e13-8244-8bd93fed712e">707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEyLTQtMS0xLTc0Mzkw_59edacd0-3dba-4992-a781-365d2852e9f8">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEzLTItMS0xLTc0Mzkw_cc9b0f0c-d8db-44b9-a724-2bfb087c2cba">171,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEzLTQtMS0xLTc0Mzkw_58239e6f-3645-40d4-aadb-d2545edf7499">157,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible book amortization </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxLiabilitiesNonDeductibleBookAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTItMS0xLTg3MTYx_4b7da5c4-33ec-4d53-b3d9-d84d8418edf9">115,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE1LTItMS0xLTc0Mzkw_319260b9-ab7d-4f0d-ae1d-071c6d6c0e4d">2,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE1LTQtMS0xLTc0Mzkw_b6ce99f2-4e85-4f6d-983e-785ef7f7d2cb">1,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxLiabilitiesConvertibleNote" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE2LTItMS0xLTc0Mzkw_e33d1139-abd9-4264-afe6-70058c3cbc22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:DeferredTaxLiabilitiesConvertibleNote" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE2LTQtMS0xLTc0Mzkw_d1115900-9670-4dee-bf15-26d5c8ad1eae">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="halo:DeferredTaxLiabilitiesRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE3LTItMS0xLTc0Mzkw_cbd91b40-6b9e-457d-9bbc-0c254d004bb1">9,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="halo:DeferredTaxLiabilitiesRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE3LTQtMS0xLTc0Mzkw_39bbeee2-dfeb-45ce-af03-a58e7c8a9746">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTItMS0xLTc0Mzkw_5ee84d92-c6ec-4afd-8a0e-ead72f523fe5">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTQtMS0xLTc0Mzkw_6ac7399c-513b-40a4-8e88-c27abab44b50">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE5LTItMS0xLTc0Mzkw_183676d0-c3bb-4220-a465-3fe61295feaa">127,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE5LTQtMS0xLTc0Mzkw_af58c52c-22ad-4490-bc80-51e4bdd7c3f0">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzIwLTItMS0xLTc0Mzkw_a1b529e8-20d2-4153-9dfa-26ecad6da1ea">44,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzIwLTQtMS0xLTc0Mzkw_6e20afa2-d8ec-473b-aba4-5f8c86674e96">155,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI0Mw_9e212427-bbdb-45e8-9f87-09d21ccadc29">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI1MA_0899e563-cb55-47ab-8346-39a45930757f">0.5</ix:nonFraction> million has been established to offset the net deferred tax assets as of December 31, 2022 and 2021, respectively, as realization of such assets is uncertain. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, we reassess the valuation allowance of our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. In 2021, we have demonstrated profitability and cumulative pretax income and are forecasting income growth. After assessing both the positive and negative evidence, we determined that it was more likely than not that our DTAs would be realized and released the valuation allowance in 2021.</span></div></ix:nonNumeric><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i749244dc29d14d669ed02b740a08c0f9" continuedAt="i574f9be134734b80adebf0927c8fa6dd"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired the outstanding shares of Antares Pharma Inc. This transaction was treated as a non-taxable acquisition, we have increased our deferred tax liabilities by approximately $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="halo:DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE2NDkyNjc0NDYwNjA_331c6260-cf89-4ca5-ba07-3341a168bde5">119.7</ix:nonFraction>&#160;million related to acquired intellectual property and a step-up to the value of inventory the amortization of which will not be tax deductible.</span></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MjM_a0850ebc-f5a5-40a6-8665-4918d2393a66" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense was comprised of the following components (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:58.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItMi0xLTEtNzQzOTA_0f53fc8f-5306-4acf-9c2e-b493c1d50666">6,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItNC0xLTEtNzQzOTA_6dd96958-7bbf-433a-960a-39b0ac1e2c6d">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItNi0xLTEtNzQzOTA_eb2877b5-3d25-4f9c-89cc-b12a6ac1d56a">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtMi0xLTEtNzQzOTA_4edf3c14-3e4b-4d12-99d9-16651ecb8b52">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtNC0xLTEtNzQzOTA_ef74a461-a648-4394-a262-aaa9df371c97">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtNi0xLTEtNzQzOTA_8dea9864-0d71-4472-aa82-ecb8af65808a">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtMi0xLTEtNzQzOTA_316f262c-7b53-4c9c-aad8-9dae680581af">44,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtNC0xLTEtNzQzOTA_95143f2c-b361-4d25-9adb-d12e5b7cf2a1">117,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtNi0xLTEtNzQzOTA_adfa311e-de71-4d80-9564-d30c3a22492e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtMi0xLTEtNzQzOTA_a9b96aca-ecdc-45f7-9093-510272b71f34">6,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtNC0xLTEtNzQzOTA_3df9deda-bff0-4c95-8f17-9e41c92ef1ec">37,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtNi0xLTEtNzQzOTA_3e778452-dc07-4d7a-8472-13b81b689974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtMi0xLTEtNzQzOTA_e33ac721-f1de-405b-ba3f-87775cdfa380">46,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtNC0xLTEtNzQzOTA_142bcebe-115e-4ab2-887c-b4fb46cc29a9">154,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtNi0xLTEtNzQzOTA_155cd49f-35d3-493d-8d39-f4cd2ec2cfc3">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MzE_32a294c5-0c08-490f-abb3-ea290afa91e4" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:58.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense (benefit) at 21% </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItMi0xLTEtNzQzOTA_08afa98a-f318-4d56-acb0-6bea43754182">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItNC0xLTEtNzQzOTA_5349403e-a4ac-4822-a2e7-8e8f2ac70ce5">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItNi0xLTEtNzQzOTA_59d60013-ea61-4dac-8a62-0650cd0e3052">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal income tax impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtMi0xLTEtNzQzOTA_fd718948-a81a-4385-91a4-6dc01ee83897">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtNC0xLTEtNzQzOTA_db12af84-2256-400b-8844-868f7c31d3e3">2.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtNi0xLTEtNzQzOTA_c9eedefc-a7f6-43a8-ab45-2abf1a6d683d">1.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtMi0xLTEtNzQzOTA_078a08b9-6ebe-4d94-9c9b-53094158fcfb">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtNC0xLTEtNzQzOTA_abaddd12-ef0e-415d-9448-7d57329a7a50">84.92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtNi0xLTEtNzQzOTA_3fb759c1-82fa-417a-aa1f-8b84011a9121">34.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worthless stock deduction of international subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtMi0xLTEtNzQzOTA_d7b70734-e207-4695-9ef9-310d02875ca6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtNC0xLTEtNzQzOTA_706e69ef-3708-4695-b01e-88bb32f92fec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" sign="-" name="halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtNi0xLTEtNzQzOTA_f08b180b-4510-4048-8c19-55e83c8b2cec">52.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income subject to tax at other than federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctMi0xLTEtNzQzOTA_44ea80b1-d23e-458e-b150-70f2f4222306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctNC0xLTEtNzQzOTA_ed6dcffa-7375-4ba7-87ce-55a05fd28e4e">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctNi0xLTEtNzQzOTA_a0206fa7-3b5b-4205-907b-f2d4bb7b09d4">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtMi0xLTEtNzQzOTA_8462d420-16d6-4834-8b05-4430c4d1bdf2">0.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtNC0xLTEtNzQzOTA_e12d776d-9a5a-4d86-9baf-fbf5d5d0a494">2.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtNi0xLTEtNzQzOTA_61291558-4d8e-4c5c-ad5d-8937611bbc09">1.89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktMi0xLTEtNzQzOTA_8cf9fb5f-d0bc-4728-8d2f-7849a6a3a086">2.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktNC0xLTEtNzQzOTA_9aeebe98-425e-4270-9a05-e0bc4d0ffc68">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktNi0xLTEtNzQzOTA_39619b02-d2fd-4a87-b1ba-183de9abefe0">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTItMS0xLTc0Mzkw_c7b0a120-4fe4-471e-9669-81f13b52c793">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTQtMS0xLTc0Mzkw_649f10f3-9a5e-483a-90ab-7de944696dcf">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTYtMS0xLTc0Mzkw_390747e4-95aa-41b3-a882-4aa766116400">1.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" sign="-" name="halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTItMS0xLTc0Mzkw_b11e8489-e4dd-470e-a891-3a7247f61410">5.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" sign="-" name="halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTQtMS0xLTc0Mzkw_049044bb-da03-4743-a5d8-940d5ad4de70">1.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTYtMS0xLTc0Mzkw_d95f48b0-2310-4afb-9a58-f253d1bd3dfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTItMS0xLTg3MzA2_72066dbf-ba39-43c8-ac28-42069585a614">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTQtMS0xLTg3MzE4_1d8b92a3-ac91-4356-b7f8-5d4b1eaefff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTYtMS0xLTg3MzI2_77f44d63-fb0c-4486-ba1f-7ed9354a2420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTItMS0xLTc0Mzkw_a02db630-654e-44c8-a4b8-c06f8a4dea23">18.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTQtMS0xLTc0Mzkw_81c97c49-0608-46b8-8ffe-bb368252f9b8">62.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTYtMS0xLTc0Mzkw_437d39fe-789e-4e98-af5a-0016a9c74859">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At December&#160;31, 2022, our unrecognized tax benefit and uncertain tax positions were $<ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzEzNDI_f884cc03-52b2-4ce8-9520-8815e92977ae">19.5</ix:nonFraction> million, which will impact the effective tax rate when resolved. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December&#160;31, 2022, 2021 and 2020, we recognized an immaterial amount of interest and penalties.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i574f9be134734b80adebf0927c8fa6dd"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MzI_ebf09f48-e897-4677-b083-e16b4ca31db3" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:58.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItMi0xLTEtNzQzOTA_59f02809-db2e-4055-a048-2e19e39f9480">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItNC0xLTEtNzQzOTA_282cd834-8d5d-453d-8cd9-518698a7898d">19,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItNi0xLTEtNzQzOTA_fd200a80-a3fa-4b16-9b8f-b191def3b361">21,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtMi0xLTEtNzQzOTA_f0e5aecb-c17a-4843-9cba-740ec16be8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtNC0xLTEtNzQzOTA_bfb350e0-d93c-477a-a679-09dd32a57c35">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtNi0xLTEtNzQzOTA_68f3f99f-be67-41f7-a2c3-c1038ec6dd26">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in tax positions for prior years and lapse in statue of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtMi0xLTEtNzQzOTA_5052045d-40a1-4a3e-94de-1bb80f54cad4">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtNC0xLTEtNzQzOTA_9b9960d8-2258-4663-a6d6-0e121cc2fde6">1,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtNi0xLTEtNzQzOTA_7781a5f3-8e8a-4bf0-8d7a-262b23f09083">2,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions related to business acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtMi0xLTEtODczNzI_c9519cef-d7e4-4fe3-8ae5-8c153239eee8">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNC0xLTEtODczODA_4ae02de7-80df-4255-a6a9-4a7a838f8260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNi0xLTEtODczODg_09215d36-8a37-4f1d-b7bb-5da104399a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for current year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtMi0xLTEtNzQzOTA_f4e7de36-2070-43f3-ab5b-39ab83ebb73e">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNC0xLTEtNzQzOTA_b97d14ae-afd0-4911-86d8-2682533c4793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNi0xLTEtNzQzOTA_9893bd4a-15ee-4619-b867-47f70df42c49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtMi0xLTEtNzQzOTA_fb3a13c3-4fde-43c5-af7b-aa4abf3afeb3">19,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtNC0xLTEtNzQzOTA_1d138044-c632-4d5e-acd8-bc180cdebc41">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtNi0xLTEtNzQzOTA_494cbb1f-5df4-4540-ae9a-0972836f8de2">19,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal, California and other state tax net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i01d046463d2847239062ac90d2a20ea2_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5Mjk_ccfcc21b-cd49-4450-8144-379f8e4e614a">31.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i605fb0614d614a189301d7b5aade275c_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5MzM_d71157c1-ab2b-4efe-8960-d645696cb6b5">237.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id17b587fd04b4b8eb4297c5113c4d2f0_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5NDA_866d3cbf-cf45-4d10-b5b3-5a11ae750de9">63.4</ix:nonFraction> million, respectively. The California and Minnesota net operating loss carryforwards begin to expire in 2028 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we acquired federal and Minnesota research and development credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i182a0e0c521c4a8e849c93a64dc49a7c_I20220524" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODY3Mw_e67aedab-25c6-4e38-80cb-cd4cdb608a77">7.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i887f9a04206a45138521ae3e2d97845c_I20220524" decimals="-4" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODY4OA_52e3a6d4-f3ac-4bac-a9e1-0a4f6cad2bba">0.72</ix:nonFraction>&#160;million, respectively. We expect to be able to fully utilize these attributes without limitation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal, California and Minnesota research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="id7aa8bd02d7448e5943ae4e632674862_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzIxOTE_62d73cdc-f211-4656-980e-33ef8262c35b">30.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i25d54b5d7bf64043bb0258fe6d02efc5_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzIxOTg_ee77c03e-9765-49fa-ad3f-0e14323fa238">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i37c7ed8f55754813819fbae73df620ee_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODg3MA_afb8aed8-5b1e-451b-b833-dd0cd34fc75f">0.7</ix:nonFraction> million, respectively. The federal research and development tax credits will begin to expire in 2030 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. The Minnesota research and development credit will begin to expire in 2023 unless previously utilized. Additionally, we had Orphan Drug Credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="if46db7bf283d452193c503c22cecc2a8_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI0NzY_ac4b5209-1b01-44b7-b73d-0ef358ba5799">70.0</ix:nonFraction> million which will begin to expire in 2034. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Internal Revenue Code Section&#160;382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section&#160;382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2020. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="INF" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM1Nzk_0b9f9cfc-ce64-4b0f-87d0-0f1a6495785a"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="INF" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM1Nzk_b10ed16a-8991-41ce-9c75-50fb5e391033">no</ix:nonFraction></ix:nonFraction> undistributed earnings in foreign subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2008 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></div></ix:continuation><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><div id="i732e51618ba84e17b469190f5cc138c6_160"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. Employee Savings Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM5MA_3ba547c4-2e9c-4fda-a262-67567e71e885" escape="true">We have an employee savings plan pursuant to Section&#160;401(k) of the Internal Revenue Code.&#160;All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately $<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzMzOQ_ba643038-3ad9-4a28-89e0-bc10601ac634">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM0Mw_c631cbbb-40ee-4731-b3ab-93a81eb8d574">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM1MA_375cfde2-6807-437c-8f68-79300a2f5876">1.1</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:nonNumeric></span></div><div id="i732e51618ba84e17b469190f5cc138c6_169"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Halozyme Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div id="i732e51618ba84e17b469190f5cc138c6_172"></div><ix:nonNumeric contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90ZXh0cmVnaW9uOmEwYjAxZTI4ZDEyMjQxMDdiNDM2ODVjNDdhYmI4Njk1XzIwNQ_24407208-ab69-4581-873c-dfec95cac4b6" continuedAt="i3bee2eab7c1f4c6aa83c6b1bbb4fc7c3" escape="true"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItMi0xLTEtNzQzOTA_c8f193b3-7d25-446d-9c4e-9074c6c3e845">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNC0xLTEtODUzNTA_6c8640f0-30cf-42c1-8ccc-3f1c888edf52">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNC0xLTEtNzQzOTA_de8e53ad-9a59-42e1-a8d6-8f11f4bd9aa3">5,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNi0xLTEtNzQzOTA_9c040c19-e4d7-4a45-b5da-590cc9b30b51">6,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItOC0xLTEtNzQzOTA_5d9925d7-1e39-4521-8a42-8c578243296c">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtMi0xLTEtNzQzOTA_50cc3bc5-7c41-4d1c-9c73-47cd8059ed4a">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtNC0xLTEtNzQzOTA_18898cbe-db4a-4f0d-8310-09744a887ea4">8,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtNi0xLTEtNzQzOTA_b55846d9-ec83-4619-a0f7-ef641a448bdd">7,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtOC0xLTEtNzQzOTA_72c0fc9b-749d-433d-8fc5-45d0b1ba4508">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtMi0xLTEtNzQzOTA_1c5264d0-95eb-46b3-9f7b-bb766fd476c5">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtNC0xLTEtNzQzOTA_39acb86a-cd44-43f4-a038-e3a159e285c9">13,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtNi0xLTEtNzQzOTA_434319ab-bc2e-4021-ac22-95d000bf1967">13,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtOC0xLTEtNzQzOTA_7d9848d8-8385-4def-bbf0-6005d5942630">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3bee2eab7c1f4c6aa83c6b1bbb4fc7c3" continuedAt="i205d06b8f54b4ba0bc0130c0c80f4120">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt"><ix:continuation id="i205d06b8f54b4ba0bc0130c0c80f4120">Allowances are for chargebacks, prompt payment discounts and distribution fees related to proprietary product sales.</ix:continuation> </span></div><div style="height:135pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ex211subsidiaries2022.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaa0b6ed1e85c41f2b751bbe6103d1a8c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:52.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State or Jurisdiction of<br>&#160;Incorporation or Organization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent Owned</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antares Pharma, Inc</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antares Pharma IPL AG</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antares Pharma AG</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr></table></div><div style="text-align:center;text-indent:22.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex231auditorconsent2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia8eeff64a8e34d1e96799b2a2e5cb2e5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;           </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statement (Form S-3 No. 333-216315) of Halozyme Therapeutics, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statement (Form S-8 No. 333-152914) pertaining to the Halozyme Therapeutics, Inc. 2008 Outside Directors&#8217; Stock Plan and Halozyme Therapeutics, Inc. 2008 Stock Plan of Halozyme Therapeutics, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statement (Form S-8 No. 333-174013) pertaining to the Halozyme Therapeutics, Inc. 2011 Stock Plan of Halozyme Therapeutics, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-188997) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.,</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-206279) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc., </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-211244) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.,</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Registration Statement (Form S-8 No. 333-224843) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.,</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Registration Statement (Form S-8 No. 333-255791) pertaining to the Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan of Halozyme Therapeutics, Inc., and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) Registration Statement (Form S-8 No. 333-255790) pertaining to the Halozyme Therapeutics, Inc. 2021 Stock Plan of Halozyme Therapeutics, Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;21, 2023, with respect to the consolidated financial statements and schedule of Halozyme Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Halozyme Therapeutics, Inc. included in this Annual Report (Form 10-K) of Halozyme Therapeutics, Inc. for the year ended December&#160;31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023 </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31110k2022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie89c4a40389a45038706c97660468737_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Annual Report on Form 10-K of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex3210k2022.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6c8045b76aaa4620ac3d6cb65c2eea9f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nicole LaBrosse, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex31210k2022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i77a34045f6684ab7afa771b303b94887_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Annual Report on Form 10-K of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>halo-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:halo="http://www.halozyme.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.halozyme.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.halozyme.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.halozyme.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cover_1" roleURI="http://www.halozyme.com/role/Cover_1">
        <link:definition>0000003 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.halozyme.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000006 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000007 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitStatement" roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement">
        <link:definition>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.halozyme.com/role/OrganizationandBusiness">
        <link:definition>0000010 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.halozyme.com/role/BusinessCombination">
        <link:definition>0000012 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.halozyme.com/role/FairValueMeasurement">
        <link:definition>0000013 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.halozyme.com/role/Revenue">
        <link:definition>0000014 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems">
        <link:definition>0000015 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000016 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtNet" roleURI="http://www.halozyme.com/role/LongtermDebtNet">
        <link:definition>0000017 - Disclosure - Long-term Debt, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.halozyme.com/role/SharebasedCompensation">
        <link:definition>0000018 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.halozyme.com/role/StockholdersEquity">
        <link:definition>0000019 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomepershare" roleURI="http://www.halozyme.com/role/NetIncomepershare">
        <link:definition>0000020 - Disclosure - Net Income per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.halozyme.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.halozyme.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeSavingsPlan" roleURI="http://www.halozyme.com/role/EmployeeSavingsPlan">
        <link:definition>0000023 - Disclosure - Employee Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>0000024 - Disclosure - Schedule II Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.halozyme.com/role/BusinessCombinationTables">
        <link:definition>0000027 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.halozyme.com/role/FairValueMeasurementTables">
        <link:definition>0000028 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.halozyme.com/role/RevenueTables">
        <link:definition>0000029 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables">
        <link:definition>0000030 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000031 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtNetTables" roleURI="http://www.halozyme.com/role/LongtermDebtNetTables">
        <link:definition>0000032 - Disclosure - Long-term Debt, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.halozyme.com/role/SharebasedCompensationTables">
        <link:definition>0000033 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.halozyme.com/role/StockholdersEquityTables">
        <link:definition>0000034 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomepershareTables" roleURI="http://www.halozyme.com/role/NetIncomepershareTables">
        <link:definition>0000035 - Disclosure - Net Income per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.halozyme.com/role/IncomeTaxesTables">
        <link:definition>0000037 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDetails" roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails">
        <link:definition>0000038 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>0000043 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentinformationDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails">
        <link:definition>0000044 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationNarrativeDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails">
        <link:definition>0000045 - Disclosure - Business Combination - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationPurchaseConsiderationDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails">
        <link:definition>0000046 - Disclosure - Business Combination -Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000047 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationIntangibleAssetsAcquiredDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails">
        <link:definition>0000048 - Disclosure - Business Combination - Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationSummaryofProformaFinancialInformationDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails">
        <link:definition>0000049 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails">
        <link:definition>0000050 - Disclosure - Fair Value Measurement - Summary of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementMaturitiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails">
        <link:definition>0000052 - Disclosure - Fair Value Measurement - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails">
        <link:definition>0000053 - Disclosure - Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenueDetails" roleURI="http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails">
        <link:definition>0000054 - Disclosure - Revenue - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTextualsDetails" roleURI="http://www.halozyme.com/role/RevenueTextualsDetails">
        <link:definition>0000055 - Disclosure - Revenue - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractwithCustomerAssetandLiabilityDetails" roleURI="http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails">
        <link:definition>0000056 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenueRemainingPerformanceObligationDetails" roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails">
        <link:definition>0000057 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenueRemainingPerformanceObligationDetails_1" roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails_1">
        <link:definition>0000057 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsreceivableDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails">
        <link:definition>0000058 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsInventoriesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails">
        <link:definition>0000059 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails">
        <link:definition>0000060 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyandEquipmentDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails">
        <link:definition>0000061 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails">
        <link:definition>0000062 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails">
        <link:definition>0000063 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1">
        <link:definition>0000063 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>0000064 - Disclosure - Goodwill and Intangible Assets-Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillRollforwardDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails">
        <link:definition>0000065 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>0000066 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails">
        <link:definition>0000067 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetNarrativeDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails">
        <link:definition>0000068 - Disclosure - Long-Term Debt, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" roleURI="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails">
        <link:definition>0000069 - Disclosure - Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>0000070 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>0000071 - Disclosure - Share-based Compensation -Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationUnrecognizedExpenseDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails">
        <link:definition>0000072 - Disclosure - Share-based Compensation - Unrecognized Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationOptionsDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationOptionsDetails">
        <link:definition>0000073 - Disclosure - Share-based Compensation - Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationValuationDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationValuationDetails">
        <link:definition>0000074 - Disclosure - Share-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails">
        <link:definition>0000075 - Disclosure - Share-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationPerformanceStockUnitsDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails">
        <link:definition>0000076 - Disclosure - Share-based Compensation - Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000077 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareRepurchasesDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails">
        <link:definition>0000078 - Disclosure - Stockholders' Equity - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails" roleURI="http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails">
        <link:definition>0000079 - Disclosure - Net Income per share - Basic and Diluted Income Per Common Share Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomepershareAntidilutiveSecuritiesDetails" roleURI="http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails">
        <link:definition>0000080 - Disclosure - Net Income per share - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeasetextualDetails" roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails">
        <link:definition>0000081 - Disclosure - Commitments and Contingencies - Operating Lease textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails" roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails">
        <link:definition>0000082 - Disclosure - Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000082 - Disclosure - Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetIncomeLossByRegionDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails">
        <link:definition>0000083 - Disclosure - Income Taxes Net - Income (Loss) By Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsDeferredTaxesDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails">
        <link:definition>0000084 - Disclosure - Income Taxes - Components Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000085 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseBenefitDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
        <link:definition>0000086 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxReconciliationDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails">
        <link:definition>0000087 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitDetails" roleURI="http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails">
        <link:definition>0000088 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeSavingsPlanDetails" roleURI="http://www.halozyme.com/role/EmployeeSavingsPlanDetails">
        <link:definition>0000089 - Disclosure - Employee Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>0000090 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="halo_NumberOfCollaborationsRoyaltiesReceived" abstract="false" name="NumberOfCollaborationsRoyaltiesReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_PartnerDMember" abstract="true" name="PartnerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsalestocollaborators" abstract="false" name="Accountsreceivablefromproductsalestocollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" abstract="false" name="AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_PaymentForCappedCallTransactions" abstract="false" name="PaymentForCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AutoInjectorTechnologyPlatformMember" abstract="true" name="AutoInjectorTechnologyPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AmendedAndRestated2021StockPlanMember" abstract="true" name="AmendedAndRestated2021StockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AntaresPharmaIncMember" abstract="true" name="AntaresPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodFourMember" abstract="true" name="DebtInstrumentInterestPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_A025ConvertibleSeniorNotesDue2027Member" abstract="true" name="A025ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" abstract="false" name="NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_OtherStatesMember" abstract="true" name="OtherStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_LongTermDebtIncludingInterestGross" abstract="false" name="LongTermDebtIncludingInterestGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_Accountsreceivablefromroyalties" abstract="false" name="Accountsreceivablefromroyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DevicePartneredProductsMember" abstract="true" name="DevicePartneredProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" abstract="false" name="SaleOfStockPremiumOverLastReportedSalePricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_A100ConvertibleSeniorNotesDue2028Member" abstract="true" name="A100ConvertibleSeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_RocheandBaxaltaMember" abstract="true" name="RocheandBaxaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodThirdMember" abstract="true" name="DebtInstrumentInterestPeriodThirdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodTwoMember" abstract="true" name="DebtInstrumentInterestPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_OtherCollaboratorsMember" abstract="true" name="OtherCollaboratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsales" abstract="false" name="Accountsreceivablefromproductsales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ProprietaryProductsSalesMember" abstract="true" name="ProprietaryProductsSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AccruedLiabilitiesNoncurrent" abstract="false" name="AccruedLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_CliffVestingFirstAnniversaryMember" abstract="true" name="CliffVestingFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_OutstandingAwardsMember" abstract="true" name="OutstandingAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DevelopmentFeesMember" abstract="true" name="DevelopmentFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AcceleratedShareRepurchaseAgreementMember" abstract="true" name="AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_PurchaseOfCappedCall" abstract="false" name="PurchaseOfCappedCall" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_UpfrontfeesMember" abstract="true" name="UpfrontfeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" abstract="false" name="GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="halo_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_A1.25ConvertibleSeniorNotesdue2024Member" abstract="true" name="A1.25ConvertibleSeniorNotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_CollaborativeAgreementsMember" abstract="true" name="CollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredTaxLiabilitiesRightofUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightofUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BulkrHuPH20Member" abstract="true" name="BulkrHuPH20Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_LongTermDebtInterestGross" abstract="false" name="LongTermDebtInterestGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_LicenseFeesAndEventBasedMember" abstract="true" name="LicenseFeesAndEventBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" abstract="false" name="NumberOfProductsForWhichRoyaltiesReceivedFromSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_DeferredTaxAssetsInterestExpenseLimitation" abstract="false" name="DeferredTaxAssetsInterestExpenseLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_XYOSTEDProprietaryProductMember" abstract="true" name="XYOSTEDProprietaryProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accruedmanufacturingexpenses" abstract="false" name="Accruedmanufacturingexpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_TLANDOProductRightsMember" abstract="true" name="TLANDOProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_PercentageVestingMember" abstract="true" name="PercentageVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardUnvestedMember" abstract="true" name="ShareBasedCompensationAwardUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_DebtInstrumentCapCallTransactionCapPricePerShare" abstract="false" name="DebtInstrumentCapCallTransactionCapPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_TreasuryStockAcquiredFeeCostPerShare" abstract="false" name="TreasuryStockAcquiredFeeCostPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_OperatingLeasesAreaLeased" abstract="false" name="OperatingLeasesAreaLeased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_A2017RocheMember" abstract="true" name="A2017RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredBonusAwards" abstract="false" name="BusinessCombinationConsiderationTransferredBonusAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DeferredTaxLiabilitiesConvertibleNote" abstract="false" name="DeferredTaxLiabilitiesConvertibleNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardsVestedMember" abstract="true" name="ShareBasedCompensationAwardsVestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" abstract="false" name="DeferredTaxLiabilitiesNonDeductibleBookAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodAxis" abstract="true" name="AnnualInterestPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_ConcentrationRiskPercentageInstantDate" abstract="false" name="ConcentrationRiskPercentageInstantDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" abstract="false" name="DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_A2021ESPPPlanMember" abstract="true" name="A2021ESPPPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RSURSAandPRSUawardsMember" abstract="true" name="RSURSAandPRSUawardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredTaxAssetTransactionRelatedExpense" abstract="false" name="DeferredTaxAssetTransactionRelatedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodDomain" abstract="true" name="AnnualInterestPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="halo_MonthlyVestingAfterOneYearMember" abstract="true" name="MonthlyVestingAfterOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromcollaborators" abstract="false" name="Accountsreceivablefromcollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_SalesbasedmilestoneMember" abstract="true" name="SalesbasedmilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" abstract="false" name="DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" abstract="false" name="ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ResearchandDevelopmentServicesMember" abstract="true" name="ResearchandDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AllowanceforDistributionFeesandDiscounts" abstract="false" name="AllowanceforDistributionFeesandDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodOneMember" abstract="true" name="DebtInstrumentInterestPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ForeignOtherMember" abstract="true" name="ForeignOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_OfficeAndResearchFacilityMember" abstract="true" name="OfficeAndResearchFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredRentPayments" abstract="false" name="DeferredRentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_OperatingLeaseAccretionOfLiability" abstract="false" name="OperatingLeaseAccretionOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>halo-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3bc7d058-6426-441c-8a3b-a2095c4eed50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3bc7d058-6426-441c-8a3b-a2095c4eed50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba1a560c-12b3-4ec1-bf0d-c8873c89c67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_ba1a560c-12b3-4ec1-bf0d-c8873c89c67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4b5c8689-2745-48bb-872f-78092a7633ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4b5c8689-2745-48bb-872f-78092a7633ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5f3463ed-135b-411e-8d77-9564fe365238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_LongTermDebt_5f3463ed-135b-411e-8d77-9564fe365238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69a8f5a0-683b-4e1a-808e-8f8d48ab16ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_StockholdersEquity_69a8f5a0-683b-4e1a-808e-8f8d48ab16ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf86f14e-c3e1-4598-af0e-865cf378e5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf86f14e-c3e1-4598-af0e-865cf378e5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_05efa5f5-2428-4c69-b0ae-443d8aea4209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a284ed8-288d-42cd-aa7a-d31fafb449bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_05efa5f5-2428-4c69-b0ae-443d8aea4209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_41866536-1b10-4d6f-b58e-c2a4af9a8df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_091c75ee-7d88-4c1d-8c51-c88365320368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41866536-1b10-4d6f-b58e-c2a4af9a8df6" xlink:to="loc_us-gaap_AccountsPayableCurrent_091c75ee-7d88-4c1d-8c51-c88365320368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f4f5e273-ad27-4234-be73-ebd4c1309cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41866536-1b10-4d6f-b58e-c2a4af9a8df6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f4f5e273-ad27-4234-be73-ebd4c1309cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f90be5d0-4c10-481c-9eb8-4695ca4182ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41866536-1b10-4d6f-b58e-c2a4af9a8df6" xlink:to="loc_us-gaap_LongTermDebtCurrent_f90be5d0-4c10-481c-9eb8-4695ca4182ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_62652093-0f94-4e90-aa3e-0e51178129fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41866536-1b10-4d6f-b58e-c2a4af9a8df6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_62652093-0f94-4e90-aa3e-0e51178129fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_513234ca-4345-4e5f-a30d-d2f6f1f3316a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:to="loc_us-gaap_CommonStockValue_513234ca-4345-4e5f-a30d-d2f6f1f3316a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b2844216-323a-495d-b2d2-8d4fa5d37ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b2844216-323a-495d-b2d2-8d4fa5d37ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33521a71-1714-4b87-b17d-b43a55c53851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33521a71-1714-4b87-b17d-b43a55c53851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ff66e536-e620-4181-b2f5-bcef6717356a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:to="loc_us-gaap_PreferredStockValue_ff66e536-e620-4181-b2f5-bcef6717356a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69ad75b6-01f3-4660-8b8a-b15cadb745a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_340f4571-4072-406e-aae8-16efc81293e9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69ad75b6-01f3-4660-8b8a-b15cadb745a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6218fbb-f71a-41c1-936c-21b3da6ac42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_AssetsCurrent_e6218fbb-f71a-41c1-936c-21b3da6ac42d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_960f87e2-8bf8-431c-843c-002fb179a2e1" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_960f87e2-8bf8-431c-843c-002fb179a2e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_90cef12c-7f10-4768-ae53-d90985c0dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_90cef12c-7f10-4768-ae53-d90985c0dfbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79984952-28d5-4d46-ae67-e0d6217757d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_Goodwill_79984952-28d5-4d46-ae67-e0d6217757d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8ba7f599-d365-429c-b36b-749cdbbb0ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8ba7f599-d365-429c-b36b-749cdbbb0ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e6bca379-a7df-40cc-9d82-85a6c5c89dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e6bca379-a7df-40cc-9d82-85a6c5c89dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c9da64-f36d-4b01-b7ea-33b142200c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63a6d4a0-7e39-44a7-a13e-d3924b4a5a3b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_18c9da64-f36d-4b01-b7ea-33b142200c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf3084d6-5608-46ca-8422-5b41cc7b76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf3084d6-5608-46ca-8422-5b41cc7b76a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6b74e993-6314-40d0-9ded-0f46031a7f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6b74e993-6314-40d0-9ded-0f46031a7f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a0355893-8d05-4e38-bae3-afb2af1caf29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a0355893-8d05-4e38-bae3-afb2af1caf29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ed3bf321-c798-4d7b-92f3-1f2b6972cf35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:to="loc_us-gaap_InventoryNet_ed3bf321-c798-4d7b-92f3-1f2b6972cf35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0993093-a15a-45c0-bd65-d126dc9136ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14e029b2-3ae8-49b0-b4d5-a93f2c27a7c4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0993093-a15a-45c0-bd65-d126dc9136ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_245a1a68-7143-48c9-9d42-6600b7e415c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2474f4ed-46f2-4065-a3be-50a851f4a545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_245a1a68-7143-48c9-9d42-6600b7e415c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2474f4ed-46f2-4065-a3be-50a851f4a545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_572c0a5f-3ec2-4169-8555-e79043bfee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_245a1a68-7143-48c9-9d42-6600b7e415c0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_572c0a5f-3ec2-4169-8555-e79043bfee66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9b587a64-a6ae-4aea-a6b5-7b64681c2ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b72e4cc8-ea91-44e5-ab35-3c1d5f7d3173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9b587a64-a6ae-4aea-a6b5-7b64681c2ccc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b72e4cc8-ea91-44e5-ab35-3c1d5f7d3173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9c493f86-69f8-4fe6-8ab5-ddd0116b9868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9b587a64-a6ae-4aea-a6b5-7b64681c2ccc" xlink:to="loc_us-gaap_CostsAndExpenses_9c493f86-69f8-4fe6-8ab5-ddd0116b9868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520c0b50-257e-4008-b987-68e16908291c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e26d3b72-4169-46e2-9fb7-148bca382e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520c0b50-257e-4008-b987-68e16908291c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e26d3b72-4169-46e2-9fb7-148bca382e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a43353ac-c247-465b-940a-7d6734618725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520c0b50-257e-4008-b987-68e16908291c" xlink:to="loc_us-gaap_InterestExpense_a43353ac-c247-465b-940a-7d6734618725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c2625b1-172f-483d-b150-7f7371088a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520c0b50-257e-4008-b987-68e16908291c" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c2625b1-172f-483d-b150-7f7371088a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62654101-7612-4fa5-a6b6-1b56b47f0395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520c0b50-257e-4008-b987-68e16908291c" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62654101-7612-4fa5-a6b6-1b56b47f0395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f238380d-29d9-4c14-849f-d0ab2755c701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6dd65266-d38d-4ec7-aa65-aaec6b494550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f238380d-29d9-4c14-849f-d0ab2755c701" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6dd65266-d38d-4ec7-aa65-aaec6b494550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6d6a98e4-0db7-4b3a-9c90-99e730d6bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f238380d-29d9-4c14-849f-d0ab2755c701" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6d6a98e4-0db7-4b3a-9c90-99e730d6bc12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_681c5640-843c-4ccd-810d-92b8320c129c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f238380d-29d9-4c14-849f-d0ab2755c701" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_681c5640-843c-4ccd-810d-92b8320c129c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e9796db1-00ea-4612-94be-7668c6e533b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f238380d-29d9-4c14-849f-d0ab2755c701" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e9796db1-00ea-4612-94be-7668c6e533b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9c83de0-8cbe-4638-a358-b61ff34e7238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8ac8a53-4ce0-4398-98c7-173b05d02e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9c83de0-8cbe-4638-a358-b61ff34e7238" xlink:to="loc_us-gaap_NetIncomeLoss_d8ac8a53-4ce0-4398-98c7-173b05d02e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3bd13bac-fa0d-4bc6-ad1b-6590c341cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9c83de0-8cbe-4638-a358-b61ff34e7238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3bd13bac-fa0d-4bc6-ad1b-6590c341cdde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1cdb5969-9d7e-4d24-8dee-3c17c1afc438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9c83de0-8cbe-4638-a358-b61ff34e7238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1cdb5969-9d7e-4d24-8dee-3c17c1afc438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4b185c45-0f56-4d87-a594-739d4442af9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9c83de0-8cbe-4638-a358-b61ff34e7238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4b185c45-0f56-4d87-a594-739d4442af9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1da2d5f4-07f9-43e4-8f62-7de11f7d4ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1da2d5f4-07f9-43e4-8f62-7de11f7d4ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a76cdb81-ea8a-43c4-9c2d-c30788181afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a76cdb81-ea8a-43c4-9c2d-c30788181afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_02e89793-74e8-4864-a199-5ea0d9c55e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_02e89793-74e8-4864-a199-5ea0d9c55e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_123d1575-001d-4ec1-be94-93a89e92a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_123d1575-001d-4ec1-be94-93a89e92a8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ba0e6125-e28f-4c97-baae-1109359494cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97488e8a-b43e-4653-9cde-6b9fb8d7b667" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ba0e6125-e28f-4c97-baae-1109359494cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e67a7591-0420-406d-9a01-cf433dee9fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e67a7591-0420-406d-9a01-cf433dee9fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_fd254908-3ebb-4fcb-b051-69320312e6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_fd254908-3ebb-4fcb-b051-69320312e6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_aee3c6c3-71f9-4fde-9ec2-1c9765ff22a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_aee3c6c3-71f9-4fde-9ec2-1c9765ff22a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9d7f4443-9323-4636-9189-5dcb0fbc0f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9d7f4443-9323-4636-9189-5dcb0fbc0f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_83f9be62-91a4-47eb-b210-4c609b8efb54" xlink:href="halo-20221231.xsd#halo_DeferredRentPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_halo_DeferredRentPayments_83f9be62-91a4-47eb-b210-4c609b8efb54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_52a91a33-5317-44c1-b97b-813c59c921b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_52a91a33-5317-44c1-b97b-813c59c921b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d3379a3-2f52-43e0-ba98-0a005189b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1d3379a3-2f52-43e0-ba98-0a005189b8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_743f6d96-d7fd-40c1-a1bb-66aa19539fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_NetIncomeLoss_743f6d96-d7fd-40c1-a1bb-66aa19539fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f4084b62-7674-49a9-84f1-2183dd1b4439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_ShareBasedCompensation_f4084b62-7674-49a9-84f1-2183dd1b4439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c340ec99-b1e3-4739-9841-259292cd6cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c340ec99-b1e3-4739-9841-259292cd6cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ddee37ec-1b71-462f-afb6-bb73f00e3601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ddee37ec-1b71-462f-afb6-bb73f00e3601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_17da9b8b-1caa-4e27-b5ba-bf097b8510a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_17da9b8b-1caa-4e27-b5ba-bf097b8510a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ec3bb85b-33d3-4fb2-877f-b3945ebc3698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ec3bb85b-33d3-4fb2-877f-b3945ebc3698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_43fcf572-6fd8-4dad-8609-d4182c8d5769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_43fcf572-6fd8-4dad-8609-d4182c8d5769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0f2b3d0b-4375-4406-8e47-a0f878eb6ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_0f2b3d0b-4375-4406-8e47-a0f878eb6ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_93fb9481-eae9-4f1b-ac9c-0e9352e211b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_93fb9481-eae9-4f1b-ac9c-0e9352e211b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_ba8a27ea-86f3-42d6-8390-d316db11d994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_ba8a27ea-86f3-42d6-8390-d316db11d994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f1c4f5fc-cbb2-4262-9427-2e56d6173872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f1c4f5fc-cbb2-4262-9427-2e56d6173872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9af75634-84ba-4113-a5f0-7c53b5bcd497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce9b393c-5a01-47ad-8205-bf7f1d5cd60b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9af75634-84ba-4113-a5f0-7c53b5bcd497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d1a8815-50f6-4d50-8ea3-bcf448cf27ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_717d425d-57a0-499b-bfe6-8b3ead9538e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d1a8815-50f6-4d50-8ea3-bcf448cf27ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_717d425d-57a0-499b-bfe6-8b3ead9538e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9698c60a-6a01-4cf7-90dc-dcb9f29f67eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d1a8815-50f6-4d50-8ea3-bcf448cf27ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9698c60a-6a01-4cf7-90dc-dcb9f29f67eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfbd4006-3253-4da4-a25a-6a30bad2f583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d1a8815-50f6-4d50-8ea3-bcf448cf27ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfbd4006-3253-4da4-a25a-6a30bad2f583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_41df9862-e3d7-4999-9b40-f3ec406566cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_41df9862-e3d7-4999-9b40-f3ec406566cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9d77eaf7-05c5-494b-a4ff-5e5d91fb12bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9d77eaf7-05c5-494b-a4ff-5e5d91fb12bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_775a332d-51d0-4f5f-aeb9-8c8f7bb90142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_775a332d-51d0-4f5f-aeb9-8c8f7bb90142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a18dfba7-219c-4edf-91d3-07bf6c02d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a18dfba7-219c-4edf-91d3-07bf6c02d9a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fc439325-adb8-4adc-9ce3-f3de9870a6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fc439325-adb8-4adc-9ce3-f3de9870a6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_268c82d4-1e70-4d88-9850-ebf0171d8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_268c82d4-1e70-4d88-9850-ebf0171d8c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_b718f2f0-e9c4-4f83-bf0d-635093184828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_b718f2f0-e9c4-4f83-bf0d-635093184828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_83757ca1-4168-4d6a-8ddb-a9852576d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_83757ca1-4168-4d6a-8ddb-a9852576d4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PurchaseOfCappedCall_f6a7c391-bd80-43ce-8078-8f4171d6b4a1" xlink:href="halo-20221231.xsd#halo_PurchaseOfCappedCall"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_halo_PurchaseOfCappedCall_f6a7c391-bd80-43ce-8078-8f4171d6b4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_da2e9049-bd9e-4c1e-8a78-5e45f692df63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_da2e9049-bd9e-4c1e-8a78-5e45f692df63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_c20cc47b-ae86-41a8-a7ae-c70d7e683176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7242569b-5bb5-46cb-90c6-85a603df8a86" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_c20cc47b-ae86-41a8-a7ae-c70d7e683176" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_665c82ec-17a4-45e5-a68e-43c4979f9512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_665c82ec-17a4-45e5-a68e-43c4979f9512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_faf36f33-b3e0-4d25-b12e-7005abb92578" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_faf36f33-b3e0-4d25-b12e-7005abb92578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fb59b37-947f-4bff-8a28-6b91adb54245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fb59b37-947f-4bff-8a28-6b91adb54245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_b21f6252-a0dc-435d-86df-02cab6f9c7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_b21f6252-a0dc-435d-86df-02cab6f9c7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_d48487fe-8135-49b8-933d-42d158133bdb" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fa7eba43-61b4-46f2-a047-deb7a874fbe4" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_d48487fe-8135-49b8-933d-42d158133bdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_449a5e86-e961-4b68-8308-2da66ee7119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_449a5e86-e961-4b68-8308-2da66ee7119e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c1fad3c8-6f80-49ab-8d44-72e9addf220c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c1fad3c8-6f80-49ab-8d44-72e9addf220c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d9fb2be2-6c0f-4ab6-b416-c785c47d8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d9fb2be2-6c0f-4ab6-b416-c785c47d8b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_de876ff6-cec7-4690-8daf-44e81c2a7688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_de876ff6-cec7-4690-8daf-44e81c2a7688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_7a7f0a2a-2403-44d8-9130-7ab28382102d" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_7a7f0a2a-2403-44d8-9130-7ab28382102d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_231b39de-2bc2-43c1-8f80-0b63ec93ddac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_231b39de-2bc2-43c1-8f80-0b63ec93ddac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_db0a2584-6898-46b3-9582-fb6e47fc2db0" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_db0a2584-6898-46b3-9582-fb6e47fc2db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_edc09461-ad47-4928-bcb8-58bdc3ba6eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_edc09461-ad47-4928-bcb8-58bdc3ba6eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_b2134dac-a0c1-4b03-b7f3-829eb3963f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_b2134dac-a0c1-4b03-b7f3-829eb3963f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3db7dbcf-b688-409e-95ad-756d7cdd0738" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3db7dbcf-b688-409e-95ad-756d7cdd0738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9c92d7c7-7e52-4b42-aac8-65f08c814a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9c92d7c7-7e52-4b42-aac8-65f08c814a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8df45ea5-e4bc-4c8c-9859-5af6a73be226" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b0c63bd1-4c36-486f-9211-ea9cade4e402" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8df45ea5-e4bc-4c8c-9859-5af6a73be226" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cf824b2-09b5-4cbc-a8dc-c1c770ef9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_85a1f491-8423-418c-b785-44d3c1949a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cf824b2-09b5-4cbc-a8dc-c1c770ef9ea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_85a1f491-8423-418c-b785-44d3c1949a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_207fb944-7da7-4d34-9406-16c381fd5798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cf824b2-09b5-4cbc-a8dc-c1c770ef9ea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_207fb944-7da7-4d34-9406-16c381fd5798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33ab975f-dffb-4061-b6a6-6d86d2a63df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cf824b2-09b5-4cbc-a8dc-c1c770ef9ea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33ab975f-dffb-4061-b6a6-6d86d2a63df7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c51632f6-9b55-4579-b500-fd832f5894c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_314d08fe-bfd0-462c-9d29-695268273d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c51632f6-9b55-4579-b500-fd832f5894c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_314d08fe-bfd0-462c-9d29-695268273d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_731db6be-7796-486b-b7b8-89e805f9959d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c51632f6-9b55-4579-b500-fd832f5894c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_731db6be-7796-486b-b7b8-89e805f9959d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccountsreceivableDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_f5a7997a-3611-4027-8322-6ab54cd62f27" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:to="loc_halo_Accountsreceivablefromroyalties_f5a7997a-3611-4027-8322-6ab54cd62f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_2af4e52b-80dd-4a6c-be83-bf72455e17b3" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:to="loc_halo_Accountsreceivablefromcollaborators_2af4e52b-80dd-4a6c-be83-bf72455e17b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1ccdd489-3cf3-49c7-8c8d-9a0b92d2c9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1ccdd489-3cf3-49c7-8c8d-9a0b92d2c9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_6611736a-14a2-4784-9a75-d255f85bc55f" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_6611736a-14a2-4784-9a75-d255f85bc55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_38fd19a0-1a24-46f0-8924-37463bfcfe1c" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_8da4ba44-3c89-4a99-87d1-0a38429926f5" xlink:to="loc_halo_Accountsreceivablefromproductsales_38fd19a0-1a24-46f0-8924-37463bfcfe1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dbcb465b-c956-4af4-aac4-ecaf4f825d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_45ea623b-153d-4df8-a41b-983b2a36d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_dbcb465b-c956-4af4-aac4-ecaf4f825d6f" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_45ea623b-153d-4df8-a41b-983b2a36d33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_20b7db2e-f60d-426d-8463-8cc65240015f" xlink:href="halo-20221231.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_dbcb465b-c956-4af4-aac4-ecaf4f825d6f" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_20b7db2e-f60d-426d-8463-8cc65240015f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cb2cdfcf-63d9-480d-81c7-ab247d98871e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bdb7808c-0941-498d-beb5-e0c1e9b68e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cb2cdfcf-63d9-480d-81c7-ab247d98871e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bdb7808c-0941-498d-beb5-e0c1e9b68e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3ed85e9e-e071-4270-a4f2-d73949dd3419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cb2cdfcf-63d9-480d-81c7-ab247d98871e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3ed85e9e-e071-4270-a4f2-d73949dd3419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_861bd765-e989-4fe2-a95f-1a59cb010c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cb2cdfcf-63d9-480d-81c7-ab247d98871e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_861bd765-e989-4fe2-a95f-1a59cb010c4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_73dfe26e-9db5-4990-9792-fbe9a596b91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c1824a39-7ffe-45d7-8ab5-1d5594957054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_73dfe26e-9db5-4990-9792-fbe9a596b91e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c1824a39-7ffe-45d7-8ab5-1d5594957054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_68f49d9c-c022-4806-884a-ad3d74ba4ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_73dfe26e-9db5-4990-9792-fbe9a596b91e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_68f49d9c-c022-4806-884a-ad3d74ba4ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_25ba82ef-2218-4817-89e1-a238be5b4dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_73dfe26e-9db5-4990-9792-fbe9a596b91e" xlink:to="loc_us-gaap_OtherAssets_25ba82ef-2218-4817-89e1-a238be5b4dba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb5a41f2-e121-45b3-b939-af3b0796af10" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82243b41-e12d-4b11-ab96-0fcef5dc02b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb5a41f2-e121-45b3-b939-af3b0796af10" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82243b41-e12d-4b11-ab96-0fcef5dc02b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3935369f-642f-448f-8af5-9417cc50a494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb5a41f2-e121-45b3-b939-af3b0796af10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3935369f-642f-448f-8af5-9417cc50a494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cebbec10-91a6-45fe-bb78-df159438309a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1a085d57-8364-4ffb-8951-505bd97a2bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cebbec10-91a6-45fe-bb78-df159438309a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1a085d57-8364-4ffb-8951-505bd97a2bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8572870-e33a-4cad-bc1d-a197506b7567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cebbec10-91a6-45fe-bb78-df159438309a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8572870-e33a-4cad-bc1d-a197506b7567" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b1ae6762-e178-4f7b-8fa0-53f9339fb479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_2423295b-66ea-493e-a645-ced694573a83" xlink:href="halo-20221231.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b1ae6762-e178-4f7b-8fa0-53f9339fb479" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_2423295b-66ea-493e-a645-ced694573a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dcb2126a-e892-41b5-81e4-3e65129d50b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b1ae6762-e178-4f7b-8fa0-53f9339fb479" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dcb2126a-e892-41b5-81e4-3e65129d50b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1766b9f5-9a08-442b-b623-9d997adcfd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_us-gaap_OperatingLeaseLiability_1766b9f5-9a08-442b-b623-9d997adcfd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_493595aa-552f-47e0-b35f-e83e0f9c440f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_493595aa-552f-47e0-b35f-e83e0f9c440f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dae60829-ee32-4312-b5b2-636ecb54284f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dae60829-ee32-4312-b5b2-636ecb54284f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_6186a23a-584b-49d5-b490-5f436d694695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_6186a23a-584b-49d5-b490-5f436d694695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_a76a9cf4-9705-4d10-b76a-ec1379b90d52" xlink:href="halo-20221231.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_halo_Accruedmanufacturingexpenses_a76a9cf4-9705-4d10-b76a-ec1379b90d52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_3772735d-ff81-4e65-805d-112186fd156d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_766b4c7b-a0ba-4f8f-b68a-1cf09dcd7563" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_3772735d-ff81-4e65-805d-112186fd156d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_877bec04-f3ef-4c70-a3e9-cbb499b08fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d126bcaf-5c03-40eb-9ff0-e24260acfd09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_877bec04-f3ef-4c70-a3e9-cbb499b08fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d126bcaf-5c03-40eb-9ff0-e24260acfd09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_939423d2-ccbe-42cb-b377-021ea5120416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_877bec04-f3ef-4c70-a3e9-cbb499b08fca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_939423d2-ccbe-42cb-b377-021ea5120416" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_064a6748-6228-45a9-8a79-f43cc356a158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_064a6748-6228-45a9-8a79-f43cc356a158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab695071-5336-4cda-bbd3-852291003a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab695071-5336-4cda-bbd3-852291003a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_13b62f5b-b8e5-4d96-822d-141f876ac459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_13b62f5b-b8e5-4d96-822d-141f876ac459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4badf1fd-7745-4136-b494-3e3e587b1cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4badf1fd-7745-4136-b494-3e3e587b1cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4be024f3-329b-4573-ad5b-33e9f2bc1ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4be024f3-329b-4573-ad5b-33e9f2bc1ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_635429c3-6a1c-4351-95a1-6ef24b61bd89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1674fbf-d8e7-4a4d-aad2-93c1de4333dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_635429c3-6a1c-4351-95a1-6ef24b61bd89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:href="halo-20221231.xsd#halo_LongTermDebtIncludingInterestGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f0a320c8-3c8a-4f95-89ce-6e08142e0b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f0a320c8-3c8a-4f95-89ce-6e08142e0b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_14a23318-94b2-4c92-90a4-997a5c65f0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_14a23318-94b2-4c92-90a4-997a5c65f0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7b2eaf8e-53ad-4302-89af-f8ef97336a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7b2eaf8e-53ad-4302-89af-f8ef97336a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8802aeaf-22c5-451a-bcb1-284646342cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8802aeaf-22c5-451a-bcb1-284646342cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_604c5605-421a-48a6-af8c-58b3d2ab9140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_604c5605-421a-48a6-af8c-58b3d2ab9140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_22accc6a-885a-42c8-8415-9ae3ad6565fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_LongTermDebtIncludingInterestGross_259d641e-7258-4f3c-9fa4-a8966e31e249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_22accc6a-885a-42c8-8415-9ae3ad6565fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6624fb89-de9a-4d08-ad65-5f223ed962f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8c7e5916-18e9-4d0c-9f01-a2f820348ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtFairValue_6624fb89-de9a-4d08-ad65-5f223ed962f9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8c7e5916-18e9-4d0c-9f01-a2f820348ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_38305ba0-b31c-4612-a061-ed15d13f31db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtFairValue_6624fb89-de9a-4d08-ad65-5f223ed962f9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_38305ba0-b31c-4612-a061-ed15d13f31db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e2d03d-a572-41bc-933a-102c4b7de4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14c82ce5-26c6-4b2b-9fb9-c47763d0daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e2d03d-a572-41bc-933a-102c4b7de4a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14c82ce5-26c6-4b2b-9fb9-c47763d0daf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_85eee8f5-d4c9-44d5-9655-3a4b09a1a4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e2d03d-a572-41bc-933a-102c4b7de4a1" xlink:to="loc_us-gaap_OperatingLeaseLiability_85eee8f5-d4c9-44d5-9655-3a4b09a1a4c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ca8151a-541e-430a-8184-cb3d10e3aef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ca8151a-541e-430a-8184-cb3d10e3aef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7907f6eb-9987-4510-b81c-049b83decb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7907f6eb-9987-4510-b81c-049b83decb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e084b252-215f-43a6-9aa6-fdb47e935ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e084b252-215f-43a6-9aa6-fdb47e935ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_659f11b1-93fd-48ef-8b52-61c389ec0e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_659f11b1-93fd-48ef-8b52-61c389ec0e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e1c06ac2-2efe-40e4-abd8-e3401eef4635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e1c06ac2-2efe-40e4-abd8-e3401eef4635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e2055d74-e99d-4fd9-96ae-df0e53f7bf19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1203bd9a-8e19-43ab-aeaa-280a16f28559" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e2055d74-e99d-4fd9-96ae-df0e53f7bf19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesNetIncomeLossByRegionDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15893a57-04fa-4cce-b293-b5e8d1585243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7d68b05a-4d3c-4f15-a513-d829315a8861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15893a57-04fa-4cce-b293-b5e8d1585243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7d68b05a-4d3c-4f15-a513-d829315a8861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ae1bd66d-685c-47de-bcf7-3fe5bcbb88a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15893a57-04fa-4cce-b293-b5e8d1585243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ae1bd66d-685c-47de-bcf7-3fe5bcbb88a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesComponentsDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7be4c1be-b604-40cb-8b72-f4076f96fbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cbc4b04b-0558-4db1-917e-749c7365c502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7be4c1be-b604-40cb-8b72-f4076f96fbac" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_cbc4b04b-0558-4db1-917e-749c7365c502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_79fcfd4d-6af2-448e-ab8c-5d22e4d41e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7be4c1be-b604-40cb-8b72-f4076f96fbac" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_79fcfd4d-6af2-448e-ab8c-5d22e4d41e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4333227a-c9a9-4be6-ae51-f54185e9a196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_815a6e8c-06e0-4d55-b659-280fe7685911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4333227a-c9a9-4be6-ae51-f54185e9a196" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_815a6e8c-06e0-4d55-b659-280fe7685911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3454dc31-e4ab-4f78-ad37-f48b00dba012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4333227a-c9a9-4be6-ae51-f54185e9a196" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3454dc31-e4ab-4f78-ad37-f48b00dba012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_77015ce6-4efe-4928-9d7b-5bb5422664a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_77015ce6-4efe-4928-9d7b-5bb5422664a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesConvertibleNote_a8d60bb0-4ae7-432b-ad4c-e738aa6ead99" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesConvertibleNote"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:to="loc_halo_DeferredTaxLiabilitiesConvertibleNote_a8d60bb0-4ae7-432b-ad4c-e738aa6ead99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesRightofUseAsset_d8732eac-178c-4aad-bbaa-4df7356ec072" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesRightofUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:to="loc_halo_DeferredTaxLiabilitiesRightofUseAsset_d8732eac-178c-4aad-bbaa-4df7356ec072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_e71b1c94-5f6c-4417-92c0-0adb86c44814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_e71b1c94-5f6c-4417-92c0-0adb86c44814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_a8b5887f-edfc-4846-a9ba-7b3c062c016d" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_59385537-bc9f-48cc-9edd-52199186b476" xlink:to="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_a8b5887f-edfc-4846-a9ba-7b3c062c016d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b3451a53-26be-45f1-8104-fc4a0435868b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b3451a53-26be-45f1-8104-fc4a0435868b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e1217d4c-e97f-4727-8ce6-b5daec08c7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e1217d4c-e97f-4727-8ce6-b5daec08c7eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_24cd1196-2c79-4ecf-a7dd-3f791ad137bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_24cd1196-2c79-4ecf-a7dd-3f791ad137bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c2f50fb-5383-476d-9450-13277d4d4e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c2f50fb-5383-476d-9450-13277d4d4e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9c4f7772-9687-45fd-bb7b-388171b9eb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9c4f7772-9687-45fd-bb7b-388171b9eb5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsInterestExpenseLimitation_0d7c6082-731c-4698-9eb3-25cafa4fb2b2" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_halo_DeferredTaxAssetsInterestExpenseLimitation_0d7c6082-731c-4698-9eb3-25cafa4fb2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsLeaseLiabilities_065dae18-cd06-49db-a9b7-0024a7f18e82" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_halo_DeferredTaxAssetsLeaseLiabilities_065dae18-cd06-49db-a9b7-0024a7f18e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_df573521-30f7-4bd3-a1cd-6bd9c565137b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_df573521-30f7-4bd3-a1cd-6bd9c565137b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetTransactionRelatedExpense_aed84020-63be-4bdb-a9c7-8810ca27a5f0" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetTransactionRelatedExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_halo_DeferredTaxAssetTransactionRelatedExpense_aed84020-63be-4bdb-a9c7-8810ca27a5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_e6b7bf55-21ed-4d79-871c-1fff7774b4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_954154a5-7759-4a6e-8ff7-9b6d9af8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_e6b7bf55-21ed-4d79-871c-1fff7774b4e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_873c4bdd-fc7a-4d5b-a5e4-277ecc4556b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4e95b283-a745-4bcb-b71e-337c725378bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_873c4bdd-fc7a-4d5b-a5e4-277ecc4556b1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4e95b283-a745-4bcb-b71e-337c725378bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1f773f49-8ce3-4171-8088-e63afe2896e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_873c4bdd-fc7a-4d5b-a5e4-277ecc4556b1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1f773f49-8ce3-4171-8088-e63afe2896e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5c4a7de4-5b29-46b1-8a26-6c984f78dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_873c4bdd-fc7a-4d5b-a5e4-277ecc4556b1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5c4a7de4-5b29-46b1-8a26-6c984f78dc64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8685bc8e-aba5-4528-94bd-2e8a3fc15bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_873c4bdd-fc7a-4d5b-a5e4-277ecc4556b1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8685bc8e-aba5-4528-94bd-2e8a3fc15bca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesScheduleofIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_0a8f3f15-cb64-4834-b0ff-b6818455127c" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_0a8f3f15-cb64-4834-b0ff-b6818455127c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_21aee1b9-7abd-4624-8061-405b2765f1fe" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_21aee1b9-7abd-4624-8061-405b2765f1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_619fada6-ab92-4f6d-be98-76f1fcdba763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_619fada6-ab92-4f6d-be98-76f1fcdba763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_5a524154-5cac-4556-8d5e-662d3ddb12e3" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_5a524154-5cac-4556-8d5e-662d3ddb12e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_014d9244-76d6-4272-b75c-2460c2fa176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_014d9244-76d6-4272-b75c-2460c2fa176e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a677459e-f52f-47f5-a687-ce2b21c56235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a677459e-f52f-47f5-a687-ce2b21c56235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c7ab9589-9b69-4c28-a73d-a039ec0fdcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c7ab9589-9b69-4c28-a73d-a039ec0fdcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e4d274e1-416a-4018-a186-3f0dc936c0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e4d274e1-416a-4018-a186-3f0dc936c0e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_65780848-cb26-4057-b3d9-1b6d15a246ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_65780848-cb26-4057-b3d9-1b6d15a246ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_332d28f7-325f-4ad5-85ba-8e7160a57bf9" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9252c014-7385-43c2-a358-ca163d1da428" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_332d28f7-325f-4ad5-85ba-8e7160a57bf9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>halo-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i1d37631cd1b945c09f3ac55563180f9a_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35ab35be-a4f0-4050-81c6-4d8c6dc8b1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35ab35be-a4f0-4050-81c6-4d8c6dc8b1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_447435f8-d0f6-402a-83cc-dd357d45308a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_447435f8-d0f6-402a-83cc-dd357d45308a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b032a77b-1f4b-4975-9644-b7766d9f871a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b032a77b-1f4b-4975-9644-b7766d9f871a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_27ad2ab2-9631-4871-81c9-46a7012a123f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_27ad2ab2-9631-4871-81c9-46a7012a123f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25ddb9ae-777d-4f84-affb-0f279f9a725b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25ddb9ae-777d-4f84-affb-0f279f9a725b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ab4c8a1-e18d-4f29-ad48-530f6763b251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_CostsAndExpenses_1ab4c8a1-e18d-4f29-ad48-530f6763b251" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96d0d789-2b6d-4e05-ae20-f7995c6cabb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_OperatingIncomeLoss_96d0d789-2b6d-4e05-ae20-f7995c6cabb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_50a7b69d-fe7f-4a96-945a-29db550e6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_50a7b69d-fe7f-4a96-945a-29db550e6b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62db128c-a60c-4ac9-8288-a1867f3f31da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62db128c-a60c-4ac9-8288-a1867f3f31da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17a8183b-a871-4554-9630-1f3e420f922f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_InterestExpense_17a8183b-a871-4554-9630-1f3e420f922f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a203a3dd-8b3e-4324-b589-133e4844954a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a203a3dd-8b3e-4324-b589-133e4844954a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83ec5185-c160-492b-879f-87eb32f71ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83ec5185-c160-492b-879f-87eb32f71ca9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68ed22d5-a753-4bcd-89be-627685018453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_NetIncomeLoss_68ed22d5-a753-4bcd-89be-627685018453" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_02613541-7a32-4b17-9cec-94edb5bded99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:to="loc_us-gaap_EarningsPerShareBasic_02613541-7a32-4b17-9cec-94edb5bded99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2972deea-8c80-43b3-9b39-e89e90beac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2972deea-8c80-43b3-9b39-e89e90beac9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc050e61-048b-40a6-b541-9f1e07013836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc050e61-048b-40a6-b541-9f1e07013836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c4b3c68-ceca-420d-9cf0-9dcb964a7676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c4b3c68-ceca-420d-9cf0-9dcb964a7676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:to="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e0a212d-a6ff-4c72-b2bf-990303c13536_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:to="loc_srt_ProductsAndServicesDomain_4e0a212d-a6ff-4c72-b2bf-990303c13536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:to="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6cde0050-b726-4093-b71e-0422b3058ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_us-gaap_RoyaltyMember_6cde0050-b726-4093-b71e-0422b3058ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d4e6bc20-a870-461d-9684-ba37ca066b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_us-gaap_ProductMember_d4e6bc20-a870-461d-9684-ba37ca066b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_6af3456f-705a-4bcb-a9a1-12bcf6017d8b" xlink:href="halo-20221231.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_halo_CollaborativeAgreementsMember_6af3456f-705a-4bcb-a9a1-12bcf6017d8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofStockholdersEquityDeficitStatement"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement" xlink:type="extended" id="ib5983a8950ca42baae036c6119342d05_ConsolidatedStatementsofStockholdersEquityDeficitStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d6272c79-8ec0-4950-bc55-d1e503dc657a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_SharesOutstanding_d6272c79-8ec0-4950-bc55-d1e503dc657a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f41d21d-c9aa-4619-af81-a1460bd93f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockholdersEquity_0f41d21d-c9aa-4619-af81-a1460bd93f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4cd4bb9-969e-43b5-b5f5-5d79d29fc7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4cd4bb9-969e-43b5-b5f5-5d79d29fc7a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0f6cc27a-b7e4-49b4-8ac3-9f7a5fed79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0f6cc27a-b7e4-49b4-8ac3-9f7a5fed79ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_72a70137-b64d-467e-8d39-8f36b17e8c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_72a70137-b64d-467e-8d39-8f36b17e8c4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bd1a3daa-719a-4246-bc34-d7a6ed88f513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bd1a3daa-719a-4246-bc34-d7a6ed88f513" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cbad0e1f-b733-48d2-8a1b-153b6947583f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cbad0e1f-b733-48d2-8a1b-153b6947583f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_acdf1145-85be-466c-ba78-8e78e941028d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_acdf1145-85be-466c-ba78-8e78e941028d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_336619bc-1172-4b46-a2b3-3ac9034ba9fb" xlink:href="halo-20221231.xsd#halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_336619bc-1172-4b46-a2b3-3ac9034ba9fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_694ceb24-fb9f-4104-9fde-4ce461c80b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_694ceb24-fb9f-4104-9fde-4ce461c80b5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11ac2da7-b7b9-49aa-b7b4-3be92c9cde2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11ac2da7-b7b9-49aa-b7b4-3be92c9cde2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_cc4aaa5a-f357-4d14-9cfc-7e99f6f0dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_cc4aaa5a-f357-4d14-9cfc-7e99f6f0dccd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_179777e1-d9d4-48bd-8577-751c45871ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_179777e1-d9d4-48bd-8577-751c45871ef7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02785435-65f6-43ba-b756-5002e2ecf053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_NetIncomeLoss_02785435-65f6-43ba-b756-5002e2ecf053" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_044d5c07-e751-4988-9af8-4ad088de262c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83887652-1b75-408d-aaca-197080e0c771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ee3fabf2-9502-4459-acc8-2482e741ab99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ee3fabf2-9502-4459-acc8-2482e741ab99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4fe24f22-5a95-4309-baac-37547b0ff502" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4fe24f22-5a95-4309-baac-37547b0ff502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a3e27fc-0c6a-482e-b77e-dd929d745eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:to="loc_us-gaap_EquityComponentDomain_1a3e27fc-0c6a-482e-b77e-dd929d745eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:to="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36b8a05c-2b85-4c8a-8307-32c53de92f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_CommonStockMember_36b8a05c-2b85-4c8a-8307-32c53de92f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_15811d4b-1657-4274-9a2e-caf30ef26562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_15811d4b-1657-4274-9a2e-caf30ef26562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6b31d10-fa66-46d4-bc34-25211a8126eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6b31d10-fa66-46d4-bc34-25211a8126eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0c74584e-2724-4177-a3db-5139fe7a5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_RetainedEarningsMember_0c74584e-2724-4177-a3db-5139fe7a5107" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#OrganizationandBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended" id="i4fcae0ec41d6496e9dd48b8ceefc4d25_OrganizationandBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfCollaborationsRoyaltiesReceived_b0982156-a5ee-4136-a398-6703de95670b" xlink:href="halo-20221231.xsd#halo_NumberOfCollaborationsRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:to="loc_halo_NumberOfCollaborationsRoyaltiesReceived_b0982156-a5ee-4136-a398-6703de95670b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_77b7bbb1-154d-4448-8052-f672d3def38a" xlink:href="halo-20221231.xsd#halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:to="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_77b7bbb1-154d-4448-8052-f672d3def38a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:to="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47ec9d9b-027b-4217-b35f-2bd829e6fe1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47ec9d9b-027b-4217-b35f-2bd829e6fe1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember_d210baf1-cc94-479c-8084-dead3b38d975" xlink:href="halo-20221231.xsd#halo_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_TakedaMember_d210baf1-cc94-479c-8084-dead3b38d975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_1c282d04-f769-43da-9b18-8a63828f2414" xlink:href="halo-20221231.xsd#halo_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_RocheMember_1c282d04-f769-43da-9b18-8a63828f2414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_ffcc596f-bd8e-4449-a181-627ad95f2831" xlink:href="halo-20221231.xsd#halo_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_JanssenMember_ffcc596f-bd8e-4449-a181-627ad95f2831" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" xlink:type="extended" id="icbbaaf0f8f1e43008d3ae1af87a62eeb_SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7efb685d-9f45-4da4-a303-2e1bf53ddea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7efb685d-9f45-4da4-a303-2e1bf53ddea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ConcentrationRiskPercentageInstantDate_8569e18c-c321-469f-b73e-9be14134365b" xlink:href="halo-20221231.xsd#halo_ConcentrationRiskPercentageInstantDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_halo_ConcentrationRiskPercentageInstantDate_8569e18c-c321-469f-b73e-9be14134365b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_55fcf5cd-ec46-4a5f-8582-861a92a2ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_55fcf5cd-ec46-4a5f-8582-861a92a2ced2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d05f02d1-8bd3-4319-9c44-c7ddd4306d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d05f02d1-8bd3-4319-9c44-c7ddd4306d50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c9f1011c-0864-4c1f-a41c-c640f9633fbf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:to="loc_srt_NameOfMajorCustomerDomain_c9f1011c-0864-4c1f-a41c-c640f9633fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:to="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheandBaxaltaMember_ad0ebde3-ea56-408f-a8c0-d48adf68b64e" xlink:href="halo-20221231.xsd#halo_RocheandBaxaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_RocheandBaxaltaMember_ad0ebde3-ea56-408f-a8c0-d48adf68b64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerAMember_dcc5acb7-9778-4092-a0ba-1e04913d9b15" xlink:href="halo-20221231.xsd#halo_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerAMember_dcc5acb7-9778-4092-a0ba-1e04913d9b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerBMember_84377df7-80b6-4fbb-bb0f-0f4c28cb74f1" xlink:href="halo-20221231.xsd#halo_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerBMember_84377df7-80b6-4fbb-bb0f-0f4c28cb74f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerCMember_c844652e-5d9e-4255-b1d1-a65485dd2024" xlink:href="halo-20221231.xsd#halo_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerCMember_c844652e-5d9e-4255-b1d1-a65485dd2024" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerDMember_05b03642-6195-4283-b707-3016a40067ff" xlink:href="halo-20221231.xsd#halo_PartnerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerDMember_05b03642-6195-4283-b707-3016a40067ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8925a008-5a8e-4ba1-b15b-1891a8550276_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:to="loc_srt_SegmentGeographicalDomain_8925a008-5a8e-4ba1-b15b-1891a8550276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:to="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_01797619-9c8e-4fff-94e3-51756b16ff6b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_US_01797619-9c8e-4fff-94e3-51756b16ff6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_a9ed9b70-3a46-4ccb-8301-cc55a5521fe8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_CH_a9ed9b70-3a46-4ccb-8301-cc55a5521fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_a73032a1-6808-41c3-87d7-73bc738dba8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_IE_a73032a1-6808-41c3-87d7-73bc738dba8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE_b2199ce4-156a-4221-8054-b995f0f10b3b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_BE_b2199ce4-156a-4221-8054-b995f0f10b3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0f75a58a-78da-45da-aa1b-5e16df5399fc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_JP_0f75a58a-78da-45da-aa1b-5e16df5399fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ForeignOtherMember_5c37a237-266b-4064-bcd2-306a201e65f6" xlink:href="halo-20221231.xsd#halo_ForeignOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_halo_ForeignOtherMember_5c37a237-266b-4064-bcd2-306a201e65f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93d91b6f-9e51-4f84-b678-94892f945bc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93d91b6f-9e51-4f84-b678-94892f945bc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3b5c4a2d-fd79-43e9-a3fd-d235c58e9533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:to="loc_us-gaap_AccountsReceivableMember_3b5c4a2d-fd79-43e9-a3fd-d235c58e9533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_49739de8-1097-4448-bf7e-dabb9978d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:to="loc_us-gaap_SalesMember_49739de8-1097-4448-bf7e-dabb9978d7a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_347520f5-a820-4f80-a1fe-dd8c1da6dcd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_347520f5-a820-4f80-a1fe-dd8c1da6dcd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_51290e1e-d2bb-40ad-a141-6010db6dd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_51290e1e-d2bb-40ad-a141-6010db6dd5b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_13beb4f1-7322-4e92-87c2-76d24174d545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_13beb4f1-7322-4e92-87c2-76d24174d545" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended" id="if991654cbe9c47c0a4f2c848a0238ed7_SummaryofSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2dbb67fd-d482-4a83-816c-41d00e2139a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2dbb67fd-d482-4a83-816c-41d00e2139a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:to="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:to="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_152ae52c-fc81-43fd-8bf4-aa534c691056_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:to="loc_srt_RangeMember_152ae52c-fc81-43fd-8bf4-aa534c691056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:to="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ec2fd9-cd3a-46cc-a358-854adfb5a271" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:to="loc_srt_MinimumMember_05ec2fd9-cd3a-46cc-a358-854adfb5a271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a4ea3b9-82d0-401d-b268-995f86d768e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:to="loc_srt_MaximumMember_5a4ea3b9-82d0-401d-b268-995f86d768e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="if7228c706d994b3cb4c49da09117f509_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0417fed5-a70c-43e1-ada9-ec9e55bc670f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0417fed5-a70c-43e1-ada9-ec9e55bc670f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:to="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f30b4429-69af-43d2-90f9-322040a93cb7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:to="loc_srt_RangeMember_f30b4429-69af-43d2-90f9-322040a93cb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:to="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17353bdf-23df-458a-a7ae-069eff6a2ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:to="loc_srt_MinimumMember_17353bdf-23df-458a-a7ae-069eff6a2ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cafc2cf-2372-4651-9475-3c2b8fa288b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:to="loc_srt_MaximumMember_7cafc2cf-2372-4651-9475-3c2b8fa288b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended" id="idb947e320c1a470cb1f85043807df060_BusinessCombinationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c23366c-afbd-4b00-a19e-aea2221cf24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c23366c-afbd-4b00-a19e-aea2221cf24a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_406f9185-e60b-4b67-b007-af7bd4b0518a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_406f9185-e60b-4b67-b007-af7bd4b0518a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d192b7ac-a1f8-48ad-8a63-8dbef6933b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d192b7ac-a1f8-48ad-8a63-8dbef6933b1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_1c47b8c1-6044-4ddf-96e2-5fe73cdb0daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_1c47b8c1-6044-4ddf-96e2-5fe73cdb0daa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd9ebc18-c232-46d0-81d0-9f3bf6c33b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd9ebc18-c232-46d0-81d0-9f3bf6c33b89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5828fac0-16b1-4c31-b138-f0a31b4d96f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5828fac0-16b1-4c31-b138-f0a31b4d96f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97abea65-a27c-4eb9-909e-f5c867ec3ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97abea65-a27c-4eb9-909e-f5c867ec3ab3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a55c2868-e237-4c62-914c-6cac7f389892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a55c2868-e237-4c62-914c-6cac7f389892" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_cbcb3985-c9d2-4485-8c38-95274dac2c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_cbcb3985-c9d2-4485-8c38-95274dac2c23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b0215b24-f4ed-48c3-94d4-5b668f0dae43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b0215b24-f4ed-48c3-94d4-5b668f0dae43" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_15c1c010-4a94-49cb-a0ca-d4687352afeb" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:to="loc_halo_AntaresPharmaIncMember_15c1c010-4a94-49cb-a0ca-d4687352afeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_696da5ff-f848-48ad-880f-a90a0ea6b208_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_696da5ff-f848-48ad-880f-a90a0ea6b208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_d63757fd-7f69-4cfb-a168-6368ad65c70b" xlink:href="halo-20221231.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:to="loc_halo_TermLoanFacilityMember_d63757fd-7f69-4cfb-a168-6368ad65c70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:to="loc_us-gaap_CreditFacilityDomain_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:to="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b400a35b-84df-43ad-a4ac-8615b788c407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b400a35b-84df-43ad-a4ac-8615b788c407" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended" id="iee84a49f55ad44789caac7814e2ab018_BusinessCombinationPurchaseConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f0170c85-d9aa-4b02-bd15-36aad17cd1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f0170c85-d9aa-4b02-bd15-36aad17cd1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_59637dab-e9a1-46c7-ba20-33543c76ac4b" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_59637dab-e9a1-46c7-ba20-33543c76ac4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_10ad1c4b-e319-457c-a341-6756f55fd6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_10ad1c4b-e319-457c-a341-6756f55fd6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8a0c22d3-3253-4c00-985d-9f001b96862d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8a0c22d3-3253-4c00-985d-9f001b96862d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8da978a5-6566-47e9-bb08-36918115edde" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8da978a5-6566-47e9-bb08-36918115edde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ccf46d9-ab67-426d-beed-bd4d20183d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ccf46d9-ab67-426d-beed-bd4d20183d7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_28b3dae2-fd6d-4e12-a355-4f49ea35d9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_28b3dae2-fd6d-4e12-a355-4f49ea35d9fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1579bac-606b-40bd-aa59-729f2f277644_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1579bac-606b-40bd-aa59-729f2f277644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_14a18ce8-e598-4cae-a672-1b56d154e602" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:to="loc_halo_AntaresPharmaIncMember_14a18ce8-e598-4cae-a672-1b56d154e602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f814acea-f3ab-4030-82e7-0956f1c1241b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f814acea-f3ab-4030-82e7-0956f1c1241b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_02e8f53e-373c-4b61-b474-76b471fb9835" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_02e8f53e-373c-4b61-b474-76b471fb9835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_b7529cdf-1448-46e8-bda0-bae4d1ef0b7e" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_b7529cdf-1448-46e8-bda0-bae4d1ef0b7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="if254b788f326457ab3143b980ec875c1_BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_39453f84-c4cf-4eb7-83f7-fec867ce0a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_39453f84-c4cf-4eb7-83f7-fec867ce0a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f38d9c2-b763-48e1-947c-afe5be605a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f38d9c2-b763-48e1-947c-afe5be605a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a66d340e-43e8-4c98-bd9d-9e14dca2e03a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a66d340e-43e8-4c98-bd9d-9e14dca2e03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a4b0bcfe-e021-41cb-8ee9-f9540867be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a4b0bcfe-e021-41cb-8ee9-f9540867be9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e6f6488-0a0c-4d44-8269-0a1be5ca54a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e6f6488-0a0c-4d44-8269-0a1be5ca54a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_edd60660-594e-469e-8d98-2fea71557a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_edd60660-594e-469e-8d98-2fea71557a12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3dd81930-e9bc-4867-b795-c108168a997a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3dd81930-e9bc-4867-b795-c108168a997a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e08ae13f-976f-4546-828e-5818b73f42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e08ae13f-976f-4546-828e-5818b73f42e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ae99a076-c6e8-4232-bc26-bdf4293e5707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ae99a076-c6e8-4232-bc26-bdf4293e5707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_0c784fe4-eef4-449c-ab6b-96c57eb440d4" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_0c784fe4-eef4-449c-ab6b-96c57eb440d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_5d5c674a-f9bb-4b3d-91e3-e90529123c2a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_5d5c674a-f9bb-4b3d-91e3-e90529123c2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3335cbfb-d7b5-4539-86f2-f0c18c0f8b9c" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3335cbfb-d7b5-4539-86f2-f0c18c0f8b9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e5cbb38-518b-45d2-b974-c920890841b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e5cbb38-518b-45d2-b974-c920890841b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_661ebfb0-9d01-467d-af0b-e52a848bb177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_661ebfb0-9d01-467d-af0b-e52a848bb177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef32a136-8640-4a46-b319-8778f9c568f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef32a136-8640-4a46-b319-8778f9c568f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e274fe8-ddc4-4f11-ae88-862a1d3b929d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_Goodwill_9e274fe8-ddc4-4f11-ae88-862a1d3b929d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_974a3f16-2105-4b54-8066-7aabd331712e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_974a3f16-2105-4b54-8066-7aabd331712e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_4b887e2f-d198-44a1-abae-8495bc071fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_4b887e2f-d198-44a1-abae-8495bc071fe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_040fd89a-e3d7-4cf9-accd-fb2c644f206f" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_040fd89a-e3d7-4cf9-accd-fb2c644f206f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_f70bcc38-266d-4dc4-9c49-a0cdbc26d5e2" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_f70bcc38-266d-4dc4-9c49-a0cdbc26d5e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_430ff739-da80-4af7-b09b-e7113d24c86c" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_430ff739-da80-4af7-b09b-e7113d24c86c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_fc54b76c-bbba-4bf7-9ea2-1d5e0874702d" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_fc54b76c-bbba-4bf7-9ea2-1d5e0874702d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_83af51dd-5d89-4220-afb3-4394b103432a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_83af51dd-5d89-4220-afb3-4394b103432a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2eb885c-b431-46e4-9817-bdd706b1d6ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2eb885c-b431-46e4-9817-bdd706b1d6ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_c9ba881d-0a0d-4680-a258-ab8955f166d6" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:to="loc_halo_AntaresPharmaIncMember_c9ba881d-0a0d-4680-a258-ab8955f166d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended" id="i46fb20ff2b8b43bcb463d34e37650ced_BusinessCombinationIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5dadf17a-a253-4ddd-9d25-6c1da8511fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5dadf17a-a253-4ddd-9d25-6c1da8511fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_79e93e99-ba9a-43d3-8e63-7ad513728f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_79e93e99-ba9a-43d3-8e63-7ad513728f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a593993-72a7-4652-8c86-038a64a5580e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a593993-72a7-4652-8c86-038a64a5580e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9126fa70-f6e5-4c10-8fa0-ff2506fea80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9126fa70-f6e5-4c10-8fa0-ff2506fea80f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd397e36-995a-425e-ae0f-dd1ffbae041f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd397e36-995a-425e-ae0f-dd1ffbae041f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_303f0e64-4c11-4f06-91b4-410dcd91c0d6" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:to="loc_halo_AntaresPharmaIncMember_303f0e64-4c11-4f06-91b4-410dcd91c0d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e07671-63ff-49be-b764-0163fc472af9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e07671-63ff-49be-b764-0163fc472af9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_3a8069c5-72bf-458a-97e7-c45ba28a3783" xlink:href="halo-20221231.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_3a8069c5-72bf-458a-97e7-c45ba28a3783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_46500101-e1c5-47b6-9696-01555f995123" xlink:href="halo-20221231.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_46500101-e1c5-47b6-9696-01555f995123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_e2025782-a5f9-4187-8ab9-d5c0db97d44a" xlink:href="halo-20221231.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_TLANDOProductRightsMember_e2025782-a5f9-4187-8ab9-d5c0db97d44a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_750dd6c8-1e42-44d4-b341-107cd27a060b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_750dd6c8-1e42-44d4-b341-107cd27a060b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e5486c2c-8ee5-4468-b4a1-85e85b350d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e5486c2c-8ee5-4468-b4a1-85e85b350d40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationSummaryofProformaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="extended" id="i3fc37b75d10d45b4be18398e10a02a7a_BusinessCombinationSummaryofProformaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_22ba1c56-e1ee-45fb-851c-f7a5d6989eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_22ba1c56-e1ee-45fb-851c-f7a5d6989eee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4bb3dc92-a6f8-49c6-b7db-b79ead5c630a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4bb3dc92-a6f8-49c6-b7db-b79ead5c630a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_629f9ce9-f36a-47d5-9483-1c79f356063d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_629f9ce9-f36a-47d5-9483-1c79f356063d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_1c92bbb2-fafb-4891-8055-fadcf386ed0a" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:to="loc_halo_AntaresPharmaIncMember_1c92bbb2-fafb-4891-8055-fadcf386ed0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i950e8bb8e1374dd2845aaa61d29fa284_FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8afdbf74-a334-435f-8939-0472b328bc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8afdbf74-a334-435f-8939-0472b328bc95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf3cb158-5b5d-485b-981f-7fb9854dcbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf3cb158-5b5d-485b-981f-7fb9854dcbd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a818acad-9b12-48fc-90f1-f46f7bb91d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a818acad-9b12-48fc-90f1-f46f7bb91d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5eed0d-5675-4d9d-9449-384af85b2820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5eed0d-5675-4d9d-9449-384af85b2820" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c80cc77d-1c44-46e1-a7f6-548b989ab5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c80cc77d-1c44-46e1-a7f6-548b989ab5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8b3976f6-0295-410b-b053-03d3ece01b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8b3976f6-0295-410b-b053-03d3ece01b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2aefc861-f1ab-44dd-ba7f-9ac097600ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2aefc861-f1ab-44dd-ba7f-9ac097600ce3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_3fc8c568-0ee8-496b-9760-4233cb4edd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_AgencySecuritiesMember_3fc8c568-0ee8-496b-9760-4233cb4edd14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2727f55e-7e89-43a2-a2f5-2b28f500df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2727f55e-7e89-43a2-a2f5-2b28f500df5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0660da7d-02bc-413a-bbfe-1242822fbc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_CommercialPaperMember_0660da7d-02bc-413a-bbfe-1242822fbc9f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended" id="i5cc2d4e2685648e999b0224f6b822f55_FairValueMeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b64fce49-0c2e-439c-a76e-a63ba09ae45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b64fce49-0c2e-439c-a76e-a63ba09ae45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a81c5738-a981-4c81-b4ae-c4bb2ab40098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a81c5738-a981-4c81-b4ae-c4bb2ab40098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_87523a23-d6be-43cf-8d85-73acd9721965" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:to="loc_halo_AntaresPharmaIncMember_87523a23-d6be-43cf-8d85-73acd9721965" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i5fc776f8f5844cb1bbc47837753f94ba_FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47ddde8a-7624-4c08-8c9d-86cd0d460904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47ddde8a-7624-4c08-8c9d-86cd0d460904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5551b48c-cb3f-4aa3-b4b0-c8dcb8b91d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5551b48c-cb3f-4aa3-b4b0-c8dcb8b91d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_28d84d41-feb6-419a-aa1d-742971ab1739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_28d84d41-feb6-419a-aa1d-742971ab1739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_38c76b72-b945-4103-9d01-8ff4edcd44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_38c76b72-b945-4103-9d01-8ff4edcd44c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99135cf5-de05-4dfc-990f-d2378cebdf7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99135cf5-de05-4dfc-990f-d2378cebdf7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3f6fc976-c6cf-49d1-b70c-0d1056a1fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3f6fc976-c6cf-49d1-b70c-0d1056a1fa82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_abc9b9df-92b4-431c-87fe-15bd6a93fa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:to="loc_us-gaap_CommercialPaperMember_abc9b9df-92b4-431c-87fe-15bd6a93fa6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca0c58ae-5721-4ffa-bad9-93bb04b83895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca0c58ae-5721-4ffa-bad9-93bb04b83895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2e2a9e8-894c-4e59-8842-e47f8a066aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2e2a9e8-894c-4e59-8842-e47f8a066aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c39c82ff-0e74-4509-9039-1ccba4b3f265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c39c82ff-0e74-4509-9039-1ccba4b3f265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_84e9a1f2-c77d-47b5-b815-c0bc1f3c9fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_84e9a1f2-c77d-47b5-b815-c0bc1f3c9fd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1b3a8659-f5bf-4b27-b8c2-f564f57daad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1b3a8659-f5bf-4b27-b8c2-f564f57daad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_efa2b7a2-ef88-410a-9287-0d027e9a9bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_AgencySecuritiesMember_efa2b7a2-ef88-410a-9287-0d027e9a9bb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_37af062c-7609-47c0-8a41-0f3589b2ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_CommercialPaperMember_37af062c-7609-47c0-8a41-0f3589b2ce11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7185be2-d961-4da0-b40f-59dfdb8d22bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7185be2-d961-4da0-b40f-59dfdb8d22bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_65a8dfcf-ba51-4adf-a943-f42f2cbe4846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_65a8dfcf-ba51-4adf-a943-f42f2cbe4846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9fee2d94-9eb9-4884-91b4-e643ff12cce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9fee2d94-9eb9-4884-91b4-e643ff12cce5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_62308edb-cf79-4741-8873-44e8d6cbf892_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_62308edb-cf79-4741-8873-44e8d6cbf892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e0269e2f-b0ed-4b8c-8218-60dfa1ee1354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e0269e2f-b0ed-4b8c-8218-60dfa1ee1354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b5732d5f-1f4c-4967-aa9c-2833f2ecd952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_CommercialPaperMember_b5732d5f-1f4c-4967-aa9c-2833f2ecd952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fa395be1-69a9-404f-9093-e451c7c1d849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fa395be1-69a9-404f-9093-e451c7c1d849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_30436d09-7790-4e0d-a036-d0548d8e4e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_30436d09-7790-4e0d-a036-d0548d8e4e6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_3ee6d6bd-9ed5-485c-9baf-4c1578cd9ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_3ee6d6bd-9ed5-485c-9baf-4c1578cd9ceb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_dd4fc6fd-ec13-4eb7-bcdf-60901bfbe327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_AgencySecuritiesMember_dd4fc6fd-ec13-4eb7-bcdf-60901bfbe327" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended" id="iaae11bafee944944a858b3203387f8cc_RevenueDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9286abda-be02-49b4-b858-fa4af1a3a37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9286abda-be02-49b4-b858-fa4af1a3a37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:to="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cba42148-cba4-4983-82fa-f3c71a7c58c3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:to="loc_srt_ProductsAndServicesDomain_cba42148-cba4-4983-82fa-f3c71a7c58c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:to="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e632bbb6-7dbc-48f4-9bae-7c5d9a0716c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_us-gaap_RoyaltyMember_e632bbb6-7dbc-48f4-9bae-7c5d9a0716c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_8de64e54-da04-4981-8c37-f4a48eefa984" xlink:href="halo-20221231.xsd#halo_BulkrHuPH20Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_BulkrHuPH20Member_8de64e54-da04-4981-8c37-f4a48eefa984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_83e328eb-8311-4322-835b-435a3270da3f" xlink:href="halo-20221231.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_ProprietaryProductsSalesMember_83e328eb-8311-4322-835b-435a3270da3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_65a92983-da40-46ce-b0d6-2f6e26d514ef" xlink:href="halo-20221231.xsd#halo_DevicePartneredProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_DevicePartneredProductsMember_65a92983-da40-46ce-b0d6-2f6e26d514ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:href="halo-20221231.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_4bf6b492-b88e-4d2d-98b3-a3ee335474f9" xlink:href="halo-20221231.xsd#halo_UpfrontfeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_UpfrontfeesMember_4bf6b492-b88e-4d2d-98b3-a3ee335474f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_48c1519f-483a-4940-ad94-1b8db0c491a0" xlink:href="halo-20221231.xsd#halo_DevelopmentFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_DevelopmentFeesMember_48c1519f-483a-4940-ad94-1b8db0c491a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_8a406497-892f-4a26-b159-df4bf450492b" xlink:href="halo-20221231.xsd#halo_SalesbasedmilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_SalesbasedmilestoneMember_8a406497-892f-4a26-b159-df4bf450492b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchandDevelopmentServicesMember_66d40012-060a-4004-979a-817f52c85626" xlink:href="halo-20221231.xsd#halo_ResearchandDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_ResearchandDevelopmentServicesMember_66d40012-060a-4004-979a-817f52c85626" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTextualsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueTextualsDetails" xlink:type="extended" id="ic3a8fbc098d741f7a2b83a0849391a1c_RevenueTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_056fa117-68f4-452b-883b-0bcfa6df3617" xlink:href="halo-20221231.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_056fa117-68f4-452b-883b-0bcfa6df3617" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_0c0815ab-7703-4054-9263-38e235c5eb9c" xlink:href="halo-20221231.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_0c0815ab-7703-4054-9263-38e235c5eb9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a3010528-2f0a-4e13-9222-bf19d1114998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a3010528-2f0a-4e13-9222-bf19d1114998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2eeb62ad-acc0-4f54-a67b-8cc339f48c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2eeb62ad-acc0-4f54-a67b-8cc339f48c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a9abd00-c7e6-45f2-8943-b73e3b90cbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a9abd00-c7e6-45f2-8943-b73e3b90cbe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_598c80d0-9490-4dd0-91bb-7b7de28f928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_598c80d0-9490-4dd0-91bb-7b7de28f928f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b2b55e5e-78ea-4aad-aa40-3eb2917caa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b2b55e5e-78ea-4aad-aa40-3eb2917caa05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5533ff28-9bc7-441f-973a-944af1a26164_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5533ff28-9bc7-441f-973a-944af1a26164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2017RocheMember_c4fbc487-b445-439e-94ea-fe910ee65f8a" xlink:href="halo-20221231.xsd#halo_A2017RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:to="loc_halo_A2017RocheMember_c4fbc487-b445-439e-94ea-fe910ee65f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherCollaboratorsMember_1e514ee8-0c7b-4a88-9f32-8616e4d367cf" xlink:href="halo-20221231.xsd#halo_OtherCollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:to="loc_halo_OtherCollaboratorsMember_1e514ee8-0c7b-4a88-9f32-8616e4d367cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:to="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f892a3e8-fa0f-49bc-9060-58db596e874b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:to="loc_srt_ProductsAndServicesDomain_f892a3e8-fa0f-49bc-9060-58db596e874b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:to="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_1c135afd-2ecd-4878-86fa-d231cccf286a" xlink:href="halo-20221231.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_1c135afd-2ecd-4878-86fa-d231cccf286a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7e1eb10a-a6a9-46ba-96c7-4aa82f131759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:to="loc_us-gaap_ProductMember_7e1eb10a-a6a9-46ba-96c7-4aa82f131759" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueRevenueRemainingPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" xlink:type="extended" id="iff5f4ccc2ac24729975e3a697b09ba52_RevenueRevenueRemainingPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81567636-2cf4-44ff-af1e-64d5c03577f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81567636-2cf4-44ff-af1e-64d5c03577f0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueRevenueRemainingPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails_1" xlink:type="extended" id="i25abe28aba104cdea0ff05050daf870d_RevenueRevenueRemainingPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="extended" id="i9bfb2e9bca244d53b7a3439fe53ac5b8_CertainBalanceSheetItemsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32679561-39c4-4730-9746-34100b753d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32679561-39c4-4730-9746-34100b753d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf7f6acb-6013-488c-8893-2dac2826b244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf7f6acb-6013-488c-8893-2dac2826b244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3e76bb11-8ba7-4bad-b8ed-d4222f5e6db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3e76bb11-8ba7-4bad-b8ed-d4222f5e6db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb1a3ee3-121c-4e75-a958-c1b929f26d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb1a3ee3-121c-4e75-a958-c1b929f26d86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_043792db-8d1c-49d5-a63f-6d44493c92ac" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_043792db-8d1c-49d5-a63f-6d44493c92ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6c8f4f44-ec65-4d90-8538-13bd2316bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6c8f4f44-ec65-4d90-8538-13bd2316bbe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_ace36790-469d-4b40-a54c-fedf56fcdf2b" xlink:href="halo-20221231.xsd#halo_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ResearchEquipmentMember_ace36790-469d-4b40-a54c-fedf56fcdf2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_8676beca-f105-46ce-9c1a-49c405f4591e" xlink:href="halo-20221231.xsd#halo_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ManufacturingEquipmentMember_8676beca-f105-46ce-9c1a-49c405f4591e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_908fa22d-b6c7-4c54-9844-36280c2ff9ef" xlink:href="halo-20221231.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_908fa22d-b6c7-4c54-9844-36280c2ff9ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_43953ae7-b007-4719-a2bb-4a9b85eecb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_43953ae7-b007-4719-a2bb-4a9b85eecb55" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="ifd67d6299f354a0ca0443a6f74d2c112_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b798ae2c-8de6-4a32-a8b0-b79bba9e9635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:to="loc_us-gaap_Goodwill_b798ae2c-8de6-4a32-a8b0-b79bba9e9635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05aa48f2-1db6-4c7e-85ff-8c94f6a8cfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05aa48f2-1db6-4c7e-85ff-8c94f6a8cfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f54a5209-60d1-4102-8386-90a8a801b3d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f54a5209-60d1-4102-8386-90a8a801b3d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_19b16cdb-1b7e-4d63-a83b-0d240d02653d" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:to="loc_halo_AntaresPharmaIncMember_19b16cdb-1b7e-4d63-a83b-0d240d02653d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:to="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32795e00-fa2f-499f-b4d4-e38722c0b764_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:to="loc_srt_RangeMember_32795e00-fa2f-499f-b4d4-e38722c0b764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:to="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d717cbd7-2eec-4c27-9871-63da3dd9ed2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:to="loc_srt_MinimumMember_d717cbd7-2eec-4c27-9871-63da3dd9ed2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f8a063f-1d31-44a9-acd2-66dbd567c63e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:to="loc_srt_MaximumMember_5f8a063f-1d31-44a9-acd2-66dbd567c63e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="id7eaf52e390b4b4e914438803a752cf5_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8e63eb97-3a09-4249-b897-cb2ce29f7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8e63eb97-3a09-4249-b897-cb2ce29f7bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eb9e4963-d60a-4cdf-a9ef-acdab0e71c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eb9e4963-d60a-4cdf-a9ef-acdab0e71c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57427e49-e8a2-4077-9f1c-ded24d17555c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57427e49-e8a2-4077-9f1c-ded24d17555c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a01000ca-21fd-49a9-848e-c79e4d7da9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a01000ca-21fd-49a9-848e-c79e4d7da9e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_65c6dce1-9d76-4631-9210-b8ac590addd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_65c6dce1-9d76-4631-9210-b8ac590addd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e23bf108-ca7c-4547-92a2-9f71d5ad84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e23bf108-ca7c-4547-92a2-9f71d5ad84eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b169eb3e-21a8-46b3-92c5-6206f7c80a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b169eb3e-21a8-46b3-92c5-6206f7c80a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_6c49d183-370f-40c2-9673-8f6ae86b04bc" xlink:href="halo-20221231.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_6c49d183-370f-40c2-9673-8f6ae86b04bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_ff34a201-1359-4656-b2cf-9b1a75fdaf92" xlink:href="halo-20221231.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_ff34a201-1359-4656-b2cf-9b1a75fdaf92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_93c610e1-8ea0-4e53-ad89-4e56b1db84f8" xlink:href="halo-20221231.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_TLANDOProductRightsMember_93c610e1-8ea0-4e53-ad89-4e56b1db84f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended" id="i65f8cfd69efd49449f15ea82f71520ab_LongTermDebtNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5163088-eb2e-4f14-9f96-516a119d1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5163088-eb2e-4f14-9f96-516a119d1f8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_652378e1-0af4-4608-af7a-24cd4d650675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_652378e1-0af4-4608-af7a-24cd4d650675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_77630ae5-5d51-44d9-aeef-b42c5e42244a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_77630ae5-5d51-44d9-aeef-b42c5e42244a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b1744ec4-c185-496e-8807-1b3262393f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b1744ec4-c185-496e-8807-1b3262393f38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1814f190-8709-43b2-bbd9-a2405edb6412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1814f190-8709-43b2-bbd9-a2405edb6412" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0864a355-27bd-43ae-b28a-d3b18a731723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0864a355-27bd-43ae-b28a-d3b18a731723" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_11c7c8ae-8049-4e84-ba9e-107cdbca6827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_11c7c8ae-8049-4e84-ba9e-107cdbca6827" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_841c8977-26ca-4f6c-866b-cbae7bc2958a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_841c8977-26ca-4f6c-866b-cbae7bc2958a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_cbb88b4d-7acf-42c0-9e98-6f502009f9da" xlink:href="halo-20221231.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_cbb88b4d-7acf-42c0-9e98-6f502009f9da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_224431ab-c52d-4996-88dd-c9e84f193945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_224431ab-c52d-4996-88dd-c9e84f193945" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4760ec67-413f-4a76-aad0-02b21a9492c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4760ec67-413f-4a76-aad0-02b21a9492c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_54506c12-1fe7-4efd-81f5-8d7de31fd743" xlink:href="halo-20221231.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_54506c12-1fe7-4efd-81f5-8d7de31fd743" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_2f555e04-e3f5-4a5a-be02-588a65719738" xlink:href="halo-20221231.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_2f555e04-e3f5-4a5a-be02-588a65719738" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40b626a2-4d4b-4a14-8185-9485dffc6c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40b626a2-4d4b-4a14-8185-9485dffc6c5f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_5c1d4c2f-41b1-4141-88d0-a9bf20e89070" xlink:href="halo-20221231.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_PaymentForCappedCallTransactions_5c1d4c2f-41b1-4141-88d0-a9bf20e89070" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_406f53a2-86cb-4f06-b05b-cffa91a2e5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_406f53a2-86cb-4f06-b05b-cffa91a2e5ce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2c10ecc2-2cb2-43a7-89d4-8530228f6058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2c10ecc2-2cb2-43a7-89d4-8530228f6058" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b2727a97-4fa6-46ce-99be-bc9868818e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b2727a97-4fa6-46ce-99be-bc9868818e95" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_afaa6c35-ebdb-4cb3-a65d-4ca2a2c0f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_afaa6c35-ebdb-4cb3-a65d-4ca2a2c0f4fa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_732e62a8-15b4-40c1-8eb1-549617a7f913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_732e62a8-15b4-40c1-8eb1-549617a7f913" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b67b2e4d-d860-4097-8768-8a8cf3510f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b67b2e4d-d860-4097-8768-8a8cf3510f54" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e8e67c6-6a5e-4914-b0f2-fda530868cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e8e67c6-6a5e-4914-b0f2-fda530868cbe" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1b6456f9-64a3-4ac4-9af3-aed9e5fe9d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1b6456f9-64a3-4ac4-9af3-aed9e5fe9d3b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_7ec38e56-d459-4f66-b128-a4525488b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_7ec38e56-d459-4f66-b128-a4525488b05c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_390b13c6-968f-448d-a474-f7fa89ac670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_390b13c6-968f-448d-a474-f7fa89ac670c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7d1a430-ebef-4df1-80ae-ff6d174c32d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7d1a430-ebef-4df1-80ae-ff6d174c32d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_cd2091bd-53f3-4923-a29b-d3287c844a6a" xlink:href="halo-20221231.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_cd2091bd-53f3-4923-a29b-d3287c844a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8e939046-120b-41ea-af1e-3e1f59e28c68" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8e939046-120b-41ea-af1e-3e1f59e28c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_cdf210bc-9530-4169-a42e-92f978684205" xlink:href="halo-20221231.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_cdf210bc-9530-4169-a42e-92f978684205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_ae0cd01d-c109-4f9a-8166-f8bbeb6171fb" xlink:href="halo-20221231.xsd#halo_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_CreditAgreementMember_ae0cd01d-c109-4f9a-8166-f8bbeb6171fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e239748c-4c95-47b7-b41a-94df83f172d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e239748c-4c95-47b7-b41a-94df83f172d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_4783a72b-d2a2-4ea8-92cb-e632008bcf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_4783a72b-d2a2-4ea8-92cb-e632008bcf60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7fc8202c-a8ac-4c97-809a-eccf145a3ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7fc8202c-a8ac-4c97-809a-eccf145a3ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a7fc14b9-a81d-4471-ba25-1e5439e5a58a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a7fc14b9-a81d-4471-ba25-1e5439e5a58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7f8a0d6d-c721-4db0-b117-5e2a7a5ed5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_us-gaap_ConvertibleDebtMember_7f8a0d6d-c721-4db0-b117-5e2a7a5ed5bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_c02edad0-cebf-44bf-8d88-49bc2a373785" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_c02edad0-cebf-44bf-8d88-49bc2a373785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_1f2465e8-6cca-4d3c-bd98-662b63ac6946" xlink:href="halo-20221231.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_halo_TermLoanFacilityMember_1f2465e8-6cca-4d3c-bd98-662b63ac6946" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b3bcfe0-df7d-48af-a864-f4870f712301_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:to="loc_srt_RangeMember_7b3bcfe0-df7d-48af-a864-f4870f712301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:to="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_833008a4-fa89-4f8b-b2ec-8b93aa115803" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:to="loc_srt_MinimumMember_833008a4-fa89-4f8b-b2ec-8b93aa115803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ac3cd1a-dc4f-414b-b416-7b004ac26771" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:to="loc_srt_MaximumMember_1ac3cd1a-dc4f-414b-b416-7b004ac26771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:to="loc_us-gaap_VariableRateDomain_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:to="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_00e289d1-df33-4657-97b0-357e561e616b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_00e289d1-df33-4657-97b0-357e561e616b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_cb0b3043-7b90-4322-b801-c33d8ab086ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_cb0b3043-7b90-4322-b801-c33d8ab086ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_44597b39-a650-46d7-9295-f80a9abea0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_BaseRateMember_44597b39-a650-46d7-9295-f80a9abea0d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdd92446-1bf3-4ca0-bcd1-c858981a6151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdd92446-1bf3-4ca0-bcd1-c858981a6151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cdf407d8-963c-4d00-839f-659572ace476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:to="loc_us-gaap_SubsequentEventMember_cdf407d8-963c-4d00-839f-659572ace476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e2508d99-d588-4104-8ddc-c710d5154a0a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e2508d99-d588-4104-8ddc-c710d5154a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_43869e42-93f4-4fe3-b719-96405e8e6aed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:to="loc_srt_ScenarioForecastMember_43869e42-93f4-4fe3-b719-96405e8e6aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_11533463-8202-4fb2-816b-731cb124fa79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:to="loc_us-gaap_CreditFacilityDomain_11533463-8202-4fb2-816b-731cb124fa79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:to="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ebc96ed6-6e0a-420b-9ef3-e20eae4a3bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ebc96ed6-6e0a-420b-9ef3-e20eae4a3bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_aae549e4-afec-4046-9fd9-96852f52dfa5_default" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_aae549e4-afec-4046-9fd9-96852f52dfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_bc5f523a-7c12-44a7-a027-1bf0c5f50b57" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_bc5f523a-7c12-44a7-a027-1bf0c5f50b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_4e562eb0-cc09-42f8-9528-44149a6bb904" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_4e562eb0-cc09-42f8-9528-44149a6bb904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThirdMember_be3004f4-e637-4051-bdc8-9f856213d05c" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodThirdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodThirdMember_be3004f4-e637-4051-bdc8-9f856213d05c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_24bf4a81-d8dc-4461-bc6b-643fa0492d8b" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_24bf4a81-d8dc-4461-bc6b-643fa0492d8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:href="halo-20221231.xsd#halo_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_180313b6-9f9e-45ef-999a-eae23eb4c2f2_default" xlink:href="halo-20221231.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:to="loc_halo_VariableRateComponentDomain_180313b6-9f9e-45ef-999a-eae23eb4c2f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:href="halo-20221231.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:to="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_06f7b06f-e73c-4b34-8528-2b77fbb0c456" xlink:href="halo-20221231.xsd#halo_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:to="loc_halo_VariableRateComponentOneMember_06f7b06f-e73c-4b34-8528-2b77fbb0c456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_a5582984-c3a7-4f35-a907-3ed2bdd7b662" xlink:href="halo-20221231.xsd#halo_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:to="loc_halo_VariableRateComponentTwoMember_a5582984-c3a7-4f35-a907-3ed2bdd7b662" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="extended" id="ie4f800a87aa44e1b8ab749af55f64941_LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11026bf2-2d9f-4cff-a74e-644129b355dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11026bf2-2d9f-4cff-a74e-644129b355dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_827e1657-f8a9-438f-b5c4-70b61b9679bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_827e1657-f8a9-438f-b5c4-70b61b9679bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_277f180e-1167-4cdd-a0ea-b394715bfbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_ConvertibleNotesPayable_277f180e-1167-4cdd-a0ea-b394715bfbc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_b0648044-585c-4092-b592-ae3ae6ba634b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_b0648044-585c-4092-b592-ae3ae6ba634b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_59764aa9-2dc9-4b90-9603-3b9364886271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_59764aa9-2dc9-4b90-9603-3b9364886271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_078f747f-df12-4724-a3b1-8c408ca895e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_078f747f-df12-4724-a3b1-8c408ca895e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_46731032-59db-4486-9c8c-2eb320cdbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_46731032-59db-4486-9c8c-2eb320cdbca1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3235764b-2714-475f-afb2-42a17e0079c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_InterestExpenseDebt_3235764b-2714-475f-afb2-42a17e0079c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b49367d-979d-47ee-9985-cc1ec0918ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b49367d-979d-47ee-9985-cc1ec0918ac3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_96cab1e1-c6a3-42d1-935e-2943ce8beb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_96cab1e1-c6a3-42d1-935e-2943ce8beb90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f289b2f2-32a1-41bb-8a48-c2c9f68045f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f289b2f2-32a1-41bb-8a48-c2c9f68045f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3a9be2e-e326-4d85-8c62-ee73b083842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3a9be2e-e326-4d85-8c62-ee73b083842a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_048e8f05-00ea-49d4-bd0f-507512f9ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_048e8f05-00ea-49d4-bd0f-507512f9ce4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dcc238ed-212e-47a0-8b22-eaf32a41882e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dcc238ed-212e-47a0-8b22-eaf32a41882e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_011f3817-45fc-4bf2-a8d0-bd4f37bb9a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_011f3817-45fc-4bf2-a8d0-bd4f37bb9a50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtIncludingInterestGross_5ed39abf-5e34-4c4f-8e86-c5ef52f8a23c" xlink:href="halo-20221231.xsd#halo_LongTermDebtIncludingInterestGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_halo_LongTermDebtIncludingInterestGross_5ed39abf-5e34-4c4f-8e86-c5ef52f8a23c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtInterestGross_d0a883c9-db2f-432d-ba12-c8b2ff076104" xlink:href="halo-20221231.xsd#halo_LongTermDebtInterestGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_halo_LongTermDebtInterestGross_d0a883c9-db2f-432d-ba12-c8b2ff076104" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1f17c703-de1f-482a-8b05-38c82db973b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1f17c703-de1f-482a-8b05-38c82db973b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1c951498-ed5b-4a7c-ba69-4b7ba0e4a671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_b3dfcba4-5995-4e0d-af29-31c3f89ebb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtFairValue_b3dfcba4-5995-4e0d-af29-31c3f89ebb00" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_575350dc-5030-4b9d-951d-62404d1e54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtCurrent_575350dc-5030-4b9d-951d-62404d1e54c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_39612a1f-15c8-48a8-91fb-265a02661e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_39612a1f-15c8-48a8-91fb-265a02661e79" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:to="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_220e09bf-eb71-40c5-b314-4ec36461503c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_220e09bf-eb71-40c5-b314-4ec36461503c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_154307ef-5a56-47ab-bf3b-9d8e50922cfa" xlink:href="halo-20221231.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_154307ef-5a56-47ab-bf3b-9d8e50922cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_20ea5b61-86b8-44c4-b264-3cdda7185cac" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_20ea5b61-86b8-44c4-b264-3cdda7185cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_b7e6b026-7cd9-4172-bdf2-ceb42c15387d" xlink:href="halo-20221231.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_b7e6b026-7cd9-4172-bdf2-ceb42c15387d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6e57d01-0564-4927-8972-f6c044a3aac8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6e57d01-0564-4927-8972-f6c044a3aac8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e61649b8-a211-4b1d-9497-aefa9dce347e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:to="loc_us-gaap_ConvertibleDebtMember_e61649b8-a211-4b1d-9497-aefa9dce347e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="i08abb297d85c4451b870b90915ab7497_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_66738f52-af83-4fc2-8375-4d1d8f362911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_66738f52-af83-4fc2-8375-4d1d8f362911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_970cea90-0a3c-4fcd-af4a-3b6d227f66e5" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_970cea90-0a3c-4fcd-af4a-3b6d227f66e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10942a9c-a254-417f-b9f3-4a7570ca7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10942a9c-a254-417f-b9f3-4a7570ca7a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e2d7924-0e11-43e5-afdf-13889bb5508c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e2d7924-0e11-43e5-afdf-13889bb5508c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_0784054c-3eba-4fca-9f4d-bf3f6aeb1dac" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_0784054c-3eba-4fca-9f4d-bf3f6aeb1dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_216a51a2-ae95-45c2-9c67-317232ba540d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_216a51a2-ae95-45c2-9c67-317232ba540d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_6438a4c2-2cee-4b3c-9d18-c4b81c746366" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_6438a4c2-2cee-4b3c-9d18-c4b81c746366" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b2958a66-42ec-474f-a06e-161c8f3ce87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b2958a66-42ec-474f-a06e-161c8f3ce87a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_3d1ba94a-ef3a-418b-b786-fb17d3f75ae8" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_3d1ba94a-ef3a-418b-b786-fb17d3f75ae8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ebbfa5b6-3c29-46d5-9839-4e1d33444e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ebbfa5b6-3c29-46d5-9839-4e1d33444e4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_ffa06446-07b8-4447-9a8c-82053603a134" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_ffa06446-07b8-4447-9a8c-82053603a134" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_32bb03d5-0ce3-4553-885d-7c593dbf337c" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_32bb03d5-0ce3-4553-885d-7c593dbf337c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10eca0f3-c2a5-41cc-b181-ecb3b0bc1145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10eca0f3-c2a5-41cc-b181-ecb3b0bc1145" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08d64fcf-0e66-40df-91f0-602f1cbdf75a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08d64fcf-0e66-40df-91f0-602f1cbdf75a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6aca81d-97c1-4409-82c8-ef972e1e1800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6aca81d-97c1-4409-82c8-ef972e1e1800" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_30eaaf16-be0c-4b10-aef5-e3a154104b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_30eaaf16-be0c-4b10-aef5-e3a154104b35" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_093c4ef9-4e77-45b9-857a-7ea7096c6f5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:to="loc_us-gaap_PlanNameDomain_093c4ef9-4e77-45b9-857a-7ea7096c6f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:to="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AmendedAndRestated2021StockPlanMember_cdd67032-fb7a-4dea-b408-df5511b0debf" xlink:href="halo-20221231.xsd#halo_AmendedAndRestated2021StockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:to="loc_halo_AmendedAndRestated2021StockPlanMember_cdd67032-fb7a-4dea-b408-df5511b0debf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_6cf81ec1-1437-4222-a14f-1a125b5b6d13" xlink:href="halo-20221231.xsd#halo_A2021ESPPPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:to="loc_halo_A2021ESPPPlanMember_6cf81ec1-1437-4222-a14f-1a125b5b6d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0489b11a-85b5-4ecc-a66a-4422ff6aca4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0489b11a-85b5-4ecc-a66a-4422ff6aca4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OutstandingAwardsMember_c8d27e63-7c82-48c9-a177-9e3fd46f5726" xlink:href="halo-20221231.xsd#halo_OutstandingAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_halo_OutstandingAwardsMember_c8d27e63-7c82-48c9-a177-9e3fd46f5726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d5ef1e4e-7258-4c80-aa4d-f075a0ddec02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_EmployeeStockMember_d5ef1e4e-7258-4c80-aa4d-f075a0ddec02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15338280-0a34-43eb-bc3f-de40f781c342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15338280-0a34-43eb-bc3f-de40f781c342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_876583eb-acd8-4d1f-98f3-bc9f653dce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_876583eb-acd8-4d1f-98f3-bc9f653dce98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3fcd82ad-b606-4b76-aa39-d125001ab1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_PerformanceSharesMember_3fcd82ad-b606-4b76-aa39-d125001ab1eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6242c5b0-b121-4b93-9dc9-5ef357a6887b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:to="loc_us-gaap_VestingDomain_6242c5b0-b121-4b93-9dc9-5ef357a6887b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:to="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CliffVestingFirstAnniversaryMember_30e406b3-fcd3-4e9a-8c1c-d0a0e2f6716d" xlink:href="halo-20221231.xsd#halo_CliffVestingFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_CliffVestingFirstAnniversaryMember_30e406b3-fcd3-4e9a-8c1c-d0a0e2f6716d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_MonthlyVestingAfterOneYearMember_df423715-49f6-4d3d-b549-8afd7e4e3e69" xlink:href="halo-20221231.xsd#halo_MonthlyVestingAfterOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_MonthlyVestingAfterOneYearMember_df423715-49f6-4d3d-b549-8afd7e4e3e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PercentageVestingMember_2009f422-7614-459b-99e5-8481f6a570fe" xlink:href="halo-20221231.xsd#halo_PercentageVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_PercentageVestingMember_2009f422-7614-459b-99e5-8481f6a570fe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="icb115407996449ab9c445028944c754c_SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dd1ae50-bd8b-4d41-8a16-a5ed4689657d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dd1ae50-bd8b-4d41-8a16-a5ed4689657d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c443947-3423-47a8-b3e0-6147606a350b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c443947-3423-47a8-b3e0-6147606a350b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cca4a109-ec29-477f-954d-0240c1033b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cca4a109-ec29-477f-954d-0240c1033b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00557025-09d2-4fee-9474-db4d3a60451a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00557025-09d2-4fee-9474-db4d3a60451a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:to="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f0df397-9c1a-46de-9c0d-7954a27577fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f0df397-9c1a-46de-9c0d-7954a27577fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e832683f-bba1-4edb-b488-d5de5bf44860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e832683f-bba1-4edb-b488-d5de5bf44860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_e9caa890-055c-4fe9-bf3d-89998a60c9d2" xlink:href="halo-20221231.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:to="loc_halo_RSURSAandPRSUawardsMember_e9caa890-055c-4fe9-bf3d-89998a60c9d2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationUnrecognizedExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails" xlink:type="extended" id="i5c0f2c6a799343c89b5a2f8d28ddffa7_SharebasedCompensationUnrecognizedExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80ca9279-fad9-4493-9711-17b45c49d1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80ca9279-fad9-4493-9711-17b45c49d1cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc311410-2da4-4cd0-92de-28da288625c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc311410-2da4-4cd0-92de-28da288625c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:to="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a12a59d-6368-415b-bc93-fc85a78b4185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a12a59d-6368-415b-bc93-fc85a78b4185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c0f74628-d807-41f4-9bde-529baac9788d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c0f74628-d807-41f4-9bde-529baac9788d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a7355642-42cb-4a04-bc27-dbd1a44e175c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_PerformanceSharesMember_a7355642-42cb-4a04-bc27-dbd1a44e175c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_36c012aa-a0bb-4408-a1dd-2c98e82f480b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_EmployeeStockMember_36c012aa-a0bb-4408-a1dd-2c98e82f480b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationOptionsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationOptionsDetails" xlink:type="extended" id="ibf09c8608ae346de958bfdb849a21873_SharebasedCompensationOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1d6fa36-1483-410a-bdcb-d6b52a348cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1d6fa36-1483-410a-bdcb-d6b52a348cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c28ff73-7cb7-4fdc-b912-bd2556823e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c28ff73-7cb7-4fdc-b912-bd2556823e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca2b260-245c-4941-a023-947a4d694677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca2b260-245c-4941-a023-947a4d694677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3d08ded8-09cd-424b-a203-055e0236f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3d08ded8-09cd-424b-a203-055e0236f9e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e88fd260-4b1b-4c24-b9b0-6d4efc840dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0306c2d7-b8db-44d9-b805-60863b19ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0306c2d7-b8db-44d9-b805-60863b19ca2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_babd7fc4-d845-47da-83b7-ce171e3a70fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_babd7fc4-d845-47da-83b7-ce171e3a70fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e058f962-54e0-49b5-b892-6fa4363a111f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e058f962-54e0-49b5-b892-6fa4363a111f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f1b911d-1bd3-4bca-a060-028721df6870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f1b911d-1bd3-4bca-a060-028721df6870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_405a9b33-5239-4a1d-aeed-5f91db9f1440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_405a9b33-5239-4a1d-aeed-5f91db9f1440" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e05ae6b8-ec21-46ab-b854-0a2751df2130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e05ae6b8-ec21-46ab-b854-0a2751df2130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8dc381d-5c1a-4a76-92a2-29bcec7490c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c55fa54e-70c8-482c-8f72-020f2d9b3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c55fa54e-70c8-482c-8f72-020f2d9b3719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9022d6c3-0426-4997-86fa-3a74dbf0cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9022d6c3-0426-4997-86fa-3a74dbf0cfad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17161459-8ca3-431e-ba98-07161853c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17161459-8ca3-431e-ba98-07161853c2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0679e509-107d-426c-ab39-e22aef3efe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0679e509-107d-426c-ab39-e22aef3efe9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6068f63e-9573-4a98-abb5-743ae2de0631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6068f63e-9573-4a98-abb5-743ae2de0631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dfb3fb4d-2b72-4b04-b686-fe49d670cab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dfb3fb4d-2b72-4b04-b686-fe49d670cab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6f4aa79-fea3-4d9b-a21e-148a821fad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6f4aa79-fea3-4d9b-a21e-148a821fad7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_385fb52a-163e-4ec4-81a9-25b69a9da249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_385fb52a-163e-4ec4-81a9-25b69a9da249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4094221-2b5c-40d7-bb3b-4acc379cb16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4094221-2b5c-40d7-bb3b-4acc379cb16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6b19a317-c934-4559-8327-9ea66ee09298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6b19a317-c934-4559-8327-9ea66ee09298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b291d8c8-ddc9-4a4e-92ff-1fc46ba274f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b291d8c8-ddc9-4a4e-92ff-1fc46ba274f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:to="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_926dbe9a-1ab1-422f-bd0c-5326888008ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_926dbe9a-1ab1-422f-bd0c-5326888008ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4b9101-5508-4810-b033-f52b985477c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4b9101-5508-4810-b033-f52b985477c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationValuationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationValuationDetails" xlink:type="extended" id="i5e8953a12e8c4bcf8110926636348630_SharebasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_75439b5c-596b-4c81-a215-b97ef7544bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_75439b5c-596b-4c81-a215-b97ef7544bc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37a0bc7e-d083-4d4d-81a7-e7ce3f0a9bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37a0bc7e-d083-4d4d-81a7-e7ce3f0a9bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3765416c-c4a4-480a-82a6-d88e568cdc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3765416c-c4a4-480a-82a6-d88e568cdc39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47edd79e-6caf-40f5-bc3f-6f38dc3eb011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47edd79e-6caf-40f5-bc3f-6f38dc3eb011" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_79f3329f-6151-4609-acd4-bc43e16674ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_79f3329f-6151-4609-acd4-bc43e16674ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:to="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:to="loc_srt_RangeMember_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:to="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_299ca0e8-be96-4111-96d9-37a82613876e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:to="loc_srt_MinimumMember_299ca0e8-be96-4111-96d9-37a82613876e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9417de86-9235-48d8-bbf5-22b75038631d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:to="loc_srt_MaximumMember_9417de86-9235-48d8-bbf5-22b75038631d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i3dc845b030384350923735fe22b507b1_SharebasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6d52dc2-a826-4fd0-a753-737ecfc13408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6d52dc2-a826-4fd0-a753-737ecfc13408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d57807b-290e-4825-9afa-dd7e3975575d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d57807b-290e-4825-9afa-dd7e3975575d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b233c3f-3f35-49b7-980c-1ab70baf390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b233c3f-3f35-49b7-980c-1ab70baf390d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ed30b95-b9b2-4977-aa59-0455b87e0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ed30b95-b9b2-4977-aa59-0455b87e0cec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_568ab045-1442-4d5a-90db-39d61e6d78cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_471a588b-2fb4-4af4-a288-45c2376db62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_471a588b-2fb4-4af4-a288-45c2376db62a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e357a323-964a-4f02-a2eb-6924092bdfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e357a323-964a-4f02-a2eb-6924092bdfaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b856fd72-4491-4ef7-ba17-a1525a3aeca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b856fd72-4491-4ef7-ba17-a1525a3aeca0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_18aa4779-75a1-4827-b7e2-9b1ebbc766bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_18aa4779-75a1-4827-b7e2-9b1ebbc766bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c84723c-8819-46f4-9067-782a0f66fdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3fa0e79b-9e35-457a-b4d5-b26a6ada425c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3fa0e79b-9e35-457a-b4d5-b26a6ada425c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f219bd28-d3c1-43f4-9374-319fd80f4be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f219bd28-d3c1-43f4-9374-319fd80f4be9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a348c9e7-3b06-4220-af26-38fdca52f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a348c9e7-3b06-4220-af26-38fdca52f6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_15fcf43b-2fce-4bfd-8335-a2e544173212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_15fcf43b-2fce-4bfd-8335-a2e544173212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:to="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c5348ef-4a31-47a2-b90e-84f00f1a9797_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c5348ef-4a31-47a2-b90e-84f00f1a9797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_30c406e7-d92e-46b0-ae3c-8d48c30d03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_30c406e7-d92e-46b0-ae3c-8d48c30d03f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationPerformanceStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails" xlink:type="extended" id="i22e23d9117a148d386bba2642cba4357_SharebasedCompensationPerformanceStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02d17f91-2d89-4cf2-a039-56e2cb154444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02d17f91-2d89-4cf2-a039-56e2cb154444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86a89c7c-ec29-4c37-86a8-d2ac0d4c48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86a89c7c-ec29-4c37-86a8-d2ac0d4c48e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2e1584f-8fa9-44fc-8ba5-08459ded026d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2e1584f-8fa9-44fc-8ba5-08459ded026d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ec43c117-1fcb-4290-ac8e-74955b10bc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ec43c117-1fcb-4290-ac8e-74955b10bc46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45f941e0-b5c6-4d4e-8e9a-4167147846ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9972a7f-bf3b-43bb-b853-7d2c54156d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9972a7f-bf3b-43bb-b853-7d2c54156d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d23dc733-72a1-4683-990c-5acb0d2fc3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d23dc733-72a1-4683-990c-5acb0d2fc3fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89fe84b2-851c-46e0-9d8c-b7db54e22dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89fe84b2-851c-46e0-9d8c-b7db54e22dee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f3ab6912-3679-41df-a312-acbb1aa076b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f3ab6912-3679-41df-a312-acbb1aa076b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7498824d-39d5-4519-b763-cb4771eea520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_7b9ae4f6-142c-4e9b-8404-de9701b0d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_7b9ae4f6-142c-4e9b-8404-de9701b0d9c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:to="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef837a92-f233-4f2e-9570-32576bbf900d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef837a92-f233-4f2e-9570-32576bbf900d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad36395e-ce76-4c93-b404-e5457ecc055e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:to="loc_us-gaap_PerformanceSharesMember_ad36395e-ce76-4c93-b404-e5457ecc055e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e3d5f1-dda5-4c1e-8804-8dce6c575d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e3d5f1-dda5-4c1e-8804-8dce6c575d8d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i072c1fd6f8424a3c8ac408246ea7e194_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80848b50-512c-4262-ad5d-8c377eb0446e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80848b50-512c-4262-ad5d-8c377eb0446e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c846e13b-e9b8-41d6-92ca-65da826d3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c846e13b-e9b8-41d6-92ca-65da826d3c1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_724f2b6b-45f7-4da6-9433-40f23f1c11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_724f2b6b-45f7-4da6-9433-40f23f1c11ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fdbe8454-fece-4410-a4aa-359721c38a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fdbe8454-fece-4410-a4aa-359721c38a03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0f7b8979-aaa8-4f84-866d-fa9e1152f35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0f7b8979-aaa8-4f84-866d-fa9e1152f35e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b0e26d4-f0e0-465f-8a96-0fd55d2a4832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b0e26d4-f0e0-465f-8a96-0fd55d2a4832" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:to="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f96e317-21be-4212-b728-b386932966ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f96e317-21be-4212-b728-b386932966ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3042dff-33e9-4aab-b73f-8c0b7e029970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3042dff-33e9-4aab-b73f-8c0b7e029970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69806019-efcd-4734-acde-de17072ac190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69806019-efcd-4734-acde-de17072ac190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_c2adaa90-7920-4b78-9952-3d3909b0fe2f" xlink:href="halo-20221231.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_c2adaa90-7920-4b78-9952-3d3909b0fe2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e4215320-efd6-45ef-a3f2-d6a3bed5c171_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e4215320-efd6-45ef-a3f2-d6a3bed5c171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_97e31c6e-d800-422b-b1f1-4cfa09a3ab51" xlink:href="halo-20221231.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_97e31c6e-d800-422b-b1f1-4cfa09a3ab51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquityShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails" xlink:type="extended" id="i3d52fab3d5174dc0b1c1eec7bcdb1a08_StockholdersEquityShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fa1256e6-4f8e-4071-a710-243fe69fceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fa1256e6-4f8e-4071-a710-243fe69fceb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_becda589-9666-414f-86d6-a74f85bbf675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_becda589-9666-414f-86d6-a74f85bbf675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ed9924a4-e7e5-4c3c-b65d-16d3a1d2dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ed9924a4-e7e5-4c3c-b65d-16d3a1d2dd6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_891453c4-019c-4644-8500-d02eddd20690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_891453c4-019c-4644-8500-d02eddd20690" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_09d0ab60-fa36-42eb-b9c5-712bdb0a5a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_09d0ab60-fa36-42eb-b9c5-712bdb0a5a57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_45f4a4c6-1cef-4215-9825-73153652f1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_45f4a4c6-1cef-4215-9825-73153652f1bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_67e0be8b-9454-4456-aaf2-78aa3ec4c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_67e0be8b-9454-4456-aaf2-78aa3ec4c3a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TreasuryStockAcquiredFeeCostPerShare_cbb93048-86ee-4b82-bcb1-ca097eef4b15" xlink:href="halo-20221231.xsd#halo_TreasuryStockAcquiredFeeCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_halo_TreasuryStockAcquiredFeeCostPerShare_cbb93048-86ee-4b82-bcb1-ca097eef4b15" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d77be8d7-d03e-4b62-b1fc-50daf947af30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d77be8d7-d03e-4b62-b1fc-50daf947af30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_a7732f5f-fdff-45e0-b1f2-2c4a875a92bf" xlink:href="halo-20221231.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_a7732f5f-fdff-45e0-b1f2-2c4a875a92bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails" xlink:type="extended" id="id1f7d6f6f25c4e5fb91d54ef3e5cbc2a_NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c9c36e0-f325-4fbb-8edf-733096520891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_NetIncomeLoss_8c9c36e0-f325-4fbb-8edf-733096520891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c7ed155-95fa-4f3c-9a38-c859024faca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c7ed155-95fa-4f3c-9a38-c859024faca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5d766a9f-f89e-4770-8827-246ef7eff87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5d766a9f-f89e-4770-8827-246ef7eff87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72f5e03e-1532-4212-8609-27405a838ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72f5e03e-1532-4212-8609-27405a838ad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_00dedc73-6413-49a5-a0aa-952c8aa0e749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_EarningsPerShareBasic_00dedc73-6413-49a5-a0aa-952c8aa0e749" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5afebd6b-b77e-4ba1-81cb-26d544c9e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5afebd6b-b77e-4ba1-81cb-26d544c9e4a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:to="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3abda363-add6-4e96-89f1-d63e56f87541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3abda363-add6-4e96-89f1-d63e56f87541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_092f8408-772b-4477-8849-00f5807f5a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_092f8408-772b-4477-8849-00f5807f5a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_59be4bfc-0a3c-48a5-bcae-44578ab80c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:to="loc_us-gaap_RestrictedStockMember_59be4bfc-0a3c-48a5-bcae-44578ab80c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:to="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1220f38-9bc1-4ae6-80d0-83b6e5233eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1220f38-9bc1-4ae6-80d0-83b6e5233eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1208a061-b0ea-4ebf-8ff1-212d8c67b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1208a061-b0ea-4ebf-8ff1-212d8c67b989" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesOperatingLeasetextualDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails" xlink:type="extended" id="i00551b79b0a0425c8e986b18a4326de5_CommitmentsandContingenciesOperatingLeasetextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeasesAreaLeased_e21cf3f1-b236-4b37-9681-a835ea530c44" xlink:href="halo-20221231.xsd#halo_OperatingLeasesAreaLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_halo_OperatingLeasesAreaLeased_e21cf3f1-b236-4b37-9681-a835ea530c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a7aebe4f-3632-49a8-992a-7f500a658c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_us-gaap_OperatingLeaseExpense_a7aebe4f-3632-49a8-992a-7f500a658c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b623f0e3-ed86-42c5-ab7a-295d125b3e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b623f0e3-ed86-42c5-ab7a-295d125b3e1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29af96db-ddaf-4716-a364-b95e640c7712_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29af96db-ddaf-4716-a364-b95e640c7712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OfficeAndResearchFacilityMember_9a66fa2a-e9ef-4166-b795-e29a7faae9d3" xlink:href="halo-20221231.xsd#halo_OfficeAndResearchFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:to="loc_halo_OfficeAndResearchFacilityMember_9a66fa2a-e9ef-4166-b795-e29a7faae9d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i901a5f57f9b04f6e8a4a9c035cb88510_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b40a68f-6b71-47eb-aa50-6c79ed46786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b40a68f-6b71-47eb-aa50-6c79ed46786d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_26aae95f-bfcd-438a-be62-7a6050cdabde" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_26aae95f-bfcd-438a-be62-7a6050cdabde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e1dfb19c-abd1-4425-8e7f-4d9b04a61fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e1dfb19c-abd1-4425-8e7f-4d9b04a61fa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6ac272f6-1868-4a0f-841d-cb37a7731bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6ac272f6-1868-4a0f-841d-cb37a7731bb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0d561360-5b17-429a-a08e-b7a77204b320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0d561360-5b17-429a-a08e-b7a77204b320" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_613c704e-437e-4106-88f3-9debd61a142a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_613c704e-437e-4106-88f3-9debd61a142a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_55fbfa29-a85f-44e4-9143-a434a978f97a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_55fbfa29-a85f-44e4-9143-a434a978f97a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2974e401-e571-4045-8bb2-63c7534e55f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:to="loc_us-gaap_DomesticCountryMember_2974e401-e571-4045-8bb2-63c7534e55f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ba979dbe-3d54-45bb-bc4c-3dd194ca3379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ba979dbe-3d54-45bb-bc4c-3dd194ca3379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_aa268f19-0573-455d-b773-374f8c309068_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_aa268f19-0573-455d-b773-374f8c309068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_ab115cd8-c5e3-4193-91d0-29d8cc405c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:to="loc_us-gaap_ResearchMember_ab115cd8-c5e3-4193-91d0-29d8cc405c83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_56cd7c9f-e72c-4886-8165-04dea944c6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:to="loc_us-gaap_GeneralBusinessMember_56cd7c9f-e72c-4886-8165-04dea944c6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_40142697-876d-4b13-a5ff-f23af1f8d70b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:to="loc_srt_SegmentGeographicalDomain_40142697-876d-4b13-a5ff-f23af1f8d70b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:to="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_24f411fe-1a36-42e7-8933-302e455e877e" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_stpr_CA_24f411fe-1a36-42e7-8933-302e455e877e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherStatesMember_3534c92d-5f26-44b3-ac97-c837e7ab34aa" xlink:href="halo-20221231.xsd#halo_OtherStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_halo_OtherStatesMember_3534c92d-5f26-44b3-ac97-c837e7ab34aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_c7938be1-0112-4ad1-b676-c52d3e1cb3a7" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_stpr_MN_c7938be1-0112-4ad1-b676-c52d3e1cb3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea47bd76-1a16-4c1d-8da4-f9747d371f96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea47bd76-1a16-4c1d-8da4-f9747d371f96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_bcfcb3d6-7f87-4fc5-a281-8d2e8c0a588a" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:to="loc_halo_AntaresPharmaIncMember_bcfcb3d6-7f87-4fc5-a281-8d2e8c0a588a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e95d893d-b904-4dbc-8ab0-a22a1ef72e53" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e95d893d-b904-4dbc-8ab0-a22a1ef72e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>halo-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_halo_DeferredRentPayments_0c92f63c-abd4-4311-be29-d12c4f721b03_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments deferred</link:label>
    <link:label id="lab_halo_DeferredRentPayments_label_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:label id="lab_halo_DeferredRentPayments_documentation_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments" xlink:href="halo-20221231.xsd#halo_DeferredRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredRentPayments" xlink:to="lab_halo_DeferredRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_29adb1cf-357d-4464-9a3e-3e250ac1de48_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_61a4b00d-c94e-4919-a558-da8b462d990b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_1c3c0b13-5154-4a7d-bfb4-af00b80981c5_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0a8945b2-0c46-4970-bc6a-fd2f72f3693e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current - state</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9311a940-a87d-4eee-be99-bdce191a8859_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2bc6d1fc-a9dc-403c-bc02-ec90e64785c5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9a5ebc5c-3eae-4165-9bf5-c4f34660ab83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Purchase Price Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f1586382-fd7d-414d-bdd6-e69ba0781207_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_17c75720-e066-4488-a6c5-ed7e8337e4fe_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9bba2ce9-c134-4e77-b385-9cfcc36776aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_55fc9925-507d-40a8-bf20-ddc9c2864302_terseLabel_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember" xlink:href="halo-20221231.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ComputerAndOfficeEquipmentMember" xlink:to="lab_halo_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_40e2d147-fde6-4a01-b8f7-b605021444dd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_57928e43-ae7f-4ffe-9d0f-908130555291_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_624df3a9-57f4-41eb-a951-b0fb2a5304c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_24495898-b20c-44d6-84c5-5a967b935577_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_45d0e3cd-b8cf-4121-ac45-74415037c98f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c23612b8-58fc-41f8-8d45-5a4f23ef4e9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95b102a1-5284-461c-8515-e6a90e85e53e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_640640ca-451d-4e8e-bf28-d61f1dcf16a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d60cc36c-9bfa-41e1-84f1-15d2ea73daa8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_4737b625-9ce9-4fa2-af84-935ba13871e0_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase maximum amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_32859dba-5288-4455-ac8a-7c581db4d8d3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f2565e2-ce8a-4450-b71e-49a90bc9153b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_067183fd-eac1-4dfc-930d-4b80ce715f57_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_b24550d4-3864-454c-9032-b09a3659ce2c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_8b61d1d3-ac43-4ab5-986c-23f201b86fcb_terseLabel_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:href="halo-20221231.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_86932f9c-76d7-4f39-8245-0889b6b96cd9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_d15eed3e-180b-4442-981b-20ac50620e09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_178a12eb-7ee4-4050-95ff-f6dbff6fddc4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_45cb6822-7a95-489d-988f-0c2a627c1f2d_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term&#160;(years)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms [Abstract]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_df53d449-8d35-4845-b337-89e6b89d4f18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b08cf5e8-0fd2-44d5-9e77-4166bd638169_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a3be5144-c25f-46b9-a67e-5847e5fed527_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b598320d-fd41-44b5-8391-bea4846b82c3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO product rights</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5c674fb3-b8e0-4db3-ba7b-3cb299237176_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3f1cd3da-bf78-4838-b488-5b4e56d5f5be_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_be45328a-6fd4-4310-bc36-9a66f06636d5_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying Stock&#160;Options</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_4c2df595-301f-481c-a43c-bb5759132c2b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b1f4c8b7-2f82-4d54-96a9-ae49b6fa1000_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_79a767c1-f601-47c6-856e-2a7dfadf8dee_terseLabel_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, accretion of liability</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_label_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_documentation_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability" xlink:href="halo-20221231.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OperatingLeaseAccretionOfLiability" xlink:to="lab_halo_OperatingLeaseAccretionOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_743ba919-be3a-46d0-91c5-e9d7b1eedae6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_20cfe383-d0a1-426e-a227-6085a87eeaf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_96ea6b83-48d0-4f4b-8f26-12b882131282_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ab4e640e-54e7-48b7-a6a8-b2406c9f2958_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_384d5989-1ac4-410c-a980-7f018fd545bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b6e1ea07-1ec1-4a72-ba60-fa4006a5947c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_78ce09ef-1d1a-4c95-af72-6876bbf36b61_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_f0dbf89f-7d9d-44dd-914b-5f6f4224e8dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a8c7b64-47c0-4bfd-b483-9f17afff4f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3b76895c-49dc-41fe-a69a-ec6d7acee84f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_716e9d89-60c5-4a47-85f7-2551e2c840a4_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:to="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9305c614-5eca-4870-8a98-8e78f4f6a008_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_093efd38-b524-40f2-bfbb-5df1bf1212c6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_180862ea-c00a-4394-852c-cdfaa189bcf5_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_ee903d7c-f5a5-42d2-aeb4-0eaa143dc817_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TLANDOProductRightsMember_d635d098-6012-4c35-84fd-fc19890aa1fb_terseLabel_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO product rights</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_label_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights [Member]</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_documentation_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember" xlink:href="halo-20221231.xsd#halo_TLANDOProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TLANDOProductRightsMember" xlink:to="lab_halo_TLANDOProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0b4fa6c5-007c-4823-a04b-921e754fe66c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3b99a30f-5921-49b4-8f29-78718bd68adb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_f95b8eff-458a-42bc-aff5-824f4e204451_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of outstanding notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ManufacturingEquipmentMember_f7440a53-ec4b-4172-9a4d-04213af3b94f_terseLabel_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember" xlink:href="halo-20221231.xsd#halo_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ManufacturingEquipmentMember" xlink:to="lab_halo_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_d439821c-839d-443b-a6f1-19a59f3a3b27_terseLabel_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_label_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_documentation_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:to="lab_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock_0737b5aa-78e1-473f-850a-044119ef9c80_terseLabel_en-US" xlink:label="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Asset and Other Long-Lived Assets</link:label>
    <link:label id="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Asset and Other Long-Lived Assets Policy [Policy Text Block]</link:label>
    <link:label id="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Asset and Other Long-Lived Assets Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:href="halo-20221231.xsd#halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:to="lab_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_768d418a-d764-4471-b1ee-b917172ab20d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d25bf84f-e547-4217-9976-3ff7d39993ad_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_19e3df2d-9038-4657-97ca-7c56aa72221e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c69a239f-6527-4fbc-af1a-17982e17fcbc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_af5f1f84-c5b0-4c45-8f70-ac992fe37857_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_627d9c81-78fe-4d8a-8807-4c1dce3477e3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8d620598-5e28-422d-b57f-2b388b7baaeb_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs surrendered to pay for minimum withholding taxes</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_60938c6d-87d7-467e-9133-06f42f1c9214_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral of unearned revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d3701549-2091-4367-9d40-646044064a9a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9ba6f1e3-0a64-4380-a110-2f3098b6007c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_30392e68-f759-45e1-9e2c-f55632f5c182_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_19a9feee-dade-49c9-9d7d-a61cdd0dd3f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PartnerAMember_2393a7c1-cffc-43ed-af25-0d29297e9f24_terseLabel_en-US" xlink:label="lab_halo_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_halo_PartnerAMember_label_en-US" xlink:label="lab_halo_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_halo_PartnerAMember_documentation_en-US" xlink:label="lab_halo_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerAMember" xlink:href="halo-20221231.xsd#halo_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PartnerAMember" xlink:to="lab_halo_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_b386ad10-9c27-4770-adca-80f9b51d4d36_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_ead9fe62-3c6a-4d40-871f-6bb1401d8411_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0be4d285-b0c0-4822-be53-adb8169559f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7d51fda8-ab97-4845-8cf0-06b41557b66c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_73bf50a1-f3d5-441a-ba59-ef2e0946eb5f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_260df955-e7c6-4a9c-af30-b0cbaee51562_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_c293e762-f2e3-47c1-b91c-427c62078616_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_432c3c6b-85bd-4c87-ac8a-f50730c36cff_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_5023148b-9a55-46a3-9dcf-a31d8b016af3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_b608b684-c1bd-464e-b443-054c8d34f075_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4541b91c-6c12-452f-887c-675bfc412986_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ab04bc3a-35f1-4de5-8d4e-c1e6a8757c5f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0cd79400-bd99-4330-bcc8-0b9837b2838f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_05cbeec0-1961-47e3-9c3c-aea52f9794ac_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_754cc5f8-a775-4fef-9095-6145196656a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_489c3022-fe97-416a-a341-93907213d7e7_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BE_35995157-6da0-4c62-a29d-173b6994e540_terseLabel_en-US" xlink:label="lab_country_BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belgium</link:label>
    <link:label id="lab_country_BE_label_en-US" xlink:label="lab_country_BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BELGIUM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BE" xlink:to="lab_country_BE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_37b32bdc-4956-4590-8a6c-d0f4a48209c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_74c0e614-6182-4e56-8ae5-4bacda1a30f3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_UpfrontfeesMember_32c74e18-a3eb-4308-9921-7d2f10159662_terseLabel_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license and target nomination fees</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_label_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_documentation_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember" xlink:href="halo-20221231.xsd#halo_UpfrontfeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_UpfrontfeesMember" xlink:to="lab_halo_UpfrontfeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_59dd1b88-0f66-40f7-9da3-fb7f9428e85e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_31a5aa73-c9d9-4399-a349-d81c277c8027_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f71fb53a-b9eb-4d20-a8d1-8a069eba8d05_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_28b9c0f3-1d46-4301-ad24-2cb2c2800d16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0f530af5-539a-40fd-bedd-a4ac4ee7b94a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_8bbc2a1d-cf32-4576-82c3-5440b9ba88d3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f56cea6e-2147-43ba-9f3b-f8cf1b79934b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in tax positions for current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_f39eb82d-355f-4c1f-962e-78c4f3c93af4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_9989c9f6-7f46-4fd4-b531-5596e8c62401_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_540bdbed-2419-4229-b8e5-85e88846b1d0_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_81c710f5-ef04-4064-abbf-91d95720e4ae_terseLabel_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees and event-based payments</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_label_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_documentation_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember" xlink:href="halo-20221231.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LicenseFeesAndEventBasedMember" xlink:to="lab_halo_LicenseFeesAndEventBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_596edfc0-8456-4e56-8317-8317b7ee0230_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_aa7dd370-ac26-46d8-af4b-070bc7120c3d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_59f84971-73b0-468e-ac21-79e4a8d7d251_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cc9e2c3a-6841-4e9e-89b6-505e0cca3d10_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_5dc66c18-007e-45e5-9009-c9c16e4b1c02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8979b699-3ed6-4c61-b743-b2ef4f0328f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_476157b6-5612-4d77-97bc-eb746cdfb1d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion rate (shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LongTermDebtIncludingInterestGross_abf8df3f-9a61-47ba-8a77-180e69a89c2f_totalLabel_en-US" xlink:label="lab_halo_LongTermDebtIncludingInterestGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_halo_LongTermDebtIncludingInterestGross_label_en-US" xlink:label="lab_halo_LongTermDebtIncludingInterestGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Including Interest, Gross</link:label>
    <link:label id="lab_halo_LongTermDebtIncludingInterestGross_documentation_en-US" xlink:label="lab_halo_LongTermDebtIncludingInterestGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Including Interest, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtIncludingInterestGross" xlink:href="halo-20221231.xsd#halo_LongTermDebtIncludingInterestGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LongTermDebtIncludingInterestGross" xlink:to="lab_halo_LongTermDebtIncludingInterestGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_427ac64e-5f21-4874-8e3b-cc27c5e67278_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax Bbenefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_351663ee-59ee-4588-8f77-1d192f6a1c3e_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a9d15f8b-b2a9-4b9b-8107-c5ff9888e2b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5e2cff6e-130d-4ad1-9dcd-71bfece8a715_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9476f8c0-3a05-4ff3-825d-32ca4cca7007_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_928ccb38-22b0-4ca2-a657-8d318c09b665_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_057c8253-9142-4aba-8930-2ebe5d6160e7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8515db69-8070-4871-84d4-2d5e51d596fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_fb88a011-5045-4cad-b86e-4bb4371df9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxAssetTransactionRelatedExpense_a931726b-5ee5-4aff-a11a-3090dabc20ca_terseLabel_en-US" xlink:label="lab_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction related expense</link:label>
    <link:label id="lab_halo_DeferredTaxAssetTransactionRelatedExpense_label_en-US" xlink:label="lab_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Transaction Related Expense</link:label>
    <link:label id="lab_halo_DeferredTaxAssetTransactionRelatedExpense_documentation_en-US" xlink:label="lab_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Transaction Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetTransactionRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:to="lab_halo_DeferredTaxAssetTransactionRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1a65ef70-8740-48c5-a6a0-c65851aa580e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_07bd5d02-226f-40cc-b5fd-5dc2d1e0d9f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_78f70670-3385-42d7-9829-96603c5ace6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0f154d4f-2f41-4716-870b-7d238a300025_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_5213c32f-eb4a-42e5-aa5d-bdce78b3577d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_df15da96-fe3a-44cc-b050-f3a05c17345c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, End of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_964410e1-8435-4852-a5f8-3ac8e2108579_terseLabel_en-US" xlink:label="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products royalties received from sales</link:label>
    <link:label id="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_label_en-US" xlink:label="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products For Which Royalties Received From Sales</link:label>
    <link:label id="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_documentation_en-US" xlink:label="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products For Which Royalties Received From Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:href="halo-20221231.xsd#halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:to="lab_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_fd1f9e93-7120-4338-af81-f3564a4d41d5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current - federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a2cefcc7-7f21-4191-a7cc-82213b8ab179_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9a2a949f-f7d8-427a-a650-cc51b064d1f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_efd79ac7-70a9-4ae6-bc0e-103dd01e7278_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7c5559d6-ce83-4f8a-bc90-ad70e260bc4c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99b6331a-64fb-473c-8799-49208425af77_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_07cff7df-397e-4fd5-a71b-d83012184527_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_de7e844f-1ffc-48aa-bc0a-a18ae4e7f32a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5a10950b-467a-4adb-93e0-4ad4dc878514_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3cb3356e-ec07-4b30-8edd-7cec336ab232_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47c12bca-e2d2-4709-8c64-72a57d8fb4d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4944a941-6086-410d-b930-abf820515b28_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5bf0bfc7-199d-490a-b883-cc28cd76b231_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_f5ec8d76-b9f5-4ece-b4a6-45e1cff8618d_terseLabel_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_6cd69530-c496-4d0d-8215-837b7331f603_verboseLabel_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Convertible Notes</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_label_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:href="halo-20221231.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:to="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_JanssenMember_58a4845a-eaed-4e9a-bacb-9ecc8a7c4ecd_terseLabel_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_halo_JanssenMember_label_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_documentation_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember" xlink:href="halo-20221231.xsd#halo_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_JanssenMember" xlink:to="lab_halo_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1bb724d9-1964-47d3-ae00-61b44c7c86aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_02a59710-b63f-4841-b579-d96d90d3d4dc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6a8a7170-c5ab-4b73-a265-61264897db21_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7f1d0d47-af74-4f43-a299-dc37c230a719_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e1a30992-de43-4df3-8ab8-69f3f3ec7f57_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ForeignOtherMember_eec90ac4-ed10-4ef5-86c4-61c273ef6c32_terseLabel_en-US" xlink:label="lab_halo_ForeignOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other foreign</link:label>
    <link:label id="lab_halo_ForeignOtherMember_label_en-US" xlink:label="lab_halo_ForeignOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Other [Member]</link:label>
    <link:label id="lab_halo_ForeignOtherMember_documentation_en-US" xlink:label="lab_halo_ForeignOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ForeignOtherMember" xlink:href="halo-20221231.xsd#halo_ForeignOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ForeignOtherMember" xlink:to="lab_halo_ForeignOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_153f6bc6-a4ee-4025-91d5-9026ec9ff498_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_db3bc7c7-6f6b-43c1-a743-bf07194af6d4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c68aa7a4-d78e-4a91-9a56-4d4ae3635183_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab399042-c8cb-49d8-a394-95d6e942dd58_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expense and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8c3b0fc9-c861-4a1d-bcdf-01fc95600970_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_99991ae0-482e-4f49-b30f-a6c651f386fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ebb92ffb-1aed-42f4-a2d6-c17a62e9985a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9155c2f7-3ad1-4a30-ab2d-5e54d843325d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4b3f2ac0-c220-4e6c-be6d-37b00657ae04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_2517836c-3147-4431-87b9-35a453f0301d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_e7903406-dc50-4ad3-8f85-a074e6e27c17_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OutstandingAwardsMember_3864c11d-c57b-4359-8950-8f0a7d7a0a46_terseLabel_en-US" xlink:label="lab_halo_OutstandingAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding awards</link:label>
    <link:label id="lab_halo_OutstandingAwardsMember_label_en-US" xlink:label="lab_halo_OutstandingAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding awards [Member]</link:label>
    <link:label id="lab_halo_OutstandingAwardsMember_documentation_en-US" xlink:label="lab_halo_OutstandingAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OutstandingAwardsMember" xlink:href="halo-20221231.xsd#halo_OutstandingAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OutstandingAwardsMember" xlink:to="lab_halo_OutstandingAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_91f769e6-fcb0-4dda-9557-e5484c332f67_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e856cea8-27c2-4f21-ba59-082a577e9d79_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a87a3646-d7c8-41ad-a72d-e5c7b0d10219_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0d55f081-1d8d-464e-8b5b-c6bf7123f941_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_56ae1894-9def-4a85-add0-1fa29571f671_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_4feeacf7-e3b3-4622-9a84-cd556acd6b91_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_93080916-f1f0-4236-b101-b4da288dd015_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in continuous unrealized loss position, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_19534fd1-35ba-409b-acf0-27f8f0790734_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da25f10d-0c25-4fd6-b913-81f5f0bd3942_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f63bd7e2-f1ca-4273-a896-de8fcd8c3df3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThirdMember_60eafb3f-113f-4d70-8678-7a732771a2b5_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThirdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThirdMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThirdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Third [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThirdMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThirdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Third</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThirdMember" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodThirdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodThirdMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodThirdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_79773ee9-8fa2-4b12-8b44-72869981705b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one but within five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_ab8821db-516e-4fb4-b889-b6d1117bce21_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_459dd7cb-942d-4faa-a982-1263e173ddf9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_2c6b7366-ff33-4dbe-9d2f-f053a7346ae5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_56e1cc53-1aa1-47e9-bbb0-6e7114f11921_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3e242037-b872-40c8-bbf5-2fb305ce1b7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e223fe27-c881-49b2-997a-0d4182246c37_terseLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2ec1003d-76f7-414b-a00f-508281900a09_totalLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_02d69164-2deb-4467-871c-bb5033668716_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_3531b1d0-1ae3-4ff8-a86e-b89a9aeaf947_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma revenue of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0f73599b-205e-4459-b9b1-a58eabfd9613_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_5e89f666-4d3a-4c2f-b8a3-7fc9ec76d40a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TakedaMember_bbfed958-92b8-42dd-9633-d52998ef1d65_terseLabel_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_halo_TakedaMember_label_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_halo_TakedaMember_documentation_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember" xlink:href="halo-20221231.xsd#halo_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TakedaMember" xlink:to="lab_halo_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7123fcf5-b2c1-4a12-b857-0b2e396019d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e66f1975-262e-4f5b-a8ce-42dd0b887382_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_c92cc576-2517-4adc-a055-7aef2ed7bb8c_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Antares equity compensation awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_754ff9fd-0569-44c1-b9bb-41d4b3ffe870_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_806cfe60-1c37-408b-836e-2af5879a6c20_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after expiration</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bbccb29-6f7e-4ef4-845f-4a04fd518ec9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_c4aa78bd-61f7-4909-86e7-4981072716c3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_3d129db5-05b1-4b9e-8337-b08441d08f8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced conversion expense related to convertible notes</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_8b2cb447-0e5e-4fe1-a9f7-51abc2ad98cc_terseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced conversion expense related to convertible notes</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_label_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_fec10469-8fb5-4ab9-9e26-03efbdf52947_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b98fe8eb-dd91-4303-a2e4-841da0acfff1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2981309d-68ca-45db-b2ce-47be0f71a8d8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_add00225-011d-4f8a-aa03-81c5362ff2c3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6a830ffc-3ef1-484e-b218-dfcd2a0a32e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6c11f789-4483-4717-ac55-ec1aa961e96a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6677cac3-9930-43df-9214-2f3f53920806_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2c7e6eef-b7d3-4337-a3ee-9fff99a48a80_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_594ecf67-900c-49b1-aa1e-d0f31104cf8d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2a979bb5-b7f8-4f52-95f9-5c0e5c03c28e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8ac07fe3-f69b-4062-b283-730979f9ee34_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_33609052-d4e5-418e-9a28-82d7d7766394_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_6bbdde2f-f731-4adc-ac57-ce00d23d0f57_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_9152355b-ec4b-47b9-9905-351b75419142_terseLabel_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_label_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Percent</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_documentation_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:to="lab_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_177f9705-1365-41d6-b61a-36154b038b06_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid for conversion of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_4aa66589-1dba-4c50-a009-6f40e95ede36_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold consecutive business days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_label_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:href="halo-20221231.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:to="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_53f3bcd7-4294-4744-b927-a4b05d5a3831_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2d5446e0-8b30-4045-b5b4-f4b99ef01e6b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1f883a7e-5deb-4136-9c96-9b35994d258e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful lives (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_50cbb468-513c-4afe-a9b7-4d71acda7547_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_102ed4f8-6401-4419-9884-fc23396dfea5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_27bb43f6-871c-412c-8cb3-c3da75c0c32c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit) (textual)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_4a4b66cf-97b5-44be-9c6a-b5397de766cc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PartnerBMember_50c1b9a5-4d21-443f-8a01-a6f0df6ebe8e_terseLabel_en-US" xlink:label="lab_halo_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_halo_PartnerBMember_label_en-US" xlink:label="lab_halo_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_halo_PartnerBMember_documentation_en-US" xlink:label="lab_halo_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerBMember" xlink:href="halo-20221231.xsd#halo_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PartnerBMember" xlink:to="lab_halo_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_5a9b2633-fa5c-4d16-b7ef-6dfc97e3c72d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk, Sources of Supply and Significant Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_03b079c7-9be9-4e9e-8604-c0f4a42468ce_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0022ecf7-7970-4e54-a7f5-bbbc9eda5ba4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxLiabilitiesRightofUseAsset_c0689f5a-53da-4769-9e00-119acbf93b74_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842 right of use asset</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesRightofUseAsset_label_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Asset</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesRightofUseAsset_documentation_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:to="lab_halo_DeferredTaxLiabilitiesRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_6410582a-c154-409f-abe2-6d642647de6d_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration related to cash bonus awards paid by Halozyme</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_a05005dc-12d6-4719-b7a5-fbb99add0408_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TermLoanFacilityMember_79ee2914-bf59-4558-9a84-4825362dff20_terseLabel_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_label_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember" xlink:href="halo-20221231.xsd#halo_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TermLoanFacilityMember" xlink:to="lab_halo_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b1b49623-f899-4a51-b463-8e6206414c16_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1151f324-b4a9-4f5e-8a11-ca86b2937791_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_91134a44-dee6-408c-883a-96e244dc900c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c704643c-3567-40d3-84a9-462e280b960f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_872431de-b508-4bff-a855-e3e54d0f84b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_c4045a00-83a7-451d-bc05-02b09e93708f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_a725d1b6-c29f-4bf4-a47e-2baca821fc33_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4e2cf8a0-3b3c-4f09-b811-9b64b8d6f5be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8f9b827c-c75e-4c52-80d9-ffffc7ae0bef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3e070e7-f57a-4235-a04e-9da89bb1738d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_17b469b0-b135-4526-813e-8c49ac59262c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_454afe2d-535a-417e-902f-77bdc1777889_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_25c5bcad-2fa6-4a0a-92bb-8f1422476c73_terseLabel_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:href="halo-20221231.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_49151af2-2fb3-4455-be08-4350478da5fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4823e8c2-8b8d-4d10-9298-0074b49f3b64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_53ec9f5f-1995-4d33-a76a-7d6f71910635_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1635ddbf-7664-4a3e-b104-1de8ee3a4ddc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and other contract assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c12ef958-5e19-4a24-b50d-1e14d3410d7c_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_fa5c05ce-fdbc-47d9-9fe2-ddca382e2b30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_eab56362-2197-41a5-a862-d9de1f6c578b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_464bc3c7-b2ed-489d-b18d-0c2b43da6ef8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7119d8cd-cd4e-4d2c-b89e-61c09eb99293_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da302f05-ca8c-42f3-8c93-b7234c357378_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d1972680-809f-439e-8da7-20a3b9ad64e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_461aac40-468f-4aa4-a410-b591b8f9bb7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_82d618a2-1bc3-415c-a223-45ea25bb4b07_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_21a3e1e3-9e4e-46e9-8143-590f54deb6f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_f12ac7dd-d115-405d-a49e-f43800ddef56_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_fcba2f46-534f-4391-9a90-9b7faf1bee63_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_a8acc631-2b54-477b-83de-c32fa94de433_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_079db715-cc0a-4a69-900d-9f4effb3a806_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0eb21425-cfc8-48c5-811f-7e6e2b7a6f71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8d5af6bd-4a75-4304-8b9b-2db399fe6fc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a8cb9db3-e9bc-496f-b204-86d0f0c64b9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0521b1a3-5daf-4d23-935c-e5704396ffe6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eb4a1b43-c013-49d2-adf0-97ec3ee555a6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80adf19f-6b81-4957-98af-11a253855883_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_1b28fa54-d901-4f60-a6ba-64743fef99f1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f104288-52ef-49ef-92c5-79553b28f617_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration for Antares shares outstanding as of May 24, 2022</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_ddba9833-af9e-4650-9005-46f414b00932_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_0117f7cd-8165-4a53-85c2-1bb5c2a03b1f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_39db5b87-84a5-4bc3-9ddf-f5eaef4a4631_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense By Type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8033b8e4-b718-4ac6-b30e-57ab0ad9882f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Fair Values of Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_05cc6ced-6e8e-4606-ae69-0281171f838d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_987931b7-f8fa-4822-bed6-24a807f704e3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_83b4658c-4b78-4f50-a6ad-8ca1f9416d70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f23acd9e-cb0e-438f-8ec1-47cf5450bdcd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1a425747-1dd2-4327-b572-054a63f59572_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2e3dfbbb-38a9-4ef9-948b-b9be7874a62a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c7ac6457-08b6-4f1d-8f24-81b28e273c5f_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f2022a77-eda2-4d72-ad99-d48682edfadd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_831804ea-fefe-4561-9279-a52d57a4f7e9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_351bea71-1106-4de1-88be-d1881d4370dd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationAbstract_8eb2c3fd-adc6-457d-9eee-136ed8d773de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_aa8301b4-31ef-4419-b895-2f251f239d5b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4f2e5720-6941-44e4-a400-5d0968219745_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_326c07d9-1b56-4519-9fbe-cecc1d6a6bd0_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_690d8dba-87c4-408e-8759-261284d64c53_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_23b191a7-d89c-4506-a213-93104f8389ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9d693f37-f189-43c3-96f4-0a9b8dbca0ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, End of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_60ad1bae-bf10-4e28-9aaa-fe405a00a24b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_27d8aa48-1d8a-4cdb-824b-d4788238c7f1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_eac62c73-7727-412c-86c3-135b2195b7cb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_76f7eeca-1f07-49e1-b241-f7903b82f6cd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4511542a-4634-4160-a8c0-31edeca8c195_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_c75f9fdd-5420-4cca-a4f8-15b6796eb7af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PartnerDMember_f038f633-3f9e-4f2e-9176-139206b0b691_terseLabel_en-US" xlink:label="lab_halo_PartnerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner D</link:label>
    <link:label id="lab_halo_PartnerDMember_label_en-US" xlink:label="lab_halo_PartnerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner D [Member]</link:label>
    <link:label id="lab_halo_PartnerDMember_documentation_en-US" xlink:label="lab_halo_PartnerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerDMember" xlink:href="halo-20221231.xsd#halo_PartnerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PartnerDMember" xlink:to="lab_halo_PartnerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_69bc9f1d-dd0a-4290-9717-1d60ddbaba32_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_aa282c3a-208a-4e2a-8a5f-53bdb5011ea8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_afa9eb28-d69a-41e9-9b48-4b64f2b4845a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae893855-89e7-4b7b-9dc2-880f2ab1e762_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_6bdb1e1e-e9ac-4b78-9450-83bbd822ed9f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_33a16643-cede-42e5-845c-fbd3182a697c_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a8e3a6f1-d8f7-4c87-82ec-34bd3866a282_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_04268a65-351c-49de-b9cf-dcb491d11b44_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_4261b17a-44ad-470f-9846-72843fb607f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Ffee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_65f9b76b-7f05-471a-a0ad-7a3785a826de_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f821ae3a-e3a4-42d2-8612-361767a12641_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_6d4ad332-9849-4428-a7cb-25b509499729_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_440f31a5-e367-4857-ba91-347853d3ad7e_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchases, employee payroll deduction percent minimum</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_29d17a2b-9650-44d9-b2a6-b9124ba55dbb_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_15ad377e-b805-4065-908d-1bb84b1639bf_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d900fb36-1580-4cce-8782-4975a4d0d12e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e7deb65e-ea39-4d47-8702-a51553d95db4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term&#160;(yrs)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_3f5eeed5-4e00-48ca-9102-45a2b870398b_negatedTerseLabel_en-US" xlink:label="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Additional Paid in Capital, Capped Call Transaction</link:label>
    <link:label id="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_label_en-US" xlink:label="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Additional Paid in Capital, Capped Call Transaction</link:label>
    <link:label id="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_documentation_en-US" xlink:label="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Additional Paid in Capital, Capped Call Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:href="halo-20221231.xsd#halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:to="lab_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_da9e38e2-e11d-47cf-9ad8-a8bd8d4b68f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e2acca4b-86ab-4866-9d84-c3f850f3ddd5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fb3f4663-0105-4f72-bb8d-e50ff4c80fef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_7f76901b-efd2-4fed-965e-7ddb15212f43_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f39f670c-79fe-4e15-ad0c-626245032c60_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_2ceba61b-08aa-4af5-902e-0f8afc465705_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 2027 Convertible Notes, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevelopmentFeesMember_5fd75930-1296-430f-be8e-f08b6619319d_terseLabel_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Event-based development milestones and regulatory milestone and other fees</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_label_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_documentation_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember" xlink:href="halo-20221231.xsd#halo_DevelopmentFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevelopmentFeesMember" xlink:to="lab_halo_DevelopmentFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e4be381a-bd3c-478c-bd63-95bda03ec698_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_449f58e5-c3c9-4383-8c55-4c4e22b4e238_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_128aa8ee-e2a9-4f8f-8219-6de664ffb586_terseLabel_en-US" xlink:label="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, increase, from acquisition of intangibles and inventory</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_label_en-US" xlink:label="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Increase, Acquisition, Intangibles and Inventory</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_documentation_en-US" xlink:label="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Increase, Acquisition, Intangibles and Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:to="lab_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_32d09eed-c26f-4586-a3b2-2dd64bbf9426_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Coupon Interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ccccd2f5-e92d-408c-b846-fe9374aec041_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets_ac84b379-e1b8-49ca-a613-615857db6a64_terseLabel_en-US" xlink:label="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets_label_en-US" xlink:label="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:label id="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets_documentation_en-US" xlink:label="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:href="halo-20221231.xsd#halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:to="lab_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_10c6ace8-e238-489b-ae53-1707392748d9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4202838-700d-4221-9295-c222beb6b84c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_efd9ae54-2118-4090-827b-ade88c23f89d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (benefit), net of federal income tax impact</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d9147a9d-ea15-49b9-9675-9f47e866f523_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred - state</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_50046010-617b-4ff0-a77e-c3b09d81605a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9bab75bd-579e-4117-8330-938a1db6b9c5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and orphan drug credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_26b2bf51-5fb0-47e9-9d5a-2dc6fbfeb584_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_f5779554-2409-4635-aeee-5f8dd857a24e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Level 3</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_754708a2-af6d-4b98-a60e-4e4d4331d6a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_73872a65-56cb-495e-9a6c-9fb8f4b08096_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_6ba78dc1-ddca-4e12-8ba5-ec0733dd9731_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Award, Unvested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_9e0bfe16-8082-404a-a8a8-74ee3fce7e42_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to partners</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:to="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1f51aaa8-6f7b-4aff-8523-8b88ad9ac852_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_714e2148-9259-4f1e-9aee-ca9545e70d9e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9c22254d-c565-4e6b-ad67-3fc4b757c9cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CliffVestingFirstAnniversaryMember_aa8dc7e2-742a-4b25-9c01-e008d76f9a69_terseLabel_en-US" xlink:label="lab_halo_CliffVestingFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff Vesting, First Anniversary</link:label>
    <link:label id="lab_halo_CliffVestingFirstAnniversaryMember_label_en-US" xlink:label="lab_halo_CliffVestingFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff Vesting, First Anniversary [Member]</link:label>
    <link:label id="lab_halo_CliffVestingFirstAnniversaryMember_documentation_en-US" xlink:label="lab_halo_CliffVestingFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff Vesting, First Anniversary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CliffVestingFirstAnniversaryMember" xlink:href="halo-20221231.xsd#halo_CliffVestingFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CliffVestingFirstAnniversaryMember" xlink:to="lab_halo_CliffVestingFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_b2c2ec0f-d81b-4f75-af63-7354c1383829_terseLabel_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of proprietary products</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_label_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales [Member]</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_documentation_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember" xlink:href="halo-20221231.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProprietaryProductsSalesMember" xlink:to="lab_halo_ProprietaryProductsSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_088802b5-068d-40a6-b21f-4383b9222c13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dc0a01d9-1006-4855-94de-e9f6448e18ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_fd5599ce-8226-4389-8609-c019d926c7a1_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f4572751-07dd-46bc-94b1-02aa1df367bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_a0163766-b289-4394-ad3b-71a2d707660c_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, cash paid per acquiree share (in usd per share)</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PurchaseOfCappedCall_a7c72a77-a661-48ab-9f5c-afc95fa5a609_negatedTerseLabel_en-US" xlink:label="lab_halo_PurchaseOfCappedCall" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call</link:label>
    <link:label id="lab_halo_PurchaseOfCappedCall_label_en-US" xlink:label="lab_halo_PurchaseOfCappedCall" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call</link:label>
    <link:label id="lab_halo_PurchaseOfCappedCall_documentation_en-US" xlink:label="lab_halo_PurchaseOfCappedCall" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PurchaseOfCappedCall" xlink:href="halo-20221231.xsd#halo_PurchaseOfCappedCall"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PurchaseOfCappedCall" xlink:to="lab_halo_PurchaseOfCappedCall" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2dbdddb0-2f5c-46b9-a1ea-9f5c78cfb9a1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_11121301-4f91-417a-9c02-20a5bd6dff7a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_077efb32-89f3-41a3-95ba-176237ec18c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_0a977aa2-a5f1-4901-b527-1a54e5585629_terseLabel_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs, RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_label_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_documentation_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember" xlink:href="halo-20221231.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RSURSAandPRSUawardsMember" xlink:to="lab_halo_RSURSAandPRSUawardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8ad022b1-9360-4427-a0fa-2d66be7c1812_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_bbec1427-304a-4723-b10a-c3804dbe7906_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0e39c067-2ea4-40e8-9a61-31abff0a9ed8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (accretion of discounts) premiums on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralBusinessMember_33218c84-710d-47cb-9d2a-e9e7eef17277_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember" xlink:to="lab_us-gaap_GeneralBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4a66e5be-5c76-484e-a298-2cdaf70d1a2d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_7eff6825-b0be-4dbc-b8a9-916200ceef62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, End of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_adbaab37-eab2-4e97-82c2-6b91866e378b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_e06e320b-f55e-414f-aa03-c6a09b45dc2e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_fbbe63fe-30cf-4a66-b5c9-2eb38fbe94f5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b2e5183c-9cb9-43d3-8cb4-5c23c4a24906_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bd0e9592-a9da-49d6-a3b8-fb9a8ac5d899_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f4ceddd0-f629-42c6-963a-240131811db9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc8e4cb7-8f45-4702-9047-a2e078f5adf5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0973b2e7-5b65-410b-8bd7-cf6ec6663391_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_52e02e6b-e66b-4e95-bd70-b58312713892_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_b5298577-3e83-468a-8a77-f933d45542ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8ac1bb81-0ee5-4662-abe2-150681871052_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fd1d3cf3-ebef-46db-b0d7-6a6b5fa8980e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4dc5bf9e-0348-4d39-999c-7fb1ee5b0920_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average stock outstanding - diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5da4747e-feff-4bd6-8855-670d5b2aa4d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2017RocheMember_ca4590fd-1fa8-4b24-aa0f-2030e2325275_terseLabel_en-US" xlink:label="lab_halo_A2017RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Roche</link:label>
    <link:label id="lab_halo_A2017RocheMember_label_en-US" xlink:label="lab_halo_A2017RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Roche [Member]</link:label>
    <link:label id="lab_halo_A2017RocheMember_documentation_en-US" xlink:label="lab_halo_A2017RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2017RocheMember" xlink:href="halo-20221231.xsd#halo_A2017RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2017RocheMember" xlink:to="lab_halo_A2017RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_33fa0114-7e40-4a1d-9d4b-15c8749786bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_9ba46c54-2c20-41dc-b312-ebc120018b60_negatedTerseLabel_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent" xlink:href="halo-20221231.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedLiabilitiesNoncurrent" xlink:to="lab_halo_AccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3f17c9eb-c205-4ccd-9edb-e3ea604a3ad4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1c526610-be34-416e-bd44-094bbbedab48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_16509a5c-b22e-47b0-a07f-342488a1d247_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3626c7ec-5205-4ac8-b1f2-76975c4fee4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_72f1b941-b0aa-4d27-a55c-54cb8b4160a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_57ad108a-10e8-4ad7-83b9-02aeabd61fe2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_06694908-51f3-48a1-8dcc-fe2689a0c911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_30f049e7-d18c-4298-9f05-db91dee0bb7f_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e6f94d1-2ca3-437d-bf9d-a65b4e7c39ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e158511c-2aa9-460b-8aa4-5763bacf7b3b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_92d34284-d94a-4f37-8a96-25fbef9d3c8b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79a3298a-f875-4fbc-8a47-a55b81bfad6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0967d395-6a7d-48f7-9663-83ce6ebc0b91_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2d8d3e18-fd95-4bcb-bc7f-642f5d57b4e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ba19bed9-c35b-405f-8041-6bbcd2010650_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a598e818-7282-4bcb-9278-06cec0a48920_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_99454132-749f-45c5-8403-b9171074a9eb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e903678a-677b-45ec-af9d-695bbe10164a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tax withholding for restricted stock units vested, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0ad9c87c-51f3-499c-958a-e5b432cc2868_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2021ESPPPlanMember_fa7fff7a-8461-4aa6-901d-27e0fccc4855_terseLabel_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_label_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan [Member]</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_documentation_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember" xlink:href="halo-20221231.xsd#halo_A2021ESPPPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2021ESPPPlanMember" xlink:to="lab_halo_A2021ESPPPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BulkrHuPH20Member_7b0097c5-6078-4411-92a8-bd1498f5eadc_terseLabel_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of bulk rHuPH20</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_label_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 [Member]</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_documentation_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 for use in collaboration products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member" xlink:href="halo-20221231.xsd#halo_BulkrHuPH20Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BulkrHuPH20Member" xlink:to="lab_halo_BulkrHuPH20Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_07d09120-41bf-4f78-8ad4-56e9f5cbe2f8_terseLabel_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued outsourced manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_label_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_documentation_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses" xlink:href="halo-20221231.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accruedmanufacturingexpenses" xlink:to="lab_halo_Accruedmanufacturingexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6cb620bb-fcaa-4861-a8a2-36defed22f98_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_8adca0e5-b8dd-462a-ae8b-8bbaf77bf9a8_terseLabel_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to licenses granted to collaboration partners</link:label>
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_label_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Partner of License and Collaborative Agreement</link:label>
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_documentation_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from partner of license and collaborative agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:href="halo-20221231.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:to="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ac829eeb-5cbe-4e99-98b8-8a58f13dde3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, End of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_10c4aca9-1e80-44d1-8a80-78c6a769ab88_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a8ed4f5f-cae7-41db-92cb-6bb4c28f9263_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_4c62f82f-fa42-4d1f-8808-bbe1a80ee7e5_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:to="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_439f55aa-5850-414e-986a-09c2b04f2919_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bbd76b34-42be-4f93-861c-89b23e6beac1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_269897ba-4533-4746-b3a3-c32e460db430_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption and Pending Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_700cbfdd-5f5a-4f56-bed9-c0f94d525e33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_28bec9a3-1066-4744-a129-4fb3fe8cebda_terseLabel_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_3d1a9b1d-0d0c-4aac-8f97-5139254144bc_verboseLabel_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Convertible Notes</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_label_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_documentation_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:href="halo-20221231.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:to="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_86b52d39-395b-444c-b750-88468911449d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_db6cc163-cbea-4da7-afe0-a2c980fee1e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_237e02d0-a8d5-47c5-882d-5ff287648645_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_4cd54220-99b6-4df8-bab5-e66d6866f599_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_439faaa3-1581-45ac-a266-16f6fe58e447_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_f346bc4f-917e-487f-ab1e-c5bb4b75fa80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ee89a932-edaf-451e-9314-8900cc3298cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value -finite</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_73d9fba0-0abb-44fb-9dff-9f7d5a3f201d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value -finite</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_211374e8-af09-4080-a243-e3bdbfabad07_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0226dc18-856c-4d73-b8c8-c8bcc66385b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_d15bac3c-0adc-48ae-b521-acd4cec22f02_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_323ed881-09bc-4478-ad41-512523962128_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9037566d-4711-4765-a485-c9f1fbc5bc08_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income subject to tax at other than federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_6f4c92d1-714f-4c86-ab5f-a69dd569c183_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in continuous unrealized loss position, less than 12 months, accumulated loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_1d8cec81-a12a-4272-adb7-75bc32423f37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_1eb31990-2df7-4873-8b5c-7f4921c74198_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from other product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsales" xlink:to="lab_halo_Accountsreceivablefromproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_10506b96-bfcf-42c1-9cbc-098f61a89c73_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_08b899bb-4537-4e2b-87d6-18214cc206a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0591b5-4d68-4770-b299-20251f2ccac5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4b01313a-8831-4b29-8bbb-c7de1af8ee1c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f91aa839-2d34-4313-b665-1a05bc2bbd7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c9ad1e07-585f-41ba-86fc-452ab7c89bc0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_b0001171-220b-438b-aff6-379674edd894_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_40f5562d-c41d-44df-b970-1f3b306e91fa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d1c752c8-dfbb-4199-b547-1f57961ff1d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, End of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c0825ba4-3f27-4510-9442-e2cf131c3692_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70a0c0ee-85b1-43db-ba48-aca83289afc8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense (benefit) at 21%</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_92284c2b-779b-4ac1-9e2e-d6dfb2b17956_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity under Approved Share Repurchase Programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_83fa45bf-133c-4914-a464-ded0d1bb77e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_2bc40cc0-be4e-41d8-a3fb-be9f224f7dfc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9cd8e236-f86e-49bf-ba20-eed34b2b2a39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_14953f22-1e15-4b2b-b810-6cb89bdbeb29_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_00061eff-3526-4733-b0b2-491a1b313f8e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_06821584-4f13-4d74-9de1-35c0349b6f6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b0fd2595-7120-4fbb-90f2-90df7b11760c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0641a3c8-048f-4589-b177-a37e4d1cf5cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_02a9d6af-92b7-4458-95c4-d2901c6d840c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and payroll taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OtherStatesMember_170bdd54-b0d2-4a9a-819a-273997a24070_terseLabel_en-US" xlink:label="lab_halo_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States</link:label>
    <link:label id="lab_halo_OtherStatesMember_label_en-US" xlink:label="lab_halo_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States [Member]</link:label>
    <link:label id="lab_halo_OtherStatesMember_documentation_en-US" xlink:label="lab_halo_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherStatesMember" xlink:href="halo-20221231.xsd#halo_OtherStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OtherStatesMember" xlink:to="lab_halo_OtherStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c96d5633-2615-4bd6-9e78-f92f7c440163_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7cefb469-5098-4648-b2fe-765e0e6f05ae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7d034fad-b0e2-44ba-b183-ca0eec21f5f3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ad0c3b71-247b-4cd1-9014-2c60dcada9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Maturities Interest Payments of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3cb12536-46e7-4b00-b593-7afd63555f0e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9daf8100-5bd8-4f1a-b1d3-6580f7566fa2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_28959bca-55ae-4209-b5b5-305286a6f7d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_71dfb859-fe61-45b0-9505-129ea72696be_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_4c29932b-ae46-4934-b68c-ca41a1b28e97_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c375c406-20cf-454b-892c-0e90167a0049_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_11c64aaf-9878-41dc-a9be-539fc740078b_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATRS-1902 (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6b9c8652-e6b7-4dc8-abd2-10ba4007322b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_570df085-b086-49db-a215-8fa50f9916dd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2d5b9e6f-7132-4854-9117-967e9c4c9933_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3cf15ba2-5c3d-4e36-88eb-2f803cb9b5a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeitures and Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8a3d91cb-63a0-464e-944d-8c2405613c76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca93101c-bf5a-4b71-b183-cfb90c0abe19_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_269c1cb0-1815-4ba7-8b3b-f9e133aa32a4_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proforma earnings loss of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b45b5f24-a052-4a30-a6c8-ac06cfe72277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7a7385a6-fb87-4f5b-b36b-a55b455f1043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6be5cc5d-2be2-4ec5-95b3-cea4818a32c8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevicePartneredProductsMember_829beb95-a510-4379-b039-2a984500b771_terseLabel_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Device Partnered Products</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_label_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products [Member]</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_documentation_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember" xlink:href="halo-20221231.xsd#halo_DevicePartneredProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevicePartneredProductsMember" xlink:to="lab_halo_DevicePartneredProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_5a41d6b2-681d-4e14-8a25-997dcd0f3a31_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d41319d-5c72-4bf8-b7c1-bfccc5d5ae00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CreditAgreementMember_fa8ac3da-89b0-45a6-a470-41e63349a891_terseLabel_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_halo_CreditAgreementMember_label_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_halo_CreditAgreementMember_documentation_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember" xlink:href="halo-20221231.xsd#halo_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CreditAgreementMember" xlink:to="lab_halo_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0475248b-6274-40e4-97ae-ecb12de307a0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for conversion of debt instrument (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_ea9662e8-c24a-4313-9be8-49440edcf656_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ee9e5f58-3387-4125-93b6-7b027359df66_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1ae554f8-b99e-49c8-a73d-997e5c51cdc1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f2dd2244-bd18-4338-adb5-0d349f24d713_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1da7b227-b6ec-4936-94f0-dac20396f25d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Ending weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a141290c-ce8d-4336-b91e-847889bbc321_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ResearchEquipmentMember_eb76a20b-4af7-4ce4-b8a7-3f750c4d7315_terseLabel_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_label_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember" xlink:href="halo-20221231.xsd#halo_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchEquipmentMember" xlink:to="lab_halo_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_eb557b7f-3a72-4b39-9bfe-e7a85db89b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c4f2602a-95b1-4565-8ae2-d87c74cf5fbe_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7abdbd51-20c4-42c6-8492-fd15b0eb419f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d82a0955-c8be-4f55-919c-3f40a8af4a87_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bc33581-5eb2-49d5-a510-98ec127ee4f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff9122fa-a13a-4b62-91c9-18f13f082e9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7e609456-9b05-4618-b7a1-071559b4d2f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_36d7bce7-ede3-4ac6-855e-889e837001b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9fde2eb4-8bf6-4e75-b224-bad28f5b1888_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81026f3d-2e5c-442d-bb4b-848a1c97fdfe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a7369e25-03c1-4c0a-bb4a-42352e5fe37e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_27c05904-4e12-4acb-b3b0-bf67fb397d13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e292dcf4-9f89-40b4-b698-e44050f10ccc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_7c74cbff-698a-4624-8b15-2dde563fa42b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_38ce6fee-c167-4516-bb16-8c43f56dde43_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6add8236-22d5-4a9f-9887-cba8171cbd1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information (unaudited)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8bfad173-c815-4147-9ed4-e2346c948b86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_674dce29-806b-44ae-bd13-b6c9cd78b611_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchases, employee payroll deduction maximum percent</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_aa95f882-fbeb-4db2-9d46-961378d6b749_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4c47b778-f011-4c4a-b3c5-7ddacb4531df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_a04cc3c9-9142-47ff-8674-f7e2d8a42527_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentTwoMember_26330b29-87a5-4bec-89ae-790b61e580dc_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember" xlink:href="halo-20221231.xsd#halo_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentTwoMember" xlink:to="lab_halo_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_b60e9051-4302-47a1-8e33-28e08ac179d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e810aa78-a22d-4c6e-bae4-dc58c6c9f83b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6888b7fb-7359-4914-acc7-dcbc1da0fc89_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3a1b9c1-4a12-4841-9e73-15651d21ede5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_df9046a2-d723-47c7-8a21-3839928c06c7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_835882a0-20e9-4257-965e-328664dd5d78_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1b5eb005-6054-4f06-af34-3daa9d3731f4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_131c3236-5a87-4cc4-b053-f36733f2175e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0417ce13-a56b-4194-be6b-ea9a79d55693_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c3578fe-0c7a-4b63-be45-b40cf82728e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_62be820a-bc95-4d88-aa01-70cdc1685c00_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba5af845-1350-4ef7-9ce1-d815f845a148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_85aa4692-b14f-4058-ae21-32b4051574ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_395ee14b-dc80-4f37-ba24-1087ba5ea834_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromcollaborators" xlink:to="lab_halo_Accountsreceivablefromcollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e78d65c2-d1a3-466a-be18-f92de0205e47_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2775bd90-6b63-4171-9e1b-d93001844ac1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_86d9b88d-a7d8-42a9-913d-b0e55ee653d7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5b0d58b5-5791-4271-8fa8-408716d496e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross balance of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_39bf3ce8-a1c9-4ef1-8a38-536c0c64efe5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PartnerCMember_0a091ecd-0b76-4793-b118-85c0c7883064_terseLabel_en-US" xlink:label="lab_halo_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_halo_PartnerCMember_label_en-US" xlink:label="lab_halo_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_halo_PartnerCMember_documentation_en-US" xlink:label="lab_halo_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerCMember" xlink:href="halo-20221231.xsd#halo_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PartnerCMember" xlink:to="lab_halo_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_92d54322-a7c6-490f-9211-b46f3dac1134_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_ce8c9df2-6871-4fc1-b266-556d38e7db11_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_984219b7-459b-4f56-ac81-895db49bb1bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxLiabilitiesConvertibleNote_362d31b4-1a08-4e54-a223-7b78ed910ec5_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesConvertibleNote_label_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Convertible Note</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesConvertibleNote_documentation_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesConvertibleNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:to="lab_halo_DeferredTaxLiabilitiesConvertibleNote" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a4184ac9-de83-4903-ba41-74763d7b8478_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_614aa321-5d52-44a5-aaa8-5f9be737697a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_5bec7f4d-35eb-4b33-96b7-5ad056a0bec1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1f04e688-0464-4140-93aa-b7e253699fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fd74de7a-fdf4-4e15-982e-9e49803ba7de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a7043bef-9074-46ae-9dbd-58b1039862b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e40f8938-e6e8-4b99-b67c-5cb980b7f3c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_50bf862e-d3e2-4f70-8447-e0e8066de934_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_da4dc0aa-760d-4171-96b2-5dba796541aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_db558fcd-bb2c-4033-bc1f-117b1d4eb483_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_15ed04b2-fe2d-41a2-bab4-82f0b6e33987_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_fd39541a-fb60-4462-bda6-32e3696f6d46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on impairment of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ba024b2d-cb4d-41fd-8ff9-b8971895c4d0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Price Paid Per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a6d41e34-144e-46f0-95d5-f2fe9a1a0c42_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_e192e01f-e9b9-4271-b0d6-2f9fd87506fc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_53849790-643f-42f7-8c5d-efafdc9de67d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_1a7e6c45-6335-4a9a-99c6-314814292a33_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period prior to expiration</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4bfbb771-caae-4c91-bbba-f5bf551524ab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c67b7620-bf6f-480e-8e21-cb3dd9ba3740_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_968e3d52-d868-4a50-8bb5-005f5162e128_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e2e56c0f-0357-47e1-b4cf-1e8166260537_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_056cfed4-b3e0-4801-a31e-0b5805b9d02a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_b265d61f-6b4b-4e7a-b9d7-a23f243e4926_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired, excluding goodwill</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5b02b22b-cf08-4723-b7c6-60aaba216329_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_d2485ce2-fae9-4699-b79a-b2af9fecf1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_47de3889-3bd8-4247-be57-6cab97c2d48a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e88e7096-3a6d-491f-bfd8-07e19e6432f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1054be3f-bc51-4722-b069-8b22884cd675_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_78738d64-c42f-4fa4-b5db-fb7c23987828_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_39a97468-d026-4db0-95bd-ea32cc24e1d8_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5dee6000-dcb4-4387-850a-f64fe9bce9c3_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_08e8ce33-5f2f-4e04-987d-df1fb0048545_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration, net of $46,548 cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_26d71713-08cb-4a17-8f8d-d52826f96c23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Net</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_42f7c782-71d4-4584-b521-eb14fe9aa00e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bce30acd-19ca-4078-87f3-3ec0999589ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_db3dfef5-b32a-4c17-a5c3-8afef51358ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0e889f97-ce56-4671-9c38-1f3c45b076ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_f91a38a0-9e92-431b-a94f-b8e6a641389e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for seller transaction costs paid by Halozyme</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OfficeAndResearchFacilityMember_c19d690a-1308-49fa-b746-8974afa427c7_terseLabel_en-US" xlink:label="lab_halo_OfficeAndResearchFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Research Facility</link:label>
    <link:label id="lab_halo_OfficeAndResearchFacilityMember_label_en-US" xlink:label="lab_halo_OfficeAndResearchFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Research Facility [Member]</link:label>
    <link:label id="lab_halo_OfficeAndResearchFacilityMember_documentation_en-US" xlink:label="lab_halo_OfficeAndResearchFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Research Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OfficeAndResearchFacilityMember" xlink:href="halo-20221231.xsd#halo_OfficeAndResearchFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OfficeAndResearchFacilityMember" xlink:to="lab_halo_OfficeAndResearchFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9abd058a-c8da-4520-9124-0ffb6d695ecc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_e5757496-eaf4-41d8-a208-7434f34bf076_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_d3985a32-a327-421e-8631-9bdbc1d6c321_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e5973987-07fc-4939-9424-3db21c0eed48_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d9919768-426d-45e0-ba30-7d1f8465bffc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_c135bed6-ff61-47a3-bd01-eadbc4e2a46e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ResearchandDevelopmentServicesMember_70c08c20-9bc7-4774-bdc8-5697c70471de_terseLabel_en-US" xlink:label="lab_halo_ResearchandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and development revenue</link:label>
    <link:label id="lab_halo_ResearchandDevelopmentServicesMember_label_en-US" xlink:label="lab_halo_ResearchandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Services [Member]</link:label>
    <link:label id="lab_halo_ResearchandDevelopmentServicesMember_documentation_en-US" xlink:label="lab_halo_ResearchandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchandDevelopmentServicesMember" xlink:href="halo-20221231.xsd#halo_ResearchandDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchandDevelopmentServicesMember" xlink:to="lab_halo_ResearchandDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_e3c705dd-9fed-4b72-8ff1-c1b42e8d7dde_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Two [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ConcentrationRiskPercentageInstantDate_91e0effd-c392-459e-8d15-54bf4370f990_terseLabel_en-US" xlink:label="lab_halo_ConcentrationRiskPercentageInstantDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage (instant date)</link:label>
    <link:label id="lab_halo_ConcentrationRiskPercentageInstantDate_label_en-US" xlink:label="lab_halo_ConcentrationRiskPercentageInstantDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage (instant date)</link:label>
    <link:label id="lab_halo_ConcentrationRiskPercentageInstantDate_documentation_en-US" xlink:label="lab_halo_ConcentrationRiskPercentageInstantDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage (instant date)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ConcentrationRiskPercentageInstantDate" xlink:href="halo-20221231.xsd#halo_ConcentrationRiskPercentageInstantDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ConcentrationRiskPercentageInstantDate" xlink:to="lab_halo_ConcentrationRiskPercentageInstantDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c971f7bf-98af-4c42-b49a-21e3b3141b63_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_99de4305-7855-4871-9578-d50d4765bfb1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_edb845ab-f9c3-4175-aa80-9ce25e0fa697_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1ea89271-653d-4445-af2c-ca18e4ef2be6_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_096b4f2a-9d2f-4aad-9843-12f41c021118_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 2028 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_23d8de87-0d74-4937-b949-48615efec195_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_dd74f6d9-e9db-4d09-8c8c-c02b31364411_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Savings Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_5d2539ed-5e92-467e-a9aa-83e5ad6fc4d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2c2f1eff-1a53-4c1f-982a-68aadc2ff72b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_17c96c8f-b551-423c-bfd5-844e820395f2_terseLabel_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for capped calls</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_label_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_documentation_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions" xlink:href="halo-20221231.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PaymentForCappedCallTransactions" xlink:to="lab_halo_PaymentForCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxAssetsLeaseLiabilities_dc5d2e20-69e4-4543-bbc9-c1f45fb61ede_terseLabel_en-US" xlink:label="lab_halo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842 lease liability</link:label>
    <link:label id="lab_halo_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_halo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_halo_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_halo_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsLeaseLiabilities" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_halo_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_3809bdc9-5b95-40ed-843d-a5cfdd0741af_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_66ba1528-f60c-47ee-861f-5b320bb8c06c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c6be5b63-a390-4ba6-a98b-8d394d11d459_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentAxis_f67857a6-a1ee-4697-b904-2be647aa451c_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_label_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis" xlink:href="halo-20221231.xsd#halo_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentAxis" xlink:to="lab_halo_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cd90818a-6642-4647-93ca-6ef5278f7794_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dbb7684e-a9b8-44b8-bd36-d7963390f5f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_6cba029b-04ac-45b0-9ed5-29aef8395985_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RocheMember_cf056dd4-0ea3-4928-80af-cf5812e9fad2_terseLabel_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_halo_RocheMember_label_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_documentation_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember" xlink:href="halo-20221231.xsd#halo_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember" xlink:to="lab_halo_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_ff881300-afd2-4c56-99c3-af4536e09e73_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3bafac42-ad3e-48e8-8482-33ac4e338b7a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_08f18748-81de-47ef-87ec-cc309d9cf09a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_335ceea4-4372-41ff-9046-f08278dc4329_terseLabel_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worthless stock deduction of international subsidiary</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_label_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective IncomeTax Rate Reconciliation Worthless Stock In Subsidiary, Percent</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_documentation_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective IncomeTax Rate Reconciliation Worthless Stock In Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:to="lab_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_10a6b95d-0626-446c-bca0-5efc1bb5f28e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AuditorInformationAbstract_2bf7fa1b-cd04-4255-a8ed-07046ffaaf07_terseLabel_en-US" xlink:label="lab_halo_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_halo_AuditorInformationAbstract_label_en-US" xlink:label="lab_halo_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_halo_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_halo_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AuditorInformationAbstract" xlink:href="halo-20221231.xsd#halo_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AuditorInformationAbstract" xlink:to="lab_halo_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_075faffe-c77f-4950-a5d1-8935c62530d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_78042fae-b622-4472-921d-cbe4f90f7568_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PercentageVestingMember_46da8b2b-f1d8-42ce-874f-f1d50f2abbd6_terseLabel_en-US" xlink:label="lab_halo_PercentageVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Vesting</link:label>
    <link:label id="lab_halo_PercentageVestingMember_label_en-US" xlink:label="lab_halo_PercentageVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Vesting [Member]</link:label>
    <link:label id="lab_halo_PercentageVestingMember_documentation_en-US" xlink:label="lab_halo_PercentageVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Vesting [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PercentageVestingMember" xlink:href="halo-20221231.xsd#halo_PercentageVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PercentageVestingMember" xlink:to="lab_halo_PercentageVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3dd2e97f-e891-4d70-8aac-fb2b0bbf7014_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_91132434-32ea-46fa-8ec5-b1a609d3d84c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f576587d-352b-45ce-b0e5-284e902eb895_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e4332c09-69c4-4492-b8b6-8e7bc4220a8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_efd66644-dcc6-47f3-be30-60d47bfb1392_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5ad28171-3b11-4810-b27a-abb8ab18db85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_79d57c63-866a-4c9d-a369-7db9132c3aab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f7a12941-41db-43f2-a34c-5a630f4c580e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_9610367f-8718-4e37-8519-e749613fb237_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year One</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_50dd21d5-3179-43f8-80da-534c4926ad5d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c955c50b-6fb2-4c40-bd46-0bb1ae9ab4f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes (including benefit from valuation allowance release)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_442d4518-ce6e-4baa-9558-cf1f49970870_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_4ca25783-f0cc-426c-8a9b-d4e3a4a8ea66_terseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_3b699d41-9d28-4f0b-80c1-d2877481013a_verboseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Convertible Notes</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027 [Member]</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:to="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d9796dc0-a9ea-4abe-98cf-8f5bc315616c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_168ac71b-f86b-4731-b741-d52a6bcab248_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_69ebd897-3a83-4bd3-8cee-65c51837a68e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_e87cbaa3-2a2b-4fdc-971f-192ba197f08f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for induced conversion related to convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5db808a2-4eec-48a6-8131-0954db41d662_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_58681f04-bc43-4470-8922-5915a04ac95f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e2554489-9f2e-46c6-b372-a88a6d03ed51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3926c1eb-ab94-4b08-99b4-80733b0025fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, End of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2c51b38e-95d5-4dd6-a14d-d21bbacd24bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LongTermDebtInterestGross_eee15f16-8f59-47f6-9c7d-116743cab831_negatedTerseLabel_en-US" xlink:label="lab_halo_LongTermDebtInterestGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amount representing interest</link:label>
    <link:label id="lab_halo_LongTermDebtInterestGross_label_en-US" xlink:label="lab_halo_LongTermDebtInterestGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest, Gross</link:label>
    <link:label id="lab_halo_LongTermDebtInterestGross_documentation_en-US" xlink:label="lab_halo_LongTermDebtInterestGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtInterestGross" xlink:href="halo-20221231.xsd#halo_LongTermDebtInterestGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LongTermDebtInterestGross" xlink:to="lab_halo_LongTermDebtInterestGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4f535ee1-bdae-4a76-858d-ae699e9ede0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss Ccarryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_71d674cd-2035-4a6f-a384-6496c93aa709_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_95412158-fddf-4516-90d2-4ac2564c1df1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_a3711658-418c-4dcf-a96a-177b42e96fba_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Awards, Vested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_365bd64d-337e-44f3-b278-4dc8f793bef1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_36729c9c-1f51-4c01-9fed-298906f18afb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_83137802-02fc-4d2a-83fb-8446b870d3e6_terseLabel_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto-Injector technology platform</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_label_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform [Member]</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_documentation_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:href="halo-20221231.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:to="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c612e3d9-9d1f-4e35-81d0-8ea2583089db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a62f2420-c282-472c-8cb3-f64a7dee8c36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_73dd2dc3-42ee-4a4b-b3ac-f3163f4380c2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in tax positions related to business acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_27b318a7-1037-4f36-a774-3e87c6cdb695_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rates:</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SalesbasedmilestoneMember_f8eaaed2-ae62-4cf3-84ad-1f238ded4874_terseLabel_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_label_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_documentation_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember" xlink:href="halo-20221231.xsd#halo_SalesbasedmilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SalesbasedmilestoneMember" xlink:to="lab_halo_SalesbasedmilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RocheandBaxaltaMember_1aad1505-cf68-4c9f-87a2-d9c99457deab_terseLabel_en-US" xlink:label="lab_halo_RocheandBaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche and Baxalta</link:label>
    <link:label id="lab_halo_RocheandBaxaltaMember_label_en-US" xlink:label="lab_halo_RocheandBaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche and Baxalta [Member]</link:label>
    <link:label id="lab_halo_RocheandBaxaltaMember_documentation_en-US" xlink:label="lab_halo_RocheandBaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche and Baxalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheandBaxaltaMember" xlink:href="halo-20221231.xsd#halo_RocheandBaxaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheandBaxaltaMember" xlink:to="lab_halo_RocheandBaxaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f3c78ffa-abfb-4312-af97-04568589632f_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (Accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4707af40-9d09-4373-acea-091632c5995b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a3d5307d-ace5-4fd4-888d-82c09b4a90f1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b1590d1b-d0d5-4b8d-b7b3-3192c6a4ea89_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_79d17bb0-a50c-4c32-9920-7e224738a9e8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_5ec03f3b-642e-4abf-883f-10124b6e73da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_16fa5068-a843-4c6a-a59c-74414268e54b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization per period of debt discount (in years):</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a3a8f069-1187-4cc0-a295-9c893350579f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_dfaf0bfd-f630-4111-b49f-4102e64be391_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_08108548-0447-4c13-88d4-0f584cc3e03a_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATRS-1902 (IPR&amp;D)- Indefinite</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58684304-2e69-4d7a-90b3-938c86d01f26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a3d00ff5-a09d-470d-9cc8-624eba0780a3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c3848b76-aa88-41ce-93b7-109e90c22a49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MN_d23d6bc5-efa8-46e3-be52-89989936c687_terseLabel_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNESOTA</link:label>
    <link:label id="lab_stpr_MN_label_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNESOTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MN" xlink:to="lab_stpr_MN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_97aad144-58dd-4f39-a2fd-68d22444d617_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_134a083f-6bb5-4d6b-87b6-5c6d9d580d89_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ddb703c6-170c-43e8-826b-306107e5f81d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e36d5701-40a4-4ec8-8e61-baa63d5c4f7d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_52cecfcd-4058-409e-8fcd-d0187059e372_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_543a82b3-4e62-40b3-bf86-ea48fefc8778_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AmendedAndRestated2021StockPlanMember_f8f3696b-8cb2-4498-896d-164e7dac17cb_terseLabel_en-US" xlink:label="lab_halo_AmendedAndRestated2021StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2021 Stock Plan</link:label>
    <link:label id="lab_halo_AmendedAndRestated2021StockPlanMember_label_en-US" xlink:label="lab_halo_AmendedAndRestated2021StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2021 Stock Plan [Member]</link:label>
    <link:label id="lab_halo_AmendedAndRestated2021StockPlanMember_documentation_en-US" xlink:label="lab_halo_AmendedAndRestated2021StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2021 Stock Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AmendedAndRestated2021StockPlanMember" xlink:href="halo-20221231.xsd#halo_AmendedAndRestated2021StockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AmendedAndRestated2021StockPlanMember" xlink:to="lab_halo_AmendedAndRestated2021StockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1df1b4df-b4ba-4a13-a4bc-d858012f4616_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred - federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d4f273bc-81be-4f6b-94c4-74aef1922a1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on foreign currency</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fb14fc9e-e058-47bb-8648-3a23dc1dc55c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_db7991a5-cd01-4472-b4c1-df7c63e54d32_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a6b3225c-025b-4984-85e3-531e231010a2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_8297d4b9-f2cd-4fba-be89-8f1f4e4d7871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e24290ed-fc52-4298-a93c-3e9dc60ef10c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CollaborativeAgreementsMember_b7f55c86-f0c9-4626-a0eb-a2c0b5b386b5_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember" xlink:href="halo-20221231.xsd#halo_CollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsMember" xlink:to="lab_halo_CollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ab4a5748-6acb-4775-9af6-0ca7376ff01d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_639391a0-ecb3-4bec-9242-36451d58312c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_e47bcf9d-3504-4eec-8804-cf2520c1c714_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares Purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_80c75575-e387-4f58-8bc1-bc84b2b393ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_60706d93-6fc7-490d-a3bc-6403a149e591_terseLabel_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Fee Cost Per Share</link:label>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_label_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Fee Cost Per Share</link:label>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_documentation_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Fee Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:href="halo-20221231.xsd#halo_TreasuryStockAcquiredFeeCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:to="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_19272e91-0a03-41dd-9d96-4b785e6aede4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_26b7296e-4393-4cd8-a62b-8f9a7c351212_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_649a843d-b925-4dc8-a4f3-c9f5a3d46533_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average&#160;Exercise Price&#160;per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_63e118e8-f24e-4fb3-be05-8125d5e32efb_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5a822997-c837-4a2e-998c-5bb8a2b065dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e371fb8c-b5f8-4505-8534-d76ea6498751_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f26a96c7-2ad5-4f83-af2d-4a85a19bc717_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_10ac2b33-e823-4bdd-8c03-e4975b1aea33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OperatingLeasesAreaLeased_fe7b457d-9592-4673-9a3b-06375773a765_terseLabel_en-US" xlink:label="lab_halo_OperatingLeasesAreaLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Area Leased</link:label>
    <link:label id="lab_halo_OperatingLeasesAreaLeased_label_en-US" xlink:label="lab_halo_OperatingLeasesAreaLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Area Leased</link:label>
    <link:label id="lab_halo_OperatingLeasesAreaLeased_documentation_en-US" xlink:label="lab_halo_OperatingLeasesAreaLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Area Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeasesAreaLeased" xlink:href="halo-20221231.xsd#halo_OperatingLeasesAreaLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OperatingLeasesAreaLeased" xlink:to="lab_halo_OperatingLeasesAreaLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentOneMember_4f8f99ec-ccca-4bd7-8f4a-9f55f221eeb2_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_label_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember" xlink:href="halo-20221231.xsd#halo_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentOneMember" xlink:to="lab_halo_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_db6d8b26-5b8e-4644-a8e8-648aea0d269b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1aa38913-e65b-445b-9bee-496f57933311_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_26d62842-a93c-49a2-bdc7-f85c69aa167b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b6b232ca-297e-42b9-9f29-3d8342f42658_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4e744953-5f00-4a1b-bf48-b1951a0a9c43_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f2f6c264-45f3-406c-a63a-c89e22cba4bc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d42b5629-7c51-48ce-9f1c-6eb82849c3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ba542e43-1c08-42d8-a8e9-8957df714e60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f4b0d56-f5be-480a-ab30-a43918e0c10d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_b95723be-8290-4c14-bf15-4b3e63113ab2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_dcc89eec-4195-42cd-93b9-d5bc6a6ba34f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_3fc873a0-c548-446d-88a6-1942d2a5e486_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2a5959c8-a089-4d20-a221-7410018fb2b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense Related To Share-based Payment Awards Excluding Acceleration of Antares Equity Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_502f7e71-b87b-4ec8-b4b0-3cb67107fdf8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a6142499-5fa1-47af-880b-d4ce99ab0d53_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_53da1276-7c6e-44b5-9f18-a40b9754af29_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_138f37a5-8098-49e0-bd77-fa343028a8a2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c3a1bcb4-7942-42a3-94ac-322ff48c607f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ab9cc843-b11b-490a-81f7-fce34d103769_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a734ae6f-8641-48c9-ba3c-e8ad788e260f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_44c5001a-3558-4dba-bc2f-a3affb0d11cc_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_8c851a04-c8a0-4762-8e5b-763fb1a284f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrecognized Estimated Compensation Cost By Type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_381e6292-19af-46df-85f7-3252c85fb0ca_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9815d196-2e36-4547-8db1-f0dd8a140fe6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_1b3ae397-5bf1-40b1-bc71-d2cac5f9ccf8_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationAbstract_b97e2fff-087b-4ef2-bd03-c5b516d47955_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationAbstract_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract" xlink:to="lab_us-gaap_DepreciationAndAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ba45b0b-c049-49ac-9b55-8c081d083673_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_81eb40f8-e9b8-4bbb-88e5-b3756e5bc0c3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5eeaa73f-69e2-4005-8717-01181ee16ba7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b8ece919-8a50-4d03-a89c-f76ad8ed5e22_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b47164b-796b-4f9f-babf-bfda1a5b652b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a15a80f4-a7b8-40ae-9f0f-16edfb665f3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average stock outstanding - basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_51ce4481-dfed-4239-bd08-585bff94a6bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_83be712c-ae32-4a70-90b2-df815c1d288d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_d5257399-99bd-4ea5-8469-c4cda52c3c79_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_3790b432-9199-4e6a-bcab-97847b31a85e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_03a8052e-53ca-462f-b864-2448562f9cc6_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_167254b1-71b9-4a41-8bfd-3884766a01fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (received), net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_NumberOfCollaborationsRoyaltiesReceived_5b663aed-13b5-4270-8188-d5b79c4d3fd1_terseLabel_en-US" xlink:label="lab_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaborations royalties from which royalties are received</link:label>
    <link:label id="lab_halo_NumberOfCollaborationsRoyaltiesReceived_label_en-US" xlink:label="lab_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Collaborations, Royalties Received</link:label>
    <link:label id="lab_halo_NumberOfCollaborationsRoyaltiesReceived_documentation_en-US" xlink:label="lab_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Collaborations, Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:href="halo-20221231.xsd#halo_NumberOfCollaborationsRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:to="lab_halo_NumberOfCollaborationsRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0b9d5b35-253e-44f2-8f8d-d25a8c031aca_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_595926dc-8a3a-4ec3-b4f2-bc7664e7564e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ed29d25e-641f-4a47-9dad-b5fe43fc0c9d_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ea44c5f4-3761-482b-b2cf-838db80fe2c3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_2759ad7f-64b6-449e-8551-aaeb2595df97_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_148390af-1265-4f80-ac2c-60b34744b25d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b9f2412f-e29b-4832-8995-88bb4b191c56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_492c81e2-4bd1-4ae0-8e81-70a9d41216e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_26f3a183-6c41-42d0-9c87-5459ac4aa4bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_cca131c4-1a17-403a-bbb1-be1c56a4a0cb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cb88d75b-6398-4a14-ad5a-72493b50cb10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Provision for Income taxes to Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_71586b38-14f8-4c9f-818d-737634113af6_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible book amortization</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_label_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Non-deductible Book Amortization</link:label>
    <link:label id="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_documentation_en-US" xlink:label="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Non-deductible Book Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:to="lab_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_516ad684-a6c7-4779-8847-3069e78d7d01_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_743475b2-0655-4d85-8147-90de24860fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7cddd054-a6a9-472e-90d8-74b40cde2eed_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_23a7f94d-d098-4b9b-bf14-7d8f611207dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c9fa7124-5d70-4beb-ad39-5b30f0aa77f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_MonthlyVestingAfterOneYearMember_17ee5cb8-54e5-4b26-b964-afe5192d5be5_terseLabel_en-US" xlink:label="lab_halo_MonthlyVestingAfterOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Vesting, after One Year</link:label>
    <link:label id="lab_halo_MonthlyVestingAfterOneYearMember_label_en-US" xlink:label="lab_halo_MonthlyVestingAfterOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Vesting, after One Year [Member]</link:label>
    <link:label id="lab_halo_MonthlyVestingAfterOneYearMember_documentation_en-US" xlink:label="lab_halo_MonthlyVestingAfterOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Vesting, after One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_MonthlyVestingAfterOneYearMember" xlink:href="halo-20221231.xsd#halo_MonthlyVestingAfterOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_MonthlyVestingAfterOneYearMember" xlink:to="lab_halo_MonthlyVestingAfterOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1f83c6d6-3dc3-4fae-aa51-52c07fd0506c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_727db9b7-8a03-4a70-bd71-80ff63216e9c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_23e82056-8647-472f-9145-2152edfb3d96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eaee585d-6e72-45c7-9c34-dfb0da5f6987_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_87d76b32-6734-44ab-9d00-8d3704c76509_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6cecc18c-3867-488b-bc0d-0c1420f47af7_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7f199733-24be-40a0-9180-7e8ef78f8c32_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock awards, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_a7ec46c1-654f-4816-a1b0-4b273d09f8a3_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalty payments</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_label_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalties</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromroyalties" xlink:to="lab_halo_Accountsreceivablefromroyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_77bd1fb5-4e17-4025-9c7b-d2c59febe636_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4303acb3-1a2a-4d6f-a87a-6999b604051d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9aeb4e15-d5ce-4c4a-bbcd-e44442cd9066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases in tax positions for prior years and lapse in statue of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_17b4618b-726b-4da6-9b6d-7ae33ee88846_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses and other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_c158cdd8-36e9-4b52-aa03-fe7cd3d41b40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_885f32d0-f815-4b86-befa-0c219f079c30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0f4dbd6a-0737-461a-8559-2dada4d0c85b_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b3d6f3d4-2c5d-421d-bac8-211433480fdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Interest Expense and the Effective Interest Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98a78c22-7ec4-470d-a222-975d6b8aba2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2097e6be-8cd9-4998-ae7d-b6df8a771518_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_826b9c5f-0f1b-4830-9961-c6441561eaed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_a59916b9-502b-4f40-88cf-52d2321d3c28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_af60a0fe-4211-4bde-a955-262dcd27ae63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_771f5a93-7354-48d3-94d8-e8022a6ce0fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_13ad0aea-fdab-4d83-8eec-2cc1064266d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_1c80f80c-ff9b-4f8a-ad2e-b8123669a154_terseLabel_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED proprietary product</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_label_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product [Member]</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_documentation_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember" xlink:href="halo-20221231.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_XYOSTEDProprietaryProductMember" xlink:to="lab_halo_XYOSTEDProprietaryProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6e3c3656-0c88-49ed-a2f0-296e3a9dca2b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current portion and unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_07f35e5e-6e51-4138-8412-1f6096e1c3b4_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap call transaction, cap price per share (in usd per share)</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_label_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_documentation_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:href="halo-20221231.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:to="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_76012686-1ac4-4661-b0c5-9fe4f82040b7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_022395f1-d804-430e-aac9-9896ec7e12fb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration related toacquiree closing indebtedness settled</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f03dd276-676d-4ccb-b98f-57a040263527_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration related to Antares closing indebtedness settled by Halozyme</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_0f899f2e-0c68-4f06-9c7b-ada631021a3a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_49222283-e88a-4d3c-ac8d-8af820a6c1b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_0ade5e57-bf46-4a8c-a906-38dfefbc96e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_efa5cafc-47a2-41b8-a5a4-525ade39bc42_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_f33e1925-1db3-4c7f-9ed5-5291b7b768fd_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OtherCollaboratorsMember_d48b27a3-2135-4820-9a54-d394c0048952_terseLabel_en-US" xlink:label="lab_halo_OtherCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OtherCollaborators</link:label>
    <link:label id="lab_halo_OtherCollaboratorsMember_label_en-US" xlink:label="lab_halo_OtherCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OtherCollaborators [Member]</link:label>
    <link:label id="lab_halo_OtherCollaboratorsMember_documentation_en-US" xlink:label="lab_halo_OtherCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OtherCollaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherCollaboratorsMember" xlink:href="halo-20221231.xsd#halo_OtherCollaboratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OtherCollaboratorsMember" xlink:to="lab_halo_OtherCollaboratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AntaresPharmaIncMember_ece4325c-c216-43e6-a61a-625dfe98cb65_terseLabel_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_label_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc [Member]</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_documentation_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AntaresPharmaIncMember" xlink:to="lab_halo_AntaresPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_34be3be6-117f-4472-b182-5ad0b863ae84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes Summarized By Region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2da514ae-6a7e-408c-8e0a-a1e285922d77_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1e2082f-d903-4b9b-a40c-18c41ae1b0a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1d7e97db-eb2f-4ee1-bb4b-40d73708fa04_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_58e2545a-aa81-464e-995e-161419da4851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bee9adaa-85a3-4f83-800e-0493606370be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b811565e-75a1-42d3-9609-3db1f2c34141_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e265babb-c46e-4c8b-86c7-a4076f648be2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dc5f01db-6b6f-4485-84ff-2c0e62a48dab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Accumulated Amortization and Weighted Average Useful Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fefd9c90-4581-4813-b55b-f0049e33a991_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_ec16477c-2acb-4c27-bdc1-984a8aba72c9_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_123a03d9-1965-4c26-ab2f-6a670546b99d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_45bc0a16-867d-4e66-9666-f8b3654c2ae9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41894f75-0599-4401-9734-e9d5621be65f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b3c7605e-a79d-41cb-b72c-64fb4c444687_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_33af7895-69f5-4a47-91f5-344f33f2f758_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_f91b1d4b-c174-4d1c-9afd-b4e7ca90e70b_terseLabel_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_label_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement</link:label>
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_documentation_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable upfront license fee payment received under collaborative agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:href="halo-20221231.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:to="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_821b6b04-c909-4011-9d89-b57bd9a6a27b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_d9a282b1-4994-4b5a-9c4b-726af4aaf00a_terseLabel_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock premium over last reported sale price, percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_label_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_documentation_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:href="halo-20221231.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:to="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cbe89103-df08-47d1-9098-98d82f8e8dab_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_56af88b2-a97a-44ae-ab1b-c2ebc29b7ed0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_764bc7e7-9ded-4abf-8145-542d06d21a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_6f6f9618-a303-40e3-8c2d-1302a20bf745_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_d2df290b-5e35-4f2d-b639-5caf7cf0b8a1_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_f64d3a98-deb1-4189-9d2a-9bb53e21f83f_negatedTerseLabel_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for distribution fees and discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_label_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Distribution Fees and Discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_documentation_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Discount and Distribution Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:href="halo-20221231.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:to="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_f9500dd3-44d6-4b40-8fe6-83f52e24d5ea_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_78b19f2d-9b3e-4751-a345-41310cd97b06_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3979fd8c-f0c1-470d-8041-a80c4d1ec805_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_a6ba9840-9eb2-48d8-9bb9-462ea735ab3c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeferredTaxAssetsInterestExpenseLimitation_0fb0a908-fe8b-435c-b116-8d96d5fee6a8_terseLabel_en-US" xlink:label="lab_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense limitation</link:label>
    <link:label id="lab_halo_DeferredTaxAssetsInterestExpenseLimitation_label_en-US" xlink:label="lab_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense Limitation</link:label>
    <link:label id="lab_halo_DeferredTaxAssetsInterestExpenseLimitation_documentation_en-US" xlink:label="lab_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:to="lab_halo_DeferredTaxAssetsInterestExpenseLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dbd205af-2ae5-436d-bb79-692f0b0af985_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_190ea391-248a-477d-8f6f-908b17558583_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentDomain_604e28ec-b79a-4551-9efd-a897da2639b5_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_label_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain" xlink:href="halo-20221231.xsd#halo_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentDomain" xlink:to="lab_halo_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_493c7846-e64f-4bd7-8d2e-0d045028202a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_ff838fd9-0a9a-440a-8e25-3f5e55fd55df_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercise price, percent of share price (percent)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_cdc4d5a3-c5be-455d-a7d9-f4b7e1d0f75f_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, initial contractual term</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_bd2dad11-f9b0-41bb-afcd-fc37d5026763_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to outstanding awards (in shares)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5e37e203-4871-45e5-b322-cb7516781237_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_51a385c5-b5fe-47b2-ad12-b867e6187a15_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_111b562b-aa24-4dbc-90eb-72ad58e0955d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_91c17f68-2ef2-42cb-80de-5ea481a956c1_terseLabel_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive compensation limitation</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_label_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Limitation, Percent</link:label>
    <link:label id="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_documentation_en-US" xlink:label="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Limitation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:to="lab_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2c749508-415c-4db7-86a7-70557ad71253_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable allowance, beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4465ab6f-c59d-480a-bc52-afd41aa41f03_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable allowance, ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_aed9497c-2c9e-4b20-a587-174c503e7c67_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d8e2af64-ab24-4430-b3e5-3d214180f7be_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3c7065fd-d834-44f9-9a9f-68ecafae78da_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4b20b9ab-a0fb-4515-a133-ef62135dfc71_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_436d6d03-5e25-4129-9813-5cfeb4421091_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2d4d10ce-8a53-4c04-badc-d781b5c15314_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_91b118ea-844e-4eda-916b-b205a6389ed7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2465881-0546-4e54-a765-669fb48b5b88_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_618d2868-ce94-4e6f-8db5-b42d470270fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>halo-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17950820-156f-4927-91d3-9a480dc6b72b,g:4445dfd8-995a-45a3-b392-fbaf5c47021e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/Cover" xlink:type="simple" xlink:href="halo-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_948aed75-cfb7-4899-bfa9-ac772741b2be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityCentralIndexKey_948aed75-cfb7-4899-bfa9-ac772741b2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_23fb3ed1-d4d1-4bcd-a0f3-ac8ccec5099e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_AmendmentFlag_23fb3ed1-d4d1-4bcd-a0f3-ac8ccec5099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_584ab997-e5f8-4df2-824a-6159c42e76b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentFiscalYearFocus_584ab997-e5f8-4df2-824a-6159c42e76b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_01bd6fa1-5a04-4bb6-aec8-e6885a2b5204" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentFiscalPeriodFocus_01bd6fa1-5a04-4bb6-aec8-e6885a2b5204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0b74bac7-ebfe-47a8-b026-7fb46d6ed22f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentType_0b74bac7-ebfe-47a8-b026-7fb46d6ed22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3512573d-7e96-472b-88b5-ccbedc71df46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentAnnualReport_3512573d-7e96-472b-88b5-ccbedc71df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3470a178-12f6-49c9-bf47-ac997af29efb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentPeriodEndDate_3470a178-12f6-49c9-bf47-ac997af29efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_942d7aae-78be-464e-9ebb-acbb109f3f87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_CurrentFiscalYearEndDate_942d7aae-78be-464e-9ebb-acbb109f3f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f10c9671-315b-4c2e-a288-c87e12651127" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_DocumentTransitionReport_f10c9671-315b-4c2e-a288-c87e12651127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad75a591-8c93-4972-b018-580244283045" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityFileNumber_ad75a591-8c93-4972-b018-580244283045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ab0ec1e8-1749-48bc-a7c1-a59fe20567e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityRegistrantName_ab0ec1e8-1749-48bc-a7c1-a59fe20567e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_76bba120-4a92-4fb0-b9d4-bdc780549f85" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityIncorporationStateCountryCode_76bba120-4a92-4fb0-b9d4-bdc780549f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fe0ac489-476e-49d9-82bc-49f6e4f51378" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityTaxIdentificationNumber_fe0ac489-476e-49d9-82bc-49f6e4f51378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a155be71-5478-4b55-8878-cd8f700cb6ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityAddressAddressLine1_a155be71-5478-4b55-8878-cd8f700cb6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4f1c423e-35df-4cd1-8bbc-276ad24987f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityAddressCityOrTown_4f1c423e-35df-4cd1-8bbc-276ad24987f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8559a5ee-31d2-48d2-8e43-cf43af9ea6df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityAddressStateOrProvince_8559a5ee-31d2-48d2-8e43-cf43af9ea6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_630dc45d-8d95-4ee8-8dfc-3da90bd752f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityAddressPostalZipCode_630dc45d-8d95-4ee8-8dfc-3da90bd752f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f5e6093b-de02-49c2-b748-09b2a58200eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_CityAreaCode_f5e6093b-de02-49c2-b748-09b2a58200eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3e5ca89a-ec6c-4fa6-979e-d3179bd6ba57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_LocalPhoneNumber_3e5ca89a-ec6c-4fa6-979e-d3179bd6ba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fe98b535-21af-45d4-af2f-49ddea49f617" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_Security12bTitle_fe98b535-21af-45d4-af2f-49ddea49f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7c52041d-027f-4290-a78c-b6d382d1444c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_TradingSymbol_7c52041d-027f-4290-a78c-b6d382d1444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2eeb37eb-db29-4e8b-a1ad-ec965b1957bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_SecurityExchangeName_2eeb37eb-db29-4e8b-a1ad-ec965b1957bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_998c7749-1708-4520-8daf-510118293ea2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_998c7749-1708-4520-8daf-510118293ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_fedadd1a-743d-4158-9d88-2af56e11b5f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityVoluntaryFilers_fedadd1a-743d-4158-9d88-2af56e11b5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0b383863-d4f4-4f72-bdf4-3dcc6e79b233" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityCurrentReportingStatus_0b383863-d4f4-4f72-bdf4-3dcc6e79b233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b355e74e-07c1-4678-9371-fe17bbd504df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityInteractiveDataCurrent_b355e74e-07c1-4678-9371-fe17bbd504df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8eb415c8-b1c0-446d-8a79-6059dc2cc71d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityFilerCategory_8eb415c8-b1c0-446d-8a79-6059dc2cc71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5a14ac7b-ef0a-4bd5-af6f-dea2fcb9cf4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntitySmallBusiness_5a14ac7b-ef0a-4bd5-af6f-dea2fcb9cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_328bd9f1-ed3b-464a-b9c2-49641b77a544" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityEmergingGrowthCompany_328bd9f1-ed3b-464a-b9c2-49641b77a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_7cbefeaa-589f-46db-976b-7fa965a25be4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_IcfrAuditorAttestationFlag_7cbefeaa-589f-46db-976b-7fa965a25be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_55de0b08-aee9-48e8-9f57-7ca87077f63b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityShellCompany_55de0b08-aee9-48e8-9f57-7ca87077f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_24c34b5b-3d71-4dc4-8f56-112e5b65934b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityPublicFloat_24c34b5b-3d71-4dc4-8f56-112e5b65934b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_89223b04-a987-436a-a8a7-5939141d0e27" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dc0e9719-46cb-4fec-a8c9-675e4d980152" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_89223b04-a987-436a-a8a7-5939141d0e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/AuditInformation" xlink:type="simple" xlink:href="halo-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_AuditorInformationAbstract_ed5d7e8f-6490-494a-b250-6edfd227b186" xlink:href="halo-20221231.xsd#halo_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_73098850-0a78-47c4-a630-5b899aacd4bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AuditorInformationAbstract_ed5d7e8f-6490-494a-b250-6edfd227b186" xlink:to="loc_dei_AuditorName_73098850-0a78-47c4-a630-5b899aacd4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7df7f99a-6212-4d1b-81d4-506e950a9452" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AuditorInformationAbstract_ed5d7e8f-6490-494a-b250-6edfd227b186" xlink:to="loc_dei_AuditorLocation_7df7f99a-6212-4d1b-81d4-506e950a9452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f5a2c3e4-b0fd-470f-9237-806283bd5108" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AuditorInformationAbstract_ed5d7e8f-6490-494a-b250-6edfd227b186" xlink:to="loc_dei_AuditorFirmId_f5a2c3e4-b0fd-470f-9237-806283bd5108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Cover_1" xlink:type="simple" xlink:href="halo-20221231.xsd#Cover_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Cover_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5785434b-35f9-4b08-a454-1487b48f4dad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_63faa924-f806-4132-843f-8584a7fa40e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_63faa924-f806-4132-843f-8584a7fa40e2" xlink:to="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c24d2fa-9597-4237-8bb7-0f23c9fa52a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c24d2fa-9597-4237-8bb7-0f23c9fa52a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_15a0e81d-6fda-4637-8866-2e9d1bf21b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_15a0e81d-6fda-4637-8866-2e9d1bf21b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1e8e8fcb-ddff-41b0-8b1a-fc6120f6b226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1e8e8fcb-ddff-41b0-8b1a-fc6120f6b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b12b5959-8815-457b-9fc7-655e2db3484b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_InventoryNet_b12b5959-8815-457b-9fc7-655e2db3484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9573e88-e87b-43a7-992f-5a08dfabd38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9573e88-e87b-43a7-992f-5a08dfabd38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_963a1cba-e987-4b0c-9c6c-f08025b9951d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d012f0c-b274-4c86-ac89-e64029c335d0" xlink:to="loc_us-gaap_AssetsCurrent_963a1cba-e987-4b0c-9c6c-f08025b9951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_63c7b9cd-522b-4c0b-830e-7b982af94fe4" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_63c7b9cd-522b-4c0b-830e-7b982af94fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ab36234d-b8d3-4c07-9303-31823fdb7298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ab36234d-b8d3-4c07-9303-31823fdb7298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2ff78977-fc4d-408a-a076-4d15e3bbd964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_Goodwill_2ff78977-fc4d-408a-a076-4d15e3bbd964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4855e7d7-449b-4afc-8e26-e7c28e8384fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4855e7d7-449b-4afc-8e26-e7c28e8384fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ac1f5b6f-089c-4f54-bd9f-a83099666c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ac1f5b6f-089c-4f54-bd9f-a83099666c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cbc26a4e-548f-48ce-aa8b-f7c650691145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cbc26a4e-548f-48ce-aa8b-f7c650691145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b7ca7328-e80b-4966-8278-93aafb531596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75257c0c-bb76-4eb8-8643-d15158da86a6" xlink:to="loc_us-gaap_Assets_b7ca7328-e80b-4966-8278-93aafb531596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_63faa924-f806-4132-843f-8584a7fa40e2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2ce64b6e-fe37-4442-921f-3911d2e8818a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:to="loc_us-gaap_AccountsPayableCurrent_2ce64b6e-fe37-4442-921f-3911d2e8818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_df6b8ba7-1f6c-49b6-b589-d1677f5d43af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_df6b8ba7-1f6c-49b6-b589-d1677f5d43af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_74948e6d-3148-46c0-bbf9-da8850293a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_74948e6d-3148-46c0-bbf9-da8850293a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b6f6f226-00c7-4989-82f4-c0ff31ba6722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:to="loc_us-gaap_LongTermDebtCurrent_b6f6f226-00c7-4989-82f4-c0ff31ba6722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6a1dd4ec-6523-4e3e-bf88-8d6c8697d932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79e1413-ccc9-4b26-b776-cc0b114dd3b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_6a1dd4ec-6523-4e3e-bf88-8d6c8697d932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d93040a-eb95-41a1-a434-349d8fb5e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d93040a-eb95-41a1-a434-349d8fb5e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e133a894-8802-4eb0-847d-96e7ce69db23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_LongTermDebt_e133a894-8802-4eb0-847d-96e7ce69db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0638e8a8-fb7d-45e7-811d-22df5e9f243b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0638e8a8-fb7d-45e7-811d-22df5e9f243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_01b934be-bf72-4fcc-b7b9-19b803e1900f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_01b934be-bf72-4fcc-b7b9-19b803e1900f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a97b9422-c823-4296-aae5-6c8ab9afb592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a97b9422-c823-4296-aae5-6c8ab9afb592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2c0a73f0-15c1-428c-b055-7bdde180dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_PreferredStockValue_2c0a73f0-15c1-428c-b055-7bdde180dac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7f5e1df8-3b4b-409c-b233-52be630c29ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_CommonStockValue_7f5e1df8-3b4b-409c-b233-52be630c29ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19f12897-7c2b-47bb-9a17-daad1f17f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19f12897-7c2b-47bb-9a17-daad1f17f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8598207-cbfb-4c45-b829-33bb8946a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8598207-cbfb-4c45-b829-33bb8946a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01cd552c-d054-4786-b218-c0a038090a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01cd552c-d054-4786-b218-c0a038090a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0941b521-2eec-443b-b654-77b000ab8cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_427fd66f-33cc-4d5e-b410-febbd1502aa4" xlink:to="loc_us-gaap_StockholdersEquity_0941b521-2eec-443b-b654-77b000ab8cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_20e3e043-cdf8-45d9-a21c-d56743182dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62e785d1-1897-4f04-b39a-3a135fa23cc5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_20e3e043-cdf8-45d9-a21c-d56743182dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98eebb44-8c44-4f22-ad5e-62492258c89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98eebb44-8c44-4f22-ad5e-62492258c89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af6505ea-fbd6-4c87-a552-7fcc7220e582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af6505ea-fbd6-4c87-a552-7fcc7220e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e584dcac-ea8b-4de5-94ca-63bfe3f19a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e584dcac-ea8b-4de5-94ca-63bfe3f19a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bffa500d-74ea-4623-aa38-50a74112cbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bffa500d-74ea-4623-aa38-50a74112cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_911bd2a0-7ca7-4566-8093-bc9ab3cc26d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_911bd2a0-7ca7-4566-8093-bc9ab3cc26d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c2100bcd-3559-42e0-814a-a36207798466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c2100bcd-3559-42e0-814a-a36207798466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9fa7f66a-9819-4ef3-a0d1-f5d9f320e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_CommonStockSharesIssued_9fa7f66a-9819-4ef3-a0d1-f5d9f320e1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7cb0f597-0c17-4df7-8597-acd6617b7fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_881dc1e5-e12d-462f-b3f0-3671824d093e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7cb0f597-0c17-4df7-8597-acd6617b7fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cf0902a8-db91-4d58-a841-671a0467fef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf0902a8-db91-4d58-a841-671a0467fef9" xlink:to="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:to="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4e0a212d-a6ff-4c72-b2bf-990303c13536" xlink:to="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6cde0050-b726-4093-b71e-0422b3058ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_us-gaap_RoyaltyMember_6cde0050-b726-4093-b71e-0422b3058ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d4e6bc20-a870-461d-9684-ba37ca066b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_us-gaap_ProductMember_d4e6bc20-a870-461d-9684-ba37ca066b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_6af3456f-705a-4bcb-a9a1-12bcf6017d8b" xlink:href="halo-20221231.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d48e5cd-5832-4811-b2e3-28df4c59f60a" xlink:to="loc_halo_CollaborativeAgreementsMember_6af3456f-705a-4bcb-a9a1-12bcf6017d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b4d2b9d2-b340-42a3-a27b-8aaf7a98e91a" xlink:to="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35ab35be-a4f0-4050-81c6-4d8c6dc8b1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ee2e55d0-3e4c-4ef9-b496-3620400f18a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35ab35be-a4f0-4050-81c6-4d8c6dc8b1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_447435f8-d0f6-402a-83cc-dd357d45308a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_447435f8-d0f6-402a-83cc-dd357d45308a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b032a77b-1f4b-4975-9644-b7766d9f871a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b032a77b-1f4b-4975-9644-b7766d9f871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_27ad2ab2-9631-4871-81c9-46a7012a123f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_27ad2ab2-9631-4871-81c9-46a7012a123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25ddb9ae-777d-4f84-affb-0f279f9a725b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25ddb9ae-777d-4f84-affb-0f279f9a725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ab4c8a1-e18d-4f29-ad48-530f6763b251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5f8a3d90-e4ed-4231-814f-6dba88c0601e" xlink:to="loc_us-gaap_CostsAndExpenses_1ab4c8a1-e18d-4f29-ad48-530f6763b251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96d0d789-2b6d-4e05-ae20-f7995c6cabb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_OperatingIncomeLoss_96d0d789-2b6d-4e05-ae20-f7995c6cabb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_50a7b69d-fe7f-4a96-945a-29db550e6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_50a7b69d-fe7f-4a96-945a-29db550e6b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62db128c-a60c-4ac9-8288-a1867f3f31da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_62db128c-a60c-4ac9-8288-a1867f3f31da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17a8183b-a871-4554-9630-1f3e420f922f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d4f3807a-fbc9-4d9d-a490-5ac3ae186311" xlink:to="loc_us-gaap_InterestExpense_17a8183b-a871-4554-9630-1f3e420f922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a203a3dd-8b3e-4324-b589-133e4844954a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a203a3dd-8b3e-4324-b589-133e4844954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83ec5185-c160-492b-879f-87eb32f71ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83ec5185-c160-492b-879f-87eb32f71ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68ed22d5-a753-4bcd-89be-627685018453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_NetIncomeLoss_68ed22d5-a753-4bcd-89be-627685018453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_02613541-7a32-4b17-9cec-94edb5bded99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:to="loc_us-gaap_EarningsPerShareBasic_02613541-7a32-4b17-9cec-94edb5bded99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2972deea-8c80-43b3-9b39-e89e90beac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_756a9d98-4760-446f-84be-53909fa2f548" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2972deea-8c80-43b3-9b39-e89e90beac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a720d42-6207-4726-aa3b-9bc085e66184" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc050e61-048b-40a6-b541-9f1e07013836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc050e61-048b-40a6-b541-9f1e07013836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c4b3c68-ceca-420d-9cf0-9dcb964a7676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_51c13fd4-9396-4222-904a-1d0e9d68a254" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c4b3c68-ceca-420d-9cf0-9dcb964a7676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_abc9fae8-7f4f-4b28-a71e-12b73a48b386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_574f9013-bd21-4681-afff-d7df42fd376f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_abc9fae8-7f4f-4b28-a71e-12b73a48b386" xlink:to="loc_us-gaap_NetIncomeLoss_574f9013-bd21-4681-afff-d7df42fd376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_abc9fae8-7f4f-4b28-a71e-12b73a48b386" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d4151761-a0eb-4abd-b782-f5b5ad416a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d4151761-a0eb-4abd-b782-f5b5ad416a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_6f51febf-efb2-4877-b82b-b0f1d86706a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_6f51febf-efb2-4877-b82b-b0f1d86706a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_49ebe41f-0af6-4dd3-bfac-bf24ba9159aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_49ebe41f-0af6-4dd3-bfac-bf24ba9159aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a6f8c2-f70d-4daa-a0d7-155cf8bbecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_057e6cd7-d2d8-4244-82ec-73897c6ac8fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a6f8c2-f70d-4daa-a0d7-155cf8bbecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c602bff-8739-4efe-b14a-f0b14891e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c602bff-8739-4efe-b14a-f0b14891e02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b00d9ff-51bc-446c-9112-3d698062d532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c602bff-8739-4efe-b14a-f0b14891e02b" xlink:to="loc_us-gaap_NetIncomeLoss_1b00d9ff-51bc-446c-9112-3d698062d532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c602bff-8739-4efe-b14a-f0b14891e02b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ce4a132-a7bf-4435-9ea6-942ee521b58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_ShareBasedCompensation_5ce4a132-a7bf-4435-9ea6-942ee521b58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fb86c45-78b0-41bd-850d-b1a435e5a0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fb86c45-78b0-41bd-850d-b1a435e5a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_65780e62-4314-4652-9a45-5c733d9ee02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_65780e62-4314-4652-9a45-5c733d9ee02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9ad510cc-25ac-46fb-8d7e-4d21c3aa389c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9ad510cc-25ac-46fb-8d7e-4d21c3aa389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_61ea9c15-526a-44ca-a54a-643a60f93e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_61ea9c15-526a-44ca-a54a-643a60f93e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eba8af38-00ce-456f-8433-e1a3de626ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eba8af38-00ce-456f-8433-e1a3de626ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_738bb64a-2776-4c9c-99a9-b54c48b90b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_738bb64a-2776-4c9c-99a9-b54c48b90b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_392ba81d-7091-4e7d-8a37-b3d9f6f805f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_392ba81d-7091-4e7d-8a37-b3d9f6f805f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_082de92d-9802-49b3-ac49-51ab8cb3b77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_082de92d-9802-49b3-ac49-51ab8cb3b77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_221a5ca7-e868-46f3-8f4b-b9ed5fc737a4" xlink:href="halo-20221231.xsd#halo_DeferredRentPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_halo_DeferredRentPayments_221a5ca7-e868-46f3-8f4b-b9ed5fc737a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_d686440e-b0a7-42e7-95b8-2f0d712a1be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_d686440e-b0a7-42e7-95b8-2f0d712a1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_0ff6b3fd-ca23-4d3b-b32d-5bd00171699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_0ff6b3fd-ca23-4d3b-b32d-5bd00171699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_deda87b3-4946-45c7-9a95-28d21e3fe586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_deda87b3-4946-45c7-9a95-28d21e3fe586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9aed23d4-7e03-4adc-8e52-20f8c30a65b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9aed23d4-7e03-4adc-8e52-20f8c30a65b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a30313f2-a89c-492e-9403-6397c6b927da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a30313f2-a89c-492e-9403-6397c6b927da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_aa045a1d-9672-4048-b389-c8c50961d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_aa045a1d-9672-4048-b389-c8c50961d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cc00b171-9ece-42c7-8de5-1442f522f113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cc00b171-9ece-42c7-8de5-1442f522f113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11751e94-5364-44bc-b086-365337084122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4348d247-7108-4786-b094-fec23924c94f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11751e94-5364-44bc-b086-365337084122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1965b34f-7124-4eb8-bb20-e7f5be5e5cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e08c145-649c-48c2-bc69-732c7b19e49b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1965b34f-7124-4eb8-bb20-e7f5be5e5cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_72ea37e1-b444-42ac-9d20-a886f2f91c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_72ea37e1-b444-42ac-9d20-a886f2f91c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_119e87a8-0df7-4fae-84b0-b4b7d2d3fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_119e87a8-0df7-4fae-84b0-b4b7d2d3fc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_11f30e42-75f9-43ec-affd-1e4aa1e9e04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_11f30e42-75f9-43ec-affd-1e4aa1e9e04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e84bb65-5b0f-48fc-aeaa-bbca04534d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e84bb65-5b0f-48fc-aeaa-bbca04534d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_772a57bd-6193-4c0b-b766-8ee046dab560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_772a57bd-6193-4c0b-b766-8ee046dab560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_851e6455-1d46-4518-867a-4123da5ca28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28269dda-218d-46b6-81be-20faf89067fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_851e6455-1d46-4518-867a-4123da5ca28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_b002a606-ddd8-49a2-9bc0-b55c2e8d2362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_b002a606-ddd8-49a2-9bc0-b55c2e8d2362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_7066a425-c1fe-4e64-836d-60decb6ffb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_7066a425-c1fe-4e64-836d-60decb6ffb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e05f2da3-c2c9-4ef4-9baa-80a3df8cd189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e05f2da3-c2c9-4ef4-9baa-80a3df8cd189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_0677420a-f123-4cb9-a618-eddfd2526e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_0677420a-f123-4cb9-a618-eddfd2526e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_a021d9b5-0503-468f-a5c8-0d4b6ca0bb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_a021d9b5-0503-468f-a5c8-0d4b6ca0bb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_68801d9f-0e0b-4753-bc26-7e41c07c5f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_68801d9f-0e0b-4753-bc26-7e41c07c5f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_db95f498-7cf8-473b-a655-4a2d278d9a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_db95f498-7cf8-473b-a655-4a2d278d9a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PurchaseOfCappedCall_2233bbcd-1e38-4c98-9736-fe8f8fe80704" xlink:href="halo-20221231.xsd#halo_PurchaseOfCappedCall"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_halo_PurchaseOfCappedCall_2233bbcd-1e38-4c98-9736-fe8f8fe80704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c3f9f8bf-a02d-4406-8d04-170b4203adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c3f9f8bf-a02d-4406-8d04-170b4203adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f7a6cf0-5cb7-4a46-a597-2a1fa1512fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f7a6cf0-5cb7-4a46-a597-2a1fa1512fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c24c7fda-9a25-405d-810e-9428dcaf42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c24c7fda-9a25-405d-810e-9428dcaf42e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af587dcd-6f9e-4f74-bb71-617ff79b8e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7319be8-1160-4e77-abce-4ee20ba2908e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af587dcd-6f9e-4f74-bb71-617ff79b8e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bb6745f-5432-46d3-a25a-af6f43639926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bb6745f-5432-46d3-a25a-af6f43639926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7641006-7d06-45f8-bcad-93e87ec17154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7641006-7d06-45f8-bcad-93e87ec17154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d65ffc4c-88fe-491d-9406-83343a62e937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d65ffc4c-88fe-491d-9406-83343a62e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e07352f4-e7a0-441d-9537-c0b2cd0aedbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e07352f4-e7a0-441d-9537-c0b2cd0aedbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_42d8aafb-c539-4d21-879e-aa9b88377d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e07352f4-e7a0-441d-9537-c0b2cd0aedbf" xlink:to="loc_us-gaap_InterestPaidNet_42d8aafb-c539-4d21-879e-aa9b88377d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_b52c664f-c18a-492a-bd42-cbe74fe43e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e07352f4-e7a0-441d-9537-c0b2cd0aedbf" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_b52c664f-c18a-492a-bd42-cbe74fe43e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_09a2a265-e2db-453b-8edd-bf0d65c473fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0bc37613-b109-4838-a3f8-896b612363e4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_09a2a265-e2db-453b-8edd-bf0d65c473fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d4ebade6-cd13-4cd7-8fc6-5b1f2a4cc2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_09a2a265-e2db-453b-8edd-bf0d65c473fe" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d4ebade6-cd13-4cd7-8fc6-5b1f2a4cc2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5a0f37d9-f3d0-4f65-b03c-6481dbfa611f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_09a2a265-e2db-453b-8edd-bf0d65c473fe" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5a0f37d9-f3d0-4f65-b03c-6481dbfa611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_697caab5-7527-48f4-812c-1eff27ac9b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_09a2a265-e2db-453b-8edd-bf0d65c473fe" xlink:to="loc_us-gaap_StockIssued1_697caab5-7527-48f4-812c-1eff27ac9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement" xlink:type="simple" xlink:href="halo-20221231.xsd#ConsolidatedStatementsofStockholdersEquityDeficitStatement"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b74d9d9e-450f-4cd5-9652-89858d7a13f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b74d9d9e-450f-4cd5-9652-89858d7a13f2" xlink:to="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ee3fabf2-9502-4459-acc8-2482e741ab99" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4fe24f22-5a95-4309-baac-37547b0ff502" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77b3c373-0c25-4ae1-91af-94be9cc125b5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4fe24f22-5a95-4309-baac-37547b0ff502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a3e27fc-0c6a-482e-b77e-dd929d745eab" xlink:to="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36b8a05c-2b85-4c8a-8307-32c53de92f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_CommonStockMember_36b8a05c-2b85-4c8a-8307-32c53de92f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_15811d4b-1657-4274-9a2e-caf30ef26562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_15811d4b-1657-4274-9a2e-caf30ef26562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6b31d10-fa66-46d4-bc34-25211a8126eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6b31d10-fa66-46d4-bc34-25211a8126eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0c74584e-2724-4177-a3db-5139fe7a5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08eb816-6fde-431c-b9df-b46c7fb7f3f1" xlink:to="loc_us-gaap_RetainedEarningsMember_0c74584e-2724-4177-a3db-5139fe7a5107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c8f1531-f423-4f22-b9b6-d8bda4898d39" xlink:to="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d6272c79-8ec0-4950-bc55-d1e503dc657a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_SharesOutstanding_d6272c79-8ec0-4950-bc55-d1e503dc657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f41d21d-c9aa-4619-af81-a1460bd93f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockholdersEquity_0f41d21d-c9aa-4619-af81-a1460bd93f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4cd4bb9-969e-43b5-b5f5-5d79d29fc7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4cd4bb9-969e-43b5-b5f5-5d79d29fc7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0f6cc27a-b7e4-49b4-8ac3-9f7a5fed79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0f6cc27a-b7e4-49b4-8ac3-9f7a5fed79ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_72a70137-b64d-467e-8d39-8f36b17e8c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_72a70137-b64d-467e-8d39-8f36b17e8c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bd1a3daa-719a-4246-bc34-d7a6ed88f513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bd1a3daa-719a-4246-bc34-d7a6ed88f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cbad0e1f-b733-48d2-8a1b-153b6947583f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cbad0e1f-b733-48d2-8a1b-153b6947583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_acdf1145-85be-466c-ba78-8e78e941028d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_acdf1145-85be-466c-ba78-8e78e941028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_336619bc-1172-4b46-a2b3-3ac9034ba9fb" xlink:href="halo-20221231.xsd#halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction_336619bc-1172-4b46-a2b3-3ac9034ba9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_694ceb24-fb9f-4104-9fde-4ce461c80b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_694ceb24-fb9f-4104-9fde-4ce461c80b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11ac2da7-b7b9-49aa-b7b4-3be92c9cde2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11ac2da7-b7b9-49aa-b7b4-3be92c9cde2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_cc4aaa5a-f357-4d14-9cfc-7e99f6f0dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_cc4aaa5a-f357-4d14-9cfc-7e99f6f0dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_179777e1-d9d4-48bd-8577-751c45871ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_179777e1-d9d4-48bd-8577-751c45871ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02785435-65f6-43ba-b756-5002e2ecf053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_NetIncomeLoss_02785435-65f6-43ba-b756-5002e2ecf053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_044d5c07-e751-4988-9af8-4ad088de262c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_SharesOutstanding_044d5c07-e751-4988-9af8-4ad088de262c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83887652-1b75-408d-aaca-197080e0c771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f756522-ade4-4167-bfe0-8d7c21353964" xlink:to="loc_us-gaap_StockholdersEquity_83887652-1b75-408d-aaca-197080e0c771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="halo-20221231.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f1b041bb-af60-42ff-96b3-6e1e9a09648a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_23978f8c-5e24-4439-b62a-90b947bcdeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f1b041bb-af60-42ff-96b3-6e1e9a09648a" xlink:to="loc_us-gaap_NatureOfOperations_23978f8c-5e24-4439-b62a-90b947bcdeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d27e2495-db1a-4c8f-85e7-7e4265c389cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c55f041c-1ba0-44f0-9dea-bdc59e99924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d27e2495-db1a-4c8f-85e7-7e4265c389cf" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c55f041c-1ba0-44f0-9dea-bdc59e99924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombination" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombination"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4cba5440-676c-4b35-a66f-db47022ede3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_77060902-6509-46ad-af08-3fefda66a671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4cba5440-676c-4b35-a66f-db47022ede3d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_77060902-6509-46ad-af08-3fefda66a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_446919b6-9d89-4725-963c-c84000c7759b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5e4e17d2-84ba-4a6b-bf2f-fb4466f49752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_446919b6-9d89-4725-963c-c84000c7759b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5e4e17d2-84ba-4a6b-bf2f-fb4466f49752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Revenue" xlink:type="simple" xlink:href="halo-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8d0a280a-4d02-4a59-9f2f-aa68a43ac825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f160f03e-2bda-48b2-9c76-cce50a65a4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8d0a280a-4d02-4a59-9f2f-aa68a43ac825" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f160f03e-2bda-48b2-9c76-cce50a65a4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4dc43033-8f46-4086-8c64-624d96268a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f0c819ec-e8b5-490c-a541-32aa340d0976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4dc43033-8f46-4086-8c64-624d96268a04" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f0c819ec-e8b5-490c-a541-32aa340d0976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_23ae6084-0272-4aff-a544-5e48578c1b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b286d07b-87b2-4bac-8e94-3641790f933c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_23ae6084-0272-4aff-a544-5e48578c1b2f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b286d07b-87b2-4bac-8e94-3641790f933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongtermDebtNet" xlink:type="simple" xlink:href="halo-20221231.xsd#LongtermDebtNet"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongtermDebtNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f20b9b1-0b5a-4812-a4e9-bf0881887efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e81fac46-1237-462d-b8b8-1f0dadaf5587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f20b9b1-0b5a-4812-a4e9-bf0881887efd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e81fac46-1237-462d-b8b8-1f0dadaf5587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10bb5e14-5c16-4dfc-bb67-22eaf70c0fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3b98219f-0451-4c4b-b435-d9a99b474d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10bb5e14-5c16-4dfc-bb67-22eaf70c0fd4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3b98219f-0451-4c4b-b435-d9a99b474d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquity" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29af12dd-131b-43e9-91fe-390138d03b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ee5cfc50-1a14-4047-8153-fa72140d0acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29af12dd-131b-43e9-91fe-390138d03b3b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ee5cfc50-1a14-4047-8153-fa72140d0acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershare" xlink:type="simple" xlink:href="halo-20221231.xsd#NetIncomepershare"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomepershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_44884157-cf81-4175-b269-33f60fc59e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ee701354-81b3-43ec-9024-003f8703bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44884157-cf81-4175-b269-33f60fc59e99" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ee701354-81b3-43ec-9024-003f8703bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c641bc30-9003-4931-a7f5-a96812191739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f9500fe8-f9f3-4812-a5bc-6b64d2c8b599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c641bc30-9003-4931-a7f5-a96812191739" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f9500fe8-f9f3-4812-a5bc-6b64d2c8b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxes" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_71ba9fc2-3ab8-4923-b5a3-4ce7c386cbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2a67f35e-38e0-4686-afc7-f4d004ec4d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_71ba9fc2-3ab8-4923-b5a3-4ce7c386cbd4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2a67f35e-38e0-4686-afc7-f4d004ec4d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EmployeeSavingsPlan" xlink:type="simple" xlink:href="halo-20221231.xsd#EmployeeSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EmployeeSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f4beb5cf-49fa-49a7-bf86-d354d57194b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_94fa611c-181e-4184-84cc-b53fa83dc178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f4beb5cf-49fa-49a7-bf86-d354d57194b9" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_94fa611c-181e-4184-84cc-b53fa83dc178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="halo-20221231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_1d1fb8b7-d3ae-4389-abc1-7fb174665516" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_a2b6d6bc-e4a5-435a-ae92-4aa3ebf00807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_1d1fb8b7-d3ae-4389-abc1-7fb174665516" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_a2b6d6bc-e4a5-435a-ae92-4aa3ebf00807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9f6d8ed5-3e56-4dd4-99ca-4e9bd450e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_UseOfEstimates_9f6d8ed5-3e56-4dd4-99ca-4e9bd450e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f323b09a-6e15-4690-863b-39868576de21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f323b09a-6e15-4690-863b-39868576de21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_a5655805-4a6d-47fa-8a73-ce64f4171367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_a5655805-4a6d-47fa-8a73-ce64f4171367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3743ae61-0bb5-4af3-91d8-6c0c2c008f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3743ae61-0bb5-4af3-91d8-6c0c2c008f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_276c5bfc-df8e-46a2-b78d-3015c8a95773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_276c5bfc-df8e-46a2-b78d-3015c8a95773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b0a1da60-f62b-46ff-886b-7eb86c96efd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b0a1da60-f62b-46ff-886b-7eb86c96efd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7e685232-4165-42b3-b0cd-603a84ea3589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7e685232-4165-42b3-b0cd-603a84ea3589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0cf21f37-6eb6-490c-b4c5-7e181760a79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_0cf21f37-6eb6-490c-b4c5-7e181760a79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0fcb9125-72cb-4785-98e7-bb9002af07af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0fcb9125-72cb-4785-98e7-bb9002af07af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c915ac6e-7c33-4a24-87e4-97b668a415bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c915ac6e-7c33-4a24-87e4-97b668a415bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8a9ba906-ab20-4b29-81cd-ebb0916b197c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8a9ba906-ab20-4b29-81cd-ebb0916b197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_10ea8d57-5dc5-41c0-897e-2823cb6596c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_10ea8d57-5dc5-41c0-897e-2823cb6596c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_90503e08-8e03-47fc-ad3c-681121a027e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_90503e08-8e03-47fc-ad3c-681121a027e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock_e4472cf6-39ce-4c26-870f-c0f54906a397" xlink:href="halo-20221231.xsd#halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock_e4472cf6-39ce-4c26-870f-c0f54906a397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_48331475-e27b-45b5-82f4-49a4757f974b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_48331475-e27b-45b5-82f4-49a4757f974b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_0c6ba0ec-0444-485a-bfdf-1abee56b1301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_0c6ba0ec-0444-485a-bfdf-1abee56b1301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7f14a87c-6739-4f6e-beb8-00685834adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7f14a87c-6739-4f6e-beb8-00685834adf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48481645-b216-45dc-aa56-d9dae59b41f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48481645-b216-45dc-aa56-d9dae59b41f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_da601496-a327-4c4b-9bd5-8832b89303b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_da601496-a327-4c4b-9bd5-8832b89303b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e911f055-b521-4569-a99d-df1eae3ebc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e911f055-b521-4569-a99d-df1eae3ebc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_96272cc4-80b4-4896-bd78-121ac136ed03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15a66aa-ccd8-4e12-827b-a9ff4bd8e35d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_96272cc4-80b4-4896-bd78-121ac136ed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8aeabae6-2025-4e19-a2c2-88eacc371c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8d19ab70-e2e5-4f56-836a-b198ad768a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8aeabae6-2025-4e19-a2c2-88eacc371c90" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8d19ab70-e2e5-4f56-836a-b198ad768a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_37ba82f4-2c28-46c3-b184-7276573c4c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_37ba82f4-2c28-46c3-b184-7276573c4c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d7d3ad4a-60df-49a2-91b0-b8d2a4917a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d7d3ad4a-60df-49a2-91b0-b8d2a4917a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_501e6a1a-0e7c-4aa7-8f9f-80b71d3c80c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_501e6a1a-0e7c-4aa7-8f9f-80b71d3c80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_78a2b655-3990-4f52-911f-9f5d47b5dad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_78a2b655-3990-4f52-911f-9f5d47b5dad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_acf3b14d-9f56-4308-bba1-4248db277ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3b1449d0-0b4c-47b3-82f1-092f1a12e056" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_acf3b14d-9f56-4308-bba1-4248db277ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_65d3de58-b14b-432f-9633-30ca8f7607b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c003efdc-541d-490d-8165-ea8640711f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65d3de58-b14b-432f-9633-30ca8f7607b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c003efdc-541d-490d-8165-ea8640711f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ba7773da-f903-45b3-850e-f087bf28e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65d3de58-b14b-432f-9633-30ca8f7607b1" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ba7773da-f903-45b3-850e-f087bf28e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_342bf1fa-e44d-41b8-afb8-53aa1026436a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65d3de58-b14b-432f-9633-30ca8f7607b1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_342bf1fa-e44d-41b8-afb8-53aa1026436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTables" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d76cf82b-7179-4573-bfd1-74b6607ed19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4c4c49d7-ed43-4a4e-baf7-f90e38a0bed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d76cf82b-7179-4573-bfd1-74b6607ed19d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4c4c49d7-ed43-4a4e-baf7-f90e38a0bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_028b3e6a-f500-446b-be5a-4392241d4bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d76cf82b-7179-4573-bfd1-74b6607ed19d" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_028b3e6a-f500-446b-be5a-4392241d4bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_efa7e9f7-5865-4f5e-8259-37ce81d5ae3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_efa7e9f7-5865-4f5e-8259-37ce81d5ae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_efe1eedc-8671-42c3-ab33-e1190b8eac97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_efe1eedc-8671-42c3-ab33-e1190b8eac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_7c562704-445a-4ab1-97b7-4abff1e68afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_7c562704-445a-4ab1-97b7-4abff1e68afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5f0d0ad8-9e81-4a53-8f07-b0bea8b5f661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5f0d0ad8-9e81-4a53-8f07-b0bea8b5f661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6ce57c3c-8b1f-496b-9207-6bd6859bbcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_14675b6f-25ee-45ac-8ca4-c8b663442079" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6ce57c3c-8b1f-496b-9207-6bd6859bbcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea825b00-6cf4-4510-9c5d-317ed42fbde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_671a4c40-5871-4f36-9efb-bd387583cdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea825b00-6cf4-4510-9c5d-317ed42fbde0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_671a4c40-5871-4f36-9efb-bd387583cdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_478e6528-a867-48a1-bc11-a1ce724dfe5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea825b00-6cf4-4510-9c5d-317ed42fbde0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_478e6528-a867-48a1-bc11-a1ce724dfe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_de839984-0007-4e1a-860e-7c2af55dec08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea825b00-6cf4-4510-9c5d-317ed42fbde0" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_de839984-0007-4e1a-860e-7c2af55dec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_08e0d782-00a2-4541-baa6-900316a0fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea825b00-6cf4-4510-9c5d-317ed42fbde0" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_08e0d782-00a2-4541-baa6-900316a0fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongtermDebtNetTables" xlink:type="simple" xlink:href="halo-20221231.xsd#LongtermDebtNetTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongtermDebtNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d61eabb4-ec97-40be-86c7-4ee105ecec8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f5ab7171-ae04-4eb7-889a-8e780612bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d61eabb4-ec97-40be-86c7-4ee105ecec8e" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f5ab7171-ae04-4eb7-889a-8e780612bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_354cf602-4f6a-4427-a713-dc374b00363f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d61eabb4-ec97-40be-86c7-4ee105ecec8e" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_354cf602-4f6a-4427-a713-dc374b00363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5b92589f-9436-46cc-a1fc-8d26865547b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d61eabb4-ec97-40be-86c7-4ee105ecec8e" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5b92589f-9436-46cc-a1fc-8d26865547b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_16275025-753d-472b-bdc6-5f177b3966b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_16275025-753d-472b-bdc6-5f177b3966b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_02d0b313-e944-4e9c-baa7-0142742de4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_02d0b313-e944-4e9c-baa7-0142742de4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_4229b724-228e-4239-bb23-dd2778b82662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_4229b724-228e-4239-bb23-dd2778b82662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_81d4b21f-d740-4f55-afae-9527571109ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_81d4b21f-d740-4f55-afae-9527571109ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_92c412d7-9802-4bb7-b5bc-feb5cdbe2914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_92c412d7-9802-4bb7-b5bc-feb5cdbe2914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_eda45cde-cf1e-4f31-a9f3-d60d4d78354f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_eda45cde-cf1e-4f31-a9f3-d60d4d78354f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_df453ba0-95ca-43a8-b31b-3f0889da73e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cad0ec5-97a7-45f9-9899-136b6063a0e5" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_df453ba0-95ca-43a8-b31b-3f0889da73e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_31011a4b-1937-42ed-b7a1-979c2c20a88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_ea4bd451-a900-43d2-a0af-f2f0fa961766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31011a4b-1937-42ed-b7a1-979c2c20a88f" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_ea4bd451-a900-43d2-a0af-f2f0fa961766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershareTables" xlink:type="simple" xlink:href="halo-20221231.xsd#NetIncomepershareTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomepershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45416936-379b-4b73-a496-b15eb53129f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be7d76b2-9fe1-4173-b228-1e7c35290a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45416936-379b-4b73-a496-b15eb53129f4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be7d76b2-9fe1-4173-b228-1e7c35290a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_061bf308-b901-44f8-ad53-2822404d7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45416936-379b-4b73-a496-b15eb53129f4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_061bf308-b901-44f8-ad53-2822404d7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9613edab-9f4e-4f54-b6e8-7050825ddb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_94378795-9179-4b1f-a2e6-2d10bca58cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9613edab-9f4e-4f54-b6e8-7050825ddb6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_94378795-9179-4b1f-a2e6-2d10bca58cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_796a80d6-7a7a-4436-aec2-6e267c8d4dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_796a80d6-7a7a-4436-aec2-6e267c8d4dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5e355ad3-b451-4100-bd5b-2b476788f6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5e355ad3-b451-4100-bd5b-2b476788f6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_94e4271d-985a-440d-a9e3-3c081267fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_94e4271d-985a-440d-a9e3-3c081267fe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_21eaf7d2-1cce-4b1e-9150-c6aca7522ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_21eaf7d2-1cce-4b1e-9150-c6aca7522ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_91a659ac-3495-41cf-a83c-8aa9005268d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_212dec4f-dcf8-400c-8a60-df80a9b13b0b" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_91a659ac-3495-41cf-a83c-8aa9005268d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#OrganizationandBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d840040-8538-4c01-a4cb-26dd81eea4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d840040-8538-4c01-a4cb-26dd81eea4a1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:to="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_47ec9d9b-027b-4217-b35f-2bd829e6fe1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember_d210baf1-cc94-479c-8084-dead3b38d975" xlink:href="halo-20221231.xsd#halo_TakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_TakedaMember_d210baf1-cc94-479c-8084-dead3b38d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_1c282d04-f769-43da-9b18-8a63828f2414" xlink:href="halo-20221231.xsd#halo_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_RocheMember_1c282d04-f769-43da-9b18-8a63828f2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_ffcc596f-bd8e-4449-a181-627ad95f2831" xlink:href="halo-20221231.xsd#halo_JanssenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e0fbae6-4a5e-48ea-b651-acdf446e1cc0" xlink:to="loc_halo_JanssenMember_ffcc596f-bd8e-4449-a181-627ad95f2831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cca339d-93c0-4614-bf44-4336eb5e2b1f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfCollaborationsRoyaltiesReceived_b0982156-a5ee-4136-a398-6703de95670b" xlink:href="halo-20221231.xsd#halo_NumberOfCollaborationsRoyaltiesReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:to="loc_halo_NumberOfCollaborationsRoyaltiesReceived_b0982156-a5ee-4136-a398-6703de95670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_77b7bbb1-154d-4448-8052-f672d3def38a" xlink:href="halo-20221231.xsd#halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54d45c8-4c26-4319-92a0-e6768d8fb14a" xlink:to="loc_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales_77b7bbb1-154d-4448-8052-f672d3def38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_8750b349-dc8b-4319-a6d1-be7abb3d8090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e9aa68cb-c616-4b3c-8a3a-e9db7ad2a571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_8750b349-dc8b-4319-a6d1-be7abb3d8090" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e9aa68cb-c616-4b3c-8a3a-e9db7ad2a571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_94541370-3db2-4d3f-ac56-49fe9092433e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94541370-3db2-4d3f-ac56-49fe9092433e" xlink:to="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c9f1011c-0864-4c1f-a41c-c640f9633fbf" xlink:to="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheandBaxaltaMember_ad0ebde3-ea56-408f-a8c0-d48adf68b64e" xlink:href="halo-20221231.xsd#halo_RocheandBaxaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_RocheandBaxaltaMember_ad0ebde3-ea56-408f-a8c0-d48adf68b64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerAMember_dcc5acb7-9778-4092-a0ba-1e04913d9b15" xlink:href="halo-20221231.xsd#halo_PartnerAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerAMember_dcc5acb7-9778-4092-a0ba-1e04913d9b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerBMember_84377df7-80b6-4fbb-bb0f-0f4c28cb74f1" xlink:href="halo-20221231.xsd#halo_PartnerBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerBMember_84377df7-80b6-4fbb-bb0f-0f4c28cb74f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerCMember_c844652e-5d9e-4255-b1d1-a65485dd2024" xlink:href="halo-20221231.xsd#halo_PartnerCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerCMember_c844652e-5d9e-4255-b1d1-a65485dd2024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PartnerDMember_05b03642-6195-4283-b707-3016a40067ff" xlink:href="halo-20221231.xsd#halo_PartnerDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7ee35d8a-ea30-429a-a1af-80f07f26303c" xlink:to="loc_halo_PartnerDMember_05b03642-6195-4283-b707-3016a40067ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8925a008-5a8e-4ba1-b15b-1891a8550276" xlink:to="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_01797619-9c8e-4fff-94e3-51756b16ff6b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_US_01797619-9c8e-4fff-94e3-51756b16ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_a9ed9b70-3a46-4ccb-8301-cc55a5521fe8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_CH_a9ed9b70-3a46-4ccb-8301-cc55a5521fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_a73032a1-6808-41c3-87d7-73bc738dba8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_IE_a73032a1-6808-41c3-87d7-73bc738dba8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE_b2199ce4-156a-4221-8054-b995f0f10b3b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_BE_b2199ce4-156a-4221-8054-b995f0f10b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0f75a58a-78da-45da-aa1b-5e16df5399fc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_country_JP_0f75a58a-78da-45da-aa1b-5e16df5399fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ForeignOtherMember_5c37a237-266b-4064-bcd2-306a201e65f6" xlink:href="halo-20221231.xsd#halo_ForeignOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed7dff24-43f0-4dab-a9a3-ce763cdd0a88" xlink:to="loc_halo_ForeignOtherMember_5c37a237-266b-4064-bcd2-306a201e65f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_93d91b6f-9e51-4f84-b678-94892f945bc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3b5c4a2d-fd79-43e9-a3fd-d235c58e9533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:to="loc_us-gaap_AccountsReceivableMember_3b5c4a2d-fd79-43e9-a3fd-d235c58e9533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_49739de8-1097-4448-bf7e-dabb9978d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a88bbbd6-050a-428b-9712-4b40fbbf4682" xlink:to="loc_us-gaap_SalesMember_49739de8-1097-4448-bf7e-dabb9978d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_347520f5-a820-4f80-a1fe-dd8c1da6dcd6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_51290e1e-d2bb-40ad-a141-6010db6dd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_51290e1e-d2bb-40ad-a141-6010db6dd5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_13beb4f1-7322-4e92-87c2-76d24174d545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5283496a-9c9d-42dd-b8cc-0a61b480b8af" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_13beb4f1-7322-4e92-87c2-76d24174d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bb430534-fab8-460b-bd86-f46c14b1ed11" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7efb685d-9f45-4da4-a303-2e1bf53ddea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7efb685d-9f45-4da4-a303-2e1bf53ddea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ConcentrationRiskPercentageInstantDate_8569e18c-c321-469f-b73e-9be14134365b" xlink:href="halo-20221231.xsd#halo_ConcentrationRiskPercentageInstantDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_halo_ConcentrationRiskPercentageInstantDate_8569e18c-c321-469f-b73e-9be14134365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_55fcf5cd-ec46-4a5f-8582-861a92a2ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_55fcf5cd-ec46-4a5f-8582-861a92a2ced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d05f02d1-8bd3-4319-9c44-c7ddd4306d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3eed817e-5797-46b2-a91b-510ac2dc4465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d05f02d1-8bd3-4319-9c44-c7ddd4306d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0679f9ba-cde2-4868-87ca-07300030f97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2164b864-32e9-442d-920d-b3ce1db526bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0679f9ba-cde2-4868-87ca-07300030f97a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2164b864-32e9-442d-920d-b3ce1db526bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_85c3af7e-0121-46b7-b05d-f3ead9adc46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85c3af7e-0121-46b7-b05d-f3ead9adc46a" xlink:to="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:to="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_152ae52c-fc81-43fd-8bf4-aa534c691056" xlink:to="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ec2fd9-cd3a-46cc-a358-854adfb5a271" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:to="loc_srt_MinimumMember_05ec2fd9-cd3a-46cc-a358-854adfb5a271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a4ea3b9-82d0-401d-b268-995f86d768e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_648b576b-3b46-4b5f-ae83-29b0840e0d5f" xlink:to="loc_srt_MaximumMember_5a4ea3b9-82d0-401d-b268-995f86d768e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_97bccae7-77b0-4969-83f5-8ea6959cce82" xlink:to="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2dbb67fd-d482-4a83-816c-41d00e2139a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07f2681d-e3aa-420b-a729-22be3a958796" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2dbb67fd-d482-4a83-816c-41d00e2139a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_074ef82c-e806-4d5f-ae4b-16a068c05cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_074ef82c-e806-4d5f-ae4b-16a068c05cbd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:to="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f30b4429-69af-43d2-90f9-322040a93cb7" xlink:to="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17353bdf-23df-458a-a7ae-069eff6a2ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:to="loc_srt_MinimumMember_17353bdf-23df-458a-a7ae-069eff6a2ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cafc2cf-2372-4651-9475-3c2b8fa288b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca335690-a94f-42d0-819f-5057be12913d" xlink:to="loc_srt_MaximumMember_7cafc2cf-2372-4651-9475-3c2b8fa288b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_165eff88-f059-4e5d-ab8a-ee56684189d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0417fed5-a70c-43e1-ada9-ec9e55bc670f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ea00df59-22d8-48e4-b2bf-687f15ef740c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0417fed5-a70c-43e1-ada9-ec9e55bc670f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SummaryofSignificantAccountingPoliciesSegmentinformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_94310cb9-f16b-4ad1-9a88-5519e2da3d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7929ad17-e9de-4b5f-9cb3-b91b8a1a1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_94310cb9-f16b-4ad1-9a88-5519e2da3d42" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7929ad17-e9de-4b5f-9cb3-b91b8a1a1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c61716de-9779-4fdd-b1c8-763b15631ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c61716de-9779-4fdd-b1c8-763b15631ea6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f53e0fa-aa43-4e98-9bcc-b2e3ddc21df0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_15c1c010-4a94-49cb-a0ca-d4687352afeb" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e692ad0-189f-422a-adec-fcdf0aa7b6ce" xlink:to="loc_halo_AntaresPharmaIncMember_15c1c010-4a94-49cb-a0ca-d4687352afeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_696da5ff-f848-48ad-880f-a90a0ea6b208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_d63757fd-7f69-4cfb-a168-6368ad65c70b" xlink:href="halo-20221231.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_577ef848-d0ce-4ffa-9676-b5a3b630f934" xlink:to="loc_halo_TermLoanFacilityMember_d63757fd-7f69-4cfb-a168-6368ad65c70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2a0dbd91-4a93-4ac2-a863-d794d5d7b6ef" xlink:to="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b400a35b-84df-43ad-a4ac-8615b788c407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_63dd86f9-b234-4faa-911c-6149392916fa" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b400a35b-84df-43ad-a4ac-8615b788c407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0777c9da-b039-4e8b-8137-b2b2a940fb46" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c23366c-afbd-4b00-a19e-aea2221cf24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c23366c-afbd-4b00-a19e-aea2221cf24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_406f9185-e60b-4b67-b007-af7bd4b0518a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_406f9185-e60b-4b67-b007-af7bd4b0518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d192b7ac-a1f8-48ad-8a63-8dbef6933b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d192b7ac-a1f8-48ad-8a63-8dbef6933b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_1c47b8c1-6044-4ddf-96e2-5fe73cdb0daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_1c47b8c1-6044-4ddf-96e2-5fe73cdb0daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd9ebc18-c232-46d0-81d0-9f3bf6c33b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd9ebc18-c232-46d0-81d0-9f3bf6c33b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5828fac0-16b1-4c31-b138-f0a31b4d96f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5828fac0-16b1-4c31-b138-f0a31b4d96f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97abea65-a27c-4eb9-909e-f5c867ec3ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97abea65-a27c-4eb9-909e-f5c867ec3ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a55c2868-e237-4c62-914c-6cac7f389892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a55c2868-e237-4c62-914c-6cac7f389892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_cbcb3985-c9d2-4485-8c38-95274dac2c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_cbcb3985-c9d2-4485-8c38-95274dac2c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b0215b24-f4ed-48c3-94d4-5b668f0dae43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_590796eb-9f02-4a88-8e48-0c5d34f49cdf" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_b0215b24-f4ed-48c3-94d4-5b668f0dae43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_91e510f8-f50f-4acf-a760-b308375c6ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_91e510f8-f50f-4acf-a760-b308375c6ee6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1579bac-606b-40bd-aa59-729f2f277644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_14a18ce8-e598-4cae-a672-1b56d154e602" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b6a9ed-38f2-4a77-b537-308af8d4db6f" xlink:to="loc_halo_AntaresPharmaIncMember_14a18ce8-e598-4cae-a672-1b56d154e602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_f814acea-f3ab-4030-82e7-0956f1c1241b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_02e8f53e-373c-4b61-b474-76b471fb9835" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_02e8f53e-373c-4b61-b474-76b471fb9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_b7529cdf-1448-46e8-bda0-bae4d1ef0b7e" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_df675dd2-bc7f-41a7-a5c2-9ff82c094367" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_b7529cdf-1448-46e8-bda0-bae4d1ef0b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4122055-fec8-4b0c-bebc-06f757b0c489" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f0170c85-d9aa-4b02-bd15-36aad17cd1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f0170c85-d9aa-4b02-bd15-36aad17cd1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_59637dab-e9a1-46c7-ba20-33543c76ac4b" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_59637dab-e9a1-46c7-ba20-33543c76ac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_10ad1c4b-e319-457c-a341-6756f55fd6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_10ad1c4b-e319-457c-a341-6756f55fd6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8a0c22d3-3253-4c00-985d-9f001b96862d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8a0c22d3-3253-4c00-985d-9f001b96862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8da978a5-6566-47e9-bb08-36918115edde" xlink:href="halo-20221231.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8da978a5-6566-47e9-bb08-36918115edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ccf46d9-ab67-426d-beed-bd4d20183d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ccf46d9-ab67-426d-beed-bd4d20183d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_28b3dae2-fd6d-4e12-a355-4f49ea35d9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_772db851-0253-49ab-8517-795a6c476f8b" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_28b3dae2-fd6d-4e12-a355-4f49ea35d9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_010483a5-fcc7-4b34-a821-e7f6ae126ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_010483a5-fcc7-4b34-a821-e7f6ae126ea0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2eb885c-b431-46e4-9817-bdd706b1d6ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_c9ba881d-0a0d-4680-a258-ab8955f166d6" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba0e68ef-8114-471a-988c-ad5bc718aeb6" xlink:to="loc_halo_AntaresPharmaIncMember_c9ba881d-0a0d-4680-a258-ab8955f166d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf6bbf75-631a-4c64-896f-700828a9700e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_39453f84-c4cf-4eb7-83f7-fec867ce0a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_39453f84-c4cf-4eb7-83f7-fec867ce0a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f38d9c2-b763-48e1-947c-afe5be605a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f38d9c2-b763-48e1-947c-afe5be605a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a66d340e-43e8-4c98-bd9d-9e14dca2e03a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a66d340e-43e8-4c98-bd9d-9e14dca2e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a4b0bcfe-e021-41cb-8ee9-f9540867be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a4b0bcfe-e021-41cb-8ee9-f9540867be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e6f6488-0a0c-4d44-8269-0a1be5ca54a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4e6f6488-0a0c-4d44-8269-0a1be5ca54a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_edd60660-594e-469e-8d98-2fea71557a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_edd60660-594e-469e-8d98-2fea71557a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3dd81930-e9bc-4867-b795-c108168a997a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3dd81930-e9bc-4867-b795-c108168a997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e08ae13f-976f-4546-828e-5818b73f42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_70433609-3b60-4349-b54e-dbe911f13ff3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e08ae13f-976f-4546-828e-5818b73f42e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ae99a076-c6e8-4232-bc26-bdf4293e5707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ae99a076-c6e8-4232-bc26-bdf4293e5707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_0c784fe4-eef4-449c-ab6b-96c57eb440d4" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_0c784fe4-eef4-449c-ab6b-96c57eb440d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_5d5c674a-f9bb-4b3d-91e3-e90529123c2a" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_5d5c674a-f9bb-4b3d-91e3-e90529123c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3335cbfb-d7b5-4539-86f2-f0c18c0f8b9c" xlink:href="halo-20221231.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_3335cbfb-d7b5-4539-86f2-f0c18c0f8b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e5cbb38-518b-45d2-b974-c920890841b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e5cbb38-518b-45d2-b974-c920890841b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_661ebfb0-9d01-467d-af0b-e52a848bb177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_8f60c8ba-6eca-403b-963c-3b85af33fbed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_661ebfb0-9d01-467d-af0b-e52a848bb177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef32a136-8640-4a46-b319-8778f9c568f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef32a136-8640-4a46-b319-8778f9c568f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e274fe8-ddc4-4f11-ae88-862a1d3b929d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_Goodwill_9e274fe8-ddc4-4f11-ae88-862a1d3b929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bdb0bf5c-3154-4e83-ad22-e46c56f21fa9" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_974a3f16-2105-4b54-8066-7aabd331712e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_974a3f16-2105-4b54-8066-7aabd331712e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_4b887e2f-d198-44a1-abae-8495bc071fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_4b887e2f-d198-44a1-abae-8495bc071fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_040fd89a-e3d7-4cf9-accd-fb2c644f206f" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses_040fd89a-e3d7-4cf9-accd-fb2c644f206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_f70bcc38-266d-4dc4-9c49-a0cdbc26d5e2" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_f70bcc38-266d-4dc4-9c49-a0cdbc26d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_430ff739-da80-4af7-b09b-e7113d24c86c" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_430ff739-da80-4af7-b09b-e7113d24c86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_fc54b76c-bbba-4bf7-9ea2-1d5e0874702d" xlink:href="halo-20221231.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_fc54b76c-bbba-4bf7-9ea2-1d5e0874702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_83af51dd-5d89-4220-afb3-4394b103432a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationAbstract_0d4fd80c-049a-45ed-917f-1ff36a984876" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_83af51dd-5d89-4220-afb3-4394b103432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d04f0e72-56e8-46f1-96a9-deeef7c61bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d04f0e72-56e8-46f1-96a9-deeef7c61bfc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd397e36-995a-425e-ae0f-dd1ffbae041f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_303f0e64-4c11-4f06-91b4-410dcd91c0d6" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00e5b763-be0e-4125-8baa-ce83073810fb" xlink:to="loc_halo_AntaresPharmaIncMember_303f0e64-4c11-4f06-91b4-410dcd91c0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84e07671-63ff-49be-b764-0163fc472af9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_3a8069c5-72bf-458a-97e7-c45ba28a3783" xlink:href="halo-20221231.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_3a8069c5-72bf-458a-97e7-c45ba28a3783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_46500101-e1c5-47b6-9696-01555f995123" xlink:href="halo-20221231.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_46500101-e1c5-47b6-9696-01555f995123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_e2025782-a5f9-4187-8ab9-d5c0db97d44a" xlink:href="halo-20221231.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a989c1-7d73-424d-ac77-9628047ac2a6" xlink:to="loc_halo_TLANDOProductRightsMember_e2025782-a5f9-4187-8ab9-d5c0db97d44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_750dd6c8-1e42-44d4-b341-107cd27a060b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e5486c2c-8ee5-4468-b4a1-85e85b350d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18cb9031-133b-4dd3-9006-2cbd8058ea35" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e5486c2c-8ee5-4468-b4a1-85e85b350d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00f82f70-ce34-4674-8ad5-5d3f49addc00" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5dadf17a-a253-4ddd-9d25-6c1da8511fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5dadf17a-a253-4ddd-9d25-6c1da8511fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_79e93e99-ba9a-43d3-8e63-7ad513728f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_79e93e99-ba9a-43d3-8e63-7ad513728f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a593993-72a7-4652-8c86-038a64a5580e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a593993-72a7-4652-8c86-038a64a5580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9126fa70-f6e5-4c10-8fa0-ff2506fea80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e7b000fd-8773-4eca-99bc-3c46bcff51aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9126fa70-f6e5-4c10-8fa0-ff2506fea80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#BusinessCombinationSummaryofProformaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7643df5c-902b-412b-a3e0-b909b38130e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7643df5c-902b-412b-a3e0-b909b38130e1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629f9ce9-f36a-47d5-9483-1c79f356063d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_1c92bbb2-fafb-4891-8055-fadcf386ed0a" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88737765-133b-4d61-b93b-4465fad4b3f3" xlink:to="loc_halo_AntaresPharmaIncMember_1c92bbb2-fafb-4891-8055-fadcf386ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26ceb445-d4ad-45fd-9f8f-90ad1a711df1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_22ba1c56-e1ee-45fb-851c-f7a5d6989eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_22ba1c56-e1ee-45fb-851c-f7a5d6989eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4bb3dc92-a6f8-49c6-b7db-b79ead5c630a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_797e8c01-9222-4c2a-9e54-572b6e08d393" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4bb3dc92-a6f8-49c6-b7db-b79ead5c630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7998b0d9-c99c-48b8-a1c6-55865d93801d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7998b0d9-c99c-48b8-a1c6-55865d93801d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2dc3275f-8ca9-4ed4-9860-62c7654c1aa6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c80cc77d-1c44-46e1-a7f6-548b989ab5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c80cc77d-1c44-46e1-a7f6-548b989ab5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8b3976f6-0295-410b-b053-03d3ece01b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8b3976f6-0295-410b-b053-03d3ece01b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2aefc861-f1ab-44dd-ba7f-9ac097600ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2aefc861-f1ab-44dd-ba7f-9ac097600ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_3fc8c568-0ee8-496b-9760-4233cb4edd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_AgencySecuritiesMember_3fc8c568-0ee8-496b-9760-4233cb4edd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2727f55e-7e89-43a2-a2f5-2b28f500df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2727f55e-7e89-43a2-a2f5-2b28f500df5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0660da7d-02bc-413a-bbfe-1242822fbc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53893944-5291-4841-916e-4790ec9573d1" xlink:to="loc_us-gaap_CommercialPaperMember_0660da7d-02bc-413a-bbfe-1242822fbc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_50d7ad01-31a3-49b7-92d8-dfc948078a06" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8afdbf74-a334-435f-8939-0472b328bc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8afdbf74-a334-435f-8939-0472b328bc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf3cb158-5b5d-485b-981f-7fb9854dcbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bf3cb158-5b5d-485b-981f-7fb9854dcbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a818acad-9b12-48fc-90f1-f46f7bb91d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a818acad-9b12-48fc-90f1-f46f7bb91d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5eed0d-5675-4d9d-9449-384af85b2820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f7d2061b-bd10-491c-af27-588e28922b97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5eed0d-5675-4d9d-9449-384af85b2820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3314461a-f145-4b79-9144-02c69e26eef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_92a914e5-ed6e-46b1-bb0f-6240179eb472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3314461a-f145-4b79-9144-02c69e26eef6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_92a914e5-ed6e-46b1-bb0f-6240179eb472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_3800bc19-4277-4559-81cb-b959a874aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3314461a-f145-4b79-9144-02c69e26eef6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_3800bc19-4277-4559-81cb-b959a874aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7a346170-8725-4a5b-ba40-286efdf7361d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3314461a-f145-4b79-9144-02c69e26eef6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7a346170-8725-4a5b-ba40-286efdf7361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3314461a-f145-4b79-9144-02c69e26eef6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a81c5738-a981-4c81-b4ae-c4bb2ab40098" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_87523a23-d6be-43cf-8d85-73acd9721965" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea674675-3deb-494d-a46b-52cc9c5716eb" xlink:to="loc_halo_AntaresPharmaIncMember_87523a23-d6be-43cf-8d85-73acd9721965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f9e395d5-9d10-4d76-9f68-c16c672199cb" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b64fce49-0c2e-439c-a76e-a63ba09ae45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_45c75e8c-d2f4-49a2-b308-04838755a372" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b64fce49-0c2e-439c-a76e-a63ba09ae45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5506ae87-9ad0-4211-ac4b-25e5b878ff8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c65df43d-c1bb-4d90-8f60-1e50624bc685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5506ae87-9ad0-4211-ac4b-25e5b878ff8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c65df43d-c1bb-4d90-8f60-1e50624bc685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eca464e3-dfbc-458b-85c6-b3acebf97947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5506ae87-9ad0-4211-ac4b-25e5b878ff8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eca464e3-dfbc-458b-85c6-b3acebf97947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04101d12-9fda-44b7-ae3c-809c89584834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5506ae87-9ad0-4211-ac4b-25e5b878ff8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04101d12-9fda-44b7-ae3c-809c89584834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c199519-b0a6-4658-a52a-d43e2d03ac7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c199519-b0a6-4658-a52a-d43e2d03ac7d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_99135cf5-de05-4dfc-990f-d2378cebdf7b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3f6fc976-c6cf-49d1-b70c-0d1056a1fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3f6fc976-c6cf-49d1-b70c-0d1056a1fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_abc9b9df-92b4-431c-87fe-15bd6a93fa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c37d0ce2-d9c6-4158-b4a2-27909e165afd" xlink:to="loc_us-gaap_CommercialPaperMember_abc9b9df-92b4-431c-87fe-15bd6a93fa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca0c58ae-5721-4ffa-bad9-93bb04b83895" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2e2a9e8-894c-4e59-8842-e47f8a066aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2e2a9e8-894c-4e59-8842-e47f8a066aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c39c82ff-0e74-4509-9039-1ccba4b3f265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c39c82ff-0e74-4509-9039-1ccba4b3f265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_84e9a1f2-c77d-47b5-b815-c0bc1f3c9fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_84e9a1f2-c77d-47b5-b815-c0bc1f3c9fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1b3a8659-f5bf-4b27-b8c2-f564f57daad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1b3a8659-f5bf-4b27-b8c2-f564f57daad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_efa2b7a2-ef88-410a-9287-0d027e9a9bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_AgencySecuritiesMember_efa2b7a2-ef88-410a-9287-0d027e9a9bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_37af062c-7609-47c0-8a41-0f3589b2ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1282e675-2d83-42cd-9731-1892dd8063de" xlink:to="loc_us-gaap_CommercialPaperMember_37af062c-7609-47c0-8a41-0f3589b2ce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a3ddc4ea-8fb7-4886-880c-a5dd0de7e079" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7185be2-d961-4da0-b40f-59dfdb8d22bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7185be2-d961-4da0-b40f-59dfdb8d22bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_65a8dfcf-ba51-4adf-a943-f42f2cbe4846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_65a8dfcf-ba51-4adf-a943-f42f2cbe4846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9fee2d94-9eb9-4884-91b4-e643ff12cce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf7ea48-90ff-4262-b0b2-9c9ef9010f87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9fee2d94-9eb9-4884-91b4-e643ff12cce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_62308edb-cf79-4741-8873-44e8d6cbf892" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e0269e2f-b0ed-4b8c-8218-60dfa1ee1354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e0269e2f-b0ed-4b8c-8218-60dfa1ee1354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b5732d5f-1f4c-4967-aa9c-2833f2ecd952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_CommercialPaperMember_b5732d5f-1f4c-4967-aa9c-2833f2ecd952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fa395be1-69a9-404f-9093-e451c7c1d849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fa395be1-69a9-404f-9093-e451c7c1d849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_30436d09-7790-4e0d-a036-d0548d8e4e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_30436d09-7790-4e0d-a036-d0548d8e4e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_3ee6d6bd-9ed5-485c-9baf-4c1578cd9ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_3ee6d6bd-9ed5-485c-9baf-4c1578cd9ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_dd4fc6fd-ec13-4eb7-bcdf-60901bfbe327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a64287-3776-43cc-ac0f-0763f82ab3ee" xlink:to="loc_us-gaap_AgencySecuritiesMember_dd4fc6fd-ec13-4eb7-bcdf-60901bfbe327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_369cf7b0-16a2-4c2c-86b3-4e1be783ebd7" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47ddde8a-7624-4c08-8c9d-86cd0d460904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47ddde8a-7624-4c08-8c9d-86cd0d460904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5551b48c-cb3f-4aa3-b4b0-c8dcb8b91d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5551b48c-cb3f-4aa3-b4b0-c8dcb8b91d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_28d84d41-feb6-419a-aa1d-742971ab1739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_28d84d41-feb6-419a-aa1d-742971ab1739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_38c76b72-b945-4103-9d01-8ff4edcd44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bf1b69f-3bda-417a-8091-bb95919fe4f6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_38c76b72-b945-4103-9d01-8ff4edcd44c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_02bc7c59-3dc1-46db-a11a-0b1eca73b3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_02bc7c59-3dc1-46db-a11a-0b1eca73b3cf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:to="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cba42148-cba4-4983-82fa-f3c71a7c58c3" xlink:to="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e632bbb6-7dbc-48f4-9bae-7c5d9a0716c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_us-gaap_RoyaltyMember_e632bbb6-7dbc-48f4-9bae-7c5d9a0716c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_8de64e54-da04-4981-8c37-f4a48eefa984" xlink:href="halo-20221231.xsd#halo_BulkrHuPH20Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_BulkrHuPH20Member_8de64e54-da04-4981-8c37-f4a48eefa984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_83e328eb-8311-4322-835b-435a3270da3f" xlink:href="halo-20221231.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_ProprietaryProductsSalesMember_83e328eb-8311-4322-835b-435a3270da3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_65a92983-da40-46ce-b0d6-2f6e26d514ef" xlink:href="halo-20221231.xsd#halo_DevicePartneredProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_e441e2f3-8096-421a-b359-eb19ca4c169c" xlink:to="loc_halo_DevicePartneredProductsMember_65a92983-da40-46ce-b0d6-2f6e26d514ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:href="halo-20221231.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3f20860-5e84-40aa-88bf-2de063168fe5" xlink:to="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_4bf6b492-b88e-4d2d-98b3-a3ee335474f9" xlink:href="halo-20221231.xsd#halo_UpfrontfeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_UpfrontfeesMember_4bf6b492-b88e-4d2d-98b3-a3ee335474f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_48c1519f-483a-4940-ad94-1b8db0c491a0" xlink:href="halo-20221231.xsd#halo_DevelopmentFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_DevelopmentFeesMember_48c1519f-483a-4940-ad94-1b8db0c491a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_8a406497-892f-4a26-b159-df4bf450492b" xlink:href="halo-20221231.xsd#halo_SalesbasedmilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_SalesbasedmilestoneMember_8a406497-892f-4a26-b159-df4bf450492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchandDevelopmentServicesMember_66d40012-060a-4004-979a-817f52c85626" xlink:href="halo-20221231.xsd#halo_ResearchandDevelopmentServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_66f697ed-d42f-4099-b87a-b4ba84abc617" xlink:to="loc_halo_ResearchandDevelopmentServicesMember_66d40012-060a-4004-979a-817f52c85626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7bdd565-dcbd-487c-9da8-cd253bce73c6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9286abda-be02-49b4-b858-fa4af1a3a37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9d5209a-dce4-4264-bae6-df18696c7825" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9286abda-be02-49b4-b858-fa4af1a3a37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTextualsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_719b4005-1f40-4920-87f9-44e071c621bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_719b4005-1f40-4920-87f9-44e071c621bd" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5533ff28-9bc7-441f-973a-944af1a26164" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2017RocheMember_c4fbc487-b445-439e-94ea-fe910ee65f8a" xlink:href="halo-20221231.xsd#halo_A2017RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:to="loc_halo_A2017RocheMember_c4fbc487-b445-439e-94ea-fe910ee65f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherCollaboratorsMember_1e514ee8-0c7b-4a88-9f32-8616e4d367cf" xlink:href="halo-20221231.xsd#halo_OtherCollaboratorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7194976-dece-4363-b906-be770833e05c" xlink:to="loc_halo_OtherCollaboratorsMember_1e514ee8-0c7b-4a88-9f32-8616e4d367cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:to="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f892a3e8-fa0f-49bc-9060-58db596e874b" xlink:to="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_1c135afd-2ecd-4878-86fa-d231cccf286a" xlink:href="halo-20221231.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_1c135afd-2ecd-4878-86fa-d231cccf286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7e1eb10a-a6a9-46ba-96c7-4aa82f131759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b93afca9-eeef-4db7-ac97-fa36f535ac64" xlink:to="loc_us-gaap_ProductMember_7e1eb10a-a6a9-46ba-96c7-4aa82f131759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_7aa65006-38f7-4386-8bdd-bc75ed881107" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_056fa117-68f4-452b-883b-0bcfa6df3617" xlink:href="halo-20221231.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_056fa117-68f4-452b-883b-0bcfa6df3617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_0c0815ab-7703-4054-9263-38e235c5eb9c" xlink:href="halo-20221231.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_0c0815ab-7703-4054-9263-38e235c5eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a3010528-2f0a-4e13-9222-bf19d1114998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a3010528-2f0a-4e13-9222-bf19d1114998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2eeb62ad-acc0-4f54-a67b-8cc339f48c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2eeb62ad-acc0-4f54-a67b-8cc339f48c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a9abd00-c7e6-45f2-8943-b73e3b90cbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a9abd00-c7e6-45f2-8943-b73e3b90cbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_598c80d0-9490-4dd0-91bb-7b7de28f928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_598c80d0-9490-4dd0-91bb-7b7de28f928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b2b55e5e-78ea-4aad-aa40-3eb2917caa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_171a1c9e-08ee-4ec8-9ed9-aa290ffe5b41" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b2b55e5e-78ea-4aad-aa40-3eb2917caa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueContractwithCustomerAssetandLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef54a0ff-28d2-4908-a2b8-66157896bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets_3a1e9049-6001-445e-8693-8b39e5dc37db" xlink:href="halo-20221231.xsd#halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef54a0ff-28d2-4908-a2b8-66157896bd3d" xlink:to="loc_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets_3a1e9049-6001-445e-8693-8b39e5dc37db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f5c744a9-690b-40d6-96ea-a8964c85a0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef54a0ff-28d2-4908-a2b8-66157896bd3d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f5c744a9-690b-40d6-96ea-a8964c85a0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f0c3ba69-3ddf-45bf-80a4-ac49cfa00e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef54a0ff-28d2-4908-a2b8-66157896bd3d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f0c3ba69-3ddf-45bf-80a4-ac49cfa00e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueRevenueRemainingPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d4ba3b2b-f319-4894-8bc7-d92dec418730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d4ba3b2b-f319-4894-8bc7-d92dec418730" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81567636-2cf4-44ff-af1e-64d5c03577f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81567636-2cf4-44ff-af1e-64d5c03577f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2f026fe8-4e73-4845-acc1-d3b9c5b37b5b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a4ab190d-6bcd-4ad6-b590-7995a91c3df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4acdc6d9-e9aa-4e25-8ecf-a2d336b4d46c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b0b13580-af17-46c9-86f6-754c87fde652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#RevenueRevenueRemainingPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccountsreceivableDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_6d9cd8aa-e8b8-4957-b5eb-54bb07731137" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_6d9cd8aa-e8b8-4957-b5eb-54bb07731137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_4710cd16-b0fa-458b-8bf6-3ea5394b6b14" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_halo_Accountsreceivablefromcollaborators_4710cd16-b0fa-458b-8bf6-3ea5394b6b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_4568f9db-254a-493b-8a9f-dec6491e118d" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_halo_Accountsreceivablefromroyalties_4568f9db-254a-493b-8a9f-dec6491e118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_ef09aba0-c88a-44ea-83dd-38b4da23b54b" xlink:href="halo-20221231.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_halo_Accountsreceivablefromproductsales_ef09aba0-c88a-44ea-83dd-38b4da23b54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b7fb9aa1-d27d-43f2-9b59-7c69436d9d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b7fb9aa1-d27d-43f2-9b59-7c69436d9d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_0d619c73-4f43-42ff-9051-bd725bf2f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_0d619c73-4f43-42ff-9051-bd725bf2f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_4419a25d-2963-4038-b7da-7c6b3a88aaa4" xlink:href="halo-20221231.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_4419a25d-2963-4038-b7da-7c6b3a88aaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4114f415-3a87-4322-a13f-4de9a8392fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_f7ab26a9-ee99-4c7c-8ec4-6fa5cadf0b86" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4114f415-3a87-4322-a13f-4de9a8392fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_89983b72-fda8-4684-bd57-f15a047b7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_11920b24-41a7-489e-878e-57e5dff22d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89983b72-fda8-4684-bd57-f15a047b7a7b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_11920b24-41a7-489e-878e-57e5dff22d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6ab84284-4af3-4a03-a3ff-35d10b79b8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89983b72-fda8-4684-bd57-f15a047b7a7b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6ab84284-4af3-4a03-a3ff-35d10b79b8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e8eb2fbb-ed52-4eb9-bbf2-77c0970f9fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89983b72-fda8-4684-bd57-f15a047b7a7b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e8eb2fbb-ed52-4eb9-bbf2-77c0970f9fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3824fc9d-a627-4ad3-9e2c-742fa1806dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89983b72-fda8-4684-bd57-f15a047b7a7b" xlink:to="loc_us-gaap_InventoryNet_3824fc9d-a627-4ad3-9e2c-742fa1806dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b8afc80c-8579-429e-b998-99146f1ec67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b8afc80c-8579-429e-b998-99146f1ec67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_728f7100-4e8b-464c-a6dc-b8812cc6e880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_728f7100-4e8b-464c-a6dc-b8812cc6e880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_aafa2265-f786-4ac9-a981-691a57e94043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_OtherAssets_aafa2265-f786-4ac9-a981-691a57e94043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_ce95e49d-5756-42c5-acde-5a637bfbfd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_ce95e49d-5756-42c5-acde-5a637bfbfd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_48fa2909-d9a2-489b-bbe2-78199fdbae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_48fa2909-d9a2-489b-bbe2-78199fdbae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4b32919c-29d7-4cb5-b750-082ff0a5f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_817514ec-dcfb-41d1-84e5-5022168a809b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4b32919c-29d7-4cb5-b750-082ff0a5f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c4a26c67-eb36-44f1-a97b-89c47afa77ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c4a26c67-eb36-44f1-a97b-89c47afa77ea" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f5e98a-da88-419f-a3e1-ddc4a3aaa29b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_ace36790-469d-4b40-a54c-fedf56fcdf2b" xlink:href="halo-20221231.xsd#halo_ResearchEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ResearchEquipmentMember_ace36790-469d-4b40-a54c-fedf56fcdf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_8676beca-f105-46ce-9c1a-49c405f4591e" xlink:href="halo-20221231.xsd#halo_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ManufacturingEquipmentMember_8676beca-f105-46ce-9c1a-49c405f4591e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_908fa22d-b6c7-4c54-9844-36280c2ff9ef" xlink:href="halo-20221231.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_908fa22d-b6c7-4c54-9844-36280c2ff9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_43953ae7-b007-4719-a2bb-4a9b85eecb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6372102-c391-4bce-8009-3bdb95651ad5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_43953ae7-b007-4719-a2bb-4a9b85eecb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3bfe3c93-5161-4f8c-bc95-a6a3f261e679" xlink:to="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32679561-39c4-4730-9746-34100b753d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32679561-39c4-4730-9746-34100b753d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf7f6acb-6013-488c-8893-2dac2826b244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf7f6acb-6013-488c-8893-2dac2826b244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3e76bb11-8ba7-4bad-b8ed-d4222f5e6db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3e76bb11-8ba7-4bad-b8ed-d4222f5e6db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb1a3ee3-121c-4e75-a958-c1b929f26d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb1a3ee3-121c-4e75-a958-c1b929f26d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_043792db-8d1c-49d5-a63f-6d44493c92ac" xlink:href="halo-20221231.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_043792db-8d1c-49d5-a63f-6d44493c92ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6c8f4f44-ec65-4d90-8538-13bd2316bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebbe236c-4170-4bd2-b4ff-1ef92cff0713" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6c8f4f44-ec65-4d90-8538-13bd2316bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5370e5a7-224c-49a3-b173-066e2cc8756e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract_5ad2ac7a-40a6-450c-b9e7-d9c2fd9c317e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5370e5a7-224c-49a3-b173-066e2cc8756e" xlink:to="loc_us-gaap_DepreciationAndAmortizationAbstract_5ad2ac7a-40a6-450c-b9e7-d9c2fd9c317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7c403fac-fc7a-471a-a516-f4dc2cffeab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract_5ad2ac7a-40a6-450c-b9e7-d9c2fd9c317e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7c403fac-fc7a-471a-a516-f4dc2cffeab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_030896ba-3287-434a-b81d-e0d7ebbcbf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract_5ad2ac7a-40a6-450c-b9e7-d9c2fd9c317e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_030896ba-3287-434a-b81d-e0d7ebbcbf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b860360c-18b2-4812-9a96-45f31e85173b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b860360c-18b2-4812-9a96-45f31e85173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_ae363e4e-b0d0-4fd8-8f4f-7211fbdf85e0" xlink:href="halo-20221231.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_halo_Accruedmanufacturingexpenses_ae363e4e-b0d0-4fd8-8f4f-7211fbdf85e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_8eb95121-eaf6-4909-a929-b5bca6a098ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_8eb95121-eaf6-4909-a929-b5bca6a098ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_40397309-b2fe-49c5-a93e-74616bcbfcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_40397309-b2fe-49c5-a93e-74616bcbfcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_297d9bbe-6e48-42a2-af40-2af80b0bcc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_297d9bbe-6e48-42a2-af40-2af80b0bcc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e64bab38-8a98-4b02-82dd-8933542a5f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_OperatingLeaseLiability_e64bab38-8a98-4b02-82dd-8933542a5f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3c224711-cca5-43b1-8cd6-54a3d7d03298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3c224711-cca5-43b1-8cd6-54a3d7d03298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_c0d70181-8bd1-4782-b158-6dbb7f4e0e17" xlink:href="halo-20221231.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_c0d70181-8bd1-4782-b158-6dbb7f4e0e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c2294ce7-37f5-43a5-a029-1b629301e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_9335e3b1-9095-46c3-9899-0476782a7841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c2294ce7-37f5-43a5-a029-1b629301e4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability_eaeef7d8-8ee0-4c32-985b-56d5a9657343" xlink:href="halo-20221231.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:to="loc_halo_OperatingLeaseAccretionOfLiability_eaeef7d8-8ee0-4c32-985b-56d5a9657343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_838347b0-abaf-468c-9543-50d87ecf89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_838347b0-abaf-468c-9543-50d87ecf89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_531922df-c7ec-4b1e-9cf6-8b4fb4903850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:to="loc_us-gaap_OperatingLeaseCost_531922df-c7ec-4b1e-9cf6-8b4fb4903850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1687298c-c670-4e4a-b3ce-362da73fbd74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0c0c22b3-6983-41c0-9fd3-50f53894f0e2" xlink:to="loc_us-gaap_OperatingLeasePayments_1687298c-c670-4e4a-b3ce-362da73fbd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a59eae6-7e1d-4755-be59-f1f8c51a5ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a59eae6-7e1d-4755-be59-f1f8c51a5ff0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f54a5209-60d1-4102-8386-90a8a801b3d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_19b16cdb-1b7e-4d63-a83b-0d240d02653d" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf9cc69-a7a6-4627-a1ae-bc7ec0d57bf9" xlink:to="loc_halo_AntaresPharmaIncMember_19b16cdb-1b7e-4d63-a83b-0d240d02653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:to="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_32795e00-fa2f-499f-b4d4-e38722c0b764" xlink:to="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d717cbd7-2eec-4c27-9871-63da3dd9ed2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:to="loc_srt_MinimumMember_d717cbd7-2eec-4c27-9871-63da3dd9ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f8a063f-1d31-44a9-acd2-66dbd567c63e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6fe21a62-731d-4295-9c28-27a55efc7b9f" xlink:to="loc_srt_MaximumMember_5f8a063f-1d31-44a9-acd2-66dbd567c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0cf7b784-5eba-452f-89fd-27f0fcbb524b" xlink:to="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b798ae2c-8de6-4a32-a8b0-b79bba9e9635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:to="loc_us-gaap_Goodwill_b798ae2c-8de6-4a32-a8b0-b79bba9e9635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05aa48f2-1db6-4c7e-85ff-8c94f6a8cfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4dd9a9b3-07da-40c9-9a1d-eeaf38cb1e47" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05aa48f2-1db6-4c7e-85ff-8c94f6a8cfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsGoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78bfb19c-006e-453b-b2a6-111f8611b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b5e69478-fb99-4900-b3c1-728c34727913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78bfb19c-006e-453b-b2a6-111f8611b8bc" xlink:to="loc_us-gaap_GoodwillRollForward_b5e69478-fb99-4900-b3c1-728c34727913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cf51d2ab-a197-43da-97e7-8c62727a675c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b5e69478-fb99-4900-b3c1-728c34727913" xlink:to="loc_us-gaap_Goodwill_cf51d2ab-a197-43da-97e7-8c62727a675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_11714495-f38c-44a1-bd86-fb6aaaccbd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b5e69478-fb99-4900-b3c1-728c34727913" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_11714495-f38c-44a1-bd86-fb6aaaccbd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3adbf6c8-8d9a-4a5f-b6ce-ba58e23a247a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b5e69478-fb99-4900-b3c1-728c34727913" xlink:to="loc_us-gaap_Goodwill_3adbf6c8-8d9a-4a5f-b6ce-ba58e23a247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df8e0b2a-e25f-4f6d-8b06-50f5e90e5ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df8e0b2a-e25f-4f6d-8b06-50f5e90e5ce9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b169eb3e-21a8-46b3-92c5-6206f7c80a12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_6c49d183-370f-40c2-9673-8f6ae86b04bc" xlink:href="halo-20221231.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_6c49d183-370f-40c2-9673-8f6ae86b04bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_ff34a201-1359-4656-b2cf-9b1a75fdaf92" xlink:href="halo-20221231.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_ff34a201-1359-4656-b2cf-9b1a75fdaf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_93c610e1-8ea0-4e53-ad89-4e56b1db84f8" xlink:href="halo-20221231.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22d3df49-a640-422b-94cb-eb197156eb00" xlink:to="loc_halo_TLANDOProductRightsMember_93c610e1-8ea0-4e53-ad89-4e56b1db84f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_40973f7f-5257-461b-b263-d36e125b24a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8e63eb97-3a09-4249-b897-cb2ce29f7bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8e63eb97-3a09-4249-b897-cb2ce29f7bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eb9e4963-d60a-4cdf-a9ef-acdab0e71c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eb9e4963-d60a-4cdf-a9ef-acdab0e71c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57427e49-e8a2-4077-9f1c-ded24d17555c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57427e49-e8a2-4077-9f1c-ded24d17555c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a01000ca-21fd-49a9-848e-c79e4d7da9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a01000ca-21fd-49a9-848e-c79e4d7da9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_65c6dce1-9d76-4631-9210-b8ac590addd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_65c6dce1-9d76-4631-9210-b8ac590addd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e23bf108-ca7c-4547-92a2-9f71d5ad84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_902c6221-cf16-4b90-b41c-94ac69c0a25a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e23bf108-ca7c-4547-92a2-9f71d5ad84eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7fed3505-52bb-49ca-976d-35db3b75665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7fed3505-52bb-49ca-976d-35db3b75665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82766556-ac3b-4e86-846a-acb9ece30991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_82766556-ac3b-4e86-846a-acb9ece30991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_82fa57eb-331c-4a6a-8149-3d967587d3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_82fa57eb-331c-4a6a-8149-3d967587d3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f7ae80e9-3eca-4e04-8ea8-b8d62c95a655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f7ae80e9-3eca-4e04-8ea8-b8d62c95a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96d541d4-420e-47e6-adb0-491c6c6a53b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96d541d4-420e-47e6-adb0-491c6c6a53b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_58c96e45-252e-403c-b5b3-514fec6f6513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_58c96e45-252e-403c-b5b3-514fec6f6513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed2606bd-dd40-4087-b80c-4582d40b2d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_147585b2-39b1-451f-8f40-255fc2f7d7df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed2606bd-dd40-4087-b80c-4582d40b2d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2ccadc55-ca07-4171-94c6-64cc5a053fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2ccadc55-ca07-4171-94c6-64cc5a053fad" xlink:to="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7d1a430-ebef-4df1-80ae-ff6d174c32d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_cd2091bd-53f3-4923-a29b-d3287c844a6a" xlink:href="halo-20221231.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_cd2091bd-53f3-4923-a29b-d3287c844a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8e939046-120b-41ea-af1e-3e1f59e28c68" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8e939046-120b-41ea-af1e-3e1f59e28c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_cdf210bc-9530-4169-a42e-92f978684205" xlink:href="halo-20221231.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_cdf210bc-9530-4169-a42e-92f978684205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_ae0cd01d-c109-4f9a-8166-f8bbeb6171fb" xlink:href="halo-20221231.xsd#halo_CreditAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cfe689b-7c6b-4926-8ea8-fb4526614229" xlink:to="loc_halo_CreditAgreementMember_ae0cd01d-c109-4f9a-8166-f8bbeb6171fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e239748c-4c95-47b7-b41a-94df83f172d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_4783a72b-d2a2-4ea8-92cb-e632008bcf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_4783a72b-d2a2-4ea8-92cb-e632008bcf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7fc8202c-a8ac-4c97-809a-eccf145a3ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1ba70226-d72e-4be7-9754-b6d6b23f00fa" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7fc8202c-a8ac-4c97-809a-eccf145a3ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7fc14b9-a81d-4471-ba25-1e5439e5a58a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7f8a0d6d-c721-4db0-b117-5e2a7a5ed5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_us-gaap_ConvertibleDebtMember_7f8a0d6d-c721-4db0-b117-5e2a7a5ed5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_c02edad0-cebf-44bf-8d88-49bc2a373785" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_c02edad0-cebf-44bf-8d88-49bc2a373785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_1f2465e8-6cca-4d3c-bd98-662b63ac6946" xlink:href="halo-20221231.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91856fe4-801d-403b-9da8-f95b7c492718" xlink:to="loc_halo_TermLoanFacilityMember_1f2465e8-6cca-4d3c-bd98-662b63ac6946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b3bcfe0-df7d-48af-a864-f4870f712301" xlink:to="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_833008a4-fa89-4f8b-b2ec-8b93aa115803" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:to="loc_srt_MinimumMember_833008a4-fa89-4f8b-b2ec-8b93aa115803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ac3cd1a-dc4f-414b-b416-7b004ac26771" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_031c4254-a94f-4a84-884b-c222f5c01bf5" xlink:to="loc_srt_MaximumMember_1ac3cd1a-dc4f-414b-b416-7b004ac26771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f0db4aa8-5b0a-4a43-8a9d-79cc9d8b8ece" xlink:to="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_00e289d1-df33-4657-97b0-357e561e616b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_00e289d1-df33-4657-97b0-357e561e616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_cb0b3043-7b90-4322-b801-c33d8ab086ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_cb0b3043-7b90-4322-b801-c33d8ab086ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_44597b39-a650-46d7-9295-f80a9abea0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_09d32eba-26b1-484a-9438-dce51bbf1406" xlink:to="loc_us-gaap_BaseRateMember_44597b39-a650-46d7-9295-f80a9abea0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fdd92446-1bf3-4ca0-bcd1-c858981a6151" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cdf407d8-963c-4d00-839f-659572ace476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5a53039f-bee1-4785-94ec-41d7e9c59fff" xlink:to="loc_us-gaap_SubsequentEventMember_cdf407d8-963c-4d00-839f-659572ace476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e2508d99-d588-4104-8ddc-c710d5154a0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_43869e42-93f4-4fe3-b719-96405e8e6aed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_86f3796b-4bbc-43dd-9cea-a79b3220a8f6" xlink:to="loc_srt_ScenarioForecastMember_43869e42-93f4-4fe3-b719-96405e8e6aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_11533463-8202-4fb2-816b-731cb124fa79" xlink:to="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ebc96ed6-6e0a-420b-9ef3-e20eae4a3bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_631fd98f-64ea-4186-83c4-2c3ed992f80d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ebc96ed6-6e0a-420b-9ef3-e20eae4a3bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:href="halo-20221231.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_aae549e4-afec-4046-9fd9-96852f52dfa5" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_bc5f523a-7c12-44a7-a027-1bf0c5f50b57" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_bc5f523a-7c12-44a7-a027-1bf0c5f50b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_4e562eb0-cc09-42f8-9528-44149a6bb904" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_4e562eb0-cc09-42f8-9528-44149a6bb904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThirdMember_be3004f4-e637-4051-bdc8-9f856213d05c" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodThirdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodThirdMember_be3004f4-e637-4051-bdc8-9f856213d05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_24bf4a81-d8dc-4461-bc6b-643fa0492d8b" xlink:href="halo-20221231.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_899a37cb-adbf-4b7a-8afc-f9b538e20221" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_24bf4a81-d8dc-4461-bc6b-643fa0492d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:href="halo-20221231.xsd#halo_VariableRateComponentAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:href="halo-20221231.xsd#halo_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentAxis_180313b6-9f9e-45ef-999a-eae23eb4c2f2" xlink:to="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_06f7b06f-e73c-4b34-8528-2b77fbb0c456" xlink:href="halo-20221231.xsd#halo_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:to="loc_halo_VariableRateComponentOneMember_06f7b06f-e73c-4b34-8528-2b77fbb0c456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_a5582984-c3a7-4f35-a907-3ed2bdd7b662" xlink:href="halo-20221231.xsd#halo_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_c75858d8-711b-4888-9899-ceb70969ee34" xlink:to="loc_halo_VariableRateComponentTwoMember_a5582984-c3a7-4f35-a907-3ed2bdd7b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c7134017-177d-459a-991b-36bff6db7464" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5163088-eb2e-4f14-9f96-516a119d1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5163088-eb2e-4f14-9f96-516a119d1f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_652378e1-0af4-4608-af7a-24cd4d650675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_652378e1-0af4-4608-af7a-24cd4d650675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_77630ae5-5d51-44d9-aeef-b42c5e42244a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_77630ae5-5d51-44d9-aeef-b42c5e42244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b1744ec4-c185-496e-8807-1b3262393f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b1744ec4-c185-496e-8807-1b3262393f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1814f190-8709-43b2-bbd9-a2405edb6412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1814f190-8709-43b2-bbd9-a2405edb6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0864a355-27bd-43ae-b28a-d3b18a731723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0864a355-27bd-43ae-b28a-d3b18a731723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_11c7c8ae-8049-4e84-ba9e-107cdbca6827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_11c7c8ae-8049-4e84-ba9e-107cdbca6827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_841c8977-26ca-4f6c-866b-cbae7bc2958a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_841c8977-26ca-4f6c-866b-cbae7bc2958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_cbb88b4d-7acf-42c0-9e98-6f502009f9da" xlink:href="halo-20221231.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_cbb88b4d-7acf-42c0-9e98-6f502009f9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_224431ab-c52d-4996-88dd-c9e84f193945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_224431ab-c52d-4996-88dd-c9e84f193945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4760ec67-413f-4a76-aad0-02b21a9492c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4760ec67-413f-4a76-aad0-02b21a9492c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_54506c12-1fe7-4efd-81f5-8d7de31fd743" xlink:href="halo-20221231.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_54506c12-1fe7-4efd-81f5-8d7de31fd743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_2f555e04-e3f5-4a5a-be02-588a65719738" xlink:href="halo-20221231.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_2f555e04-e3f5-4a5a-be02-588a65719738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40b626a2-4d4b-4a14-8185-9485dffc6c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40b626a2-4d4b-4a14-8185-9485dffc6c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_5c1d4c2f-41b1-4141-88d0-a9bf20e89070" xlink:href="halo-20221231.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_halo_PaymentForCappedCallTransactions_5c1d4c2f-41b1-4141-88d0-a9bf20e89070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_406f53a2-86cb-4f06-b05b-cffa91a2e5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_406f53a2-86cb-4f06-b05b-cffa91a2e5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2c10ecc2-2cb2-43a7-89d4-8530228f6058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2c10ecc2-2cb2-43a7-89d4-8530228f6058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b2727a97-4fa6-46ce-99be-bc9868818e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b2727a97-4fa6-46ce-99be-bc9868818e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_afaa6c35-ebdb-4cb3-a65d-4ca2a2c0f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_afaa6c35-ebdb-4cb3-a65d-4ca2a2c0f4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_732e62a8-15b4-40c1-8eb1-549617a7f913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_732e62a8-15b4-40c1-8eb1-549617a7f913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b67b2e4d-d860-4097-8768-8a8cf3510f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b67b2e4d-d860-4097-8768-8a8cf3510f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e8e67c6-6a5e-4914-b0f2-fda530868cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8e8e67c6-6a5e-4914-b0f2-fda530868cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1b6456f9-64a3-4ac4-9af3-aed9e5fe9d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1b6456f9-64a3-4ac4-9af3-aed9e5fe9d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_7ec38e56-d459-4f66-b128-a4525488b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_7ec38e56-d459-4f66-b128-a4525488b05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_390b13c6-968f-448d-a474-f7fa89ac670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f35222b4-bdea-43c7-a7f2-32ef1ca32ff3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_390b13c6-968f-448d-a474-f7fa89ac670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6116324-da0d-4790-91e4-425ca4668222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6116324-da0d-4790-91e4-425ca4668222" xlink:to="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:to="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_220e09bf-eb71-40c5-b314-4ec36461503c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_154307ef-5a56-47ab-bf3b-9d8e50922cfa" xlink:href="halo-20221231.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_154307ef-5a56-47ab-bf3b-9d8e50922cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_20ea5b61-86b8-44c4-b264-3cdda7185cac" xlink:href="halo-20221231.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_20ea5b61-86b8-44c4-b264-3cdda7185cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_b7e6b026-7cd9-4172-bdf2-ceb42c15387d" xlink:href="halo-20221231.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7838dc8-71c1-4b36-a780-55d22c3e72ac" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_b7e6b026-7cd9-4172-bdf2-ceb42c15387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c6e57d01-0564-4927-8972-f6c044a3aac8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e61649b8-a211-4b1d-9497-aefa9dce347e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7874f0ba-2919-4847-aa6b-9fdf8d13ca18" xlink:to="loc_us-gaap_ConvertibleDebtMember_e61649b8-a211-4b1d-9497-aefa9dce347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_684d3981-2f2c-46f3-a06c-aa10f762f80e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11026bf2-2d9f-4cff-a74e-644129b355dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11026bf2-2d9f-4cff-a74e-644129b355dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_827e1657-f8a9-438f-b5c4-70b61b9679bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_827e1657-f8a9-438f-b5c4-70b61b9679bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_277f180e-1167-4cdd-a0ea-b394715bfbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_ConvertibleNotesPayable_277f180e-1167-4cdd-a0ea-b394715bfbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_b0648044-585c-4092-b592-ae3ae6ba634b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_b0648044-585c-4092-b592-ae3ae6ba634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_59764aa9-2dc9-4b90-9603-3b9364886271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_59764aa9-2dc9-4b90-9603-3b9364886271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_078f747f-df12-4724-a3b1-8c408ca895e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_078f747f-df12-4724-a3b1-8c408ca895e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_46731032-59db-4486-9c8c-2eb320cdbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_46731032-59db-4486-9c8c-2eb320cdbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3235764b-2714-475f-afb2-42a17e0079c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_InterestExpenseDebt_3235764b-2714-475f-afb2-42a17e0079c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b49367d-979d-47ee-9985-cc1ec0918ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b49367d-979d-47ee-9985-cc1ec0918ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89ddc56d-fe0a-4fff-80d3-9a99633b3dd3" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_96cab1e1-c6a3-42d1-935e-2943ce8beb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_96cab1e1-c6a3-42d1-935e-2943ce8beb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f289b2f2-32a1-41bb-8a48-c2c9f68045f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f289b2f2-32a1-41bb-8a48-c2c9f68045f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3a9be2e-e326-4d85-8c62-ee73b083842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3a9be2e-e326-4d85-8c62-ee73b083842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_048e8f05-00ea-49d4-bd0f-507512f9ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_048e8f05-00ea-49d4-bd0f-507512f9ce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dcc238ed-212e-47a0-8b22-eaf32a41882e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_dcc238ed-212e-47a0-8b22-eaf32a41882e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_011f3817-45fc-4bf2-a8d0-bd4f37bb9a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_011f3817-45fc-4bf2-a8d0-bd4f37bb9a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtIncludingInterestGross_5ed39abf-5e34-4c4f-8e86-c5ef52f8a23c" xlink:href="halo-20221231.xsd#halo_LongTermDebtIncludingInterestGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_halo_LongTermDebtIncludingInterestGross_5ed39abf-5e34-4c4f-8e86-c5ef52f8a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LongTermDebtInterestGross_d0a883c9-db2f-432d-ba12-c8b2ff076104" xlink:href="halo-20221231.xsd#halo_LongTermDebtInterestGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_halo_LongTermDebtInterestGross_d0a883c9-db2f-432d-ba12-c8b2ff076104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1f17c703-de1f-482a-8b05-38c82db973b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1f17c703-de1f-482a-8b05-38c82db973b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1c951498-ed5b-4a7c-ba69-4b7ba0e4a671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1c951498-ed5b-4a7c-ba69-4b7ba0e4a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_b3dfcba4-5995-4e0d-af29-31c3f89ebb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtFairValue_b3dfcba4-5995-4e0d-af29-31c3f89ebb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_575350dc-5030-4b9d-951d-62404d1e54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtCurrent_575350dc-5030-4b9d-951d-62404d1e54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_39612a1f-15c8-48a8-91fb-265a02661e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_850f62b6-710a-4d11-9050-db0700fb9808" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_39612a1f-15c8-48a8-91fb-265a02661e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54970142-b1d6-45e9-b8b9-31cd4159af06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54970142-b1d6-45e9-b8b9-31cd4159af06" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_093c4ef9-4e77-45b9-857a-7ea7096c6f5c" xlink:to="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AmendedAndRestated2021StockPlanMember_cdd67032-fb7a-4dea-b408-df5511b0debf" xlink:href="halo-20221231.xsd#halo_AmendedAndRestated2021StockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:to="loc_halo_AmendedAndRestated2021StockPlanMember_cdd67032-fb7a-4dea-b408-df5511b0debf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_6cf81ec1-1437-4222-a14f-1a125b5b6d13" xlink:href="halo-20221231.xsd#halo_A2021ESPPPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e951e7be-e727-457d-806a-93e6d40b207c" xlink:to="loc_halo_A2021ESPPPlanMember_6cf81ec1-1437-4222-a14f-1a125b5b6d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0489b11a-85b5-4ecc-a66a-4422ff6aca4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OutstandingAwardsMember_c8d27e63-7c82-48c9-a177-9e3fd46f5726" xlink:href="halo-20221231.xsd#halo_OutstandingAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_halo_OutstandingAwardsMember_c8d27e63-7c82-48c9-a177-9e3fd46f5726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d5ef1e4e-7258-4c80-aa4d-f075a0ddec02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_EmployeeStockMember_d5ef1e4e-7258-4c80-aa4d-f075a0ddec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15338280-0a34-43eb-bc3f-de40f781c342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15338280-0a34-43eb-bc3f-de40f781c342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_876583eb-acd8-4d1f-98f3-bc9f653dce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_876583eb-acd8-4d1f-98f3-bc9f653dce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3fcd82ad-b606-4b76-aa39-d125001ab1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0babc16f-c88b-4e56-b8e1-aad67c7abbfe" xlink:to="loc_us-gaap_PerformanceSharesMember_3fcd82ad-b606-4b76-aa39-d125001ab1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6242c5b0-b121-4b93-9dc9-5ef357a6887b" xlink:to="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CliffVestingFirstAnniversaryMember_30e406b3-fcd3-4e9a-8c1c-d0a0e2f6716d" xlink:href="halo-20221231.xsd#halo_CliffVestingFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_CliffVestingFirstAnniversaryMember_30e406b3-fcd3-4e9a-8c1c-d0a0e2f6716d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_MonthlyVestingAfterOneYearMember_df423715-49f6-4d3d-b549-8afd7e4e3e69" xlink:href="halo-20221231.xsd#halo_MonthlyVestingAfterOneYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_MonthlyVestingAfterOneYearMember_df423715-49f6-4d3d-b549-8afd7e4e3e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PercentageVestingMember_2009f422-7614-459b-99e5-8481f6a570fe" xlink:href="halo-20221231.xsd#halo_PercentageVestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2162d689-273f-4ef9-8580-d84a82c0dfc6" xlink:to="loc_halo_PercentageVestingMember_2009f422-7614-459b-99e5-8481f6a570fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1b78fd28-8a47-42df-8b38-67629c89f0ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_66738f52-af83-4fc2-8375-4d1d8f362911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_66738f52-af83-4fc2-8375-4d1d8f362911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_970cea90-0a3c-4fcd-af4a-3b6d227f66e5" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards_970cea90-0a3c-4fcd-af4a-3b6d227f66e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10942a9c-a254-417f-b9f3-4a7570ca7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10942a9c-a254-417f-b9f3-4a7570ca7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e2d7924-0e11-43e5-afdf-13889bb5508c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e2d7924-0e11-43e5-afdf-13889bb5508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_0784054c-3eba-4fca-9f4d-bf3f6aeb1dac" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_0784054c-3eba-4fca-9f4d-bf3f6aeb1dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_216a51a2-ae95-45c2-9c67-317232ba540d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_216a51a2-ae95-45c2-9c67-317232ba540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_6438a4c2-2cee-4b3c-9d18-c4b81c746366" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_6438a4c2-2cee-4b3c-9d18-c4b81c746366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b2958a66-42ec-474f-a06e-161c8f3ce87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b2958a66-42ec-474f-a06e-161c8f3ce87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_3d1ba94a-ef3a-418b-b786-fb17d3f75ae8" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_3d1ba94a-ef3a-418b-b786-fb17d3f75ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ebbfa5b6-3c29-46d5-9839-4e1d33444e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ebbfa5b6-3c29-46d5-9839-4e1d33444e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_ffa06446-07b8-4447-9a8c-82053603a134" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice_ffa06446-07b8-4447-9a8c-82053603a134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_32bb03d5-0ce3-4553-885d-7c593dbf337c" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm_32bb03d5-0ce3-4553-885d-7c593dbf337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10eca0f3-c2a5-41cc-b181-ecb3b0bc1145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10eca0f3-c2a5-41cc-b181-ecb3b0bc1145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08d64fcf-0e66-40df-91f0-602f1cbdf75a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08d64fcf-0e66-40df-91f0-602f1cbdf75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6aca81d-97c1-4409-82c8-ef972e1e1800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6aca81d-97c1-4409-82c8-ef972e1e1800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_30eaaf16-be0c-4b10-aef5-e3a154104b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30178ca6-ff03-42b7-8204-e0036d9997f2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_30eaaf16-be0c-4b10-aef5-e3a154104b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9b46551-672e-4af1-a3ef-65167afd8a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9b46551-672e-4af1-a3ef-65167afd8a67" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7c443947-3423-47a8-b3e0-6147606a350b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cca4a109-ec29-477f-954d-0240c1033b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cca4a109-ec29-477f-954d-0240c1033b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00557025-09d2-4fee-9474-db4d3a60451a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c23691fa-2d37-48ce-b682-58dbf036dc2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00557025-09d2-4fee-9474-db4d3a60451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:to="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f0df397-9c1a-46de-9c0d-7954a27577fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e832683f-bba1-4edb-b488-d5de5bf44860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e832683f-bba1-4edb-b488-d5de5bf44860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_e9caa890-055c-4fe9-bf3d-89998a60c9d2" xlink:href="halo-20221231.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c3fbcc-3bb9-4748-ae73-33868ac91109" xlink:to="loc_halo_RSURSAandPRSUawardsMember_e9caa890-055c-4fe9-bf3d-89998a60c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e9de0fb7-b518-4885-be78-f8673887f4ac" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dd1ae50-bd8b-4d41-8a16-a5ed4689657d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32f5ad2b-c9dc-4c69-a704-f0583c98e53e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dd1ae50-bd8b-4d41-8a16-a5ed4689657d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationUnrecognizedExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80c56b25-99f0-4d32-bf4e-37e85b3d9597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80c56b25-99f0-4d32-bf4e-37e85b3d9597" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:to="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_61d8d9f3-d8bb-4dfc-af67-ef87cbaf05e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a12a59d-6368-415b-bc93-fc85a78b4185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a12a59d-6368-415b-bc93-fc85a78b4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c0f74628-d807-41f4-9bde-529baac9788d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c0f74628-d807-41f4-9bde-529baac9788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a7355642-42cb-4a04-bc27-dbd1a44e175c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_PerformanceSharesMember_a7355642-42cb-4a04-bc27-dbd1a44e175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_36c012aa-a0bb-4408-a1dd-2c98e82f480b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_258f6c32-0cb0-4c97-897a-37c5d11065db" xlink:to="loc_us-gaap_EmployeeStockMember_36c012aa-a0bb-4408-a1dd-2c98e82f480b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63b1b916-5be8-4c19-9aba-9c371b251c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80ca9279-fad9-4493-9711-17b45c49d1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80ca9279-fad9-4493-9711-17b45c49d1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc311410-2da4-4cd0-92de-28da288625c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_486a545e-655b-4ac1-babc-f39c0a6addb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc311410-2da4-4cd0-92de-28da288625c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationOptionsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15757229-75a0-45df-9223-f8d8801a5a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15757229-75a0-45df-9223-f8d8801a5a7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:to="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4b9101-5508-4810-b033-f52b985477c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_926dbe9a-1ab1-422f-bd0c-5326888008ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4b9101-5508-4810-b033-f52b985477c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0515278f-bb99-4307-a78e-745f05b45e6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1d6fa36-1483-410a-bdcb-d6b52a348cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1d6fa36-1483-410a-bdcb-d6b52a348cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c28ff73-7cb7-4fdc-b912-bd2556823e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c28ff73-7cb7-4fdc-b912-bd2556823e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca2b260-245c-4941-a023-947a4d694677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca2b260-245c-4941-a023-947a4d694677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3d08ded8-09cd-424b-a203-055e0236f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3d08ded8-09cd-424b-a203-055e0236f9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e88fd260-4b1b-4c24-b9b0-6d4efc840dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_3f8f9cd9-edbf-46f5-94fe-d009ec32f6f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e88fd260-4b1b-4c24-b9b0-6d4efc840dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0306c2d7-b8db-44d9-b805-60863b19ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0306c2d7-b8db-44d9-b805-60863b19ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_babd7fc4-d845-47da-83b7-ce171e3a70fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_babd7fc4-d845-47da-83b7-ce171e3a70fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be33deb7-1223-4d98-b4b1-2cd408b03492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e058f962-54e0-49b5-b892-6fa4363a111f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e058f962-54e0-49b5-b892-6fa4363a111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f1b911d-1bd3-4bca-a060-028721df6870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f1b911d-1bd3-4bca-a060-028721df6870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_405a9b33-5239-4a1d-aeed-5f91db9f1440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_405a9b33-5239-4a1d-aeed-5f91db9f1440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e05ae6b8-ec21-46ab-b854-0a2751df2130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e05ae6b8-ec21-46ab-b854-0a2751df2130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8dc381d-5c1a-4a76-92a2-29bcec7490c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae2eae7f-c2d0-4b7c-a991-d1049c5ec28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8dc381d-5c1a-4a76-92a2-29bcec7490c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c55fa54e-70c8-482c-8f72-020f2d9b3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c55fa54e-70c8-482c-8f72-020f2d9b3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9022d6c3-0426-4997-86fa-3a74dbf0cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9022d6c3-0426-4997-86fa-3a74dbf0cfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17161459-8ca3-431e-ba98-07161853c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17161459-8ca3-431e-ba98-07161853c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0679e509-107d-426c-ab39-e22aef3efe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0679e509-107d-426c-ab39-e22aef3efe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6068f63e-9573-4a98-abb5-743ae2de0631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract_d4405866-3649-4a17-a766-1e7500fe334e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6068f63e-9573-4a98-abb5-743ae2de0631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:href="halo-20221231.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dfb3fb4d-2b72-4b04-b686-fe49d670cab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dfb3fb4d-2b72-4b04-b686-fe49d670cab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6f4aa79-fea3-4d9b-a21e-148a821fad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6f4aa79-fea3-4d9b-a21e-148a821fad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_385fb52a-163e-4ec4-81a9-25b69a9da249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_2145d6aa-776a-4229-8452-26ec08c9f26a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_385fb52a-163e-4ec4-81a9-25b69a9da249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8aa50589-f709-4355-955f-3a99971aecbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4094221-2b5c-40d7-bb3b-4acc379cb16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4094221-2b5c-40d7-bb3b-4acc379cb16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6b19a317-c934-4559-8327-9ea66ee09298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6b19a317-c934-4559-8327-9ea66ee09298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b291d8c8-ddc9-4a4e-92ff-1fc46ba274f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_440120f3-07ad-4570-9fd7-b5ebc8ce37d9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b291d8c8-ddc9-4a4e-92ff-1fc46ba274f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationValuationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d97b3de2-21f2-411f-b152-8cb5a4aa451e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d97b3de2-21f2-411f-b152-8cb5a4aa451e" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:to="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6a6af9d5-b86b-4120-9020-c5e5b36f4c3a" xlink:to="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_299ca0e8-be96-4111-96d9-37a82613876e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:to="loc_srt_MinimumMember_299ca0e8-be96-4111-96d9-37a82613876e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9417de86-9235-48d8-bbf5-22b75038631d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6dbe7be5-5e98-4bcb-a3a2-ac8db4956f17" xlink:to="loc_srt_MaximumMember_9417de86-9235-48d8-bbf5-22b75038631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:href="halo-20221231.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_0686aa67-7894-4b9e-b556-ecafa5ee1a9c" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_75439b5c-596b-4c81-a215-b97ef7544bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_75439b5c-596b-4c81-a215-b97ef7544bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37a0bc7e-d083-4d4d-81a7-e7ce3f0a9bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37a0bc7e-d083-4d4d-81a7-e7ce3f0a9bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3765416c-c4a4-480a-82a6-d88e568cdc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3765416c-c4a4-480a-82a6-d88e568cdc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47edd79e-6caf-40f5-bc3f-6f38dc3eb011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47edd79e-6caf-40f5-bc3f-6f38dc3eb011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_79f3329f-6151-4609-acd4-bc43e16674ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_d1ede8ed-0602-46a2-9ef4-4bd0c0f30d1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_79f3329f-6151-4609-acd4-bc43e16674ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f8b9dca-4404-4a72-9ea0-2a6ce5d8d078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f8b9dca-4404-4a72-9ea0-2a6ce5d8d078" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:to="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c5348ef-4a31-47a2-b90e-84f00f1a9797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_30c406e7-d92e-46b0-ae3c-8d48c30d03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7630e11-5ccd-4816-9df8-d2278dba4da5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_30c406e7-d92e-46b0-ae3c-8d48c30d03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c36f9b9-b9a9-4416-955c-fc8cbd729c11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6d52dc2-a826-4fd0-a753-737ecfc13408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6d52dc2-a826-4fd0-a753-737ecfc13408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d57807b-290e-4825-9afa-dd7e3975575d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d57807b-290e-4825-9afa-dd7e3975575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b233c3f-3f35-49b7-980c-1ab70baf390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b233c3f-3f35-49b7-980c-1ab70baf390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ed30b95-b9b2-4977-aa59-0455b87e0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ed30b95-b9b2-4977-aa59-0455b87e0cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_568ab045-1442-4d5a-90db-39d61e6d78cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_568ab045-1442-4d5a-90db-39d61e6d78cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_471a588b-2fb4-4af4-a288-45c2376db62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_471a588b-2fb4-4af4-a288-45c2376db62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e357a323-964a-4f02-a2eb-6924092bdfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e357a323-964a-4f02-a2eb-6924092bdfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b856fd72-4491-4ef7-ba17-a1525a3aeca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b856fd72-4491-4ef7-ba17-a1525a3aeca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_18aa4779-75a1-4827-b7e2-9b1ebbc766bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_18aa4779-75a1-4827-b7e2-9b1ebbc766bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c84723c-8819-46f4-9067-782a0f66fdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_da5ace05-b8e3-4fda-b94a-16365a1bc9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c84723c-8819-46f4-9067-782a0f66fdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3fa0e79b-9e35-457a-b4d5-b26a6ada425c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3fa0e79b-9e35-457a-b4d5-b26a6ada425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f219bd28-d3c1-43f4-9374-319fd80f4be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48c10091-69a8-4b46-b1c6-c4efb2b14fbc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f219bd28-d3c1-43f4-9374-319fd80f4be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2159f766-caf2-4618-b2bd-addd8f4b3910" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a348c9e7-3b06-4220-af26-38fdca52f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a348c9e7-3b06-4220-af26-38fdca52f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_15fcf43b-2fce-4bfd-8335-a2e544173212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_63627f03-8b71-45c1-9669-7756d70c6f5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_15fcf43b-2fce-4bfd-8335-a2e544173212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#SharebasedCompensationPerformanceStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d391bc3a-1137-4d8d-b0aa-47ef1363d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d391bc3a-1137-4d8d-b0aa-47ef1363d287" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:to="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ef837a92-f233-4f2e-9570-32576bbf900d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad36395e-ce76-4c93-b404-e5457ecc055e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:to="loc_us-gaap_PerformanceSharesMember_ad36395e-ce76-4c93-b404-e5457ecc055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e3d5f1-dda5-4c1e-8804-8dce6c575d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734f80ec-88f3-4c37-9502-ccd85d86f704" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e3d5f1-dda5-4c1e-8804-8dce6c575d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90eb66b8-fb4f-45f1-a918-f87ca00b9108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02d17f91-2d89-4cf2-a039-56e2cb154444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02d17f91-2d89-4cf2-a039-56e2cb154444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86a89c7c-ec29-4c37-86a8-d2ac0d4c48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86a89c7c-ec29-4c37-86a8-d2ac0d4c48e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2e1584f-8fa9-44fc-8ba5-08459ded026d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2e1584f-8fa9-44fc-8ba5-08459ded026d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ec43c117-1fcb-4290-ac8e-74955b10bc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ec43c117-1fcb-4290-ac8e-74955b10bc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45f941e0-b5c6-4d4e-8e9a-4167147846ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_498dbb25-5904-46ce-a985-bcbf5a11ca6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45f941e0-b5c6-4d4e-8e9a-4167147846ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9972a7f-bf3b-43bb-b853-7d2c54156d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9972a7f-bf3b-43bb-b853-7d2c54156d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d23dc733-72a1-4683-990c-5acb0d2fc3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d23dc733-72a1-4683-990c-5acb0d2fc3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89fe84b2-851c-46e0-9d8c-b7db54e22dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89fe84b2-851c-46e0-9d8c-b7db54e22dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f3ab6912-3679-41df-a312-acbb1aa076b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f3ab6912-3679-41df-a312-acbb1aa076b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7498824d-39d5-4519-b763-cb4771eea520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_573c4c8e-7cae-4ffd-8fd2-23e61c547677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7498824d-39d5-4519-b763-cb4771eea520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_7b9ae4f6-142c-4e9b-8404-de9701b0d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d5e4b6-aed2-414e-848a-3cb1d2e26710" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_7b9ae4f6-142c-4e9b-8404-de9701b0d9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a44c5a3-bf72-47ea-9b3a-ca0d8dd35644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a44c5a3-bf72-47ea-9b3a-ca0d8dd35644" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:to="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f96e317-21be-4212-b728-b386932966ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3042dff-33e9-4aab-b73f-8c0b7e029970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3042dff-33e9-4aab-b73f-8c0b7e029970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69806019-efcd-4734-acde-de17072ac190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69806019-efcd-4734-acde-de17072ac190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_c2adaa90-7920-4b78-9952-3d3909b0fe2f" xlink:href="halo-20221231.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96d5024a-593a-4451-9f84-22ca77caf0d1" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_c2adaa90-7920-4b78-9952-3d3909b0fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e4215320-efd6-45ef-a3f2-d6a3bed5c171" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_97e31c6e-d800-422b-b1f1-4cfa09a3ab51" xlink:href="halo-20221231.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b183ec03-6622-4064-8dfd-637d326e73e6" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_97e31c6e-d800-422b-b1f1-4cfa09a3ab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_442ede34-5951-4b4e-ac48-5db4dbd2efc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb5b4b77-25d8-44a1-b0fd-b820a7201bda" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80848b50-512c-4262-ad5d-8c377eb0446e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80848b50-512c-4262-ad5d-8c377eb0446e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c846e13b-e9b8-41d6-92ca-65da826d3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c846e13b-e9b8-41d6-92ca-65da826d3c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_724f2b6b-45f7-4da6-9433-40f23f1c11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_724f2b6b-45f7-4da6-9433-40f23f1c11ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fdbe8454-fece-4410-a4aa-359721c38a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fdbe8454-fece-4410-a4aa-359721c38a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0f7b8979-aaa8-4f84-866d-fa9e1152f35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0f7b8979-aaa8-4f84-866d-fa9e1152f35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b0e26d4-f0e0-465f-8a96-0fd55d2a4832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c8b683d-d2c6-4a53-80ef-1e6df7191dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b0e26d4-f0e0-465f-8a96-0fd55d2a4832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#StockholdersEquityShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2cc8960e-ee29-464c-873e-f0fa46b6d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2cc8960e-ee29-464c-873e-f0fa46b6d0a9" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d77be8d7-d03e-4b62-b1fc-50daf947af30" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_a7732f5f-fdff-45e0-b1f2-2c4a875a92bf" xlink:href="halo-20221231.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_db4ecd3c-b1f2-4cbe-81fd-b43223c9eb08" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_a7732f5f-fdff-45e0-b1f2-2c4a875a92bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c06b9355-039f-4850-b5bd-2778cb922c03" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fa1256e6-4f8e-4071-a710-243fe69fceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fa1256e6-4f8e-4071-a710-243fe69fceb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_becda589-9666-414f-86d6-a74f85bbf675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_becda589-9666-414f-86d6-a74f85bbf675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ed9924a4-e7e5-4c3c-b65d-16d3a1d2dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ed9924a4-e7e5-4c3c-b65d-16d3a1d2dd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_891453c4-019c-4644-8500-d02eddd20690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_891453c4-019c-4644-8500-d02eddd20690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_09d0ab60-fa36-42eb-b9c5-712bdb0a5a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_09d0ab60-fa36-42eb-b9c5-712bdb0a5a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_45f4a4c6-1cef-4215-9825-73153652f1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_45f4a4c6-1cef-4215-9825-73153652f1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_67e0be8b-9454-4456-aaf2-78aa3ec4c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_67e0be8b-9454-4456-aaf2-78aa3ec4c3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TreasuryStockAcquiredFeeCostPerShare_cbb93048-86ee-4b82-bcb1-ca097eef4b15" xlink:href="halo-20221231.xsd#halo_TreasuryStockAcquiredFeeCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bea075ef-0f0c-48ba-9fe6-2d4b4827d6c6" xlink:to="loc_halo_TreasuryStockAcquiredFeeCostPerShare_cbb93048-86ee-4b82-bcb1-ca097eef4b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_65ae5962-be29-45e6-9b45-6ea73e5798ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_65ae5962-be29-45e6-9b45-6ea73e5798ee" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:to="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3abda363-add6-4e96-89f1-d63e56f87541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_092f8408-772b-4477-8849-00f5807f5a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_092f8408-772b-4477-8849-00f5807f5a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_59be4bfc-0a3c-48a5-bcae-44578ab80c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be81af53-496a-4df7-8ba8-7e9d041761a0" xlink:to="loc_us-gaap_RestrictedStockMember_59be4bfc-0a3c-48a5-bcae-44578ab80c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:to="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1220f38-9bc1-4ae6-80d0-83b6e5233eab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1208a061-b0ea-4ebf-8ff1-212d8c67b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_511b530f-f2cf-4329-98b9-9d559cb73dbe" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1208a061-b0ea-4ebf-8ff1-212d8c67b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0565b02d-0128-4f1e-99ae-88078217e5f4" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c9c36e0-f325-4fbb-8edf-733096520891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_NetIncomeLoss_8c9c36e0-f325-4fbb-8edf-733096520891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c7ed155-95fa-4f3c-9a38-c859024faca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c7ed155-95fa-4f3c-9a38-c859024faca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5d766a9f-f89e-4770-8827-246ef7eff87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5d766a9f-f89e-4770-8827-246ef7eff87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72f5e03e-1532-4212-8609-27405a838ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72f5e03e-1532-4212-8609-27405a838ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_00dedc73-6413-49a5-a0aa-952c8aa0e749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_EarningsPerShareBasic_00dedc73-6413-49a5-a0aa-952c8aa0e749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5afebd6b-b77e-4ba1-81cb-26d544c9e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_dd18d904-b6e1-4f0b-abbb-fba2b5bf399c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5afebd6b-b77e-4ba1-81cb-26d544c9e4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#NetIncomepershareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41bad74c-10b2-401c-ada6-4322f0ba5a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a90c2bf8-0b9c-4fdb-89c8-13b91f859ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41bad74c-10b2-401c-ada6-4322f0ba5a57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a90c2bf8-0b9c-4fdb-89c8-13b91f859ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesOperatingLeasetextualDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a81780f8-5b99-43e1-bb3d-85248e2d529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a81780f8-5b99-43e1-bb3d-85248e2d529f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_29af96db-ddaf-4716-a364-b95e640c7712" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OfficeAndResearchFacilityMember_9a66fa2a-e9ef-4166-b795-e29a7faae9d3" xlink:href="halo-20221231.xsd#halo_OfficeAndResearchFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_402d3474-e2ec-4377-87dd-edbd68c5680c" xlink:to="loc_halo_OfficeAndResearchFacilityMember_9a66fa2a-e9ef-4166-b795-e29a7faae9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_66b28cce-b7cd-4ba8-b5bf-84d67263a66f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeasesAreaLeased_e21cf3f1-b236-4b37-9681-a835ea530c44" xlink:href="halo-20221231.xsd#halo_OperatingLeasesAreaLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_halo_OperatingLeasesAreaLeased_e21cf3f1-b236-4b37-9681-a835ea530c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a7aebe4f-3632-49a8-992a-7f500a658c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_us-gaap_OperatingLeaseExpense_a7aebe4f-3632-49a8-992a-7f500a658c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b623f0e3-ed86-42c5-ab7a-295d125b3e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00b0ad89-d566-4492-96b8-4bd509f1796c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b623f0e3-ed86-42c5-ab7a-295d125b3e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b3f8487b-2b05-4d72-bc44-22817cc392fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b3f8487b-2b05-4d72-bc44-22817cc392fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2c4a1e8-200f-443d-9e3f-bfdd82649cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2c4a1e8-200f-443d-9e3f-bfdd82649cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e7e989a-54cf-4cf0-86fb-691a136854e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e7e989a-54cf-4cf0-86fb-691a136854e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cde121b-7ade-45de-a43a-d95ef931317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cde121b-7ade-45de-a43a-d95ef931317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9f8f17a0-43da-42b2-84c0-709b7d526c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9f8f17a0-43da-42b2-84c0-709b7d526c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c7a65875-120d-4a39-b9e4-9fcefd8f837d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c7a65875-120d-4a39-b9e4-9fcefd8f837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de44497f-a139-4f4f-b147-b3effb5eba32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de44497f-a139-4f4f-b147-b3effb5eba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95867afc-67e4-48cd-abf1-34bee41af5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95867afc-67e4-48cd-abf1-34bee41af5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_35d07ea5-01e1-47a0-9ced-e1cbb39fb98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94ec2edb-c4ef-4a40-b85a-ef20c4cf37e5" xlink:to="loc_us-gaap_OperatingLeaseLiability_35d07ea5-01e1-47a0-9ced-e1cbb39fb98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="halo-20221231.xsd#CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesNetIncomeLossByRegionDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e069397b-270a-468c-aa58-121bcfd202e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6ec693ba-d585-470e-b7df-34db29e787af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e069397b-270a-468c-aa58-121bcfd202e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6ec693ba-d585-470e-b7df-34db29e787af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8215519f-1f90-4ba0-88b1-7feb5a8af9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e069397b-270a-468c-aa58-121bcfd202e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8215519f-1f90-4ba0-88b1-7feb5a8af9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a6e1816c-f831-4d55-9dbf-43ee59b512f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e069397b-270a-468c-aa58-121bcfd202e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a6e1816c-f831-4d55-9dbf-43ee59b512f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesComponentsDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_20e612e1-8ce6-40b7-8d7d-7569b017ffbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_20e612e1-8ce6-40b7-8d7d-7569b017ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_be2b8815-2321-4cc5-9e3b-1e2ced843309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_be2b8815-2321-4cc5-9e3b-1e2ced843309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74665991-94ad-4d46-a7af-47d5ea04e977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74665991-94ad-4d46-a7af-47d5ea04e977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e85d700e-661d-4f7d-9534-15482c753189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e85d700e-661d-4f7d-9534-15482c753189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsLeaseLiabilities_1aae4545-fb0d-4ade-8c6e-a9fd64a0adb5" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxAssetsLeaseLiabilities_1aae4545-fb0d-4ade-8c6e-a9fd64a0adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fad901d8-8037-4987-b916-02e88769dd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fad901d8-8037-4987-b916-02e88769dd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetTransactionRelatedExpense_41809fb0-4bd9-480b-aab3-346bf2a9f979" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetTransactionRelatedExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxAssetTransactionRelatedExpense_41809fb0-4bd9-480b-aab3-346bf2a9f979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_5a34b88d-091a-44d7-bd4a-acb19f5c5ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_5a34b88d-091a-44d7-bd4a-acb19f5c5ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxAssetsInterestExpenseLimitation_a7b784d4-9275-4900-9308-a9393315cac6" xlink:href="halo-20221231.xsd#halo_DeferredTaxAssetsInterestExpenseLimitation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxAssetsInterestExpenseLimitation_a7b784d4-9275-4900-9308-a9393315cac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_25ece34c-96e6-457a-a474-9d9632507de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_25ece34c-96e6-457a-a474-9d9632507de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cfba8b5e-77d8-40c3-a3c5-ac8dc44dfd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_cfba8b5e-77d8-40c3-a3c5-ac8dc44dfd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_938445bc-6076-4e0f-9563-e7f666cae0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_938445bc-6076-4e0f-9563-e7f666cae0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b982be64-44c3-4dcd-9069-ff04a41dcf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b982be64-44c3-4dcd-9069-ff04a41dcf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_a144c57b-a165-4696-a6e6-e63181aedb04" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization_a144c57b-a165-4696-a6e6-e63181aedb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc32a384-b214-4c0a-8aa3-490306dc3cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cc32a384-b214-4c0a-8aa3-490306dc3cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesConvertibleNote_f0cf02f0-e215-4264-8aca-eabd2908f214" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesConvertibleNote"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxLiabilitiesConvertibleNote_f0cf02f0-e215-4264-8aca-eabd2908f214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilitiesRightofUseAsset_19bf2e2a-df6d-4664-a0d1-0d6c3d2c2195" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilitiesRightofUseAsset"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_halo_DeferredTaxLiabilitiesRightofUseAsset_19bf2e2a-df6d-4664-a0d1-0d6c3d2c2195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_bc48dbfb-69d3-4596-8e54-72e88c342794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_bc48dbfb-69d3-4596-8e54-72e88c342794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_accc2b64-1b8b-49a9-ab99-c2960da1085e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_accc2b64-1b8b-49a9-ab99-c2960da1085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_809f44aa-74b4-45a7-ad93-821375771af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702c95d4-ad97-4247-afd8-e87b0189c81c" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_809f44aa-74b4-45a7-ad93-821375771af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d69433e0-9b92-4dd3-aa5a-4062e16228c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d69433e0-9b92-4dd3-aa5a-4062e16228c9" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_55fbfa29-a85f-44e4-9143-a434a978f97a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2974e401-e571-4045-8bb2-63c7534e55f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:to="loc_us-gaap_DomesticCountryMember_2974e401-e571-4045-8bb2-63c7534e55f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ba979dbe-3d54-45bb-bc4c-3dd194ca3379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b1e5a850-b660-4777-8b9b-15c4e559de48" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ba979dbe-3d54-45bb-bc4c-3dd194ca3379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aa268f19-0573-455d-b773-374f8c309068" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_ab115cd8-c5e3-4193-91d0-29d8cc405c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:to="loc_us-gaap_ResearchMember_ab115cd8-c5e3-4193-91d0-29d8cc405c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_56cd7c9f-e72c-4886-8165-04dea944c6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8751942c-d225-44b6-8c42-a72629fb4158" xlink:to="loc_us-gaap_GeneralBusinessMember_56cd7c9f-e72c-4886-8165-04dea944c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_40142697-876d-4b13-a5ff-f23af1f8d70b" xlink:to="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_24f411fe-1a36-42e7-8933-302e455e877e" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_stpr_CA_24f411fe-1a36-42e7-8933-302e455e877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherStatesMember_3534c92d-5f26-44b3-ac97-c837e7ab34aa" xlink:href="halo-20221231.xsd#halo_OtherStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_halo_OtherStatesMember_3534c92d-5f26-44b3-ac97-c837e7ab34aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_c7938be1-0112-4ad1-b676-c52d3e1cb3a7" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2e6ab5fa-fbe9-4d00-88b2-9c15aa90c277" xlink:to="loc_stpr_MN_c7938be1-0112-4ad1-b676-c52d3e1cb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea47bd76-1a16-4c1d-8da4-f9747d371f96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_bcfcb3d6-7f87-4fc5-a281-8d2e8c0a588a" xlink:href="halo-20221231.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7511d47-3e06-4293-8c31-eb1cafa671b8" xlink:to="loc_halo_AntaresPharmaIncMember_bcfcb3d6-7f87-4fc5-a281-8d2e8c0a588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_723c9f6c-af93-44f5-866a-5bf9975dd88e" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b40a68f-6b71-47eb-aa50-6c79ed46786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8b40a68f-6b71-47eb-aa50-6c79ed46786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_26aae95f-bfcd-438a-be62-7a6050cdabde" xlink:href="halo-20221231.xsd#halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory_26aae95f-bfcd-438a-be62-7a6050cdabde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e1dfb19c-abd1-4425-8e7f-4d9b04a61fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e1dfb19c-abd1-4425-8e7f-4d9b04a61fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6ac272f6-1868-4a0f-841d-cb37a7731bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6ac272f6-1868-4a0f-841d-cb37a7731bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0d561360-5b17-429a-a08e-b7a77204b320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0d561360-5b17-429a-a08e-b7a77204b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_613c704e-437e-4106-88f3-9debd61a142a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01348743-bcf3-43f6-a299-810a7f853188" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_613c704e-437e-4106-88f3-9debd61a142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aff2427e-a7a0-42fc-aab6-c5355b6be843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aff2427e-a7a0-42fc-aab6-c5355b6be843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_888e7521-674b-4c0c-b042-a8a90b4f3c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_888e7521-674b-4c0c-b042-a8a90b4f3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5d4d90df-64bf-41d7-b0bd-ba450bb0ef39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5d4d90df-64bf-41d7-b0bd-ba450bb0ef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_64c4f2bf-4a40-4b83-bebf-fcea5acde639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_64c4f2bf-4a40-4b83-bebf-fcea5acde639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e58ccc8d-73e7-4bcc-a85f-e15d04c8cd13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dc22a8c1-f6ca-4b16-b632-4a738663ebae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e58ccc8d-73e7-4bcc-a85f-e15d04c8cd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesScheduleofIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a4fdab1f-6a1d-4217-90fa-d736b28f3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a4fdab1f-6a1d-4217-90fa-d736b28f3c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5d53cd57-734e-4daa-846e-7b7e92519052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5d53cd57-734e-4daa-846e-7b7e92519052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_05c68e8c-92a3-48d9-a5ed-14ff88a811bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_05c68e8c-92a3-48d9-a5ed-14ff88a811bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_81774c09-9e13-4149-88b3-685ec067ebab" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent_81774c09-9e13-4149-88b3-685ec067ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2bd62c2a-f266-409c-a1d4-bbb85b1ce6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2bd62c2a-f266-409c-a1d4-bbb85b1ce6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8c19e5e1-c359-4030-88bd-cee71d24f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8c19e5e1-c359-4030-88bd-cee71d24f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_931af18b-6f0d-43b7-9f3d-dbe3b6967c3e" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent_931af18b-6f0d-43b7-9f3d-dbe3b6967c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_adaad170-7a52-4d6f-83f9-ca56b9e02bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_adaad170-7a52-4d6f-83f9-ca56b9e02bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_70dcf51f-b512-459a-96bb-35ab09b8ae76" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_70dcf51f-b512-459a-96bb-35ab09b8ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_108d6535-4ff0-4919-88af-156d64a56775" xlink:href="halo-20221231.xsd#halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_108d6535-4ff0-4919-88af-156d64a56775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba77b154-965a-4441-aef1-d58c8e2aa88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa7a6e83-d8e4-4c3c-85c8-991c855903c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba77b154-965a-4441-aef1-d58c8e2aa88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3f26b37c-ed26-4c51-bc30-5830741b3a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3f26b37c-ed26-4c51-bc30-5830741b3a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_09ed0493-28d7-43ba-ada0-0d55992d93d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_09ed0493-28d7-43ba-ada0-0d55992d93d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9769ef3-7713-4a67-a618-84f76fdcb0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d9769ef3-7713-4a67-a618-84f76fdcb0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_e67d0b54-ba27-4cfa-869a-fd822e89cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_e67d0b54-ba27-4cfa-869a-fd822e89cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8da10116-1387-42d2-a587-5b41880f2d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8da10116-1387-42d2-a587-5b41880f2d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_26de8b9d-35e8-489c-a0a9-38515118235c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74fcbdaf-29b4-4d26-b00f-169eab1f642f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_26de8b9d-35e8-489c-a0a9-38515118235c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EmployeeSavingsPlanDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#EmployeeSavingsPlanDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EmployeeSavingsPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ea637882-e2b0-4a88-b7d6-4f2aab077338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3b3bf67a-dd3a-4ab0-815b-83c549507c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ea637882-e2b0-4a88-b7d6-4f2aab077338" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3b3bf67a-dd3a-4ab0-815b-83c549507c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="halo-20221231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_22e6f9be-7922-4b56-b4a5-0ee9f3c065f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_22e6f9be-7922-4b56-b4a5-0ee9f3c065f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_c0420a85-b59c-4746-9bcf-5a25ef5f131a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_c0420a85-b59c-4746-9bcf-5a25ef5f131a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d6f60586-9a36-40c6-8dfc-612bb16723de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d6f60586-9a36-40c6-8dfc-612bb16723de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_61adbab3-21c3-44f1-be81-ecbad20db1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_61adbab3-21c3-44f1-be81-ecbad20db1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_934a8466-8186-45fe-8ac4-3bb930654f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec15d3ff-d91e-458d-8884-4edb846ccf32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_934a8466-8186-45fe-8ac4-3bb930654f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>halo-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,S8
M )*2  (    #,S8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "F 9D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\[5]-D\;4Y2[O\O^'/D<^G>K"'9?G_PP %F 4$DG  [U]4Z;:_8=)M+3_GA
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MHD&EZU#=6B"..\5F9%& '4C./KD'ZYK*OAO9+G@SEQF 6'C[6D]CNO!GB?\
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M/J,UYM\3/$3W-Q'X<TTEW9E^T!.K,?NI_(_E78>*-=A\+>'6G7!EVB*VC/\
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MZ6V.3'("?Q7_ !KU.O+?C!_Q]Z5_N2?S6A :GQ$O'C^'MD@;FY>%7]P$+?S
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MEL<6#HO%8AU)[;O_ "-BBBBO8/J0HHHH **** "BBB@ HHHH **** "BBB@
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M@ #H*X8Q]I6<WLM$<<(>VQ+JO:.B]>HZBBBNH]$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDL@BA>1@2$4L0/844
M4">Q@^#[$1Z6^J2X:ZU1OM,K#L&Y51[ '^==#116=/2",L.DJ4;=@HHHK0V"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>halo-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #-#(
M )*2  (    #-#(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 2S W # 2(  A$! Q$!_\0
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M\OXH/[7P?\WX/_(]@HKQ_P#X7?=_] .'_P "#_\ $T?\+ON_^@'#_P"!!_\
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M**\?_P"%WW?_ $ X?_ @_P#Q-'_"[[O_ * </_@0?_B:/[,Q7\OXH/[7P?\
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M#_\ $T?\+ON_^@'#_P"!!_\ B:/[,Q7\OXH/[7P?\WX/_(]@HKQ__A=]W_T
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M[O\ Z </_@0?_B:/[,Q7\OXH/[7P?\WX/_(]@HKQ_P#X7?=_] .'_P "#_\
M$T?\+ON_^@'#_P"!!_\ B:/[,Q7\OXH/[7P?\WX/_(]@HKQ__A=]W_T X?\
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MW]C_ /BJ^BJ*/[8K_P J_'_,/[!P_P#,_P /\CYU_P"%;^+O^@-)_P!_8_\
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M2?\ ?V/_ .*KZ*HH_MBO_*OQ_P P_L'#_P S_#_(^=?^%;^+O^@-)_W]C_\
MBJ/^%;^+O^@-)_W]C_\ BJ^BJ*/[8K_RK\?\P_L'#_S/\/\ (^=?^%;^+O\
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M_P#XJC_A6_B[_H#2?]_8_P#XJOHJBC^V*_\ *OQ_S#^P</\ S/\ #_(^=?\
MA6_B[_H#2?\ ?V/_ .*H_P"%;^+O^@-)_P!_8_\ XJOHJBC^V*_\J_'_ ##^
MP</_ #/\/\CYU_X5OXN_Z TG_?V/_P"*H_X5OXN_Z TG_?V/_P"*KZ*HH_MB
MO_*OQ_S#^P</_,_P_P CYU_X5OXN_P"@-)_W]C_^*H_X5OXN_P"@-)_W]C_^
M*KZ*HH_MBO\ RK\?\P_L'#_S/\/\CYU_X5OXN_Z TG_?V/\ ^*H_X5OXN_Z
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M * TG_?V/_XJOHJBLO[8K_RK\?\ ,U_L'#_S/\/\CYU_X5OXN_Z TG_?V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_,@_MZC_ "/\#Z6HKYI_X37Q-_T';_\ [_&C_A-?$W_0=O\ _O\ &C^QJO\
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M_P"_QH_X37Q-_P!!V_\ ^_QH_L:K_,@_MZC_ "/\#Z6HKYI_X37Q-_T';_\
M[_&C_A-?$W_0=O\ _O\ &C^QJO\ ,@_MZC_(_P #Z6HKYI_X37Q-_P!!V_\
M^_QH_P"$U\3?]!V__P"_QH_L:K_,@_MZC_(_P/I:BOFG_A-?$W_0=O\ _O\
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MV_\ ^_QH_L:K_,@_MZC_ "/\#Z6HKYI_X37Q-_T';_\ [_&C_A-?$W_0=O\
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ME;Y/R^XSG0H)-P=_FO/[_P"NYR]%%%=QYH4444 %%%% !1110 4444 %%%%
M!171>"+*VO\ Q!)#>P)/&+.=PKC(W!"0?P-=MIGA+1M2F\-F"VA^TQVL5Q?6
M[#Y;B%P1OQW(8#/UKDK8J%&5I+^M?\CNH8*=>*E%_P!:?YGD]%>C6UII<5KX
M;LI-%L[D:M<7$,\I0B90)=H*L#Q@']*?9^$])FATF"6$3;;B_P#,,9VO=B%C
ML3(]<=JEXR"W3Z_A?_(M8"<OA:Z?C;_,\VHK>N]036[7[/;^'+2UN#.L<4UF
MKIM)_@89(8GU//6NK\8^%K71?#]K>V&GQ>;I4J0W1?#+= J,NP!SC?E<'%:2
MQ"C*,9*S?H91PDIQE.#NH^IYM17I>IV&F3W6IPII5C;+#H*W2-%%M*R/L);K
MVR<?6H#8Z7:>,;7PF- AN;698T:\.[[1(64$S*^< #/3&.#6:Q::OR^?R-7@
M9)VYEO;KO_2/.Z*]*M/"6DWOAFQMH1&=5-[<>1+C_C[2*3#(3ZE>1]*X_P 8
MVL%EXRU2VM(EA@BN"J1H,!1Z"M*6)C5FX+S_  =C*MA)T8*<GH[?BKF+1117
M2<84444 %%%% !7L/P0_Y!NK_P#7:/\ ]!->/5[#\$/^0;J__7:/_P!!->;F
M?^ZR^7YGK9/_ +Y'Y_D>HT445\@?=!1110 4444 -DD6*-I)#A5&2:K)#+=
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M0>WC81IT7*C@>PJG)X:LY&=?.NDMI&+/:),1$Q)R>.H!/4 XK650JA5 "@8
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M(K)G.W:1@#CIBD/BS63K"ZF;O_2%B\E1Y:^6(\8V;,;=OMBE["O?XOQ?W?\
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MB@ HHHH LV&HW6F7!GL)C#*4:,L #\K#!'/M5J'Q)J]O>VEW!?2)/9PB"!U
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M_O2?]]FCZ_B?YV']FX/_ )]H\\_X4IHO_01O_P T_P#B:/\ A2FB_P#01O\
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M/^%*:+_T$;_\T_\ B:/^%*:+_P!!&_\ S3_XFO0_LZ?WI/\ OLT?9T_O2?\
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MHQR6RQBU4QDK(N$&T[]H ).X,3VS0!TP\-VQB@^RZG>Q7< <_;(Y$:5UD(+
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MEQ$T,,=H(U6)";>)W93C<?G9AR3CD4 6K3PKIMG+I<D8E9]+A,,!9_O#& 6
MX) )P>VYO6JW_"$V/V:XM6O+TV<L,D,=MO0) K_>VX7)]!O+8' Q71T4 9,V
MBBX\6P:O*$VVML8HP&.6=FZL.GRC(7_KH_2M:BB@ JIJD<LVF3QV\YMY67"2
MA Q0YZX/!_&K=177_'LWX?SH#<P_[$\0_P#0VS?^ $/^%']B>(?^AMF_\ (?
M\*Z&BM?:R\ON7^1C[&/=_>_\SGO[$\0_]#;-_P" $/\ A1_8GB'_ *&V;_P
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ML%GY<<?V2#9$ACC7RQA$(P5 [ @#BH[32--L(HXK'3[6VCB<R1I# J!&(P6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6TV[U7R+]+C3YIXU7?YH,2A@7D).[<.3\HV_[5=\UI;M)YC01%]P?<4&=P&
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MV;\/YU+5+6+&WU'2Y;6\C\R%]NY=Q7.&!'((/44U:^HG>VA=HKG?^$#\-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MBNO^/9OP_G4M177_ ![-^'\Z ):*** "BBB@"&Z_X]S]1_,5-4-U_P >Y^H_
MF*FH **** "HKK_4?\"7_P!"%2U%=?ZC_@2_^A"@"6BBB@ HHHH BN?]3_P-
M?_0A4M17/^I_X&O_ *$*EH **** "HKG_4C_ 'T_]"%2U%<_ZD?[Z?\ H0H
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M6S!\B-(E42,JNB<JKJ#AP.P;(%:U% %+3].^Q7%],TIEDO+CSF)&-HVJJK^
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M\>S?A_.I:BNO^/9OP_G0!+1110 4444 0W7_ ![GZC^8J:H;K_CW/U'\Q4U
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MAI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BNO^/9
MOP_G4M17/_'K)_NT 2T4#I10 4444 0W7_'N?J/YBIJBNO\ CU?Z5+0 4444
M %177^H_X$O_ *$*EJ*Z_P"/9_I0!+1110 4444 17/^I_X&O_H0J6HKG_CW
M;ZC^=2T %%%% !45S_J1_OI_Z$*EJ*Y_X]S]1_,4 2T444 %%%% $5Q_JU_Z
MZ)_Z$*EJ*Y_X]S]1_,5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&1Q7;C0-,&@C11:C^SPFP0[VZ9SC.<]?>F3>&](GM[J":R1XKN432H6;!D
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M7E!Y)?.W;<J2/EVY(-:D'Q2T@PO=7]EJ.GV+6TEU:7=S"-EY''C<4 8MG!!
M8 D&@#MJ*X/6/'^HVVBP7L7A[4K"7^T[2W>WO8%+SQ2O@^7M<J6QQ@G@XR*A
MO_C+H6G:;;3W5I>1W4TL\3V4K0QR0M"VV3<SR!.#P &)/:@#T*BJFDZI::WI
M%KJ>G2>;:W<2RQ/C&5(R*MT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1W/_'M)_NFI*BN?^/63_=- $HZ"B@=!10 4444
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M); ^; &>,50CUO5+S7O[.T;Q0][9O<6Z_;1:Q.R*R2EU5U4(Q^1><?+T()H
M]%HKAGUV]CGBL]5UMM+M(YKJ)M3:.)6E:-P(T)93&I*DG[HW;>,<BJ>K^)-?
M@U6.&ROK95%O UJ)LQ'4&;[Q\KR78\X&U&4KU/!% 'HM%87A>;4;J/4;G4KU
MIP=0N(8(3$J+#'',Z* 0,L2 .2?3WSNT %%%% !1110 4444 %%%% !1110
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MOA)()"DC&>=P5=V>E:$/A;4HM/9M/>VTNZ:Y8QP0NSQ6T$BJLD:G YRID'
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M;9(5VO@ GY2>A]*FLK.==-DTVX0);Q0K;PRH_P TB^6 6Q_#SD#Z9K-M;/Q
MNFII5Q!IRV\-N8?M*2L3* A5<1[0$/0GEL8( YX -EM3M$M;6X,C&*[9%A98
MV;<7^[T' ]S@#O4US_Q[GZC^8KC8O \]C'9QZ8+:W1+:!+G:[ S2H>7)Q\QP
M2-QY/>HI? \UEI:0::EK'%]B@CNH2[ 7DJ."PD;&2&&Y2QR>>01Q0!WE%<IH
M7AN]L;;756&TT@:B1]FBL9&=;;]T$R/E4 [ANPH _')K(;P+>74P4Z=ING0_
M9E@G^RW,FZY(FB<NV%')5&Y.6YY- 'H50VEY!?0&:U?S(Q(\9."/F1BC#GT9
M2/PKD;GP?-#=/]DT_3KO3%N6DBTF9C'  T<8W8"E0P97(&TCYR>#6WX3TJXT
M3PW#8W@B$R2S.1"[.BAY7< ,W)P& YH MZMI]GJ-B8M0M8;F,,"%F0, <]>:
MMQ11P0K%!&L<:#"H@P%'H!3;K_CW;ZC^=2T[NUA65[A1112&%%%% !1110 4
M444 %%%% '"ZWXKU.PA\1QV]M>.UI<(EO=1Q1F*$&.,X.3D\L3T/6KA\=-_:
MT\":1<M:13R6PN!'-RZ9R2?+\L)N4C.\GOBMP6.DZA'J5L(XYEFF"WJ!CS($
M7@^AV[/TII\-:2=2DOC9@SR%BWSMLW,-K,$SM#$<%@,XSSS0!DZ=XIU?5(+8
M6NB6ZW<MFE[)#+?X6..3.Q=PC.7.T\8VC'WJ;/XVDCUQK*/1[F2&&:."XF6.
M5BDCA2<%8S&0N]<DNO? /&=*_P!#T.06,%Y%Y15/LMMY<SQ,R[<^7E2"RX7.
MTY'%3/X;TF348[YK-1-'M("LP0E1A24!VL5'0D$C QT% &59^++Z=;>YN=(B
M@L;J\:SAD6\WR;P[(K,FP *2O9B1D9'7&)8>+M<A%H]Y;B\NKD>4MK'.JQ;F
MN6C#ES&&& .1TP.A-=+H_@[2](:.41^?<QRRS+(S,%#NS,6$>=H;#$;@,GUY
MJ:ZTS0=,CAN[N&&W2&1%CD=B KM+E1UZF1_S- %6[UZ[?P=KUV(EM-0TV*X4
MB-_-59$CW*5)49'*GD"J#^+KR/6H_-TZ]@M(]/:>>.Y1%+ 2QJ9%VEB=JLQ(
MXS717-IID4$]K<I&L>J2,DJ,3^_9DP1]2J_I3KW2H;I)&C"Q7+6KVT<Y7=L1
ML9&,X/(!_"@#E]0\;R6>IRSQP//8B%TMXHAO-S*)XXE8;5+ ;F8<;N!G!Z5<
MM?&%U=01PKI#IJ4MU]FCAF,D,3?NS(7WR1J^T*#_  9SP,CFM4>&=(^P16;V
M4;0PVHM$!XQ$,' QTY4'(Y!&11_PC.D_V;]A^RL8O-\[>9G\WS/[_FYW[NV<
MYQQTXH Q]3\1:MI>K6$FH6D%O9+9W=Q>1QW'F,?*"D%/D&>#QDKU.1QRS4=1
MUG4]VCW.F&REN["6[M9[+4CO#(T8V$A5(;]X#P2O&,FN@AT+3;=852U4^2DB
M(9&+DB3&_)8DMNP,DYS5.UT'0/#][%>PPBWN'7['#)),[D*Y!$2[B=JY4848
M'% &=':>((KWR0]PULE\+A9&E!S%YFSRLDY("#?S[=^*G\1ZKJ=K=7Z:8RJ;
M32);I0Y 5I"<*2=I/RA6.,8.>:Z$74+7C6HD7STC$C1]PI) /Y@_E61?P::V
MO22WEW&#+9BSGMF_C61\)SGC)WCWS[4 9=KXPU-MT$VDPM*LL-G$XO.)[AX5
ME/\ !\J!2<MUXX4YIS>,M0@NI+:]T6*%X;U;6:7[86A4-&CJV_9QNW[0&"@D
M<D9&=9]-T*YM;^U>.$Q+*K70WE3'(J+M;=G*D*$(((Q@&L[2]$\(ZE9R3Z9&
MMQ$)_-F;SY27D"KS)DY?*JA^;(( //% ">'?$.HW.H/8ZK#$7EO+U8I(I=P1
M(9% 4C8O]['X>]0/XUOQ8"_BTBWDM!927LG^FL)(T0'J/*Q\Q&!\WJ>QK9.A
MZ)JVGQ21PAX99&NHIH)GC;=)RS!U(8;L\@'!HC\*:-#=&>*U="T:Q-$L\@B9
M%7:%,6[81MXP10!3UKQ5/INIP:?:::+J>?R FZX\M096=>3M/"[,GJ?0>L$/
MC*X3;-J>EI:VJS7%O)(ESYC"6%79MJ[!N0B-L'(/^R*U;3POH]EL\BT)*2)(
MK22O(RE 0F"Q)P-QPO09/%61H]@"A%LG[NX>Y7KQ(X8,WXAV_.@#D];\7ZW:
MZ<K#28[9KNU-S:RQ7:R,-KQ_(RLH 8B3J"5'K71:?J]W+J\FF:I8QVMQY'VB
M(PW'G(Z;MIR2JD,#CC&.>"><5_\ A!O#A#A],216B:'9)([JL;$$HH)(525'
MRC X'%:&FZ'I^D/*]C"RR2@!Y))7E<@=%W.2=HR<#.!DT 8K^+KW=;W46DQO
MI=Q?_8EG-WME!\PQES'LQMW _P 6>F0.<5[3QU<_V5;7VJ:.+5;ZP^VVD45T
M)7<;HUV/E5"DF9,')')SC%;$GA+1)=1%])8@S+/]H4>8^Q9?^>@3.T-ZL!DY
M.>IJR=!TMK:"W>RB>&WM6LXXV&56%@H*8/4'8O7TH S=-U35I_%TMAJEM#:H
ME@LZQPS^<C,9",[BJMG QC&/3-=%67IGAS2](NY;JPMF6YE01R323/*[(#D*
M6<DX&3@=LUJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5%<_\>LG^Z:EJ*Y_X]9/]TT 2CH**!T%% !7.W?B>:WU
M"[2*PCDL[&YBMKF9KC;('D"$%(]IW >8O5@3S@''/153ETC39]1CU">PMI+R
M(82X>%3(OT;&1UH XV'Q%XC>:2-[6VN2#J!,?VG8@6*=57YO+SG!*@8YZDU<
MC^(*W&H1QVNE74EH3;J\_E2D@S(C+C;&4P!(N<NIZX!XSTT]C:QP2O';0JQ5
M\E8P"=YRWYGD^IIAT'2&N;>Y;2[,SVRJL$A@7=$!T"G' ';'2@#*LO%4\_@W
M^W[S35MA)@P0+<ARP9@J%FP N20>^!R?2I)M>U*WD@LY-.L_[2N)C''&M^3#
M@(7)+^7N!P.FPD_3)&TME:K9?8UMH1:[-GD!!LV^FWICVJF/#>B#3VL!I%B+
M1G#F#[.FPMZXQC/O0!E6_C-);2]EDLQ$UG9M<.IG!#,DLL;J#CD!HN&[AAP*
MAE\4WTK2H=+BBMWNY+&&5[KYFE5&8$H$X0E2,Y)']TBMZ;0=(N%M5GTRSD%I
M_P >X>!3Y/3[O''0=/2GW5E:_9F_T:'Y9#,/D'#G@M]>3S[T <3IGC'6+NQT
M]+V 1&*.SEN[N&96,IER=@0Q]PO)&.O%7;'Q]<WUF\T6A3YDMQ<6JE9E\Q2R
MC#%H1SA@<1^9GD#)QGJAIVG6T>Y;.VB5 IR(E 4(/E[?P]O2N>DG\(01L(])
MBE_M"!;B>.WTQI&:-CD-(%0D G)^;N#Z4 :-SXA9=.TN6QMXKBXU1PD"FXVQ
M ^6SDE]I.,*<84DG''7%6/QAFUNWFLA'-:6D]Q(@G#*6B<JRJV.1D?>QW&0#
MQ5JYNO#USH\D%Q';7&G06BW1C,&^,0C.U@,8XVG@<\53FN/"L\;03Z=#+!I*
M%T+:>6CA P6"';C(R,@<_E0!FR>+-4M[G5FN[.*6TCOH(H_WY'V>)K=)&9L1
MYQENIX!;DJHS3V\4ZDFCWZV4274UE;SW$]Q=7"0LJ[Y NQ0FUL!.^T<#))S7
M2:AI.FWD#/<6%K.6E2?+Q*V7  #\CJ  ,^@IUWX?T>_$8O=*LK@1;O+$MNK;
M=QRV,CN>3ZT <W8>.I9KV"U;3;B:)7AMYKH12Y,KHIR,1F/;\XZN#UXZ9?XI
MUS6=-UF6+3UC-LM@LRJ'&]I//1<8*XY!QDMWSCBNC.AZ4U_%>MIMH;J%0L<Y
M@7>@ P #C(P*L365K<2;Y[:*5MNW<Z G&0<<]L@'ZB@#E;SQO<V,YL)=)WZD
M+@PF.!Y9H@!$LF[<D3/T8#&SKGG'-7+W79+KPC:ZI DEF9KB!769,% 9E1@=
MP'OR0.O:M>[T?3+^.5+W3[6X69P\@EA5M[ 8!.1R0 !GTHN;"T_LAK'[+#]D
MVB/[/Y8\O;G&W;TQ[4 90U>?RO$/F:A;VYM[AHK26X*JD9$*-SZ@,Q)SFI_#
M-\\^FF*^N9WO(IGBE2Z\OS%8 $KE %88((('0C-78M$TJ&WA@BTVT2* L8HU
M@4+'N!#8&.,@D'UR:6VT;3+)8!::?:P"V+&'RX57RMWWMN!QGOCK0!=HHHH
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MA/\ :1)YDI"X(4R8<YW'<-O!(XR,>F44 >87VC^);D6;"*\MQ]BC2TB@8O\
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M?W![>E_,OO,MO#&I-X@M)WL87DAU+[3-JANVW31?-A-F.V5&T_*-N1VJ]?\
MA>;5/%'VC4 )M,\[S# 9FPW[E5 *C@C<"<'CH:M?\)[X7_Z#,'Y-_A1_PGOA
M?_H,P?DW^%'L:G\K^X/;TOYE]Y):Q:OIOA.VMUMDO[V-?+=#<;?EY .X@Y(&
M.M<OJ'@_5WTUK5;.&\N3;0QVUY]M:+[&54!E  S@D$Y'WMV&XKI/^$]\+_\
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M_!J=O&T0DRKQL<E&!P1GO3E0J0ASR5D3#$4IS=.,KLUZ***Q-PHHHH ****
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M,,'+#EB!P">GN>:<WA<W"ROJ&IW%Q<LJ+#.$5#"$;>I  P3N ))ZXQC%;]%
M&3I>BS6.H7E]>:A+?3W:1QMNC5%14W8"@>NXYR35>#PP8]/?3)M2GFTKR&@C
MM2B@HA& -^,G:.!T[9S6]10!S<GA.:[NDGU/6;FZ:)$2,>4B !9HY<G Y8F(
M GT["K-UX:6749M0MKR6VO'F6:.0*K!"(Q&5VGJ"H_/I6W10!S>H^$$U-K>>
MZO!+>11M$]Q-:Q2;T)S@*5PI!Z$?CFI+CPE#)I=W8V]RT,5TZ,VZ)7VA8P@
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MKJ'AJ6\UB]U&"5+:[,<8L[@#)0@,&5QW1LC(_'@@&@#2C\0:7+IL]_'=JUK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLVCGC8@E 0RA@, X/3WJ[#JFCP7XT"%/*:,>4(A;,(0=F_RPVW9G9SMSG&:
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M_#KVMVX+-,9%C5U98E)'RKMC0 <9P% R370U%=?\>[?4?SJ6@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKG_CW/U'\Q0!+1110 4444 177_'NWU'\ZEJ*Z_X]V^H_G4M !1110 4444
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M2X5FD=8][*X"@(2,D8+#@\CC(!V-%<?XP\37>G3&RL&:VD15D>=55B5:.<X
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M+G1M L[Y+F[18I+J5HHEDG<(TL@(.Q"VT.PW9*@$Y//)IUGX0T.Q39!9;HQ
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M  CYP<9;;TP,B2758[C49M(FU(:?->PI+>7=O*LAB6!ONE5WE?,P-V,]NG-
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MG/S9QCC%'M9]P]C3[&U_PA\7_0<UW_P8O1_PA\7_ $'-=_\ !B]5;2UUVT\
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MK7+;2C= J]PRK*8_(.1N^\!YF.OS?A1[:?</8T^QM-X1A12SZ[KBJHR2=2<
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MHZ]<X[=:@U/QQ:6^CW%YIEM<W_E6?VHO%"62(%-R!^_([ $@<G'%:Z:9I_\
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MTQ;>]A$<FR^C,<X\P\J9))./3YIG_,>E &G<_P#'NWU'\ZEJ&YXMC^'\ZFH
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M9C)&,E7"DKP>&!/7&#W5S_Q[M^'\ZEH H:&MRF@V2WUO';7 A420Q*%5#CH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HKG_CUD_W34M17/\ QZR?[IH E'044#H** "BBB@"*Z_X
M]9/I4M177_'K)]*EH **** "HKK_ (]7^E2U%=?\>K_2@"6BBB@ HHHH BN?
M^/=OP_G4M17/_'NWX?SJ6@ HHHH *BN?^/<_4?S%2U%<_P#'N?J/YB@"6BBB
M@ HHHH BNO\ CW;ZC^=2U%=?\>[?4?SJ6@ HHHH **** "BBB@ HHHH ****
M .1U'P!H^L>(KJ^UB_OKX7%K-;+I\]P##"LJJLAC4 ,"0@[X'4"J"?";3C,\
MM_KNN:C,R6\8DO+B-RJ03"9%&$'&X8/J,]^:K:H-"_M#Q/'=Q0-K;W -CY<6
M;HOY$>PQD#=][N.!@YXS5O4TUZ^U2+4[.VAG710J@M<-&TDN ;C:@0A\K\@R
M1SGZT .U#X8:-J5Q,)-5U*(3:DVIS013H%>0E#@C;D >6N",,,GYN:@NOA'X
M>U=-7^WW^H7[ZE-',9)98W-NR,Q38-F#C>1\X;CCI5"RA67QQ-J%U#:0:;-J
M#SP7Z6I\^5A O[IW[(5.1P<[2.#C-S39;.X\,W*>$H[(7VN7)#Q6Y$2P(5Z.
M44["(EQG!.]O>@#0TKX8Z'HXTS[+-<;]/6Y",%BC\TSHJ.6"(H) 48P![YK?
MT#2[+PWH%AH=G.SPV%ND$9F<%RJC )P!S@>E<='>'0K_ $"RU_R+%-,O)41Q
M,7B$#V\GE?O&5<X^YR!RON*ATY](/BG7)-1?1&62\E<I+:[KN2(PKRC9R01G
M& >,B@#TO(SC//I35E1V*HZL1U .<5S7A**>"XNTU=9/[2*J4>4Y/V7GRESZ
MKR&_VLGH16+H%M?:/X5EN+.UTY+Z_=X+3RK4Q2M(TC8,K\[@!EB<= >M 'H#
M,JJ69@%'4D\4AE0.$+J&/1<\FO-KFT;2M!;0M;^S64<%PES9/*6N[4KSE)V9
M%^4ON&2.-Z8.:?8Z"_B'6GG2RM=,A%E8L/,M2UQ;XWMMBDR-N,8Z=^G:@#T9
M9$9RJNI9>H!Y% D1G*JZEEZ@'D5Y?IEAJ(UV_>"WM+&Y>34I--N(K8K)=2F2
M4;)9"?X258#'(P0?E-:'DZ#<0:?;>&[=HM:\Z,3E(RMS$FX><;ANOW=P^8G+
M%<9XH [>SU73]1FGBT^_MKJ2V;9.D$RN8F]& /!XZ&K>0<X[=:Y'PIX&7PSJ
MEQ=">%Q("%6&$H6)/)8ECV X  XSBJ)OYK2)W:_?3K2ZU:Z^VZA&BLT14[8T
M)8%5!"@;B"/E ZL* .\!STHKS+2-7GB@(NM9N-.TZXO+R0:D+54:=Q( BG>I
M5<KEA\HW8XQTI^EZWXEN-)NM1GU*Y=(((5V_8%4@-(PDG*;=Q*H 0G;'(- '
MI1..M%>:W-S<ZN]U:VOB&]U&RM[_ $QX;A8(@<M/\XWB/:X& <@<$8/>K.H>
M*=5319;>SN6_MBT:_>ZB$ +1QHDQA8C&,9\G!_BR.N30!Z#17!WD_B'3EU-O
M[:NKD:?9PWB9M8@9G8MOC.$^Y\@P!\PS][I2WWB;4DMI;.VN6_M6"^O3-#Y(
M+);*LS1,1C[N/)PW<D#)R: .[HKS^>X\26EA>2_VW=3-:Z.NI#-K$/,GPY,?
M"?ZL[1\H^;G[U+J_B"_BOKD#6;BROH[^**#3$M%D66 N@W\J6.5+$N& 7H1P
M: ._!STYHKSCPOJ=Q FF6MEJL]U<M=R1W&EO;*BPP^8V9/N[UP,$,6(;H!\P
MQZ/0 4444 %%%% !1110 45D^(;ZYLK.VCLG6*:\NH[83NNX0[C]['<\8 /<
MBL35M:O_  ?,1+<SZ['):O,D4WEQRJZNBXW*JKM;S.XX(Z\\ '8T5S)\4WD=
MP^GSZ7"-5\Z**.&.[+1-O1W#&0H","-\_*>@QG-3S:YJL=Q;6":1 VIS)+,T
M37N(5C0J"PDV$G)=0!M'?.,4 ;]%<9;>,+JYU5H[2V\\WB6RVEK*XC$;LDSR
M;W / $1Z!N@QUS5Z'Q1>WDT=E8:5&^H 2FXBFNMD<7EOL.'"$MDGCY1QUV]*
M .EHKE+#QL;NSC:736@NKC8+:V,X8RDR&-AN _A*DG&>"#].KH **** "BBB
M@ HHHH ***YG7M2N;'Q1ISQW#)9V]O+->1#[KH7C0$_[NXM] : .FHKA].\1
M7R^*)#-+YMEJDMN;17.%BB99@"ONWEHW_ ZI:[XAUBXDU$Z9<I:FW1XTSN9#
MLNECW<$?-C(Z^HH ]%HKAM/UW69=8O-+L9;',37-P\M_*[MA9V3:JC&$]\G;
MP,&J:>-M1DNWEL+669]1:V%O P\Q;?,#2.<97=G;QR,]: /1:*Y6YUN[OOAU
M>7Q5K"\:.2 -&P)23<8PRX)QSSC.1T[51OM;U"8Z9;VUT8Y["\B34B!]\M(8
M55AZ,3O^@7UH [BBN+N_'%W%I\DEMIXEN+?RK:YB!SY=W)((PG49 Y8\C(9,
M'YLU4F\8ZE$(;F]M6BDLY+E)H58(L^V%74D;FV8W#().,9Z4 =_17'W7B36[
M*9M.>+3I]0:6V5)8RXB59F=?F')RNPGK\P(Z4EMXIU:.1)=1MK0VRWDUA(+?
M=YCR1H[>8N3@ [,;.3SG=VH [&BN4TSQ%JMQJNCQW@TUK75[=[B(6\C&2(!0
MP'/#CYAEACGMS75T %%%% !1110 4444 %%%% !1110 4444 %%%% !45S_Q
MZR?[IJ6JVHS"VTVXF9))!'&6*1(69O8 =3[4;AL61T%%<\/&$&/^0-KO_@LE
M_P */^$PA_Z VN_^"R7_  K7V4^QE[:GW.AHKGO^$PA_Z VN_P#@LE_PH_X3
M"'_H#:[_ ."R7_"CV4^P>VI]S<NO^/63Z5+7-3^+X&MW']CZX,CJ=,D_PJ3_
M (3"#_H#:[_X+)?\*/93[![:GW.AHKGO^$PA_P"@-KO_ (+)?\*/^$PA_P"@
M-KO_ (+)?\*/93[![:GW.AJ*Z_X]7^E8?_"80_\ 0&UW_P %DO\ A4<_B^!H
M'']CZX,CJ=,D_P */93[![:GW.EHKGO^$PA_Z VN_P#@LE_PH_X3"'_H#:[_
M ."R7_"CV4^P>VI]SH:*Y[_A,(?^@-KO_@LE_P */^$PA_Z VN_^"R7_  H]
ME/L'MJ?<W+G_ (]V_#^=2US4_B^!H6']CZX.G)TR3U^E2?\ "80_] ;7?_!9
M+_A1[*?8/;4^YT-%<]_PF$/_ $!M=_\ !9+_ (4?\)A#_P! ;7?_  62_P"%
M'LI]@]M3[G0U%<_\>Y^H_F*P_P#A,(?^@-KO_@LE_P *CG\7P-"1_8^N#D<G
M3)/7Z4>RGV#VU/N=+17/?\)A#_T!M=_\%DO^%'_"80_] ;7?_!9+_A1[*?8/
M;4^YT-%<]_PF$/\ T!M=_P#!9+_A1_PF$/\ T!M=_P#!9+_A1[*?8/;4^YN7
M7_'NWU'\ZEKSOQ=\4%T>WABM-(N_M$QSB_A> !0>HR,FNK\*>(H_%'AV#4XX
M3 7)5XR<[6!P<'N*<J%2$%.2T(AB*4ZCIQ>J-FBBBL3H"BBB@ HHHH ****
M"BBB@##@\7:5)K-WI<UPD%W;W/V<1NW+GRU<'VR&P >3@XJ])K6F16R7$M]
ML,D!N%<N,&,8^;/I\P_.LV7PRTD>HA;E5:]U6WU#=Y?W1$83M//)/D]>V[VK
M/@\)S3V^IMYK6TC78:P$J!E@2.3S%!4'E6DW'&0=I4<8% &B?&FBL\8MKR.=
M?-\N<AL&W_=L^7!Y'"'^=7=1\1:1I*JVI:A!;A@K+O;E@Q(7 [Y(./6L"?P9
M?ZI?7-UK&H6VZX*@I:VY0(HBECQDL23^]SD^F*FA\*ZA/J=E?ZO?6LLUFT01
M8("JLB!^3EC\Q+Y]!M]Z -E?$6D/J,MBNH0FYB5B\>[IM&6&>F0#DCJ*I_\
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M&XJPX)W8!&2#G-=E0!GVF@:/87C75EI=G;W#$DRQ0*K<]>0,\UH444 %%%%
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MQ!(+NV%''3)[]*Y&X\#7]Q;W4 CT^*62.X1M221_M%X) P"RC;P!N'\3?=&
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M7!E9&W *)/N9(/ ST-=Q10!YY9V>IMXI>]OXKS^QI-0:[@@2S(DCF$*[2_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*Y_P"/63_=-2U%<_\
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MY#8YVX(SSTKL** *8:Z:UF-XD:'S2(Q&2?DW?*3[GK^-7*BNO^/=OJ/YU+0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR$DDHV,@# R2,BLN]\2:M;>*+B&\/V:QBGL]J1.KN Z2LZL"G0[.Q)X&#R:
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M7<6,%N(DN/+5RY:7$:.'$8#$[4X^Z, 9Z5@/;>(;K3+&T2TOX9M.M3#<2/*
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MP5#LP4R<[2QY&< &K]KX'M]0AAEU8W44MO-*B+YBL7B$AV?,P+#Y-JY5E)7
M)H VX_">AQK<JM@I2Y0QNC.S*JD[BJ*3A 3SA<<@'L*L66@Z;I\D,EK;;9(?
M,VR,[._SD%R68DL3M7DY/ K'\26DTNJVS7-C?7^F"!E$%C+L:.;(PS ,I(V\
M Y^4Y]<USUAX:UEM%N;F\CU+^T8-.@%DDM\S%)EWD]&PS<J"QZT =1K^BVMQ
M]MN+N^%K#>00VC[D##>)?W9YXY9]N.^1@BL>/1] T&YNK?Q#>K<WVHK$S;$F
MW!8V;8P8N\@(9F^8OD< 8 JIJ^DZC<7;)+IFHW6H-JT,RWD=P! +5;E' P6
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MJ[L8.)LY&3U]*BN-'U:6.[B%G?MJ+PW:WET\^8+I6C<1JBEL=3'@8&T*0?<
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MU# $$9&>1T-+10 4444 %%%% !1110 4CHLBE74,IZ@C(I:* "BBB@ HHHH
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M,)#>';(#(Y_M/W_ZYU)_:?BK_H7++_P:?_:JW+K_ (]V^H_F*EHYX_RK\?\
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M;.PE:?-];1$N^"/*5F:/@%=YW;!NVCUYK:U9SS:RMXDMY?1O86:_Z1;#:_\
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M_(K#*_-DAP1@A@1GN%((H W:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *BNO^/63Z5+535+J*RTN>XN"PCC7+;$+G\@"3^%-)MV0FTE=E
MNBN>_P"$XT/^_>_^"ZX_^(H_X3C0_P"_>_\ @NN/_B*T]C4_E?W&?MJ7\R^\
MZ&BN>_X3C0_[][_X+KC_ .(H_P"$XT/^_>_^"ZX_^(H]C4_E?W![:E_,OO-R
MZ_X]V^H_G4M<U<>-]$: @/>9R/\ F'7'K_N5)_PG&A_W[W_P77'_ ,11[&I_
M*_N#VU+^9?>=#17/?\)QH?\ ?O?_  77'_Q%'_"<:'_?O?\ P77'_P 11[&I
M_*_N#VU+^9?>=#45U_Q[-^'\ZP_^$XT/^_>_^"ZX_P#B*CN/&^B- P#WF>/^
M8=<>O^Y1[&I_*_N#VU+^9?>=+17/?\)QH?\ ?O?_  77'_Q%'_"<:'_?O?\
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MA"3&3G:02",]^0:J="I""G):,B&(I5)NG%W:-2BBBL#H"BBB@ HHHH ****
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M *BN?^/63Z5+45U_QZR?2@"6BBB@ HHHH BN>+=L>H_G4M177_'NWU'\ZEH
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MD?!!!(=U!/(]!BHK3P9=6>V[AU*-M22X\\231RS1G]WY>"LDK/G;W#CTZ<4
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M.I:BNO\ CV;\/YT 2T444 %%%% $5U_Q[M]1_,5+45U_Q[M]1_,5+0 4444
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MW!O=*:06V?,D,Z*WF/</%%"J@8)RH!8D #GF@#NZ*YFX\72:7:WDNMZ>ML;
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M)Z_[M2?\)YX;_P"@E_Y D_\ B:/8U/Y7]P>WI?S+[SHJ*YW_ (3SPW_T$O\
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MRG<TGF%@P.0=YSP:T** ,A/"NC)Y)^Q[G@<R)))*[N6+HY9F))8[HHSDD_=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !45U_P >LGTJ6HKK_CUD^E $M%%% !1110!%=?\ 'NWU'\ZEJ*Z_X]V^
MH_G4M !1110 5%=?\>S?A_.I:BNO^/9OP_G0!+1110 4444 177_ ![M]1_,
M5+45U_Q[M]1_,5+0 4444 %17/\ J#_O+_,5+45S_J#_ +R_S% $M%%% !11
M10!%<_ZG_@2_S%2U%<_ZG_@2_P Q4M !1110 4444 %%%% !1110 4444 >2
M>)[G1)_'6MP?$77;K2+:VBB;142^DM4>,Q@O*FPCS)!)D;3G&%XYKA-9U/QK
M<6,]Q?ZT]I<'PQ9S/'+ RR%3?,BL0'&UV #$XZ';CBO?M5UG2K6\6VO(9+JX
MC7S2D%H]P8E/\1VJ=N<=^N/:HI?$>BRW]I;A);I[^'?!+%:/)')&""3O"E0
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M8,0PP,?7 MW.BZC!MABL[]YUM[>/3)8+C$5H54!]_P W][))(;<,#GI7H%%
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M6^7JH(^7-=3X2AN;?PY#%>6[V\BNX"2,Q8KN.UB"S%<C!VY.,XK:HH ****
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M9G?8_%W_ $&=*_\ !<__ ,=H^Q^+O^@SI7_@N?\ ^.ULP:A:7=F;NSN8KF
M_O('#J<=>1Q5>UUJUO)[2&$2;KNT^UQ[EQ\GR]??YAQ1[5]E]R#V4>[^]F=]
MC\7?]!G2O_!<_P#\=J.>S\6B+YM9THC(_P"8<_K_ -=:U--UJ'5+JYBM[>X5
M+=VC\]T CD96*L%().001@@'N,CFKES_ *@_[R_S%'M7V7W(/91[O[V8?V/Q
M=_T&=*_\%S__ !VC['XN_P"@SI7_ (+G_P#CM=#11[5]E]R#V4>[^]G/?8_%
MW_09TK_P7/\ _':/L?B[_H,Z5_X+G_\ CM=#11[5]E]R#V4>[^]GBGQ'G\:6
MFKP17-W,]ML!BDT^)XHV;/((!)W?4^E>I>$7U.3PGI[Z\&%^8OWN\8;J<9]\
M8S[UJ7!Q%Q_>7^8J6M*E?VE-0Y4K=3&EAO9U95.9N_0****YCK"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_,5+45U_P >[?4?S%2T %%%% !45S_J#_O+_,5+45S_ *@_[R_S% $M%%%
M!1110!%<_P"I_P"!+_,5+45S_J?^!+_,5+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5%=?\>LGTJ6HKK_CUD^E $M%%% !1110!%=?\>[?4
M?SJ6HKK_ (]V^H_G4M !1110 5%=?\>S?A_.I:BNO^/9OP_G0!+1110 4444
M 177_'NWU'\Q4M177_'NWU'\Q4M !1110 5%<_Z@_P"\O\Q4M17/^H/^\O\
M,4 2T444 %%%% $5S_J?^!+_ #%2U%<_ZG_@2_S%2T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5%=?\ 'K)]*EJ*Z_X]9/I0!+1110 4444 177_
M ![M]1_.I:BNO^/=OJ/YU+0 4444 %177_'LWX?SJ6HKK_CV;\/YT 2T444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>halo-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #-30
M )*2  (    #-30  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" .Y P0# 2(  A$! Q$!_\0
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ML/\ RO\ #_,^BJ*^=?\ A9'BW_H,R?\ ?J/_ .)H_P"%D>+?^@S)_P!^H_\
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MHKYU_P"%D>+?^@S)_P!^H_\ XFC_ (61XM_Z#,G_ 'ZC_P#B:/['K_S+\?\
M(/[>P_\ *_P_S/HJBOG7_A9'BW_H,R?]^H__ (FC_A9'BW_H,R?]^H__ (FC
M^QZ_\R_'_(/[>P_\K_#_ #/HJBOG7_A9'BW_ *#,G_?J/_XFC_A9'BW_ *#,
MG_?J/_XFC^QZ_P#,OQ_R#^WL/_*_P_S/HJBOG7_A9'BW_H,R?]^H_P#XFC_A
M9'BW_H,R?]^H_P#XFC^QZ_\ ,OQ_R#^WL/\ RO\ #_,^BJ*^=?\ A9'BW_H,
MR?\ ?J/_ .)H_P"%D>+?^@S)_P!^H_\ XFC^QZ_\R_'_ "#^WL/_ "O\/\SZ
M*HKYU_X61XM_Z#,G_?J/_P")H_X61XM_Z#,G_?J/_P")H_L>O_,OQ_R#^WL/
M_*_P_P SZ*HKYU_X61XM_P"@S)_WZC_^)H_X61XM_P"@S)_WZC_^)H_L>O\
MS+\?\@_M[#_RO\/\SZ*HKYU_X61XM_Z#,G_?J/\ ^)H_X61XM_Z#,G_?J/\
M^)H_L>O_ #+\?\@_M[#_ ,K_  _S/HJBOG7_ (61XM_Z#,G_ 'ZC_P#B:/\
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M4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\
M&O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY
M7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?
ME?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5
MQ_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-
M7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_
M *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;
M+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"
MD;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'
M_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^
M-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_OR
MO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\
MORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&K
MC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:
MN/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_
M $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V
M7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%
M(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\ S/+O
M^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/_,\N
M_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D_/\
MS/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#_D_/
M_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9>#_D
M_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!_9>#
M_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_Y!_9
M>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7\_Y!
M_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1Q7\_
MY!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/[1Q7
M\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:*/[1
MQ7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O4:*/
M[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\ &O4:
M*/[1Q7\_Y!_9>#_D_/\ S/+O^%(V7_0:N/\ ORO^-'_"D;+_ *#5Q_WY7_&O
M4:*/[1Q7\_Y!_9>#_D_/_,\N_P"%(V7_ $&KC_ORO^-'_"D;+_H-7'_?E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7,44?5J'\B^Y!];Q'_/Q_>SI_P#A8_BW_H-2_P#?N/\ ^)H_X6/XM_Z#4O\
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MJQ] C2*354B1447[X51@#Y$K3@N4G4X^5U^^C=5-"106@E=%6(2.9)&SC+8
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MX:FX.-];GAYAED\75512MI;\SY?XHXKZ@_X1K0O^@+IW_@(G^%'_  C6A?\
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M!=._\!$_PH_X1K0O^@+IW_@(G^%']LP_D8?V!4_G7W'S!FC-?3__  C6A?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0-YKS.J
M2! H'\.<TOES_P#/<?\ ?O\ ^O2I_P ?$O\ P&I:=Q6(?+G_ .>X_P"_?_UZ
M/+G_ .>X_P"_?_UZFHHN%BM*MPD3,)URHS_J_P#Z]/\ +G_Y[C_OW_\ 7IUQ
M_P >TG^Z:D'2BX6(?+G_ .>X_P"_?_UZ/+G_ .>X_P"_?_UZFHHN%B'RY_\
MGN/^_?\ ]>F8N/.V>>N-N?\ 5^_UJS47_+V?]S^M%PL)Y<__ #W'_?O_ .O1
MY<__ #W'_?O_ .O4U%%PL0^7/_SW'_?O_P"O2%+@*3YXX'_//_Z]3TC?<;Z4
M7"Q!&MP\:L9U^8 _ZO\ ^O3O+G_Y[C_OW_\ 7I\/_'O'_NC^5/HN%B'RY_\
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M0-&-M;)#9VNZZ%T^Y&DV[%3"')(R6STX%5M5\,>(=6T[25N(6^T6-I-#.$N
MJW.&0!20<[9%4_3OBDJ-+F5Y::]?N&Z]91=HZV71_/\ /\#N&U_2UD=#>)O2
M=+8K@Y\QAE5 QSD<Y'&*;J?B/2-&N8;?5+V.VDF&4#@\C.,Y P!GUK*;P]O\
M>:?JR6/EV\=B5?+#Y)1@)E<\D*6&?UINO>%_[>\66LEXDQTU;)XY?+FV!V+J
M0C ')4@'CI62A2YE=Z6-7.MRNRUOIN:X\2:0=:.D?;HQ? X\D@@YQG&<8SCG
M&:9%XIT2;5?[-BU*!KK<4" \%A_"&Z$^V<US3^%]1;QW-JCPR263W2E8A, J
M_N=HG"YZJ<CGG!XIB:'K3^'K/PP^DQ11VTT9.J"92A5'#;U7[^]L=QU)YK3V
M5+3WNBZK^M.QG[:MK[O5]'\OO[['46WBG1;O56TV#4(FNU=D,1!4EE."H)&"
M1Z"IXM;TZ<VPBND;[5))'#@'YV0D./PVG\JY&#1=:FN$T^32S!!'K;ZA]O>9
M"/+\TN J@ELD<<@=33;;PWK,]Q:Z=<6OV6WLI+UQ?"96$HFW[=J@[@1OYSCI
M0Z5+^;\5Y_\  T&JU7^7\'Y?\'78Z6/QAH$MW);1:I \L88D G#;1DA3C#$>
M@R:M:1KNFZ[ \VDW2W,<;;69588/IR!6+H UBSM].TFZ\.Q1Q6:"-[P7">7A
M1@.BC+9/7! [\U:\-Z3=VGA&33[U3;SR27/(8$J'E<J<CV8&LYPIQ3M^:?<N
MG4J2:OY]&NVFI9@\5:'<ZG_9\&IP/<[BH0-PS#L&Z$^P.:NQZG92ZA<6,=PC
M75JJO-$#R@;D$_6N<T!-9TVST_1[CP[$8K)0C7BW">6P4??1?O;CZ$#OS69I
M7A_Q)9Z[%K-S;VI>\DE%Y'&_[U4DY 8D[2$VJ!CWJG2AKKZ:K4E5JEEIZZ/0
MZ^+Q!I4]I:W4-[&\-W)Y4#KDAVYX]CP>OI4%AXMT+4VE%CJ,4IBC,KC!!V#J
MP!'('M7%:=X)UG3AH30)B$2^=?VK2*?*E 8"1><<@@$#V-6+#0=<N=-TJSN=
M*-D=*MIU,SSQL9V=&4(H4G .<DG'2K=&BKVE^*\_Z_$S5>N[7C^#\OZ^5CJI
M?&.@03P0S:G%&\\:2Q[@P!1_NDG& #[XK1N=3LK.YM;>YN4CEO'*0(QYD(&<
M#\*X1=%UVTM;BS31/M0OM'MK(NT\82%T#AMP)R0-X/ /2G:OX4\17UQ&UM]E
M/]EVD,-G)<,=[R)AFD3!P"2H7YNU+V-*_P 7XHKV]:U^77T?];'53^+M"MKZ
MXLY]01+BV4O,A1OD4#).<8IG_"9^'Q8K>-J<:P-)Y2NR,,MC)X(ST/7I6)K6
MBZMJ<VLW"615KW18X$3S%_UVYB4Z]LCGI[U4N='U=O#T"6VCZD=0AE9H9KG4
MHWD@;8 ""208SR"N?PH5*DTM?Q0I5JR;T_!]ST%65U#(0RL,@@\$4M16HF%G
M"+K;Y_EKYFS[N['./;-2UQG<M@HHHH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!$G_'Q+_P !J6HD_P"/B7_@-2T %%%% $=Q_P >TG^Z
M:D'2H[C_ (]I/]TU(.E !1110 5%_P O9_W/ZU+47_+V?]S^M $M%%% !2-]
MQOI2TC?<;Z4 -A_X]X_]T?RI],A_X]X_]T?RI] !1110!%)_KX?J?Y5+44G^
MOA^I_E4M !1110 5%;?\>Z_C_.I:BMO^/=?Q_G0!+1110 4444 %%%% !5'6
M-6@T737O+E)9%4@".!-SN2>BCN>_T!J]69JN@66MSV[:I&+F"WW,ENXRA<\;
MS[@9 _WC0!1U+Q=%IL[ Z;=W%N+0W:W4+Q>6Z<#C+@YRP'(QSUQ1!XOBGDBA
M73+SSGN&MWC#1-Y9"JQ)8.5;AP<*2>&X^4TA\&V1T_[#YLGV86[VL<1"D)$S
MAP@XY "A1GM3/^$*MXK:&SLKR:TL89C(EK$B!%7<'"KQP0P.&'(!(]* -F^U
M%;&XLHWADD%W/Y =-N(SM9@6R0<?+CC-8J^.+.262.*RNY)-YCMU7RR;EA)L
M(7Y_E^;^_MXYK4&@V,:VZVD0MDANOM6V,<.^"#G_ +ZJI<>%;662\NH)/L]_
M<SI/]KCC7<I3[@QC# 9/7KN- ")XKB?[.PTZ^$4DJPS2E%"V\AD,81OF^8[Q
M@[-V.IXYJ;5O$"Z7=>2+*:[?;&=L+*&+22"-%^8@<G)R2.%-5(/"UQ;WEG+%
MK,QBMV:1H9((V$DKN6DD)QPQ+$<= >*EU;0I]2U222*<VR/% 5G4!F22&4NO
MRG@@[CGZ4  \8:9"RPZKYNFW;2>6+6X4%R<;LC86!7'.0<#!ST-7;OQ!IEDI
M-Q= '"$(B,[MOSMVJH);.UC@ \ GM5&'PK&;LWFH7LUY=21R12RLJIN5E"X
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M<*/^FK'/KCMQ5:^\.ZE!"E[;WDVHZI$Z>7,WEQ-&@5EP%V[6^^V<XZ\$8 H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,\F+S_/
M\M/-V[/,VC=MSG&?3/:GT44 %%%% !1110 4444 %%%% !1110!$G_'Q+_P&
MI:B3_CXE_P" U+0 4444 1W'_'M)_NFI!TJ.X_X]I/\ =-2#I0 4444 %1?\
MO9_W/ZU+47_+V?\ <_K0!+1110 4C?<;Z4M(WW&^E #8?^/>/_='\J?3(?\
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MXVBE2XN%T_3GCM[B-(I&BDWCYW9@-H*93J?6N\^PVGER1_98=D@"NOEC# =
M1WQ2_9+;R9(?L\7E2DETV#:Y/4D=ZKV\'O'^M/\ (GZM42TG_5V_U/+]9U_6
MM.B\1-]HGDL)K]K>&9)#OLY 5(&>R,#CV/UJYJERB:IXCEL=9NT:RL' A:_8
MYG8;F94W<!5P.!P2?2O1/L5J89(C;0^7(=SIY8PQ]2._05%_9.F^<\O]GVOF
M2 AW\E<MGKDXYS36(A_+_6G^0GAI_P W]:_YG):!I]UJ6A6Y6]+NEU%)(T6L
M2W&Y,#>I;C!(_AZ>]7=&T/Q!9ZK:RZAJAGM86D)C\YF)#@]<_>P=N,]!FNDM
M;*UL4*65M#;JQR5BC" GUXJ>LI5FV[;,VCATDK[HY?Q[)=KI%C%82R1RSZA#
M%B.X: N&)&TNO(!]1FL/Q#>:OI'AO2M#DU*X_M20-+-<VR23.J)DJ/E&X@ML
M3<1SSFO09(8YMOFQI)L8.NY0=K#H1[T>3'YWG>6OF[=F_:-VW.<9]*(5E%)-
M;!4H.;;3M?0\O\4^(;W4H]#O=-NKBU2>S:28QW#Q+ P=%9V4?>"$G*GMFIM9
M^UVDOBQX-7OP]M!:F%OM3E8VE/S,JYP.G'H.*]%_L^S((-I!A@P/[H<ACEAT
M[GKZTILK5E<-;0D2!0X,8^8+T!]<=JT6(BDDH[?YW_X!B\+*3;<M_P#)K_@G
MENL^(=:W:G:7L\UG>V.F*LIBF9$D;SEQ,I'3<IZ]1R*/$-WJ-KI.EK9WLIR;
MIY&M=8EG "A/G,F 6VYSMQC&:]2FLK6X+&XMH92R;&WQALKG..>V>U-CTRPA
MC5(;*WC1=V%6)0!NX;MW[^M4L3!6]W^K"EA)N_O;_P"9S/C%[[_A&]'BLKMY
M+BXO((FEBN&@\_*G/SKRH/7C-<SXC.NZ5-HMC<:K<>?'9YN+F.Z=4B)F51(P
M'^L"AL'/7K7J!MH#''&88]D)!C78,(1TP.V*);2WG8F>WBE)0H2Z Y4]5Y[>
MU9TZZA96-*F'<[N]MC@[Z]CGO-<DUOQ#<Z7<V+$6<,5SY*^6$!639_RTW'/7
M([5FW&J7,[WUWJ^LW.EW\&EV]Q! ER8U,Q5B1Y6<-D@ C'>O2Y=/LYY(Y)[2
M"1XO]6SQ E/H2.*273K*:Z6YFL[>2=<;97B4L,=,'&:J.(BNG]?\$F6&F^O]
M?\ \_P!0UZ]2'6HKJ\EM+^;^SS;VWG%7!;;O"#.?[V<>^:M+>6MW?:I/K_B6
MZTJ[M;UHHH([H0K%&#\A$9X?<.<D'K7<R6=M-<1W$MO$\T?W)&0%D^AZBFRV
M%G/<I<3VL$D\?W)7C!9?H3R*7MXVVM_2_P BOJ\[WYK_ -/_ #.:\/0,OCC7
ME:^O9X[<0^5'+<LZ+YB;FPI..O3TK.>[M;S4M8D\0>)+K2;BSNS'!#'=^2(X
MAC8P3H^[KD@^E=VL,22O*D:+))C>X4 MCID]ZBFL+.XN$GN+6"6:/[DCQAF7
MZ$]*A5ES7:Z+^OF4Z#Y;)]7^/^1PGB#Q7-:>,('@NKC[#IGEI<K'"[1S>9]\
MLRC:-BE3SW)K.UW7]9TV/Q5.EQ/+ISS-;121N=UG+Y2%&![(V[''0X/>O3_L
ML'ERQ^1'LF),B[!AR>#D=\TW[%:^3)%]FA\N7_6)Y8VOQCD=^ /RK2->$;>Z
M9RP]25_?W_X8\XO]2DM]2UB[AUJZ74[?4XXK2Q^U%EF4A,IY1.,'+<XXJ2:\
M:ZU>WMM2UBZM+1]6U"-Y$O6APJ ;%W9' /05Z"-.L5O/M8L[<7/7SA$N_P#[
MZQFDFTO3[A=MQ8VTJ[B^'A5OF/4\CJ?6CZQ'33^K!]6GKK_5[_\  //+SQ%?
MR^#;.RCO[K[1=W4R0W\,3O*UO$QVR[4&3N^49QSDFKIOVUZ^\(WJWE[;F\:2
M.Z@BN7C4O&A)!4$<[@<^U=XMO DBND,:NB>6K!0"J_W0?3VIJV=JCJZVT*LK
MEU81@$,>I^I]:7MX](]_Q_I#^KSOK*^WX6_X/WGF&CW-Y=Z!J4LNO):S2;D2
M>;5W9E/G8"F,\1 @;=P.1FNZ\(7T>H>&+::)[API>-C<2^:VY6((WC[XR,!N
MXQ5]=(TU/-V:?:KYPVR8@4;QZ'CFK,4,<$*Q01K'&@PJ(H 4>@ J:M:,U9+J
M51H2IM-OI8?1117,=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXE_X#4M1)_Q\2_\  :EH **** ([C_CVD_W34@Z5'<?\>TG^Z:D'2@ HHHH
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M>2 >B45YYX:T&^C&E6KQ-!:3QF[OHF5^"DS-"N6[G<,@\XB&>IKT.@ HHHH
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MHH7GEO[-(TE\IY&F0!9/[I.>&]NM5M2U/1=&A8736J/*-X@4IOE!(&0IQNH
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MKKJ52+IRY91U'3E&K%3A*Z?]=C/\[6?^?*Q_\#'_ /C5'G:S_P ^5C_X&/\
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M?!UPUBUA:7ENMM,MN)3/;M*X,6T#:2_ ^4=<X))KK** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** (D -Q+D?W:DVCT'Y50F;41>R_8X[5H\+S+(R
MG/X*:3?K?_/"P_[_ #__ !-5RLAR2Z&AM'H/RHVCT'Y5G[];_P">%A_W^?\
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MX:YO9[R[,T@D\M02[$Y'RHIYH Z"BH;6\MKU'>TF298Y&C<H<[6!P5/N*FH
M**** "BBB@ HJ.">*YC\RWD61-S+N4Y&02"/P((HAGBN$+P2+(JNR$J<X925
M8?4$$?A0!)14%W>VUA 9[V=((@<%Y&P,U)%+'/"DT+AXY%#(RG(8$9!% #Z*
M*C,\0N5MS(HF9"X3/)4$ G\R/SH DHHIDTT=O!)-.ZQQ1J7=V. H R2: 'T4
MBLKH&0@JPR".XI: "BBB@ HHHH **** "BBJBZOIKW4MLFH6K7$ +2Q"92\8
M'4L,Y'XT 6Z*** "BBHKFZM[*W:>\GCMX4^])*X55^I/% $M%0VMY;7UNL]C
M<17,+9 DA<.IQ[CBGRS1P)OFD2-<@;G8 9)P!^).* 'T444 %%-21)4#QLKJ
M>C*<@TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (D_X^)?\ @-2U$G_'Q+_P&I: "BBB@".X_P"/
M>3_=-2#I4=Q_Q[2?[IJ0=* "BBB@ J+_ )>S_N?UJ6HO^7L_[G]: ):*** "
MD;[C?2EI&^XWTH ;#_Q[Q_[H_E3Z9#_Q[Q_[H_E3Z "BBB@"*3_7P_4_RJ6H
MI/\ 7P_4_P JEH **** "HK;_CW7\?YU+45M_P >Z_C_ #H EHHHH **** "
MBBB@ K)U*TG.KVU_:VR3O;VLZ@$@$NVPJ,GUVGGM6M6%X@^WB:'^S]2D@G88
MM[6.-3YK@Y+.2#\@&,XQCUR0* ,%_"&M16L]J+Y9AJ,D4UQ/ GE-%,LJN9.6
M.XE<CC'W%QBM:]TO4[G0)+.*&VMXD3RVM(T'[W# [D<M\N1T#+P>I[UCOJ>M
M2VMK/;:F6:^BDGGB;RT^RI'(NX(Q7Y2 2I+YY':K?@75KRY\VUUB^O+F\9=P
M$\:*HV!0^TJJG.6!((&,@#H:!E"7PUJDD;$6$V)-X@1KB/?$6=3FX.<.I(SA
M=WIR>1LZW8S0Z5XBG:,".X"2?+_&JHH?CZ U6&O:PNI!K6-+N-UOW,,L@B5%
MAF2->0I.<!N/5N>@J^GBZ*733=QVV1]IB@5#)AB'17#=/1NGM0!F7GAW5KV3
M4)O/N WE3M8^5>,@$K2,R-@''"[<9X'2IV\,7<FK)"\EU_98<R%!>N"S&(#D
MAMV-W.,XSS38O&6I&V,]QHT$:)917\NV\+%87SP/D&7&UN.G'WJDO?&5S:0K
M=_V= ]E)<36\9^UXE+1AR24VX&3&> 21GF@16MM$UVPAL9XVN;B9(H9+R-KS
M)FE5OF +'&=I/H#@9I9M U>_^VW5RUU%(]O,]I +TJ(IBY,>=K8) "^JC)'-
M69?$6H-&BW%M'93K)9S;(IO-#Q33",JQ*C!'/3/L:V-%NY[EM1CN7WFWO9(D
M; ^[A6 X] V/PH YZUTCQ&OBA+FZFD9&N/,:96^018_U6/,_#B/WW52\8W#I
MJ5_ )+A[Z:.,:>(;TPF(G@@1Y!<DY.5#>AVXKT&B@#A6T'68XY8S!/*SB3[(
M\%YY2VDC32-O<;AN!#(> QX(QZNM-!U:*^D5;>X@G;4)IOMXO<PF!I&8KY0;
MJ0>FW@G.[/%=Q10!Q%SI7B#4;2V26WDA>SABB.^Y5A-(K@F5<'T7@G#?-TJS
M8Z!JEM-!>/).UV+U-^^[9D%OY85@%SMZY/3.>:ZZB@#DM1T[6CK][<V,4S1'
MR9%S=;0^QT)C0;L#(5@=RCD_>(/%6YTG5+G5TU"]TR\N+=_/S:Q7RQR1!C'L
M!PX!^X3@-@9[UV]% '&V^D:S%-!_:D-SJ,BI$()8K\QK;8^\'Y!;M\P5BW<"
MDO=(UK4=/N=,GAE\I8[T><UR-MSYF[RE&#N&-PSNP!CC-=G10!PU_H.KA)(;
M:VNY9<P"TN(M0,:6\:J@9&7=DG(<]&W;N2.SI?#>NQ6"_P!FW<T=[/#.MU++
M=,_)<%  6P.,@%<8S7;T4 <-;:-KB6H^TQ74MD+D,^GK<".1TV$9#>:W&X@[
M3(,X[=#.-/\ $-O9RPI'/+]KM?(C_P!+!-F?,<J78G+81U!9<G*=^#7944 8
M7AVRO[.\U/[:DHADFWPO-/O9^3GC<0%Z8X4]B.,G=HHH **** "N#F\(W$^F
M:U<S-<O<&>^DM+/;&$S)O4,"%#'*L>&8CGITQWE<?>^)M6TO6+B.Z2WNK9;V
M&VCBMK9_./F*6')<@G@#H!W. * *%RGB$7D8C_MI;W[8PF:#8;46_P VS:&.
M"=NS_:W9SQ4,=GXJN=)FF6XU6">ULF-HAD'[Z<2-AF!Y.5"_(Q/!YS6[=?$'
M1K-8A<><DS!VE@?8KP!&*L6!89P0>%W$XX!J6+QM874LL5A:7UXZ3&",0Q#$
M[*,L4)8 J 02Q('(&<\4 9EY:ZQ9WDEM++K%QI"3Y\RVDW7#9C4CYA\VP/NX
M'(..U1)#XCD\)P'5K>2Z2.Y61H94#W;*MSD9"_(?D X%:D7CNQN"XM=.U2=H
M4:2=4M<&%5D>,E@2.=T3?*,L0,@&H#X_TZT:1;V6.5C-(8A;D+B!2!O8NP!Z
M_P .2>P/- &9J=OK,TU[J7AVPN--MKAH$N(S&8YI@F_=(JJ=P/,:YX8A3C@"
MH[?3/$U_LDU.6\DAA2$P6S*H5S]H.2X;)9EC .3@]#C<*['2O$-EK-Y<P6'F
M.MN$/G;1L<,H88YST(Z@9[9P:YN_\8ZL+L1Z;!$^X7311K937#2^3*(PA*'$
M>X[OF;@<4 )J4/B\V$Z6\DJBSD2W#JV7NX=VYY0%YW;=B]CGS,=14-O_ ,)#
M]CM3JW]K-9 R[!8@K<!LKY>_)+%<;\9]MPZ5I-X@UN&UO=5ECL6T^SN7BEM@
MC"945MI82;BK$==NT9Z9%/L-=U<7174C92Q?VJ;#-O"\94!"P8Y=LDMM&/K0
M!I>$[:YL_">GP7T;Q7"18D23;N!R>NWC/TXK8HHH **** //YSXBM;K66TR2
MZMHX1>WD:+:A_M,JE/+3+*?E(W#"X)SP1BKK-XF;6+?3!J5TD$DJO+?+9Q[E
M5H9&*+E"H =4P2"1G!)SFNSHH X.VU;Q/;6-A>7S7,PN((KB[C%D!]F FC5U
M557=DHS$@Y;Y25QTJ1K_ ,1ZE<7=Q9W5U:64=O-<6RBQ4-,5<B-3O4D @'C
M8@@Y'?N** .#M=<\4S>+(XIX?*@>=%^S%'V" H"7R(3\V2>LH&1@KWKO***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@")/^/B7
M_@-2UGS7TEO>RHEA=7 PIWQ!,?JP-)_:TO\ T"+_ /[YC_\ BZKE;)YTC1HK
M._M:7_H$W_\ WRG_ ,71_:TG_0*O_P#OA/\ XJGR,7/$NW'_ ![2?[IJ0=*X
M'XB^+M4T?PZCZ79W%J\TOEO<3QJ0@P3QR1D^]:WP\UV_\1>$8KW5%'GB1H_,
M"[1*!_%C]/PK1T)JE[5[&4<1"57V2WM<ZBBBBL#H"HO^7L_[G]:EJ+_E[/\
MN?UH EHHHH *1ON-]*6D;[C?2@!L/_'O'_NC^5/ID/\ Q[Q_[H_E3Z "BBB@
M"*3_ %\/U/\ *I:BD_U\/U/\JEH **** "HK;_CW7\?YU+45M_Q[K^/\Z ):
M*** "BBB@ HHHH *HWFB:5J-PD^H:;9W4R#:LD\"NRC.< D9 S5ZB@"FND::
MLD\BZ?:A[D@SL(5S*0<C<<<\^M2QV-K%>2W<5M"ES, )9EC =P.@+=3BIZ*
M*5II5M:&4JN\R22OF0 E1(VYU''W2W./6E&CZ8+I+D:=:BX2/REE$"[E3&-H
M.,XQQBKE% $!L+0HR&U@*M&(67RQ@H,X7_=&3QTYJ!]$TJ2[>ZDTRS>X?[\S
M6ZEVXQR<9Z<5>HH IW6E6UV\+,FPQ.CY0 %PA)52<?=!.<>M/L;&.QCE6-G<
MRS/,[N1DLQSV]. /8"K-% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSSCIGM4LNA1_;+=[=@D2WK7LZG),CE"HQZ#)!_ 5K44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 1)_Q\2_\!J6HD_X^)?\ @-2T %%%% %>_MX;JPFAN88YHF4Y210RG\#4
ML,,=O"D4$:Q1H,*B* %'H *2X_X]I/\ =-2#I3N[6%97N%%%%(85%_R]G_<_
MK4M1?\O9_P!S^M $M%%% !2-]QOI2TC?<;Z4 -A_X]X_]T?RI],A_P"/>/\
MW1_*GT %%%% $4G^OA^I_E4M12?Z^'ZG^52T %%%% !45M_Q[K^/\ZEJ*V_X
M]U_'^= $M%%% !1110 4444 %%%9VL:U!HL=F]S'(XN[R*T3RP.'D;:"<D<>
MM &C162OBSP\\L\::[IK26V[SU%VF8MI ;<,\8)&<],BEC\4^'Y88)8M<TYX
M[F4P0.MVA$L@ZHISRWL.: -6BLI_%.@1V=Q=OKFG+;6LODSS&Z0)$_\ =8YP
M#[&ED\3Z##);1RZUIZ/=JC6ZM=(#,&)"E1GY@2#C'7% &I1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ@@+E550G3[N%''ZU$/"@:S^S3ZQJ4R1[/LQ=X\VQ0Y5E(0;B,#E]V1USDT
M#>,=,$T1WLL#)(9&EC>.2-U9%"&)EW;F,@P,9/& <BIO^$LTGR$D$MP7>4Q"
MW%I*9]P 8CRMN\8!!Z="#WJK)X+LY_WMU>WLUYN+F[9D$F_*%6P%"C;Y:X &
M.N0<FJ]_X9OK=HKS2;J:XU/S&:6[FG2*1E957;_JF3;A%XV=L@YSD T[;Q-H
MNI6+SV]UYL&Y(FS$XR7;8HP1DY;(_ TL/A?2H4N%$,SBXA,#^==2R$1GJBEF
M.Q?9<#IZ5DZ-X/EL;O29KR42-8P2&4B0MYLSN6!.1R$WR8/7YSP*ZV@!%4*H
M50  , #M2T44 %%%% !1110!S[>*8[:_U-=3CBM+33P"\C2,TN#@!_+"_=.3
M@@GH<XJQ!XJTB>X$"SRI)N*,)K:2,1L!NVN64!21R <$CD57E\.V%]?W3RZC
M<3%25,)E5OL^YDD('&X E5.&) '3%3OH.FZG'-.)6G@O+E;PE'!1R(EC !'\
M)51_C0 Q_%FGM$K6A>5FDA4++&\6Y))%3S%+*-RC=G(R/?FHW\9:6+N"-)&\
MB2.25KB2-XTV( =REEPX.<94GMZU771-'=85N]9>\"B%+833Q?*F\,B#:!NW
M&/&3DG:<'K2W/@[3WM5BU34;N>RBB-O#!<21B.)6P ,[06((4 L3^.: )SXH
MT2PM%6$O#)+*R1VS6DL;M(07.4V;AGEMQ&.I[5)8>+--O##"\VRX<() L<C1
M1R,@?9YI4+G!XS@GTJ'3_!6G:?(LL;N9%9CN2**('<A3!$:*. 3VZT^/P[I?
M]FR6$=PTD<%PDT@,BDJZ(N%; X&T*2.N#0!:L?$FEZC>1VMK-(998S+$'MY$
M$J#&65F4!AR.0>]4U\6(;?6W^R-YFF2M''&'R;GLI''&7RO?&,U4\.Z+?KJ5
MI?W=TLMG:VK16BI<B965]N""(UXPHP26)SU]=)_#^GPW5M<RSR(8KB20!I %
ME>1B0K<<X8Y4>H'6@!UGXGTVYTBWOY9U@64*&# _(QC$F"<= ISGICFF-XJL
M62%H-Y#S(C^?&\!1&!(DPZC*_*>>G7FJL/@VT%Y*LX,EB-/6Q2)GSO&"K,W
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M;^C_ /05L?\ P)3_ !H_M_1_^@K8_P#@2G^-%G_+^877\_Y#?MNI_P#0(/\
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MJ-^1_JQ@D=FSGBKTOC!?[.BF@T^YM&G6*2V^V(H66-I$5B K$@@.#AL'VZT
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MEO=2%C)I][9RO ;A#<*FUT! ZJQP?F'!P?45JT %%%% !1110 4444 %%%%
M!1110 4444 %%%% $2?\?$OT6I:I3V\]Q</Y%[+:X SY:(=W_?2FH_[.O?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTJXGMM4LQ'+9-8""V3:2/+<EB3NZY!P.. 6]:E;1-'TZ-/M!F*/-$D8GN))
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M]!*S_P"_Z_XU0UKQ=HNC:3->SWT,RH,"."17=R>@ !IJ$V[)"=2$5=LV8?\
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M_P#?(K@_B4OBA/"V;"99(_,'V@64+I($Q_O$XSUQ5GX5-K;>%Y/[=\_;YO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\J?0 4444 12?Z^'ZG^52U$W_'U'_NM_2I: "BBB@ J*V_X]U_'^=2U';?\
M'K%_N#^5 $E%%% !1110 4444 %4M6UG3=!L#?:S>P6-JK!3-.X503T&35VN
M2^)&BZEKGAB"WT6*26YAOH+C;%.D+[4;)*NX*AO3(- &_#K>EW$]K#!J%O))
M>0F>W5) 3+&,9=?4#(Y]ZJGQ;X>$=C(=:L0FHL4M&,Z@3D'!"\\\\5Y:WPZ\
M7_8;&YM5M[74M-L$M+3$RD!)9)!,&(P"RQNI)Q@LO%7XO!'B#1+?3;'1-(MY
M?[.O95M+Z6\7]W;-,K[9(R#O0C/ ^8,JD8ZT >MT444 %%%% !1110 4444
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MI0_VW)I4>GJA2*)8_F!7<97+J<KG*\8'RMSGI1L?&FH26L<]QID1MHEM1<W
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M^WX_\ U:*S_^$?T?_H%67_@.O^%'_"/Z/_T"K+_P'7_"BT>_]?>%Y]OQ_P"
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MN=;THVLH&IV9)0_\O">GUJ7^W-)_Z"=G_P"!"?XT6?\ +^877\WY#/[0O_\
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ME2U$W_'W'_N-_2I: "BBB@ J*V_X](?]Q?Y5+45M_P >D/\ N+_*@"6BBB@
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MP'WB  35NBB@ HHHH **** "BBB@ HHHH **** ,.^\'Z-JEU=7.J6D=Y<7
M"K-,BEX% P%C.,K@Y8=\DFH8O"$:3EI=3O)H,RR) ^P*DDBE7<$*"2=SG!.
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M+P.U;5 !1110!%'_ ,?,OT6I:SI=*M+N^FDG60OA1E9W7MZ @4?V#8?W9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"AJ]S865HEQJBDQQS(8]L32-YF<+A5!).3V%03:=HOB>W
MMKV>VAO8]N8I&!^Z>JGH<9'*GTY%,\4Z=<:GHZPVD1E=+B*4QK<- 6"N"0'7
ME3@=17/P^'-=M-.-I;Q0%+NS^RLINC_H2B61EP=O[PA),$\$E/?- &U#::+J
MVK02V;Q.VFS/<M$D>/WKAHPY)'48D'']!6D^C:=)%'')90LD0<(I3(4/][\^
M]<<?!^IQ7$DLEO;W]L90TED\Y1;A=TQ&XXQQYB'!R"0>X%3+X>U^UM9;:!89
M$OK=8&+73?Z"!+(P R,N DH4=#\@['@ W+KP_P"'K/1;@7=E$MG%FYE8[BP*
MJ?FW?>R!D<=LCO3-/M_#FLV-S:V=FGDYC$T$EL\++M4>6=K ,, #!]N.E9]E
MX;U"+0O$E@\<48U#SA;9F+LQ=6&68 =R,'&['!)P*CUWP6SZ7!'HQ<D3+)=Q
M3SF4W0"E54M-OR%)R%/''8T :DO@K1)KF%Y+-### T20@8 W,&9L]<DCGGGO
M5F\\+:'J#JUYI=M+M01A2F%*K]T$#@@=L].U<L/ M]/IS&[D\R\CM(X[1VN3
MFW82LQVE0 ,*57('08Z4W4/#,D'B6&"#1X+_ $W;/+%9/.R1+D0#.,%<[@QP
M?4D<T =C;VVEB_G2WAB%S#N:7"X(\WYF/_ MH)^E5=&T[3)+I-:TW:8Y+-+6
MV BV"*%23M (SR?7T%<]#X)OE@EN)WCEU-5MOLTQG=O)V2%F )YX4[=W5@.:
MP-<TRYMK633+JU%_JLMM'':S>;*'MVZ$1D+R">201U(;@4 >A:AIVG0)JM]J
MI$EC<0(;F%X]ZC8#EL 9)QC_ +Y&*:VC>'["R2![.%(;B4* REC([J5Y)R3E
M21SVKF[KPEJ\WVQ88H8[N07.=4^U-ON5D5PD;+C@#<G<A=G%3OX7U%M>MYGL
M;:22+41=2:HUTWF219)$>S'8$ +G;\N1S0!IS6GA;PZ)8Y+5(V=(V=5B>9V7
MS $' 9C\Y& ._..M)=Z]H4FJZ=>37\A6*%I(PMM(8TWG8'=PN(\;77YB,9.>
ME4_$.EW6HZUJ$5O"TIDM["6,"9H=PBN)&=1(O*G!!R.>:9HW@H^<K:W'NA2W
M$<=O'=R;5'G2.(Y "!* K*"6!R0<]>0#KK:[@O$=K:3>(Y&B;@C#*<$<^XJ:
ML7PW$RIJ<Q4JEQJ,TD>5(R!A<X/J5)K:H **** "BBB@ HHHH **** "BBB@
M"*/_ (^9OHM2UGS:78WU[(]Y:0SNJJ TB D#FD_X1[1_^@9:_P#?H57N]62W
M+HOZ^XT:*SO^$>T?_H&6O_?H4?\ "/:/_P! RU_[]"BT>_\ 7WBO/M^/_ +E
MS_QZ2_[A_E4M9-SX?T@6LI&FVN0A_P"60]*E_P"$>T?_ *!EK_WZ%%H]_P"O
MO"\^WX_\ T:*SO\ A'M'_P"@9:_]^A1_PCVC_P#0,M?^_0HM'O\ U]X7GV_'
M_@&C7,+X\\.CQ.^D?;Q]J9Q$#L.S?R-N[IG/%:W_  CVC_\ 0,M?^_0KC8_A
M)I2^+#J*W<RVZ2B<6@48#9SC=Z9'3'XUM2C0=_:-^1A6EB%;V:7F>AT445SG
M4%(_W&^E+2/_ *MOI0 V#_CWC_W1_*GTR#_CWC_W1_*GT %%%% $3?\ 'U'_
M +K?TJ6HF_X^H_\ =;^E2T %%%% !45M_P >D/\ N+_*I:BMO^/2'_<7^5 $
MM%%% !1110 4444 %%%17-Q%:6LMS<,$BA0N['L ,F@"6BN;N?&4$&G:?<K:
M.KWLCQF&XF2$PLH)97+' (QC%2IXG>\CB.D:5<WK-;I<2+N2/R@XRJDL<%B.
M<#MWY&0#?HK&F\1QP-%&]G<I-<HK6T+J%:9B<%,'H5ZG/;GD U:U/4_[,-F6
M@>5;FY2W+*P'EES@$YZC/I0!?HK-_M:1M2U"QALG>:TBCE3]XH$P?=@ ]N5(
MYI=%U235K26:6S>U\N9H@&D5P^W@L".V<C\* -&BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK-U#7+;3M4LK*9)&>[8C>@RL0Z
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MZ?XOL9;C3UDB:%PLL4H&Y<]#QQ@_TJU!N'/RZ&;FE/V;EJ7/[9'_ $#]0_\
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MO^ZO]: ):*** "D?_5M]*6D?_5M]* &P?\>\?^Z/Y4^F0?\ 'O'_ +H_E3Z
M"BBB@")O^/J/_=;^E2U$W_'U'_NM_2I: "BBB@ J*V_X](?]Q?Y5+45M_P >
MD/\ N+_*@"6BBB@ HHHH **** "L+Q=XGA\)Z7;:A=B,6\EY#;RR22;%B1VP
M7)P>@YQ6[69KNFV&IV]JNIS>3';7<5U&=X7,D;;E!SU''2@#F[+XJ^'YK.XN
M[JY5;<7DMO:M:I)<&>.,*3+M120HW<GH/6K%U\1M&^W06VF7"7;?:8XIV\N7
M:JO&T@*,J$.Q !"Y&1GGU+OX=:1?3RWEO?:C9W%Q-+,US97(1F64+OCS@C8=
MBGUXX-2P_#S1K6W6&Q>ZM4CNTO(A%(/W<B0^4N,@\;>><\\T 1I\4?"CZ:M\
MM[<F)I7A5183^8S( 7PFS=A<C)Q@9YJROQ#\,/K,.EQZEON9S$(RD,AC8R+N
MC_>!=HW#IS[5F6WPJTNSTV"TMM9UR-[9I/)N5NU$J))@R1@A<;6(#'(SGG-7
MK?X>Z% J_8_/CB%Q:W"(DH*J;==L8&1G&!SSD^M '54444 %%%!( ))P!U)H
M ** <C(Y%)O7GYA\O7GI0 M% .1D<BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **8\\4<D<<DJ(\I*QJS %R!D@#OP"?PISNL:,\C!5499F. !ZT
M +138I4FB26%UDC=0R.IR&!Z$'N*9;75O>VZ7%G/'<0O]V2)PRMVX(X- $M%
M%% !12,P52S$!0,DD]*@M;^TOEW65U#<+L63,4@8;6&5;CL1R#WH L4444 %
M%%% !1110 45'-/#;ION)4B7.-SL%&?QIT<J2H'B=74]&4Y% #J**1G5,;V"
MY.!DXR?2@!:*0L P!(R>@SUJ)+NVDG:&.XB>5?O1JX+#\* )J**BGNK>U -S
M/'"&Z>8X7/YT 2T4@=2VT,"V,XSSCUI: "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 11_\?4WT6I:BC_X^IOHM2T %%%%
M$5U_QZ2_[A_E4M177_'I+_N'^52T %%%% !42?\ 'U+_ +J_UJ6HD_X^I?\
M=7^M $M%%% !2/\ ZMOI2TC_ .K;Z4 -@_X]X_\ ='\J?3(/^/>/_='\J?0
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MFD$!W E8^2P'3#1\YZ8]. !-'U1_$,EW=V=PZ:=Y:PP%57)DQEWY!Y4L%P>
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M[U>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBC11&J_/&5*N^/OD%1U[$C/3 !MOXIT:.SCN7O5"2.45=C&0L.HV8W<#D\<
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M\W._KSV+C/KM[5HZ-836NK:E-*A6-A!#$3_RT")RWTRQ'X4 ;-%%% !1110
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M]X_]T?RI],@_X]X_]T?RI] !1110!$W_ !]1_P"ZW]*EJ)O^/J/_ '6_I4M
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M_NM_2I: "BBB@ J*V_X](?\ <7^52U%;?\>D/^XO\J ):*** "BBB@ HHHH
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M-6..F2*RKSPAH=_"D-U8[HUA,!597421_P!U\,-XY/#9ZGU-;*(L<:H@PJ@
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MX]X_]T?RI],@_P"/>/\ W1_*GT %%%% $3?\?4?^ZW]*EJ)O^/J/_=;^E2T
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M[N.P^88J)0IJ-T^G?T-(SJN5FNO;UZC[KQ/HEEJ0T^[U.WBNB0/+9^A/0$]
M?K5LZG9#51IAN8_MK1><(,_-LSC-<Y!I6MZ7=WUK9V&G7MG>W;7)N+B4J4#'
M)5DVG<1C@Y]/2J<OA;7G\5'Q$L]J)EO%*VVSYC;@;-OF9XRI+;<=>]/V=/\
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MMO\ CTA_W%_E0!+1110 4444 %%%% !116=KOB#3/#6FG4-;NOLMJ&"&4HS
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MI6_0 4444 %%%% !16/XH>=-$)A:=(_-C%R]L#YB0[AO*XYSCN.0,D<US?\
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MJ7Z$@C...O>IW\5Z%$+@RZI;HMLI:5F;"J <$YZ$ D XZ4 :]%1P3QW5O'/
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MK;26RVT\<$J#SU5=H+$J2#CC*[<C@YJ2;P7IES=)+/)<21J9B8"R[6\W<'Y
MW $.> 0#A<@E1CH:* ,5?#,;P^5>ZE?WT:M&R+<2)A AR!\JC.>A)RQ]:AC\
M'VR6S0-J%]+&L!M[<2M&PMHR1E5!3# A0#OWY QW.>@HH Y5OAWHAN+>;#EH
M4C1R\<3F;RP I+,A9> !\A7BKH\*6XOH9EO[];>"Y-U'9"1?)60Y)/W=Q&6)
MVEL G@#BMVB@#+GT"UGU234?,FCN7,)#HP&WRR^,<=Q(P/J#VK-MO 6D6>HR
MWEIO@9_,*".*%3$SYW,'";R?F/#,0,].!CIJ* .=M_!UO90QI8:EJ%HRQF*2
M2!HU,R%F;:1LVK@LV-@4C/&*G;PM:/J9NGN+IHFE$[V9=3$TH39O/R[L[>V[
M&><9K;HH Y_0?!FE^';QKC3UPWE^5&#%$OEID';E$5FZ#ERQXZ]:T4T6S&EW
M6G2(TMM=M,TR2'.[S69G'TRQJ_10!S6F^!-*TS_4ERWFQ2!A%#&1Y;;E'[M%
MR,]2<D^M;=CI\.GFY\@N?M,[3ON.?F;&<>W%6J* "BBB@ HHHH **** "BBB
M@ HHHH BC_X^IOHM2U%'_P ?4WT6I: "BBB@"*Z_X])?]P_RJ6HKK_CTE_W#
M_*I: "BBB@ J)/\ CZE_W5_K4M1)_P ?4O\ NK_6@"6BBB@ I'_U;?2EI'_U
M;?2@!L'_ ![Q_P"Z/Y4^F0?\>\?^Z/Y4^@ HHHH B;_CZC_W6_I4M1-_Q]1_
M[K?TJ6@ HHHH *BMO^/2'_<7^52U%;?\>D/^XO\ *@"6BBB@ HHHH **** "
MN7U;QK;:%XDN;+5%$5G;Z>EV9U#.[.TOEB,(!DDG& .23745S7B7PQH.H-<Z
MGKDTEOOMDMS,)_+\K;)O1U/9P^"#0!EV7Q2TN2.]EO8;J-8[UK:U@BM)7N)0
ML2.S&(+N7;NP<CCCUJU-\4/"\23R)=7-Q% L3-+;V<LBGS "@!53DD'..O!]
M*@M_ASH-Q8)-9:GJAEEF:Z34X;]O/8NBHW[P=58*N1[=JE3X>>'+C0[S3M.D
MNK>SNI(Q)]DNBNTQ+Y>T'\.0<Y//6@!!\2-*MI;H:@[-MNC%;QV=M--*R"-'
M+L@3(P'&2,@9'-=/I6IVNLZ3;:EI[F2VNHQ+$Q4J2IZ'!Y%<L?AUX=N))%M+
MJ^@N8)B7EM;UEE3=&BM&6'.UE1"0>>]=1H^E6VAZ-:Z98[_L]I$(H][;FVCI
MD]Z +E%%1K/$UP\"R*9HU5V0'E0<@$CT.T_D: )**H7.N:79VZSW6H6\43NR
M*S2#YF4X8#UP1@^E7()XKF!)K>1)8I!N1T8%6'J"* 'T5#;W=O=J[6LT<PCD
M:)RC [74X93[@]J8^HV<=M-<2742PV[%99"XPA'4$]C0!9HJM::C97Z@V5U#
M.&02#RW#?*20#],@C\#5F@ HK,'B313J%M8C5K,W=T@D@@\]=\JGH5&<D5?E
MN8()(HYIDC>9MD2LP!=L$X'J< G\* )**1F"J68X &23VIL,T=Q DT$BR12*
M&1T.0P/0@T /HJ/[1%]I^S^8OG;-_EY^;;G&<>F:3[7;_;?L?G1_:?+\WR=P
MW;,XW8],\9H EHHJ-;B%[AX$D4S1J&= >5!S@D>^#^5 $E%,GGBMK>2>XD6*
M*-2[NYP%4<DD^E/!R,CD4 %%%% !1110 45D7>N2Q7\MKI^F7%^;< W#Q,BB
M,D9"C<1N;'.!ZCGFI)O$>D6TD<5Y?P6LTB*XAG<(Z[N@(/0^QH TZ*R?^$IT
M'R1*-7LS&TAC#"92"PQD?AD9],U7L?%^FW.G_;;N1+" LBQM<3)\^Z-9.,$]
MF'7Z],&@#>HK);Q+ID4EQ]INHX(H615F=QMEWH'&T]^#4ESXCT6S6)KK5;2)
M9H_,C9YE 9/[P/I[T :5%5XM0LYA"8;J)_/9EBVN#O*YW >N,'/TJQ0 4444
M %%%% !1110 444B.LBAD8,IY!!R#0 M%%-$B,[*K*63[P!Y'UH =12.ZQQL
M\C!4499F. !ZTAEC5D#.H,AP@)^]QGCUXH =1110 4444 %%1I<0R2%(Y4=P
M,E58$@9(_F"/P-/+J) A8;R"0N>2!C)_4?G0 M%(CK(NZ-@RY(RISTX--2>*
M262..5'DB($BJP)0D9&1VXH ?1137D2/'F.J[CM&3C)]* '44V.1)HUDB=71
MAE64Y!'L:=0 4444 %%%% !1110 4444 11_\?4WT6I:BC_X^IOHM2T %%%%
M $5U_P >DO\ N'^52U%=?\>DO^X?Y5+0 4444 %1)_Q]2_[J_P!:EJ)/^/J7
M_=7^M $M%%% !2/_ *MOI2TV0@1L20  <DT )!_Q[Q_[H_E3ZAM)8YK2-H9$
MD7:!N1@1T]JFH **** (F_X^H_\ =;^E2U$W_'U'_NM_2I: "BBB@ J*V_X]
M(?\ <7^52U%;?\>D/^XO\J ):*** "BBB@ HHHH *S/$%M)=:7Y<-J]T1(C%
M8IA%(N#G?&QXW X(!(!QUK3HH X&ZTCQ=-<6TK2N'^SQ*GD$!8) 3O9P)D4Y
MXSA7'4 #N^ZT36DBNU^S7L_F+,;,65^+<02M)(V]_F&00R$?>Q@C;Z]W10!Q
M$7A[4[47$K0W<RW%S#)=0P7I62=1 JG:Q<!<29)&Y<@=>@.;J\MSI=J8]8N+
ML.;63[# FJ>5) Q9MF]MP\U@-@^7S""#P<Y/I-! /44 >=IX>\2?V5%.;B]E
MFEG#W$#7+,S1B(!0H\V,+ALDC<">^>E=%X:TW4[.X>;527=[.&/>Q!;<KRG:
M?F/(#J,Y.?4]:Z*B@#B-(@U"UT^SU'3K(7LILFM2 5WP2K(Q)PS*""QPWS _
M*O7LVTL]?MK&=X-/F62\BN4-M#.J+:3/)E6^8C*\YW+D^@KN:* .*.D:Q'(X
MOH+Z^@W2^2EI?^2R.9&(=CO7(*[<<G&#\O--&@ZJCZB;RSDOH;FX:2&&.[$7
MDJ=N3U&YCC*L>0P ^4<UV]% '#GP]K5U#<W=RURE\M@$M2ER(RTJR2,IDV$*
M6P4SU7)-6H=*U=]8W7,=X':XD,UU]M_<26[9Q&L8;(8 J,[1@@G<>AZZB@#B
MM#^'MK:KI-Y=274-U:01B2V$^^-G4#DDY)Y Z'' JYKNA:MK6JM<6]S;V:6B
M!;/SH3*2^0YD!#C9R O(/ /K74T4 <FMKKEWFTNK6YBBDNI+AYOM2[?*:,XA
M^5MV0S8Z;>,@]*SX?#^L6>GVMI'#>EXK2".UDAO]L=I(H^<R*7RXSST?(XP.
M_>44 <SKVC:AJ&KQR6S2QPM%%%++!/Y3X$P9P"#D97/2L.[L=9.HW^E:;=2A
MHEWQ1FX,DAMS(AV[BX8$_O ,LIP,9 Y'H5% '#VVE:XEK -2AO[NU620_8[>
M[\F9,A=A+><=RC#\>8<;AUQQ+<:!J0O;J]@AN<SP6B31I?'S)43?YB*Q( ;E
M?F^7//(R379T4 <(VDWT/GWNJ/?0:7;6ERT5K+?%RI.W:LF&.\XWX!+ ;@,G
MBNPTJ*6#1K*&Y_UT=O&LG^\% /ZU;HH **** "BBB@#'N='O1J$]SI.I+9BZ
M \]'MQ*-P &].1M;  YW#@<=<TKWPI<7"74%OJGEVU[)'+<"6W$DC.@09#Y
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>halo-20221231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #-#(
M )*2  (    #-#(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" (1 O$# 2(  A$! Q$!_\0
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MF!7YL9SU!]*P/%'QET_PEK3:=J7A3Q5)FY%K!<P:<IANI#T6)BXWD]@.3@T
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M48&XG)P.3S0!XAX6OVT7X$_$-[)%65];OK2V11CYY?+B0*/JXP*UO'OB/2_
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M&"XBEEMF"3QHX+1,5# ,!T)5@<'L0>] $M%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M'OQ!_P!^-/\ _D6NDHH YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\
M?C3_ /Y%KI** .;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1:Z2B@#F_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6NDHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .#2#_XJ@#I**YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\ X-(/_BJ
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M(_Z'+P__ .#2#_XJ@#I**YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\
MX-(/_BJ .DHKF_\ A8W@C_H<O#__ (-(/_BJ/^%C>"/^AR\/_P#@T@_^*H Z
M2BN;_P"%C>"/^AR\/_\ @T@_^*H_X6-X(_Z'+P__ .#2#_XJ@#I**YO_ (6-
MX(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\ X-(/_BJ .DHKF_\ A8W@C_H<O#__
M (-(/_BJ/^%C>"/^AR\/_P#@T@_^*H Z2BN;_P"%C>"/^AR\/_\ @T@_^*H_
MX6-X(_Z'+P__ .#2#_XJ@#I**YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O
M#_\ X-(/_BJ .DHKF_\ A8W@C_H<O#__ (-(/_BJ/^%C>"/^AR\/_P#@T@_^
M*H Z2BN;_P"%C>"/^AR\/_\ @T@_^*H_X6-X(_Z'+P__ .#2#_XJ@#I**YO_
M (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\ X-(/_BJ .DHKF_\ A8W@C_H<
MO#__ (-(/_BJ/^%C>"/^AR\/_P#@T@_^*H Z2BN;_P"%C>"/^AR\/_\ @T@_
M^*H_X6-X(_Z'+P__ .#2#_XJ@#I**YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C
M_H<O#_\ X-(/_BJ .DHKF_\ A8W@C_H<O#__ (-(/_BJ/^%C>"/^AR\/_P#@
MT@_^*H Z2BN;_P"%C>"/^AR\/_\ @T@_^*H_X6-X(_Z'+P__ .#2#_XJ@#I*
M*YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\ X-(/_BJ .DHKF_\ A8W@
MC_H<O#__ (-(/_BJ/^%C>"/^AR\/_P#@T@_^*H Z2BN;_P"%C>"/^AR\/_\
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M1=M?^PUI7_IPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M KF_B-_R2SQ7_P!@:\_]$/725S?Q&_Y)9XK_ .P->?\ HAZ .DHHHH ****
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M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
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M]:BWU6U6=5.Z-\E7B;^\CC#(WNI!K%QXD\,]/,\2Z6OKM6^A'Z+, /\ =?\
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ML!ECR>OK5VB@#F_'G_(NVO\ V&M*_P#3A;UTE<WX\_Y%VU_[#6E?^G"WKI*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[Q'XE:<W5
MAI.HP:9:VIV:EKD[*L=GZQQEOE:;'KPG4Y.%(!?U77+F[U&30O#!1]04#[5=
MNNZ+3U/=A_%(1]V/\6P.NAHNAV7A^Q>*TWL\C&6YN9FW2W$AZN[=S^@
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MEJ5X=.N8YM-U95);3[P!)"!U9""5D7_:0D>N#Q0!MT444 %<W\1O^26>*_\
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M/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4 =)17E'_"6?$0Z9_;P?0/\
MA&\[_MO]F3>?Y.<>?Y/VK'EX^;[^[;SMSQ79_8?&_P#T,/A__P $,_\ \F4
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M826[#,#%E)RP4%#GDM&Q[BNTHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#F_'G_ "+MK_V&M*_].%O725S?CS_D7;7_ +#6E?\ IPMZZ2@
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M_P#$T?\ "N?!'_0F^'__  5P?_$UTE% '-_\*Y\$?]";X?\ _!7!_P#$T?\
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M;7_L-:5_Z<+>NDKF_'G_ "+MK_V&M*_].%O724 %%%% !1110 4444 %%%%
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M7;^7:QW 2U\YL9P%<^8 !R6*84<DBM35M7M/#,-OI6A:='/J5UG['IMLHC!
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M$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'G_(NVO\
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M]#\/^3_;VLZ?IGG[O*^VW20^9MQG;N(SC(SCU%9O_"QO!'_0Y>'_ /P:0?\
MQ5%]_P E3T+_ + VI?\ H^QKI* .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/
M^AR\/_\ @T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\/_\
M@T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\/_\ @T@_^*KI
M** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\/_\ @T@_^*KI** .;_X6
M-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\/_\ @T@_^*KI** .;_X6-X(_Z'+P
M_P#^#2#_ .*H_P"%C>"/^AR\/_\ @T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_
M .*H_P"%C>"/^AR\/_\ @T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%
MC>"/^AR\/_\ @T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\
M/_\ @T@_^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*H_P"%C>"/^AR\/_\ @T@_
M^*KI** .;_X6-X(_Z'+P_P#^#2#_ .*KG_'WC[P?>?#?Q+:V?BO0Y[B;2;J.
M**+4H6>1C"P"J V223@ 5Z)10!S?_"QO!'_0Y>'_ /P:0?\ Q5'_  L;P1_T
M.7A__P &D'_Q5=)10!S?_"QO!'_0Y>'_ /P:0?\ Q5'_  L;P1_T.7A__P &
MD'_Q5=)10!';7,%Y:Q75G-'/;S()(I8G#)(I&0RD<$$'((J2N;^'/_)+/"G_
M &!K/_T0E=)0 4444 %%%% !1110 4444 %%%% !1110!S?CS_D7;7_L-:5_
MZ<+>NDKF_'G_ "+MK_V&M*_].%O724 %%%% !1110 4444 %%%% !1110 44
M44 07=C::A 8+^UANHCUCFC#J?P-<7XF\!:;:Z7#=>%M"9;RUU"RNA::?/\
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M0_\ C%=)10!S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q7244
M<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",5TE% '-_\)YI'_/G
MX@_\)S4/_C%'_">:1_SY^(/_  G-0_\ C%=)10!S?_">:1_SY^(/_"<U#_XQ
M1_PGFD?\^?B#_P )S4/_ (Q7244 <W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX
M@_\ "<U#_P",5TE% '-_\)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_  G-0_\
MC%=)10!S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q7244 <W_P
MGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",5TE% '$VVO6FM_%/2/L<
M.H1>3HVH;OMNFW%IG,]EC;YR+NZ<XSCC/45VU<W??\E3T+_L#:E_Z/L:Z2@
MHHHH ***CN97@M998H)+EXT++#$5#R$#(5=Q"Y/09('J10!)17-_\)1J_P#T
M(GB#_O\ Z?\ _)5<I?\ QB-EXUBT670Y8762.UFT^:\M!>O/,-T1C47&PI@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .;OO^2IZ%_V!M2_]'V-=)7-WW_)4]"_[ VI?^C[
M&NDH **** "BBB@ HHHH *C>"&66*62)'DA),;LH)0D8)![<$C\:DHH HPZ'
MI-O8W=G!I=E%:WK.UU EN@2X+C:Q=0,,2  <YR*@_P"$6\/_ &B]G_L+3/.U
M!62\D^QQ[KE6.2)#C+@]P<UJT4 9NF>'-#T0J=&T;3]/*APOV2U2+ ?;N^Z!
MUV)GUVKZ"H;_ ,(^&]56-=4\/:5>B-I'07%E')L:1M[D;E."S$L3W)R:V**
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M  Y)( KG)_B58Q^$['Q'!HVLW=A=V3W[M!;I_HL" %FD9G"@X/W5+,<' .*
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M@C^(5Z[10!YWK/PUO)E\/0Z!J,=A_96EW=D]ZH*3F22U2"*8;1RP\M23N!
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M-5H_ 6II:>"OM%_#?7VAW*2ZA>SEO,N0L,B8!P2V&DXW$<9/6N^HH \N\2>
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M+[=NW*8VG&Q<<<;1Z"K":5IT=G;6<=A:K;6A5K>!85"0E?NE%QA<=L=*MT4
M5FTRP>P-B]E;M:,<FW,2F,G=N^[C'7GZ\U*+:!;I[I88Q<.BQM*$&]E4DA2>
MI +,0/<^M244 5)=)TZ>\%W/86LER"A$SPJ7^0L4^8C/REFQZ;CCJ:1M(TU]
M,ETYM/M6L9M_FVI@7RGWL6?*8P=S$DY')))JY10!F0^&M"MX[:.WT73HDLTD
MCME2T11 LGWU0 ?*&[@=>]1-X0\-/HZ:2_A[2FTU)/-6S-E&85?GY@FW:#R>
M<9YK8HH I#1M+$PE&FV@D$XN _D+D2A/+$F<?>"?+NZ[>.E)+HNE3ZS#J\^F
M6<FIVZ&.&]>W4S1KS\JN1N ^9N ?XCZU>HH J?V5IXTL:;]@M?L 0(+7R5\H
M+Z;,8Q[8IHT;2QC&FV8P\KC]POWI<F0].KY.X]\\YJ[10!C)X.\,QZ7)IL?A
MW25L)6#26HL8A$Y!R"4VX)!]JL)X>T:.)HH](L%C8Q%D6V0 F+'E$C'\&U=O
M]W QC%:-% %"WT2P@TF#36MXY[:!E=$FC5@&5MZMC& 0P!& ,$#&,4'0=',/
MDG2K'RO(DMMGV9-OE2$&2/&/NL0"5Z''-7Z* ,F/PKX>AL390Z#ID=H8FA,"
MV<8C\MFW,FW&-I;DCH3S37\(^&Y;&&RD\/:4]I!()(H&LHS'&^,;E7;@'  R
M.PK8HH H1:#I$#[X-*LHV^;YDMT!^9%0]!W5$4^RJ.@%8-U\.-&O/%%CK4Q8
M?V?Y7V6TCMK9(XA&/W:AUB$NU6PP3S-N0.,<5UM% %>33[.::6::T@DEFA\B
M5VB!9X\D["<<K\S<'CD^M48?"OAZWL!96^@Z9%:*) +=+.-8QYB[7^4#'S*2
M#ZC@UK44 4Y='TR9)TFTZTD6XV><KP*1+L^YNXYVX&,].U,GT+2;G6(-6N=+
MLIM2MUV0WLENC31+SPKD;@/F;@'N?6K]% &1'X3\.0P7$,6@:6D5U*LT\:V4
M86:13E788^9@>03R#4[:#H[0^4VE6)C\F6#8;9-OERG,B8Q]UR 6'0]\UH44
M 9C>&M";4)K]M%TXWD\/D2W!M4\R2/:%V,V,E< #!XP,4^;0-'N/]?I-C+_J
MC\]LA_U6?+ZC^')V^F>,5H44 4;[1=*U2ZM+K4],L[RXL7\RUEN+=9'MVR#N
M0D$J<JIR,=!Z5/'96L,<R0VT,:7#L\RK& )&;[Q;U)[D]:GHH RM/\+Z!I)B
M.EZ'IMD87\R,VUI''L;:R[AM P<.PSZ,1W-6$T;2XXXDCTVS1(6D:)5@4!#)
MGS".."VYLXZY.>M7:* ,5/!OAB/3)-.C\.:2MC,P:2U6QB$3D'()3;@D$DCC
MO5O^PM(\LQ_V59;#%'"5^SI@QQG,:8Q]U225'09XJ_10!E_\(OH'VRYN_P"P
M]-^TWBLES-]DCWSJPPP=L98$<'/6I;#0M(TJ&&+2]+LK*.WW>2EM;I&(]WWM
MH4#&<#..M7Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270229616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0488686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12390 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-8889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,366,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271220160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270852592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 234,195<span></span>
</td>
<td class="nump">$ 118,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">128,599<span></span>
</td>
<td class="nump">622,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net and other contract assets</a></td>
<td class="nump">231,072<span></span>
</td>
<td class="nump">90,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">100,123<span></span>
</td>
<td class="nump">53,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">45,024<span></span>
</td>
<td class="nump">40,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">739,013<span></span>
</td>
<td class="nump">926,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">75,570<span></span>
</td>
<td class="nump">8,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">26,301<span></span>
</td>
<td class="nump">13,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">409,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">546,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">44,426<span></span>
</td>
<td class="nump">155,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,841,511<span></span>
</td>
<td class="nump">1,104,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,693<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">96,516<span></span>
</td>
<td class="nump">24,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">13,334<span></span>
</td>
<td class="nump">89,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">130,789<span></span>
</td>
<td class="nump">117,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">1,492,766<span></span>
</td>
<td class="nump">787,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">30,433<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent liability</a></td>
<td class="nump">15,472<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">27,368<span></span>
</td>
<td class="nump">256,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(922)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (Accumulated deficit)</a></td>
<td class="nump">143,217<span></span>
</td>
<td class="num">(58,912)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">169,798<span></span>
</td>
<td class="nump">196,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,841,511<span></span>
</td>
<td class="nump">$ 1,104,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270773024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">135,154,000<span></span>
</td>
<td class="nump">137,498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">135,154,000<span></span>
</td>
<td class="nump">137,498,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256269970480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 660,116<span></span>
</td>
<td class="nump">$ 443,310<span></span>
</td>
<td class="nump">$ 267,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">139,304<span></span>
</td>
<td class="nump">81,413<span></span>
</td>
<td class="nump">43,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">43,148<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">66,607<span></span>
</td>
<td class="nump">35,672<span></span>
</td>
<td class="nump">34,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">143,526<span></span>
</td>
<td class="nump">50,323<span></span>
</td>
<td class="nump">45,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">392,585<span></span>
</td>
<td class="nump">167,408<span></span>
</td>
<td class="nump">123,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">267,531<span></span>
</td>
<td class="nump">275,902<span></span>
</td>
<td class="nump">144,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">5,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="num">(2,712)<span></span>
</td>
<td class="num">(20,960)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(16,947)<span></span>
</td>
<td class="num">(7,526)<span></span>
</td>
<td class="num">(20,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">248,918<span></span>
</td>
<td class="nump">248,518<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">46,789<span></span>
</td>
<td class="num">(154,192)<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 202,129<span></span>
</td>
<td class="nump">$ 402,710<span></span>
</td>
<td class="nump">$ 129,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares used in computing net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">136,844<span></span>
</td>
<td class="nump">140,646<span></span>
</td>
<td class="nump">136,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">140,608<span></span>
</td>
<td class="nump">146,796<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 360,475<span></span>
</td>
<td class="nump">$ 203,900<span></span>
</td>
<td class="nump">$ 88,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">191,030<span></span>
</td>
<td class="nump">104,224<span></span>
</td>
<td class="nump">55,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 108,611<span></span>
</td>
<td class="nump">$ 135,186<span></span>
</td>
<td class="nump">$ 123,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270164528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 202,129<span></span>
</td>
<td class="nump">$ 402,710<span></span>
</td>
<td class="nump">$ 129,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on foreign currency</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 201,827<span></span>
</td>
<td class="nump">$ 402,068<span></span>
</td>
<td class="nump">$ 128,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267660832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 202,129<span></span>
</td>
<td class="nump">$ 402,710<span></span>
</td>
<td class="nump">$ 129,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">24,397<span></span>
</td>
<td class="nump">20,820<span></span>
</td>
<td class="nump">17,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,493<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">43,148<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">7,839<span></span>
</td>
<td class="nump">3,642<span></span>
</td>
<td class="nump">14,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (accretion of discounts) premiums on marketable securities</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized loss on marketable securities</a></td>
<td class="nump">1,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of equipment</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferral of unearned revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of deferred revenue</a></td>
<td class="num">(2,494)<span></span>
</td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(4,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredRentPayments', window );">Lease payments deferred</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Loss on impairment of right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="nump">2,712<span></span>
</td>
<td class="nump">20,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes (including benefit from valuation allowance release)</a></td>
<td class="nump">40,005<span></span>
</td>
<td class="num">(155,434)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(83,941)<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
<td class="num">(38,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(17,481)<span></span>
</td>
<td class="nump">7,371<span></span>
</td>
<td class="num">(31,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(9,064)<span></span>
</td>
<td class="num">(11,555)<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">24,535<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="num">(41,208)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">240,110<span></span>
</td>
<td class="nump">299,440<span></span>
</td>
<td class="nump">55,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(255,208)<span></span>
</td>
<td class="num">(652,515)<span></span>
</td>
<td class="num">(226,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">746,127<span></span>
</td>
<td class="nump">247,683<span></span>
</td>
<td class="nump">305,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of business, net of cash acquired</a></td>
<td class="nump">999,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,810)<span></span>
</td>
<td class="num">(1,457)<span></span>
</td>
<td class="num">(2,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of assets</a></td>
<td class="nump">26,006<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(487,005)<span></span>
</td>
<td class="num">(406,289)<span></span>
</td>
<td class="nump">78,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from term loan</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of term loan</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of revolving credit facilities</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2027 Convertible Notes, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">784,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">77,453<span></span>
</td>
<td class="nump">369,064<span></span>
</td>
<td class="nump">19,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of 2028 Convertible Notes</a></td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PurchaseOfCappedCall', window );">Purchase of capped call</a></td>
<td class="num">(69,120)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="num">(7,104)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(200,002)<span></span>
</td>
<td class="num">(350,058)<span></span>
</td>
<td class="num">(150,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</a></td>
<td class="nump">14,050<span></span>
</td>
<td class="nump">12,536<span></span>
</td>
<td class="nump">63,393<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">362,371<span></span>
</td>
<td class="nump">77,865<span></span>
</td>
<td class="num">(106,284)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">115,476<span></span>
</td>
<td class="num">(28,984)<span></span>
</td>
<td class="nump">27,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">119,219<span></span>
</td>
<td class="nump">148,203<span></span>
</td>
<td class="nump">120,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">234,695<span></span>
</td>
<td class="nump">119,219<span></span>
</td>
<td class="nump">148,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">6,107<span></span>
</td>
<td class="nump">3,296<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid (received), net</a></td>
<td class="nump">16,224<span></span>
</td>
<td class="num">(375)<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">34,435<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for induced conversion related to convertible notes</a></td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Rent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PurchaseOfCappedCall">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of capped call</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PurchaseOfCappedCall</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272048976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) Statement - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th">
<div>Adjustment </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th">
<div>Adjustment </div>
<div>Retained Earnings (Accumulated Deficit)</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares outstanding (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 91,765<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 695,066<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="num">$ (603,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">17,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan</a></td>
<td class="nump">63,393<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">63,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(150,117)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">(150,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible notes</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">129,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares outstanding (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">151,047<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">625,483<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(474,593)<span></span>
</td>
<td class="num">$ (52,564)<span></span>
</td>
<td class="num">$ (65,535)<span></span>
</td>
<td class="nump">$ 12,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">20,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes</a></td>
<td class="nump">13,104<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">13,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan</a></td>
<td class="nump">12,536<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">12,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(350,058)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">(350,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">402,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares outstanding (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">196,953<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">256,347<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">(58,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">24,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan</a></td>
<td class="nump">14,050<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction', window );">Adjustment to Additional Paid in Capital, Capped Call Transaction</a></td>
<td class="num">(69,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(200,002)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(199,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">202,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares outstanding (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 169,798<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 27,368<span></span>
</td>
<td class="num">$ (922)<span></span>
</td>
<td class="nump">$ 143,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to Additional Paid in Capital, Capped Call Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256279627088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving&#160;the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids.&#160;We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex, that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver.&#160;Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma (International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC)(&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries disclosed in Note 2.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276092720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of December&#160;31, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2022 and 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer&#8217;s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2022 and 2021. Approximately 52% of the accounts receivable balance at December&#160;31, 2022 represents amounts due from Janssen and Roche. Approximately 90% of the accounts receivable balance at December&#160;31, 2021 represents amounts due from Janssen, Roche and Takeda. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or  (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,  TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and  (ii)&#160;product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256369353952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">Business Combination<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#8217; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $19.7&#160;million and seller transaction costs paid by us on behalf of Antares of $22.9&#160;million. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#8220;BofA&#8221;) and other lenders that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;, collectively with the Revolving Credit Facility, the &#8220;2022 Facility&#8221;) as described in Note 8. We recognized transaction costs of $21.9&#160;million in the twelve months ended December&#160;31, 2022. These costs are reported in selling, general and administrative expenses in our condensed consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Consideration</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:87.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in our consolidated statements of income in twelve months ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on valuations and management estimates. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the allocation of the purchase price, therefore, the fair value estimates assigned to intangible assets, goodwill and the related tax impacts of the acquisition, among other items, are subject to change as additional information is received to complete our analysis and certain tax returns are finalized. As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:50.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as adjusted )</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $46,548 cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable unit. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A contingent liability with a preliminary value of $130.0&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded measurement period adjustments in fourth quarter of 2022 to decrease intangible assets as a result of revised future cash flow estimates from the initial purchase price allocation and adjustments to accrued expenses. These measurement period adjustments were made to reflect facts and circumstances that existed as of the acquisition date. We also recorded a measurement period adjustment in the fourth quarter of 2022 to reduce the acquisition-date fair value of contingent liability by $114.3&#160;million as a result of revised future cash flow estimates. The measurement period adjustment has been recorded to reflect facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Identifiable Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#8217; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;D will be tested annually for impairment and will not be amortized. Useful lives and preliminary values are presented in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include Antares&#8217; results of operations from the date of acquisition on May 24, 2022 through December&#160;31, 2022. Total revenues and net loss after taxes attributable to Antares during this period and included in our consolidated financial statements for the twelve months ended December&#160;31, 2022 total $112.7&#160;million and $67.6&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:78.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal year 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276015040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Government Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 20 available-for-sale marketable securities with a fair market value of $117.2&#160;million were in a gross unrealized loss position of $0.9 million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of December&#160;31, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:66.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no available for sale securities that were classified within Level 3 as of December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276214992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:70.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Device Partnered Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development milestones and regulatory milestone and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $429.5 million. This amount represents royalties and sales milestone earned in the current period, as well as $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. We also recognized revenue of $2.0 million during the year ended December&#160;31, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:78.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $80.7 million of which $75.2 million relates to unfulfilled product purchase orders and $5.5 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $44.1&#160;million as of December&#160;31, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276035648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d">Right of use of assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $6.5 million, $3.0 million, and $3.3 million, inclusive of ROU asset amortization of $3.0 million, $1.6 million and $1.7 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b">Lease liability</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $0.5 million, $0.3 million and $0.5 million for the twelve months ended December&#160;31, 2022, 2021 and 2020, respectively. Total lease expense for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $3.3 million, $1.9 million and $2.2 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $4.2 million, $2.7 million and $3.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275988768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares. A Goodwill balance of $409.0&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk1OQ_f58b5d2c-2f99-454c-b819-957e5d1ad0df">seven</span> to ten years. The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:46.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256277228224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt, Net</a></td>
<td class="text">Long-Term Debt, Net<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2028 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of December&#160;31, 2022, no capped calls have been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the Condensed Consolidated Balance Sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of December&#160;31, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#8217; fee of $12.7 million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3 million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Operations for the twelve months ended December&#160;31, 2022. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which is included in other income (expense) of the consolidated statements of income. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment of $13.5&#160;million to effect the redemption in March 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of the Convertible Notes</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:71.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of December&#160;31, 2022, the unamortized debt issuance cost related to the revolving credit facility was $3.1&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities and interest payments of long-term debt as of December&#160;31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:85.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amount representing coupon interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross balance of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion and unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275896688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently grant stock options, restricted stock awards, performance stock units and restricted stock units under the Amended and Restated 2021 Stock Plan (&#8220;2021 Stock Plan&#8221;), which was approved by the stockholders on May 5, 2021 an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides for the grant of up to 17.8 million shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended December&#160;31, 2022, we granted share-based awards under the 2021 Stock Plan. At December&#160;31, 2022, 6,550,075 shares were subject to outstanding awards and 14,764,481 shares were available for future grants of share-based awards. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity awards was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:70.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of December&#160;31, 2022, 2,650,103 shares were available for future purchase. The offering period is generally for a six-months period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the twelve months ended December&#160;31, 2022, 32,124 shares were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Options granted under the Plans must have an exercise price equal to at least 100% of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest at the rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option award activity as of and for the year ended December&#160;31, 2022 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:45.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.748%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Underlying<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price&#160;per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$33.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,225&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$126.0</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $14.22 per share, $18.21 per share and $20.74 per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $21.6 million, $33.5 million and $49.7 million, respectively. Cash received from stock option exercises for the years ended December&#160;31, 2022, 2021 and 2020 was approximately $15.3 million, $16.6 million and $66.2 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:56.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.91-50.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.01-46.45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.57-51.82%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37-4.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.36-1.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22-1.67%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:49.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(yrs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.1</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $8.6 million, $6.6 million and $10.1 million, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $11.3 million, $19.0 million and $14.0 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A PSU is a promise by us to issue a share of our common stock upon achievement of a specific performance condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:74.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40.66</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$41.42</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$63.41</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,746)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$46.01</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the PSUs was based on the closing market value of our common stock on the date of grant. The fair value of PSUs vested during the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276070048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we issued an aggregate of 789,870, 1,179,032 and 4,705,843 shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately $15.3 million, $16.6 million and $66.2 million, respectively. For the years ended December&#160;31, 2022, 2021 and 2020, we issued 254,907, 299,958 and 571,963 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU holders surrendered 68,425, 94,795 and 142,905 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $4.4 million, $8.2 million and $5.5 million, respectively. Stock options and unvested restricted units totaling approximately 6.6 million, 5.9 million and 6.7 million shares of our common stock were outstanding as of December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Board of Directors authorized a capital return program to repurchase up to $550.0 million of outstanding common stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzgzNg_6d31b2bd-233b-4e57-aa4d-35605e28c115">three</span>-year period. During 2020, we repurchased 6.5&#160;million shares of common stock for $150.0&#160;million at an average price of $23.05. During 2021, we repurchased 4.6&#160;million shares of common stock for $200.0&#160;million at an average price of $43.02 under the program. The shares were purchased through open market transactions and through an ASR agreement. The $550.0&#160;million share repurchase program was completed in October 2021 having repurchased a total of 22.3&#160;million shares at an average price of $24.72.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzOTc_69d1271f-c244-47f4-82d2-6cf455ace36c">three</span>-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $150.0&#160;million of common stock. At inception pursuant to the agreement, we paid $150.0&#160;million  and took initial delivery of 3.5&#160;million shares. In June 2022, we finalized the transaction and received an additional 0.4&#160;million shares. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, concurrent with the sale of  2028 Convertible Notes and the 2022 Induced Conversion, we repurchased 2.1&#160;million shares of common stock in open market purchases for $90.2&#160;million. Also, in August 2022, we entered into an ASR agreement to repurchase $109.8&#160;million of our common stock. At inception, pursuant to the agreement, we paid $109.8&#160;million and took an initial delivery of 2.0&#160;million shares.  In December 2022, we finalized the transaction and received an additional 0.4&#160;million shares. We retired the repurchased shares and they resumed their status of authorized and unissued shares. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:50.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200,000</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Included in the total cost of shares purchased is a commission fee of $0.02 per share.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Included is 0.4&#160;million shares delivered in December 2022 upon completion of the ASR.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275900480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income per share</a></td>
<td class="text">Net Income per share<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:64.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:65.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1). The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275888384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and research facilities are located in San&#160;Diego, California. In addition, we have an office in Ewing, New Jersey. We also lease a building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. We lease an aggregate of approximately 194,000 square feet of space. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we assumed Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately 73,238 square feet of space in office and research facilities which commenced on December 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $3.3 million, $2.0 million and $2.3 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate annual future minimum operating lease payments as of December&#160;31, 2022 are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:84.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term of our operating leases is approximately 7.64 years. </span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276070048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income (loss) before income taxes summarized by region were as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:58.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:70.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,995&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible book amortization </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A valuation allowance of $0.7 million and $0.5 million has been established to offset the net deferred tax assets as of December 31, 2022 and 2021, respectively, as realization of such assets is uncertain. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, we reassess the valuation allowance of our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. In 2021, we have demonstrated profitability and cumulative pretax income and are forecasting income growth. After assessing both the positive and negative evidence, we determined that it was more likely than not that our DTAs would be realized and released the valuation allowance in 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired the outstanding shares of Antares Pharma Inc. This transaction was treated as a non-taxable acquisition, we have increased our deferred tax liabilities by approximately $119.7&#160;million related to acquired intellectual property and a step-up to the value of inventory the amortization of which will not be tax deductible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense was comprised of the following components (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:58.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:58.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense (benefit) at 21% </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal income tax impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worthless stock deduction of international subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income subject to tax at other than federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At December&#160;31, 2022, our unrecognized tax benefit and uncertain tax positions were $19.5 million, which will impact the effective tax rate when resolved. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December&#160;31, 2022, 2021 and 2020, we recognized an immaterial amount of interest and penalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:58.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in tax positions for prior years and lapse in statue of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions related to business acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for current year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal, California and other state tax net operating loss carryforwards of approximately $31.2 million, $237.4 million and $63.4 million, respectively. The California and Minnesota net operating loss carryforwards begin to expire in 2028 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we acquired federal and Minnesota research and development credits of approximately $7.4&#160;million and $0.72&#160;million, respectively. We expect to be able to fully utilize these attributes without limitation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal, California and Minnesota research and development tax credit carryforwards of approximately $30.8 million, $17.0 million and $0.7 million, respectively. The federal research and development tax credits will begin to expire in 2030 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. The Minnesota research and development credit will begin to expire in 2023 unless previously utilized. Additionally, we had Orphan Drug Credit carryforwards of $70.0 million which will begin to expire in 2034. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Internal Revenue Code Section&#160;382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section&#160;382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2020. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2022 and 2021, there were no undistributed earnings in foreign subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2008 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276075648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Savings Plan</a></td>
<td class="text">We have an employee savings plan pursuant to Section&#160;401(k) of the Internal Revenue Code.&#160;All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately $2.6 million, $1.1 million and $1.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276021152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:37.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div>(1)Allowances are for chargebacks, prompt payment discounts and distribution fees related to proprietary product sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267836560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of December&#160;31, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2022 and 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, Sources of Supply and Significant Customers</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer&#8217;s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2022 and 2021. Approximately 52% of the accounts receivable balance at December&#160;31, 2022 represents amounts due from Janssen and Roche. Approximately 90% of the accounts receivable balance at December&#160;31, 2021 represents amounts due from Janssen, Roche and Takeda. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, </span></div>and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div>We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, NetProperty and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsWe account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock', window );">Goodwill, Intangible Asset and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or  (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,  TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of SalesCost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationAs a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and  (ii)&#160;product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption and Pending Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Intangible Asset and Other Long-Lived Assets Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276075648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270086624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Total Purchase Price Consideration</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:87.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in our consolidated statements of income in twelve months ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:50.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts recognized as of Acquisition date (as adjusted )</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $46,548 cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Acquired Finite-Lived Intangible Assets by Major Class</a></td>
<td class="text">Useful lives and preliminary values are presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class</a></td>
<td class="text">Useful lives and preliminary values are presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information (unaudited)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:78.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270408016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale marketable securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Government Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date [Table Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:66.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275985632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:70.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Device Partnered Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development milestones and regulatory milestone and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:78.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256269923376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">Property and equipment, net consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d">Right of use of assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b">Lease liability</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256277235856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets Accumulated Amortization and Weighted Average Useful Lives</a></td>
<td class="text">The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:46.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text">The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:46.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto-Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270429952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Fair Values of Convertible Notes</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Components of Interest Expense and the Effective Interest Rates</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:71.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of December&#160;31, 2022, the unamortized debt issuance cost related to the revolving credit facility was $3.1&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Maturities Interest Payments of Long-term Debt</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities and interest payments of long-term debt as of December&#160;31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:85.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amount representing coupon interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross balance of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion and unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271131696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Compensation Expense Related To Share-based Payment Awards Excluding Acceleration of Antares Equity Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity awards was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-based Compensation Expense By Type</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Total Unrecognized Estimated Compensation Cost By Type</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:70.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Award Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option award activity as of and for the year ended December&#160;31, 2022 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:45.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.748%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Underlying<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price&#160;per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$33.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,225&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$126.0</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The assumptions used in the Black-Scholes model were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:56.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.91-50.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.01-46.45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.57-51.82%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37-4.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.36-1.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22-1.67%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:49.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(yrs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of PSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSU activity during the year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:74.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40.66</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$41.42</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$63.41</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,746)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$46.01</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276138544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Activity under Approved Share Repurchase Programs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:50.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200,000</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Included in the total cost of shares purchased is a commission fee of $0.02 per share.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Included is 0.4&#160;million shares delivered in December 2022 upon completion of the ASR.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275925056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:64.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:65.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275986336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate annual future minimum operating lease payments as of December&#160;31, 2022 are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:84.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267633104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes Summarized By Region</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income (loss) before income taxes summarized by region were as follows (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:58.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:70.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,995&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible book amortization </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC 842 right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense was comprised of the following components (in thousands):</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:58.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred - state</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Provision for Income taxes to Federal Income Tax Rate</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:58.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense (benefit) at 21% </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal income tax impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worthless stock deduction of international subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income subject to tax at other than federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Change in Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:5pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:58.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in tax positions for prior years and lapse in statue of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions related to business acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions for current year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267586720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>collaborator </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_NumberOfCollaborationsRoyaltiesReceived', window );">Number of collaborations royalties from which royalties are received | collaborator</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales', window );">Number of products royalties received from sales</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales', window );">Number of products royalties received from sales</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales', window );">Number of products royalties received from sales</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfCollaborationsRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Collaborations, Royalties Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NumberOfCollaborationsRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Products For Which Royalties Received From Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256265766528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract', window );"><strong>Restricted Cash and Investments, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267570112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">660,116,000<span></span>
</td>
<td class="nump">443,310,000<span></span>
</td>
<td class="nump">$ 267,594,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">660,116,000<span></span>
</td>
<td class="nump">443,310,000<span></span>
</td>
<td class="nump">267,594,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">437,989,000<span></span>
</td>
<td class="nump">293,089,000<span></span>
</td>
<td class="nump">106,918,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">166,836,000<span></span>
</td>
<td class="nump">134,117,000<span></span>
</td>
<td class="nump">95,949,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">30,552,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">Belgium | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,088,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">20,086,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47,939,000<span></span>
</td>
<td class="nump">11,934,000<span></span>
</td>
<td class="nump">10,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=halo_ForeignOtherMember', window );">All other foreign | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,261,000<span></span>
</td>
<td class="nump">$ 3,957,000<span></span>
</td>
<td class="nump">$ 3,445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=halo_RocheandBaxaltaMember', window );">Roche and Baxalta | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ConcentrationRiskPercentageInstantDate', window );">Concentration Risk, Percentage (instant date)</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=halo_PartnerAMember', window );">Partner A | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=halo_PartnerBMember', window );">Partner B | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=halo_PartnerCMember', window );">Partner C | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=halo_PartnerDMember', window );">Partner D | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ConcentrationRiskPercentageInstantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Percentage (instant date)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ConcentrationRiskPercentageInstantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=halo_ForeignOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=halo_ForeignOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=halo_RocheandBaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=halo_RocheandBaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=halo_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=halo_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=halo_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=halo_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=halo_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=halo_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=halo_PartnerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=halo_PartnerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270088960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276287184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256274022432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful lives (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256275900480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272069776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Narrative (Details) - Antares Pharma, Inc - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">$ 1,045,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare', window );">Consideration transferred, cash paid per acquiree share (in usd per share)</a></td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related toacquiree closing indebtedness settled</a></td>
<td class="nump">$ 19,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Consideration for seller transaction costs paid by Halozyme</a></td>
<td class="nump">22,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="nump">15,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Pro forma revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Proforma earnings loss of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256266364640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination -Purchase Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Cash consideration for Antares shares outstanding as of May 24, 2022</a></td>
<td class="nump">$ 956,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">45,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Consideration for seller transaction costs paid by Halozyme</a></td>
<td class="nump">22,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related to Antares closing indebtedness settled by Halozyme</a></td>
<td class="nump">19,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredBonusAwards', window );">Cash consideration related to cash bonus awards paid by Halozyme</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">1,045,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Equity Compensation Awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Equity Compensation Award, Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredBonusAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Bonus Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredBonusAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardsVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardsVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267805056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total purchase consideration, net of $46,548 cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,120<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="nump">409,049<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">$ 46,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total purchase consideration, net of $46,548 cash acquired</a></td>
<td class="nump">999,120<span></span>
</td>
<td class="nump">999,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">82,160<span></span>
</td>
<td class="nump">82,160<span></span>
</td>
<td class="nump">82,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories, net</a></td>
<td class="nump">34,379<span></span>
</td>
<td class="nump">28,068<span></span>
</td>
<td class="nump">28,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Prepaid expenses and other assets</a></td>
<td class="nump">28,661<span></span>
</td>
<td class="nump">28,661<span></span>
</td>
<td class="nump">28,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangibles, net</a></td>
<td class="nump">987,500<span></span>
</td>
<td class="nump">589,800<span></span>
</td>
<td class="nump">589,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">7,197<span></span>
</td>
<td class="nump">7,197<span></span>
</td>
<td class="nump">7,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">33,705<span></span>
</td>
<td class="nump">41,654<span></span>
</td>
<td class="nump">41,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability', window );">Deferred revenue, current portion</a></td>
<td class="nump">2,509<span></span>
</td>
<td class="nump">2,509<span></span>
</td>
<td class="nump">2,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">159,094<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="nump">135,088<span></span>
</td>
<td class="nump">20,788<span></span>
</td>
<td class="nump">20,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="nump">799,639<span></span>
</td>
<td class="nump">590,071<span></span>
</td>
<td class="nump">590,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 199,481<span></span>
</td>
<td class="nump">409,049<span></span>
</td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationAbstract', window );"><strong>Measurement period adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory', window );">Inventories, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267459520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Intangible Assets Acquired (Details) - Antares Pharma, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">TLANDO product rights</a></td>
<td class="nump">$ 589,800<span></span>
</td>
<td class="nump">$ 987,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">ATRS-1902 (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived intangible assets acquired</a></td>
<td class="nump">48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Auto-Injector technology platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">XYOSTED proprietary product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">TLANDO product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256274189536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Summary of Proforma Financial Information (Details) - Antares Pharma, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total Revenues</a></td>
<td class="nump">$ 712,683<span></span>
</td>
<td class="nump">$ 627,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 218,723<span></span>
</td>
<td class="nump">$ 295,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271867328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 129,541<span></span>
</td>
<td class="nump">$ 622,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(944)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">128,599<span></span>
</td>
<td class="nump">622,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">32,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">32,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,139<span></span>
</td>
<td class="nump">58,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,130<span></span>
</td>
<td class="nump">58,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">111,469<span></span>
</td>
<td class="nump">231,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">110,535<span></span>
</td>
<td class="nump">230,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,004<span></span>
</td>
<td class="nump">282,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 7,004<span></span>
</td>
<td class="nump">$ 282,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256265778864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in unrealized loss position | security</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in continuous unrealized loss position, less than 12 months</a></td>
<td class="nump">$ 117,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in continuous unrealized loss position, less than 12 months, accumulated loss</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256274050640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 114,353<span></span>
</td>
<td class="nump">$ 500,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one but within five years</a></td>
<td class="nump">14,246<span></span>
</td>
<td class="nump">121,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 128,599<span></span>
</td>
<td class="nump">$ 622,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267102544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">$ 128,599,000<span></span>
</td>
<td class="nump">$ 622,203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value Disclosure</a></td>
<td class="nump">320,303,000<span></span>
</td>
<td class="nump">740,910,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">191,704,000<span></span>
</td>
<td class="nump">118,707,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">7,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">2,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value Disclosure</a></td>
<td class="nump">305,023,000<span></span>
</td>
<td class="nump">349,468,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value Disclosure</a></td>
<td class="nump">15,280,000<span></span>
</td>
<td class="nump">391,442,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">7,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">1,146,000<span></span>
</td>
<td class="nump">32,692,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">1,146,000<span></span>
</td>
<td class="nump">32,692,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">7,130,000<span></span>
</td>
<td class="nump">58,799,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,799,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">110,535,000<span></span>
</td>
<td class="nump">230,761,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">110,535,000<span></span>
</td>
<td class="nump">230,761,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">110,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,761,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. Government securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">2,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">2,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">7,004,000<span></span>
</td>
<td class="nump">282,731,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,731,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,731,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">191,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,707,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272138480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 660,116<span></span>
</td>
<td class="nump">$ 443,310<span></span>
</td>
<td class="nump">$ 267,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">360,475<span></span>
</td>
<td class="nump">203,900<span></span>
</td>
<td class="nump">88,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">191,030<span></span>
</td>
<td class="nump">104,224<span></span>
</td>
<td class="nump">55,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member', window );">Sales of bulk rHuPH20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">82,084<span></span>
</td>
<td class="nump">80,960<span></span>
</td>
<td class="nump">38,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember', window );">Sale of proprietary products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">72,849<span></span>
</td>
<td class="nump">23,264<span></span>
</td>
<td class="nump">17,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember', window );">Sale of Device Partnered Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,097<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">108,611<span></span>
</td>
<td class="nump">135,186<span></span>
</td>
<td class="nump">123,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember', window );">Upfront license and target nomination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">37,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevelopmentFeesMember', window );">Event-based development milestones and regulatory milestone and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">69,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember', window );">Sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ResearchandDevelopmentServicesMember', window );">Device Licensing and development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,611<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_BulkrHuPH20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_UpfrontfeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevelopmentFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevelopmentFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ResearchandDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ResearchandDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256265793840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Textuals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Revenue related to licenses granted to collaboration partners</a></td>
<td class="nump">$ 429,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of deferred revenue</a></td>
<td class="num">(2,494)<span></span>
</td>
<td class="num">$ (1,496)<span></span>
</td>
<td class="num">$ (4,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Deferred Credits and Other Liabilities</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">44,102<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember', window );">License fees and event-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of deferred revenue</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred Credits and Other Liabilities, Current</a></td>
<td class="nump">75,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_A2017RocheMember', window );">2017 Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Development milestones</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OtherCollaboratorsMember', window );">OtherCollaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">$ 80,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront license fee payment received under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from partner of license and collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_A2017RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_A2017RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OtherCollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OtherCollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270201024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Contract with Customer, Asset and Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets', window );">Accounts receivable, net</a></td>
<td class="nump">$ 186,970<span></span>
</td>
<td class="nump">$ 90,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">44,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">$ 5,499<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256274184528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Revenue, Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256277001200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsalestocollaborators', window );">Accounts receivable from product sales to partners</a></td>
<td class="nump">$ 62,979<span></span>
</td>
<td class="nump">$ 18,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromcollaborators', window );">Accounts receivable from revenues under collaborative agreements</a></td>
<td class="nump">18,776<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromroyalties', window );">Accounts receivable from royalty payments</a></td>
<td class="nump">100,900<span></span>
</td>
<td class="nump">63,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsales', window );">Accounts receivable from other product sales</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">44,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Subtotal</a></td>
<td class="nump">232,986<span></span>
</td>
<td class="nump">92,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AllowanceforDistributionFeesandDiscounts', window );">Allowance for distribution fees and discounts</a></td>
<td class="num">(1,914)<span></span>
</td>
<td class="num">(1,140)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable</a></td>
<td class="nump">$ 231,072<span></span>
</td>
<td class="nump">$ 90,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromcollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromcollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsalestocollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales to collaborators</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsalestocollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromroyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromroyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllowanceforDistributionFeesandDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for Discount and Distribution Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AllowanceforDistributionFeesandDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267633264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 13,792<span></span>
</td>
<td class="nump">$ 10,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">40,361<span></span>
</td>
<td class="nump">17,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">45,970<span></span>
</td>
<td class="nump">25,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 100,123<span></span>
</td>
<td class="nump">$ 53,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270037472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 51,694<span></span>
</td>
<td class="nump">$ 47,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">4,647<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">14,984<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expense and other assets</a></td>
<td class="nump">71,325<span></span>
</td>
<td class="nump">53,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(26,301)<span></span>
</td>
<td class="num">(13,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expense and other assets, current</a></td>
<td class="nump">$ 45,024<span></span>
</td>
<td class="nump">$ 40,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271790944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 49,857<span></span>
</td>
<td class="nump">$ 19,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(14,756)<span></span>
</td>
<td class="num">(13,100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">35,101<span></span>
</td>
<td class="nump">6,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">40,469<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</a></td>
<td class="nump">$ 75,570<span></span>
</td>
<td class="nump">$ 8,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
<td class="text">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,380<span></span>
</td>
<td class="nump">$ 7,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">27,893<span></span>
</td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,855<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,729<span></span>
</td>
<td class="nump">$ 1,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270827904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationAbstract', window );"><strong>Depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 6,493<span></span>
</td>
<td class="nump">$ 2,997<span></span>
</td>
<td class="nump">$ 3,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">ROU amortization</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272065280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Summary of Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and payroll taxes</a></td>
<td class="nump">$ 19,939<span></span>
</td>
<td class="nump">$ 9,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accruedmanufacturingexpenses', window );">Accrued outsourced manufacturing expenses</a></td>
<td class="nump">12,190<span></span>
</td>
<td class="nump">6,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Taxes Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Contract with Customer, Refund Liability</a></td>
<td class="nump">30,261<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">29,771<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">34,788<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">126,949<span></span>
</td>
<td class="nump">24,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccruedLiabilitiesNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(30,433)<span></span>
</td>
<td class="num">(544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">96,516<span></span>
</td>
<td class="nump">24,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_OperatingLeaseAccretionOfLiability', window );">Operating lease, accretion of liability</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Total accrued expenses, current<span></span>
</td>
<td class="text">Total accrued expenses, current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accruedmanufacturingexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accruedmanufacturingexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OperatingLeaseAccretionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Accretion Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OperatingLeaseAccretionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267590656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets-Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="nump">$ 199,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256276154672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill Rollforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">409,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 409,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267698448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 541,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">43,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value -finite</a></td>
<td class="nump">497,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">ATRS-1902 (IPR&amp;D)- Indefinite</a></td>
<td class="nump">48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total Intangibles, net</a></td>
<td class="nump">$ 546,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember', window );">Auto-Injector technology platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">34,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value -finite</a></td>
<td class="nump">$ 367,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember', window );">XYOSTED proprietary product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">8,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value -finite</a></td>
<td class="nump">$ 127,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember', window );">TLANDO product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value -finite</a></td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256277018688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets -Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 71,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">141,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value -finite</a></td>
<td class="nump">$ 497,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256260406864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Narrative (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>businessDay </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,538,483,000<span></span>
</td>
<td class="nump">$ 895,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2027 Convertible Notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">784,875,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,104,000<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PaymentForCappedCallTransactions', window );">Payment for capped calls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,453,000<span></span>
</td>
<td class="nump">369,064,000<span></span>
</td>
<td class="nump">19,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount paid for conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock issued for conversion of debt instrument (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712,000<span></span>
</td>
<td class="nump">20,960,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2027 Convertible Notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare', window );">Cap call transaction, cap price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.4075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage', window );">Sale of stock premium over last reported sale price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lender Ffee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.8517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2027 Convertible Notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lender Ffee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays', window );">Convertible, threshold consecutive business days | businessDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,483,000<span></span>
</td>
<td class="nump">$ 90,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount paid for conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock issued for conversion of debt instrument (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lender Ffee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Convertible Debt | Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Variable Rate Component One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Fed Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period prior to expiration | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period prior to expiration | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period prior to expiration | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period prior to expiration | Base Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period after expiration | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period after expiration | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period after expiration | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Period after expiration | Base Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cap Call Transaction, Cap Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentCapCallTransactionCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Consecutive Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Premium Over Last Reported Sale Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_SaleOfStockPremiumOverLastReportedSalePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThirdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThirdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256265844160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">$ 1,538,483,000<span></span>
</td>
<td class="nump">$ 895,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="nump">32,383,000<span></span>
</td>
<td class="nump">19,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying amount</a></td>
<td class="nump">1,506,100,000<span></span>
</td>
<td class="nump">876,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">1,666,769,000<span></span>
</td>
<td class="nump">878,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">7,839,000<span></span>
</td>
<td class="nump">3,642,000<span></span>
</td>
<td class="nump">$ 14,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">22,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">9,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">9,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">9,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">812,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">724,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_LongTermDebtIncludingInterestGross', window );">Total minimum payments</a></td>
<td class="nump">1,587,399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_LongTermDebtInterestGross', window );">Less amount representing interest</a></td>
<td class="num">(48,916,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross balance of long-term debt</a></td>
<td class="nump">1,538,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized debt discount</a></td>
<td class="num">(32,383,000)<span></span>
</td>
<td class="num">(19,262,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Present value of long-term debt</a></td>
<td class="nump">1,506,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion of long-term debt</a></td>
<td class="num">(13,334,000)<span></span>
</td>
<td class="num">(89,419,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion and unamortized debt discount</a></td>
<td class="nump">1,492,766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total Coupon Interest</a></td>
<td class="nump">5,444,000<span></span>
</td>
<td class="nump">3,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">4,867,000<span></span>
</td>
<td class="nump">3,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">10,311,000<span></span>
</td>
<td class="nump">7,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">2024 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">13,483,000<span></span>
</td>
<td class="nump">90,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">1,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying amount</a></td>
<td class="nump">13,334,000<span></span>
</td>
<td class="nump">89,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 32,176,000<span></span>
</td>
<td class="nump">$ 159,678,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized debt discount</a></td>
<td class="num">$ (149,000)<span></span>
</td>
<td class="num">$ (1,517,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">2024 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total Coupon Interest</a></td>
<td class="nump">771,000<span></span>
</td>
<td class="nump">1,906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">357,000<span></span>
</td>
<td class="nump">838,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 1,128,000<span></span>
</td>
<td class="nump">$ 2,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates:</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">2027 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="nump">14,359,000<span></span>
</td>
<td class="nump">17,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying amount</a></td>
<td class="nump">790,641,000<span></span>
</td>
<td class="nump">787,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 784,770,000<span></span>
</td>
<td class="nump">$ 718,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized debt discount</a></td>
<td class="num">$ (14,359,000)<span></span>
</td>
<td class="num">$ (17,745,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">2027 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total Coupon Interest</a></td>
<td class="nump">2,013,000<span></span>
</td>
<td class="nump">1,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">3,386,000<span></span>
</td>
<td class="nump">2,804,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 5,399,000<span></span>
</td>
<td class="nump">$ 4,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates:</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="nump">17,875,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total carrying amount</a></td>
<td class="nump">702,125,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 849,823,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized debt discount</a></td>
<td class="num">$ (17,875,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">2028 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total Coupon Interest</a></td>
<td class="nump">2,660,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">1,124,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 3,784,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates:</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_LongTermDebtIncludingInterestGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt Including Interest, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_LongTermDebtIncludingInterestGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_LongTermDebtInterestGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_LongTermDebtInterestGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271979568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,764,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=halo_CliffVestingFirstAnniversaryMember', window );">Cliff Vesting, First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=halo_MonthlyVestingAfterOneYearMember', window );">Monthly Vesting, after One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_OutstandingAwardsMember', window );">Outstanding awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards', window );">Shares subject to outstanding awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,550,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice', window );">Options, exercise price, percent of share price (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm', window );">Options, outstanding, initial contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, granted weighted average grant date fair value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.22<span></span>
</td>
<td class="nump">$ 18.21<span></span>
</td>
<td class="nump">$ 20.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercised, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,600<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="nump">$ 49,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="nump">$ 66,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Percentage Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=halo_AmendedAndRestated2021StockPlanMember', window );">Amended and Restated 2021 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember', window );">2021 ESPP Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Share purchases, employee payroll deduction percent minimum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Share purchases, employee payroll deduction maximum percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Employee purchase maximum amount</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=halo_CliffVestingFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=halo_CliffVestingFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=halo_MonthlyVestingAfterOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=halo_MonthlyVestingAfterOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_OutstandingAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_OutstandingAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=halo_PercentageVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=halo_PercentageVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=halo_AmendedAndRestated2021StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=halo_AmendedAndRestated2021StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270483392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation -Schedule of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 24,397<span></span>
</td>
<td class="nump">$ 20,820<span></span>
</td>
<td class="nump">$ 17,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10,973<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">8,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSAs, RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">13,424<span></span>
</td>
<td class="nump">10,568<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9,903<span></span>
</td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 14,494<span></span>
</td>
<td class="nump">$ 13,828<span></span>
</td>
<td class="nump">$ 11,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271784576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Unrecognized Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 26,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 26,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 3,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">1 year 10 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">5 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272249840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Options (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract', window );"><strong>Shares Underlying Stock&#160;Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning (in shares) | shares</a></td>
<td class="nump">4,965,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,773,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(789,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Forfeitures and Expirations in Period | shares</a></td>
<td class="num">(581,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending (in shares) | shares</a></td>
<td class="nump">5,368,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, End of period (in shares) | shares</a></td>
<td class="nump">5,368,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable, End of period (in shares) | shares</a></td>
<td class="nump">3,176,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average&#160;Exercise Price&#160;per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning (in usd per share) | $ / shares</a></td>
<td class="nump">$ 20.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">37.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">19.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">33.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending (in usd per share) | $ / shares</a></td>
<td class="nump">24.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Ending weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">24.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract', window );"><strong>Weighted Average Remaining Contractual Term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, End of period</a></td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, End of period</a></td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, End of period</a></td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, End of period | $</a></td>
<td class="nump">$ 171.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, End of period | $</a></td>
<td class="nump">171.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, End of period | $</a></td>
<td class="nump">$ 126.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271786624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Valuation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">39.91%<span></span>
</td>
<td class="nump">41.01%<span></span>
</td>
<td class="nump">47.57%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.81%<span></span>
</td>
<td class="nump">46.45%<span></span>
</td>
<td class="nump">51.82%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267378608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Restricted Stock Units (Details) - RSUs - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning (in shares)</a></td>
<td class="nump">858,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants (in shares)</a></td>
<td class="nump">706,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(320,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(204,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending (in shares)</a></td>
<td class="nump">1,039,381<span></span>
</td>
<td class="nump">858,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Beginning (in usd per share)</a></td>
<td class="nump">$ 29.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">39.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">26.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">35.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Ending (in usd per share)</a></td>
<td class="nump">$ 35.76<span></span>
</td>
<td class="nump">$ 29.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term&#160;(yrs)</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vested in period, fair value</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 11.3<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267419584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Performance Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning (in shares)</a></td>
<td class="nump">69,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants (in shares)</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(53,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending (in shares)</a></td>
<td class="nump">142,844<span></span>
</td>
<td class="nump">69,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Beginning (in usd per share)</a></td>
<td class="nump">$ 40.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">41.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">63.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Ending (in usd per share)</a></td>
<td class="nump">$ 46.01<span></span>
</td>
<td class="nump">$ 40.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning (in shares)</a></td>
<td class="nump">858,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants (in shares)</a></td>
<td class="nump">706,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(320,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(204,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending (in shares)</a></td>
<td class="nump">1,039,381<span></span>
</td>
<td class="nump">858,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Beginning (in usd per share)</a></td>
<td class="nump">$ 29.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">39.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">26.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">35.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Ending (in usd per share)</a></td>
<td class="nump">$ 35.76<span></span>
</td>
<td class="nump">$ 29.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 11.3<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256266372576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised (in shares)</a></td>
<td class="nump">789,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding in shares)</a></td>
<td class="nump">5,368,225<span></span>
</td>
<td class="nump">4,965,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised (in shares)</a></td>
<td class="nump">789,870<span></span>
</td>
<td class="nump">1,179,032<span></span>
</td>
<td class="nump">4,705,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 66.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards, net (in shares)</a></td>
<td class="nump">254,907<span></span>
</td>
<td class="nump">299,958<span></span>
</td>
<td class="nump">571,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of RSUs surrendered to pay for minimum withholding taxes</a></td>
<td class="nump">68,425<span></span>
</td>
<td class="nump">94,795<span></span>
</td>
<td class="nump">142,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options And Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding in shares)</a></td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272006912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share Repurchases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,002,000<span></span>
</td>
<td class="nump">$ 350,058,000<span></span>
</td>
<td class="nump">$ 150,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Total Number of Shares Purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,500,216<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,500,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Weighted Average Price Paid Per Share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 44.44<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 44.44<span></span>
</td>
<td class="nump">$ 43.02<span></span>
</td>
<td class="nump">$ 23.05<span></span>
</td>
<td class="nump">$ 24.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_TreasuryStockAcquiredFeeCostPerShare', window );">Treasury Stock Acquired, Fee Cost Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember', window );">Accelerated Share Repurchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,800,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_TreasuryStockAcquiredFeeCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired, Fee Cost Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_TreasuryStockAcquiredFeeCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256260271248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per share - Basic and Diluted Income Per Common Share Computation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 202,129<span></span>
</td>
<td class="nump">$ 402,710<span></span>
</td>
<td class="nump">$ 129,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average stock outstanding - basic (USD per share)</a></td>
<td class="nump">136,844<span></span>
</td>
<td class="nump">140,646<span></span>
</td>
<td class="nump">136,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average stock outstanding - diluted (USD per share)</a></td>
<td class="nump">140,608<span></span>
</td>
<td class="nump">146,796<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic (USD per share)</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted (USD per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">2,265<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256270157504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per share - Anti-dilutive Securities (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256266361888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=halo_OfficeAndResearchFacilityMember', window );">Office and Research Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_OperatingLeasesAreaLeased', window );">Operating Leases, Area Leased | ft&#178;</a></td>
<td class="nump">73,238<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OperatingLeasesAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Area Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OperatingLeasesAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=halo_OfficeAndResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=halo_OfficeAndResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256271105792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Annual Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">6,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">17,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">47,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(12,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 34,788<span></span>
</td>
<td class="nump">$ 2,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267824864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Net - Income (Loss) By Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 248,918<span></span>
</td>
<td class="nump">$ 248,071<span></span>
</td>
<td class="nump">$ 130,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">$ 248,918<span></span>
</td>
<td class="nump">$ 248,518<span></span>
</td>
<td class="nump">$ 129,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256272062640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,887<span></span>
</td>
<td class="nump">$ 42,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development and orphan drug credits</a></td>
<td class="nump">96,133<span></span>
</td>
<td class="nump">109,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">6,353<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxAssetsLeaseLiabilities', window );">ASC 842 lease liability</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">10,168<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxAssetTransactionRelatedExpense', window );">Transaction related expense</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related reserves</a></td>
<td class="nump">18,395<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxAssetsInterestExpenseLimitation', window );">Interest expense limitation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">3,054<span></span>
</td>
<td class="nump">3,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">172,661<span></span>
</td>
<td class="nump">157,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">171,954<span></span>
</td>
<td class="nump">157,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization', window );">Non-deductible book amortization</a></td>
<td class="num">(115,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(2,559)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxLiabilitiesConvertibleNote', window );">Convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxLiabilitiesRightofUseAsset', window );">ASC 842 right of use asset</a></td>
<td class="num">(9,061)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, net</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(127,528)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 44,426<span></span>
</td>
<td class="nump">$ 155,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxAssetTransactionRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Transaction Related Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxAssetTransactionRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxAssetsInterestExpenseLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Expense Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxAssetsInterestExpenseLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxLiabilitiesConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Convertible Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxLiabilitiesConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Non-deductible Book Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxLiabilitiesRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxLiabilitiesRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256260115776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="nump">$ 707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory', window );">Deferred tax liability, increase, from acquisition of intangibles and inventory</a></td>
<td class="nump">119,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax Bbenefits</a></td>
<td class="nump">19,482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,692,000<span></span>
</td>
<td class="nump">$ 19,167,000<span></span>
</td>
<td class="nump">$ 21,483,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed foreign earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss Ccarryforwards</a></td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">30,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward | Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | General Business Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss Ccarryforwards</a></td>
<td class="nump">237,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Other States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss Ccarryforwards</a></td>
<td class="nump">63,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward | Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward | MINNESOTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Increase, Acquisition, Intangibles and Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=halo_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=halo_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256273811648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current - federal</a></td>
<td class="nump">$ 6,157<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current - state</a></td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred - federal</a></td>
<td class="nump">44,757<span></span>
</td>
<td class="num">(117,925)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred - state</a></td>
<td class="num">(6,650)<span></span>
</td>
<td class="num">(37,509)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 46,789<span></span>
</td>
<td class="num">$ (154,192)<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267756448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense (benefit) at 21%</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (benefit), net of federal income tax impact</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="num">(1.59%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">(Decrease) increase in valuation allowance</a></td>
<td class="num">(0.39%)<span></span>
</td>
<td class="num">(84.92%)<span></span>
</td>
<td class="nump">34.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent', window );">Worthless stock deduction of international subsidiary</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(52.07%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income subject to tax at other than federal statutory rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(0.66%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(1.89%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent', window );">Executive compensation limitation</a></td>
<td class="nump">2.61%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses and other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.54%<span></span>
</td>
<td class="num">(1.64%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent', window );">Foreign-derived intangible income</a></td>
<td class="num">(5.06%)<span></span>
</td>
<td class="num">(1.18%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent', window );">Transaction costs</a></td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">18.80%<span></span>
</td>
<td class="num">(62.05%)<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Limitation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective IncomeTax Rate Reconciliation Worthless Stock In Subsidiary, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256267802336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, beginning of period</a></td>
<td class="nump">$ 17,692<span></span>
</td>
<td class="nump">$ 19,167<span></span>
</td>
<td class="nump">$ 21,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases in tax positions for prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases in tax positions for prior years and lapse in statue of limitations</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(2,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Increases in tax positions related to business acquisition</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases in tax positions for current year</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, end of period</a></td>
<td class="nump">$ 19,482<span></span>
</td>
<td class="nump">$ 17,692<span></span>
</td>
<td class="nump">$ 19,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256277161440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256273594448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Accounts receivable allowance, beginning balance</a></td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquired</a></td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">5,946<span></span>
</td>
<td class="nump">8,131<span></span>
</td>
<td class="nump">13,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(6,096)<span></span>
</td>
<td class="num">(7,994)<span></span>
</td>
<td class="num">(13,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Accounts receivable allowance, ending balance</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="nump">$ 1,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>halo-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:halo="http://www.halozyme.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="halo-20221231.xsd" xlink:type="simple"/>
    <context id="i1d00237089024881bd1f90f6a648378f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75e409ee707b430fa8ecc2238eb488b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia117119a079043f09f5bfce4b51e42fe_I20230214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2023-02-14</instant>
        </period>
    </context>
    <context id="if0faa2d5cad4416b986007776707121f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i528d79391acd4adabf0eb110ab4c0d71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cddd407fea442d591705c36d0c6b738_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e37d51271604aea8b4052a4f33ab467_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i658b6d0704704e0b8064188c8e0a801d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9afa1af705a047488d2ed7629419da96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8be6b96e36e440009875fac05281e167_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7db3fb4810984f62a4337b6b494f3743_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9749fc8e01b42f3bc4d2a62a57108c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99205eb539fe44e688694e9c32636419_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c116ced97cc4fe5b21319832ce43f61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85f04615dfbd45e198c13ee612a4296b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie53b6dc71630413f9a2aeceedcc0e052_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ee6817d503e4a18b7eb816904b0aebe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa017f03308949e29662213e518d9cb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaed2278944d84aca8963978003d797f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i185f758e56d34e259efb04a87b79e6fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cb480a816cd4772ba95677abf4d9f15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c457ab9e1fd454291cd030cc56319d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5ffb5ed70da4329a8be32a8e3f59679_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a3a0d1278564dac88cdb6a4890dbeb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bfa39e1da314354bf34589788f5d3f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47eab477396949258aac7c749bf0936c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02ca925601544b0d9818b83003b6a173_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaaa88a5eb896493187880ac27c0e4dae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5286105d8e646a890ecc12d4b237245_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6665e5678736405d8d250f39ff73c605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60ddf1b282954e588fac184cee2096f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if03f2e05bd964f27b59d8e973985f611_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d0f4252003945d1b7cf619e91241e33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60c9f6a3aea6447bb885f06a67eeffbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia03e264b59b746d98f5b7e2c7a6418fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0fb48210945840e8bf77e3e377c72c8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8a632685f724b3dbe494cea07cd7170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:RocheandBaxaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d74a6abc13a425a8418a3669d66efc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:RocheandBaxaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f9c44c518d2425ea72beec31a2cfebc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0043cfac8af6431f80518ace0a62f8c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib244486e83334e049f9f415b79e745f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c942b53e0e34ec598f5d722217d08af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d4a9fcdff314021b35297f8bb703b1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b260f831be1449294bba3c541338639_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea80ef23e3af4bc4be5f2356bb7d3fd5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a2b61270d2f40c6863815f87fb3703c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia36466ed48de4b458fea7a53fde94578_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01dfe5b9a34240f480cb63ff4e1b02c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4698a330a0b744d6b6d168b99f00f6e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idce4eddf7dff4d1f9f2c4573eb5f3534_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">halo:PartnerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64016d8d05444060803595ff46f871b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61fb9df557854a4aadba56811dda6704_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac11f44bfb95456296f38ba52920a3c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7de7cf8a78e4bf89bff3256afe84223_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica047ad710284104a38c9d206a018d0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieae824ce4a274eccaa7296d3a60e81c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if724606c27844c38bcc67de0fd811b33_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2db9f9565034499aa800a640e58be214_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i161c82ffd29845e4a51dc871f1f5be81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d2c71a5430c427b9f25c98b1682de64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79b127d42f404009be3f5197ca82946e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe33da92d9bb4158bc8a5df544e374a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id97526871a974553b87645589cdb1f48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie834c01de6184c509a71caad06bb9266_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbe8666679dc4bae993f8d56771a1678_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i514044e6ba7547189405fbf239f8caea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16b5b3910fab4729b3312f22278dd16b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibad21366e94841b6b92a3ed6b8d2c8c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:ForeignOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27889e318d8545478c0d04d0e999f6a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb93b74a42f341839f733106bc085ac3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f6d5252a77b41629cc0e5e24355f1dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfd51566fb48417294740b3e09f08d33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2e016f17e20404aa3c14094fdf86c28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ide8e0bb6ebfa47f385eb8b8a3556d019_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i5b5cf73d12df4c3bbe1f1cedfe244210_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i2d619669e18b442786311ba013af06b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if78cce61194d43d69a49bc5e102059f3_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardsVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="id0189c904b3b4a0381ae6dda4687bd18_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4843830e52a4d92a52b5a09eac1bca4_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c84478a64df453893c7636f8f759caa_D20220524-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0ac13fbf17f4f2e89a956199a4d633c_D20220524-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id94bd204eed14a56b841b0ecdc83ef00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46732f52d6ca44279534ffa554f17160_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc2cc80566cd460e9bc994220806e7aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5224a272d9e145089365401ed07c3c98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35353e8145c94fd192b2662112671742_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cab7782001e401d90fa7549f89275f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26f722a27dd74b5a9adc18b420c72150_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e4382062e1f4fcfa9e54b30b7e489a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i043b1eced14f4b38ba17b9e0e8ab15b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1deac62ace9c4a888e48f6d9be99dc47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0bddbb8047a491eb63c197e05eb5ca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43b8615d6e094174ae8446257115cc1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77bcd41a7e814a89918feebb95c129d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib382d0872eaf4b9bbec1ce9d6cceaaab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb83fc6f4b8a45c282238332c7a95841_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5560b65f4f134a1a914172192531d861_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00d7d10d24c84281aed5c4277d167461_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia7c4df731a4f4a4f8fec1bae60a10484_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i295651e13dfb4e4cb45f942c4b96e6f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i615de6d5889a4f7d9b1e1d3352937654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab7b7b97519c44cdb7226898a6b54701_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2eb9ad4bee4649d78ef3bbf1a1aea014_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id61a0f73d0f4425b9a935315a9005c6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e9ffaaa4bdf4e638aa15b0e3a30d7a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c7ded3a1a584de3b69284715edd8be3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee9996ff38f74a49bde5979244e15762_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54544bbec51b460cbeee6e64fdecbc48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i950980fb07fe4ca48b48af65c8b224d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3553503311549e6857ea8d049b691a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib53f54adb1e5481b8288c131402733b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d1c66ed8e4d4b888d17e06a9f8a1c64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23f0a156c29745f4a1204a53f9dce5d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i877577fc197a449885cec3a196905eba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadbcfda7fe5a4065a2147788d3d2fc7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ee689853b26446da4160f945de64c92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f39c15bffce464ca04a0703850470a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78115efa8e2a4a209a2d9ea8a508c0a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib225da12484b414eaf886beb6791a1b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8074c437f714421b84dc5a2ed6b754ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7988ef80a8a4481095a9cd1737928a5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i712a0cd86d3144a297233b33d9781be8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i732cceb6359a4dd8865fb5bfa8aeddc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie14a2f85de0e485aa57a080d39183883_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e565d32284c4425b05dd65037f38a6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f73c68191284413968a1e7705daeae2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib07f947ffcad43d1a6fdf23e3ea0bfce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9eaf51e78af04c08b9c64c703cd9221e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8112a093b0c7415eac739e594b629a96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4880129e17ee45a6a5ecb048862fed65_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb52ba56d5ce40bbbf9715e825b909b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i597a7d3db45a491e997fe35aa9195b3c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd9e40e7d2f244e7b9f66aabd6640852_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75bae0cb0a8a47fb8fcca30b77f6d60e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c6fd44e583748d3937db0246f9e5e4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f2f770cb08e46b1a34f5576b2a08663_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0700499fc900499a90faac950d6d4b98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i023f24dd6ed643a38263bb9cabdf7718_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b10c333e5154705818149064609c145_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1416bdf7345c4bbabccb8d19a9cf5196_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41fcd05c589b426dac58da8abe28d615_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice50c8c082a44a54a348b09d6dad8248_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf4ba887d67549afa576d9763e0d4017_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if85e98d198d2439aa49f4b9aba5ac485_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i616018ae8ce340d4a55a54fe3fc0c272_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8aaaf000b7794cc1afa3317b68317e08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ResearchandDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b67aab8964449fb89bd5540b396933d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:A2017RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a90a57424684701b78e04f25324c4d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69070eb1e6084fa48dccbf68b4d6f8d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OtherCollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cbad069681845ec855aab295e5acbce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4592615a3c74e559071621a0a01a228_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b33c1eddff241b7b992cad79cd90321_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5103cb702ff64758983fc79a04fae1aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie21db3970f77426c9be0b7002d0bc269_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i358cffcf78784467b140596c17157c72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96c68a9508eb404082e43ef1e4a75c24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia230ccd2446e49578990a8e709b8b5cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i026e429b3e77423ca0b1a2eddcd26847_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba6d68430cff43a0ae03fd967d945fa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1892e4c1066a4e5ca9ecbf598525a0af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida924054054447ada0707db648939f23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61f2f3a242d74ae0839b985994afacfe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i092e2002b6d245c29ce295a98666505c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1746187612e2471bb184a56028b058f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i653f9955b2014441a9bd9524de9a0b9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic24180acc66b4c2788f9aa46657e38d0_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ifb78064361704a2b8da472621b690b46_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="ia37a3aaaa88549e188282c778e953fba_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ie370140c043940ccaecdf292abc511eb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2f827aac2a7f4d6ba5ee22c890a4ad04_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iade1f569835e40b9a1f4b38283707214_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ifb55488282dd4b958067934ecba25817_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1520c9eee1f745169c91ccff5d6b28d5_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea1c2507713c4df99577b5f739d6ca30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i331533d9ad814e1893350fa816c1bff2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55fe4bb4bcec457485790bf0cbd54177_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2dda495c5d645e186db199b0df8597d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bc071eb48f04102a50c800a5c43ac33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3193ab8c85db49f3a4a9823da38d8dc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3c657f7c7aa4b2cb4c74f3daa87f921_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79bfd4954a6f40fa97c846c2ec979f5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6640df7e0ae2463c8b79ef848a1764c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f407711aaf64227803041f2eee55522_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fda7522287d46afb55413abf54c3425_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide89d55cf7d0475f89869db8cc5fdbe8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e4625c024584b4d8d8743379dc7d92c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i703c64067ee4482fa9fb83302bac63af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0b58f9782c2498893a72173de677682_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dbbe44f2ba045c184c92f9829993116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie09d99918fc743c484565395961829c3_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i4742da9fb4d0482b803c94968d340b74_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i59247bc7b3264b0e86653efe7c50ef9a_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i8ea8d2ab91694fe48abae65438654fbd_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i689f2de5af2642238ab9ec7684b8feaa_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="if8462f2e104247cfb928c19b4f5a2e9b_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i8aaeded4049949cc8d23c4b49d1bfbee_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThirdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i6503f2b3881e494aad8c2e128e68f23e_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i65af036188ba41eb9fe14b30fb6f1f23_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="iad72bf7f121e428cab4063032f673cf8_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i8764e1163d9d4b42a29fc48e21d37b26_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="if262c47c59524111aa76f3840681c866_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i2000d717e3b8448690bbc1088fd76ea0_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i26f1c68d52374db68ae5953d4cd57bf9_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="idbde07f8da7e4c42b763a251cf0afea0_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="id6dbdd6695e246f4ad6f672de1aadaa2_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i8c06e4fe9e8a43a382f8063e6334c895_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i492b1e853ac0430faf0bcfe39c9d177f_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i3d39948aab61416789923cae1ff3c69e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6347633a08434f869706fa2b2f074866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:AmendedAndRestated2021StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01989d60674a45c6ab5875f437acf6a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:OutstandingAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7d039d4e0614847a563288bd41158dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdeb7c5afc384d8ba911a737f1419fb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc18d66d2f8f44a4b0473fbc86ab01c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id935d90decb947c3a71099b77bbdac41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec84c34382b44c1e86f9926be1ce3983_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdcc06b9a17743358ff945dd4bed0581_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id969cad6a23d405695239ec30d807f30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica423dbca19f432daae40901ef390ee8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7bcc82bb2f64c658849f7c71cab48e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95e361b0a7e3429099a5544603eb7191_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69087abdb2354c6392a5a633290514cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8de33c335a241468926b3ab8403600b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d4a09f254e64faa9bec7e186cb4016f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae176b036399446d884c8a71d329328e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i808656e5b1f84f9e8f223c40572ea0cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd57b3450df84c0c9a4020d97056c443_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23d72a210e204519967ca7ede33dc391_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i99cb9a7240414e81abe47db83af3899f_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i0f0d2c8d2d884311ac502e7ea910dc91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i744eaed75e9d41b98136429882bab1e4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf745bbf6d154e1899189c7bcad6fc6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i949d937237ca46f89a339135fe399f09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibec91f8bf02b4770a0909a40dcb95e52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81f8ea5c34ea42f0b18170ff0ca21581_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id26cfa0230994968ac1d99e765d751b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d3ceb791c29431382f44988704a8808_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9fa634e741e4e6c976c685332948c76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb2a521823a94cd4a32245c29e206a17_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:CliffVestingFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3bbc2ed39e364802b20b15e694472966_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:MonthlyVestingAfterOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7acdf8fbc6a64af7bd0d8bed1ab7c3df_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">halo:PercentageVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f301c76e72f45fc8bd78b64ae95e300_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i813698ed62b94b59be1b62617f5dd7cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bca0917c34b4c89a31b6213fad20334_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec2a39ae6cf344228e691d7fec6bd39c_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62f9407bb50f40638225cd8fe3f7988f_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7953193d06b84f52adffe498a800882d_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c1972749fa94302ad6f4164caadc9fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9826afc8d63f4d5ca646159f99d34e57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0a9b9adaae647398fdba511e9ef1777_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9b9ab30830f4339a4ee873a5fc79362_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28fdc2cdaf2a4fa09d8fe1a529c0e500_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie346c01929994c85883bfeb74a94e8e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f6362e86b7647058ad2270b025883b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">halo:OfficeAndResearchFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia95727628f324bdb89c986083075e8bf_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">halo:OfficeAndResearchFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01d046463d2847239062ac90d2a20ea2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i605fb0614d614a189301d7b5aade275c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id17b587fd04b4b8eb4297c5113c4d2f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">halo:OtherStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i182a0e0c521c4a8e849c93a64dc49a7c_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i887f9a04206a45138521ae3e2d97845c_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="id7aa8bd02d7448e5943ae4e632674862_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25d54b5d7bf64043bb0258fe6d02efc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37c7ed8f55754813819fbae73df620ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if46db7bf283d452193c503c22cecc2a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="collaborator">
        <measure>halo:collaborator</measure>
    </unit>
    <unit id="product">
        <measure>halo:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>halo:segment</measure>
    </unit>
    <unit id="security">
        <measure>halo:security</measure>
    </unit>
    <unit id="trading_day">
        <measure>halo:trading_day</measure>
    </unit>
    <unit id="businessday">
        <measure>halo:businessDay</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8xLTEtMS0xLTc0Mzkw_28c6115e-6ed0-41bd-a18f-ad76eb678d6b">0001159036</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8yLTEtMS0xLTc0Mzkw_e535d3b9-c1a5-4d4b-af3a-2eb27b614432">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF8zLTEtMS0xLTc0Mzkw_947832ce-ddd3-444f-8fce-4c92c62fa4b7">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl80L2ZyYWc6OTU2MDgwNmQ3M2U4NDVmZGFkYjBiNjVmNGRmZDQzODkvdGFibGU6ZTM4N2ZjOTJkOGM3NDhkMmE1NDFlOWJhMDgxZmRjOWQvdGFibGVyYW5nZTplMzg3ZmM5MmQ4Yzc0OGQyYTU0MWU5YmEwODFmZGM5ZF80LTEtMS0xLTc0Mzkw_41215f0d-42ab-4a22-8f7d-e3750030384c">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8">http://www.halozyme.com/20221231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d">http://www.halozyme.com/20221231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk1OQ_f58b5d2c-2f99-454c-b819-957e5d1ad0df">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibb2a521823a94cd4a32245c29e206a17_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzAtMS0xLTEtNzQzOTA_616895c8-a73a-4bef-a0dd-c72d2fa4ce88"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3bbc2ed39e364802b20b15e694472966_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzEtMS0xLTEtNzQzOTA_63d70a6f-18ac-44f9-98b6-e53f429e3830"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7acdf8fbc6a64af7bd0d8bed1ab7c3df_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDUvZnJhZzo2NDZjOWFlYTU2ZTc0YTMwYjQ0N2ViZTk0ODk1MGRhNi90YWJsZTpiNGJjODg0ZDE2MmI0MzQ2YmI4M2NmN2M3MDU0YjBkOC90YWJsZXJhbmdlOmI0YmM4ODRkMTYyYjQzNDZiYjgzY2Y3YzcwNTRiMGQ4XzItMS0xLTEtNzQzOTA_124d781a-7042-4ef1-90ae-08fef44cd78a"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzgzNg_6d31b2bd-233b-4e57-aa4d-35605e28c115">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzOTc_69d1271f-c244-47f4-82d2-6cf455ace36c">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <dei:DocumentType
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcz_3039f082-efea-448c-8c46-e62ba4c15d89">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6ZTgxNTBmNjAxZGVhNGJjMGEwZmIyMTA3NDY4YjJiZGEvdGFibGVyYW5nZTplODE1MGY2MDFkZWE0YmMwYTBmYjIxMDc0NjhiMmJkYV8wLTAtMS0xLTc0Mzkw_7f39f248-0a13-4020-8516-c0824bee77fc">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8xMTY_7eaed370-9f1d-468e-8c96-9ba467b5eb21">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8xMTY_c3892bcb-f581-454b-ae35-8ab9b084f3d7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NWU1MjBjNWY3MGJhNDQ1NTk3YTE5N2JmNmIxMjJjZDgvdGFibGVyYW5nZTo1ZTUyMGM1ZjcwYmE0NDU1OTdhMTk3YmY2YjEyMmNkOF8wLTAtMS0xLTc0Mzkw_78f611b7-b20b-4cdf-a17f-7a0b005f4600">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY4_5ace5fa1-fd3d-4f88-abfc-76ad0de4058f">001-32335</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY5_1c19f32a-0569-49e1-90c5-1c247a6f0d4c">HALOZYME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8wLTAtMS0xLTc0Mzkw_a9f6ecf9-937f-4539-9b4b-6e1111276700">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8wLTItMS0xLTc0Mzkw_12644291-c215-4ced-85a2-ff213d278c6e">88-0488686</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8zLTAtMS0xLTc0Mzkw_5b05c6e6-2593-4574-9e4f-b7ceaba8af1d">12390 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl8zLTItMS0xLTc0Mzkw_8e8c48d9-662f-45ac-bd20-bc390819aea4">92130</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl80LTAtMS0xLTc0Mzkw_868f0ba3-14c8-4ff5-a43d-8091cc114ecf">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6NzIwZjBkNjE2Y2IxNDM2Zjk0NzM5NDVlNTczODdiMzYvdGFibGVyYW5nZTo3MjBmMGQ2MTZjYjE0MzZmOTQ3Mzk0NWU1NzM4N2IzNl81LTAtMS0xLTc0Mzkw_175bd6bb-a43f-4677-bcd6-bfcefb1011bc">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcw_847e41bd-d898-4fa2-9b66-96d0e93d12cb">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc0_4b1558bc-efb0-4a63-85af-afea7f87cae0">794-8889</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTAtMS0xLTc0Mzkw_b05df7d9-61e0-4add-b522-fcdf6ed07e1e">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTEtMS0xLTc0Mzkw_268ca402-2cc8-4eb2-bf0f-5646053e7653">HALO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6OTY3Y2Y4Y2Y2YmRkNDUzMzhhZjdiNjNkMTNkMWY3ZjAvdGFibGVyYW5nZTo5NjdjZjhjZjZiZGQ0NTMzOGFmN2I2M2QxM2QxZjdmMF8xLTItMS0xLTc0Mzkw_06bb8112-91f9-4bbb-9e88-e503c37a7481">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc1_bd9c31a9-460a-4527-a216-a77d4a755572">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcx_2e005afd-4bbb-403a-a8c8-549146d74fa8">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzcy_0e29ec34-4273-4ddb-8649-bab6098d44d6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzc2_477c2d3c-256d-4fe1-80aa-c4ddf9422d2d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8wLTAtMS0xLTc0Mzkw_0ef607d1-d028-423d-87cb-11b074ff40bf">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8xLTQtMS0xLTc0Mzkw_4d89ee9b-03cd-43ad-a893-05bb8ed9d01c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGFibGU6MGRmNjZjMDQ3MDdmNDA3ZWEzN2EzYzY1YzUxNDMwYTAvdGFibGVyYW5nZTowZGY2NmMwNDcwN2Y0MDdlYTM3YTNjNjVjNTE0MzBhMF8xLTUtMS0xLTc0Mzkw_525bea12-5a7b-4876-9293-c9cf3a2f3e86">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY1_d41450ca-c7c6-4d6e-a18b-20e34c7eeab3">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMzY2_659a0e1f-0c27-4d04-9469-e1d0490d1471">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i75e409ee707b430fa8ecc2238eb488b2_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8yNDg2_981a5fd0-935b-46e4-94d2-239462a4724b"
      unitRef="usd">5100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia117119a079043f09f5bfce4b51e42fe_I20230214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xL2ZyYWc6Y2I0Njk2YTUwM2VmNGRkZmFmMTVhMzkwOWRiZDg5MzYvdGV4dHJlZ2lvbjpjYjQ2OTZhNTAzZWY0ZGRmYWYxNWEzOTA5ZGJkODkzNl8zMDA5_24d4463a-57f1-45d9-8293-0ca694e15c65"
      unitRef="shares">135366862</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl84Mi9mcmFnOmFmNTZkOTVkNjU0NjQ3NGFiZDhiMzg2M2Q4MzgxNzE5L3RhYmxlOjA1MjZlNWNiODJjMzRkODQ4OWFkNDZiZGQ3MGZiOGQ2L3RhYmxlcmFuZ2U6MDUyNmU1Y2I4MmMzNGQ4NDg5YWQ0NmJkZDcwZmI4ZDZfMS0wLTEtMS03NDM5MC90ZXh0cmVnaW9uOjQ3NDc5NDY5YTEwZDQxMWI5MzdhOTRkZDE4OTA1YjRmXzYz_06dd525a-6e80-4e3c-86b9-0c00a091f65e">42</dei:AuditorFirmId>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0faa2d5cad4416b986007776707121f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RhYmxlOjk2MzJjNDgwZGI1NTQwODhiOTYxYTFhNjI3ZGMxYTUyL3RhYmxlcmFuZ2U6OTYzMmM0ODBkYjU1NDA4OGI5NjFhMWE2MjdkYzFhNTJfMi0yLTEtMS03NDM5MC90ZXh0cmVnaW9uOmViMzFlOTI2NTE1ZDRjZjJiNWZiZDE1OGExZTc2MmQ2XzM0OA_a35f0aea-824f-4c7d-b6db-97af468f7940"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:AuditorName
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RleHRyZWdpb246ZTg2MTExNjA4MjAyNGY3MGFkMmY4ZWM3NzMxN2VhNzJfMzgyOA_c3c8cc93-8cb7-4be3-b702-76746396deed">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85MS9mcmFnOmU4NjExMTYwODIwMjRmNzBhZDJmOGVjNzczMTdlYTcyL3RleHRyZWdpb246ZTg2MTExNjA4MjAyNGY3MGFkMmY4ZWM3NzMxN2VhNzJfMzgzMA_4e09691a-bde9-4e6c-ac38-8a993a013daa">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMy0yLTEtMS03NDM5MA_181dbfb6-a9e9-44cb-bbcd-cd44c9159966"
      unitRef="usd">234195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMy00LTEtMS03NDM5MA_c36bc1bb-7cd2-4769-8aa4-78a5efef11ba"
      unitRef="usd">118719000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNC0yLTEtMS03NDM5MA_183ed636-f38a-4e91-b2e5-02d01081e7f6"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNC00LTEtMS03NDM5MA_46577cd9-a795-499f-be75-44ded45e5a4e"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNS0yLTEtMS03NDM5MA_11f345d9-4422-4abb-8451-648233675f11"
      unitRef="usd">231072000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNS00LTEtMS03NDM5MA_6a3474db-b864-48e9-bc65-af605eaa6e10"
      unitRef="usd">90975000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNi0yLTEtMS03NDM5MA_4d18f8f1-f73f-4a7e-8922-a0f39b1d603f"
      unitRef="usd">100123000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNi00LTEtMS03NDM5MA_962fcf97-b485-4cb2-a640-79eb1751bb55"
      unitRef="usd">53908000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNy0yLTEtMS03NDM5MA_ddac6b8f-0baa-420c-817a-3d5d79fc9e19"
      unitRef="usd">45024000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfNy00LTEtMS03NDM5MA_99bb485b-9013-4ea4-bc91-e941411ea3d3"
      unitRef="usd">40482000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOC0yLTEtMS03NDM5MA_533a81e3-6228-47af-9570-2fee5d78b5cf"
      unitRef="usd">739013000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOC00LTEtMS03NDM5MA_08fe6d72-3da3-4115-b560-8ee3dd6cec45"
      unitRef="usd">926287000</us-gaap:AssetsCurrent>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOS0yLTEtMS03NDM5MA_aaab9fb0-9942-4793-a70e-6072dd13c39e"
      unitRef="usd">75570000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfOS00LTEtMS03NDM5MA_109cf565-a0ca-4f26-99ce-4ba2474d6649"
      unitRef="usd">8794000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTAtMi0xLTEtNzQzOTA_33b942e6-b8c9-40ab-a167-dc7d69a85e0b"
      unitRef="usd">26301000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTAtNC0xLTEtNzQzOTA_26dfbeaa-ea8b-4324-8bac-3f5b79b8c0d2"
      unitRef="usd">13414000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtMi0xLTEtNzY4MzY_8ad3e54a-03cb-4973-942d-398445d87ca7"
      unitRef="usd">409049000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtNC0xLTEtNzY4NDA_74fbe102-f74a-45ed-b66a-796756e15d24"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItMi0xLTEtNzY4NDQ_dd85f5d2-f186-4591-b4c4-f3b079f86a67"
      unitRef="usd">546652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItNC0xLTEtNzY4NDg_c15d0ed4-34b3-4601-b977-3abe52414903"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtMi0xLTEtNzQzOTA_d1a39fad-32f2-4183-abb8-c8e8806ae8ce"
      unitRef="usd">44426000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTEtNC0xLTEtNzQzOTA_23bacede-bf7f-4eac-ac1f-944360293da6"
      unitRef="usd">155434000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItMi0xLTEtNzQzOTA_5aab020c-86a3-4097-9101-e37c073dd56a"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTItNC0xLTEtNzQzOTA_de845456-e1ca-4817-9a89-6ea58e850bd1"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTMtMi0xLTEtNzQzOTA_defaa3fa-4737-4150-8c4c-cd8a3a5ad02f"
      unitRef="usd">1841511000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTMtNC0xLTEtNzQzOTA_fb22da81-1189-4d65-b093-edef36a2fa9d"
      unitRef="usd">1104429000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTctMi0xLTEtNzQzOTA_533b12a0-5f11-463d-8d11-51c0d4e87cd8"
      unitRef="usd">17693000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTctNC0xLTEtNzQzOTA_e77c80d9-2dbb-4a3e-84f5-3e0eab4f647e"
      unitRef="usd">1541000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTgtMi0xLTEtNzQzOTA_340d532b-9679-4727-a433-8341dcb97734"
      unitRef="usd">96516000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTgtNC0xLTEtNzQzOTA_e111b956-411b-45aa-85f0-d10be76aba12"
      unitRef="usd">24441000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTktMi0xLTEtNzQzOTA_10587122-0fac-49e8-bac9-324ef3b6514e"
      unitRef="usd">3246000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMTktNC0xLTEtNzQzOTA_7b6237ee-6701-4e2a-8a18-ea45aed96dc6"
      unitRef="usd">1746000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjAtMi0xLTEtNzQzOTA_60fcd98e-fb6f-4982-a31c-eb9cbc936eda"
      unitRef="usd">13334000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjAtNC0xLTEtNzQzOTA_88f30245-f625-4447-88a6-6568321c0c3b"
      unitRef="usd">89419000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjEtMi0xLTEtNzQzOTA_cb76e6a0-f890-4ead-9b8b-234fda5b49be"
      unitRef="usd">130789000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjEtNC0xLTEtNzQzOTA_333b72e9-ddf4-4514-85ff-fec77f12a29e"
      unitRef="usd">117147000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjItMi0xLTEtNzQzOTA_9654e333-7bc9-49f1-b578-93e8280f76d6"
      unitRef="usd">2253000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjItNC0xLTEtNzQzOTA_2a4b4aa2-e753-4b27-bfeb-bb8891658877"
      unitRef="usd">2530000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjMtMi0xLTEtNzQzOTA_8736d116-f1ad-49da-b896-dfbe52a7896b"
      unitRef="usd">1492766000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjMtNC0xLTEtNzQzOTA_b09bffae-4b98-4b40-b4ec-f40c14766b8c"
      unitRef="usd">787255000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjQtMi0xLTEtNzQzOTA_fdb9d7e5-80ce-40f4-92e2-8c68b23f054d"
      unitRef="usd">30433000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjQtNC0xLTEtNzQzOTA_7b89acf0-f265-4515-8ee0-4f0c92e58959"
      unitRef="usd">544000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMi0xLTEtODY5MDk_3cae766c-f545-4b36-a6a7-68de5b53dfeb"
      unitRef="usd">15472000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctNC0xLTEtODY5MTQ_63f56b2c-e5a4-4755-acf9-923a09030f62"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjUtMi0xLTEtNzQzOTA_9bf93c2b-350b-43d3-8eab-7c615f2f0a5d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjUtNC0xLTEtNzQzOTA_726a3816-4054-4c86-b22d-c049ef06f390"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8yMg_307f3c94-3982-485c-b40a-9c6166eec83f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8yMg_c497ac7d-82a3-4a77-a97e-40ce3a28df96"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8zNg_94cbf721-c694-4bfe-be28-03a875c5f877"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF8zNg_c53025d5-a24a-46f3-b25b-fbf76a1d1323"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_31124b5e-5321-4ff7-af46-860973f6dcba"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_701f6031-ffa8-4816-8022-2672f2e4686e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_ab756c43-2b9f-4161-9e23-bd3614b42d0a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmOWRiZWM3NTAyYTc0NDY1YmUwMGFkNDA2OTcyYjc2OF81OA_bf6b48b9-e3db-4ff1-979f-2caadb5f2bdf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctMi0xLTEtNzQzOTA_0a90b709-ab05-4e48-84d1-a8ee87fbf25f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjctNC0xLTEtNzQzOTA_562b5ea1-0dbb-4fcc-8523-c77b669757cf"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8xOQ_996531a4-7e04-42d5-b187-ddc159b979ca"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8xOQ_ef4b20fc-eeaa-4e7f-9fee-1c8057311ff9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8zMw_384bce4e-d729-4ed2-90d7-3ef9a38b4728"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV8zMw_7e861bc9-0006-4218-a169-ad5289014493"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV81NQ_56c453fe-a82b-4f02-9d4f-d26d35ad1281"
      unitRef="shares">135154000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV81NQ_eb3ce5ce-d3f3-4229-bba9-13096dab3f8d"
      unitRef="shares">135154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV82Nw_7cd60df6-6a14-4652-a7e8-c9f4b808dd3c"
      unitRef="shares">137498000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiNGIzZDc2OGU3NWI0MjNhYWExY2ZjODRkOTlmZDFmNV82Nw_9ecbcd2b-7757-4bca-8959-6e255d65263b"
      unitRef="shares">137498000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtMi0xLTEtNzQzOTA_edc52c73-4219-4d38-9b6e-f05ccd43e7ae"
      unitRef="usd">135000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjgtNC0xLTEtNzQzOTA_48b58c8b-0246-436d-b5df-7b2da8cabfcd"
      unitRef="usd">138000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjktMi0xLTEtNzQzOTA_9d9dab43-a56d-4a46-9647-ca9761d97e11"
      unitRef="usd">27368000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMjktNC0xLTEtNzQzOTA_e61ae07b-c026-4131-8fef-259bec2c3665"
      unitRef="usd">256347000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzAtMi0xLTEtNzQzOTA_b4ea27d6-27b9-485e-8826-b60a231f111c"
      unitRef="usd">-922000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzAtNC0xLTEtNzQzOTA_8383f539-9071-4b7f-879a-bc8206fd861f"
      unitRef="usd">-620000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzEtMi0xLTEtNzQzOTA_30be9517-d122-4958-b772-850dfc262ca7"
      unitRef="usd">143217000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzEtNC0xLTEtNzQzOTA_eef3c2e9-c0cf-4d63-a207-5da9fecc602a"
      unitRef="usd">-58912000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzItMi0xLTEtNzQzOTA_8568c4bd-5052-4056-8234-93a59f6fdbfa"
      unitRef="usd">169798000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzItNC0xLTEtNzQzOTA_2e28b2b7-a19d-469d-a1c1-95ec94300ca7"
      unitRef="usd">196953000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzMtMi0xLTEtNzQzOTA_ab52509b-d9ad-41ad-a61d-786ffc827423"
      unitRef="usd">1841511000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl85NC9mcmFnOmEwMTg3YjkxNWNkNTQ5NjFhZmIzZDVhMDgzYWYyYTMzL3RhYmxlOjhmOWEyZWI3NjIyMTQ3NWNiNzY3MjNlNzI5MDk4MWRhL3RhYmxlcmFuZ2U6OGY5YTJlYjc2MjIxNDc1Y2I3NjcyM2U3MjkwOTgxZGFfMzMtNC0xLTEtNzQzOTA_16098ea0-8596-44df-9d32-4364c3e6cbf4"
      unitRef="usd">1104429000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtMi0xLTEtNzQzOTA_f9ebb5a0-26b2-4bc1-88fb-37a1d5d40db2"
      unitRef="usd">360475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtNC0xLTEtNzQzOTA_519de520-b7e0-4a04-ab99-847e49b9c1c3"
      unitRef="usd">203900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzMtNi0xLTEtNzQzOTA_a811c11f-4248-465f-bfa4-9174dfef170f"
      unitRef="usd">88596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtMi0xLTEtNzQzOTA_9f5706fc-be28-44fe-a7a9-65c544c50a9e"
      unitRef="usd">191030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtNC0xLTEtNzQzOTA_073e7e48-d773-4798-b05f-2360125cd06c"
      unitRef="usd">104224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzQtNi0xLTEtNzQzOTA_601b8964-8cd4-4f40-9802-08a7b0551810"
      unitRef="usd">55987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtMi0xLTEtNzQzOTA_ba626d84-a40f-4c0d-8528-ea980b47127e"
      unitRef="usd">108611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtNC0xLTEtNzQzOTA_36ae2c29-53a9-48d0-b84f-99dcf0f99210"
      unitRef="usd">135186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzUtNi0xLTEtNzQzOTA_a6f8e8db-150a-4fb7-a861-cbd94bc21ca7"
      unitRef="usd">123011000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtMi0xLTEtNzQzOTA_de2cbc55-43af-4569-b720-00638e5c67d7"
      unitRef="usd">660116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtNC0xLTEtNzQzOTA_45f528d0-ff54-4731-b11b-f2fc15a12015"
      unitRef="usd">443310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzYtNi0xLTEtNzQzOTA_a4a678ae-1cff-4340-a621-9e9e3c373d80"
      unitRef="usd">267594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtMi0xLTEtNzQzOTA_cabfe48f-2aa6-4498-808a-43b9a0ebd4e5"
      unitRef="usd">139304000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtNC0xLTEtNzQzOTA_ed5115da-09a8-4770-b620-c6a87541b412"
      unitRef="usd">81413000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzgtNi0xLTEtNzQzOTA_2ea0d77e-3d6f-4ff3-8ce1-5789d6e73eec"
      unitRef="usd">43367000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktMi0xLTEtNzY4NjI_d8b1d1d2-47d3-46c7-932a-2232e4a9818a"
      unitRef="usd">43148000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNC0xLTEtNzY4NzI_b63fcc55-de43-4a59-8289-d8019732925a"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNi0xLTEtNzY4NzY_f59a0f34-ba74-4df1-af71-4e035d71506b"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktMi0xLTEtNzQzOTA_ac3ec183-ecdb-471d-97c6-585fc761e225"
      unitRef="usd">66607000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNC0xLTEtNzQzOTA_9317833a-3977-4367-b3cf-c011513a2a20"
      unitRef="usd">35672000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzktNi0xLTEtNzQzOTA_a51e77a9-0f8d-4986-b4ee-7ae07258b765"
      unitRef="usd">34236000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTItMS0xLTc0Mzkw_d1b8a53e-2b25-4548-bf00-e1a39ef5e547"
      unitRef="usd">143526000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTQtMS0xLTc0Mzkw_bdcc3658-2025-4172-b654-75e8bfa322e2"
      unitRef="usd">50323000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEwLTYtMS0xLTc0Mzkw_1737ed17-2f28-4f47-ac38-85033d068e1b"
      unitRef="usd">45736000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTItMS0xLTc0Mzkw_499de6b4-4e7a-4cdc-9431-a4158e31822a"
      unitRef="usd">392585000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTQtMS0xLTc0Mzkw_363fc5ec-e1fe-4304-b387-68902fd177d6"
      unitRef="usd">167408000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzExLTYtMS0xLTc0Mzkw_7be2228a-7ed1-4cc3-ab86-73e8df342bba"
      unitRef="usd">123339000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTItMS0xLTc0Mzkw_f4551fbf-a648-4e10-8e3f-0de0d80ab028"
      unitRef="usd">267531000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTQtMS0xLTc0Mzkw_ed4554d5-4bae-4134-a497-3a917f2631fb"
      unitRef="usd">275902000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzEyLTYtMS0xLTc0Mzkw_a217b5ea-15e7-4ed5-b389-ad78f6a9fb33"
      unitRef="usd">144255000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTItMS0xLTc0Mzkw_a9da85b3-79fe-464c-a38e-b9a1cad42d38"
      unitRef="usd">1046000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTQtMS0xLTc0Mzkw_b2cc8265-45f1-4136-8870-099d08a43e09"
      unitRef="usd">1102000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE0LTYtMS0xLTc0Mzkw_b3963e39-0000-4a30-9bc8-a83280e3e6e2"
      unitRef="usd">5425000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTItMS0xLTc0Mzkw_48ec0d53-97c4-4169-8055-7ac2c16a4578"
      unitRef="usd">2712000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTQtMS0xLTc0Mzkw_b25017f5-3c1e-4ef5-8001-185c1bbe6061"
      unitRef="usd">20960000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE1LTYtMS0xLTc0Mzkw_9dc434a9-ecab-4116-90bb-e2e42fa32605"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InterestExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTItMS0xLTc0Mzkw_be50dc35-9ba4-436f-a11b-45969541b406"
      unitRef="usd">16947000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTQtMS0xLTc0Mzkw_9f10e8b0-7690-42b3-90a0-4bed02e74cb3"
      unitRef="usd">7526000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE2LTYtMS0xLTc0Mzkw_80132c04-5ebf-4364-af8d-8affdb4378e2"
      unitRef="usd">20378000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTItMS0xLTc0Mzkw_6f76cc98-4df1-4009-aa56-a0b23d35557b"
      unitRef="usd">248918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTQtMS0xLTc0Mzkw_9db9460a-4322-4982-9bfc-70b8cad900a3"
      unitRef="usd">248518000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE3LTYtMS0xLTc0Mzkw_893f5b2f-a833-405c-a7be-0eb60fb84e24"
      unitRef="usd">129302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTItMS0xLTc0Mzkw_e20e5b70-f29f-43d8-b7c4-06004e8e8882"
      unitRef="usd">46789000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTQtMS0xLTc0Mzkw_a0780544-573f-4cb4-8b6c-f6007d9dd940"
      unitRef="usd">-154192000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE4LTYtMS0xLTc0Mzkw_a640f14f-90de-4e3e-b6d2-074e64df7228"
      unitRef="usd">217000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTItMS0xLTc0Mzkw_96f0c3aa-5c12-4f25-8a6d-7e953e1fb2f2"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTQtMS0xLTc0Mzkw_7e055fc6-a221-4fb5-81d1-f6527016c7fd"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzE5LTYtMS0xLTc0Mzkw_85c586ac-332a-441c-9326-5aad2eab2861"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTItMS0xLTc0Mzkw_5ea474a3-4935-409f-b1f6-0c23528ff704"
      unitRef="usdPerShare">1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTQtMS0xLTc0Mzkw_56f1e55e-92db-4580-a49b-a8162671c9e3"
      unitRef="usdPerShare">2.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIyLTYtMS0xLTc0Mzkw_28d865af-ab4a-4652-bafa-35d9d6a9e59e"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTItMS0xLTc0Mzkw_1f7e6d42-1220-4c3f-a723-65bddbead965"
      unitRef="usdPerShare">1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTQtMS0xLTc0Mzkw_90df12ad-38ef-4119-be81-f951e22ece70"
      unitRef="usdPerShare">2.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzIzLTYtMS0xLTc0Mzkw_5eb74c41-2581-408f-b2c4-7a744ae4cfb7"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTItMS0xLTc0Mzkw_3076df54-8ef5-4524-9d7e-f6c57fbf9dfe"
      unitRef="shares">136844000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTQtMS0xLTc0Mzkw_ba9ced94-83bc-49c5-9009-ad4e10599866"
      unitRef="shares">140646000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI2LTYtMS0xLTc0Mzkw_298d4fd9-3775-4a46-9f66-7affba1ac200"
      unitRef="shares">136206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTItMS0xLTc0Mzkw_74b905ce-f502-4fa1-8b55-93de403f236c"
      unitRef="shares">140608000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTQtMS0xLTc0Mzkw_94bb954b-67ff-48db-95b6-866bfd1e0e93"
      unitRef="shares">146796000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDAvZnJhZzphNDM3ZjE3M2UxYTc0NmNlYmM4NjVmYmY1ZDhhMDU1Mi90YWJsZTpmYTg1M2Q0Yzg4MTQ0MWE4YjE1MjNhNGVlM2ZhYTA0Ny90YWJsZXJhbmdlOmZhODUzZDRjODgxNDQxYThiMTUyM2E0ZWUzZmFhMDQ3XzI3LTYtMS0xLTc0Mzkw_c30ec5df-84e0-4b73-8e45-88775ac98820"
      unitRef="shares">141463000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItMi0xLTEtNzQzOTA_d47a8eb9-7523-40e8-aa3f-4971ec57c4bf"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItNC0xLTEtNzQzOTA_60be4c5b-6178-4b18-9f60-bc8026e75c51"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzItNi0xLTEtNzQzOTA_347f3216-c688-4900-b9d7-1ca9ed2c1afd"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtMi0xLTEtNzQzOTA_3e0c6bce-d898-4978-a133-7e947ca76ce0"
      unitRef="usd">-349000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtNC0xLTEtNzQzOTA_039c9754-b31b-423a-a1ce-9cdd66ee9943"
      unitRef="usd">-683000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzQtNi0xLTEtNzQzOTA_438cc356-f4a1-46bc-a044-3561dde959e4"
      unitRef="usd">-164000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtMi0xLTEtNzQzOTA_d157fe0a-0a2a-449c-8dbe-bdb5e69c2b1e"
      unitRef="usd">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtNC0xLTEtNzQzOTA_59fa7019-d860-4e25-8ab1-38c04c337bd7"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzUtNi0xLTEtNzQzOTA_c0f80336-b932-4725-8c3a-59a39a855d0b"
      unitRef="usd">32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtMi0xLTEtNzQzOTA_080b16f7-f5e4-4aaf-856b-f4aecbe4b98f"
      unitRef="usd">39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtNC0xLTEtNzQzOTA_e65c5a9e-a9d2-483c-95eb-17138f9210af"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzYtNi0xLTEtNzQzOTA_b46b55f4-5a2a-4edc-9246-9f3f735f83d4"
      unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctMi0xLTEtNzQzOTA_735aed52-6500-45d7-b3c6-682d277d58f4"
      unitRef="usd">201827000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctNC0xLTEtNzQzOTA_983fd84f-bc66-4eaf-8430-d75a642cf15c"
      unitRef="usd">402068000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDMvZnJhZzphNTAzNzAyMTg1ZDU0NzZlOWM3NjdmNzZhMDBmNmFiMC90YWJsZTpiM2RmYjI5M2M0MDA0ZmI3YmEwY2FjOTY1YWJhMWMxOS90YWJsZXJhbmdlOmIzZGZiMjkzYzQwMDRmYjdiYTBjYWM5NjVhYmExYzE5XzctNi0xLTEtNzQzOTA_719ff727-cac1-47e5-a7fd-dea1f55762a6"
      unitRef="usd">128867000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtMi0xLTEtNzQzOTA_42f5ebf3-6fc0-4f51-8ef4-0e4267cbf0c5"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtNC0xLTEtNzQzOTA_7bf5bc56-f203-4d2c-abdf-1366d821a929"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMtNi0xLTEtNzQzOTA_d3adb040-6081-49b7-bb7b-3ee7cccb81cd"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtMi0xLTEtNzQzOTA_7d235115-9957-440c-902d-ac5b9ad2c954"
      unitRef="usd">24397000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtNC0xLTEtNzQzOTA_5ba6d948-ac7b-441f-9b17-432e6ef29459"
      unitRef="usd">20820000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUtNi0xLTEtNzQzOTA_ab2a02c6-5a1c-4ec9-8c25-23dc2b6f346b"
      unitRef="usd">17204000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtMi0xLTEtNzQzOTA_c7c61460-2c4e-48ac-82d0-993672e1890d"
      unitRef="usd">6493000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtNC0xLTEtNzQzOTA_acd892d3-cfb7-4391-8db4-ec8cd16affc7"
      unitRef="usd">2997000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzYtNi0xLTEtNzQzOTA_76f7e2b5-7812-401e-8285-e97b4a6fa342"
      unitRef="usd">3284000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctMi0xLTEtNzY5MDA_3eea5411-bb42-4951-9bc1-de5cacecd8af"
      unitRef="usd">43148000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNC0xLTEtNzY5MDY_1741ea51-9805-4678-9e4b-b97f9f99af0a"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNi0xLTEtNzY5MTI_9d32dafb-0eb8-40d9-8ecc-f20977165c79"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctMi0xLTEtNzQzOTA_94eeef79-b224-489e-9e40-063274644846"
      unitRef="usd">7839000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNC0xLTEtNzQzOTA_585668e1-ccde-475a-a909-0e7e308f760a"
      unitRef="usd">3642000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzctNi0xLTEtNzQzOTA_6df86f6a-fdcb-4fd6-bba2-bc658b99aab8"
      unitRef="usd">14136000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktMi0xLTEtNzQzOTA_0c4bc317-47b6-42cb-bb52-d574c025ebd2"
      unitRef="usd">-1106000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktNC0xLTEtNzQzOTA_53b64d99-ba80-4076-a0d7-da4ad5d9b99f"
      unitRef="usd">-2257000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzktNi0xLTEtNzQzOTA_828a1e72-bb24-48a2-b4bb-e53172affa00"
      unitRef="usd">-839000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTItMS0xLTg4MDA5_5761c0c8-e0e9-457f-b31b-e0afc06ce4f7"
      unitRef="usd">-1727000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTQtMS0xLTg4MDEz_e3b40dd5-65d4-416d-9d48-3b4231c4d917"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTYtMS0xLTg4MDE3_31220cd1-2546-42c7-97aa-c72be04879cb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTItMS0xLTc0Mzkw_e39a5423-9a25-45d6-a666-581322c2c00f"
      unitRef="usd">-129000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTQtMS0xLTc0Mzkw_460c9289-4926-4b0b-8e1c-7cae63a719a9"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEwLTYtMS0xLTc0Mzkw_0fadeb90-e63d-4fc0-b0c4-dfa5c6bac988"
      unitRef="usd">772000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTItMS0xLTc0Mzkw_5130b374-2d1c-4e71-a5e1-9274372d5819"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTQtMS0xLTc0Mzkw_1844b6de-e940-4df6-b845-9f644a2d0d05"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzExLTYtMS0xLTc0Mzkw_a942900d-4764-49a1-9120-a50190ba391f"
      unitRef="usd">4632000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTItMS0xLTc0Mzkw_87d71244-5ef2-4848-a4e8-a9ff3b9a4682"
      unitRef="usd">2494000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTQtMS0xLTc0Mzkw_48cae35b-907f-4be6-bcad-040294a66227"
      unitRef="usd">1496000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEyLTYtMS0xLTc0Mzkw_d2d8f1f7-ed4f-4066-812e-64151dc88a9b"
      unitRef="usd">4119000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <halo:DeferredRentPayments
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTItMS0xLTc0Mzkw_6aa07ac4-8fa0-4f88-959d-ae3c36c7808e"
      unitRef="usd">903000</halo:DeferredRentPayments>
    <halo:DeferredRentPayments
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTQtMS0xLTc0Mzkw_70667c77-0429-4c80-92e5-53e12bdb5b55"
      unitRef="usd">751000</halo:DeferredRentPayments>
    <halo:DeferredRentPayments
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzEzLTYtMS0xLTc0Mzkw_6bb966d9-a9c6-4e47-967c-9f4519b34c02"
      unitRef="usd">1033000</halo:DeferredRentPayments>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTItMS0xLTc0Mzkw_1f25b14c-b6d2-45df-8255-7f38ea2ac542"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTQtMS0xLTc0Mzkw_c6302169-1ca9-4015-913b-021e4ba73740"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE0LTYtMS0xLTc0Mzkw_257390fd-4222-48e5-9876-2068f0582d51"
      unitRef="usd">577000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTItMS0xLTc0Mzkw_91a296ab-cc7d-45e1-b76c-6fb887d5509e"
      unitRef="usd">2712000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTQtMS0xLTc0Mzkw_73987c3d-7589-4010-94a4-326dc81f65af"
      unitRef="usd">20960000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE3LTYtMS0xLTc0Mzkw_8d2abd63-de83-4376-aeba-f1e01f666a82"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTItMS0xLTc0Mzkw_65dd5155-e1bb-49c0-baea-7a06f17f316a"
      unitRef="usd">-40005000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTQtMS0xLTc0Mzkw_eb96da9c-c628-4a75-9da6-6d90a66bc50a"
      unitRef="usd">155434000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE4LTYtMS0xLTc0Mzkw_6d175cbf-60c5-4b98-99f8-cd52e378ab2e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTItMS0xLTc0Mzkw_ade32cf0-821c-46e0-8c09-ed7e8c1ccc66"
      unitRef="usd">-227000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTQtMS0xLTc0Mzkw_96181b95-b950-464f-929e-608da54d5c8b"
      unitRef="usd">-3000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzE5LTYtMS0xLTc0Mzkw_93ba43dc-1293-45ea-b21d-d7e434db9e57"
      unitRef="usd">-13000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTItMS0xLTc0Mzkw_65e655bc-5d13-4dd8-8b48-87985da39704"
      unitRef="usd">83941000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTQtMS0xLTc0Mzkw_a6bc8359-d787-49dc-b4ae-d8544e7cbb99"
      unitRef="usd">-6755000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIxLTYtMS0xLTc0Mzkw_21294b13-6c01-4ce2-8c78-634672ff383b"
      unitRef="usd">38288000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTItMS0xLTc0Mzkw_c6339382-a96c-474e-8db8-01565c677545"
      unitRef="usd">17481000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTQtMS0xLTc0Mzkw_439a2f5b-ffa5-4962-bb35-52007ac0ac23"
      unitRef="usd">-7371000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIyLTYtMS0xLTc0Mzkw_c1a6d217-8329-41a5-a976-5f98475ea86a"
      unitRef="usd">31388000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTItMS0xLTc0Mzkw_16e1413a-cbf4-4d44-b235-f4255c2638f0"
      unitRef="usd">9064000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTQtMS0xLTc0Mzkw_2918daec-ce03-4aa5-98e6-00a7fbf0aad2"
      unitRef="usd">11555000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzIzLTYtMS0xLTc0Mzkw_05b8063d-3dd3-4c63-bacd-39e32b9de6fa"
      unitRef="usd">-2518000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTItMS0xLTc0Mzkw_ae7bdb64-e27c-4f52-b6f6-ef6504adb15d"
      unitRef="usd">24535000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTQtMS0xLTc0Mzkw_d59bd880-024b-4ecc-8e95-9fa8e9f57569"
      unitRef="usd">1167000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI0LTYtMS0xLTc0Mzkw_987ec089-c006-4466-b879-11e529a7f945"
      unitRef="usd">-41208000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTItMS0xLTc0Mzkw_531789fd-177b-4b44-9c09-30c5e482771c"
      unitRef="usd">240110000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTQtMS0xLTc0Mzkw_b992558e-2828-4566-8a12-9cc672e33b9a"
      unitRef="usd">299440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI1LTYtMS0xLTc0Mzkw_5f6994f6-0f78-4247-9e54-9f24f28a7a0e"
      unitRef="usd">55454000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTItMS0xLTc0Mzkw_98897996-c70f-4b8a-b11f-edb250c6de77"
      unitRef="usd">255208000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTQtMS0xLTc0Mzkw_9bda6867-ae0b-40fb-82d3-0427e536406f"
      unitRef="usd">652515000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI3LTYtMS0xLTc0Mzkw_6bbae1ff-9dbf-473f-8622-76d53fa095a0"
      unitRef="usd">226185000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTItMS0xLTc0Mzkw_3276e6d8-07e6-45a1-9bd2-15886e024d2b"
      unitRef="usd">746127000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTQtMS0xLTc0Mzkw_d2dea306-1637-4f67-8481-fceba6f275de"
      unitRef="usd">247683000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI4LTYtMS0xLTc0Mzkw_84bcb6b0-d918-43c9-9e43-0fa7ee7fe5b9"
      unitRef="usd">305967000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTItMS0xLTc2OTI2_aa126c95-6988-4fb8-b7a3-0f32cf10e21f"
      unitRef="usd">999120000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTQtMS0xLTc2OTMw_244feffb-c953-4ff1-ae09-19a6a3c89994"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTYtMS0xLTc2OTM0_e8c05ebd-4598-4fa8-89b9-f68a3debda8a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTItMS0xLTc0Mzkw_df83708b-9a1f-4ed0-aaf4-d4d064fe9ff3"
      unitRef="usd">4810000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTQtMS0xLTc0Mzkw_bff5d5fa-2e16-4b0a-bc0f-90d86c4ec87f"
      unitRef="usd">1457000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzI5LTYtMS0xLTc0Mzkw_00b72011-14f9-4a12-aaba-af2bc360d451"
      unitRef="usd">2504000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTItMS0xLTc0Mzkw_c16b0ece-8ba8-4155-9f1a-64d1faf9f7b8"
      unitRef="usd">26006000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTQtMS0xLTc0Mzkw_856debca-7cec-4c16-beeb-1a17445d7f20"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMwLTYtMS0xLTc0Mzkw_5d9b4b4b-6a15-4a5d-8d61-629d639de513"
      unitRef="usd">1076000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTItMS0xLTc0Mzkw_e716790d-a920-47e9-aca5-ef58db3626ca"
      unitRef="usd">-487005000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTQtMS0xLTc0Mzkw_3dd44252-8f1b-42ca-9e4c-69df8fe33832"
      unitRef="usd">-406289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzMxLTYtMS0xLTc0Mzkw_f9e1cbbd-a09b-4e16-a4f2-021bcd1ee1dd"
      unitRef="usd">78354000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTItMS0xLTc2OTcw_d03c5f2a-a543-4462-b4d9-828d6106b07a"
      unitRef="usd">250000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTQtMS0xLTc2OTc4_fb3afc26-61d7-49f4-a706-dcbbb01c710e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTYtMS0xLTc2OTgz_b97b431a-db66-4e55-a0b8-a9e4b49bd841"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTItMS0xLTc2OTcw_6e149abe-30c0-47db-aaa1-2a36bdc5252f"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTQtMS0xLTc2OTc4_84a8ed51-2c56-4a84-9c6d-38ff2d3988e9"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTYtMS0xLTc2OTgz_81424a0b-ef27-45a7-9639-7991c70de6f2"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTItMS0xLTc2OTcw_fe60a0a0-d3af-4502-9e83-26ee7d55a1b2"
      unitRef="usd">120000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTQtMS0xLTc2OTc4_cdcd42ce-5a40-4af4-85e9-458bd792c256"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTYtMS0xLTc2OTgz_cbce0e6c-7b41-486e-a86d-f1239f8a163e"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTItMS0xLTc2OTcw_fb2d6334-6341-4d61-b414-df8ae1270258"
      unitRef="usd">120000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTQtMS0xLTc2OTc4_332b82d4-a687-45d3-946e-b1a58e84585b"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTYtMS0xLTc2OTgz_1bb40fa6-f4d6-4531-b7ae-9fe0215fb592"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTItMS0xLTc0Mzkw_f6bbdf7b-d87d-4432-becf-40a681847534"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTQtMS0xLTc0Mzkw_b929485f-04d3-4ba7-8a5e-d77783370664"
      unitRef="usd">784875000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM0LTYtMS0xLTc0Mzkw_cede7f3b-fd53-4d57-b9be-3707cdbbcbd7"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTItMS0xLTc0Mzkw_01b9bcc2-de22-4c0d-8fea-40542e59093e"
      unitRef="usd">77453000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTQtMS0xLTc0Mzkw_60617d4c-77eb-4577-87bd-060f632769bb"
      unitRef="usd">369064000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM1LTYtMS0xLTc0Mzkw_1bd7ea81-1bd0-403d-afa9-871c4a785825"
      unitRef="usd">19560000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTItMS0xLTc2OTc0_a05e9fa1-32a6-4939-aa54-1fc6c3f89c65"
      unitRef="usd">702000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTQtMS0xLTc2OTkx_72a57861-8571-4d64-9bc8-4ce497df643c"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTYtMS0xLTc2OTk2_66f79e47-17b2-4806-8c4c-92546cd29279"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <halo:PurchaseOfCappedCall
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTItMS0xLTc2OTc0_0791ef14-6572-4255-8e19-bd3f72cae461"
      unitRef="usd">69120000</halo:PurchaseOfCappedCall>
    <halo:PurchaseOfCappedCall
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTQtMS0xLTc2OTkx_204785bd-397b-4e99-9be8-3eb2c58a4ea2"
      unitRef="usd">0</halo:PurchaseOfCappedCall>
    <halo:PurchaseOfCappedCall
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQzLTYtMS0xLTc2OTk2_60c70162-9ea3-4982-93dd-8858d7b508de"
      unitRef="usd">0</halo:PurchaseOfCappedCall>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTItMS0xLTc0Mzkw_08d5d031-9ac2-42af-9b50-8680347e61db"
      unitRef="usd">7104000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTQtMS0xLTc0Mzkw_b5b8cd95-a634-4906-a00d-7e8ac2e4eae5"
      unitRef="usd">424000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM2LTYtMS0xLTc0Mzkw_4161a0a5-813a-4aa9-95fa-05453aac667b"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTItMS0xLTc0Mzkw_dc54b3ff-a8ba-4df0-b863-0b077ca74b7b"
      unitRef="usd">200002000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTQtMS0xLTc0Mzkw_e9d786dc-102b-44d0-96c3-f634926a2986"
      unitRef="usd">350058000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM3LTYtMS0xLTc0Mzkw_504b8563-56b6-4e8a-835f-86977ca08aaa"
      unitRef="usd">150117000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTItMS0xLTc0Mzkw_5a4d298f-2512-4e5b-9e75-68835bf2574c"
      unitRef="usd">14050000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTQtMS0xLTc0Mzkw_08630b10-4ea5-4850-b7b9-d204c947e88d"
      unitRef="usd">12536000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM4LTYtMS0xLTc0Mzkw_a5e3c07d-f24b-4088-bdf8-d84a58268d69"
      unitRef="usd">63393000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTItMS0xLTc0Mzkw_8c123702-7174-45b8-b205-a0e4e1ecc7a0"
      unitRef="usd">362371000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTQtMS0xLTc0Mzkw_16d344d0-ca1f-4aab-b0b1-b3b2a8b3bba9"
      unitRef="usd">77865000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzM5LTYtMS0xLTc0Mzkw_64eea650-a8a5-44f6-adbb-0116fe331f95"
      unitRef="usd">-106284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTItMS0xLTc0Mzkw_65c5f9ea-da2d-4cd1-a034-93aea2063a9a"
      unitRef="usd">115476000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTQtMS0xLTc0Mzkw_f267f751-1e10-455a-b356-378370dd8bc8"
      unitRef="usd">-28984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQwLTYtMS0xLTc0Mzkw_4a82a8f9-8943-4196-8faa-0635e58d535a"
      unitRef="usd">27524000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTItMS0xLTc0Mzkw_aec1aa5f-5f01-4ce0-bf57-312859992bd7"
      unitRef="usd">119219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTQtMS0xLTc0Mzkw_bf385dd4-1b87-43e6-8447-f4adb1315f75"
      unitRef="usd">148203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQxLTYtMS0xLTc0Mzkw_4d4098f1-322a-4d57-9d89-a98be0823960"
      unitRef="usd">120679000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTItMS0xLTc0Mzkw_9da26be3-f10f-4959-94c0-c912042208be"
      unitRef="usd">234695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTQtMS0xLTc0Mzkw_3c3f4393-466b-4c50-acd6-068561746e43"
      unitRef="usd">119219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQyLTYtMS0xLTc0Mzkw_7e7434e1-88dc-4755-8b0f-27d6fbaed56f"
      unitRef="usd">148203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTItMS0xLTc0Mzkw_8eceea71-c9ee-4823-a8ab-188f65528838"
      unitRef="usd">6107000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTQtMS0xLTc0Mzkw_d020018c-6796-4512-b219-ee890f55dbcb"
      unitRef="usd">3296000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ1LTYtMS0xLTc0Mzkw_e23fd59a-c00d-4b06-b134-927b94081c2e"
      unitRef="usd">6534000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTItMS0xLTc0Mzkw_ec617a10-26b6-4ca8-9553-6561533a894a"
      unitRef="usd">16224000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTQtMS0xLTc0Mzkw_cfd27d88-968c-4ec4-a82f-6a77a9cadd18"
      unitRef="usd">-375000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ2LTYtMS0xLTc0Mzkw_c03c70cc-a874-4382-930f-08583bd06df4"
      unitRef="usd">180000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTItMS0xLTc0Mzkw_20ff97ea-9d4a-47c9-8b19-bc84638225e4"
      unitRef="usd">6229000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTQtMS0xLTc0Mzkw_5d0511fb-7006-45cc-83f7-91fd53f9b4d7"
      unitRef="usd">72000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzQ4LTYtMS0xLTc0Mzkw_71aae187-d9d6-4db3-8ff1-86871fe0a20f"
      unitRef="usd">117000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTItMS0xLTc0Mzkw_9eb84721-3aab-4293-b345-d82c9c7c4fc6"
      unitRef="usd">34435000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTQtMS0xLTc0Mzkw_fc0afc53-2528-4daa-aa98-23e558cb3ed5"
      unitRef="usd">318000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUwLTYtMS0xLTc0Mzkw_0b396591-f81a-4f8c-9547-8a2768540ae9"
      unitRef="usd">1746000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTItMS0xLTc0Mzkw_b0f46168-2df2-4e22-9b1e-00333f8ad59c"
      unitRef="usd">1018000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTQtMS0xLTc0Mzkw_501a86eb-c2df-4a78-be1d-14994def0513"
      unitRef="usd">7865000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDYvZnJhZzo5OWZhMWVmYmFmNjg0ZTA2OGQ0YzRhMjFhNmExNjgwZS90YWJsZTo1N2ExNTJiNzZhNmM0MTJmYWMyZjIzZDZjMjZiN2FlZC90YWJsZXJhbmdlOjU3YTE1MmI3NmE2YzQxMmZhYzJmMjNkNmMyNmI3YWVkXzUxLTYtMS0xLTc0Mzkw_bef8481c-9ac3-464b-a828-6d4f76b7ac0d"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:SharesOutstanding
      contextRef="i658b6d0704704e0b8064188c8e0a801d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMi0xLTEtNzQzOTA_85238cde-6de5-4bad-8916-9cc0cd0414ae"
      unitRef="shares">136713000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i658b6d0704704e0b8064188c8e0a801d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItNC0xLTEtNzQzOTA_cfc3696e-3161-42ad-8c1e-844355274a8e"
      unitRef="usd">137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9afa1af705a047488d2ed7629419da96_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItNi0xLTEtNzQzOTA_d6b0596f-4fb2-4c3c-ab6c-71e922a50630"
      unitRef="usd">695066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8be6b96e36e440009875fac05281e167_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItOC0xLTEtNzQzOTA_ddeb55ca-c893-478b-b559-dd56b2a63045"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7db3fb4810984f62a4337b6b494f3743_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMTAtMS0xLTc0Mzkw_b1c03e57-86fb-4c38-ba76-039105b7b00e"
      unitRef="usd">-603678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzItMTItMS0xLTc0Mzkw_c775e75f-1270-4358-bdf2-a8f8032bc6c7"
      unitRef="usd">91765000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzQtNi0xLTEtNzQzOTA_85ca7cae-4b02-4745-9ffa-35ea7f842358"
      unitRef="usd">17204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzQtMTItMS0xLTc0Mzkw_96a4faf7-8fd9-46bd-9082-ba4e63772e96"
      unitRef="usd">17204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtMi0xLTEtNzQzOTA_8a37a70d-656c-420a-a560-9a642c00971e"
      unitRef="shares">5278000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtNC0xLTEtNzQzOTA_b31cbcc9-2076-468c-8e7d-16a288225a80"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtNi0xLTEtNzQzOTA_739131a3-f866-4eda-a1b8-b18324a390a1"
      unitRef="usd">63388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzYtMTItMS0xLTc0Mzkw_96044f1d-f108-4366-86bd-896a5ecb2f08"
      unitRef="usd">63393000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzctMi0xLTEtNzQzOTA_90326c3a-922f-47e3-a4fe-fea3845379f5"
      unitRef="shares">61000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtMi0xLTEtNzQzOTA_b2659564-bef2-49ff-af1a-9f42c29fa714"
      unitRef="shares">7022000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="iba9e4b78d18746c08c5fd5007c7f871b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtNC0xLTEtNzQzOTA_f975eb4f-b033-4afb-b8fd-73cc150bc0e7"
      unitRef="usd">7000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtNi0xLTEtNzQzOTA_fb9bda6a-c4c0-4ef6-8a2c-722634d2018d"
      unitRef="usd">150110000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzgtMTItMS0xLTc0Mzkw_8554d68f-36af-4be5-82ea-001518eafd38"
      unitRef="usd">150117000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="if0289d0351994fd0ac51c5c9658c6edf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzktNi0xLTEtNzQzOTA_b84b0a52-784f-4dc2-a37a-a8c6bc31bfb4"
      unitRef="usd">-65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzktMTItMS0xLTc0Mzkw_2e1bddcd-9af0-4b2f-bc83-9ab6f01f13ca"
      unitRef="usd">-65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ie9749fc8e01b42f3bc4d2a62a57108c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEwLTgtMS0xLTc0Mzkw_59a3fed4-260e-4022-b533-f05286161837"
      unitRef="usd">-218000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEwLTEyLTEtMS03NDM5MA_3de2ba28-9537-4cde-8b24-2eaed8f91295"
      unitRef="usd">-218000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzExLTEwLTEtMS03NDM5MA_1e245937-ab76-4c40-8f4d-db595f62f8cd"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzExLTEyLTEtMS03NDM5MA_4223148b-1f35-44fa-ac2b-f27319413816"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i99205eb539fe44e688694e9c32636419_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTItMS0xLTc0Mzkw_fece5f31-8da2-4063-86ac-74738205d6bd"
      unitRef="shares">135030000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i99205eb539fe44e688694e9c32636419_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTQtMS0xLTc0Mzkw_6cc37b37-06ae-43b3-a581-c8e295e6431a"
      unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c116ced97cc4fe5b21319832ce43f61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTYtMS0xLTc0Mzkw_dc7bff86-da75-41a5-b9ce-309465c24e70"
      unitRef="usd">625483000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i85f04615dfbd45e198c13ee612a4296b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTgtMS0xLTc0Mzkw_62380bb1-5d6f-4064-b5f5-614a595345e4"
      unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie53b6dc71630413f9a2aeceedcc0e052_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTEwLTEtMS03NDM5MA_cc05262b-7bf0-41a1-85a7-f5b939e7e7ea"
      unitRef="usd">-474593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEyLTEyLTEtMS03NDM5MA_5604ccc6-6eaf-43c9-8333-267187a26c07"
      unitRef="usd">151047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ee6817d503e4a18b7eb816904b0aebe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTYtMS0xLTc3MDYw_42d90888-0e2a-4922-90f3-89aed6290766"
      unitRef="usd">-65535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa017f03308949e29662213e518d9cb3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTEwLTEtMS03NzA2NA_f4c209d9-958b-4185-b9d9-c0a829222217"
      unitRef="usd">12971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaed2278944d84aca8963978003d797f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzEzLTEyLTEtMS04NTI3NA_58ad16c6-aa06-44d7-9bab-db0fc5533914"
      unitRef="usd">-52564000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTYtMS0xLTc0Mzkw_7bf82bf6-eaf6-46aa-bc64-4e5d1e38f39f"
      unitRef="usd">20820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE0LTEyLTEtMS03NDM5MA_0db9fc45-867c-4cea-9704-6a406befe3eb"
      unitRef="usd">20820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTItMS0xLTc3MDcx_3a9528e9-2c6b-4727-b3e5-bcf1fff5bb06"
      unitRef="shares">9083000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTQtMS0xLTc3MDgy_73bb399e-d0fb-455f-a58d-eb3eae8631ad"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE2LTYtMS0xLTc3MDg2_77e1c285-b5b3-4432-9c41-8269239001ff"
      unitRef="usd">13095000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTEyLTEtMS04MzE4Nw_5dcb3cdb-6744-43db-be94-4da70fc60900"
      unitRef="usd">13104000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTItMS0xLTc0Mzkw_fbedc20b-e88f-496d-b6b1-4b06680a7c67"
      unitRef="shares">1497000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTQtMS0xLTc0Mzkw_2823904d-b920-4ced-b32b-31ec668e5697"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTYtMS0xLTc0Mzkw_85b88e70-459a-4490-a217-f7377efc2eb2"
      unitRef="usd">12534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE1LTEyLTEtMS03NDM5MA_61564cea-c0e5-4287-b6bb-c40e394a4d40"
      unitRef="usd">12536000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTItMS0xLTc0Mzkw_b848a224-8b52-49f4-b58e-4d20305a553b"
      unitRef="shares">8112000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i5d2202b1db7344f99640cc810dd4b405_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTQtMS0xLTc0Mzkw_73592b2c-efe9-4bfd-a076-b2cb8eaa23fb"
      unitRef="usd">8000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="id21090e0d2524743ad4edde0fe51ace8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTYtMS0xLTc0Mzkw_8a18a440-7868-4a8f-90a1-cdf64468da94"
      unitRef="usd">350050000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE3LTEyLTEtMS03NDM5MA_5fd31c0d-050a-4cdc-936b-aae6f1328caf"
      unitRef="usd">350058000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i185f758e56d34e259efb04a87b79e6fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE5LTgtMS0xLTc0Mzkw_15360597-fe81-4d86-90f4-ba99ad284cb3"
      unitRef="usd">-642000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzE5LTEyLTEtMS03NDM5MA_2db08823-1bd9-419c-b43f-10d33b5bd4f5"
      unitRef="usd">-642000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0cb480a816cd4772ba95677abf4d9f15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIwLTEwLTEtMS03NDM5MA_24fd6654-3390-4047-bd3c-c6eb05b4b24b"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIwLTEyLTEtMS03NDM5MA_1527a884-8a02-4ced-8d08-0017bb71a04b"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6c457ab9e1fd454291cd030cc56319d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTItMS0xLTc0Mzkw_30427e81-38ef-4bb5-aa80-08a2eb3d5fa5"
      unitRef="shares">137498000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6c457ab9e1fd454291cd030cc56319d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTQtMS0xLTc0Mzkw_3e7d7137-8c2d-4818-96ad-1e247af925c8"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5ffb5ed70da4329a8be32a8e3f59679_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTYtMS0xLTc0Mzkw_210b5dc1-aac6-4e4d-8810-007000dedee3"
      unitRef="usd">256347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a3a0d1278564dac88cdb6a4890dbeb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTgtMS0xLTc0Mzkw_12ffc752-cfdb-4e6c-a7c8-be7248bb3a9a"
      unitRef="usd">-620000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9bfa39e1da314354bf34589788f5d3f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTEwLTEtMS03NDM5MA_50690b0e-7f58-4821-8921-5afb4cb0ce9e"
      unitRef="usd">-58912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIxLTEyLTEtMS03NDM5MA_6564f586-233b-4462-be9c-41050d3b901f"
      unitRef="usd">196953000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIzLTYtMS0xLTc0Mzkw_1f2674f3-38b5-4982-b9e5-6796321cc495"
      unitRef="usd">24397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzIzLTEyLTEtMS03NDM5MA_2583660c-e291-4721-a923-8597fd86ed84"
      unitRef="usd">24397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTItMS0xLTc0Mzkw_bb88eae5-e37a-4924-9b00-acacb3d5b526"
      unitRef="shares">1512000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTQtMS0xLTc0Mzkw_9a26f679-d9dd-469f-9e51-e38c4b2e72e0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTYtMS0xLTc0Mzkw_51d3859e-4982-4056-a216-ea7c71cb22f6"
      unitRef="usd">1692000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI1LTEyLTEtMS03NDM5MA_8e15ab2d-d863-4680-97f8-448f65b02145"
      unitRef="usd">1693000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTItMS0xLTc0Mzkw_d8787bad-b1ea-4933-aca5-625d06656339"
      unitRef="shares">1077000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTQtMS0xLTc0Mzkw_cff7308d-4a9c-4150-85a3-de27fe8ce08a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTYtMS0xLTc0Mzkw_9fd7e45c-af68-4c3e-be36-b1560506e01d"
      unitRef="usd">14049000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI2LTEyLTEtMS03NDM5MA_9451a4ae-303a-4ebc-b9c6-82a965dcf34a"
      unitRef="usd">14050000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction
      contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTYtMS0xLTg2OTM0_86bec908-a1aa-45bf-bc44-a924a0025596"
      unitRef="usd">69120000</halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction>
    <halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTEyLTEtMS05NDUyNg_d19ff79b-e3e3-47a6-92aa-1cb1fffed9c8"
      unitRef="usd">69120000</halo:AdjustmentToAdditionalPaidInCapitalCappedCallTransaction>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTItMS0xLTc0Mzkw_884dc7cf-9db2-42dd-bb08-3894d6d5a643"
      unitRef="shares">4933000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i02ca925601544b0d9818b83003b6a173_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTQtMS0xLTc0Mzkw_64fe92e8-e3f7-451d-ad69-ede6ff7240ac"
      unitRef="usd">5000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i47eab477396949258aac7c749bf0936c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTYtMS0xLTc0Mzkw_9d7c0554-baa6-4e94-9086-635e7e178e06"
      unitRef="usd">199997000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzI4LTEyLTEtMS03NDM5MA_5d3eed11-b842-4bb5-b8d4-95b0e1b462a9"
      unitRef="usd">200002000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="iaaa88a5eb896493187880ac27c0e4dae_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMwLTgtMS0xLTc0Mzkw_7ed3b20a-4e44-4c08-9752-961a637c6127"
      unitRef="usd">-302000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMwLTEyLTEtMS03NDM5MA_be9cf10d-26b0-4882-a8f2-33ee09cd052f"
      unitRef="usd">-302000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia5286105d8e646a890ecc12d4b237245_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMxLTEwLTEtMS03NDM5MA_6dbabfa2-67e7-4334-a063-39b58eebd0b2"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMxLTEyLTEtMS03NDM5MA_7a1e0644-dc83-4345-8aa5-adcc0df7696d"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6665e5678736405d8d250f39ff73c605_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTItMS0xLTc0Mzkw_9838ce9c-00e7-45ce-8404-58982a0a99b2"
      unitRef="shares">135154000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6665e5678736405d8d250f39ff73c605_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTQtMS0xLTc0Mzkw_37322953-3666-48a4-bdd0-f9803aa1c313"
      unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60ddf1b282954e588fac184cee2096f3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTYtMS0xLTc0Mzkw_5c4afba6-121f-40da-b9ce-431e311f11d9"
      unitRef="usd">27368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if03f2e05bd964f27b59d8e973985f611_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTgtMS0xLTc0Mzkw_eb6943db-fbdb-4efa-9c87-01201640f6d1"
      unitRef="usd">-922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d0f4252003945d1b7cf619e91241e33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTEwLTEtMS03NDM5MA_74051915-ae32-42a2-956c-e8ee9c015d04"
      unitRef="usd">143217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMDkvZnJhZzowOWIwOTk3NmJiNWY0MzA5YWIzZWY1NzU4ZGQwZTE1NS90YWJsZToxNGU3NjYyNDYzYzE0NjdlYWFmNWZjZGFmOTQwNTNkYS90YWJsZXJhbmdlOjE0ZTc2NjI0NjNjMTQ2N2VhYWY1ZmNkYWY5NDA1M2RhXzMyLTEyLTEtMS03NDM5MA_50829b5d-dea4-4690-a209-82f754547a60"
      unitRef="usd">169798000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM5MjQ_7b45fa0b-62d0-470a-a71c-3abc1d74757c">Organization and Business &lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving&#160;the patient experience and potentially outcomes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#x201c;SC&#x201d;) delivery of injected drugs and fluids.&#160;We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; drug delivery technology (&#x201c;ENHANZE&#x201d;) with the partners&#x2019; proprietary compounds.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our first commercially approved product Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recombinant (&#x201c;Hylenex&#x201d;), and our ENHANZE partners&#x2019; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex, that works by breaking down hyaluronan (&#x201c;HA&#x201d;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#x201c;IV&#x201d;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver.&#160;Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#x201c;Roche&#x201d;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#x201c;Takeda&#x201d;), Pfizer Inc. (&#x201c;Pfizer&#x201d;), Janssen Biotech, Inc. (&#x201c;Janssen&#x201d;), AbbVie, Inc. (&#x201c;AbbVie&#x201d;), Eli Lilly and Company (&#x201c;Lilly&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), Alexion Pharma (International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC)(&#x201c;Alexion&#x201d;), argenx BVBA (&#x201c;argenx&#x201d;), Horizon Therapeutics plc. (&#x201c;Horizon&#x201d;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#x201c;ViiV&#x201d;) and Chugai Pharmaceutical Co., Ltd (&#x201c;Chugai&#x201d;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through our recent acquisition of Antares Pharma, Inc. (&#x201c;Antares&#x201d;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TLANDO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOCDURNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#x201c;Teva&#x201d;), Covis Group S.a.r.l. (&#x201c;Covis&#x201d;) and Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#x201c;Idorsia&#x201d;) and Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except where specifically noted or the context otherwise requires, references to &#x201c;Halozyme,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; and &#x201c;us&#x201d; in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries disclosed in Note 2.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <halo:NumberOfCollaborationsRoyaltiesReceived
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyMzE_49549d09-71cc-470c-bef2-3e51d37e3e94"
      unitRef="collaborator">3</halo:NumberOfCollaborationsRoyaltiesReceived>
    <halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales
      contextRef="i60c9f6a3aea6447bb885f06a67eeffbe_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNDE_81354fb8-29b6-4bd5-a0c5-8b614ba92e18"
      unitRef="product">1</halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales>
    <halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales
      contextRef="ia03e264b59b746d98f5b7e2c7a6418fd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNDk_a77eb4d0-845a-4fdd-a6ef-53fe3bdc07ec"
      unitRef="product">3</halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales>
    <halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales
      contextRef="i0fb48210945840e8bf77e3e377c72c8b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTUvZnJhZzo3NjUzZWQ1Yzc0ZGI0YjgxYTNhYzMxM2Q3NDljM2JiMS90ZXh0cmVnaW9uOjc2NTNlZDVjNzRkYjRiODFhM2FjMzEzZDc0OWMzYmIxXzM4NDgyOTA3MDcyNTk_d76fcc2e-9de6-480e-a60d-dde37eb605b7"
      unitRef="product">1</halo:NumberOfProductsForWhichRoyaltiesReceivedFromSales>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTk3_53b1c6d4-2560-45ce-91af-f3da4055e27c">Summary of Significant Accounting Policies&lt;div style="margin-top:7pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#x2019;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of December&#160;31, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2022 and 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk, Sources of Supply and Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer&#x2019;s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2022 and 2021. Approximately 52% of the accounts receivable balance at December&#160;31, 2022 represents amounts due from Janssen and Roche. Approximately 90% of the accounts receivable balance at December&#160;31, 2021 represents amounts due from Janssen, Roche and Takeda. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or  (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,  TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of the Makena&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and  (ii)&#160;product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Financial &lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Early adoption is permitted, including adoption in an interim period)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTc5_8f5263c6-91c6-49c2-b9b3-bf9fa9051c12">&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDk0_055d2b49-083f-47a3-a1bd-c225d5674cd2">&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of December&#160;31, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQz_a4aa5050-2ab3-4362-b25f-7ba4d32189d5">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQ1_346a8ba8-a558-4f65-9baf-cf0bbe0b0315">&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2022 and 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzI4MzY_5aab020c-86a3-4097-9101-e37c073dd56a"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDg5_7657b110-68e1-499e-b51c-4e54dd8da89c">&lt;div style="margin-top:7pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTQy_3f05ed6d-c10f-413a-b7a8-b6cb34da053f">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk, Sources of Supply and Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer&#x2019;s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2022 and 2021. Approximately 52% of the accounts receivable balance at December&#160;31, 2022 represents amounts due from Janssen and Roche. Approximately 90% of the accounts receivable balance at December&#160;31, 2021 represents amounts due from Janssen, Roche and Takeda. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxMDg_222e8aaf-6104-4708-aa1e-ca0ff2ffe61f"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxMDg_a5b4d569-5fa1-4021-b05d-f479cc1739aa"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <halo:ConcentrationRiskPercentageInstantDate
      contextRef="ic8a632685f724b3dbe494cea07cd7170_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcxNjQ_7e976ea8-8bd1-4dc1-ad38-f99e7b773074"
      unitRef="number">0.52</halo:ConcentrationRiskPercentageInstantDate>
    <halo:ConcentrationRiskPercentageInstantDate
      contextRef="i4d74a6abc13a425a8418a3669d66efc8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzcyNzg_20f5d549-2a7e-4ac6-96bc-353209fac5b9"
      unitRef="number">0.90</halo:ConcentrationRiskPercentageInstantDate>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDgw_dc04d637-0310-42ae-8d14-0e6a82040632">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We attribute revenues under collaborative agreements, including royalties, to the individual countries where&#160;the customer is headquartered.&#160;We attribute revenues from product sales to the individual countries to which the product&#160;is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6f9c44c518d2425ea72beec31a2cfebc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItMi0xLTEtNzQzOTA_f1636e92-ce43-4430-9bdf-cbd16d3d678d"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0043cfac8af6431f80518ace0a62f8c4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItNC0xLTEtNzQzOTA_a290a0ca-40f8-4247-99fd-f5aa41de1a32"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib244486e83334e049f9f415b79e745f0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzItNi0xLTEtNzQzOTA_1fd0ee28-373c-4e38-865b-49c6c0d2eaf6"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c942b53e0e34ec598f5d722217d08af_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtMi0xLTEtNzQzOTA_c65e9d8e-f0ca-43c8-bd06-99bb84023f84"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7d4a9fcdff314021b35297f8bb703b1f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtNC0xLTEtNzQzOTA_e84f90d0-44d7-4573-82c1-299a21bb9014"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5b260f831be1449294bba3c541338639_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzMtNi0xLTEtNzQzOTA_d6884ed5-bbb1-45b9-ab31-113950b7d269"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iea80ef23e3af4bc4be5f2356bb7d3fd5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtMi0xLTEtNzQzOTA_1b65de95-127a-4d8a-b931-1011591a3145"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a2b61270d2f40c6863815f87fb3703c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtNC0xLTEtNzQzOTA_36005c02-ab65-465e-9dfa-899e3b99b645"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia36466ed48de4b458fea7a53fde94578_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzQtNi0xLTEtNzQzOTA_012467b1-3e79-4956-9f1e-7bf8afdd8dac"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i01dfe5b9a34240f480cb63ff4e1b02c2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtMi0xLTEtNzQzOTA_88e02cf2-c24c-41c6-a43d-f4c9141fcc84"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4698a330a0b744d6b6d168b99f00f6e0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtNC0xLTEtNzQzOTA_65484e45-49af-4bb2-9b92-e9d101f35aca"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idce4eddf7dff4d1f9f2c4573eb5f3534_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZToyMDg3MmVmNTQ2M2U0YzA0OTY1YzQ1NjRmYmZjY2Q1Yi90YWJsZXJhbmdlOjIwODcyZWY1NDYzZTRjMDQ5NjVjNDU2NGZiZmNjZDViXzYtNi0xLTEtNzQzOTA_66daf3d9-7437-4611-a227-2aeec576d8c9"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64016d8d05444060803595ff46f871b5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItMi0xLTEtNzQzOTA_c57587cc-9a25-4a18-874d-936b047de763"
      unitRef="usd">437989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61fb9df557854a4aadba56811dda6704_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItNC0xLTEtNzQzOTA_989fccf9-63f4-49bf-b1db-743e5e42b76e"
      unitRef="usd">293089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac11f44bfb95456296f38ba52920a3c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzItNi0xLTEtNzQzOTA_7056c737-1cc7-4e56-b501-ecf00c7dbd24"
      unitRef="usd">106918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7de7cf8a78e4bf89bff3256afe84223_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtMi0xLTEtNzQzOTA_a41f8cef-8ecf-4599-af82-ec7d8c9be998"
      unitRef="usd">166836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica047ad710284104a38c9d206a018d0a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtNC0xLTEtNzQzOTA_9823a9a4-a447-4afd-a8a8-36cdc43d72b0"
      unitRef="usd">134117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieae824ce4a274eccaa7296d3a60e81c1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzMtNi0xLTEtNzQzOTA_aea77b12-3faa-4ffa-89c2-e99c87aaa310"
      unitRef="usd">95949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if724606c27844c38bcc67de0fd811b33_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtMi0xLTEtNzQzOTA_d62d12f4-d8e7-41a4-96ea-01fcbdab7e3a"
      unitRef="usd">3000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2db9f9565034499aa800a640e58be214_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtNC0xLTEtNzQzOTA_6bcfc95b-a514-4082-8ea7-f956ab409d56"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i161c82ffd29845e4a51dc871f1f5be81_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzQtNi0xLTEtNzQzOTA_f4957bd9-8c6d-4024-8f00-0b6de3fe86be"
      unitRef="usd">30552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d2c71a5430c427b9f25c98b1682de64_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtMi0xLTEtNzQzOTA_42597817-7a87-4089-966b-7e1ed62da410"
      unitRef="usd">2088000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79b127d42f404009be3f5197ca82946e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtNC0xLTEtNzQzOTA_66b26118-d18b-4798-a464-20fe463ced6c"
      unitRef="usd">199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe33da92d9bb4158bc8a5df544e374a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzUtNi0xLTEtNzQzOTA_d2f424d5-752c-46e4-9cc9-3d28e5dd64e9"
      unitRef="usd">20086000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id97526871a974553b87645589cdb1f48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtMi0xLTEtNzQzOTA_8feefe0d-e2cd-4bc0-b660-23fc97e639b3"
      unitRef="usd">47939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie834c01de6184c509a71caad06bb9266_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtNC0xLTEtNzQzOTA_914723e2-f128-4787-8c93-b5b1f55b72e3"
      unitRef="usd">11934000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbe8666679dc4bae993f8d56771a1678_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzYtNi0xLTEtNzQzOTA_16d27fcb-dd92-499b-b0d3-3309f53f426b"
      unitRef="usd">10644000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i514044e6ba7547189405fbf239f8caea_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctMi0xLTEtNzQzOTA_cf256883-34d8-4122-a2d3-b346788c7ed9"
      unitRef="usd">5261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16b5b3910fab4729b3312f22278dd16b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctNC0xLTEtNzQzOTA_dcf5b9bb-9aa2-4c2b-b020-1b61ed7bf7ca"
      unitRef="usd">3957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibad21366e94841b6b92a3ed6b8d2c8c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzctNi0xLTEtNzQzOTA_10671869-ba64-4dca-9fc4-344680f4c03f"
      unitRef="usd">3445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27889e318d8545478c0d04d0e999f6a4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtMi0xLTEtNzQzOTA_b3a61bb5-3ccb-4965-9f7f-d8aae645d26f"
      unitRef="usd">660116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb93b74a42f341839f733106bc085ac3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtNC0xLTEtNzQzOTA_a14c9cd9-7bc0-4018-95e2-7b6f2d28b68b"
      unitRef="usd">443310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f6d5252a77b41629cc0e5e24355f1dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90YWJsZTpjNzQ2ZjBmNmFmNDE0NjIwYmI0OWRlM2FmZDZmNzk0Yi90YWJsZXJhbmdlOmM3NDZmMGY2YWY0MTQ2MjBiYjQ5ZGUzYWZkNmY3OTRiXzgtNi0xLTEtNzQzOTA_603df498-d213-434f-93a4-93bfe53ecf09"
      unitRef="usd">267594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTI2_4dc25a72-89ff-42e3-8190-a25349f80e94">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzg1NzA_8d90cc5d-a43b-4053-a934-2013e32e68c2"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzg1NzA_ffed0aae-1550-4ba6-8873-88ac4004b49f"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTky_492fddd9-9bce-4661-a33f-6bffd18797bb">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, &lt;/span&gt;&lt;/div&gt;and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDQ0_83f79d5e-3734-4464-8f1e-52e3fa3b46da">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="icfd51566fb48417294740b3e09f08d33_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzk2NTM_6d2e546a-57fd-422c-a06c-fe2ed7aceb70">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia2e016f17e20404aa3c14094fdf86c28_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzk2NTk_aefea1e0-d0aa-453d-92fd-c16ed3fa2ca2">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDkw_3bf08919-4646-4ac9-a012-cfcffb5a906f">Property and Equipment, NetProperty and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzExMzE3_9ccab25d-9707-48fa-8cf5-76fd1a733c39">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzExMzIz_dca088eb-d835-4950-bb4e-75b627d0ac2b">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDUz_d1ecbc5c-6f71-47af-b07e-d8de7d6fb694">Impairment of Long-Lived AssetsWe account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDU4_7e8761b1-5bf2-44aa-a58c-9de75d2d1161">&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM4NDgyOTA3ODA0ODk_ed76da53-d539-4614-8509-3f40bdd7cfb6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <halo:GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM4NDgyOTA3ODA0OTA_6134271b-e813-4b30-a817-b4b3c39758e8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</halo:GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDYw_98a43518-1c61-491b-b336-f9a1ecd1b336">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or  (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,  TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of the Makena&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDgx_40656374-27a0-4e28-bb38-2ba05b11c976">Cost of SalesCost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MDMw_8f097b02-4524-4a45-8cfb-afaf731434f8">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTcw_a0e109ef-d292-4fae-b3ec-0fb8f119933f">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTkw_5c28e065-3871-4cc1-8af7-95a6deeaed94">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTg1_4f30eba5-a4d4-4b2b-b17a-eb5890b6671c">Segment InformationAs a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and  (ii)&#160;product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM2Mjg2_e8eddb05-b6f2-4f2b-adb1-0f6696147af8"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMTgvZnJhZzpmNjc0YjNlZGUwMDE0NmUwYWYwMTFlZjA2OGY3YjRkZi90ZXh0cmVnaW9uOmY2NzRiM2VkZTAwMTQ2ZTBhZjAxMWVmMDY4ZjdiNGRmXzM3MTkz_94d285c9-71e8-42a3-a1d5-8b5c23149ef0">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Financial &lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Early adoption is permitted, including adoption in an interim period)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDM_10b1beed-aa44-4793-bcc7-6a4f80478127">Business Combination&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#x201c;Merger Agreement&#x201d;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#x201c;Merger Consideration&#x201d;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#x2019; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $19.7&#160;million and seller transaction costs paid by us on behalf of Antares of $22.9&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#x201c;BofA&#x201d;) and other lenders that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;, collectively with the Revolving Credit Facility, the &#x201c;2022 Facility&#x201d;) as described in Note 8. We recognized transaction costs of $21.9&#160;million in the twelve months ended December&#160;31, 2022. These costs are reported in selling, general and administrative expenses in our condensed consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for Antares shares outstanding as of May 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for Antares equity compensation awards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for seller transaction costs paid by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration related to Antares closing indebtedness settled by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration related to cash bonus awards paid by Halozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in our consolidated statements of income in twelve months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Fair Value of Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on valuations and management estimates. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the allocation of the purchase price, therefore, the fair value estimates assigned to intangible assets, goodwill and the related tax impacts of the acquisition, among other items, are subject to change as additional information is received to complete our analysis and certain tax returns are finalized. As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts recognized as of Acquisition date (as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts recognized as of Acquisition date (as adjusted )&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Total purchase consideration, net of $46,548 cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired, excluding goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable unit. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A contingent liability with a preliminary value of $130.0&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded measurement period adjustments in fourth quarter of 2022 to decrease intangible assets as a result of revised future cash flow estimates from the initial purchase price allocation and adjustments to accrued expenses. These measurement period adjustments were made to reflect facts and circumstances that existed as of the acquisition date. We also recorded a measurement period adjustment in the fourth quarter of 2022 to reduce the acquisition-date fair value of contingent liability by $114.3&#160;million as a result of revised future cash flow estimates. The measurement period adjustment has been recorded to reflect facts and circumstances that existed as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#x2019; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;amp;D will be tested annually for impairment and will not be amortized. Useful lives and preliminary values are presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Pro Forma Results&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include Antares&#x2019; results of operations from the date of acquisition on May 24, 2022 through December&#160;31, 2022. Total revenues and net loss after taxes attributable to Antares during this period and included in our consolidated financial statements for the twelve months ended December&#160;31, 2022 total $112.7&#160;million and $67.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal year 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjAyMg_f8c020c3-14f2-4ac8-b58c-01e76dd3ae43"
      unitRef="usd">1045700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA0Ng_0131515f-3cc5-41b7-ac93-375412669de5"
      unitRef="usdPerShare">5.60</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA2Nw_69f51dd8-98d9-4942-a47e-24ed97e35093"
      unitRef="usd">19700000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjA5Ng_06570eb1-c636-41ea-a9e5-9bae2cd4f1cb"
      unitRef="usd">22900000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ide8e0bb6ebfa47f385eb8b8a3556d019_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjEyNA_6cd1a311-f19e-41a7-a39f-80695742d6d2"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5b5cf73d12df4c3bbe1f1cedfe244210_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjE1MQ_00f31d3c-9402-40f1-abb9-e1bf4903b135"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjI2Nw_6ea3a7ec-c416-43f9-be47-7e3c5f1375f1"
      unitRef="usd">21900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDU_f5e88c75-2425-4f6e-8f86-268db9ef1e6d">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for Antares shares outstanding as of May 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for Antares equity compensation awards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for seller transaction costs paid by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration related to Antares closing indebtedness settled by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration related to cash bonus awards paid by Halozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in our consolidated statements of income in twelve months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzAtMi0xLTEtODQ5OTU_9204a4ed-9a41-4f58-9cd3-c19f0489fac5"
      unitRef="usd">956886000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzEtMi0xLTEtODQ5OTU_ff591229-1884-4d34-a679-688cff7391ab"
      unitRef="usd">45828000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzItMi0xLTEtODQ5OTU_86b68553-464e-47da-8cd8-3a2b8e986461"
      unitRef="usd">22906000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzMtMi0xLTEtODQ5OTU_dd52f06e-80da-4257-8ed2-8b5881ecd95f"
      unitRef="usd">19683000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <halo:BusinessCombinationConsiderationTransferredBonusAwards
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzQtMi0xLTEtODQ5OTU_699fc417-3c0b-48f3-9645-6e0015df1863"
      unitRef="usd">365000</halo:BusinessCombinationConsiderationTransferredBonusAwards>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTo5OGRjMmE5MDVhMTU0Y2E1ODBiY2IzNWNkNjY0OTZjMC90YWJsZXJhbmdlOjk4ZGMyYTkwNWExNTRjYTU4MGJjYjM1Y2Q2NjQ5NmMwXzUtMi0xLTEtODQ5OTU_6bbbaf04-bcfb-4a1c-9c54-01c20b15130c"
      unitRef="usd">1045668000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="if78cce61194d43d69a49bc5e102059f3_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjI5Ng_8c0f2522-7bfb-4d78-b561-99a0fdcf5bd2"
      unitRef="usd">32200000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="id0189c904b3b4a0381ae6dda4687bd18_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjMyNQ_ac689e2b-3f9f-48e9-8224-1dafb6a0d168"
      unitRef="usd">13600000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjM1Mw_b3daade6-071b-4ffb-89dc-e3142ac1b05a"
      unitRef="usd">8700000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDg_c575a054-943c-440a-8e27-da9593b1ebeb">As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts recognized as of Acquisition date (as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts recognized as of Acquisition date (as adjusted )&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Total purchase consideration, net of $46,548 cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired, excluding goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEtMC0xLTEtNzc5NDUvdGV4dHJlZ2lvbjplYzYxZGI3MWIxYzI0YTRkYmUyMDk2MDRlMWY3ZTk3MV81NDk3NTU4MTM5NTE_6ed90206-ee12-49c2-b904-c2def953faa5"
      unitRef="usd">46548000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEtMi0xLTEtODUwMDA_ad53d8ce-967e-4722-82b6-0eed33244124"
      unitRef="usd">999120000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzItNi0xLTEtOTUzOTI_cd106ee3-123f-41cf-bed1-86142a6fd0cd"
      unitRef="usd">999120000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzMtMi0xLTEtODUwMDI_9b28d3f9-21be-4669-b94c-3e69d7407214"
      unitRef="usd">498000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzQtNi0xLTEtOTUzOTI_f5e254ae-e2dc-4d64-9f75-50bf3199549b"
      unitRef="usd">498000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzQtMi0xLTEtODUwMDI_9172fdc5-563e-406e-a305-a1ef5087ab22"
      unitRef="usd">82160000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzUtNi0xLTEtOTUzOTI_21bd31ce-862f-4feb-84a0-6d2a4654877b"
      unitRef="usd">82160000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzUtMi0xLTEtODUwMDI_93fc0e43-ab4f-4422-857b-763d5259cfea"
      unitRef="usd">34379000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtNC0xLTEtOTU0MDA_528f80a4-2d3e-4e9e-b78f-cb71442ca9e1"
      unitRef="usd">-6311000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtNi0xLTEtOTUzOTI_c6d98772-b019-4a69-9924-92072f331996"
      unitRef="usd">28068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzYtMi0xLTEtODUwMDI_d004608e-35e0-460d-9e02-f66856ec5772"
      unitRef="usd">5241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzctNi0xLTEtOTUzOTI_1e72ac55-464e-48ef-a3ca-6605de054e03"
      unitRef="usd">5241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzctMi0xLTEtODUwMDI_9cf64b72-0671-4125-b5d6-ba642fe7b3e6"
      unitRef="usd">28661000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzgtNi0xLTEtOTUzOTI_5b97814d-7483-40c3-8d94-7aa481554091"
      unitRef="usd">28661000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzgtMi0xLTEtODUwMDI_59dbf8c5-2f47-45df-b6fa-8ad9862b80c2"
      unitRef="usd">987500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzktNC0xLTEtOTU0MDA_f88d5736-2fab-40d2-99a2-9461edb280b1"
      unitRef="usd">-397700000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzktNi0xLTEtOTUzOTI_db362d08-4e98-4539-a4b5-5e18e1541bca"
      unitRef="usd">589800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEwLTItMS0xLTg1MDA0_5980040d-75fc-409a-b97a-6e62b1993061"
      unitRef="usd">7197000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzExLTYtMS0xLTk1Mzky_d1c736ec-1611-4a46-8ec7-83991598be3e"
      unitRef="usd">7197000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzExLTItMS0xLTg1MDA0_63f0aefe-0f6b-41c9-911f-b3e07d1e2adc"
      unitRef="usd">33705000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTQtMS0xLTk1NDAw_d4bb60d0-4288-4565-866f-ec304f19ebdf"
      unitRef="usd">7949000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTYtMS0xLTk1Mzky_ff48979d-815f-4cde-b0a7-8eff33b6bacb"
      unitRef="usd">41654000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEyLTItMS0xLTg1MDA0_fc7ba025-db68-47ea-8316-51d7c73073c8"
      unitRef="usd">2509000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEzLTYtMS0xLTk1Mzky_2070084a-7ad3-4d1d-adaf-1830c74b124a"
      unitRef="usd">2509000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzEzLTItMS0xLTg1MDA0_01b1da5f-68be-4fdd-846f-ea8ac342aaa2"
      unitRef="usd">1207000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE0LTYtMS0xLTk1Mzky_c773be7b-4483-4420-8a37-19b43c8993d4"
      unitRef="usd">1207000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE0LTItMS0xLTg1MDA0_d5a621f9-04c6-4fe6-9897-73ed0cbab0b0"
      unitRef="usd">159094000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTQtMS0xLTk1NDAw_8e61584f-57c1-43d3-81e3-c2a7806e6b97"
      unitRef="usd">-88092000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTYtMS0xLTk1Mzky_1536e488-82c5-418a-90a2-a6b37d52aa18"
      unitRef="usd">71002000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE1LTItMS0xLTg1MDA0_9884b71a-e98a-4fc0-a463-11ee9e160b2e"
      unitRef="usd">135088000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTQtMS0xLTk1NDAw_35809ce6-0017-4da9-bce5-1b97bc26c443"
      unitRef="usd">-114300000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTYtMS0xLTk1Mzky_76175999-8da9-4925-8ee2-721db0f28739"
      unitRef="usd">20788000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE2LTItMS0xLTg1MDA0_8eee26d3-27fe-4124-9194-078a3403221d"
      unitRef="usd">799639000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTQtMS0xLTk1NDAw_891ab693-cbc5-4abb-85b7-c0f46fe8dfb2"
      unitRef="usd">-209568000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTYtMS0xLTk1Mzky_b42faba2-0a92-4f54-a133-0a67bd5afbfc"
      unitRef="usd">590071000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE3LTItMS0xLTg1MDA0_273c2e26-b65e-4f05-ac8d-95bab6c03cdb"
      unitRef="usd">199481000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i6dd7555fd6a14b8bb566cc28a52219e2_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE4LTQtMS0xLTk1NDAw_57115ffa-0351-4617-8aac-0bf3e1ff9f5e"
      unitRef="usd">209568000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphNDgwOTAyYjY4ZGI0NDI0ODZkMTAxMTk2YTcxYzg5MC90YWJsZXJhbmdlOmE0ODA5MDJiNjhkYjQ0MjQ4NmQxMDExOTZhNzFjODkwXzE4LTYtMS0xLTk1Mzky_722f2c33-1558-4f4b-b408-f82343d1f888"
      unitRef="usd">409049000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib0e2d0eac3754ad98e02fd455dd5aed7_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzE2NDkyNjc0NTQ2Nzk_f47eb009-16df-429d-842b-233f9fb15db7"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id4843830e52a4d92a52b5a09eac1bca4_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MjExNjI_f8e65733-9087-4b41-961b-fd2bc3528b46"
      unitRef="usd">-114300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDY_6b435435-8ccc-4fcb-9d04-cb8c22b88b63">Useful lives and preliminary values are presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDY_a240009b-32e3-44fc-9de5-56228b18d64d">Useful lives and preliminary values are presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i3c84478a64df453893c7636f8f759caa_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzEtMi0xLTEtODUwMDY_e311293b-bae6-4568-a52b-2375301f96fb"
      unitRef="usd">402000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3c84478a64df453893c7636f8f759caa_D20220524-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzEtNC0xLTEtODUwMDg_2e267498-b4a0-4ef7-a182-d9a37a71ced9">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzItMi0xLTEtODUwMDY_0e6550fa-62b2-452f-9f19-5e43ea841b0b"
      unitRef="usd">136200000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8a0c93185a7a4ff094fd2844ead444a0_D20220524-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzItNC0xLTEtODUwMDg_b5898edd-52a0-4e99-8fd5-9df5db1806dc">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzMtMi0xLTEtODUwMDY_7aa4bee9-abd4-46e1-9973-4f757d1a75ed"
      unitRef="usd">2900000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie04fcf0106464046b05fd28a545a9d99_D20220524-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzMtNC0xLTEtODUwMDg_0c16b277-997a-4735-bd32-7cb6ad401212">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="id0ac13fbf17f4f2e89a956199a4d633c_D20220524-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzQtMi0xLTEtODUwMDY_c46daf3e-b738-4138-94f0-0483f9c5bb8c"
      unitRef="usd">48700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZTphZTg3ZGRlNzk2MzQ0MWNiYjBlZWQ2ODc2MzU2MjgxMS90YWJsZXJhbmdlOmFlODdkZGU3OTYzNDQxY2JiMGVlZDY4NzYzNTYyODExXzUtMi0xLTEtODUwMDY_a12627a7-e488-41ea-b625-b3462b07f2a4"
      unitRef="usd">589800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjUxMg_7768de69-fad0-4da0-804a-97667b33f2a3"
      unitRef="usd">112700000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzU0OTc1NTgyMjU0MQ_7bc9d3c9-561a-49f7-a1f5-3cbf541b5d7a"
      unitRef="usd">-67600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90ZXh0cmVnaW9uOmE1YzI2YzVjZmE2YjQzM2ZiZDU0ZDYyNDFmNjEzMmM0XzM4NDgyOTA3MDU5NDc_b1ca775b-6c87-4343-91d1-818f1f07ee02">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzItMi0xLTEtODUwMTM_2b6a2122-8b87-4a7c-93ec-f55e19d9f24c"
      unitRef="usd">712683000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzItNC0xLTEtODUwMTU_4b62ba4e-aa18-4e6f-86cf-431a750fcc6e"
      unitRef="usd">627292000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i2d619669e18b442786311ba013af06b8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzMtMi0xLTEtODUwMTM_e480f4a0-316b-485d-906f-eb9d1e1ca472"
      unitRef="usd">218723000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ic4f1fd4cefe24310a00885c5c2a24b08_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjEvZnJhZzphNWMyNmM1Y2ZhNmI0MzNmYmQ1NGQ2MjQxZjYxMzJjNC90YWJsZToxYzQ0NjBiZjJkMmQ0NTY1YWZlOTVhZmZkNTc4MzAxOC90YWJsZXJhbmdlOjFjNDQ2MGJmMmQyZDQ1NjVhZmU5NWFmZmQ1NzgzMDE4XzMtNC0xLTEtODUwMTU_aa48a5fa-937d-4163-b535-167e1e47239b"
      unitRef="usd">295634000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMTU_e2ce47d8-93ac-4cc0-9956-4510ab370a5f">Fair Value Measurement&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, 20 available-for-sale marketable securities with a fair market value of $117.2&#160;million were in a gross unrealized loss position of $0.9 million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of December&#160;31, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no available for sale securities that were classified within Level 3 as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMzM_d01a3859-031c-4615-8ad3-64fe620d86dd">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItMi0xLTEtNzQzOTA_b56e2341-eeb6-45b2-bcc3-f5e79e35cf09"
      unitRef="usd">1146000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItNC0xLTEtNzQzOTA_62438e6f-6b84-4f3c-97eb-2e5d222fe7ce"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItNi0xLTEtNzQzOTA_2305c7f2-1ded-495e-a36f-3a36b6449af6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzItOC0xLTEtNzQzOTA_2f4373c6-fe50-4727-8cb9-e20f91448e42"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtMi0xLTEtNzQzOTA_5fe28ff2-c5e4-4bb4-9b78-334d422ef736"
      unitRef="usd">7139000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtNC0xLTEtNzQzOTA_ea6e809a-1d97-4ed9-9586-d93629a1adaa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtNi0xLTEtNzQzOTA_3098513f-be4d-4c4c-b4fa-6dcd3297d563"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzMtOC0xLTEtNzQzOTA_23e0bcbc-45d5-4dcf-a835-2b04b901bfcf"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtMi0xLTEtNzQzOTA_26c7c89c-787f-4a81-bc79-82f22f4123c1"
      unitRef="usd">111469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtNC0xLTEtNzQzOTA_bc8cadab-a481-4d52-98a0-bcd1a09e0115"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtNi0xLTEtNzQzOTA_77bc74d8-409d-4eaa-b365-a9280a0b2c12"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id94bd204eed14a56b841b0ecdc83ef00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzQtOC0xLTEtNzQzOTA_2b5258e5-20cf-4640-afdd-3ce9bc03bf88"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i46732f52d6ca44279534ffa554f17160_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtMi0xLTEtODYyMTQ_20b5b859-055e-4071-8eb2-e3824d9efe35"
      unitRef="usd">2783000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i46732f52d6ca44279534ffa554f17160_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNC0xLTEtODYyMjI_f1e8fdb6-1158-4128-9448-b7e62b41fe3d"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i46732f52d6ca44279534ffa554f17160_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNi0xLTEtODYyMzA_cee6d1c4-5c80-4d68-ab5c-d5b0248f28ea"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46732f52d6ca44279534ffa554f17160_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtOC0xLTEtOTQ1NDE_ef7d15a1-4d6a-4fb8-a603-8c8f4f646640"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtMi0xLTEtNzQzOTA_67a0e6e9-137b-4cfc-b808-27074e366ec7"
      unitRef="usd">7004000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNC0xLTEtNzQzOTA_b84f1b60-e47e-4752-925c-330f4e9013ac"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtNi0xLTEtNzQzOTA_813a84c6-5cc3-4594-8e17-6348769918f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc2cc80566cd460e9bc994220806e7aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzYtOC0xLTEtNzQzOTA_d96667b9-2879-4694-b47f-1be1e387eeed"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctMi0xLTEtNzQzOTA_2aeb7495-094c-4591-aa0c-04eae83b8081"
      unitRef="usd">129541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctNC0xLTEtNzQzOTA_dc4fb9f7-fc4c-4843-8ce0-e2bf3dd7819c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctNi0xLTEtNzQzOTA_1f0f73f3-e40c-493e-977c-b8ea97517f19"
      unitRef="usd">944000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTpjMDg5Y2QxYjEwNjg0NTExODViZGMwMDNhYjA0ODY1MS90YWJsZXJhbmdlOmMwODljZDFiMTA2ODQ1MTE4NWJkYzAwM2FiMDQ4NjUxXzctOC0xLTEtNzQzOTA_5c6afcff-574f-4270-bf1d-832d1664d997"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5224a272d9e145089365401ed07c3c98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItMi0xLTEtNzQzOTA_0f108e2d-d99f-43c8-b9fb-c35dfc9020b4"
      unitRef="usd">32745000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5224a272d9e145089365401ed07c3c98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItNC0xLTEtNzQzOTA_aa00cb01-6c8f-4f5e-9c53-23bd41a8076a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5224a272d9e145089365401ed07c3c98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItNi0xLTEtNzQzOTA_3d2c5525-32f0-46d4-9325-d8fb44ad2e01"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5224a272d9e145089365401ed07c3c98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzItOC0xLTEtNzQzOTA_82f894d5-c6f0-4cda-b1a9-a8b27fcb3b13"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i35353e8145c94fd192b2662112671742_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtMi0xLTEtNzQzOTA_60ee536e-85fd-4c30-8cee-b5312e6f0e7d"
      unitRef="usd">58885000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i35353e8145c94fd192b2662112671742_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtNC0xLTEtNzQzOTA_5150e635-0ca5-4519-ab8c-b96d1bb40d8f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i35353e8145c94fd192b2662112671742_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtNi0xLTEtNzQzOTA_574d3b01-fb38-46fa-a9fb-3ae5edcb5180"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35353e8145c94fd192b2662112671742_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzMtOC0xLTEtNzQzOTA_3ad610a6-2302-49f1-9abe-e6f6cf7f0486"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtMi0xLTEtNzQzOTA_2e46f26c-082d-45d0-9562-a155be08d85e"
      unitRef="usd">231230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtNC0xLTEtNzQzOTA_7b11f873-2bad-4301-9889-7eeb60e67066"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtNi0xLTEtNzQzOTA_7fede8fb-4d3a-4736-9a64-e36da9b1a114"
      unitRef="usd">469000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i597db5b80c0d4a4e9b9958e08a9fa4e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzQtOC0xLTEtNzQzOTA_671390e7-df98-4a98-9020-0060b44d5ea3"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtMi0xLTEtNzgxNTI_9be69273-d155-47fb-a0d0-e4afb51818f9"
      unitRef="usd">17232000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNC0xLTEtNzgxNTY_1a56b7d7-fb7b-4507-a1c8-cdb55c3d3e0a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNi0xLTEtNzgxNjA_cc182308-0d7a-464a-93d1-f597fd9d3e8b"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37ea93e8180f4b39b87c751b2e1c9e85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtOC0xLTEtODMxOTU_5fd7f6f0-d827-4521-b032-326703c06c0b"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtMi0xLTEtNzQzOTA_34867402-06d5-4f53-a27d-da5fcaacfd66"
      unitRef="usd">282731000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNC0xLTEtNzQzOTA_c3ed9e3a-8916-4e59-8f16-0a04cffb7bab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtNi0xLTEtNzQzOTA_21b4d99e-8478-4b4a-af98-1e9e39a3ded5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cab7782001e401d90fa7549f89275f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzUtOC0xLTEtNzQzOTA_0b4a57d5-bcb2-4f83-bca4-d25094efa36f"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtMi0xLTEtNzQzOTA_92e46b45-de7d-433a-9aeb-1af5a47a8a87"
      unitRef="usd">622823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtNC0xLTEtNzQzOTA_1e0ecec6-a4f0-42bc-804e-c4cdee22540d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtNi0xLTEtNzQzOTA_a34690eb-1f38-47a4-b389-e07ba3f10974"
      unitRef="usd">620000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo1ZWViNTQ1YTllYjM0Yzg0YWRiNTA2ZjAzMzk4ZGUxMC90YWJsZXJhbmdlOjVlZWI1NDVhOWViMzRjODRhZGI1MDZmMDMzOThkZTEwXzYtOC0xLTEtNzQzOTA_7976797e-da27-48d5-be52-110a3d842c6a"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEyOQ_4202b5f3-03b0-4172-a3ec-717f988b6134"
      unitRef="security">20</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzIwMQ_3b759b89-5452-4b10-88b0-4c2d4c28c874"
      unitRef="usd">117200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzI0OA_f4eb9abb-2999-4fed-a0c5-780b5e4591dc"
      unitRef="usd">900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMjg_60f78136-f391-4e8d-b885-4d8cb1a42058">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzEtMi0xLTEtNzQzOTA_85a88e4b-db5f-4726-846a-67bd03a1f6f7"
      unitRef="usd">114353000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzEtNC0xLTEtNzQzOTA_c23db440-1e50-4467-8f33-5f37af5f66a6"
      unitRef="usd">500965000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzItMi0xLTEtNzQzOTA_dd58e9ec-76d6-4ed4-9b4b-37e514556ae4"
      unitRef="usd">14246000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzItNC0xLTEtNzQzOTA_fa1d765d-8813-45a6-a7ed-f0cce49cc1ef"
      unitRef="usd">121238000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzMtMi0xLTEtNzQzOTA_b4273f5a-ff0b-475c-b7cf-4cb5e6c3dff1"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTo0NzhiZDAxNmNhMTg0YmMwODE5NGFjY2VhNGVlNDQ4YS90YWJsZXJhbmdlOjQ3OGJkMDE2Y2ExODRiYzA4MTk0YWNjZWE0ZWU0NDhhXzMtNC0xLTEtNzQzOTA_f2d6072f-05f6-44d9-bbfa-65c358932f07"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzEwMzA_1b840746-530b-4e4d-97bc-ec194585ebe0">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26f722a27dd74b5a9adc18b420c72150_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMi0xLTEtNzQzOTA_41cc1b4c-545f-493c-bf0d-884a7592fe78"
      unitRef="usd">191704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e4382062e1f4fcfa9e54b30b7e489a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtNC0xLTEtNzQzOTA_f2606eea-c338-41b9-9409-8a954c5dcb0c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i043b1eced14f4b38ba17b9e0e8ab15b0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtNi0xLTEtNzQzOTA_8398edf1-593a-404e-bae9-691a061d0d3a"
      unitRef="usd">191704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1deac62ace9c4a888e48f6d9be99dc47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtOC0xLTEtNzQzOTA_5cde5dc0-7e95-4a1f-975a-7e13bc402d36"
      unitRef="usd">118707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0bddbb8047a491eb63c197e05eb5ca4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMTAtMS0xLTc0Mzkw_db2ad7cb-91ec-4152-bc58-6e8a01b5ffa9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i43b8615d6e094174ae8446257115cc1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzMtMTItMS0xLTc0Mzkw_bf683083-d7a7-445f-8529-22b6639a47f8"
      unitRef="usd">118707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77bcd41a7e814a89918feebb95c129d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMi0xLTEtNzQzOTA_79fd4d6d-719b-4a35-9de2-439bb3eaf9a7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib382d0872eaf4b9bbec1ce9d6cceaaab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtNC0xLTEtNzQzOTA_e0c0ec3c-0c6d-4131-b88f-abbc42f2d3d4"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f7c5c27f20b465b8dd461326e12ba5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtNi0xLTEtNzQzOTA_efa81c1e-501c-4783-ad2a-db442117599c"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb83fc6f4b8a45c282238332c7a95841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtOC0xLTEtNzQzOTA_7a27c3eb-b0ed-46a5-ba09-3899b04c473d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5560b65f4f134a1a914172192531d861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMTAtMS0xLTc0Mzkw_2eb64b55-a41d-438c-aeb4-1c2cd8e523bf"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5224a272d9e145089365401ed07c3c98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzgtMTItMS0xLTc0Mzkw_614341a0-3992-43c3-8ab4-dd90941cd6f3"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00d7d10d24c84281aed5c4277d167461_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMi0xLTEtNzQzOTA_3b85c7c0-e148-4b44-afb1-c0866a5090be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7c4df731a4f4a4f8fec1bae60a10484_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktNC0xLTEtNzQzOTA_f5153236-de23-4adf-b962-9f15fc8e5df1"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbb3b0de847c46569b96fe8e12cdd1e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktNi0xLTEtNzQzOTA_af10d751-3914-4288-9bb7-06523f34b38e"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i295651e13dfb4e4cb45f942c4b96e6f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktOC0xLTEtNzQzOTA_18e9e971-43d3-4b06-bb33-4e68ab7f87c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i615de6d5889a4f7d9b1e1d3352937654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMTAtMS0xLTc0Mzkw_7f571c9c-163d-46df-a472-1048f54b1cc7"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35353e8145c94fd192b2662112671742_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzktMTItMS0xLTc0Mzkw_0ed4edab-9985-48f3-8742-15963edd8b0f"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab7b7b97519c44cdb7226898a6b54701_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTItMS0xLTc0Mzkw_34266971-fc7c-4d28-80af-38ae6c44a95d"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2eb9ad4bee4649d78ef3bbf1a1aea014_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTQtMS0xLTc0Mzkw_546053f9-db71-47d3-86e4-945601e151fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id61a0f73d0f4425b9a935315a9005c6a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTYtMS0xLTc0Mzkw_7255e293-d805-448d-b746-7014e60b9d5d"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e9ffaaa4bdf4e638aa15b0e3a30d7a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTgtMS0xLTc0Mzkw_6fd2b15e-8956-4bc5-9bae-c7ec31d15704"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c7ded3a1a584de3b69284715edd8be3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTEwLTEtMS03NDM5MA_dcc45ea7-7bff-4dc6-b7bf-1d97ee5e50e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee9996ff38f74a49bde5979244e15762_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEwLTEyLTEtMS03NDM5MA_fea108c2-7669-4afc-b58a-66ae2a52bfe1"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54544bbec51b460cbeee6e64fdecbc48_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTQtMS0xLTc0Mzkw_73923599-9c5d-4d6e-b2c0-4ae231811c4f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i950980fb07fe4ca48b48af65c8b224d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTYtMS0xLTc0Mzkw_9d150699-fe9e-4b08-867c-76dac01da38d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3553503311549e6857ea8d049b691a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTEwLTEtMS03NDM5MA_b037a254-3db9-44fa-926c-8af251133330"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib53f54adb1e5481b8288c131402733b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzExLTEyLTEtMS04NTMxMA_95ad9544-bc2d-4c02-b086-d0f5071fcc83"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d1c66ed8e4d4b888d17e06a9f8a1c64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTItMS0xLTg2MjQx_91e2ba2c-ae02-4561-854b-1e11a9c73c45"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23f0a156c29745f4a1204a53f9dce5d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTQtMS0xLTg2MjUx_5e0cd3ad-33ac-4431-8452-eb7badea6bd6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i877577fc197a449885cec3a196905eba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTYtMS0xLTk0NTUw_55a02427-b847-4431-914a-1ff7bf9436e0"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadbcfda7fe5a4065a2147788d3d2fc7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTItMS0xLTc0Mzkw_4283a1d8-5514-416f-943f-27050334fb75"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ee689853b26446da4160f945de64c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTQtMS0xLTc0Mzkw_5a4f03a1-83f5-4ebb-ad30-9350292d564f"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f39c15bffce464ca04a0703850470a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTYtMS0xLTc0Mzkw_0b87257d-2b9b-4c59-9e56-ea4c85be828e"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78115efa8e2a4a209a2d9ea8a508c0a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTgtMS0xLTc0Mzkw_bb9988ab-bcf0-4a72-8fcc-ca7e0c8eda1c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib225da12484b414eaf886beb6791a1b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTEwLTEtMS03NDM5MA_c6e786b6-ef9c-4f25-84c6-1ee62e1245c2"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8074c437f714421b84dc5a2ed6b754ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEyLTEyLTEtMS03NDM5MA_b1e965a0-41a2-46ea-9a4f-6c053cbddbcc"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7988ef80a8a4481095a9cd1737928a5f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTItMS0xLTc0Mzkw_72f00942-2361-41f1-8dd5-c9b08a3bb254"
      unitRef="usd">305023000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i712a0cd86d3144a297233b33d9781be8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTQtMS0xLTc0Mzkw_e823bed0-a480-48d8-8368-c74e6079823c"
      unitRef="usd">15280000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTYtMS0xLTc0Mzkw_d907cda4-a81d-45f1-a9cc-71d743da02f9"
      unitRef="usd">320303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i732cceb6359a4dd8865fb5bfa8aeddc9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTgtMS0xLTc0Mzkw_9fd86423-f525-492c-b2ea-7ec4ad74f638"
      unitRef="usd">349468000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie14a2f85de0e485aa57a080d39183883_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTEwLTEtMS03NDM5MA_e65268b4-48fa-49d0-8fe6-aae7f321af50"
      unitRef="usd">391442000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90YWJsZTplNjM3NjYxYTJmNzI0ODA4YWFmMTFhOWRhZDZmMzU3My90YWJsZXJhbmdlOmU2Mzc2NjFhMmY3MjQ4MDhhYWYxMWE5ZGFkNmYzNTczXzEzLTEyLTEtMS03NDM5MA_d5a57d44-41e3-459a-8779-c9b23ced04fc"
      unitRef="usd">740910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2e565d32284c4425b05dd65037f38a6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzk0OA_961b4647-fb14-4e5c-a717-3106e968b88f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2f73c68191284413968a1e7705daeae2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzk0OA_ebe3ebfc-3787-4d54-bef0-0033c46d3338"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjQvZnJhZzphZWExYzZlYjI2Zjg0NDYxOTk5ZjIxNGQxMzIwNTNmYS90ZXh0cmVnaW9uOmFlYTFjNmViMjZmODQ0NjE5OTlmMjE0ZDEzMjA1M2ZhXzU0OTc1NTgxNjEwMA_4c7e0e4b-f60b-440a-b707-dac7545fbed7"
      unitRef="usd">15700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4Mzc_12c04c1c-4a44-4b43-b235-1af4142bcbfc">Revenue&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Device Partnered Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Event-based development milestones and regulatory milestone and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales-based milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $429.5 million. This amount represents royalties and sales milestone earned in the current period, as well as $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. We also recognized revenue of $2.0 million during the year ended December&#160;31, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $80.7 million of which $75.2 million relates to unfulfilled product purchase orders and $5.5 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized contract assets of $44.1&#160;million as of December&#160;31, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4NDA_5760a95d-36e2-4291-bcd2-ff19375c73e5">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Device Partnered Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Event-based development milestones and regulatory milestone and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales-based milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f00b40aca7542d28313161e68a2d895_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItMi0xLTEtNzQzOTA_4546fb48-73ee-4383-9bca-7a4115abbebd"
      unitRef="usd">360475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if875bb1e63e949878fcf8a681e6ec0ce_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItNC0xLTEtNzQzOTA_482ccb13-55ef-45bc-835a-998066c30261"
      unitRef="usd">203900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f6f85c9a63a466fbdfef62bc7562524_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzItNi0xLTEtNzQzOTA_4250e05c-3e4e-41cb-9f79-6948db3a1e68"
      unitRef="usd">88596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib07f947ffcad43d1a6fdf23e3ea0bfce_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtMi0xLTEtNzQzOTA_5f015124-38dd-4e7c-9df9-5f6d0a76b339"
      unitRef="usd">82084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eaf51e78af04c08b9c64c703cd9221e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtNC0xLTEtNzQzOTA_ed80f446-05b4-4ab7-a56f-259f4646d8ac"
      unitRef="usd">80960000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8112a093b0c7415eac739e594b629a96_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzUtNi0xLTEtNzQzOTA_f5bf3c37-fdf6-4910-97e3-c4e4e98871d8"
      unitRef="usd">38956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4880129e17ee45a6a5ecb048862fed65_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtMi0xLTEtNzgzMTc_a5be6214-c229-428c-9c2d-36b01e26a1fc"
      unitRef="usd">72849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb52ba56d5ce40bbbf9715e825b909b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtNC0xLTEtNzg0MDI_11be0f85-58d7-416a-a58d-993d344e0ac8"
      unitRef="usd">23264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i597a7d3db45a491e997fe35aa9195b3c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzYtNi0xLTEtNzgzOTA_87e9774b-e72e-4925-ab8d-e4ab8173e81a"
      unitRef="usd">17031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd9e40e7d2f244e7b9f66aabd6640852_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctMi0xLTEtNzgzMzI_f3aa467c-cded-468d-97b9-85a448cb263c"
      unitRef="usd">36097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75bae0cb0a8a47fb8fcca30b77f6d60e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctNC0xLTEtNzgzMzY_4e4c4ab4-7ce2-481e-b63b-6e704cc4c329"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6fd44e583748d3937db0246f9e5e4f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzctNi0xLTEtNzgzNDI_106fcd07-d757-41af-b8a9-920e715c1e31"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0911d5f6918c4f1083743c5111a08024_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtMi0xLTEtNzQzOTA_da4f4601-36a6-489f-8518-3cdc28c6251f"
      unitRef="usd">191030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ca632ce7334a4992d8adfb08d11006_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtNC0xLTEtNzQzOTA_b7ae06af-4c12-44a9-88d2-cfc2a8602569"
      unitRef="usd">104224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i344b333a61af4787b8a9e0e2b935d46a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzgtNi0xLTEtNzQzOTA_fc839084-bfb6-49f8-9512-077cfe3627d9"
      unitRef="usd">55987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f2f770cb08e46b1a34f5576b2a08663_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTItMS0xLTc0Mzkw_52c46979-1365-4831-a902-c91d9efa27fa"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0700499fc900499a90faac950d6d4b98_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTQtMS0xLTc0Mzkw_333e5015-d485-43be-8d1a-3d398ec77033"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i023f24dd6ed643a38263bb9cabdf7718_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzExLTYtMS0xLTc0Mzkw_01f794b1-2e8e-47d1-b19b-dfd04b642e60"
      unitRef="usd">37264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0faa2d5cad4416b986007776707121f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTItMS0xLTc0Mzkw_a35f0aea-824f-4c7d-b6db-97af468f7940"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b10c333e5154705818149064609c145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTQtMS0xLTc0Mzkw_600dfc6f-f139-4661-b867-878fc4dac2cc"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1416bdf7345c4bbabccb8d19a9cf5196_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEyLTYtMS0xLTc0Mzkw_c47714da-a3b1-4a1c-bec9-97a8f3a89215"
      unitRef="usd">69500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41fcd05c589b426dac58da8abe28d615_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTItMS0xLTc0Mzkw_9a3f6219-9eb2-408e-a64f-0a5ec2645ea1"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice50c8c082a44a54a348b09d6dad8248_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTQtMS0xLTc0Mzkw_171009ed-2eb8-473d-a08d-d6ad0116e7ca"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf4ba887d67549afa576d9763e0d4017_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzEzLTYtMS0xLTc0Mzkw_7ac55d36-80de-4b59-84c5-acf3556402ec"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if85e98d198d2439aa49f4b9aba5ac485_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTItMS0xLTc0Mzkw_74cb8d2a-269d-40b0-add0-7954a2f815b1"
      unitRef="usd">9611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i616018ae8ce340d4a55a54fe3fc0c272_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTQtMS0xLTc0Mzkw_db210134-992c-490e-9bae-a53e915e8e8b"
      unitRef="usd">1186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aaaf000b7794cc1afa3317b68317e08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE0LTYtMS0xLTc0Mzkw_2d13fee8-ad53-41a3-af45-955e4d870d00"
      unitRef="usd">1247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f2ee03eb3ae42acae06c554688ff728_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTItMS0xLTc0Mzkw_efe983de-83ea-49d5-9011-40d782a92226"
      unitRef="usd">108611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8cb45d74ed44b0a910586f81c3f482b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTQtMS0xLTc0Mzkw_1525f97e-fc37-471c-b4c4-922121b77947"
      unitRef="usd">135186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3218e59ea5c54aa5860ecd3f237d34d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE1LTYtMS0xLTc0Mzkw_1f77b4a5-4256-4c0d-aac3-61152cb0c7f9"
      unitRef="usd">123011000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTItMS0xLTc0Mzkw_62f81c8b-ece3-4a81-a5e9-280d04cc59f4"
      unitRef="usd">660116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTQtMS0xLTc0Mzkw_7be1b223-75df-424b-a7d8-6de357730a75"
      unitRef="usd">443310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTo0NzI4NzM0ZjFlNzA0NTg2YTZlMjY1NTE5NGJiNTY0NS90YWJsZXJhbmdlOjQ3Mjg3MzRmMWU3MDQ1ODZhNmUyNjU1MTk0YmI1NjQ1XzE3LTYtMS0xLTc0Mzkw_2bccc657-7867-446a-b37d-56a1fb06af3d"
      unitRef="usd">267594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzIxMg_46d11c31-ba1b-415c-a07b-3e87d5e07d63"
      unitRef="usd">429500000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
    <halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement
      contextRef="i2b67aab8964449fb89bd5540b396933d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzMxMQ_36d71683-b9ca-4936-88f9-7e7d2fa4108d"
      unitRef="usd">59000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9a90a57424684701b78e04f25324c4d3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzUwNg_eb68afa3-f8ef-4ccf-a810-fbfef44f61b5"
      unitRef="usd">-2000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE4MjQ_e91a886c-f25b-40e9-9940-fa78c3f83ec9">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzEtMi0xLTEtNzQzOTA_1ddac736-e799-451d-bf53-06b40e075d35"
      unitRef="usd">186970000</halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets>
    <halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzEtNC0xLTEtNzQzOTA_58d5eec4-4cb3-40ee-b8c0-a7c89c502bc5"
      unitRef="usd">90975000</halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzItMi0xLTEtNzQzOTA_495cf8b1-1d14-4187-8f0e-93b027f3414d"
      unitRef="usd">44102000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzItNC0xLTEtNzQzOTA_6b7066b1-183d-4304-930f-7ff6cfac441c"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzMtMi0xLTEtNzQzOTA_d9a88b22-423a-4830-a806-40d30d3119f3"
      unitRef="usd">5499000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90YWJsZTpjMmEzOGZiZWZjOGU0MDdjYjRlYWU0M2U2YzgyMTJjZC90YWJsZXJhbmdlOmMyYTM4ZmJlZmM4ZTQwN2NiNGVhZTQzZTZjODIxMmNkXzMtNC0xLTEtNzQzOTA_5a222fda-370e-49ab-9904-984673c4cb2e"
      unitRef="usd">4276000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i69070eb1e6084fa48dccbf68b4d6f8d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExMTE_3291e636-6b28-40ae-88d0-151933416d60"
      unitRef="usd">80700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="i1cbad069681845ec855aab295e5acbce_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExMjM_32435db4-723d-4b16-b72a-a5a3b8aa3e4c"
      unitRef="usd">75200000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzExNzc_7fa525a1-f32d-4d83-bf56-441de41c4cc6"
      unitRef="usd">5500000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzEzNDU_7fa525a1-f32d-4d83-bf56-441de41c4cc6"
      unitRef="usd">5500000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie4592615a3c74e559071621a0a01a228_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzEzNDk_210fcdb5-34ad-4c80-bfe3-130003ebcfac"
      unitRef="usd">3200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ie4592615a3c74e559071621a0a01a228_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzE0MDg_1935b20c-7613-44ec-947d-279bb0b34b95">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMjcvZnJhZzo1NTY2YWU4YzBkNTk0YzJkOTc1YjZiYzUwY2M0YjUzYi90ZXh0cmVnaW9uOjU1NjZhZThjMGQ1OTRjMmQ5NzViNmJjNTBjYzRiNTNiXzM4NDgyOTA3MDA4OTk_9650a637-7a02-40ca-911e-868a0a9ec48c"
      unitRef="usd">44100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExOTc_c7b2067b-5060-403d-b35f-a3d3ad1b7766">Certain Balance Sheet Items&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d"&gt;Right of use of assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was approximately $6.5 million, $3.0 million, and $3.3 million, inclusive of ROU asset amortization of $3.0 million, $1.6 million and $1.7 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense associated with the accretion of the lease liabilities was approximately $0.5 million, $0.3 million and $0.5 million for the twelve months ended December&#160;31, 2022, 2021 and 2020, respectively. Total lease expense for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $3.3 million, $1.9 million and $2.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts related to leases for the twelve months ended December&#160;31, 2022, 2021 and 2020 was $4.2 million, $2.7 million and $3.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMjE_09a2cb8e-c60b-44d4-9509-c56dea78aa31">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzEtMi0xLTEtNzQzOTA_d2aa5d71-4c9e-4082-9b7c-b043a3a4c2f4"
      unitRef="usd">62979000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzEtNC0xLTEtNzQzOTA_7250f87d-1fc7-4503-a62e-99b07d6521ab"
      unitRef="usd">18504000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzItMi0xLTEtNzQzOTA_61723767-d297-42cb-9eb0-d60b3a9759af"
      unitRef="usd">18776000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzItNC0xLTEtNzQzOTA_2976a900-1ea2-4bbb-9e7c-cc5c4cc54b8c"
      unitRef="usd">5422000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromroyalties
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzMtMi0xLTEtNzQzOTA_f5619f27-ac77-4704-b0ff-1aeb4e1adc4d"
      unitRef="usd">100900000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromroyalties
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzMtNC0xLTEtNzQzOTA_5c5911bf-957b-422b-92e3-6b590725afcc"
      unitRef="usd">63555000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromproductsales
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzQtMi0xLTEtNzQzOTA_c8b639df-1321-4ebe-a5ca-ce82caff5c62"
      unitRef="usd">6229000</halo:Accountsreceivablefromproductsales>
    <halo:Accountsreceivablefromproductsales
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzQtNC0xLTEtNzQzOTA_2ee1723c-cd14-45fa-9685-f04cde78aa6d"
      unitRef="usd">4634000</halo:Accountsreceivablefromproductsales>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzUtMi0xLTEtNzQzOTA_495cf8b1-1d14-4187-8f0e-93b027f3414d"
      unitRef="usd">44102000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzUtNC0xLTEtNzQzOTA_6b7066b1-183d-4304-930f-7ff6cfac441c"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzYtMi0xLTEtNzQzOTA_fe05ad17-7b7b-4a34-9642-ee4e0fbc80c7"
      unitRef="usd">232986000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzYtNC0xLTEtNzQzOTA_89cde978-cee8-40e6-a324-5b348e4451e3"
      unitRef="usd">92115000</us-gaap:AccountsReceivableGrossCurrent>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzctMi0xLTEtNzQzOTA_8d4ac7f2-fc43-48dc-b6ac-8ef4e40e151b"
      unitRef="usd">1914000</halo:AllowanceforDistributionFeesandDiscounts>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzctNC0xLTEtNzQzOTA_004e0c10-f4e3-4e7f-99c1-e0c94656749b"
      unitRef="usd">1140000</halo:AllowanceforDistributionFeesandDiscounts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzgtMi0xLTEtNzQzOTA_9f646636-ede8-4f6c-93f5-cf38966ec874"
      unitRef="usd">231072000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpkYzI2NjFjZWY0YWU0MGIyYmZjNTNhMWIyMzA0YmIxNy90YWJsZXJhbmdlOmRjMjY2MWNlZjRhZTQwYjJiZmM1M2ExYjIzMDRiYjE3XzgtNC0xLTEtNzQzOTA_59431d01-f8e7-4019-9a8f-18caa3549abf"
      unitRef="usd">90975000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMjI_238342d5-ed9d-4901-8837-c6e29f4c6bf8">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzEtMi0xLTEtNzQzOTA_40b00e95-174d-4b90-8197-8bee3610acd7"
      unitRef="usd">13792000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzEtNC0xLTEtNzQzOTA_536aa3f8-407e-4fb4-95c1-ab6ee0b1ab48"
      unitRef="usd">10672000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzItMi0xLTEtNzQzOTA_db675912-8bb3-4bf8-98d0-6f93ad3c71ca"
      unitRef="usd">40361000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzItNC0xLTEtNzQzOTA_9163b76d-284f-4693-9d7c-5819c6edc50c"
      unitRef="usd">17451000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzMtMi0xLTEtNzQzOTA_b25e9078-41bc-48e4-b5ba-b6c9d3fab54f"
      unitRef="usd">45970000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzMtNC0xLTEtNzQzOTA_999d6488-295e-4023-9613-10cd8fb4049e"
      unitRef="usd">25785000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzQtMi0xLTEtNzQzOTA_bee0a077-a34b-441e-b8d3-5ebf510540ef"
      unitRef="usd">100123000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpjOTA4ZDJmMWE4NDU0ZDk3OWM0OTBkZDg0OTVlOTg5NC90YWJsZXJhbmdlOmM5MDhkMmYxYTg0NTRkOTc5YzQ5MGRkODQ5NWU5ODk0XzQtNC0xLTEtNzQzOTA_18218ae9-bec6-4b42-a236-695389c714c9"
      unitRef="usd">53908000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNzY_5f2c8aa1-dc31-4cdc-ae01-a7eadd8f5f54">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzEtMi0xLTEtNzQzOTA_d7b9cd46-06fa-4a40-97c7-1532b51877b0"
      unitRef="usd">51694000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzEtNC0xLTEtNzQzOTA_d7cb5c61-5af2-45c1-81f5-9353270589c7"
      unitRef="usd">47991000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzMtMi0xLTEtNzQzOTA_3ceec5f1-fff7-405a-b958-d62ec2e88fc6"
      unitRef="usd">4647000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzMtNC0xLTEtNzQzOTA_8394f522-7189-4900-b64c-4388752fde8e"
      unitRef="usd">3809000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzQtMi0xLTEtNzQzOTA_3640b1bf-b3ed-4678-9e1c-eb017eb4363d"
      unitRef="usd">14984000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzQtNC0xLTEtNzQzOTA_d73c1ec4-9ca0-4879-8e4d-c2b84d5c1238"
      unitRef="usd">2096000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzUtMi0xLTEtNzQzOTA_af7ac967-f996-434d-a1be-a49cc9a89d6f"
      unitRef="usd">71325000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzUtNC0xLTEtNzQzOTA_5bcc451a-0890-44ae-aeda-785989fccaa7"
      unitRef="usd">53896000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzYtMi0xLTEtNzQzOTA_f0f5ef94-e568-4918-8f66-69211f181c02"
      unitRef="usd">26301000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzYtNC0xLTEtNzQzOTA_3376c587-aec6-47be-8060-6e794ccdf247"
      unitRef="usd">13414000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzctMi0xLTEtNzQzOTA_ad8d030e-bacb-41dc-879d-523162b19809"
      unitRef="usd">45024000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo1ZmVhNjQ2ZDY2ZmU0OGM0ODNjZWNmNzZiODAxOTE1Zi90YWJsZXJhbmdlOjVmZWE2NDZkNjZmZTQ4YzQ4M2NlY2Y3NmI4MDE5MTVmXzctNC0xLTEtNzQzOTA_2a928fde-214d-4df9-80dc-1903d62b6e2e"
      unitRef="usd">40482000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEyMTc_d36430b4-625c-4d87-adbb-8613e01f1893">Property and equipment, net consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_448cd850-2be6-463b-8de1-bb14dbbf7fb8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMC0xLTEtNzQzOTA_ede7b25f-2f11-40a5-a02b-ef6b0387739d"&gt;Right of use of assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b33c1eddff241b7b992cad79cd90321_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzEtMi0xLTEtNzQzOTA_a78ec63c-bd99-4a06-b6b4-612487da3d80"
      unitRef="usd">7380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5103cb702ff64758983fc79a04fae1aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzEtNC0xLTEtNzQzOTA_d481b2d2-ff55-4779-ac13-56ef831da746"
      unitRef="usd">7174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie21db3970f77426c9be0b7002d0bc269_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzItMi0xLTEtNzQzOTA_b7445fb3-6a01-4100-a9d7-7efb85b29ca0"
      unitRef="usd">27893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i358cffcf78784467b140596c17157c72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzItNC0xLTEtNzQzOTA_c4a57458-7483-4756-ba85-6a873b78e83e"
      unitRef="usd">5719000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96c68a9508eb404082e43ef1e4a75c24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzMtMi0xLTEtNzQzOTA_a2a5d844-3da2-4e59-8082-7eec7e9b0952"
      unitRef="usd">7855000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia230ccd2446e49578990a8e709b8b5cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzMtNC0xLTEtNzQzOTA_bd863739-ed01-4818-ae04-32013fa8c642"
      unitRef="usd">5370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i026e429b3e77423ca0b1a2eddcd26847_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzQtMi0xLTEtNzQzOTA_4aaf0b2c-4293-49a1-aeff-d26842915cda"
      unitRef="usd">6729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iba6d68430cff43a0ae03fd967d945fa0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzQtNC0xLTEtNzQzOTA_e222de22-b99d-4165-8517-c443ab87d8e3"
      unitRef="usd">1628000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzUtMi0xLTEtNzQzOTA_8b7a0d97-a11b-49c7-8184-f74eed8412ac"
      unitRef="usd">49857000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzUtNC0xLTEtNzQzOTA_f1673df3-b4e4-4a30-ad8b-6eaa0eb6d9ae"
      unitRef="usd">19891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzYtMi0xLTEtNzQzOTA_9720be8d-79b9-49f4-8f0f-d6da8d7cd3ca"
      unitRef="usd">14756000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzYtNC0xLTEtNzQzOTA_d4a48926-676c-4ea1-98b0-45008c678506"
      unitRef="usd">13100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzctMi0xLTEtNzQzOTA_9e060dd4-3c65-4480-8176-4a0404a9c082"
      unitRef="usd">35101000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzctNC0xLTEtNzQzOTA_aa84a261-f2f5-495c-a8ac-11832800aa2d"
      unitRef="usd">6791000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtMi0xLTEtNzQzOTA_1c1d6fb5-55d6-4e21-a8e4-3cae6e5fae42"
      unitRef="usd">40469000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzgtNC0xLTEtNzQzOTA_b64d7123-46f2-477f-8f34-bf453bc72272"
      unitRef="usd">2003000</us-gaap:OperatingLeaseRightOfUseAsset>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzktMi0xLTEtNzQzOTA_7946445b-3fe1-4586-ae15-912c6cdbd6b2"
      unitRef="usd">75570000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTo5YTk3NjYyZDQyZWM0NzQxYmM1MzEzYTIxY2NiNGM1NC90YWJsZXJhbmdlOjlhOTc2NjJkNDJlYzQ3NDFiYzUzMTNhMjFjY2I0YzU0XzktNC0xLTEtNzQzOTA_aeb2d788-69e2-4cb3-adcc-3ab3c723cfa3"
      unitRef="usd">8794000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY4Ng_8488e3bc-9b0d-4a28-b4bd-f9adb1e9616a"
      unitRef="usd">6500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY4Ng_c8cad1dc-e876-4b39-a595-d0ac6f65774a"
      unitRef="usd">6500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzY5MA_f022c007-c4c9-45dd-bb3c-a83a3a16912b"
      unitRef="usd">3000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzU0OTc1NTgxNTEyNg_b2145956-c92d-4e07-997e-618029e16878"
      unitRef="usd">3300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc0MQ_2e7301a5-e435-4aa4-a502-2ba7fb89cdad"
      unitRef="usd">3000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc0NQ_b2f40e14-0891-4951-88da-b8d9374e1876"
      unitRef="usd">1600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzc1Mg_c09ef873-3fc0-4f46-bb1c-87f7e757baba"
      unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExODE_ed6367a8-9cf7-492a-92a4-df5616624343">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_96a58706-5437-43e3-8bef-1e9a7d164c08"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMC0xLTEtNzQzOTA_b2283dac-e84d-4b20-8dda-8396866dd07b"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzItMi0xLTEtNzQzOTA_b671cbd8-0449-44c9-b3ca-c425d533bfa3"
      unitRef="usd">19939000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzItNC0xLTEtNzQzOTA_2a335f1f-56be-43de-a487-2070cd5157f8"
      unitRef="usd">9858000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <halo:Accruedmanufacturingexpenses
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzMtMi0xLTEtNzQzOTA_f60d8db3-26fc-41da-876b-c1c2c682be94"
      unitRef="usd">12190000</halo:Accruedmanufacturingexpenses>
    <halo:Accruedmanufacturingexpenses
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzMtNC0xLTEtNzQzOTA_2001ef1c-0af0-4e5c-b4b1-d764cd34769f"
      unitRef="usd">6514000</halo:Accruedmanufacturingexpenses>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtMi0xLTEtNzg2MDA_a06cace9-d199-4edd-85c6-a0787d9ec7f8"
      unitRef="usd">0</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtNC0xLTEtNzg2MDQ_573e2ccb-87d6-4477-b246-30a61cf4f5bb"
      unitRef="usd">1439000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMi0xLTEtNzg2MDA_f69e6767-a968-403f-b2a4-fd9bb99e4476"
      unitRef="usd">30261000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtNC0xLTEtNzg2MDQ_e15e29e1-d156-44a8-bb59-8a33f4c43343"
      unitRef="usd">706000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtMi0xLTEtNzQzOTA_167e03b0-e392-4d12-8de8-3a8b0079518a"
      unitRef="usd">29771000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzQtNC0xLTEtNzQzOTA_36f4a89c-e0b0-42e5-8c79-bdcb828a82aa"
      unitRef="usd">3648000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtMi0xLTEtNzQzOTA_c073f310-4f97-434c-a0a7-cf6e4fab4c23"
      unitRef="usd">34788000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzUtNC0xLTEtNzQzOTA_d358bd7d-f5dc-4470-9d8c-cecf621cc397"
      unitRef="usd">2820000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzYtMi0xLTEtNzQzOTA_3861f857-60c7-43ac-83fb-df521850f2a7"
      unitRef="usd">126949000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzYtNC0xLTEtNzQzOTA_f4381c3a-8fbf-4843-8c22-1c7c8d7f300d"
      unitRef="usd">24985000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzctMi0xLTEtNzQzOTA_b47b5db9-ea87-49a5-830d-9937de03210d"
      unitRef="usd">30433000</halo:AccruedLiabilitiesNoncurrent>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzctNC0xLTEtNzQzOTA_bab86996-63e6-406f-b91b-fc7830967130"
      unitRef="usd">544000</halo:AccruedLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzgtMi0xLTEtNzQzOTA_407c971c-626d-4906-a5e5-cc644a35ab3d"
      unitRef="usd">96516000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90YWJsZTpmYzI2YmM0MDRjOWI0NmRiOTZiNWI5MmFmZWJkZTFiMS90YWJsZXJhbmdlOmZjMjZiYzQwNGM5YjQ2ZGI5NmI1YjkyYWZlYmRlMWIxXzgtNC0xLTEtNzQzOTA_23cf7631-d131-4da6-b403-d3d8de213c60"
      unitRef="usd">24441000</us-gaap:AccruedLiabilitiesCurrent>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzkzNw_5ea3d222-ffc1-4ed5-98e9-bd5e4bf5f366"
      unitRef="usd">500000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzk0MQ_4ecf3846-239d-462e-9fac-60550f6ac9e9"
      unitRef="usd">300000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzk0OA_a2941c35-3b66-496f-b1ad-685e44ecbf0c"
      unitRef="usd">500000</halo:OperatingLeaseAccretionOfLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNDQ_3b632798-d5c8-466e-b867-57245a671f92"
      unitRef="usd">3300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNDk_38985484-b8f5-4aab-89cc-ffb2bd20fec2"
      unitRef="usd">1900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzEwNTY_d662dd5c-eb42-43f4-9c51-c43bff088efd"
      unitRef="usd">2200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNDY_cd5883b2-d13c-45db-8972-0feff683234b"
      unitRef="usd">4200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNTA_3be62fc5-51ee-485b-aec6-76f18bfefce5"
      unitRef="usd">2700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzAvZnJhZzpkYjRjYjI2MDBiZmQ0ZDc5YmM4ZDU4Mzg1NTQzNGQzMS90ZXh0cmVnaW9uOmRiNGNiMjYwMGJmZDRkNzliYzhkNTgzODU1NDM0ZDMxXzExNTc_7363817f-be7c-45cc-a5f1-f8beb85ce3fe"
      unitRef="usd">3200000</us-gaap:OperatingLeasePayments>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDM_d314ae57-8384-4771-a767-b1a89313ff63">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares. A Goodwill balance of $409.0&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk1OQ_f58b5d2c-2f99-454c-b819-957e5d1ad0df"&gt;seven&lt;/span&gt; to ten years. The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDkzOA_5bb0edc5-af11-4fdb-90b4-4c69b4a64f35"
      unitRef="usd">409000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDQ_d77cba80-0901-4c40-afc7-c7e165b77c30">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzAtMi0xLTEtODUxMjA_3901922d-a846-4a0b-9872-9cb151380c74"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzEtMi0xLTEtODUxMjA_6d88dd73-b1a4-4a0b-bf16-fdf6bea605cf"
      unitRef="usd">409049000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTozYWIyZjk4NmU3YTc0ZmJmODc2OTViNGFkMzZkZmFkMS90YWJsZXJhbmdlOjNhYjJmOTg2ZTdhNzRmYmY4NzY5NWI0YWQzNmRmYWQxXzItMi0xLTEtODUxMjA_e97b1e2a-57fd-4ce6-abcb-2fd0e8b5f981"
      unitRef="usd">409049000</us-gaap:Goodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzU0OTc1NTgxNDk3MA_9211750f-8b39-41f5-a219-0b05b8380879">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDU_6dfb0689-d7a1-4eec-9c67-ced3e312ae88">The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDU_96f0eade-0a68-4cd5-8b47-3993390cd3d9">The following table shows the cost, accumulated amortization and weighted average remaining life in years for our acquired intangible assets as of December&#160;31, 2022 (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto-Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1892e4c1066a4e5ca9ecbf598525a0af_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtMi0xLTEtODUxMjY_44e4f062-dbb4-4250-b600-aa744554fed6">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ida924054054447ada0707db648939f23_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtNC0xLTEtODUxMjg_fdc2e711-92f4-4813-83c6-81dd0929be02"
      unitRef="usd">402000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ida924054054447ada0707db648939f23_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtNi0xLTEtODUxMzA_15b2b81d-d8ed-44ca-b3b5-ce79e19f6872"
      unitRef="usd">34735000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ida924054054447ada0707db648939f23_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzEtOC0xLTEtODUxMzI_06480cde-a441-4003-ab36-87d561e92de0"
      unitRef="usd">367265000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i61f2f3a242d74ae0839b985994afacfe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItMi0xLTEtODUxMjY_4585a527-3310-413e-b592-e015bddf4094">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i092e2002b6d245c29ce295a98666505c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItNC0xLTEtODUxMjg_d9c98209-b02d-4dc7-96b0-0d428b369e23"
      unitRef="usd">136200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i092e2002b6d245c29ce295a98666505c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItNi0xLTEtODUxMzA_f595f2b7-f1bd-42de-80d6-0562fcb51aed"
      unitRef="usd">8238000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i092e2002b6d245c29ce295a98666505c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzItOC0xLTEtODUxMzI_64ce580e-aa05-4b32-b474-be6dfcc9a941"
      unitRef="usd">127962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1746187612e2471bb184a56028b058f5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtMi0xLTEtODUxMjY_1899cb27-4d98-43cf-91e1-82ba1de4eec3">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtNC0xLTEtODUxMjg_4e86f7bd-fe0d-44f4-940d-571bdaa81ea9"
      unitRef="usd">2900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtNi0xLTEtODUxMzA_62e23ee4-7ca0-4280-b62b-0444cd90473d"
      unitRef="usd">175000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i653f9955b2014441a9bd9524de9a0b9e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzMtOC0xLTEtODUxMzI_2e454fd6-d766-44eb-985c-64f868ad987d"
      unitRef="usd">2725000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtNC0xLTEtODUxMjg_29600986-ed4d-4e6b-b385-2923c7eedf66"
      unitRef="usd">541100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtNi0xLTEtODUxMzA_bcf92c3e-9c79-45ea-b755-2daaee9ca2b0"
      unitRef="usd">43148000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzQtOC0xLTEtODUxMzI_e1237bc9-0fb3-433c-8066-07507796ae83"
      unitRef="usd">497952000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzUtOC0xLTEtODUxMzI_7bfa58bf-3c2f-4ece-88bc-c12f699d10ad"
      unitRef="usd">48700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTo3ZTk5NGZiODA0ZjY0NWUxOTg4YmY4Nzc1YzM0YjE1OC90YWJsZXJhbmdlOjdlOTk0ZmI4MDRmNjQ1ZTE5ODhiZjg3NzVjMzRiMTU4XzYtOC0xLTEtODUxMzI_ed210064-3e50-4d70-9911-9b5487d64216"
      unitRef="usd">546652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90ZXh0cmVnaW9uOmRlY2M5NDRiN2JlNDQ3ZTI4YzExZDYyMGVmNjU5OWMxXzM4NDgyOTA2OTgzMDY_0167d37e-b11c-4302-aae4-b7bee97e6ce9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzEtMi0xLTEtODUxNDk_b19cc93b-bba3-4b41-9c13-f266014f0f31"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzItMi0xLTEtODUxNDk_13dc6270-f3c2-472d-a036-7ae830df834f"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzMtMi0xLTEtODUxNDk_30234fc3-5669-4aa1-9a3e-31999005422e"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzQtMi0xLTEtODUxNDk_f49d85c5-6f6e-44a9-b834-f8223f15efa8"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzUtMi0xLTEtODUxNDk_930d7fe4-41a4-4c85-893e-6476bc855a13"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzYtMi0xLTEtODUxNDk_9553e5e8-5142-493c-9343-570a5174a005"
      unitRef="usd">141257000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzYvZnJhZzpkZWNjOTQ0YjdiZTQ0N2UyOGMxMWQ2MjBlZjY1OTljMS90YWJsZTplZGE0MjNiZThhNjE0MDMxOTQ2NzM0NjAyZTIzMjgyOS90YWJsZXJhbmdlOmVkYTQyM2JlOGE2MTQwMzE5NDY3MzQ2MDJlMjMyODI5XzctMi0xLTEtODUxNDk_7f0b392b-c9b0-4647-99a3-a935e41a1483"
      unitRef="usd">497952000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDkz_61d232a1-1f48-42bb-ae52-8aee60ab67e0">Long-Term Debt, Net&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.00% Convertible Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#x201c;2028 Convertible Notes&#x201d; and collectively with the 2024 and the 2027 Convertible Notes the &#x201c;Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2028 Convertible Notes are not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#x201c;Capped Call Transactions&#x201d;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of December&#160;31, 2022, no capped calls have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to their terms, the capped calls qualify for classification within stockholders&#x2019; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#x2019; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the Condensed Consolidated Balance Sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#x2019;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.25% Convertible Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#x201c;2027 Convertible Notes&#x201d; and collectively with the 2024 Convertible Notes the &#x201c;Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#x2019; fee of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of December&#160;31, 2022, the 2027 Convertible Notes are not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.25% Convertible Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#x201c;2024 Convertible Notes&#x201d;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#x2019; fee of $12.7 million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3 million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of December&#160;31, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#x201c;2021 Note Repurchases&#x201d; or the &#x201c;2021 Induced Conversion&#x201d;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Operations for the twelve months ended December&#160;31, 2022. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#x201c;2022 Note Repurchases&#x201d; or the &#x201c;2022 Induced Conversion&#x201d;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which is included in other income (expense) of the consolidated statements of income. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment of $13.5&#160;million to effect the redemption in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of the Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon Interest:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Coupon Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit and Term Loan Facilities (May 2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#x201c;2022 Credit Agreement), evidencing a credit facility (the &#x201c;2022 Facility&#x201d;) that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#x2019; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#x201c;Amendment&#x201d;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#x201c;Administrative Agent&#x201d;) and swing line lender (in such capacity, the &#x201c;Swing Line Lender&#x201d;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#x201c;Credit Agreement&#x201d;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of December&#160;31, 2022, the unamortized debt issuance cost related to the revolving credit facility was $3.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities and interest payments of long-term debt as of December&#160;31, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amount representing coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross balance of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion and unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,492,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA0MA_a62746b6-1f35-4970-ac0d-a44effac3ed3"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA2NA_93f41eb6-c414-4bb3-9ea2-447581f25b1c"
      unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDA4Ng_64109338-a653-49bb-acc8-6705e049e7f2"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDEwNw_5a7b20b2-3af1-465a-8cf9-019d1c815e0e"
      unitRef="usd">18000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDEzNw_c02fd79c-bcc9-4caa-a918-ac7e80d8d506"
      unitRef="usd">702000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE2Ng_47b2ec02-5cd9-43df-abaa-0255861d7353"
      unitRef="usd">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE4Ng_a2cfa316-3484-4769-bb80-2d4c354d4f23"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDE5OA_805ee6e8-f084-4381-9379-21ca799232f0"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIwNw_18480a9a-0c18-4a06-a736-d2e692f3ca40"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i8442bf2908144a9e9b2a160cebe7c5e2_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIxNA_a32cff64-d168-403a-b080-63f430e01862"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays
      contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIyMg_ab333ca6-5ea2-4d9d-a7aa-969dc68361a2"
      unitRef="businessday">5</halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIyOA_27c7300d-7cc5-4a49-84d8-08d4e709f891"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDIzNA_6416f21a-223c-41f1-8e4f-d378c12fc94e"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i26feb30a349f4629ab23f872b2ca1479_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI0MA_0195e4f5-495c-49f4-8e08-3e3f6370628a"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="if55871e494994b2eb51eefb6ffaa9eee_D20220801-20220831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI2NQ_8a791e9e-65e4-4af2-9f55-3377a95ea2b2"
      unitRef="number">17.8517</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ic24180acc66b4c2788f9aa46657e38d0_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDI5Ng_bdab0f0b-e305-46ca-ab91-ac572dc76360"
      unitRef="usdPerShare">56.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <halo:DebtInstrumentCapCallTransactionCapPricePerShare
      contextRef="ifb78064361704a2b8da472621b690b46_I20220831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDMyOA_b42c17bd-e9b1-494a-b1a6-ce9548caa5b4"
      unitRef="usdPerShare">75.4075</halo:DebtInstrumentCapCallTransactionCapPricePerShare>
    <halo:SaleOfStockPremiumOverLastReportedSalePricePercentage
      contextRef="i972d75b65de044d88aaa7a44774f336d_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM1NQ_b43d0696-d0be-4ce3-9d74-9b9785ed8d38"
      unitRef="number">0.75</halo:SaleOfStockPremiumOverLastReportedSalePricePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia37a3aaaa88549e188282c778e953fba_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM0NA_55bb62ed-d07b-4455-abb4-e54d7c0d71eb"
      unitRef="usdPerShare">43.09</us-gaap:SaleOfStockPricePerShare>
    <halo:PaymentForCappedCallTransactions
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMDM3NA_06769d75-0c93-4518-913e-861e6ea316ae"
      unitRef="usd">69100000</halo:PaymentForCappedCallTransactions>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzI4_1b498e78-f228-4cd6-80d0-4d082b679f6e"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzk4_2154fe00-d4a9-4244-bba8-83944a14f665"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzEzNA_b2c51a1d-939f-45ae-a0d1-8440c63869b7"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQwMw_c2f37d80-143e-468b-8fd6-9dae5d1abac1"
      unitRef="usd">20100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i2f827aac2a7f4d6ba5ee22c890a4ad04_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQyNQ_813832c6-76a9-435c-886a-9da8469fcca9"
      unitRef="usd">784900000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQ4Ng_f366c9b8-bdbe-410f-aa0d-7002eda9c43b"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzcwNg_7b6c21d9-7cdd-4800-a67f-5e0cd9425821"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2MjI_d4bd48eb-3aaa-4770-9753-2d663250a3bd"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2NzA_0e7b5152-d033-4b17-8f76-754835da22be"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i0c293ba73ec14d8ab2e369c1c9e20059_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzE2OTc_25070eeb-b714-4765-8f06-68527c560829"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDc3_d1ee043c-0841-4e78-a66f-ae82a69b541f"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDg1_04486b50-3628-48d7-b60d-6236e9fde370"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i25f1666399a640d8a20a056007f7d2f0_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzIxMTc_b44d4495-ebd0-4ae4-b4fa-4939c28a6cf1"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="icf33756e393d4e4dab1584c3d86547d0_D20210301-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzMxODk_eb966ad5-a0e7-46ba-8968-8d32755f1a00"
      unitRef="number">12.9576</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ie370140c043940ccaecdf292abc511eb_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzMzMjM_3359c6a6-3f2b-4847-bf58-0e82d32fe1f6"
      unitRef="usdPerShare">77.17</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM1NDc_5679bbb7-3278-4068-986c-4dd4ca203295"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM2MjA_378426b9-6762-4315-ba8f-22e6e17b1866"
      unitRef="usd">460000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM2NTY_754f1c84-a818-44ed-9483-0b762340d99e"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4Mjc_916421cb-4bfd-46b1-b814-373e3370d440"
      unitRef="usd">12700000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4NDk_78e80aec-8083-49ec-8652-d02e38d8a933"
      unitRef="usd">447300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4OTg_4dea3285-87c5-4e54-a479-75fe7dca1c0f"
      unitRef="usd">300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzQxNDQ_9e728caa-fbfe-4b0b-beb1-d109d5500437"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUwNjc_ac1f5bce-5c9e-44a7-b162-68f0b8a396f4"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUxMTU_0109801f-3a30-43b7-bf5d-38845bea47be"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifb55488282dd4b958067934ecba25817_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUxNDI_36de6fa4-6c66-41a8-82b1-fc7c2cf63cba"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUyNzk_737b3bed-02b0-4e42-8436-039ae1869326"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUzMzA_e53fd116-2d8b-4368-b13b-f55f15ceb25d"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzUzNzA_5fa9800d-cc65-4faa-aaac-e29530a9ccbf"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="iabacd803b5ad450bac3486fe6ad635f0_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU1NTY_877e8dcf-1658-48d7-b921-8b1ee67b5a64"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i3fe4bdf447e146d884d45ac743fa3649_D20191101-20191130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY0MTQ_208dbab3-0c78-4d57-8dba-f6188c68a8dc"
      unitRef="number">41.9208</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="iade1f569835e40b9a1f4b38283707214_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY1NDg_cd0834f4-4584-48ca-b1f0-48b35debc8b5"
      unitRef="usdPerShare">23.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY3MDI_6c78706d-0707-4d06-8366-be25421ca36b"
      unitRef="usd">369100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY4Njc_4a60ec0a-58d3-48db-acbd-bc325384d0fb"
      unitRef="usd">370200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i5ebad8a2b3ab4c8d923acb99e7f8c557_D20210301-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzY5NTE_44585733-7563-412d-ba8e-380e1feb8685"
      unitRef="shares">9080000.00</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzcxNjI_638c865d-072d-48a5-8ad3-8ade8d8f9bb3"
      unitRef="usd">21000000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTI4Ng_a352148c-3600-48cd-8929-d2e3696e0f7e"
      unitRef="usd">77400000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTMxNQ_ba3d53de-250a-4bc1-9abd-b821da106c25"
      unitRef="usd">77600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTM0Mw_71ef3d20-9504-4fd3-9d73-eac5dfb1e8f5"
      unitRef="shares">1510000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzMTM3MA_516c0550-5d1b-4bf6-8681-fe6708823f50"
      unitRef="usd">2700000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i1520c9eee1f745169c91ccff5d6b28d5_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzM4NDgyOTA3MjIyOTM_b07f7b85-6cb5-400e-93a2-d3811b9c2809"
      unitRef="usd">13500000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDc4_95e7b770-f706-4121-8023-65cd1f04187d">&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzItMi0xLTEtNzQzOTA_3445b9b3-abd7-47c3-a010-8ba73828dabc"
      unitRef="usd">13483000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzItNC0xLTEtNzQzOTA_fb7c3503-30e2-4836-9c33-bcb89f21c19d"
      unitRef="usd">90936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzMtMi0xLTEtNzQzOTA_f3af7336-7f03-47dd-8fd1-4c4485ebb9dd"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzMtNC0xLTEtNzQzOTA_2e00bf2e-8bec-41e4-945b-77ce9d0ed6ee"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id2dda495c5d645e186db199b0df8597d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtMi0xLTEtNzkyMDI_1a072152-37d7-42e3-bdca-6be33b27cdc4"
      unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtNC0xLTEtNzkxOTQ_e6660325-4fa5-4219-b9eb-7cd7183f38fb"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtMi0xLTEtNzQzOTA_675045ec-c9c5-4202-a81c-8ebed64b4a22"
      unitRef="usd">1538483000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzQtNC0xLTEtNzQzOTA_b20c417c-8ff4-4a09-9e72-f88daead9587"
      unitRef="usd">895936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzctMi0xLTEtNzQzOTA_ee6daef2-c60c-4c3c-9ef3-13b6b73af342"
      unitRef="usd">149000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzctNC0xLTEtNzQzOTA_11b8e64b-3263-4cf5-bb43-00d47f334e6e"
      unitRef="usd">1517000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzgtMi0xLTEtNzQzOTA_745014d4-5806-4f8b-ab03-7db4d30a0e94"
      unitRef="usd">14359000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzgtNC0xLTEtNzQzOTA_18d85f50-ec4c-4fa7-973e-da20b851fef9"
      unitRef="usd">17745000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="id2dda495c5d645e186db199b0df8597d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEwLTItMS0xLTc5MjM4_7f95fc23-5fae-45c9-84a5-daeac2692a1d"
      unitRef="usd">17875000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEwLTQtMS0xLTc5MjMw_363fbd0c-55bb-401c-b0d8-9cb2e3c43c48"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzktMi0xLTEtNzQzOTA_168443e5-fcb7-4f7c-b103-6e5734f0f1f0"
      unitRef="usd">32383000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzktNC0xLTEtNzQzOTA_647106a7-f549-495b-8f7d-a828f886d85b"
      unitRef="usd">19262000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayable
      contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEyLTItMS0xLTc0Mzkw_e6b9b7c4-2c56-4d06-8d23-80ed26c612e1"
      unitRef="usd">13334000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEyLTQtMS0xLTc0Mzkw_98cc6e1f-6343-4b38-85dd-30cfb3ca624d"
      unitRef="usd">89419000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEzLTItMS0xLTc0Mzkw_c6311f0d-ac30-4992-b102-d36b1e64dd63"
      unitRef="usd">790641000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzEzLTQtMS0xLTc0Mzkw_6486100e-e772-4df3-aa3c-29ef3d3db286"
      unitRef="usd">787255000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="id2dda495c5d645e186db199b0df8597d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE2LTItMS0xLTgzMjQ3_cdfddfb7-fc4e-46e3-9c92-29554e47116b"
      unitRef="usd">702125000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE2LTQtMS0xLTgzMjU1_bd6c95df-5f3a-4294-ad6e-bc14c17f883f"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE0LTItMS0xLTc0Mzkw_9d30c1aa-8335-45be-b032-3b97c58e0454"
      unitRef="usd">1506100000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE0LTQtMS0xLTc0Mzkw_ead307a2-1cf8-4e05-a0da-2fff5a7f39f2"
      unitRef="usd">876674000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iea1c2507713c4df99577b5f739d6ca30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE3LTItMS0xLTc0Mzkw_c7332748-037e-4aaf-9e4c-167c8feec6bb"
      unitRef="usd">32176000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i76bc9547c7f444b18e2ad2b95607f4c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE3LTQtMS0xLTc0Mzkw_ba5edeb1-1858-4d53-8a9b-b38eb439b51a"
      unitRef="usd">159678000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i331533d9ad814e1893350fa816c1bff2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE4LTItMS0xLTc0Mzkw_1c94d487-d91a-48cc-9d19-231aa653e23d"
      unitRef="usd">784770000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i55fe4bb4bcec457485790bf0cbd54177_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE4LTQtMS0xLTc0Mzkw_c3a7228b-5ac0-4c31-9ba4-1ba0e2d92c33"
      unitRef="usd">718889000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id2dda495c5d645e186db199b0df8597d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTItMS0xLTc5MjUx_ea377ec4-75a1-4993-a41e-5d05d69f3b24"
      unitRef="usd">849823000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5bc071eb48f04102a50c800a5c43ac33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTQtMS0xLTgzMjU3_32ee4e60-f009-4ee1-9b3c-3f5c482b125b"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE5LTItMS0xLTc0Mzkw_94274bf1-aafb-4c8c-b95d-c01019e75088"
      unitRef="usd">1666769000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzE5LTQtMS0xLTc0Mzkw_6e902ce1-2418-47f4-ab3b-f383fb64650a"
      unitRef="usd">878567000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ic4cad7588dd84f14b8c473eab048f4ff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTItMS0xLTc0Mzkw_05564cbf-b573-448e-b1b4-a19d9d81bc35">P1Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i3193ab8c85db49f3a4a9823da38d8dc6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIyLTQtMS0xLTc0Mzkw_24848fd6-5585-479b-bb21-d63f906a9d3a">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="if3c657f7c7aa4b2cb4c74f3daa87f921_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzIzLTItMS0xLTc0Mzkw_115a8dce-1c97-42ba-8973-7883bb7a5a4d">P4Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i79bfd4954a6f40fa97c846c2ec979f5f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzI3LTQtMS0xLTgzMjYx_0d7f85f2-3b74-4935-948f-eaacc18ec8e9">P5Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i6640df7e0ae2463c8b79ef848a1764c9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTpiNjBjY2UwZjdkNGQ0Nzg3ODM5YzgxNjJmZGJmOGE0NS90YWJsZXJhbmdlOmI2MGNjZTBmN2Q0ZDQ3ODc4MzljODE2MmZkYmY4YTQ1XzI4LTItMS0xLTc5MjYx_1560fc6d-bfbf-437b-804d-c69ea5db6425">P5Y7M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDg2_848cf99f-57a3-4fe5-8299-b5ce5c02fa1b">&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon Interest:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Coupon Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit and Term Loan Facilities (May 2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#x201c;2022 Credit Agreement), evidencing a credit facility (the &#x201c;2022 Facility&#x201d;) that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#x2019; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#x201c;Amendment&#x201d;)  among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#x201c;Administrative Agent&#x201d;) and swing line lender (in such capacity, the &#x201c;Swing Line Lender&#x201d;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#x201c;Credit Agreement&#x201d;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of December&#160;31, 2022, the unamortized debt issuance cost related to the revolving credit facility was $3.1&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzMtMi0xLTEtNzQzOTA_25e791fa-a351-47fc-bfbc-1c72c7649022"
      unitRef="usd">771000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzMtNC0xLTEtNzQzOTA_e3c9703f-5534-42bb-8155-dd4301e5faeb"
      unitRef="usd">1906000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzQtMi0xLTEtNzQzOTA_75b1b9c5-a887-4835-971f-bf44e2730641"
      unitRef="usd">2013000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzQtNC0xLTEtNzQzOTA_dc3003c8-f78b-4f45-9280-14868e2c4cb2"
      unitRef="usd">1677000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtMi0xLTEtNzkzMzg_ac87696e-094f-4317-87c5-8f4685299f6c"
      unitRef="usd">2660000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtNC0xLTEtNzkzMzQ_f3c9ac4c-9788-4343-8a3f-2fbb982267ce"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtMi0xLTEtNzQzOTA_ef416488-bb95-48f8-9085-0134c491fb7a"
      unitRef="usd">5444000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzUtNC0xLTEtNzQzOTA_c7dd6977-00ac-4ce1-b8bb-9fd250192a38"
      unitRef="usd">3583000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzgtMi0xLTEtNzQzOTA_f7568901-3a93-4854-a220-b1cd548849db"
      unitRef="usd">357000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzgtNC0xLTEtNzQzOTA_75463287-0fe1-4a60-a6a9-2d2bbf179a80"
      unitRef="usd">838000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzktMi0xLTEtNzQzOTA_588c5536-9d6a-4379-82fe-5186c3f362be"
      unitRef="usd">3386000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzktNC0xLTEtNzQzOTA_4a1194cf-2730-4688-b618-3a123a4d4cb5"
      unitRef="usd">2804000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzExLTItMS0xLTc5MzU4_d2b17169-1d02-4ba4-8296-cff55a38c0dc"
      unitRef="usd">1124000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzExLTQtMS0xLTc5MzUz_89f3bbbe-274b-4f39-87b1-eb7e610dbf3e"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEwLTItMS0xLTc0Mzkw_d4ef8ae6-6cfb-40f1-b99d-75f4d30a2a5e"
      unitRef="usd">4867000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEwLTQtMS0xLTc0Mzkw_ce551230-1bb3-459e-9f9d-ada857a974ec"
      unitRef="usd">3642000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i6f407711aaf64227803041f2eee55522_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEzLTItMS0xLTc0Mzkw_ffcb6154-4ed8-4640-a7fc-cae86a81ed0d"
      unitRef="usd">1128000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib81a77ff4873498cb333ff94745ee997_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzEzLTQtMS0xLTc0Mzkw_28b91e2b-3994-413c-8e24-bc53db284528"
      unitRef="usd">2744000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ieb249df73c554100acb70a04e107a1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE0LTItMS0xLTc0Mzkw_97c75b85-640e-464a-b578-036ba7c82f01"
      unitRef="usd">5399000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ibef86c7a001d44acabeecacd35d4757e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE0LTQtMS0xLTc0Mzkw_140ca618-584a-46d2-aea9-9bdc31dc5406"
      unitRef="usd">4481000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9fda7522287d46afb55413abf54c3425_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE3LTItMS0xLTgzMjY3_a33a11b5-3470-4cb7-a72a-9754dde00441"
      unitRef="usd">3784000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1976532762e34e4b9532e9d5532eb102_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE3LTQtMS0xLTgzMjc0_178e2f2c-c7a9-4903-9223-920cb04f4d2b"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6d424a7f2fa64b0ca5577aac7fc5537a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE1LTItMS0xLTc0Mzkw_845914c9-23ac-4248-8baf-7aff3b4cfe1a"
      unitRef="usd">10311000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i478f49b7e7a3468bb3395af3044839e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE1LTQtMS0xLTc0Mzkw_753a82cb-13f4-4943-9dba-1193a17efbd1"
      unitRef="usd">7225000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ide89d55cf7d0475f89869db8cc5fdbe8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE4LTItMS0xLTc0Mzkw_5727978c-251f-4ce3-a7fb-6cac6a239718"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1e4625c024584b4d8d8743379dc7d92c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE4LTQtMS0xLTc0Mzkw_2b8e3c08-2f07-4c1a-a574-dc274487fe0e"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i703c64067ee4482fa9fb83302bac63af_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzE5LTItMS0xLTc0Mzkw_6b198f92-9e03-49f5-8deb-1e4dcf31fdc1"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id0b58f9782c2498893a72173de677682_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzIyLTQtMS0xLTgzMjgw_b3bd4dc8-c36a-41cd-94ae-4e01687fd73b"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0dbbe44f2ba045c184c92f9829993116_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZTplNGEyMmE0ZDY5NTM0MGEwYjhmY2VlYTcyMWUxZDYyMy90YWJsZXJhbmdlOmU0YTIyYTRkNjk1MzQwYTBiOGZjZWVhNzIxZTFkNjIzXzIzLTItMS0xLTgzMjc2_f2ffbb22-e707-4e29-803b-c45e6bf446cc"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie09d99918fc743c484565395961829c3_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODMxOA_1272a142-aa8e-4005-b610-e560dbc88844"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4742da9fb4d0482b803c94968d340b74_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM0NQ_d4f5ec34-f52b-425a-b2dc-707f46a148bb"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i59247bc7b3264b0e86653efe7c50ef9a_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM3Mg_3afa6f62-d433-4fa4-8953-635c84521395"
      unitRef="usd">120000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i8ea8d2ab91694fe48abae65438654fbd_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODM5OQ_19019e94-8d12-4cb1-a381-1d8a4959fd20"
      unitRef="usd">250000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i689f2de5af2642238ab9ec7684b8feaa_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQxOQ_610f51e1-6ed5-4f5c-bb8d-5749f4cafc9b"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8462f2e104247cfb928c19b4f5a2e9b_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQzMg_505a90d6-b3f9-4469-b963-fd08cc3ebd09"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8aaeded4049949cc8d23c4b49d1bfbee_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ0NQ_7b0e135f-cc48-480a-8665-32289316ce12"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ1OQ_1bd52f8e-aa92-4511-8870-06c75184e264"
      unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7b8f6b3e1e1496b952d76ad8f6aed71_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ1OQ_21e93b6e-b3ae-4438-9f0f-c21463ad29cb"
      unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6503f2b3881e494aad8c2e128e68f23e_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ3Mw_5c8b9bea-a918-4566-8c91-e918e7bbb16c"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i65af036188ba41eb9fe14b30fb6f1f23_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ4Ng_44227ea2-1b17-472e-acd5-b5d593c1c25a"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iad72bf7f121e428cab4063032f673cf8_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODQ5OQ_de04651c-d0e1-46ea-ae19-31169ad9f52d"
      unitRef="number">0.0110</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8764e1163d9d4b42a29fc48e21d37b26_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUxMg_618c3f05-6728-406d-ae99-1369fb5cc764"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if262c47c59524111aa76f3840681c866_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUyNQ_8385bc31-7483-4137-899e-2fcc8db9f797"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2000d717e3b8448690bbc1088fd76ea0_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODUzOA_0cb0e7f1-67b5-4faf-9031-c6180c19f20b"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i26f1c68d52374db68ae5953d4cd57bf9_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU1MQ_e0181319-7a2d-44c2-bef0-8eb85d7105dc"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idbde07f8da7e4c42b763a251cf0afea0_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU2NA_b82a2418-7fcd-4df9-8448-9029aceb45e7"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="id6dbdd6695e246f4ad6f672de1aadaa2_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU3Nw_f921e839-8a5d-4084-b0e3-8e43c6f61eba"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i8c06e4fe9e8a43a382f8063e6334c895_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODU5MA_2723cbdb-9ed2-43aa-ab23-e5a0fdc35e81"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie09d99918fc743c484565395961829c3_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODYxMA_fc7d5447-92b4-4ab9-97b4-32e5e78a6681"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i492b1e853ac0430faf0bcfe39c9d177f_I20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODYzNw_259a423f-e64b-4371-99ac-f7657b826e5a"
      unitRef="usd">575000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ie09d99918fc743c484565395961829c3_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODY2NA_1f0f47a7-da6e-4ddb-9fe1-a964e49520a4"
      unitRef="usd">3600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i3d39948aab61416789923cae1ff3c69e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzU0OTc1NTgzODY5MQ_68205490-fd5a-485f-aa74-4f15d6bcc44a"
      unitRef="usd">3100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90ZXh0cmVnaW9uOjgyZWQ4ZThhMWViODQ0N2Y5ZGExY2M0N2QzNjgyMTljXzExMDgw_b548e943-918c-4a67-8430-6ae917a17226">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities and interest payments of long-term debt as of December&#160;31, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amount representing coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross balance of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion and unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,492,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzAtMi0xLTEtNzQzOTA_4b68052b-a075-45d1-b06a-d836a9feb988"
      unitRef="usd">22745000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEtMi0xLTEtNzQzOTA_b9ffc44f-5647-4165-9516-5a329c2725a3"
      unitRef="usd">9213000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzItMi0xLTEtNzQzOTA_d97c2787-d6d9-437b-9cfc-3a95a4bea107"
      unitRef="usd">9213000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzMtMi0xLTEtNzQzOTA_9f2823a2-a059-43aa-9260-6fb0481dc986"
      unitRef="usd">9213000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzQtMi0xLTEtNzQzOTA_ed050b2f-2437-4884-a73f-2d7bdd4faa18"
      unitRef="usd">812535000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzUtMi0xLTEtNzQzOTA_adb2ca7f-3770-4e86-9ab6-3c89eeeb176f"
      unitRef="usd">724480000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <halo:LongTermDebtIncludingInterestGross
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzYtMi0xLTEtNzQzOTA_5ebffe69-c5e4-41d2-92eb-a40e84722990"
      unitRef="usd">1587399000</halo:LongTermDebtIncludingInterestGross>
    <halo:LongTermDebtInterestGross
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzctMi0xLTEtNzQzOTA_a6bdbcd5-9f69-409d-af3d-ebd393ca7c7c"
      unitRef="usd">48916000</halo:LongTermDebtInterestGross>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzgtMi0xLTEtNzQzOTA_78f19b30-baff-4bd5-a9e2-4705565d7f78"
      unitRef="usd">1538483000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzktMi0xLTEtNzQzOTA_6fae817b-4e7f-44e1-803f-d40d586124b1"
      unitRef="usd">32383000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEwLTItMS0xLTc0Mzkw_e666cc00-735b-4d1c-a5f0-3861a6bfba40"
      unitRef="usd">1506100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtCurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzExLTItMS0xLTc0Mzkw_5f363caa-13ed-4778-a440-1fc1738e1a91"
      unitRef="usd">13334000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xMzkvZnJhZzo4MmVkOGU4YTFlYjg0NDdmOWRhMWNjNDdkMzY4MjE5Yy90YWJsZToxMTgxNmJkYmZiYmI0MTY5ODQ1NGJmMWVlMDQ1MDA1Ni90YWJsZXJhbmdlOjExODE2YmRiZmJiYjQxNjk4NDU0YmYxZWUwNDUwMDU2XzEyLTItMS0xLTc0Mzkw_d15a2e88-1330-43f2-8217-16caecce754c"
      unitRef="usd">1492766000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMzk_7c8af158-3736-4ac1-8747-1807e0fbbce8">Share-based Compensation&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently grant stock options, restricted stock awards, performance stock units and restricted stock units under the Amended and Restated 2021 Stock Plan (&#x201c;2021 Stock Plan&#x201d;), which was approved by the stockholders on May 5, 2021 an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provides for the grant of up to 17.8 million shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended December&#160;31, 2022, we granted share-based awards under the 2021 Stock Plan. At December&#160;31, 2022, 6,550,075 shares were subject to outstanding awards and 14,764,481 shares were available for future grants of share-based awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#x2019;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of December&#160;31, 2022, 2,650,103 shares were available for future purchase. The offering period is generally for a six-months period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the twelve months ended December&#160;31, 2022, 32,124 shares were issued pursuant to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Options granted under the Plans must have an exercise price equal to at least 100% of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest at the rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option award activity as of and for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&#160;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$33.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$171.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$171.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$126.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair values of options granted during the years ended December&#160;31, 2022, 2021 and 2020 were $14.22 per share, $18.21 per share and $20.74 per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $21.6 million, $33.5 million and $49.7 million, respectively. Cash received from stock option exercises for the years ended December&#160;31, 2022, 2021 and 2020 was approximately $15.3 million, $16.6 million and $66.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#x201c;Black-Scholes model&#x201d;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.91-50.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.01-46.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.57-51.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37-4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.36-1.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22-1.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity during the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$29.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$26.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$59.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $8.6 million, $6.6 million and $10.1 million, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was approximately $11.3 million, $19.0 million and $14.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;A PSU is a promise by us to issue a share of our common stock upon achievement of a specific performance condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSU activity during the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$40.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$41.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$63.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$27.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$46.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the PSUs was based on the closing market value of our common stock on the date of grant. The fair value of PSUs vested during the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6347633a08434f869706fa2b2f074866_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMQ_c861d380-90bc-40c2-b444-c757ddf1c007"
      unitRef="shares">17800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards
      contextRef="i01989d60674a45c6ab5875f437acf6a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzczOA_b6a3b0be-5458-4f83-bfea-4112290d57b2"
      unitRef="shares">6550075</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4Xzc4Nw_688efd1e-9432-480c-a393-34031d2e57d0"
      unitRef="shares">14764481</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTA_4b28467d-ce81-4c85-8372-aab331a137a9">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7d039d4e0614847a563288bd41158dd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItMi0xLTEtNzQzOTA_3842ae28-6bbe-4947-99a2-0c01b6211f31"
      unitRef="usd">9903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibdeb7c5afc384d8ba911a737f1419fb9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItNC0xLTEtNzQzOTA_08f556a9-8077-4036-914f-da57a316a3ce"
      unitRef="usd">6992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc18d66d2f8f44a4b0473fbc86ab01c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzItNi0xLTEtNzQzOTA_ad34a0a6-1d61-4625-af19-2c6cbc16951b"
      unitRef="usd">5484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id935d90decb947c3a71099b77bbdac41_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtMi0xLTEtNzQzOTA_70ab1d60-afe9-4442-bcf0-64df8f8fc2f7"
      unitRef="usd">14494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec84c34382b44c1e86f9926be1ce3983_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtNC0xLTEtNzQzOTA_7f145e42-3ebd-4e61-b422-cc3b7d3cbde5"
      unitRef="usd">13828000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifdcc06b9a17743358ff945dd4bed0581_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzMtNi0xLTEtNzQzOTA_4ba8d7ad-1612-4cf4-8e1f-3aee1ddd4a7e"
      unitRef="usd">11720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtMi0xLTEtNzQzOTA_1ec244c8-0683-43cb-aa20-cc860c503c68"
      unitRef="usd">24397000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtNC0xLTEtNzQzOTA_f67aaafa-4fa0-4cf5-a155-8065d576fd9e"
      unitRef="usd">20820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpkYWUyYjY3YTBlNjE0MjM5ODhkMjM1NDc4ZWFhZjA3NC90YWJsZXJhbmdlOmRhZTJiNjdhMGU2MTQyMzk4OGQyMzU0NzhlYWFmMDc0XzQtNi0xLTEtNzQzOTA_88b65a1a-dc42-465a-bf19-ee6958eb53db"
      unitRef="usd">17204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTE_6d5118d9-d4eb-4824-9d46-36535d6c0ea1">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItMi0xLTEtNzQzOTA_06877995-7eb2-42fd-8a62-e8e55cb7dc6a"
      unitRef="usd">10973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItNC0xLTEtNzQzOTA_63f35339-3b29-4b8e-a61e-11d85813909b"
      unitRef="usd">10252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzItNi0xLTEtNzQzOTA_6c2e37d5-3a31-4f92-8ef4-4cae440db100"
      unitRef="usd">8955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7bcc82bb2f64c658849f7c71cab48e6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtMi0xLTEtNzQzOTA_51194f4e-91e1-4589-830e-fff4302791dd"
      unitRef="usd">13424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95e361b0a7e3429099a5544603eb7191_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtNC0xLTEtNzQzOTA_1b059a9c-a253-4014-adbd-76a6440155e6"
      unitRef="usd">10568000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69087abdb2354c6392a5a633290514cd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzMtNi0xLTEtNzQzOTA_eb7e9e09-f8da-4e24-a838-83b633ea5fd7"
      unitRef="usd">8249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtMi0xLTEtNzQzOTA_2de17cb1-32b2-4b7a-b1d1-1ecaf981f2ed"
      unitRef="usd">24397000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtNC0xLTEtNzQzOTA_9db80a5c-8c97-403f-b960-0ccade5bb473"
      unitRef="usd">20820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpiMDhiMzcwN2VhNjk0ZmFiODFhODI2ZGMxZGM0ZWUyOC90YWJsZXJhbmdlOmIwOGIzNzA3ZWE2OTRmYWI4MWE4MjZkYzFkYzRlZTI4XzQtNi0xLTEtNzQzOTA_83b51e13-d87a-4526-b80d-fb5399972ca6"
      unitRef="usd">17204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMDA_81aaccb7-2593-4877-9d9e-ad178a755147">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib8de33c335a241468926b3ab8403600b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzItMi0xLTEtNzQzOTA_065b38f5-e39a-4288-9414-0437b5e32a4d"
      unitRef="usd">26730000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzItNC0xLTEtNzQzOTA_c979de26-6d96-44c9-8fb3-2f21ea2cd464">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzMtMi0xLTEtNzQzOTA_5e34d8cf-d616-4c0f-94d4-b3bd7579ce9e"
      unitRef="usd">26488000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzMtNC0xLTEtNzQzOTA_564ff225-b6c9-4005-80ad-6625462b1e39">P2Y3M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzQtMi0xLTEtNzQzOTA_981945e4-daf1-4e02-af42-beea4c28171f"
      unitRef="usd">3986000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzQtNC0xLTEtNzQzOTA_c0e046e5-25ca-4e47-99b1-c039d1c30162">P1Y10M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idd57b3450df84c0c9a4020d97056c443_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzUtMi0xLTEtNzQzOTA_85cbb308-0679-4080-af9e-f6a74fb97d87"
      unitRef="usd">247000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i23d72a210e204519967ca7ede33dc391_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo2ZmVlZDhmMWY1ZTk0OTdiYjhjMTNmNTk0M2NjZmVkNS90YWJsZXJhbmdlOjZmZWVkOGYxZjVlOTQ5N2JiOGMxM2Y1OTQzY2NmZWQ1XzUtNC0xLTEtNzQzOTA_744f378b-b113-4a1c-a426-4e416f7efedf">P0Y5M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE1MTc_58e8537c-5ea8-44c5-a6c7-b36eb7091b4c"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="i99cb9a7240414e81abe47db83af3899f_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE3MTk_c7e2b162-7307-4335-8417-ac7bfcb3be71"
      unitRef="number">0.01</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i99cb9a7240414e81abe47db83af3899f_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE3MzI_e02f5961-34a7-4d79-b012-088dccb5217c"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE4NTQ_751bfbb2-8f13-4ea0-8256-d4bb37fe6661"
      unitRef="usd">25000</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0f0d2c8d2d884311ac502e7ea910dc91_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzE5MTQ_46e182d9-b48c-4eb7-863e-94c16f39d358"
      unitRef="shares">2650103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="ie15c7376a90243deab24b59f9d6ac8d4_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxNDM_5e9590be-5a24-4952-87e1-976de53bdff5">P6M</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i744eaed75e9d41b98136429882bab1e4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU0OTc1NTgyMTEwMw_be2c7f3e-ba17-4bce-bcf6-800e93d3b656"
      unitRef="shares">32124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzI0NDM_ea6aa13b-c387-43a8-a1c7-f183c7c70ac7"
      unitRef="number">1</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzI1NzA_c3776739-bd0c-494e-9c7b-5c6905faddaf">P10Y</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMjA_9de894c7-2c78-48a3-8b01-f413360dc9fe">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option award activity as of and for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&#160;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$33.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$171.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$171.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$126.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzEtMi0xLTEtNzQzOTA_3e82fe02-2d78-4897-a000-d9dc367a43a5"
      unitRef="shares">4965374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzEtNC0xLTEtNzQzOTA_cdbc910e-6248-49b7-8175-b0ce6d8cef6d"
      unitRef="usdPerShare">20.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzItMi0xLTEtNzQzOTA_7021a696-88b8-4b4f-a370-80a3e71bae7d"
      unitRef="shares">1773912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzItNC0xLTEtNzQzOTA_a8d6451d-776c-4f67-94d9-8c654f81bac5"
      unitRef="usdPerShare">37.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzMtMi0xLTEtNzQzOTA_a65d93de-88b9-4597-bb4a-c060203e536e"
      unitRef="shares">789870</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzMtNC0xLTEtNzQzOTA_dd90cae5-7dab-4894-8049-efd78c7bf5fc"
      unitRef="usdPerShare">19.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzQtMi0xLTEtNzQzOTA_c5afc763-45b5-428a-8462-868b3f62719b"
      unitRef="shares">581191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzQtNC0xLTEtNzQzOTA_4e9a603d-e878-4533-aaee-4bb97ab795fa"
      unitRef="usdPerShare">33.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtMi0xLTEtNzQzOTA_f6aa5243-b498-4f91-9c52-0e1ac44ad3ed"
      unitRef="shares">5368225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtNC0xLTEtNzQzOTA_d1965781-261f-4f8c-8dcf-a538bf296a58"
      unitRef="usdPerShare">24.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtNi0xLTEtNzQzOTA_ee21eaa4-2445-483c-aca2-20a02cf133ce">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzUtOC0xLTEtNzQzOTA_32d57543-1a5f-4a33-83d3-fd40507c0d81"
      unitRef="usd">171300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtMi0xLTEtNzQzOTA_bc6cfce7-109f-4152-ae6a-34f0b6532396"
      unitRef="shares">5368225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtNC0xLTEtNzQzOTA_bf15b7ac-80bb-43a7-a141-d1e99bf41ce0"
      unitRef="usdPerShare">24.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtNi0xLTEtNzQzOTA_18f15636-a711-40f0-9b01-f99552ac9125">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzYtOC0xLTEtNzQzOTA_a8d73a3c-7c3e-488e-bab7-d741228cc5c0"
      unitRef="usd">171300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctMi0xLTEtNzQzOTA_5a385dcc-9f4b-4c5e-93de-55fd41018cd4"
      unitRef="shares">3176691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctNC0xLTEtNzQzOTA_5ce518d1-23d0-464c-a9e3-30855c5d0f02"
      unitRef="usdPerShare">17.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctNi0xLTEtNzQzOTA_fb6b6a46-676a-416d-8992-8be2f2d39f32">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToyMzQ3NTUzMzVkMDQ0OTY2OWFlNTE0YWE3ODFmN2MyZC90YWJsZXJhbmdlOjIzNDc1NTMzNWQwNDQ5NjY5YWU1MTRhYTc4MWY3YzJkXzctOC0xLTEtNzQzOTA_8c7f0b65-efcb-473b-bef1-d353ab3b52da"
      unitRef="usd">126000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMTM_b2680287-3773-4d59-8808-b2777751ae90"
      unitRef="usdPerShare">14.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwMjc_2331eab2-70cb-4984-a459-c19a948fea1f"
      unitRef="usdPerShare">18.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMwNDQ_0ea32591-4377-461a-9c04-a1c55f832b47"
      unitRef="usdPerShare">20.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNjM_a058ebb8-6aef-4aa0-b3ce-6032e8c1f666"
      unitRef="usd">21600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNjc_25689326-40c0-4c26-a600-0ddec4441f13"
      unitRef="usd">33500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMxNzQ_de66576f-a3af-4986-939c-151b5519b51a"
      unitRef="usd">49700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyNzU_0e18aae0-5a18-43e0-a167-1218165b256a"
      unitRef="usd">15300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyNzk_6de71b2d-a5e1-4b7f-91e0-2d2decfc2a40"
      unitRef="usd">16600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzMyODY_e12e4216-d2ff-4d91-919c-feb0025b1eef"
      unitRef="usd">66200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxMTM_93a5fbaf-ba83-4776-b14d-eec47a908253">The assumptions used in the Black-Scholes model were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.91-50.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.01-46.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.57-51.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37-4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.36-1.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22-1.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyMmJkZjBhZDRkMDI0MDQwOGY5YjU5OWY2NTQ0YTlhMF80_054c943c-6f06-4c2b-bf5b-d0e92d6cd242"
      unitRef="number">0.3991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyMmJkZjBhZDRkMDI0MDQwOGY5YjU5OWY2NTQ0YTlhMF83_52f76993-437f-4c3d-939e-6416b400f514"
      unitRef="number">0.5081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="icf745bbf6d154e1899189c7bcad6fc6a_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNjMxOWMxZDUyNDE0ZTRlOWNlNjkxZDU5OWFlMDZlNF80_507fc7da-67bd-447b-8357-98f3d157fc13"
      unitRef="number">0.4101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i949d937237ca46f89a339135fe399f09_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNjMxOWMxZDUyNDE0ZTRlOWNlNjkxZDU5OWFlMDZlNF83_1f6c1e6b-1fbb-4309-953b-26d7c05e57c8"
      unitRef="number">0.4645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ibec91f8bf02b4770a0909a40dcb95e52_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjo4NGM2NmY0MTljNTE0NjM2OWJjYTRhMDE4MGNmMGQyNV80_174fd7d8-4c2f-4393-8e8b-c780033bc0f8"
      unitRef="number">0.4757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i81f8ea5c34ea42f0b18170ff0ca21581_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzItNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjo4NGM2NmY0MTljNTE0NjM2OWJjYTRhMDE4MGNmMGQyNV83_dcbb937c-d62d-4135-aee3-7835b6765779"
      unitRef="number">0.5182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtMi0xLTEtNzQzOTA_53851a75-4a14-4e5c-9449-5838e87db346">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtNC0xLTEtNzQzOTA_b8a228c3-ac69-4890-aef4-c9d5df566975">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzMtNi0xLTEtNzQzOTA_f6fa26c0-d9b2-44ea-84b8-fc53457bb8a6">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyM2YzYTY2ZTg4MWY0NWI5OWQ4ZjM2MjUwMjEwZTg0Zl80_a3cffc41-e913-4532-af6f-d9fe68f94ada"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtMi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjoyM2YzYTY2ZTg4MWY0NWI5OWQ4ZjM2MjUwMjEwZTg0Zl83_b58a7ef2-9b43-483e-8f95-42deaec073ac"
      unitRef="number">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNDgwN2QxODYzMzA0NDMzOTNmZDhlOGI1ZmY2ZTEzOV80_92c6c13b-01ab-4c39-a045-05131d362865"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNC0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpmNDgwN2QxODYzMzA0NDMzOTNmZDhlOGI1ZmY2ZTEzOV83_842eb2d0-1166-429f-8225-86e5509c33ac"
      unitRef="number">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiYmMyNjgwOGI5M2M0OGVhOTkxZDY5YjNmYzA1NWZlOF80_c03a2a9b-34fe-4ccc-a84f-764e39a85b83"
      unitRef="number">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzQtNi0xLTEtNzQzOTAvdGV4dHJlZ2lvbjpiYmMyNjgwOGI5M2M0OGVhOTkxZDY5YjNmYzA1NWZlOF83_b057bfc3-caa9-4b8f-b110-26a5a1c66502"
      unitRef="number">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtMi0xLTEtNzQzOTA_9d542880-55c6-4601-9559-b7fb57945861"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtNC0xLTEtNzQzOTA_2bc2e924-cea0-46b8-a8e4-e0d66bc16ef3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTpjNzM1OGNhZjdkNDA0NWEwOWUwMDAxYmVlYWIyYzVjNC90YWJsZXJhbmdlOmM3MzU4Y2FmN2Q0MDQ1YTA5ZTAwMDFiZWVhYjJjNWM0XzUtNi0xLTEtNzQzOTA_2340cf4d-851e-487d-878a-42114e6f37ff"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYxNDI_3389530c-f0e8-48ac-af77-0d5f4c76638d">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity during the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$29.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$26.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$59.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id26cfa0230994968ac1d99e765d751b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzEtMi0xLTEtNzQzOTA_5fe74f2c-1d1a-4096-8987-2bdb171fb198"
      unitRef="shares">858742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id26cfa0230994968ac1d99e765d751b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzEtNC0xLTEtNzQzOTA_3889b2aa-b444-4c53-b08a-b1cf478ef09f"
      unitRef="usdPerShare">29.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzItMi0xLTEtNzQzOTA_b2af6158-c602-4415-b155-dd305e185abc"
      unitRef="shares">706096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzItNC0xLTEtNzQzOTA_9aa289cb-1988-4ae4-b86f-da63f95a5fb1"
      unitRef="usdPerShare">39.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzMtMi0xLTEtNzQzOTA_22abd24d-57ea-4bf9-b172-5357eaa346a7"
      unitRef="shares">320767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzMtNC0xLTEtNzQzOTA_4aec6d9b-c5d2-4c4e-bacb-a35c431c2193"
      unitRef="usdPerShare">26.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzQtMi0xLTEtNzQzOTA_6a595368-6723-4c0e-b961-4c6c98a93b11"
      unitRef="shares">204690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzQtNC0xLTEtNzQzOTA_a92b62fd-28de-489a-8ac1-efd1867ba893"
      unitRef="usdPerShare">35.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtMi0xLTEtNzQzOTA_a478ed01-6b47-468e-9940-6a2444b0a35d"
      unitRef="shares">1039381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtNC0xLTEtNzQzOTA_433cff86-fa06-4cae-8b48-4207d7198052"
      unitRef="usdPerShare">35.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtNi0xLTEtNzQzOTA_6080def6-d61d-4d45-a664-d8810778dac8">P1Y3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i7d4a09f254e64faa9bec7e186cb4016f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZTo0NWM0NTdlOTY1NGQ0ZmJhOWJkOTQ1ZWQ4MTEyN2ZmNi90YWJsZXJhbmdlOjQ1YzQ1N2U5NjU0ZDRmYmE5YmQ5NDVlZDgxMTI3ZmY2XzUtOC0xLTEtNzQzOTA_c65e7b2f-f3fa-4b84-9e05-c12b6890c6c7"
      unitRef="usd">59100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NDY_2d15db81-2a73-42dc-b4ec-cbfb5fed40a2"
      unitRef="usd">8600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NTA_1ccde901-d99f-4ee6-8a4e-4e64361527cf"
      unitRef="usd">6600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU1NTc_c1ac2010-8b3b-46c9-b40b-a21624d08fe9"
      unitRef="usd">10100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NDk_ea1e508c-0ed8-4a72-bd68-7d852088760a"
      unitRef="usd">11300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NTM_54221237-93eb-42ab-a873-0fc3c5743dff"
      unitRef="usd">19000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzU2NjA_d060b7ce-aa9b-499d-8cad-42f3447dd899"
      unitRef="usd">14000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwOTg_06e5d27f-3039-48ec-a564-ec6438300eae">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSU activity during the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$40.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$41.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$63.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$27.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$46.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzEtMi0xLTEtNzQzOTA_dd07c96a-e046-4562-b179-6dd397381914"
      unitRef="shares">69382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i308da0fe12c54b17bfdd7c6211a23ca7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzEtNC0xLTEtNzQzOTA_c08fc0b7-2ad8-4dc3-bce5-099deb63c915"
      unitRef="usdPerShare">40.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzItMi0xLTEtNzQzOTA_0a1ce1bc-1915-4470-a546-0d3a83e5ea42"
      unitRef="shares">129773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzItNC0xLTEtNzQzOTA_c06cf36e-e472-47fd-8a97-4f75ee98d453"
      unitRef="usdPerShare">41.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzMtMi0xLTEtNzQzOTA_c0b096ca-dcfe-411a-9d5e-1318cf9e545b"
      unitRef="shares">2565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzMtNC0xLTEtNzQzOTA_93c900b0-5ae6-4d3b-ab7a-2986372e394a"
      unitRef="usdPerShare">63.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzQtMi0xLTEtNzQzOTA_43a810f9-a77d-486d-9236-855abcefae1c"
      unitRef="shares">53746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzQtNC0xLTEtNzQzOTA_6a718371-06df-4469-8704-30beafc9d505"
      unitRef="usdPerShare">27.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzUtMi0xLTEtNzQzOTA_ce72d61f-13a9-4a54-a8f1-06014068fbae"
      unitRef="shares">142844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i808656e5b1f84f9e8f223c40572ea0cd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90YWJsZToxNDM1NTc0NmYyNzg0YzIwYjMxMTQwYzllZGRhZWU1NS90YWJsZXJhbmdlOjE0MzU1NzQ2ZjI3ODRjMjBiMzExNDBjOWVkZGFlZTU1XzUtNC0xLTEtNzQzOTA_a1648be8-9006-4ad6-a597-441d5db65855"
      unitRef="usdPerShare">46.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwNzI_a780acab-6c57-437c-b938-57f42a5c5026"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="id9fa634e741e4e6c976c685332948c76_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDIvZnJhZzoxNzUyZGJjMzhlZTQ0MDZkYWI0YThlYTI4Nzg2Mzg5OC90ZXh0cmVnaW9uOjE3NTJkYmMzOGVlNDQwNmRhYjRhOGVhMjg3ODYzODk4XzYwNzk_6e20ee62-6d23-43fe-879c-f7dd941e5e42"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMjQ_b85770cf-d431-44fe-9f16-76a2e1f63bac">Stockholders&#x2019; Equity&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we issued an aggregate of 789,870, 1,179,032 and 4,705,843 shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately $15.3 million, $16.6 million and $66.2 million, respectively. For the years ended December&#160;31, 2022, 2021 and 2020, we issued 254,907, 299,958 and 571,963 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU holders surrendered 68,425, 94,795 and 142,905 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $4.4 million, $8.2 million and $5.5 million, respectively. Stock options and unvested restricted units totaling approximately 6.6 million, 5.9 million and 6.7 million shares of our common stock were outstanding as of December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Board of Directors authorized a capital return program to repurchase up to $550.0 million of outstanding common stock over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzgzNg_6d31b2bd-233b-4e57-aa4d-35605e28c115"&gt;three&lt;/span&gt;-year period. During 2020, we repurchased 6.5&#160;million shares of common stock for $150.0&#160;million at an average price of $23.05. During 2021, we repurchased 4.6&#160;million shares of common stock for $200.0&#160;million at an average price of $43.02 under the program. The shares were purchased through open market transactions and through an ASR agreement. The $550.0&#160;million share repurchase program was completed in October 2021 having repurchased a total of 22.3&#160;million shares at an average price of $24.72.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzOTc_69d1271f-c244-47f4-82d2-6cf455ace36c"&gt;three&lt;/span&gt;-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $150.0&#160;million of common stock. At inception pursuant to the agreement, we paid $150.0&#160;million  and took initial delivery of 3.5&#160;million shares. In June 2022, we finalized the transaction and received an additional 0.4&#160;million shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2022, concurrent with the sale of  2028 Convertible Notes and the 2022 Induced Conversion, we repurchased 2.1&#160;million shares of common stock in open market purchases for $90.2&#160;million. Also, in August 2022, we entered into an ASR agreement to repurchase $109.8&#160;million of our common stock. At inception, pursuant to the agreement, we paid $109.8&#160;million and took an initial delivery of 2.0&#160;million shares.  In December 2022, we finalized the transaction and received an additional 0.4&#160;million shares. We retired the repurchased shares and they resumed their status of authorized and unissued shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Price paid Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)  Included in the total cost of shares purchased is a commission fee of $0.02 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)  Included is 0.4&#160;million shares delivered in December 2022 upon completion of the ASR.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzgy_06cc318c-422b-4b3d-9bf3-ea80f59c2eee"
      unitRef="shares">789870</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzg2_b892cbcf-7f20-4466-8d6c-361e6f1c08d9"
      unitRef="shares">1179032</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzkz_4a5f1db7-21f9-444f-9720-8e5c262e2bc2"
      unitRef="shares">4705843</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIxOQ_ff0ec140-9c33-414c-9df9-09d28b4859a6"
      unitRef="usd">15300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIyMw_1d4539cc-dcd1-41ab-864e-a12d71083de3"
      unitRef="usd">16600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMA_4fe6c09f-52fb-4dc3-ad59-4446de4c933a"
      unitRef="usd">66200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI4Mg_3faa253b-d748-44e2-9c49-dcd0e8a7b1f8"
      unitRef="shares">254907</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI4Ng_890368d7-e94e-482d-8ae6-c2583aed8212"
      unitRef="shares">299958</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzI5Mw_103b52eb-e596-47a6-bcaf-55b7e7af0157"
      unitRef="shares">571963</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQxMA_86b4e4d6-08f1-4251-b346-1293b587c44e"
      unitRef="shares">68425</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQxNA_59fc98fe-e1b1-4065-977e-5a5dae87234e"
      unitRef="shares">94795</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzQyMQ_6bb671c1-8a01-461c-b6d3-8aef08a8bd6e"
      unitRef="shares">142905</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae176b036399446d884c8a71d329328e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUwNA_6b1b6532-9779-46f1-8d24-fa03c22b9f33"
      unitRef="usd">4400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i343bc01f8f0942cf9275d4c949a77c16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUwOA_7f3d3813-a948-4672-aa72-07655c7c2ba3"
      unitRef="usd">8200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2d3ceb791c29431382f44988704a8808_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzUxNQ_e8387f18-1d3e-4692-900c-6d900c4bf97b"
      unitRef="usd">5500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6f301c76e72f45fc8bd78b64ae95e300_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYwMA_0253f9e0-166b-412b-a196-743dff7cb52b"
      unitRef="shares">6600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i813698ed62b94b59be1b62617f5dd7cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYwNA_92555a1a-1616-4d39-b5ac-87c05e3dc2d6"
      unitRef="shares">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2bca0917c34b4c89a31b6213fad20334_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzYxMQ_d05048a9-0c77-40a5-b45e-0db037339d2f"
      unitRef="shares">6700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iec2a39ae6cf344228e691d7fec6bd39c_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzc5OA_c4834c82-6ef5-44ea-9d80-22901273442f"
      unitRef="usd">550000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzg3OA_40c68a28-1ba7-46d0-a77e-77ebba422c6d"
      unitRef="shares">6500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzkwOA_6b8a6b96-886e-4fc3-a0ba-c441b25c9d97"
      unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzkzNA_8668c92f-ff4b-404a-a979-84b1ea76d020"
      unitRef="usdPerShare">23.05</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxODI0Nw_78387462-c476-4075-882b-25339a84a062"
      unitRef="shares">4600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3Xzk5Ng_af3eff85-fa35-4650-bd0b-d0017a91a324"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxODI3Mw_cece3ba7-1fbf-4b1e-ab2c-858c2053ad47"
      unitRef="usdPerShare">43.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iec2a39ae6cf344228e691d7fec6bd39c_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzExMzc_6e48a9c0-4bbb-4a7b-932d-894d083e12d1"
      unitRef="usd">550000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEyMjU_c92432dd-a3bc-43a7-bca3-99efa16aa8c5"
      unitRef="shares">22300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i74164c14ea3649b094fefcea1de47a86_D20191101-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEyNTg_a0c5bf7e-58ea-4deb-9831-ab2acb0432d2"
      unitRef="usdPerShare">24.72</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzEzNjY_bf195f7a-c5fa-4266-b076-d700c3bb51b9"
      unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i62f9407bb50f40638225cd8fe3f7988f_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE1Mjk_2af24972-4fdb-4565-bcc1-43c2c78f28ad"
      unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE1OTc_bbc6bf6d-d67e-4802-87ba-880cca5756da"
      unitRef="usd">150000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ide75dd3a7cec43c9aca6de0900df29cf_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE2NDg_1486ca84-09e0-4bed-bc3f-940636b97c51"
      unitRef="shares">3500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7953193d06b84f52adffe498a800882d_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNjYwMg_30937324-34a1-4605-a71b-95a819ead2fb"
      unitRef="usd">400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzE5Ng_41d42d14-22bb-48a6-a299-7a9abcd68a66"
      unitRef="shares">2100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzE2OQ_ee6022f8-804e-4458-926d-2f1f7a40be0d"
      unitRef="usd">90200000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzIyNA_388fa2c6-b45a-48c2-a2b5-d5b3556955a3"
      unitRef="usd">109800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i872c067c40d8467aae4064ed65b90e53_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzI1NQ_95468259-9e39-4e8b-bd71-57e6f18980d8"
      unitRef="usd">109800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i83fe1ea8906d44e5af191657e63f7673_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzI4Mw_64549627-1ec5-40a1-bd4a-b60c599455ba"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzU0OTc1NTgxNzEzOA_c7665f9c-16e0-4629-8fc9-d44e3e353192"
      unitRef="shares">400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIzMjA_671d4717-94f1-4873-a3f8-fc1818c4b9fe">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Price paid Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)  Included in the total cost of shares purchased is a commission fee of $0.02 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)  Included is 0.4&#160;million shares delivered in December 2022 upon completion of the ASR.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItMi0xLTEtNzQzOTA_d47f53ce-81fe-49fd-b033-ab6fc3e70a0a"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItNC0xLTEtNzQzOTA_768720c0-37d7-4694-b9a0-ee499fcc8eb0"
      unitRef="usdPerShare">0.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib289a864e55c4d9bb5fce58d7c2f4137_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzItNi0xLTEtNzQzOTA_1277c105-0b59-46d1-903f-bef62241659d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtMi0xLTEtNzQzOTA_59383df2-d2e1-45cb-bb77-63b4b898b22f"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtNC0xLTEtNzQzOTA_e121d3d1-069d-4343-84c0-312e9fc413f8"
      unitRef="usdPerShare">0.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i10c22ab1a82c44e98c1945ff6ca11fb1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzMtNi0xLTEtNzQzOTA_1cad5d4e-59db-441d-a17a-b18f7d9577b8"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtMi0xLTEtNzQzOTA_43e82fe2-1a76-4795-9583-9c87d890281d"
      unitRef="shares">4500216</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtNC0xLTEtNzQzOTA_9850e034-5a1c-414a-bc3f-410e32ed27e1"
      unitRef="usdPerShare">44.44</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ide1edaec452a47868225d8de6edeb1a6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzQtNi0xLTEtNzQzOTA_fc6fb5e2-69f4-4c41-add8-c95fc2af667b"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtMi0xLTEtNzQzOTA_5a99e1c3-81c7-4273-a98e-34db6bc283ff"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtNC0xLTEtNzQzOTA_628ea29b-26a6-4599-8f20-0b5d94e1e421"
      unitRef="usdPerShare">0.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib067d2a38b944a20ab5677a6d1b9eea7_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzUtNi0xLTEtNzQzOTA_ce8d2dea-fd3c-43c8-8b96-b03ae6b42683"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtMi0xLTEtNzQzOTA_6536d069-adab-4119-b5b4-8fadb214e461"
      unitRef="shares">4500216</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtNC0xLTEtNzQzOTA_9648ce9a-f7cd-4446-abc5-09619b203232"
      unitRef="usdPerShare">44.44</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90YWJsZTpmNGQ0MWVmODJmYjA0Y2NkOTFmMWQ5Y2E2NjM2ZjFjMy90YWJsZXJhbmdlOmY0ZDQxZWY4MmZiMDRjY2Q5MWYxZDljYTY2MzZmMWMzXzYtNi0xLTEtNzQzOTA_750bf2b7-f3fb-4ef5-a813-2fe6417a9370"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <halo:TreasuryStockAcquiredFeeCostPerShare
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzE5NjY_4d351685-b403-4adf-b391-43d97ba90ff1"
      unitRef="usdPerShare">0.02</halo:TreasuryStockAcquiredFeeCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2eaaadf3de07488eaa7c634589624fce_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNDgvZnJhZzo0N2U5YWI4YWI4MzQ0YTQ2YmE4YWFlMmUxNTk0ODgzNy90ZXh0cmVnaW9uOjQ3ZTlhYjhhYjgzNDRhNDZiYThhYWUyZTE1OTQ4ODM3XzIwMDQ_d013e6a9-0e2f-4426-a55b-95dfe581e7ba"
      unitRef="shares">400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTc_c512f175-a0f5-4c21-9d90-e583645021b8">Net Income per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1). The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTg_8e6890b9-e5ce-45b6-a2b4-3ae7b64261c0">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtMi0xLTEtNzQzOTA_d47a8eb9-7523-40e8-aa3f-4971ec57c4bf"
      unitRef="usd">202129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtNC0xLTEtNzQzOTA_60be4c5b-6178-4b18-9f60-bc8026e75c51"
      unitRef="usd">402710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzMtNi0xLTEtNzQzOTA_347f3216-c688-4900-b9d7-1ca9ed2c1afd"
      unitRef="usd">129085000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtMi0xLTEtNzQzOTA_ffef96f5-5082-4888-abd0-5b6d0ddc4cba"
      unitRef="shares">136844000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtNC0xLTEtNzQzOTA_ebf56050-deb5-4552-bd80-4762873d27fb"
      unitRef="shares">140646000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzUtNi0xLTEtNzQzOTA_2791f2b4-6e44-45ce-9780-e44a7049bec5"
      unitRef="shares">136206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctMi0xLTEtNzQzOTA_54c196e1-a571-4577-b338-0ae3035ec51b"
      unitRef="shares">2265000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id969cad6a23d405695239ec30d807f30_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctNC0xLTEtNzQzOTA_31ed96ba-475e-4c69-b484-f0ad6bf2d814"
      unitRef="shares">2737000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ica423dbca19f432daae40901ef390ee8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzctNi0xLTEtNzQzOTA_09b157f0-5380-4e38-beb3-5d0c09f6734a"
      unitRef="shares">2317000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5c1972749fa94302ad6f4164caadc9fe_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtMi0xLTEtNzQzOTA_06511dcb-0037-411b-83b7-ccc703507e47"
      unitRef="shares">422000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9826afc8d63f4d5ca646159f99d34e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtNC0xLTEtNzQzOTA_e2ae39f9-0c4a-49f3-92b0-9ba282e2cb65"
      unitRef="shares">555000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib0a9b9adaae647398fdba511e9ef1777_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzgtNi0xLTEtNzQzOTA_4d43e9eb-fcb9-49cb-be78-5f577d8a8da6"
      unitRef="shares">627000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if9b9ab30830f4339a4ee873a5fc79362_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktMi0xLTEtNzQzOTA_190b1195-604e-44d0-a87a-052f56b2c40c"
      unitRef="shares">1077000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i28fdc2cdaf2a4fa09d8fe1a529c0e500_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktNC0xLTEtNzQzOTA_a1471ce9-423d-4d3c-b5b4-d99c47945e10"
      unitRef="shares">2858000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie346c01929994c85883bfeb74a94e8e9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzktNi0xLTEtNzQzOTA_8e903fb4-fca3-4d10-8ecc-ed05bc012f3e"
      unitRef="shares">2313000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTItMS0xLTc0Mzkw_5e98007f-7911-4c4d-967b-53c249117d3a"
      unitRef="shares">140608000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTQtMS0xLTc0Mzkw_b0681b73-7880-4324-bf8f-df0cf420dc53"
      unitRef="shares">146796000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEwLTYtMS0xLTc0Mzkw_b7d34828-411e-404c-af6a-baa01bdc049d"
      unitRef="shares">141463000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTItMS0xLTc0Mzkw_5ea474a3-4935-409f-b1f6-0c23528ff704"
      unitRef="usdPerShare">1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTQtMS0xLTc0Mzkw_56f1e55e-92db-4580-a49b-a8162671c9e3"
      unitRef="usdPerShare">2.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEyLTYtMS0xLTc0Mzkw_28d865af-ab4a-4652-bafa-35d9d6a9e59e"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTItMS0xLTc0Mzkw_1f7e6d42-1220-4c3f-a723-65bddbead965"
      unitRef="usdPerShare">1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTQtMS0xLTc0Mzkw_90df12ad-38ef-4119-be81-f951e22ece70"
      unitRef="usdPerShare">2.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo4ZThjN2IxNDUzYTQ0ZGU0OWUyZDE4YTMwNmNkYjNjMy90YWJsZXJhbmdlOjhlOGM3YjE0NTNhNDRkZTQ5ZTJkMThhMzA2Y2RiM2MzXzEzLTYtMS0xLTc0Mzkw_5eb74c41-2581-408f-b2c4-7a744ae4cfb7"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90ZXh0cmVnaW9uOjA5ZmZiNjk2N2I5NzRjM2RhMGQxZmI4ZTEwMmI2MGZlXzE2NTk_5c2a9c9a-6af4-4305-babc-0b12c0e91534">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItMi0xLTEtNzQzOTA_f7b62039-1288-4177-af00-084a8af45898"
      unitRef="shares">20700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItNC0xLTEtNzQzOTA_97f8908f-4c18-4cda-93bc-c472f44c09b3"
      unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTEvZnJhZzowOWZmYjY5NjdiOTc0YzNkYTBkMWZiOGUxMDJiNjBmZS90YWJsZTo1ODQ0ODdhNDlhMTg0NGM2YWNlOGQyMWY2NmNiNjdkNy90YWJsZXJhbmdlOjU4NDQ4N2E0OWExODQ0YzZhY2U4ZDIxZjY2Y2I2N2Q3XzItNi0xLTEtNzQzOTA_a84dd32c-5977-439d-b319-b47bfb28045e"
      unitRef="shares">18600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzI1MTg_4bac8898-579b-462d-bb2b-030f7cfc7292">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and research facilities are located in San&#160;Diego, California. In addition, we have an office in Ewing, New Jersey. We also lease a building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. We lease an aggregate of approximately 194,000 square feet of space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we assumed Seismic&#x2019;s office lease, as amended with Kilroy Realty L.P. for approximately 73,238 square feet of space in office and research facilities which commenced on December 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $3.3 million, $2.0 million and $2.3 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate annual future minimum operating lease payments as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term of our operating leases is approximately 7.64 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <halo:OperatingLeasesAreaLeased
      contextRef="i5f6362e86b7647058ad2270b025883b0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzE4NA_44d05109-01a0-460b-ba82-411d639107bf"
      unitRef="sqft">194000</halo:OperatingLeasesAreaLeased>
    <halo:OperatingLeasesAreaLeased
      contextRef="ia95727628f324bdb89c986083075e8bf_D20220301-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzM4NDgyOTA3MDQ5Mjk_f1aeba6e-3e48-4c42-921a-4b53dbb53292"
      unitRef="sqft">73238</halo:OperatingLeasesAreaLeased>
    <us-gaap:OperatingLeaseExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY0MA_84a8cac0-140f-4b1e-bf12-756f64a31f8f"
      unitRef="usd">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY0NA_e7170a4a-3d24-43d2-a849-2e1f7cce4c6e"
      unitRef="usd">2000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzY1MQ_375ea6eb-cdaa-4857-a95f-a61bd5e040a6"
      unitRef="usd">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1XzI1MDk_44c54801-0aeb-425b-aa9e-2d6a120c805e">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate annual future minimum operating lease payments as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzEtMi0xLTEtNzQzOTA_ba12b4a4-ad5e-43dd-926d-6a21eff7f798"
      unitRef="usd">7800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzItMi0xLTEtNzQzOTA_ea2d4c04-8759-4532-8629-ee367ba8bbff"
      unitRef="usd">6173000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzMtMi0xLTEtNzQzOTA_5926d74a-329f-4737-a8c0-af75b291a516"
      unitRef="usd">5464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzQtMi0xLTEtNzQzOTA_e32b386b-5a63-4f20-b8b5-9d06eb5a784f"
      unitRef="usd">5149000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzUtMi0xLTEtNzQzOTA_c40dfbcb-83ef-469a-a1fe-980523bd6518"
      unitRef="usd">5296000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzYtMi0xLTEtODUzNzc_953e4ad0-d1e1-4201-b5de-c0d68f3dc730"
      unitRef="usd">17133000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzYtMi0xLTEtNzQzOTA_3d39ff47-48e1-444d-a6ac-34b4d0e762c3"
      unitRef="usd">47015000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzctMi0xLTEtNzQzOTA_f65a66b8-f77e-46ea-9ffa-ed2a741aeb28"
      unitRef="usd">12227000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90YWJsZTplNzRkMWM2NTk0NzY0ZmZiODZlZjhhMTNlZTM5YmQ1My90YWJsZXJhbmdlOmU3NGQxYzY1OTQ3NjRmZmI4NmVmOGExM2VlMzliZDUzXzgtMi0xLTEtNzQzOTA_12083406-1283-49f8-91a7-ae213fe65829"
      unitRef="usd">34788000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTQvZnJhZzo5NmNkOGE3ZDA2OGM0NzcyYjMxZWRmOWI4YjNjMmVjNS90ZXh0cmVnaW9uOjk2Y2Q4YTdkMDY4YzQ3NzJiMzFlZGY5YjhiM2MyZWM1Xzg3Nw_f2a96ed0-4d27-4165-a1e1-87c54a7a65aa">P7Y7M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5NDE_93d82016-87ee-44bd-a558-956c5a8c1d9e">&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income (loss) before income taxes summarized by region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASC 842 lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible book amortization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASC 842 right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A valuation allowance of $0.7 million and $0.5 million has been established to offset the net deferred tax assets as of December 31, 2022 and 2021, respectively, as realization of such assets is uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a periodic basis, we reassess the valuation allowance of our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. In 2021, we have demonstrated profitability and cumulative pretax income and are forecasting income growth. After assessing both the positive and negative evidence, we determined that it was more likely than not that our DTAs would be realized and released the valuation allowance in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired the outstanding shares of Antares Pharma Inc. This transaction was treated as a non-taxable acquisition, we have increased our deferred tax liabilities by approximately $119.7&#160;million related to acquired intellectual property and a step-up to the value of inventory the amortization of which will not be tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense was comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current - federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current - state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred - federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred - state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense (benefit) at 21% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit), net of federal income tax impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worthless stock deduction of international subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income subject to tax at other than federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive compensation limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At December&#160;31, 2022, our unrecognized tax benefit and uncertain tax positions were $19.5 million, which will impact the effective tax rate when resolved. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December&#160;31, 2022, 2021 and 2020, we recognized an immaterial amount of interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases in tax positions for prior years and lapse in statue of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions related to business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions for current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had federal, California and other state tax net operating loss carryforwards of approximately $31.2 million, $237.4 million and $63.4 million, respectively. The California and Minnesota net operating loss carryforwards begin to expire in 2028 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of Antares, we acquired federal and Minnesota research and development credits of approximately $7.4&#160;million and $0.72&#160;million, respectively. We expect to be able to fully utilize these attributes without limitation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had federal, California and Minnesota research and development tax credit carryforwards of approximately $30.8 million, $17.0 million and $0.7 million, respectively. The federal research and development tax credits will begin to expire in 2030 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. The Minnesota research and development credit will begin to expire in 2023 unless previously utilized. Additionally, we had Orphan Drug Credit carryforwards of $70.0 million which will begin to expire in 2034. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Internal Revenue Code Section&#160;382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section&#160;382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2020. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2022 and 2021, there were no undistributed earnings in foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2008 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MTk_92cae4eb-0119-4312-bd4e-5445c4cd85a4">&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income (loss) before income taxes summarized by region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItMi0xLTEtNzQzOTA_82addc02-91fc-4242-83df-4434e0053b54"
      unitRef="usd">248918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItNC0xLTEtNzQzOTA_0d670333-0135-4b4a-9dce-68af34e6e3da"
      unitRef="usd">248071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzItNi0xLTEtNzQzOTA_2ae7ee56-3c8c-423a-b4da-76a45e9601c7"
      unitRef="usd">130427000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtMi0xLTEtNzQzOTA_085a76bd-b715-41d2-925a-fb4d9b10600b"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtNC0xLTEtNzQzOTA_6057014c-6c62-405c-aa87-ed3ece45b637"
      unitRef="usd">447000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzMtNi0xLTEtNzQzOTA_c57ba34f-4094-420e-8bfe-280607786d83"
      unitRef="usd">-1125000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtMi0xLTEtNzQzOTA_f23619ef-19a7-4d01-abd0-9215a5671e4d"
      unitRef="usd">248918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtNC0xLTEtNzQzOTA_b33b165c-df43-42a5-ad33-44aed6ccd237"
      unitRef="usd">248518000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmNDNiNWY3ZWQxZDg0YjU0OGQwYjU3ZWQ3MDkwNDZjNy90YWJsZXJhbmdlOmY0M2I1ZjdlZDFkODRiNTQ4ZDBiNTdlZDcwOTA0NmM3XzQtNi0xLTEtNzQzOTA_de9347cf-f0c6-414a-b972-2711c8d4b826"
      unitRef="usd">129302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5Mzg_eca1d787-c676-4fd5-ae73-2f2765fcaa71">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASC 842 lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction related expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible book amortization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASC 842 right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzMtMi0xLTEtNzQzOTA_d08f9c98-c344-4847-a2e6-90f58afbf6be"
      unitRef="usd">32887000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzMtNC0xLTEtNzQzOTA_33bd1cc1-43c2-4727-9406-9444ebdce90c"
      unitRef="usd">42182000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzQtMi0xLTEtNzQzOTA_6ce7588c-2d24-4729-96c1-ade100ba474f"
      unitRef="usd">837000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzQtNC0xLTEtNzQzOTA_486fb87a-2c0d-4109-bfe7-bb446e29abe9"
      unitRef="usd">909000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzUtMi0xLTEtNzQzOTA_df78d31e-5eb1-4019-8259-fe2eea28a14e"
      unitRef="usd">96133000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzUtNC0xLTEtNzQzOTA_68da0f0a-598f-4f72-bece-6eee919b9e6b"
      unitRef="usd">109041000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzYtMi0xLTEtNzQzOTA_3cd8401c-c589-44b5-ba13-192c7e71ed7b"
      unitRef="usd">6353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzYtNC0xLTEtNzQzOTA_f2e5b4df-bb83-4172-850b-fbfaffd115a3"
      unitRef="usd">1814000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <halo:DeferredTaxAssetsLeaseLiabilities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzgtMi0xLTEtNzQzOTA_3c7c079e-fa6a-4129-8852-6f3e64af7ea7"
      unitRef="usd">2480000</halo:DeferredTaxAssetsLeaseLiabilities>
    <halo:DeferredTaxAssetsLeaseLiabilities
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzgtNC0xLTEtNzQzOTA_d25dd7d1-494c-42ed-bc39-9fe43bcb1a73"
      unitRef="usd">600000</halo:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktMi0xLTEtODcxNDE_d9b53911-ea04-4ed2-9cd3-14be95011f65"
      unitRef="usd">10168000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktNC0xLTEtODcxNDk_cf9912bc-d15b-4da1-8cbb-3987329eb396"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <halo:DeferredTaxAssetTransactionRelatedExpense
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTItMS0xLTg3MTQx_fec5e7cc-16e4-4ef3-bdf9-32a44c134bca"
      unitRef="usd">2354000</halo:DeferredTaxAssetTransactionRelatedExpense>
    <halo:DeferredTaxAssetTransactionRelatedExpense
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTQtMS0xLTg3MTQ5_0a921c65-b7d2-491c-a151-8e6e8c96eabe"
      unitRef="usd">0</halo:DeferredTaxAssetTransactionRelatedExpense>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTItMS0xLTg3MTQx_67b7f859-209c-4b09-a8ad-8e5354b7d798"
      unitRef="usd">18395000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTQtMS0xLTg3MTQ5_f44814cd-9ee9-4844-a357-ae149c34b549"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInventory>
    <halo:DeferredTaxAssetsInterestExpenseLimitation
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktMi0xLTEtNzQzOTA_4a6e9b0d-1871-488d-a944-800b5c37c5e5"
      unitRef="usd">0</halo:DeferredTaxAssetsInterestExpenseLimitation>
    <halo:DeferredTaxAssetsInterestExpenseLimitation
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzktNC0xLTEtNzQzOTA_0233d55b-d07b-4e72-bdf5-f481220aee36"
      unitRef="usd">0</halo:DeferredTaxAssetsInterestExpenseLimitation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTItMS0xLTc0Mzkw_d55bee8f-89b3-4a60-9a71-095f3b20e86e"
      unitRef="usd">3054000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEwLTQtMS0xLTc0Mzkw_65e1652e-3e7a-4f91-8210-05c26f3dbbf9"
      unitRef="usd">3449000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTItMS0xLTc0Mzkw_5b4e5ccc-52af-40ec-b9e7-c34ee334ef1f"
      unitRef="usd">172661000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzExLTQtMS0xLTc0Mzkw_f5eb369a-f8df-4eba-bf63-cfaa72ccfc6f"
      unitRef="usd">157995000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEyLTItMS0xLTc0Mzkw_977f38d4-bc1a-4e13-8244-8bd93fed712e"
      unitRef="usd">707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEyLTQtMS0xLTc0Mzkw_59edacd0-3dba-4992-a781-365d2852e9f8"
      unitRef="usd">500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEzLTItMS0xLTc0Mzkw_cc9b0f0c-d8db-44b9-a724-2bfb087c2cba"
      unitRef="usd">171954000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzEzLTQtMS0xLTc0Mzkw_58239e6f-3645-40d4-aadb-d2545edf7499"
      unitRef="usd">157495000</us-gaap:DeferredTaxAssetsNet>
    <halo:DeferredTaxLiabilitiesNonDeductibleBookAmortization
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTItMS0xLTg3MTYx_4b7da5c4-33ec-4d53-b3d9-d84d8418edf9"
      unitRef="usd">115578000</halo:DeferredTaxLiabilitiesNonDeductibleBookAmortization>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE1LTItMS0xLTc0Mzkw_319260b9-ab7d-4f0d-ae1d-071c6d6c0e4d"
      unitRef="usd">2559000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE1LTQtMS0xLTc0Mzkw_b6ce99f2-4e85-4f6d-983e-785ef7f7d2cb"
      unitRef="usd">1185000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <halo:DeferredTaxLiabilitiesConvertibleNote
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE2LTItMS0xLTc0Mzkw_e33d1139-abd9-4264-afe6-70058c3cbc22"
      unitRef="usd">0</halo:DeferredTaxLiabilitiesConvertibleNote>
    <halo:DeferredTaxLiabilitiesConvertibleNote
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE2LTQtMS0xLTc0Mzkw_d1115900-9670-4dee-bf15-26d5c8ad1eae"
      unitRef="usd">17000</halo:DeferredTaxLiabilitiesConvertibleNote>
    <halo:DeferredTaxLiabilitiesRightofUseAsset
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE3LTItMS0xLTc0Mzkw_cbd91b40-6b9e-457d-9bbc-0c254d004bb1"
      unitRef="usd">9061000</halo:DeferredTaxLiabilitiesRightofUseAsset>
    <halo:DeferredTaxLiabilitiesRightofUseAsset
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE3LTQtMS0xLTc0Mzkw_39bbeee2-dfeb-45ce-af03-a58e7c8a9746"
      unitRef="usd">426000</halo:DeferredTaxLiabilitiesRightofUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTItMS0xLTc0Mzkw_5ee84d92-c6ec-4afd-8a0e-ead72f523fe5"
      unitRef="usd">330000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE4LTQtMS0xLTc0Mzkw_6ac7399c-513b-40a4-8e88-c27abab44b50"
      unitRef="usd">433000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE5LTItMS0xLTc0Mzkw_183676d0-c3bb-4220-a465-3fe61295feaa"
      unitRef="usd">127528000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzE5LTQtMS0xLTc0Mzkw_af58c52c-22ad-4490-bc80-51e4bdd7c3f0"
      unitRef="usd">2061000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzIwLTItMS0xLTc0Mzkw_a1b529e8-20d2-4153-9dfa-26ecad6da1ea"
      unitRef="usd">44426000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo5NjVhN2YwZjM0NTA0NjBhODQxNGQ3ZDkyY2MzYzBmOS90YWJsZXJhbmdlOjk2NWE3ZjBmMzQ1MDQ2MGE4NDE0ZDdkOTJjYzNjMGY5XzIwLTQtMS0xLTc0Mzkw_6e20afa2-d8ec-473b-aba4-5f8c86674e96"
      unitRef="usd">155434000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI0Mw_9e212427-bbdb-45e8-9f87-09d21ccadc29"
      unitRef="usd">700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI1MA_0899e563-cb55-47ab-8346-39a45930757f"
      unitRef="usd">500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <halo:DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE2NDkyNjc0NDYwNjA_331c6260-cf89-4ca5-ba07-3341a168bde5"
      unitRef="usd">119700000</halo:DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MjM_a0850ebc-f5a5-40a6-8665-4918d2393a66">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense was comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current - federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current - state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred - federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred - state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItMi0xLTEtNzQzOTA_0f53fc8f-5306-4acf-9c2e-b493c1d50666"
      unitRef="usd">6157000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItNC0xLTEtNzQzOTA_6dd96958-7bbf-433a-960a-39b0ac1e2c6d"
      unitRef="usd">-9000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzItNi0xLTEtNzQzOTA_eb2877b5-3d25-4f9c-89cc-b12a6ac1d56a"
      unitRef="usd">-11000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtMi0xLTEtNzQzOTA_4edf3c14-3e4b-4d12-99d9-16651ecb8b52"
      unitRef="usd">2525000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtNC0xLTEtNzQzOTA_ef74a461-a648-4394-a262-aaa9df371c97"
      unitRef="usd">1251000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzMtNi0xLTEtNzQzOTA_8dea9864-0d71-4472-aa82-ecb8af65808a"
      unitRef="usd">228000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtMi0xLTEtNzQzOTA_316f262c-7b53-4c9c-aad8-9dae680581af"
      unitRef="usd">44757000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtNC0xLTEtNzQzOTA_95143f2c-b361-4d25-9adb-d12e5b7cf2a1"
      unitRef="usd">-117925000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzQtNi0xLTEtNzQzOTA_adfa311e-de71-4d80-9564-d30c3a22492e"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtMi0xLTEtNzQzOTA_a9b96aca-ecdc-45f7-9093-510272b71f34"
      unitRef="usd">-6650000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtNC0xLTEtNzQzOTA_3df9deda-bff0-4c95-8f17-9e41c92ef1ec"
      unitRef="usd">-37509000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzUtNi0xLTEtNzQzOTA_3e778452-dc07-4d7a-8472-13b81b689974"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtMi0xLTEtNzQzOTA_e33ac721-f1de-405b-ba3f-87775cdfa380"
      unitRef="usd">46789000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtNC0xLTEtNzQzOTA_142bcebe-115e-4ab2-887c-b4fb46cc29a9"
      unitRef="usd">-154192000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpjNDBkZjcxYjUzODg0MTZkYjI3NDUwZjJhZWQxMmFkMy90YWJsZXJhbmdlOmM0MGRmNzFiNTM4ODQxNmRiMjc0NTBmMmFlZDEyYWQzXzYtNi0xLTEtNzQzOTA_155cd49f-35d3-493d-8d39-f4cd2ec2cfc3"
      unitRef="usd">217000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MzE_32a294c5-0c08-490f-abb3-ea290afa91e4">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense (benefit) at 21% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit), net of federal income tax impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worthless stock deduction of international subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income subject to tax at other than federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive compensation limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItMi0xLTEtNzQzOTA_08afa98a-f318-4d56-acb0-6bea43754182"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItNC0xLTEtNzQzOTA_5349403e-a4ac-4822-a2e7-8e8f2ac70ce5"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzItNi0xLTEtNzQzOTA_59d60013-ea61-4dac-8a62-0650cd0e3052"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtMi0xLTEtNzQzOTA_fd718948-a81a-4385-91a4-6dc01ee83897"
      unitRef="number">0.0082</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtNC0xLTEtNzQzOTA_db12af84-2256-400b-8844-868f7c31d3e3"
      unitRef="number">0.0267</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzMtNi0xLTEtNzQzOTA_c9eedefc-a7f6-43a8-ab45-2abf1a6d683d"
      unitRef="number">-0.0159</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtMi0xLTEtNzQzOTA_078a08b9-6ebe-4d94-9c9b-53094158fcfb"
      unitRef="number">-0.0039</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtNC0xLTEtNzQzOTA_abaddd12-ef0e-415d-9448-7d57329a7a50"
      unitRef="number">-0.8492</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzQtNi0xLTEtNzQzOTA_3fb759c1-82fa-417a-aa1f-8b84011a9121"
      unitRef="number">0.3459</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtMi0xLTEtNzQzOTA_d7b70734-e207-4695-9ef9-310d02875ca6"
      unitRef="number">0</halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent>
    <halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtNC0xLTEtNzQzOTA_706e69ef-3708-4695-b01e-88bb32f92fec"
      unitRef="number">0</halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent>
    <halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzYtNi0xLTEtNzQzOTA_f08b180b-4510-4048-8c19-55e83c8b2cec"
      unitRef="number">-0.5207</halo:EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctMi0xLTEtNzQzOTA_44ea80b1-d23e-458e-b150-70f2f4222306"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctNC0xLTEtNzQzOTA_ed6dcffa-7375-4ba7-87ce-55a05fd28e4e"
      unitRef="number">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzctNi0xLTEtNzQzOTA_a0206fa7-3b5b-4205-907b-f2d4bb7b09d4"
      unitRef="number">0.0016</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtMi0xLTEtNzQzOTA_8462d420-16d6-4834-8b05-4430c4d1bdf2"
      unitRef="number">0.0066</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtNC0xLTEtNzQzOTA_e12d776d-9a5a-4d86-9baf-fbf5d5d0a494"
      unitRef="number">0.0250</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzgtNi0xLTEtNzQzOTA_61291558-4d8e-4c5c-ad5d-8937611bbc09"
      unitRef="number">0.0189</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktMi0xLTEtNzQzOTA_8cf9fb5f-d0bc-4728-8d2f-7849a6a3a086"
      unitRef="number">0.0261</halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent>
    <halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktNC0xLTEtNzQzOTA_9aeebe98-425e-4270-9a05-e0bc4d0ffc68"
      unitRef="number">0.0232</halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent>
    <halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzktNi0xLTEtNzQzOTA_39619b02-d2fd-4a87-b1ba-183de9abefe0"
      unitRef="number">0.0161</halo:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTItMS0xLTc0Mzkw_c7b0a120-4fe4-471e-9669-81f13b52c793"
      unitRef="number">-0.0040</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTQtMS0xLTc0Mzkw_649f10f3-9a5e-483a-90ab-7de944696dcf"
      unitRef="number">0.0054</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEwLTYtMS0xLTc0Mzkw_390747e4-95aa-41b3-a882-4aa766116400"
      unitRef="number">-0.0164</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTItMS0xLTc0Mzkw_b11e8489-e4dd-470e-a891-3a7247f61410"
      unitRef="number">-0.0506</halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTQtMS0xLTc0Mzkw_049044bb-da03-4743-a5d8-940d5ad4de70"
      unitRef="number">-0.0118</halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzExLTYtMS0xLTc0Mzkw_d95f48b0-2310-4afb-9a58-f253d1bd3dfd"
      unitRef="number">0</halo:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTItMS0xLTg3MzA2_72066dbf-ba39-43c8-ac28-42069585a614"
      unitRef="number">0.0088</halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTQtMS0xLTg3MzE4_1d8b92a3-ac91-4356-b7f8-5d4b1eaefff8"
      unitRef="number">0</halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzEyLTYtMS0xLTg3MzI2_77f44d63-fb0c-4486-ba1f-7ed9354a2420"
      unitRef="number">0</halo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTItMS0xLTc0Mzkw_a02db630-654e-44c8-a4b8-c06f8a4dea23"
      unitRef="number">0.1880</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTQtMS0xLTc0Mzkw_81c97c49-0608-46b8-8ffe-bb368252f9b8"
      unitRef="number">-0.6205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTpmMjYyNjk0MmU4NDA0OTU5OGYwN2JjNzJkZjE3NGYxZi90YWJsZXJhbmdlOmYyNjI2OTQyZTg0MDQ5NTk4ZjA3YmM3MmRmMTc0ZjFmXzE1LTYtMS0xLTc0Mzkw_437d39fe-789e-4e98-af5a-0016a9c74859"
      unitRef="number">0.0017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzEzNDI_f884cc03-52b2-4ce8-9520-8815e92977ae"
      unitRef="usd">19500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM5MzI_ebf09f48-e897-4677-b083-e16b4ca31db3">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases in tax positions for prior years and lapse in statue of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions related to business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions for current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItMi0xLTEtNzQzOTA_59f02809-db2e-4055-a048-2e19e39f9480"
      unitRef="usd">17692000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItNC0xLTEtNzQzOTA_282cd834-8d5d-453d-8cd9-518698a7898d"
      unitRef="usd">19167000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzItNi0xLTEtNzQzOTA_fd200a80-a3fa-4b16-9b8f-b191def3b361"
      unitRef="usd">21483000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtMi0xLTEtNzQzOTA_f0e5aecb-c17a-4843-9cba-740ec16be8e9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtNC0xLTEtNzQzOTA_bfb350e0-d93c-477a-a679-09dd32a57c35"
      unitRef="usd">21000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzMtNi0xLTEtNzQzOTA_68f3f99f-be67-41f7-a2c3-c1038ec6dd26"
      unitRef="usd">41000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtMi0xLTEtNzQzOTA_5052045d-40a1-4a3e-94de-1bb80f54cad4"
      unitRef="usd">1148000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtNC0xLTEtNzQzOTA_9b9960d8-2258-4663-a6d6-0e121cc2fde6"
      unitRef="usd">1496000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzQtNi0xLTEtNzQzOTA_7781a5f3-8e8a-4bf0-8d7a-262b23f09083"
      unitRef="usd">2357000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtMi0xLTEtODczNzI_c9519cef-d7e4-4fe3-8ae5-8c153239eee8"
      unitRef="usd">2151000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNC0xLTEtODczODA_4ae02de7-80df-4255-a6a9-4a7a838f8260"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNi0xLTEtODczODg_09215d36-8a37-4f1d-b7bb-5da104399a4a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtMi0xLTEtNzQzOTA_f4e7de36-2070-43f3-ab5b-39ab83ebb73e"
      unitRef="usd">787000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNC0xLTEtNzQzOTA_b97d14ae-afd0-4911-86d8-2682533c4793"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzUtNi0xLTEtNzQzOTA_9893bd4a-15ee-4619-b867-47f70df42c49"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtMi0xLTEtNzQzOTA_fb3a13c3-4fde-43c5-af7b-aa4abf3afeb3"
      unitRef="usd">19482000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtNC0xLTEtNzQzOTA_1d138044-c632-4d5e-acd8-bc180cdebc41"
      unitRef="usd">17692000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90YWJsZTo4NTE0ZWM3NmY0NjU0NzJmYTAzNGJlYjlmZjM5YTUzYS90YWJsZXJhbmdlOjg1MTRlYzc2ZjQ2NTQ3MmZhMDM0YmViOWZmMzlhNTNhXzYtNi0xLTEtNzQzOTA_494cbb1f-5df4-4540-ae9a-0972836f8de2"
      unitRef="usd">19167000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i01d046463d2847239062ac90d2a20ea2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5Mjk_ccfcc21b-cd49-4450-8144-379f8e4e614a"
      unitRef="usd">31200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i605fb0614d614a189301d7b5aade275c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5MzM_d71157c1-ab2b-4efe-8960-d645696cb6b5"
      unitRef="usd">237400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id17b587fd04b4b8eb4297c5113c4d2f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzE5NDA_866d3cbf-cf45-4d10-b5b3-5a11ae750de9"
      unitRef="usd">63400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i182a0e0c521c4a8e849c93a64dc49a7c_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODY3Mw_e67aedab-25c6-4e38-80cb-cd4cdb608a77"
      unitRef="usd">7400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i887f9a04206a45138521ae3e2d97845c_I20220524"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODY4OA_52e3a6d4-f3ac-4bac-a9e1-0a4f6cad2bba"
      unitRef="usd">720000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id7aa8bd02d7448e5943ae4e632674862_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzIxOTE_62d73cdc-f211-4656-980e-33ef8262c35b"
      unitRef="usd">30800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i25d54b5d7bf64043bb0258fe6d02efc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzIxOTg_ee77c03e-9765-49fa-ad3f-0e14323fa238"
      unitRef="usd">17000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i37c7ed8f55754813819fbae73df620ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzU0OTc1NTgxODg3MA_afb8aed8-5b1e-451b-b833-dd0cd34fc75f"
      unitRef="usd">700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="if46db7bf283d452193c503c22cecc2a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzI0NzY_ac4b5209-1b01-44b7-b73d-0ef358ba5799"
      unitRef="usd">70000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM1Nzk_0b9f9cfc-ce64-4b0f-87d0-0f1a6495785a"
      unitRef="usd">0</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNTcvZnJhZzoxZjE2NjA0NTU0Zjc0MDllYWNhMGFhZDM0N2IzZmI3MC90ZXh0cmVnaW9uOjFmMTY2MDQ1NTRmNzQwOWVhY2EwYWFkMzQ3YjNmYjcwXzM1Nzk_b10ed16a-8991-41ce-9c75-50fb5e391033"
      unitRef="usd">0</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM5MA_3ba547c4-2e9c-4fda-a262-67567e71e885">We have an employee savings plan pursuant to Section&#160;401(k) of the Internal Revenue Code.&#160;All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately $2.6 million, $1.1 million and $1.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzMzOQ_ba643038-3ad9-4a28-89e0-bc10601ac634"
      unitRef="usd">2600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM0Mw_c631cbbb-40ee-4731-b3ab-93a81eb8d574"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNjAvZnJhZzo2NjgwZGFhZjk1YzU0ODhhODRjZDA5MWVkNzRlOWNjMS90ZXh0cmVnaW9uOjY2ODBkYWFmOTVjNTQ4OGE4NGNkMDkxZWQ3NGU5Y2MxXzM1MA_375cfde2-6807-437c-8f68-79300a2f5876"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90ZXh0cmVnaW9uOmEwYjAxZTI4ZDEyMjQxMDdiNDM2ODVjNDdhYmI4Njk1XzIwNQ_24407208-ab69-4581-873c-dfec95cac4b6">&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable allowances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable allowances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the year ended December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable allowances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;(1)Allowances are for chargebacks, prompt payment discounts and distribution fees related to proprietary product sales.</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItMi0xLTEtNzQzOTA_c8f193b3-7d25-446d-9c4e-9074c6c3e845"
      unitRef="usd">1140000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNC0xLTEtODUzNTA_6c8640f0-30cf-42c1-8ccc-3f1c888edf52"
      unitRef="usd">924000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNC0xLTEtNzQzOTA_de8e53ad-9a59-42e1-a8d6-8f11f4bd9aa3"
      unitRef="usd">5946000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1d00237089024881bd1f90f6a648378f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItNi0xLTEtNzQzOTA_9c040c19-e4d7-4a45-b5da-590cc9b30b51"
      unitRef="usd">6096000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i231989e09dcb42a4b75eea0d7ffce3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzItOC0xLTEtNzQzOTA_5d9925d7-1e39-4521-8a42-8c578243296c"
      unitRef="usd">1914000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtMi0xLTEtNzQzOTA_50cc3bc5-7c41-4d1c-9c73-47cd8059ed4a"
      unitRef="usd">1003000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtNC0xLTEtNzQzOTA_18898cbe-db4a-4f0d-8310-09744a887ea4"
      unitRef="usd">8131000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i54c84ef2171e42ca93a2621b872b7fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtNi0xLTEtNzQzOTA_b55846d9-ec83-4619-a0f7-ef641a448bdd"
      unitRef="usd">7994000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i528d79391acd4adabf0eb110ab4c0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzQtOC0xLTEtNzQzOTA_72c0fc9b-749d-433d-8fc5-45d0b1ba4508"
      unitRef="usd">1140000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5e37d51271604aea8b4052a4f33ab467_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtMi0xLTEtNzQzOTA_1c5264d0-95eb-46b3-9f7b-bb766fd476c5"
      unitRef="usd">797000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtNC0xLTEtNzQzOTA_39acb86a-cd44-43f4-a038-e3a159e285c9"
      unitRef="usd">13276000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9f306a63827f49a487bcdc0be2476c7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtNi0xLTEtNzQzOTA_434319ab-bc2e-4021-ac22-95d000bf1967"
      unitRef="usd">13070000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3cddd407fea442d591705c36d0c6b738_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczMmU1MTYxOGJhODRlMTdiNDY5MTkwZjVjYzEzOGM2L3NlYzo3MzJlNTE2MThiYTg0ZTE3YjQ2OTE5MGY1Y2MxMzhjNl8xNzIvZnJhZzphMGIwMWUyOGQxMjI0MTA3YjQzNjg1YzQ3YWJiODY5NS90YWJsZTpiMDM3Njg5MzU1YzY0YjUxOGUxYmJiMzMyYjMwMWY0Ny90YWJsZXJhbmdlOmIwMzc2ODkzNTVjNjRiNTE4ZTFiYmIzMzJiMzAxZjQ3XzYtOC0xLTEtNzQzOTA_7d9848d8-8385-4def-bbf0-6005d5942630"
      unitRef="usd">1003000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-7"S<A2286U,68:JEH +%\1H&$?1/&28\"!+W-Q.9HEH-"4<=A*IAC$L_ZR
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M74"1\9>+2G5_T</.-IB@O%5:U+O!H* NF^U_]KA+Q,$ '(X,(+L!Y*4#Z&X
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M=<.5EF5NNB@#6J=$&SY1,%P[WS$Z5M?S"?L!M:U%GF5B0P6G(8ZPM5 <ACB
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M++7H\8KD5)(MY1L@%P^+.Y*#+-_X9=LTE-ZCPMM\,+:ATW,<?#W;_?S.137
M^S5X_S7@A&YT(B3[C1T798FV$I>F@ST6_. 5OQ?0'0(;W$'-';R*FRFU.<,<
M'*"\A#T5T: <U)2#5U'B!J TS6*6K4^B#LZBGHIHH YKU.%)U)E(4URO_U*^
MPT[E>RZJ03VJJ4>=J;O6[NA@ZGRGO7B[1#:PQS7VN#MVA](='X"X?N &_4/D
MMLAA?SPZBNPZ?[<XISMTUTJN/+N@MX:VL]M[.[4Y)GVA<LTR13BL4.OTAKB2
M97GR*!M:Y,7FO10:CP+%;8*G-9 F )^OA-#/#7,>J,]_X1]02P,$%     @
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M^C0@PQ&Q=], 64S(?"3_30W*T)_(*!FJ7P/<"YIUV83$V,EI+@!=DJ2QO98
MLBE2O#\"\M0 #_4#3W\@K-:;B&]6K'MUI?+_JAK>=I6A.L9>AFE5OPL@<5C4
M12[T'-9LP!H 8 A%-+&#-D WE7%,Z@Q[5X>3"(]5@*$BZJ>BQ<DN@TP$C^RI
MJ"K5_BHL9W7!P>0"!7 )S3%R3M(!.IIB>TMV">EP&"<CF\?4@!/U@]-Y[IG*
MBWM] WDA0N.Y';\".JA^EI!N6#]#WP:DZ-P;OSZTNUTW566E/G=3\J:MV2%S
MM"YEB475G1LO> 7&MM0+:^?&MA<M;7FITH9G- W/17Z>^U3),%!V(+U:@"<L
M7<**46CG&0$5P<[)"JBLB(S,#)$!ML@/;)^.-Z_UJO>FV[ECJZO1 "("$DPQ
MMB%F <BFQ DAH,+2$=B)#+Y%^&?[?L6KJ>[_1QDK.>:A50\^-^L%Q[,/SEZR
MM.6E2AO6ND',R(^8=]MN(^YE\TU.+<'NYY*\D4N+LHO9:PN@2NQCCH!FE#DC
MPYS1*T>MG,,ZTN"CR(I*4U3 ON?ZE(&N WW.0WY=%D^C1V\C%_8(I<YF)"1#
M-FH#(I30D0QP='0JW<^-BV.:5IC=-W'A'OLY][A/_\N#@_2A[6L!J "0!%3V
M?#([>EAFR^HG_=!1$^A]Y.ZID\.GAP>;[O3C/-;G']#[9?=XDBFF>UKJUZR6
M&-7(ME_+(L-WB;RKNGL J7LC^$X_DO/(A>!;_7+#,AFB*('\?LUE9?5OU \<
M'@.[_1]02P,$%     @ :(-55B OPH D"@  /60  !@   !X;"]W;W)K<VAE
M971S+W-H965T."YX;6S5G6MSFT@:A?\*I9W:=:JBB&YN(FN[:BQSJ]J+*\[L
M?B82MMA(H %D9_[]-!(6ZHLZ0G-J:Y(/L9#Z?5X:G>ZF^P"Z?BVKK_4RRQKC
MVWI5U#>C9=-L/DXF]7R9K=/Z0[G)"O;)4UFMTX9M5L^3>E-EZ6(7M%Y-J&FZ
MDW6:%Z/;Z]U[#]7M=;EM5GF1/51&O5VOT^JWNVQ5OMZ,R.CMC4_Y\[)IWYC<
M7F_2Y^PQ:W[9/%1L:W*@+/)U5M1Y61A5]G0S^IE\3"RO#=B5^$^>O=9'KXVV
M*E_*\FN[D2QN1F:[1]DJFS<M(F5_7K)9MEJU)+8?OW;0T2%G&WC\^HT>[BK/
M*O,EK;-9N?IOOFB6-Z/IR%AD3^EVU7PJ7^.LJY#3\N;EJM[];[QV9<V1,=_6
M3;GN@MD>K/-B_S?]UAV(HP!BG0B@70 ]-\#J BPA@'HG NPNP!8";/=$@-,%
M.&+ J4J[78![;AV\+L 3 JSIB8!I%S 5 AQR(L#O OR='/;?W^[+OT^;]/:Z
M*E^-JBW-:.V+G8)VT>P[SXM6[(]-Q3[-65QS.RN+NESEB[3)%L9CP_XP)3>U
M43ZQK7+^=5FN%EE5_\T(?MWFS6_&U7WVE,_SYEU?V!@;OSS>&U<_O3/J95IE
MM9$7QN=EN:W38E&_-W[BMJ\G#=OM-OEDWNWBW7X7Z8E=_%PVZ4H1-M.'S<KU
MFK6F72T4T??ZZ)\7B[QMC>G*>$CSQ3@IC%FZR=5[$GR'-9]OU]O5[A#_NUEF
ME<'VC75-R[;/>,F,I)B7Z\RX^D=9U^\4^%"/_Y0UK%-C[""MBKQXKHVKXXQO
M7Y@"''WO&/R/";#]BA6Q\;FQQJ!#F9R-O:C:$]8\#FV$'MH(W26U3R2]RY[S
MHDUAW*6KM)AG[]^$SD:/NF&J;C^[8BK?O_W.2!N6?_[!L,A[@YK$5XE>F[,=
MXS[6FW2>W8R84NJL>LE&MW_]"W'-OZN:PA[F[F#M^/9R2RS7(];UY.58\\B<
M 1(6(F$1$A8C80D(QLG8.LC8&B;CLV2Z9WI'RO*)YSJ\L&9R*6)Y@OCD,J[O
MF*[+%POD8M0V^3*A7&;LFDSP4[Y<I#T@0X6 A"4@&"<$^R $6RN$Q[:7&K>G
MB N#C3SLO+E.=V>>V;?V=::2@2UW,!XU;4$&VKP##]']62D#9,H0"8N0L!@)
M2T P3GS.07R.5GQ)76]WG0\[PV3TILKG[7!=MZ=I1OJ:5NTI8\%F>4?CJ4J0
MVBQ#AT]'DII+A-X+F2] PD(D+$+"8B0L <$XT;H'T;IGBW:^GU?L!;O95NTG
MC=&4K/?,JGE>[PKM/RTW;;=:&^P,T7AA6F_'7I7LMT7>[$MMLFJW@-'F4A<[
MJW%H:S.T<;A2XW"H.-+>(S,&2%B(A$5(6(R$)2 8USR\0_/P_GS-0VH3;8&W
M!0BV0RQ\6RS89#MX?'@P-NR,5]52/+GGMRQ?F#?-/.E\4S@!OE=RID(K";2'
M<:BPD; ("8N1L 0$XX0]/0A[JA7VIXPI>+Y,:UG:W^F!M=RA/?!4$M?8,RD5
M)(A,&2!A(1(6(6$Q$I: 8)Q2_8-2_0N5JE*G+PN*."8API1]YLOS;'%6?PHE
M3-D#[>X/%102%B%A,1*6@&"<H(C9.P.F5E+=BG^[0E 6[8KK3EC%2U8U^9=5
M9A1EDZF7\TU9$]**D3[YT+6"<U(&T)0AE!9!:3&4EJ!HO Z/'"JBU>'>,IES
MEDG>62:K$Y;)7<?D!$')5!2A-O-@$2)IP5DU"*$Y(R@MAM(2%(U78>\!$;T)
M]"\VP]BK3BDWA0%#?7,J]7I(-^$>2@N@M!!*BZ"T&$I+4#1>F+VK0_2V3K"W
M'R^S)JFI5#/2ZIAU--Z<=$Q+.$.\AV8-H+002HN@M!A*2U T7LV]-47TWA2O
MYO/4JC"*'&+:XF2F*\>;E.(ZC@+F4L>>6N*YI%Q.G)"'BC)CV[,=<7DI4NS9
MV*&.*WA=L:J<ZSAB)1)53:GO]98&_^7TU@W1>S>7&(=$]E:H.:6F^.4@O8+[
M\Y(&T*0AE!9!:3&4EJ!HO Q[,X9<Z,8\E97!)@OL/&VQG>\TVLY6N^LR]Y<%
M-:4\AS6N- MY^GT9/!;*9@H[2Q0OTX'F#*"T$$J+H+082DM0-%[EO:="+C15
M+E2Y4MRR;4$L(EW6063_PQ<EJR*9OK0$ W5 H+0(2HNAM 1%X[78VR!$[X/\
M:/ZWOCJ#.VW9?R&V+RZ$0W,&4%H(I4506@RE)2@:WU!Z%X;H;9@?V DGLI-#
MJ&.YXE@@>T*B$7F")%ZYIS^4@R4.]82@M!A*2U T_EKXWA:B>EOH<D]<#QY\
MR;O"\ID2(HH1FC2 TD(H+8+28B@M0=%XS?86$M5;2,/<<:IP7BS'-!W1/NH*
M<NLQXH5Q)V'B8H2^"H.E!?6%H+082DM0-%Y:O2]$];[01>XDE>VBL6M345Y0
MLPA*"\ZJ00C-&4%I,926H&B\"GL3B.I-(+T[264'QC:I)UZC,],G&2PXJ)\#
MI85G'I$(FC6&TA(4C9=<[]30(4[-4-^1*'6JS3CX!%'A"UF>[4LC-#)K *6%
M4%H$I<506H*B\6KNK2VJM[;TOJ-:K;+)1'S7=\2+Q[MRO.\HB5#A6#FN)9J8
M@:+<V!6-K5!5RIGZXN0HTA^4P8* FDPH&B^(WF2B>I/I$J^3RNX.M2UQI7"F
MSSQXF#TK:0!-&D)I$9060VD)BL;+L'>!Z/_7!=)ZG?I]&3S^*BPA1UZ?0>8,
MH+002HN@M!A*2U T7N6]OT0O])> 7B=5N#BN=*=75XH;K$7%*D%4[&^A!@Z4
M%D%I,926H&B\$GL#A_X)#9P_X'3JJS.XRU8X-Z8G.IW0G &4%D)I$9060VD)
MBL8_2Z:W@2R]#?0#.YV6[!P16UJ0GW7%=$.!FF0+%\<$^D,Y5.)06@2EQ5!:
M@J+Q$N]=(TOO&AT];(QI67B,6?M0N^XQ9N_;%QNFO5FZ6AF?JY1-%7>/<E2*
M3^$'N6QF+JD/>FO2F5D#:-802HN@M!A*2U T7JF]"67I3:C+/7D]>.CY@Z5P
MA6S?$J]OA28-H+002HN@M!A*2U T7K-'3Z/36U;#/'E+-FS&U&3_1-/44CP;
M3KS)0P4C/OLG+IKIJS!86M";B*"T&$I+4#1>6KTU9>FMJ8L\>4NVB\:6+"^D
MZ7$/I05GU2"$YHR@M!A*2U T7H6]I63I+26])V^I;E&BA/JBX* W1D%I 906
MGGE$(FC6&$I+4#1><KUI9>E-JS_FR5.E3J'W/UFR644LASBV.$)#[X""TD(H
M+8+28B@M0=%X-??>EZ7WOO2>O%JM\IU*Q/4]\9J/F:J<="^PHA#U+%=\J)NB
MV-B7;@969;0M*CYR*=(?D\%Z@+I$*-I>#Y.C7RUH?UCCGVGUG!>UL<J>&-[\
MX+&^M-K_5L5^HRDWNQ\R^%(V3;G>O5QFZ2*KV@+L\Z>R;-XVVM]&./QBR.WO
M4$L#!!0    ( &B#55:+[4JN.0H  *\9   8    >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&ULG5EK;]LX%OTKA <8M(#C)&YG.FC3 $[Z2&?3)&C:S.XL]@,M
MT1:GDJ@A*3_ZZ_?<2U*2G33H[I=$C\O+^SSW4#Y9&_O5%4IYL:G*VKT>%=XW
M+P\/75:H2KJ):52--PMC*^EQ:Y>'KK%*YKRH*@^G1T>_'E92UZ/3$WYV8T]/
M3.M+7:L;*UQ;5=)NSU1IUJ]'QZ/TX)->%IX>')Z>-'*I;I7_TMQ8W!UV6G)=
MJ=II4PNK%J]'L^.79\])G@7NM%J[P;4@3^;&?*6;#_GKT1$9I$J5>=(@\6^E
MSE59DB*8\7?4.>JVI(7#ZZ3]'?L.7^;2J7-3_J%S7[P>_382N5K(MO2?S/I"
M17]^(7V9*1W_%>LH>S026>N\J>)B6%#I.OR7FQB''UDPC0NF;'?8B*U\([T\
M/;%F+2Q)0QM=L*N\&L;IFI)RZRW>:JSSI]=V*6O]3880U;DX:QU$G#LY]%!/
M0H=95'465$V_H^IX*CZ:VA=.O*USE>\J.(1=G7'39-S9]%&-;U0V$<^.QV)Z
M-)T^HN]9Y^PSUO?L!YP=BW-3.U/JO/?]QBJG:A\>F(5XIVM99UJ6XA8/%6K1
M._'OV=QYBVKZST,A"@8\?]@ ZK"7KI&9>CUJ:"^[4J/3GW\Z_O7HU2/N/>_<
M>_Z8]O\ME_^G*G$A2_-M6RGQN5!6-JKU.G-C\:%&JK034LRU:0J)AA%>945M
M2K/<BJ:4GA!$9*9J9+T5OI!>--:L=*Z<T'5M5I+ZDS?+M;-MP[?(4$M&./2%
M+[!,B:5!0I =7?'Z>LE/&RQ'?H3:-,KB*@NJ&N/Q%"DLMP*8A.V5FXCKUM+F
M#00]H$BHFEP:"WO1WEQ,C\;D2>M4+KP1"YGI4E/^>1_7SK/6RUJ9UHDG/__T
MVW1Z].KVG"^.7ST%(I2P&SK)POHO@ _4Y+9=.K9G4;8ZAP5_*%'J#."F8)8=
MA@I;=B',.+QP-X1-(U1XC9XOY=Q8#AC\RA7^F88\RML,)<K!Q9(Y4L;JWUY=
MS*[^?"M0:B^>OV)S>D,'>R=_HGSG5!?[1EI?*^OHS?&+5SM!)!M-6^<QO@MM
M'5M1*9N%!,B&,H9X1$O%Q;94M=HDNZP*1DOD,9D219(I8X[BT*=]D_8W"7%/
M.V:XH99')*55#.A05_>9)]6H)10-7@P-*MI*UJ+8RK*UIH8.I"[4S22MIK*A
M*(51@_0OK<JY*G6=?!V'[/#4%?.MF&.4?J4BSLVZ5X^=N@#,!KZ+6OK6AFK.
MLM9:6IE).S?%-K>A1J&=&[&2?QD;LE*3#2A(,DYM"+TP!MM26@AYJS?IW>VY
M8'B:H+O)%X6U5EJ-[>!)FZG@WUQB8V6Y5-OR:RAJ_ 5<P32S)J/0[;%#$4?*
M0&40;R &)+'-L$T*3$ZX[]" ?+E"SU<J=H^<EXH: O7)0./:K!#205UMLA*1
M*J'=Z[G)J3NX.&"B%7!NR1V;0 HK0 7:4D$)UJ\1 ?KO*IC<O]MO4G"$X"CG
MM6G0M-UX2%F_#Q)#[X(Y 0$0DZ";=HX%O(,%M#@5]BXF1/3L.K^#Q$?!@HHA
MP8.A;-NO('K!&*O^;C47$-[,49L+[3ESUE0Q^.3H2LM4&Q8(JL@GF8.*:!J#
M)#(!^D>W>:<J5ML0''0-X96JAZCYX:Y'3;8H0E8>'!LV>1^+L4#W2E% &8Q6
MM5C"<JK\'*71H%Q]-Q$2]',M=II,+.5N8GATH&>;YZW-5<WE(2'EP.S(#U=
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MRJ6XV<$KAR6HL%K&(,W>!\8I-\BC%%]N=U4&';W.FX7^AG+;D0G/>IG?9>W
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M94D [Q<&=L8;VJ#[C>;TOU!+ P04    " !H@U56 G:$$D<J  !:A0  &0
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MH]\OGS\&O?SK4.&N!Y_U+6BFCRYS8;6XR]R#PM_R)OMUWF?Y<@DJF5E@P]2
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M@@>DLCG^HR,QPMOF +#*P<U&:F4-N$A>-;0C\IB,!^)T6$.#IOP5+6S8BKX
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MOEG('!LUS&4"8M5BTOW4FJ1"AMVKT8?S[)W5<M]&+8<@Y-T1#1@=&JNF.I?
M3N3GF29KBH'"/(Y*S3#=)[+=E$DUS#RN@#&3/!N205QF90]2JE;H)"LN"1"
M!$H'D2-9230N0?-SG4"P2RA;_ MI6B00!C11C8%.T\+.SNE*'[B8%*W9Q:C'
M3MJD'3.@L)"[9Z^/LH6N [@%$*'J-A*:_1XMS?>@2TI0RT3_7U*^(%-4TP-R
M0!/9@A,E%Y69K@M($*<^&'G.JTDF2P ACD=!91)X0/]@Z;G\U]:2JNQH-(&U
M"V.F$0K$+(0DDY'E@%1H(!!LVZ*QMYP<>#U524;<%0H="&C2LC(11,SPQ6(:
M1K3"/;8\.II^V1^Y-W97_!+*)19O=Y*"PL)9P>6XO@6J;AHP5@WE!2S#5[8T
M*_HQL##6!)RX&6?9E,4X^*+Y&I8Y6O_2=8)JZ3&4#DV&:U681';B9W*PA90G
M'< 2K-X8X9&J,R*0) &;I/C3[%6M5@BD>@V#/JB6&^N/,;A->I=X7. VOGJP
M&^-]2A*"0E,IP8(TYRNP!2M<\HC2"?G&<\S$7YXB%E59(GQ'L\J^8JS%)BA
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M26\GAR8VS"KY:*\P^#.U5@F=S$#!]8'IM<:@;[$TL.A:9-EV4Q4QN4_3</F
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M;^YMNA,V\ZB"<4]7$=$8\!P\2'-R>EH,L2V,).7)94PNJ-$8Z*(H@.Z3<S[
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MW_0=WG2=>%N7*UU)$M7+"P/*]/TB<U3>6"KI(U0FJ?BEKLRV$S]7N<KW"5R
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MP0Z+7:</W?8>,V!%E34_)S"5 ^VHE6"%G#SJ1AV4L[.8>LM98MZW7MH1\+C
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MCD=7LQ.;WO@'4S=\.7E5&U.7_'.KX#,M#<#W=0T!N =:(-Q6?_W_4$L#!!0
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M*+<4VJ K]3Y]R+P1UG0U^MC)M_MEO2U([CO?-0<$H+:9=6T3LN@#1Q$_3/W
M,\J01T@5I<5W&]KRN-\\S=*3L!_VLQ/GY3Q(%U3K*5H'FM#G@^Z3* 11&&/0
M*_[EDVA UH,D36EQ$"_F[-SX5O+(P&!0QN8!BV@>QTK#_=].I"MS;%6M_E_Q
M[(F3]2S9*%(4IP>@5DEL(D[>(28HLFU)!KEZ.EJ&X\6PZG=%F17L:#$;Q_MI
M3S]'W%:NVVJ->0#TW;!I=5:@-:!(<U(V.O9H=J]<*"GC2XKLQU_N3@V@84J[
M%_.4>R1WXG7'P0VH2%GWSJ](9"HT"^W#CJ1,Q^RS9YIU;>$IU4DS!C8'[&@Z
MB "$5]PVWG1_0DNM<'7G4]?GRJ6N2S2*U*(9L=K]$W;2,)"JQP1T<I^,H_V)
M_#ER^00-%.$90<VI3>8/--651V-1;1IQL<(EH_7_:R :$)I#_>OYCD5))"S/
M-@SV9$-/D-Y'W%HH_8[V7<R!Z7N1CYJG;Z;PS31*.J+W2EZ:8= H+" I$LN0
M;D%7+BQ8M9;6]?R&3%7.X4?'D/D<0J%S4E=?9(X00M>FUZ$^+>-#_](G@ZL4
M #?NPFB8TQY_J]K/[N^DY_XJ=K_<7V@_X;]=*2'Q8HVM*,'9B&E_2?0O5C7N
M8K92%M:[88%[M="T -_72MG^A0[8W]3/_@-02P,$%     @ :(-55EX<Z25^
M!@  QQ   !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULK5A=;^.V$OTK
MA!L4&X!KB]3W-@FPR;;H ETTR-ZV#Q=]H&7:)DJ)+DG%27_]/:1DQ][&:6^;
MEUBB.&>^SLR0N=@:^YM;2^G)0ZL[=SE9>[]Y-YNY9BU;X:9F(SM\61K;"H]7
MNYJYC95B$85:/>-)4LQ:H;K)U45<N[57%Z;W6G7RUA+7MZVPC]=2F^WEA$UV
M"W=JM?9A879UL1$K^5GZGS:W%F^S/<I"M;)SRG3$RN7EY#U[=YV%_7'#STIN
MW<$S"9[,C?DMO'Q<7$Z28)#4LO$!0>#G7MY(K0,0S/A]Q)SL50;!P^<=^G?1
M=_@R%T[>&/V+6OCUY:2:D(5<BE[[.[/]7H[^Y &O,=K%OV0[[,WR"6EZYTT[
M"L."5G7#KW@8XW @4"4G!/@HP*/=@Z)HY0?AQ=6%-5MBPVZ@A8?H:I2&<:H+
M2?GL+;XJR/FK&VD]4D>NA19=(\GGR(2/7K;N8N:A(&R;-2/8]0#&3X Q3CZ9
MSJ\=^;9;R,4QP R6[<WC._.N^8N('V0S)2FCA"><OX"7[MU-(UYZ N_8S3NI
MA9<+\D&Y1AO76^G(?]_/G;<@RZ_/^3^@9\^CAP)ZYS:BD9<35(B3]EY.KK[^
MBA7)-R_8GNUMSUY"_W]3]8_!R/NF,7WG'8JND>I>S+4DC4$=NA LLR1^+<G2
M:!2TZE;D#6#\VO1.= MW_HX@9[*=2QOS=O3R'/#2FI9LK%GTC2=.:*3 &[(1
MUG?2.G)&"D[KLL8#JVB>9*=!K+R770_Y'N2SL%AK,3=6A+(G8F6E1#.!''#*
MLB YS3A_ <T\"NT?8<GC*)8DM$X24J0TS_/3@@;1L5]X5%#.:Y+1(LW(#2HD
M\(L(YR3DLXRRA).OOZHXX]^0S_W<&R\T'.8I7*\*/-6<,@:=(>0Q7>C&9(%\
M6#7O8W=;2JA! L+J:-@;1FN6G8=?EB7GY#\15CQC=U#%:%+RH I>ECGYV"&8
MWE@%V%?)_9W8HF]Y:970(:TLI64=%+*$%M#\"YKW6]6]1> :Z1"6A*8%(ZRD
M6<[(=ZI3:'(+LC)F@8\YC$P(SVE9Y:-CZL#BLY@MQE,\Y2G25I%;*S="+8A\
MP#QS8["&7(V)>!4W=VI:T?5+9+FW07ZO%.8P6M09'K*2UC4C/XYT^<(Z<"4K
M24JKI!ZWC%:R#)S("*=)78R>_TGX3ZZ=D9+1E.=#."I(_A!BK$VW>HN4H "-
MC31ZPPN:)BR0)J598,_?5$$QK*Q% H)G.4UX=#&A6<7_*B:J:W2_D,0>,H02
MIXTG0Q<5QQ0?];8#CR,T6D:SJZMC-3BOB$[]$2'<%.75K/>BPLI0!AHNJ*62
M$6;[!0]WM'J$HP<$#J*]"URQD2M_0SL)KJA&#L*-:3=:>CE%>'#$LF@UP3?Y
M>Z\VH>%0TJ$AOT[I(8C"PN\]>" $3:LD_K(R(Y^.4[/?QTNP)46O+%F-SM5N
M>A]"'Y*P7,*7@ZW8B;:8TQ2%^8/$06EM](*H%H&\'SMO04NT010 KP[[7%9#
MM Q%BP>4!%IKW_;#:%Y(4*]10P"#7N0.5!TC^@;54.;%0%>4_/DA;)ICB84)
M@D[#2#QOAC B;>%GUW[!T:(.]92D+Z8"H<II7H:888"@A#^\:-I(;[(%;<0&
M07A0@3WZD9P5TQQ'.:VQC9*S=)H\O048K*1/*[$Z7!AAL/GNQY\&NX]UX<LQ
MS!F;%KNW 9--R_W"<N3L(UCAB Q'M6/"A,-6_,NB,!X2&DIQ(^,96C].0XYL
M+P\:PFL=$")J* [ /H464]@"CWCQ,+3WFM9I.!0$ZE1[.=PZG.EM(T\V&X9)
M6F.(TYQE&')0)$=0J(C#<#>(&<V@X7:<XU8"J1OZSS#3Q7X8IPGE&%5E4NQ:
M]9?!X36.' SMO,BJH3B(5F*NM +74G"XJL# BB=/0_H8 !ZC,]=9<)F'"9"?
M[."P)DM3E$2>9><G\ Z[=1UB40RX6<;(MR-QP3,3V VQK?+KF-. (W>4"POZ
MR)<P>I_A>W+$]^2)W0,U#S[OJ>FW4H/R[7";^&<4'5P?+-Q5X[_!CZX=%R?*
MJCYVAD_YT^=C>VZ$6P_3*EBQFT%VO(-@]$13W2O8F!T: 9/*8QO3DS8^=TN9
M'5PN6VE7\0H=ZAWF#_?,_>K^EOY^N)P^;1^N^)^$72D4D99+B";3$I=B.UR;
MAQ=O-O&J.C<>%]_XN)8"I_FP =^7QOC=2U"P_]_%U?\ 4$L#!!0    ( &B#
M55;CVWI_W 0  +(*   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)U6
M;6\3.1#^*Z. $$C;9M_R5MI(*06NTD&KM@>'3O?!V9U-?'CM8'L;<K_^9KS9
M)!RE2'Q)QNN99]['<[HV]K-;(GKX6BOMSGI+[U<G_;XKEE@+=VQ6J.FF,K86
MGHYVT7<KBZ(,0K7JIW$\[-="ZM[T-'R[MM-3TW@E-5Y;<$U="[LY1V769[VD
MUWVXD8NEYP_]Z>E*+/ 6_1^K:TNG_@ZEE#5J)XT&B]59;Y:<G.?,'Q@^2%R[
M QK8D[DQG_EP69[U8C8(%1:>$03]W>,K5(J!R(PO6\S>3B4+'M(=^IO@._DR
M%PY?&?51EGYYUAOWH,1*-,K?F/5ON/5GP'B%42[\PKKE'60]*!KG3;T5)@MJ
MJ=M_\74;AP.!<?P#@70KD :[6T7!R@OAQ?34FC58YB8T)H*K09J,DYJ3<NLM
MW4J2\].WQI1KJ10(7<*E]D(OY%PAS)Q#[T[[GG0P9[_8XIVW>.D/\)(4WAGM
MEPY>ZQ++;P'Z9-S.PK2S\#Q]%/$"BV/(D@C2.$T?P<MV'F<!+_LEC^%"ND(9
MUUB$OV9SYRW5S=\/Q:'5DC^LA7OIQ*U$@6<]:A:']AY[TV=/DF'\\A$?\IT/
M^6/HOY"U1_$>MO8G@=I=7VEX)S:0YFV*(E@C-=N71EHL01 #S0)'TJ74"T#Z
M[C<@M4=21#"F@AEAT^$89GO0N5!"%\C73_-X<AQ3\2O%?;P6CJ9!819:_DL*
M:"Z!7R+@UP)=@.-386ALE&A%:'U*HG856C;(W&,KH&GBB=:5O;7DJ<40 DW?
M6]P5#1#D[_>H&PP\A7$>W$:C74@\4%K/*;!\7:^$W@165E%3V,HPGLC: MG1
M[1#L1,-P"H$A2:(I4HLN%-+!UB("F?,8A>>2G%J:QI$&]^($SK?1$L$6ZAA2
M26YNNR:!I_#LR3A-TI?[ .]\INA&<3[Y"49*&!WG][5PU=@]H-Q?=_&E9A*U
ML3YDK''L'GO-W<53\XCK$6HDE_8)DA:H0"0-WB"#5:- T00/YCE.!GP,,Y?S
M1C+TA%".^!UB>"4K#&':H+#N!;RUAJKCE;!VP]<?A*)4SHJBJ1L5-,Q:^]J"
M>4^U\7_>QINC2_T/%0-7'!9+;919;&!%\OPXPBB$*(WB."8JRZ-1-F!B.(K2
MX0#^_'1U>_?Z@G)I5E:BY^P373:%AR2&)!M&])+".$JS,23I*)H,4[C[??;^
MXFK'9]E?Q^QI-"'F9#0@:I0.X,YXH?@Y(O<]'G&@#C/AHE#O3V&0)U$2#,RS
M*,G'3$Q(UR"%V=W-[5$RB5-X?GE]\TS4JY<7+RC9'2CDXVA$HJVJRX>PA]&0
M@.ZX;7:IJQK/PU1HW9"8. PS)?(']G:50[7OEF:M(10\4K<KJO]0/X+8J),*
M_QTLMZQV"-Y0NW _TUU [VQ9H96F=-2GC2JAE!7-!JBLJ5F'VQOON!D$(3AZ
MX]G:4.-.LA;RNN1J])(AZ=0UNP\]+&W-(R1BR\A:0\"D0G#QT*#[1$5Y\FW)
M?=O2W'(9A7241%DVX5-^0 \.Z.$!/>IHR@!M:!7-6$@HX>E@M,W:/ML/O4+]
M@SVBIMD6MJ40)NW;E6+W=;>0S=H]9,_>;G/O!(U&[4!A1:+Q\6C0:ZNW.WBS
M"EO)W'C:<0*YI*42+3/0?66,[PZL8+>F3O\#4$L#!!0    ( &B#55:RU)&8
M;A4  +57   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;.T\6W/;-M9_
M!>--=NP9EB8I491RFW&<S38[:9I)TMV'G7V 2,AF2Y$J0=K1_OH]Y^!"4")I
M)VW:?-_D(;$D @?G?@/ )[=5_8N\%J)A'[=%*9^>7#?-[M'YN4ROQ99+O]J)
M$IYLJGK+&_A:7YW+72UX1I.VQ7D4!(OS+<_+DV=/Z+>W];,G5=L4>2G>UDRV
MVRVO]\]%4=T^/0E/S _O\JOK!G\X?_9DQZ_$>]'\M'M;P[=S"R7+MZ*4>56R
M6FR>GER$CY[/<3P-^&<N;J7SF2$EZZKZ!;^\RIZ>!(B0*$3:( 0.?V[$I2@*
M! 1H_*IAGM@E<:+[V4!_2;0#+6LNQ655_"O/FNNG)\L3EHD-;XOF777[O=#T
MQ @OK0I)_[-;-39*3EC:RJ;:ZLF P38OU5_^4?/!F; ,1B9$>D)$>*N%",L7
MO.'/GM35+:MQ-$###T0JS0;D\A*%\KZIX6D.\YIGKZORZKM&U%OV0JP;C[T1
MS9/S!@#CX_-4 WFN@$0C0,*(_5"5S;5D?RLSD?4!G -&%JW(H/4\FH3X0J0^
MFX4>BX(HFH WLV3."-YL%-ZZ82]RF1:5;&O!_GVQEDT-*O&?(6H5K/DP+#23
M1W+'4_'T!.Q BOI&G#S[ZU_"1?!X M.YQ70^!?V^ ID$,HPB0?[0@\Q"/P@>
MLLNJO!%UDZ\+P=Y4C9 L:P6R?LE>E>RBO0(])$EX[%:PM-KN"M&(C#77@DD.
MDZH->Y!$@1^ BA8%6EL.!G=U58LKW@BVJ_,RS7>\8'Q;M66#XX]7?B_*O*H/
M$3C%1?[ZEV44!8_IAR-DZ6'XF/$R ]P*LO<;4>S!DIIKPA'FS>FQ_I(,4.PL
M,[;"F<\^P*@2^+:KJU2(3"*=:566VL?8%7,I6UZFQ!F]Z #F'N,;$#5XD:P%
M .65FEOF30Z\VK5U>@T.IZ;UP^0QVPC%ZG#9<1I$PB7C.\#H8PY>"@E_D 11
M-\)G_Q*,%[("R&E;UR XGF4Y(@RK9&@9%MVTD@WPHFIX@>@\"%TP+P:&&JY.
M(\UK5 )0Q!+5!O%5ZV9@D:@0BK'#3&([O@?PP"<!6BC%-O^.EV7+BV)/6@8$
M\5HRX/Y+L:Y;B"PLC$$,B)E67?H.C!,\O69[&,YX \^9@L-JU%&CDI.H(!U7
MHA0US&I+*8"=0$^U+G+0<^"1XD?-RU\ 4=)FP+#&P(#P@1 (9PVP%\11P"/D
M@<A*(5']./*6B8_()PFTR79=U5E><F39")@IU2(LQ*^644?S25D1$?$QEZ1]
MB/RF;=!!%CE?YP7(5&C<D/2R @%4/<P\>B V&VMU/[=$.!)9 A6:1WUB%>;B
M8R.4,\!O-[QHK;UP*05H%\U&S&0+DG-A>(0LK@U^'(RGK8G.'M.&^(RS*EBA
M[E%X"I91M!E98,TS@3SBP$MYA@A5;<W(<!#9VG (EI)YEO,: $PJS36_ 8(@
M:,.TO-FS3*N;54Z*<DN??5\5&1@.C-RC4T$PR(R\'E5'\[S:D?NI2B5JY. &
M/&%UBQ2E>9VV6]F@U<I'[#0\ ^]:*WG#0N"_RPQ, C2E1F<$[AW4(Z7GY)T0
MVM$H^(8C8%$(U6*[AI],N/98KH18<""O%KNJ1FE0H(!( *YC!Z/E-0H/V(#K
M 1C(=%+0UX_*K88S" Y:%Q0K* M4TR$55:8, X %A> 4GDATB%3&]]*0B !F
M <) 74(5[0^S="B%LGK@=10XXPU*.; (1$_.%NPU%33@D$F/V6ETYB*RP>5=
M5-:MS$DM"1<7JF(]"NAHDHL/<#*O,G9*]G&/D9X;Y[; .-!D<@;JL0ETJ$2W
MUWFJ@ID!TPGO0>@%03 8UTO23"NB >8=+TLAK-!NL&2KI94]1#4,C>;K_32*
M[-75*OS0'B!C I>C72H.'(\%.<[.6+NKE&55J7(&*KJG8)*<LH :T$((X@8H
MD^@I(+PU=;YN56A  SW S,-8F F9PBCEY6D!\*:D,UNQ!9!EUFZ)H>/>'C"<
MGZ'9W9*I%HJ$3A3@@<66?(1*DT[C,Q4"]ZR!$HMMZFI[9 !..%4>"D)>DQ>*
M:Y!'$_E6@S5S0/<J (/%8]86Z(0=GKL*OA: F% *X7I&GUU(!#S@5L;IM]$I
M[9[X[">46"=?2EYO(9FAC"+E\MIR%8)-4RB-Q #9J34&1#T&['R;MUOR;I!N
M%7F*$>(8J <"+<#ZM$+*(Q\'\#C^LL8P16Y[H[#!U8;G>"@M5!Y3S:J 8Y*N
M0QV>5A9,,\+$7\9A,H:B8^-Y.6CF8UD')!SY#?I!E>8<.^]J<YBLQ@L_B*8M
M6)%[2";0 4'X9^ (K97]#.&49 @XRVIK+1$,4(D(-60M]$BA1(LVP-.T;C&1
MJT'%=SS/;+XYH8TH=QBC*@"HB'+*BFU2E5:P."^[%!F&HILK*]1WL&]D9X;T
M &'@]:X($A)N3,J#L Z9IG8>D'> OH <E+Q5_NZS2V F8'Z)2WX 7R%YJB:\
M&BY,K&^YHS !Z@3Q@'A1@8+2.N1<&G<=@MPYP18G[2#\45KE%E4CB/9KJU%R
M*,O\N -RX+%.P4%Y +,:BR<PSPJ32>1.EA?D<?'AM4ZIAJ)"VW</TQPAJ^W;
M($9=JWT=![1H*'7<@&/161;8MTZ\)3(7Z:G16&J5J&[Y+Z0 F !)V86_8\LC
MUZ[]',P=1E<;#-]U5M=,L3>7QIE0^1C[\R")Q_,T#X.PJN<H3S3.$<<E\4/&
MU]6-F([86,?.9WZPFL@&J_(@28YTD.H9OF%]YP DF'&F,U=LI<B[Z)\P\[*G
M^SJ;7PN!HA)UFDN1^>QM6V-5;&HRR,AI64_GSLYTK,?RS9Y<3PK,D?D& HFU
MT5R3KO76U-"H*(U-[5''!&1Y&25[59%G5.ZL>4$NB)J!ND!2R&PX_*?JJUR2
M%\3TB[*P3-51QB-B'E:A1*DA0F4(2!CF 6$NZA-(]JFBY@.YU .OOUCYH>T6
MF8#ER <(Z(JR+MZZSD>U(#R=J:)SA50<RC_38JA56T5Y J?E@>A\A[;*=WG#
M"\/62\O62Y>MSS5;WQ-;[^&FI #_A_&IYR=[WG2]9ZWLG++K7"][+M2SF0W^
M8-2XK],#7240:5;1-$Z5.?D@)2XM+:GZ :ZE##B1[SOW.3C"K*)*7%A# R7*
MP#_LM(E.VU[@1_%$$S+!6/8#KT'&\"V<ZD$N@_A3>I#'"P_U()/#'N1 ^_">
M/<@_H>TX@.SGMAVCH#/9X;;C<NZO?H^V8^#/_]"VXU!#^-YM1Z6:H6P(J_=B
MUZ@8@K_<W70D'9Q$Y'Y-1TIP__#.XZ!V=:C\ >U'6FS]9[0@.[:OO[(NY) 6
MC74AM?92NI/<T8,<U,ZOH0?YC[;$-I^G \2W_N.W_N.W_N.7ZC\.>($OTG]T
M(BD9]N)>_<??T'A$[ZF<FO'J3CL12]XK7F>%4YXCH*OJR+]Y?QIMG2_XC+[J
M6.[QK:\ZT%<=8I;1FC#R5W&R^$W-U<'$ZC.:JTGBA\GOV5S]ZCNBX70U.<=J
M\@V@0LA'0;B:*BCGBT\\U'*?@G+.3KMB<J H_+2Z;QC&_6J\XY,ED9],EGCS
M>>+/)DJ\X[JN5];-_M"R;JC@OG=91SFEJ>JLMA\6=1X8_%5>EFXBJ@PB\,9.
MF;@%WQ"*7W/!-ZAJWPJ^+U'P42IV_Z)O2)/&BKY.G4E5YW?4?8-*^C74?:IX
MG5F#^U;X?2O\OA5^7ZKP&W #7Z3P<X+H_$O7?'<516/QV2F([$E$L_-EDA+C
MN(W+WV/J^0]>TJ$:[%0AUX!7:@HNB(P[W+/. <A-I3:_[-8SQ!A56QUL$W=]
M_R'$:<]+%T1WE5^PPG2]-5PV3*N+C9[ST%]%P?(WE4B#J<AGE$C1S%_&OV^)
M-+5AA9OE@"*M78HK$+].N_ 80W9P(.'!K+=/.L2)"6X[949(/[%WHI?ZXY:5
M%I@[])7&Y=+BTI4D(^=*1N81[4/;O[,D\".WL%(EOO+]RA=@LM[K&)AC.B9]
M-X<!)/[8A[_R0;D,]$[)CAQT[QB#JCS <98R3W5NB#=^,N-H<#<<+XVT [T!
M[<-4>('G>E%T!*46+@4>VOBW<\D!X4ZU; M7FJ.\M#O<#Z*P7YD.*! >F(&@
M;+@J#6/)X?](Z2C\@B>E3O50FWB.;(:_;^"/.F(! W_LJG%C]\VM*" !V*KK
M0 *O QU[5]-E&478BD5MD#KG%VQJY@A1:\#A>9ZCTS1'D\BG=AO@%90L.6Y.
M]O;7AVW+G[X9\VE&GB3=?N=OL/'H_C8>?::-#\T;M7$@:_'E3#STX_#_LHF/
MLM(Q\:X9\SD67DU:>._LD.S9M9KR_\5*G8QK1@PVZD2Y5]KE+%VR.I5A4!/
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MRG_=Z_ JV%-2?UE1^'NEUY[0E"0)25"K8-3M1%X0SE"623+&P @$?>AP#G"
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MS^UQ!Z[+0SH1@)1&?AP\]""G"_!/@M\(:AC0FV#,!J<Y^3&BKAW:GKE@0D<
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MQ>I_-/56O["^J9NF+O7CAJ<YE[0 \ZNZ;OH?=,#P'PP7_P502P,$%     @
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M2CYDB](H-^$._(!-^.!:4]8(# ;K8GF#X0JG*_+N,'HG<30+IX=Q.RQ:&+*
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M67P?N,<"'V1"DP#V5PJCKUN0@?X3;_X/4$L#!!0    ( &B#55:+L 4Z' 4
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MIG' M'^U^XE5M7LIKY7%=[<;%M@[09, [F\4TFPG=,#^K]/B7U!+ P04
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MO#P>D>L^?[I)L$W\Y%C9@ ^8."SQQ<A.%N!]86T8)N)@]PUZ^1=02P,$%
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MI:F86C)5:U9"-"I7: U%(0Y65\)4E^-"\H4LI)$"CGO:'_XI)[Q_+/BU-09
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M/=!-'VTF5BWKWC53ECIA;1;TZT'M'&A_KI3=3%R ]F<V^@=02P,$%     @
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M:'Q^,0I #X_9,+&J\P_(4EGJMA\Z.:)V#F1?*65W$Y=@_Q_%[#]02P,$%
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MST*=)OJQ4U!^O8.7V&L.7\.!*PY,PT;6V+P:+BH!9B<[S42I+Z_A3\Y4GW7
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MH%5Z*.#Q&/#XN0&_,FHMRX)\N,<1;@=J_-$Q\[RCW:XT'$3?G8:-'K6MIZ^
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M4,?S4\=/J+6(S59AZCW$A", 4N_IU<Y[=9DN7L#P!5>O ''Q?X'X(F*1630
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MS"Q3'']!: -\O^!<;38Z@!VHHS]02P,$%     @ :(-55BIC> <\ @  -@4
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MAPUM2*#]TAC_%(3>V3V5^5]02P,$%     @ :(-55A;13YAK!@  KC$  !D
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M!B/=-V@?6-6&-[Y3UG5,6-9NIH'V">Z\5,H> ]\VXY3,_P%02P,$%     @
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MN.+91T>M^Y'N':N:,$8'9=U0!K-VKR!H'^#.2Z7LV?&3.;ZKQ0M02P,$%
M  @ :(-55J41 !)\ @  F <  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULO55M3]LP$/XKITR:F,3(2TM;L382!:8A#:FBVO9AV@>37!(+OP3;H?#O
M9SNM*1+-ATGL2^*7>YY[SF??S3=2W>L&T< 39T(OHL:8]BR.==$@)_I$MBCL
M3B45)\9.51WK5B$I/8BS.$N22<P)%5$^]VLKE<]E9Q@5N%*@.\Z)>EXBDYM%
ME$:[A5M:-\8MQ/F\)36NT?QH5\K.XL!24HY"4RE 8;6(SM.SY<S9>X.?%#=Z
M;PPNDCLI[]WDNEQ$B1.$# OC&(C]/>(%,N:(K(R'+6<47#K@_GC'_M7';F.Y
M(QHO)/M%2],LHED$)5:D8^96;K[A-IY3QU=(IOT7-KWMU!H7G3:2;\%6 :>B
M_Y.G[3GL =+) 4"V!61>=^_(J[PDAN1S)3>@G+5E<P,?JD=;<52XI*R-LKO4
MXDR^[I,!LH(UK06M:$&$@?.BD)TP5-2PDHP6%#5\AI6RET&99R"BA*N'CK8V
M/0:.+M$0RO2G>6RL)$<<%UOWR]Y]=L!]FL&-%*;1<"5*+%\3Q#:6$%"V"VB9
M#3)>8G$"H_08LB3+!OA&X8!&GF]\@.^&"LH[_E9H@T#WFLYT2PI<1/:Y:%2/
M&.4?/Z23Y,N K'&0-?;LHP.R=JDXAA5S"7N=D=_?K3E<&^3ZSUO*Q^^@_#0H
M/QT\T!?E;5"..^7'T&FL.@;,OE4-1\](U-OW:MC)"#QR0.XDR)T,YY\\'<K_
M(/ ?3W$:9$W?,?_3=U ^"\IG_R/_PT[2Y/ %B/>J)4=5^YZ@P1>\OG"&U=!V
MSOMJ^V+>]ZP;HFHJ-#"L+#0YF=I;J?H^T$^,;'WMO9/&5G(_;&SK1.4,['XE
MI=E-G(/0C/._4$L#!!0    ( &B#55:&>)30-P(  ,<$   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;'U438_3,!#]*Y:1$$BH3M)N%Y4D4KL%P6%1
MU0HX( YN,DFL=>Q@.\WR[_%'&HJT[27QV#-OWAO/.!VD>M(-@$'/+1<ZPXTQ
MW8H073304CV3'0A[4DG54F--51/=*:"E#VHY2:)H25K*!,Y3O[=3>2I[PYF
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MDE]&@-471=9!/5\S)M]NL@&J?P\L_@-02P,$%     @ :(-55JW,)S<L!
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MG*%U/+6M+ET(;%N'@]\Z YE!@H7<I 4MYSA(*%?+.9;G\D*^TUL !R$2>#,
MQ=C5"-A#SW>/(M#NXJ4AJ-0^]KFI78E#H-XN*,EXL;3_T]070U;)7:]_S-WJ
MUZ7<SH';.6/J]1)? F/'U5<!Y+R>2JO7][SC_&T?]%*H0YUEMQ8R3:<R^@=]
MSC>J676CNM.S>86^ 1<GF#LMP+I2JP?F4(+9O>Z/;[O3*JPKM7H$#O6:W5ZP
M=76.%</4<MMQ*N5D0?L>Q9I]J-;LUG+HW$2X0L]D<SH3.JWCNE*K1^90R=F#
M=\B$CBJP(@+O4<_9AX+._G\JNF*8:O5JN][K3.BTIC,KUQPIL)6^_9%U"LV(
MR&\\RM[RANE.WZN8A\_SZZE'S%8QX2B!I32U;@8R95E^XY,W!%WK2Y,%%8*F
M^C$"+".G/I#OEY2*?4,-4-Z[3?X%4$L#!!0    ( &B#55;%P:G7? <  #(Y
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;+U;77.C-A3]*QIWI[,[
MDZR1^#)IXIDD0)N939O9[+8/G3X04&RZ@+P@DNR_KP#'&$04V+WN2V+PO4?2
MN>)*YV*=/K+\2[&FE*.G-,F*L]F:\\W)?%Z$:YH&Q7NVH9GXYI[E:<#%9;Z:
M%YN<!E'ME"9SHFG6/ WB;+8\K>_=Y,M35O(DSNA-CHHR38/\VP5-V./9#,^>
M;WR,5VM>W9@O3S?!BMY2_GESDXNK^0XEBE.:%3'+4$[OSV;G^,37C<JAMO@S
MIH_%WF=4#>6.L2_5Q55T-M.J'M&$AKR"",2_!WI)DZ1"$OWXN@6=[=JL'/<_
M/Z/[]>#%8.Z"@EZRY*\XXNNSV6*&(GH?E G_R!Y_H]L!F15>R)*B_HL>M[;:
M#(5EP5FZ=18]2..L^1\\;8G8<\#Z"PYDZT#Z#N8+#OK60>\[6"\X&%L'H^]@
MO.!@;AW,L0[6UL&JN6_(JIEV QXL3W/VB/+*6J!5'^IPU=Z"X#BK9M8MS\6W
ML?#CRXNR$'>* EVR]"[.@CK<Q^A6S."H3"AB]^B\*"@OT'GXM8QS&J$@B]"'
M.+B+DYC'M*B^+U-Q_ZU+>1 GQ3OA__G616_?O$-O4)RA3VM6%L*K.)UST>6J
MX7FX[=YETSWR0O=L=,TROBZ0ET4T&O!WU?Z8* #F@JL=8>29L NB1+P.OB%B
M'"&B$3(T'K6W2\/W2,<ONKL_YNZ-=\<#[OYX=TU!I;Z;>WJ-I[\V]^JI5<3U
MW/O[@[B'KCA-BW\&NGC10!K#D%4>/BDV04C/9B+1%C1_H+/ESS]A2_ME*%B0
M8"XDF <)Y@.!=8)L[()LJ-"7GQ@/$K0I\W M%@ 4,K$H132O$\T1RL3:*5+,
M&\,Z,HT%"H-B+1:;)M$,15_9UM3H0X*Y#9A=@U7+^</2<1Q</2</^W&5S7H6
MOLJB$P%S%P%3^9CMY>J3(4Y-2$XAP5Q(, \2S <"Z\33VL734CY1OS(6/<9)
M,A1+I>?46%K23#0T1S.<[H1U&S/K%3-/1NO/?*#.=TBU=Z3:2E+/,QX(5'2S
M#L1^]0A=9>$0OTJ0J?Q"@KF08!XDF \$U@GK8A?6!?P68P$99$@P%Q+,@P3S
M@< Z079V07:4S^[E:[L&1TYDEMAN=-//I;*1J9&"!/,@P7P@L$ZDL-;*3>U_
MW YN&]M?>X9V79<C[5QUYZ>&#13-AT+K!FZO3H"5F;2I @QN(+>>0 D3%,T%
M1?- T7PHM&Y$21M1HGP4;]<LY\><YBF*LP=:\)1F?*A&<[$%ZFSQG'[Z'&/D
MCC'RU/V>S#(06I?EML:!E>IZ>1Z&K!2\HIR&-'X([A):Y[E!GG6)G041/>DS
M/<K,'6?FJ?L_F>U#U!IP6VS ZFK#E9C(&6>YT+HOLVQ(O.B&;CM]EF4SLM L
M:4:/,O/4_9[,,A!:E^6VH("5^G9YD]--$$>(/FUH5@C55)6$&5_3' 7U,C%(
MNRD191(#]UD?8^6.LO+4HYC,^2$T/VY%/U:K_N_C7-;F9&%9$NFCS-QQ9IYZ
M()-I/T15 +=E :RN"UQE/,A6L<C:BH1BR[O+A6UJ4MZ6[<R%L^C;N2/M/'77
M)Q-]")V.6Z&.U4K]M2HE!E7EH&@N*)H'BN9#H77#VDISK-;FN^W/3?"MVOL,
MAM:1YKN-';O_](RQ<D=9>>I.3Z;X$)*:M)*:J"6UH#@O:;LR#%%,9 &LZ[9F
M]C@>,#.P91H]DL>9>>I^3V49"JW+<JM_B5*-+5UZ3_/J]7=.Q1:S%)OXL!37
M&4<;(:-BE@W2CN45T]3Z.\U15NXH*T\]BLF<'T*ADE:A$K5"E3G?%HC&4"\K
M34RT?E(99>6.LO+4@YE,_2%D*VEE*U'+UAWU/'A"2;LVO[@)(K+:Q*:C.4:?
M<=G.QII&^I2/,O/4HYC,^2'$*VG%*U&+US_JW7S"LE53E=FC?9!Q67EBW=06
M_<+,@)V8O'TS=YR9IQ[#9,8/(61)*V2)6LC^+M))HYYV9>8CL8Z&21G%V0JM
M%&]:B2Q!;<>Q="FY#TA51]/LOK@::>>I1S29_T.(6M**6O+]K[*)_,(8.XZQ
MZ(M7,N[]LSN -_B>6MWER00?0KZ25KX26ZFJKFE0E#E-Z\62YC&+4!#]6S:U
MWD'60=]P@Z*YH&@>*)H/A=:-<ZN>B5+&C:I[JB$FAW8A/7;'EHZEM 8JC4'1
M?"BT;LQ::4S4TGA,:4D-,3EFLC@^UAW;EBI0H,UZH&@^%%KW)ZNMVM9_7&VK
M(2;_2%56V[8C+6^@;7J@:#X46C=DK7371TKWL5I&C3<Y?K)P/UXL-*<O>4!;
M]4#1?"BT;@3;0H"N+@1,5$9JM,GQD]7_,<:&+F5-T&8]4#0?"JT;P+U?^JO+
M"3\@M-3(DX,IUQ6.B>:8TGM=T&8]4#0?"JT;S+9.H:OK%"K5IG:='"U#TFS#
MP8)LU0-%\Z'0FF#-]XYZI31?U8?R"E2_9&D.,>WN[@[^G=?'W7KW77SB-\?W
M6ICF-.%UD*_BK$ )O1>0VGO;G*&\.:#77'"VJ0^4W3'.65I_7-,@HGEE(+Z_
M9XP_7U0-[(Y)+O\#4$L#!!0    ( &B#55;5-)'O P0  - 3   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;+58;8_:.!#^*U:NJG:E[B8.[UM 8J%5
MD;I7M.RV=SK=!Y,8XFMBI[:SE']_=A(24E)WEX8O$#N>)_.,9\://-PR_E4$
M&$OP/0JI&%F!E/&-;0LOP!$2URS&5+U9,QXAJ89\8XN88^2G1E%HNX[3M2-$
MJ#4>IG,+/AZR1(:$X@4'(HDBQ'>W.&3;D06M_<0]V0123]CC88PV>(GE8[S@
M:F07*#Z),!6$4<#Q>F1-X,T4#K1!NN(SP5MQ\ PTE15C7_5@[H\L1WN$0^Q)
M#8'4WQ.>XC#42,J/;SFH57Q3&QX^[]'?I^05F142>,K"+\27P<CJ6\#':Y2$
M\IYM/^"<4$?C>2P4Z2_8YFL="WB)D"S*C94'$:'9/_J>!^+ 0.'4&[BY@?NC
M0>LG!JW<H)42S3Q+:<V01.,A9UO ]6J%IA_2V*36B@VA>AN7DJNW1-G)\6TB
MU(P08,JB%:$HC>T5F%.)Z(:L0@PF0F IP,3[EA".?7 QPQ*14%RJ91.UC&,!
M%@%2(7VCS#PU^[B<@8M7E^ 5(!0\!"P1B/IB:$OEK_ZJ[>6^W6:^N3_QK0?N
M&)6! .^HC_VJO:UX%F3=/=E;UP@XP]XU:,$WP'5<M\:?J=G\#NV VZZSKGC3
M*D+?2N%:OPI]&EI!TM#_\U'-@;G$D?BW+F(99+L>4M?\C8B1AT>6*FJ!^1.V
MQJ__@%WG;1W=AL J[-L%^[8)??SP<?+G[!.(.?,33P*NRZTV1S*87@JCF]+3
MN-,?]!UG:#\=<CE>-NCW.@?+*EYV"B\[1B\G#_?+*SAP7' Q7]R_1E'\=G99
MYZ41YJ7[TA!8A7&W8-QM/BN[3;)O"*S"OE>P[QGW>ZXZS9I0(O%5J(X77W6P
MHA&BK!&BO!'6Q2$#[QXD8;O?.TI5HPLG$NP7!/OFA$XDNYK3_]0IRCB0V LH
M"]EF!^(02:T*ZF@9(5^ZO0V!5=@/"O:#YI-[T"3[AL J[*%3'O:.<???GY[:
M.?)A@VT[2BS^F-QF#TYE>"!GH)'AH\#K) 0A66-PL<.(B]IV_0N4'DA-ZS;0
M;'DJ/[?DYQH]^^OO3\N'=S-];L:<*"7&=_LSM):G$>VER=L46I5[J9?@&003
M;%0Q-856C4"IF:!9-/U._1X+)-CJNL?U:_3@5(:EWH)FP?7<^C6C0,=0P.=0
M5["45]"H7YZO>\TX+T[<<Z@J6,HJV#M#Z38DE/((G$-VP5)W0;/P^IW2[1^5
MKCLX+MQS""M8*BMHE"[/+EPSBK%P&]5.]L&=283Y)KU*$L!C"979]4DQ6UQ7
M3=)+&KM<GMUUW2&^(52 $*^5J7/=4QV&9]='V4"R.+V!63$I690^!ACYF.L%
MZOV:,;D?Z \4EWCC_P%02P,$%     @ :(-55DTZ-""G @  B@8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&ULK55=;]HP%/TK5E9-K=0UQ.&C[2 2
M'ZN&M$ZHM-O#M >37(C5Q*:V ]V_W[43,DI3MH>]@'U]S\DYMG/2WTKUJ%,
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MS7W&E,4QY8N01&!#-I1K([%Z!F +K1JPZDCP!8\!L-5S %MHU4RH?@:_]2@
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M"G7QF:"U"DBS=U1JLD^ )/V)"[8^*7-2J<G>ZNR$,%BP]?L%V\%5T&\ZM@J
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M]X>BJ+\_:7X4X_@K*(O_ 5!+ P04    " !H@U56\20/4^4%  # *   &0
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M4K*L>%P!B8'K >K]@C'YVM 3U!=5L_\!4$L#!!0    ( &B#559EE+S5@ (
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M :,.,'*%MLI<62MJ:)HHN2/*9B.;'3AO'!JK8<)^Q1NC<)4ASJ37L 71 /E
MEE(8A:ZB %.2I=L:U"E9:(V'B8J<?&5TS3@S#^1X!88RKD\0=WNS(L=')^2(
M,$&^E[+1F*L3WZ ZNX>?=4HN6R71"TI6D)V147A*HB"*!N#+M\/#IW ?/>F-
MB7IC(L<W^H<QA9+5"]Z07XNU=O._A\IM^>-A?GL[+W1-,YA[>/TTJ"UXZ?MW
MX23X.%3\?R)[8L6HMV+T&GNZR#+9"*/QUF; MG3-X90(,$-%MTQ3QV0[R#8-
MSR>S:9#XV_UR#M-FP6PZ[K.>Z(Q[G?&K.ONO1.V1'3R"+<%D;]\X#H/HF;K#
MK&!8V;A7-GY5V0H*4 IR=-"=JD%MXP-/QO%L]DS:85(<32?/U/E[_<#VXF]4
M;9C0A$.!L.!LBBRJ[6]M8&3M6L1:&CS9;ECB+P&43<#U0DKS&-BNT_]DTK]0
M2P,$%     @ :(-55J-[5&U4 @  RP4  !D   !X;"]W;W)K<VAE971S+W-H
M965T-38N>&ULK51M:]LP$/XKAU=&"VWL.&DW,L?0-ALKK"PTZ_:A](-BGQ-1
MO7B2\K)_OY/LF@S2C$+!V'?2W:/G.?DNVVCS9)>(#K92*#N.EL[5HSBVQ1(E
MLSU=HZ*=2AO)'+EF$=O:("M#DA1QFB07L61<17D6UJ8FS_3*":YP:L"NI&3F
MSQ4*O1E'_>AYX8XOELXOQ'E6LP7.T-W74T->W*&47**R7"LP6(VCR_[H:NCC
M0\!/CAN[8X-7,M?ZR3LWY3A*/"$46#B/P.BSQFL4P@,1C=\M9M0=Z1-W[6?T
M+T$[:9DSB]=:_.*E6XZCCQ&46+&5<'=Z\Q5;/><>K]#"AC=LVM@D@F)EG99M
M,C&07#5?MFWKL).0IB\DI&U"&G@W!P66$^98GAF] >.C"<T;06K()G)<^4N9
M.4.[G/)<?H=K5"N$,VBM4S+\97*U@"F:<.VJ0/@^%WS!0B6/)^@8%_;D-5FG
M\'E;TU5@"3^X]'&Z@AEMV8H53<#,,>. 9" \7&ZY?1Q!FJ2#LZ1/#QP!5W#+
MA:!8F\6.Q'L)<=$*O6J$IB\(G6#1@T'_U$.F<#^;P/'1R;\P,=6N*V#:%3 -
MN(/#!7R# L##-\*&&X?2/NX3V! 9[B?BNW=D:U;@.*+VM&C6&.7OW_4ODD\'
M9 XZF8-#Z*^1>2GU2KE] IHCSL,1?EJL\T$OS>+U'E[#CM?PK7C]]_^C1*[+
M?<0/<^BG(+5R2[NOSO%.;_HQ=\O,@BL+ BL"2WH?J!RF&1V-XW0=VG6N'35_
M,)<T;='X -JOM';/CI\ W?S._P)02P,$%     @ :(-55J7)GNMA P  0PH
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M*7BI2YK!R,$<TZ#6X*1?O_BQ][W/[7\B>^<][+R'A]C3!UKAO3*@&.6])]G
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M.8?YPN4/1/(ENO]>)@4X*-'[&86D5'R D,?%#+U_^P&]18#R^YJ5 F+%R)1
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M4J?<+X2ODER@E,:09EW[@,)W!\?=0+)"G[V>F(23G+Y<PV&;<A4 SV/&Y,M
M'>>JX_OD'U!+ P04    " !H@U56T[?I_J0"  "!!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6RM55U/VS 4_2M6AB:0@*1)V@)+(]&&:3RP512V
M9Y/<-A9)'&RGA?WZ73MIUN\QB9?$'^<<WW-M7P<++IYE"J#(:YX5<F"E2I57
MMBWC%'(JSWD)!<Y,N<BIPJZ8V;(40!-#RC/;=9R>G5-66&%@QL8B#'BE,E;
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M1!1F6AH<#W0Z*:IS?E50?%&>?!^XTN?H\C('G($P#73]C'/U7# =-%];)G\
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ME;UG^?Y]?B)HDFV!/U A:)0=K@CV"5,#Y/T%I>+I1"4HOZ),_P=02P,$%
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MC#)-:]E<,U#?F61>IW/B4#,)I3$434Y<F$EBTWKXHB$]?K@_11NRIMG0#X-
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M\F88T/_]?=V?FH[?#!MXKIO?]\N^_3]02P,$%     @ :(-55EQ#.'-U!P
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M$OVL6"%_=TV/IO^9NW^3-#_(/4W8U41G1<G$ YNL?_Q+N C^ZI(&$BR&!"-
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M0*'9O!]YXM#+^^=*2:4=K&&=&@W<5M8+,III2+08%(U H=ERX%X._,;9K!T
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MA_*%NWQHV(OC#KY&4:!;4GZ5'37O>K/PL5WXJF6UYDN]YH_R)SK,GT9_H%N
M/F?0K^(?[2Q[J)98QT8#-EH%XX-R+'@@^D2EO;A6FV.NSBY+G(%_",]M.CQY
M)YB+TU9&IRX>F6-1HV7(K66?9WZC96VPOS 6 N,G"$!NSPAH %+\[MJ[HT;8
MD%-M#M@AM)*[C1]#WN@8<NM8]WZAE=1M;%B10KA!A9K4!=K(&7(?D"[G<T[F
M6!+P7<UBJL[R"7C&V;)U<X"^XEB$&IE#!QR,/F["5%IH!;8&@P_9 /8&[=D
M-=J&W-IVP-:UBZS2M7W1&EU#>YV)VG:J72C68+1-@C[OD_RM"XR<\+FYIA$@
M8<M"VKN,NK:^"KJT%R!-<WN/=(>YVM<)D)&9ZJKV9"H&W%[-V!?)2G,=\L*D
M9+DI+@A6)WC=0/T_8TQN7O0 ]079]']02P,$%     @ :(-55J^S?/.E P
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M<YLX&,:_BL;;V6EG$HP$!I--/).$MMM#FDPR:0\[>R"V;#,%Y$JRW7S[E8
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M6X!KDHKAQ**\0T[!':;YN,KF&#QP,O\!'K.8,_ ^Q#R*$_9!I'E\",'[=Q_
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M<F&;D%&S;TI-)53;?:CUHZT5;@ DMPL)^59G%!FUU*;45$:UJ88'N.K&8C>
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MF4"\7Q+"7VYD =7!J=E_4$L#!!0    ( &B#55;_ 6A-?P0  $,5   9
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MOB723RR6@D:O&YK$F/'?P+<?.1%OX'?P@!A#:D; ),0"D81?R=;G90@F7Z[
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M9+O+LQE'LNG()0E?,F0F<SR7Z"VUOG5*[YS(;YP">&J T58 FF+?;SO V'3
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M<?9UB?TYIFF ^/V9$+Y92!-LWQ(>_@M02P,$%     @ :(-55NCP_$FG!
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M6AJT'C<M\6\"R@;@^XV4YK"P!_3_I_0?4$L#!!0    ( &B#559\NJ29=0,
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MUZK=0ZX-U/TE8W(_T ^H&\C@?U!+ P04    " !H@U56@AG?H!,#   ["P
M&0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6RMEEUOFS 4AO^*Q:JID];R
M&2!=@M0FJC:IE:)^;!?3+EQR$JR"S6R3M/]^-E":!DHJM)O$!K_'SWL,G#/9
M,OXH$@")GK*4BJF12)F?F::($\BP.&4Y4'5GQ7B&I9KRM2ER#GA9BK+4="S+
M-S-,J!%-RFL+'DU8(5-"8<&1*+(,\^<+2-EV:MC&RX4;LDZDOF!&DQROX1;D
M?;[@:F8V498D RH(HXC#:FJ<VV<SNQ24*WX2V(J=,=)6'AA[U),?RZEA:2)(
M(98Z!%9_&YA!FNI(BN-O'=1H]M3"W?%+],O2O#+S@ 7,6/J++&4R-4(#+6&%
MBU3>L.UWJ V-=+R8I:+\1=MZK66@N!"29;58$62$5O_XJ4[$CL#VWA$XM<#Y
MJ,"M!6YIM"(K;<VQQ-&$LRWB>K6*I@=E;DJU<D.H/L9;R=5=HG0RFK$L(U*=
MBQ0(TR6:,2H)70.-"0AT@LXI+7"*+@M9<$#7A)*LR- 5J,RA!7ZNA,=SD)BD
MXHL2W-_.T?'1%W2$"$5W"2N$"BLFIE2P>DLSKL$N*C#G'; YQ*?(M;\BQW*<
M#OGLXW+[K=Q4*6KRY#1Y<LIX[J \S8F(4R9TBGZ?/PC)U=/YI\MSM8G7O8E^
M9<]$CF.8&NJ=%, W8$2?/]F^]:TK _\IV)M\N$T^W+[HD4JKVV6P4@6E2G]"
M-E$06M;$W.R"]X8>".XUX-XA<*\+O%+Y.^"^';A[X+VA!X*/&O#1(?!1%_BH
M!3[R?&\/O#?T0'"_ ?</@?M=X'X;W/;&>^"]H0>"!PUX< @\Z (/VN#.V-\#
M[PT]$#QLP,->\+L$5$E?2>!=^&$+WPYL=_]1[]UA(/^XX1_W\S.I:DY6%YNT
M+#9Y76RZ'(U;CKS LD=[CGKW'.C(ME[KK-7KZ0J$0"3+"PE+51K5V8"0G671
M:KDYL1U'/XIO[/3O-]3/3M]@'SZC3GZ[50)<+PC#??SV,B=T7BM%A67N=#:Z
MK;S&?$VH4,_$2LFLTT!]V'C5J543R?*RV7E@4K5.Y3!1W2UPO4#=7S$F7R:Z
M?VKZY>@?4$L#!!0    ( &B#558%L*RYSP(  "H(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#@R+GAM;*U674_;,!3]*U:&)I &29PT!99&HF1H2&-"%+:'
M:0]N<MM8)'9GNRW\^]E.FO4C='W@I;5OSCF^YSJ]M_&2BV=9 "CT4I5,#IQ"
MJ=FEZ\JL@(K(,SX#II],N*B(TELQ=>5, ,DMJ2I=['F16Q'*G"2VL7N1Q'RN
M2LK@7B YKRHB7H=0\N7 \9U5X(%."V4";A+/R!1&H)YF]T+OW%8EIQ4P23E#
M B8#Y\J_3".#MX ?%)9R;8V,DS'GSV9SFP\<SR0$)63**!#]M8!K*$LCI-/X
MTV@Z[9&&N+Y>J=]8[]K+F$BXYN5/FJMBX)P[*(<)F9?J@2^_0N.G9_0R7DK[
MB98UMJ_!V5PJ7C5DG4%%6?U-7IHZK!'\Z T";@AXFQ"^00@:0G H(6P(H:U,
M;<76(26*)+'@2R0,6JN9A2VF96O[E)EK'RFAGU+-4\DMRW@%Z)&\@$3?]6MV
MBIK0\3<NY0D:OJ('F)HK.DY!$5KJV"EZ&J7H^.@$'2'*T&/!YY*P7,:NTBD9
M83=KCA_6Q^,WCO<QNN-,%1)]83GDFP*N]M(:PBM#0[Q7,87L# 7^)X0]C#L2
MNCZ<[G?0T\/IWAXW07L]@=4+_GL]**4R*[F<"T"_KL92"?V3^=U5\5HQ[%8T
M;>12SD@& T?W"0EB 4[R\8,?>9^[JO6>8ND[B6U4,FPK&>Y33YX859"CD2(*
M.E_4FMZW=-,L%PD.SR_\\]A=K!>D$^;U_4U8N@OS R_$_1:V8:+7FNCM-:%;
MG6YDK"O]FABM'>AM9;Z+",/^5MJ[F%/?Q[WNK*,VZVAOUJ:MT/I%'H.>5+#:
M*=-UNLQ$A]U%)ZRW#4MW83Z^"#R\Y<I=ZZ(5B*F=1A)E?,Y4W7_::#OPKFR?
MWXH/]2"LY]8_F7J*WA$QI4RB$B9:TCOKZWJ+>C+5&\5GME>/N=*=WRX+/<Q!
M&(!^/N%<K3;F@/;O0?(74$L#!!0    ( &B#55::,9K\W@0  .D1   9
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M4-\OTU0^;N0)=O_<8/8_4$L#!!0    ( &B#55;D3FXH$ ,  +()   9
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;*U66V^;,!C]*Q:KIE9:"SA<TBY!
M:D*G]:%2U<OV,.W!@8\$%>S,-DGV[V<#H0F0+ ]]"=B<<WS.9\?V:,WXFU@
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M41!9%@45/^X@Y[N9$SC[%T_9>J/T"V\^W=(U/(/Z<_LH\,EK4=*L "8SSHB
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M8[QCB;K=K1\4WU8-X)(K;">KX08H9HV>@-]7G*O]@UZ@_:?#_']02P,$%
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MF(BZUZ;\#8:GM\+-NXF.Q41,5S2>UE69SJJBHPLZ:GT 81>YK0X[@G$,9D<
MP^)@#C".86%Q_J?Q#-'Q& SS-K0B0Y0S1#F&94.FU0>+8^=$^K"/-(J"( RQ
M&9U.K0ZFV+R%(7SM:I@W8&!Q(-++YAI?;3Q#]N<!MJ;[,@0;*9Z)V$CQN0;$
M/F_ B"+[:F-Q@(&M I8[$-\>!W+*S@D"6%7,&W8%XT@480CDHCU'PQ"9G1 ^
M]O7!KI(@B"([ IC=01!@"%R-.((Y  \8$@35<W#G>>0USREO\R_UY"]02P,$
M%     @ :(-55I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M3P;(SN8<0"8(9/(3(>\"1/B 97K);C>].S!%(-.305[I9@,@,P0R.QTDMVL
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MXWCXQ_'+,^VK=GC.%\O_6FY^ 5!+ 0(4 Q0    ( &B#558'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ :(-55C:_CA/N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ :(-55IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !H@U56
M"O[>TP@'   5+0  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ :(-55IM@Y\<^ @  Q 4  !@
M     ("!2P\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M &B#559'J_WYJ 8  )L;   8              " @;\1  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " !H@U56-E59-.D"   +"@  &
M            @(&=&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ :(-55A2B4?FC!@  G2(  !@              ("!O!L  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &B#55:)Z]XM7@,  #T+
M   8              " @94B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " !H@U56G(?/T0L+   2-@  &               @($I)@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ :(-55B OPH D
M"@  /60  !@              ("!:C$  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( &B#55:+[4JN.0H  *\9   8              "
M@<0[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !H@U56
M G:$$D<J  !:A0  &0              @($S1@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( &B#55;O7@JW^1   +DN   9
M      " @;%P  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ :(-55D#_9F;$!0  * \  !D              ("!X8$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !H@U56*8%_798&  "U#P
M&0              @('<AP  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( &B#559>'.DE?@8  ,<0   9              " @:F.  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ :(-55N/;>G_<
M!   L@H  !D              ("!7I4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " !H@U56LM21F&X5  "U5P  &0
M@(%QF@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &B#
M558+%M[HD@L  ,T@   9              " @1:P  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ :(-55KT$J4&X!0  [@T  !D
M         ("!W[L  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " !H@U56B[ %.AP%  !&#0  &0              @('.P0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &B#55;'VA"/> 8  (\.
M   9              " @2''  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ :(-55BO.F_SW"P  A2   !D              ("!T,T
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !H@U56JL/G
MM.$"  !,!@  &0              @('^V0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( &B#55;1V'$ R (  -@&   9
M  " @1;=  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M:(-55I;H6V?M.@  ,<L  !D              ("!%>   'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " !H@U56(IU(@_ #  !="   &0
M            @($Y&P$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( &B#55;EKVGSQ@<  'L4   9              " @6 ? 0!X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ :(-55C0YJB=!!0
M=PX  !D              ("!72<! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " !H@U56I3<9S4L$  #?"0  &0              @('5
M+ $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &B#55:
M-GJ]N 4  %H/   9              " @5<Q 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ :(-55A,6H\FU!   4 X  !D
M     ("!1C<! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B#55:LA?9 T (   H&   9              "
M@6I6 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ :(-5
M5LJXNUN/!P  P1,  !D              ("!<5D! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " !H@U56Q@)OF_4"  !<"P  &0
M        @($W80$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( &B#558J8W@'/ (  #8%   9              " @6-D 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ :(-55A;13YAK!@  KC$
M !D              ("!UF8! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " !H@U56(KS4]# "   Q!0  &0              @(%X;0$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &B#55:%W'(,
M%0(  &,%   9              " @=]O 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ :(-55J41 !)\ @  F <  !D
M ("!*W(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !H
M@U56AGB4T#<"  #'!   &0              @('>= $ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &B#559K=_,TRP0  "H8   9
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M970T."YX;6Q02P$"% ,4    " !H@U56-.U>Z9@%  "K(P  &0
M    @(%\CP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M &B#559%=D2@+@,  $(*   9              " @4N5 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ :(-55EH->_B" @  :08  !D
M             ("!L)@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " !H@U56KK5A6YP)   190  &0              @(%IFP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &B#55;Q) ]3Y04
M , H   9              " @3RE 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ :(-55D0=S(&;!   M!H  !D              ("!
M6*L! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !H@U56
M992\U8 "  !P!@  &0              @($JL $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( &B#55:C>U1M5 (  ,L%   9
M      " @>&R 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ :(-55J7)GNMA P  0PH  !D              ("!;+4! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !H@U56-#=V_IP"  #M!@
M&0              @($$N0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( &B#558G36WI\P(  *0(   9              " @=>[ 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ :(-55J ,3&/=
M P  R@\  !D              ("! ;\! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " !H@U56T[?I_J0"  "!!P  &0
M@($5PP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &B#
M558X1ZH1@P0  (@2   9              " @?#% 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ :(-55O!Y7ZAM P  >1$  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( &B#55;D1+3EB@T  (&:   9
M  " @1?S 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M:(-55EQ#.'-U!P  NS@  !D              ("!V  " 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " !H@U56"8V#A@@$  !4%0  &0
M            @(&$" ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( &B#558S7C!5@0,  * /   9              " @<,, @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ :(-55GJPXGJW!
M+!,  !D              ("!>Q " 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " !H@U56K[-\\Z4#  "C$   &0              @(%I
M%0( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( &B#558-
M(\I\&@4  *88   9              " @449 @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ :(-55FCLIMS?!0  1"4  !D
M     ("!EAX" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B#559\NJ29=0,  $P.   9              "
M@=XW @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ :(-5
M5H(9WZ 3 P  .PL  !D              ("!BCL" 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    " !H@U56!;"LN<\"   J"   &0
M        @('4/@( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( &B#55::,9K\W@0  .D1   9              " @=I! @!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ :(-55@DN8:75!@  Z$
M !D              ("![T8" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    " !H@U56Y$YN*! #  "R"0  &0              @('[30(
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( &B#559S[&$(
M@@0  ( 0   9              " @4)1 @!X;"]W;W)K<VAE971S+W-H965T
M.#8N>&UL4$L! A0#%     @ :(-55A0_U1)J P  *0L  !D
M ("!^U4" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " !H
M@U56J4 @4W("  ",!@  &0              @(&<60( >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( &B#55;Q"%!4* ,  $(*   9
M          " @45< @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#
M%     @ :(-55D77"!M> P  LA8   T              ( !I%\" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !H@U56EXJ[',     3 @  "P
M    @ $M8P( 7W)E;',O+G)E;'-02P$"% ,4    " !H@U56BE6/Z6\&  #$
M.@  #P              @ $69 ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ :(-55CAE:^>: @  <C0  !H              ( !LFH" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :(-55J>1ZEDW @  WS(
M !,              ( !A&T" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ &$ 80">&@  [&\"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>326</ContextCount>
  <ElementCount>500</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>112</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Long-term Debt, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongtermDebtNet</Role>
      <ShortName>Long-term Debt, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Income per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomepershare</Role>
      <ShortName>Net Income per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Employee Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EmployeeSavingsPlan</Role>
      <ShortName>Employee Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Schedule II Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/BusinessCombination</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/FairValueMeasurement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/Revenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Long-term Debt, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongtermDebtNetTables</Role>
      <ShortName>Long-term Debt, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/LongtermDebtNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SharebasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/StockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Net Income per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomepershareTables</Role>
      <ShortName>Net Income per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/NetIncomepershare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CommitmentsandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/OrganizationandBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Business Combination - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationNarrativeDetails</Role>
      <ShortName>Business Combination - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Business Combination -Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails</Role>
      <ShortName>Business Combination -Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Business Combination - Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business Combination - Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails</Role>
      <ShortName>Business Combination - Summary of Proforma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fair Value Measurement - Summary of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Summary of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Fair Value Measurement - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails</Role>
      <ShortName>Fair Value Measurement - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Revenue - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Revenue - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueTextualsDetails</Role>
      <ShortName>Revenue - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails</Role>
      <ShortName>Revenue - Contract with Customer, Asset and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails</Role>
      <ShortName>Revenue - Revenue, Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Goodwill and Intangible Assets-Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets-Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets -Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Long-Term Debt, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails</Role>
      <ShortName>Long-Term Debt, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails</Role>
      <ShortName>Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Share-based Compensation -Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation -Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Share-based Compensation - Unrecognized Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails</Role>
      <ShortName>Share-based Compensation - Unrecognized Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Share-based Compensation - Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationOptionsDetails</Role>
      <ShortName>Share-based Compensation - Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Share-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationValuationDetails</Role>
      <ShortName>Share-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Share-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Share-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Share-based Compensation - Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails</Role>
      <ShortName>Share-based Compensation - Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Stockholders' Equity - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails</Role>
      <ShortName>Stockholders' Equity - Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Net Income per share - Basic and Diluted Income Per Common Share Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails</Role>
      <ShortName>Net Income per share - Basic and Diluted Income Per Common Share Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Net Income per share - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Income per share - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Commitments and Contingencies - Operating Lease textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Income Taxes Net - Income (Loss) By Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails</Role>
      <ShortName>Income Taxes Net - Income (Loss) By Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Income Taxes - Components Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Components Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Employee Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EmployeeSavingsPlanDetails</Role>
      <ShortName>Employee Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/EmployeeSavingsPlan</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="halo-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:StockRepurchaseProgramPeriodInForce1 -  halo-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="halo-20221231.htm">halo-20221231.htm</File>
    <File>ex211subsidiaries2022.htm</File>
    <File>ex231auditorconsent2022.htm</File>
    <File>ex31110k2022.htm</File>
    <File>ex31210k2022.htm</File>
    <File>ex3210k2022.htm</File>
    <File>halo-20221231.xsd</File>
    <File>halo-20221231_cal.xml</File>
    <File>halo-20221231_def.xml</File>
    <File>halo-20221231_lab.xml</File>
    <File>halo-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>halo-20221231_g1.jpg</File>
    <File>halo-20221231_g2.jpg</File>
    <File>halo-20221231_g3.jpg</File>
    <File>halo-20221231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="1268">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "halo-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 35,
   "baseTaxonomies": {
    "http://fasb.org/srt/2021-01-31": 1,
    "http://fasb.org/us-gaap/2021-01-31": 1268,
    "http://xbrl.sec.gov/dei/2021q4": 36
   },
   "contextCount": 326,
   "dts": {
    "calculationLink": {
     "local": [
      "halo-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "halo-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "halo-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "halo-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "halo-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "halo-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 778,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 14
   },
   "keyCustom": 55,
   "keyStandard": 445,
   "memberCustom": 51,
   "memberStandard": 54,
   "nsprefix": "halo",
   "nsuri": "http://www.halozyme.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.halozyme.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Business Combination",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.halozyme.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.halozyme.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.halozyme.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Certain Balance Sheet Items",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Long-term Debt, Net",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.halozyme.com/role/LongtermDebtNet",
     "shortName": "Long-term Debt, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Share-based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.halozyme.com/role/SharebasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.halozyme.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Income per share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.halozyme.com/role/NetIncomepershare",
     "shortName": "Net Income per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.halozyme.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.halozyme.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.halozyme.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Employee Savings Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.halozyme.com/role/EmployeeSavingsPlan",
     "shortName": "Employee Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Schedule II Valuation and Qualifying Accounts",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts",
     "shortName": "Schedule II Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Business Combination (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.halozyme.com/role/BusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.halozyme.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.halozyme.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Certain Balance Sheet Items (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Long-term Debt, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.halozyme.com/role/LongtermDebtNetTables",
     "shortName": "Long-term Debt, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Share-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.halozyme.com/role/SharebasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.halozyme.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Net Income per share (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.halozyme.com/role/NetIncomepershareTables",
     "shortName": "Net Income per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.halozyme.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.halozyme.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:NumberOfCollaborationsRoyaltiesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Organization and Business (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.halozyme.com/role/OrganizationandBusinessDetails",
     "shortName": "Organization and Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:NumberOfCollaborationsRoyaltiesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i27889e318d8545478c0d04d0e999f6a4_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "icfd51566fb48417294740b3e09f08d33_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "icfd51566fb48417294740b3e09f08d33_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "if83b76ce39de4877b20f0f0b0cb35dc0_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails",
     "shortName": "Summary of Significant Accounting Policies Segment information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Business Combination - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
     "shortName": "Business Combination - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524",
      "decimals": "2",
      "lang": "en-US",
      "name": "halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Business Combination -Purchase Consideration (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
     "shortName": "Business Combination -Purchase Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ia89f5fb71f2c4d32bf25abedaa5f869d_D20220524-20220524",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAcquiredFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i6bbe58cfd64b4f4dbc7dfe41009a162b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Business Combination - Intangible Assets Acquired (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
     "shortName": "Business Combination - Intangible Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "id0ac13fbf17f4f2e89a956199a4d633c_D20220524-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IndefinitelivedIntangibleAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i2d619669e18b442786311ba013af06b8_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
     "shortName": "Business Combination - Summary of Proforma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i2d619669e18b442786311ba013af06b8_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fair Value Measurement - Summary of Available for Sale Securities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails",
     "shortName": "Fair Value Measurement - Summary of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Fair Value Measurement - Maturities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails",
     "shortName": "Fair Value Measurement - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement -Summary by Major Security of Fair Value Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Revenue - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails",
     "shortName": "Revenue - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ib07f947ffcad43d1a6fdf23e3ea0bfce_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Revenue - Textuals (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.halozyme.com/role/RevenueTextualsDetails",
     "shortName": "Revenue - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails",
     "shortName": "Revenue - Contract with Customer, Asset and Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ie4592615a3c74e559071621a0a01a228_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails",
     "shortName": "Revenue - Revenue, Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ie4592615a3c74e559071621a0a01a228_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails",
     "shortName": "Certain Balance Sheet Items - Accounts receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Certain Balance Sheet Items - Inventories (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
     "shortName": "Certain Balance Sheet Items - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails",
     "shortName": "Certain Balance Sheet Items - Prepaid expenses and other assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails",
     "shortName": "Certain Balance Sheet Items - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails",
     "shortName": "Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
     "shortName": "Certain Balance Sheet Items - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Goodwill and Intangible Assets-Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets-Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ie98514e5657646ff8056ebd166bc8eb7_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i528d79391acd4adabf0eb110ab4c0d71_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
     "shortName": "Goodwill and Intangible Assets -Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Long-Term Debt, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
     "shortName": "Long-Term Debt, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ia752a965c91b4639a4d3a6868c58d432_D20191101-20191130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails",
     "shortName": "Long-term Debt, Net - Carrying Value of Debt, Components of Interest Expense and Future Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Share-based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Share-based Compensation -Schedule of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation -Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ib8de33c335a241468926b3ab8403600b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Share-based Compensation - Unrecognized Expense (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
     "shortName": "Share-based Compensation - Unrecognized Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "ib8de33c335a241468926b3ab8403600b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i528d79391acd4adabf0eb110ab4c0d71_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Share-based Compensation - Options (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
     "shortName": "Share-based Compensation - Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Share-based Compensation Valuation (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.halozyme.com/role/SharebasedCompensationValuationDetails",
     "shortName": "Share-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "id26cfa0230994968ac1d99e765d751b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Share-based Compensation - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Share-based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "iae176b036399446d884c8a71d329328e_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i308da0fe12c54b17bfdd7c6211a23ca7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Share-based Compensation - Performance Stock Units (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
     "shortName": "Share-based Compensation - Performance Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "idcbcc66c6a704edba3c61082d5d29dc5_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i2be6a28da01a408e930dc4476e7b546d_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i528d79391acd4adabf0eb110ab4c0d71_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Stockholders' Equity - Share Repurchases (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails",
     "shortName": "Stockholders' Equity - Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "iec2a39ae6cf344228e691d7fec6bd39c_I20191130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Net Income per share - Basic and Diluted Income Per Common Share Computation (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails",
     "shortName": "Net Income per share - Basic and Diluted Income Per Common Share Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "if9b9ab30830f4339a4ee873a5fc79362_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Net Income per share - Anti-dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails",
     "shortName": "Net Income per share - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i658b6d0704704e0b8064188c8e0a801d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i658b6d0704704e0b8064188c8e0a801d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Commitments and Contingencies - Operating Lease textual (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails",
     "shortName": "Commitments and Contingencies - Operating Lease textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Annual Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Income Taxes Net - Income (Loss) By Region (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails",
     "shortName": "Income Taxes Net - Income (Loss) By Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Income Taxes - Components Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails",
     "shortName": "Income Taxes - Components Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i231989e09dcb42a4b75eea0d7ffce3dd_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "halo:DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i528d79391acd4adabf0eb110ab4c0d71_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Employee Savings Plan (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.halozyme.com/role/EmployeeSavingsPlanDetails",
     "shortName": "Employee Savings Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i528d79391acd4adabf0eb110ab4c0d71_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "shortName": "Schedule II Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i5e37d51271604aea8b4052a4f33ab467_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Organization and Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.halozyme.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20221231.htm",
      "contextRef": "i1d00237089024881bd1f90f6a648378f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 112,
   "tag": {
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BELGIUM",
        "terseLabel": "Belgium"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.halozyme.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "halo_A025ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.25% Convertible Senior Notes due 2027",
        "label": "0.25% Convertible Senior Notes due 2027 [Member]",
        "terseLabel": "0.25% Convertible Senior Notes due 2027",
        "verboseLabel": "2027 Convertible Notes"
       }
      }
     },
     "localname": "A025ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A1.25ConvertibleSeniorNotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.25% Convertible Senior Notes due 2024 [Member]",
        "label": "1.25% Convertible Senior Notes due 2024 [Member]",
        "terseLabel": "1.25% Convertible Senior Notes due 2024",
        "verboseLabel": "2024 Convertible Notes"
       }
      }
     },
     "localname": "A1.25ConvertibleSeniorNotesdue2024Member",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A100ConvertibleSeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.00% Convertible Senior Notes due 2028",
        "label": "1.00% Convertible Senior Notes due 2028 [Member]",
        "terseLabel": "1.00% Convertible Senior Notes due",
        "verboseLabel": "2028 Convertible Notes"
       }
      }
     },
     "localname": "A100ConvertibleSeniorNotesDue2028Member",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A2017RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Roche [Member]",
        "label": "2017 Roche [Member]",
        "terseLabel": "2017 Roche"
       }
      }
     },
     "localname": "A2017RocheMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A2021ESPPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 ESPP Plan",
        "label": "2021 ESPP Plan [Member]",
        "terseLabel": "2021 ESPP Plan"
       }
      }
     },
     "localname": "A2021ESPPPlanMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AcceleratedShareRepurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase Agreement",
        "label": "Accelerated Share Repurchase Agreement [Member]",
        "terseLabel": "Accelerated Share Repurchase Agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseAgreementMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromcollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from collaborators",
        "terseLabel": "Accounts receivable from revenues under collaborative agreements"
       }
      }
     },
     "localname": "Accountsreceivablefromcollaborators",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsales": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales",
        "label": "Accounts receivable from product sales",
        "terseLabel": "Accounts receivable from other product sales"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsales",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsalestocollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales to collaborators",
        "label": "Accounts receivable from product sales to collaborators",
        "terseLabel": "Accounts receivable from product sales to partners"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsalestocollaborators",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromroyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from royalties",
        "terseLabel": "Accounts receivable from royalty payments"
       }
      }
     },
     "localname": "Accountsreceivablefromroyalties",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AccruedLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Noncurrent",
        "label": "Accrued Liabilities, Noncurrent",
        "negatedTerseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "AccruedLiabilitiesNoncurrent",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accruedmanufacturingexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses",
        "label": "Accrued manufacturing expenses",
        "terseLabel": "Accrued outsourced manufacturing expenses"
       }
      }
     },
     "localname": "Accruedmanufacturingexpenses",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AdjustmentToAdditionalPaidInCapitalCappedCallTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to Additional Paid in Capital, Capped Call Transaction",
        "label": "Adjustment to Additional Paid in Capital, Capped Call Transaction",
        "negatedTerseLabel": "Adjustment to Additional Paid in Capital, Capped Call Transaction"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalCappedCallTransaction",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AllowanceforDistributionFeesandDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for Discount and Distribution Fees",
        "label": "Allowance for Distribution Fees and Discounts",
        "negatedTerseLabel": "Allowance for distribution fees and discounts"
       }
      }
     },
     "localname": "AllowanceforDistributionFeesandDiscounts",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AmendedAndRestated2021StockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated 2021 Stock Plan [Member]",
        "label": "Amended and Restated 2021 Stock Plan [Member]",
        "terseLabel": "Amended and Restated 2021 Stock Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2021StockPlanMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AnnualInterestPaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period",
        "label": "Annual Interest Payment Period [Axis]",
        "terseLabel": "Annual Interest Payment Period [Axis]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodAxis",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_AnnualInterestPaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period [Domain]",
        "label": "Annual Interest Payment Period [Domain]",
        "terseLabel": "Annual Interest Payment Period [Domain]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodDomain",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AntaresPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antares Pharma, Inc",
        "label": "Antares Pharma, Inc [Member]",
        "terseLabel": "Antares Pharma, Inc"
       }
      }
     },
     "localname": "AntaresPharmaIncMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]",
        "terseLabel": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.halozyme.com/20221231",
     "xbrltype": "stringItemType"
    },
    "halo_AutoInjectorTechnologyPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auto Injector Technology Platform",
        "label": "Auto Injector Technology Platform [Member]",
        "terseLabel": "Auto-Injector technology platform"
       }
      }
     },
     "localname": "AutoInjectorTechnologyPlatformMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BulkrHuPH20Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bulk rHuPH20 for use in collaboration products",
        "label": "bulk rHuPH20 [Member]",
        "terseLabel": "Sales of bulk rHuPH20"
       }
      }
     },
     "localname": "BulkrHuPH20Member",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredBonusAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Bonus Awards",
        "label": "Business Combination, Consideration Transferred, Bonus Awards",
        "terseLabel": "Cash consideration related to cash bonus awards paid by Halozyme"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredBonusAwards",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "terseLabel": "Consideration for Antares equity compensation awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "terseLabel": "Consideration transferred, cash paid per acquiree share (in usd per share)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill",
        "terseLabel": "Net assets acquired, excluding goodwill"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_CliffVestingFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cliff Vesting, First Anniversary [Member]",
        "label": "Cliff Vesting, First Anniversary [Member]",
        "terseLabel": "Cliff Vesting, First Anniversary"
       }
      }
     },
     "localname": "CliffVestingFirstAnniversaryMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_CollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements [Member]",
        "label": "Collaborative Agreements [Member]",
        "terseLabel": "Revenues under collaborative agreements"
       }
      }
     },
     "localname": "CollaborativeAgreementsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer and Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ConcentrationRiskPercentageInstantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Percentage (instant date)",
        "label": "Concentration Risk, Percentage (instant date)",
        "terseLabel": "Concentration Risk, Percentage (instant date)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentageInstantDate",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentCapCallTransactionCapPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "label": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "terseLabel": "Cap call transaction, cap price per share (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentCapCallTransactionCapPricePerShare",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Threshold Consecutive Business Days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Business Days",
        "terseLabel": "Convertible, threshold consecutive business days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveBusinessDays",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_DebtInstrumentInterestPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Four",
        "label": "Debt Instrument, Interest, Period Four [Member]",
        "terseLabel": "Year four"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodFourMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period One",
        "label": "Debt Instrument, Interest, Period One [Member]",
        "terseLabel": "Year One"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodOneMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodThirdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Third",
        "label": "Debt Instrument, Interest, Period Third [Member]",
        "terseLabel": "Year three"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodThirdMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Two",
        "label": "Debt Instrument, Interest, Period Two [Member]",
        "terseLabel": "Year two"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodTwoMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DeferredRentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Rent Payments",
        "label": "Deferred Rent Payments",
        "negatedTerseLabel": "Lease payments deferred"
       }
      }
     },
     "localname": "DeferredRentPayments",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxAssetTransactionRelatedExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Transaction Related Expense",
        "label": "Deferred Tax Asset, Transaction Related Expense",
        "terseLabel": "Transaction related expense"
       }
      }
     },
     "localname": "DeferredTaxAssetTransactionRelatedExpense",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxAssetsInterestExpenseLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Expense Limitation",
        "label": "Deferred Tax Assets, Interest Expense Limitation",
        "terseLabel": "Interest expense limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpenseLimitation",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "ASC 842 lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxLiabilitiesConvertibleNote": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Convertible Note",
        "label": "Deferred Tax Liabilities, Convertible Note",
        "negatedTerseLabel": "Convertible note"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleNote",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxLiabilitiesNonDeductibleBookAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Non-deductible Book Amortization",
        "label": "Deferred Tax Liabilities, Non-deductible Book Amortization",
        "negatedTerseLabel": "Non-deductible book amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNonDeductibleBookAmortization",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxLiabilitiesRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-Use Asset",
        "label": "Deferred Tax Liabilities, Right-of-Use Asset",
        "negatedTerseLabel": "ASC 842 right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightofUseAsset",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Increase, Acquisition, Intangibles and Inventory",
        "label": "Deferred Tax Liability, Increase, Acquisition, Intangibles and Inventory",
        "terseLabel": "Deferred tax liability, increase, from acquisition of intangibles and inventory"
       }
      }
     },
     "localname": "DeferredTaxLiabilityIncreaseAcquisitionIntangiblesAndInventory",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DevelopmentFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Fees [Member]",
        "label": "Development Fees [Member]",
        "terseLabel": "Event-based development milestones and regulatory milestone and other fees"
       }
      }
     },
     "localname": "DevelopmentFeesMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DevicePartneredProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Partnered Products",
        "label": "Device Partnered Products [Member]",
        "terseLabel": "Sale of Device Partnered Products"
       }
      }
     },
     "localname": "DevicePartneredProductsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Percent",
        "terseLabel": "Foreign-derived intangible income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Limitation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Limitation, Percent",
        "terseLabel": "Executive compensation limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationPercent",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCostsPercent",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective IncomeTax Rate Reconciliation Worthless Stock In Subsidiary, Percent",
        "label": "Effective IncomeTax Rate Reconciliation Worthless Stock In Subsidiary, Percent",
        "terseLabel": "Worthless stock deduction of international subsidiary"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWorthlessStockInSubsidiaryPercent",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_ForeignOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign, Other",
        "label": "Foreign, Other [Member]",
        "terseLabel": "All other foreign"
       }
      }
     },
     "localname": "ForeignOtherMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Intangible Asset and Other Long-Lived Assets Policy",
        "label": "Goodwill, Intangible Asset and Other Long-Lived Assets Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Asset and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillIntangibleAssetAndOtherLongLivedAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "halo_JanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration [Member]",
        "label": "Janssen [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_LicenseFeesAndEventBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees And Event-Based [Member]",
        "label": "License Fees And Event-Based [Member]",
        "terseLabel": "License fees and event-based payments"
       }
      }
     },
     "localname": "LicenseFeesAndEventBasedMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_LongTermDebtIncludingInterestGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt Including Interest, Gross",
        "label": "Long-term Debt Including Interest, Gross",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LongTermDebtIncludingInterestGross",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_LongTermDebtInterestGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest, Gross",
        "label": "Long-term Debt, Interest, Gross",
        "negatedTerseLabel": "Less amount representing interest"
       }
      }
     },
     "localname": "LongTermDebtInterestGross",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment [Member]",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_MonthlyVestingAfterOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Vesting, after One Year [Member]",
        "label": "Monthly Vesting, after One Year [Member]",
        "terseLabel": "Monthly Vesting, after One Year"
       }
      }
     },
     "localname": "MonthlyVestingAfterOneYearMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable upfront license fee payment received under collaborative agreement.",
        "label": "Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_NumberOfCollaborationsRoyaltiesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Collaborations, Royalties Received",
        "label": "Number Of Collaborations, Royalties Received",
        "terseLabel": "Number of collaborations royalties from which royalties are received"
       }
      }
     },
     "localname": "NumberOfCollaborationsRoyaltiesReceived",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_NumberOfProductsForWhichRoyaltiesReceivedFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Products For Which Royalties Received From Sales",
        "label": "Number Of Products For Which Royalties Received From Sales",
        "terseLabel": "Number of products royalties received from sales"
       }
      }
     },
     "localname": "NumberOfProductsForWhichRoyaltiesReceivedFromSales",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_OfficeAndResearchFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Research Facility [Member]",
        "label": "Office and Research Facility [Member]",
        "terseLabel": "Office and Research Facility"
       }
      }
     },
     "localname": "OfficeAndResearchFacilityMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_OperatingLeaseAccretionOfLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Accretion Of Liability",
        "label": "Operating Lease, Accretion Of Liability",
        "terseLabel": "Operating lease, accretion of liability"
       }
      }
     },
     "localname": "OperatingLeaseAccretionOfLiability",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_OperatingLeasesAreaLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Area Leased",
        "label": "Operating Leases, Area Leased",
        "terseLabel": "Operating Leases, Area Leased"
       }
      }
     },
     "localname": "OperatingLeasesAreaLeased",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "halo_OtherCollaboratorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OtherCollaborators",
        "label": "OtherCollaborators [Member]",
        "terseLabel": "OtherCollaborators"
       }
      }
     },
     "localname": "OtherCollaboratorsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_OtherStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other States",
        "label": "Other States [Member]",
        "terseLabel": "Other States"
       }
      }
     },
     "localname": "OtherStatesMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_OutstandingAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding awards [Member]",
        "label": "Outstanding awards [Member]",
        "terseLabel": "Outstanding awards"
       }
      }
     },
     "localname": "OutstandingAwardsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PartnerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner A",
        "label": "Partner A [Member]",
        "terseLabel": "Partner A"
       }
      }
     },
     "localname": "PartnerAMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PartnerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner B",
        "label": "Partner B [Member]",
        "terseLabel": "Partner B"
       }
      }
     },
     "localname": "PartnerBMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PartnerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner C",
        "label": "Partner C [Member]",
        "terseLabel": "Partner C"
       }
      }
     },
     "localname": "PartnerCMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PartnerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner D",
        "label": "Partner D [Member]",
        "terseLabel": "Partner D"
       }
      }
     },
     "localname": "PartnerDMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PaymentForCappedCallTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Capped Call Transactions",
        "label": "Payment for Capped Call Transactions",
        "terseLabel": "Payment for capped calls"
       }
      }
     },
     "localname": "PaymentForCappedCallTransactions",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_PercentageVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Vesting [Member]",
        "label": "Percentage Vesting [Member]",
        "terseLabel": "Percentage Vesting"
       }
      }
     },
     "localname": "PercentageVestingMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from partner of license and collaborative agreement.",
        "label": "Proceeds from Partner of License and Collaborative Agreement",
        "terseLabel": "Revenue related to licenses granted to collaboration partners"
       }
      }
     },
     "localname": "ProceedsFromPartnerOfLicenseAndCollaborativeAgreement",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "label": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ProprietaryProductsSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary Products Sales",
        "label": "Proprietary Products Sales [Member]",
        "terseLabel": "Sale of proprietary products"
       }
      }
     },
     "localname": "ProprietaryProductsSalesMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PurchaseOfCappedCall": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of capped call",
        "label": "Purchase of capped call",
        "negatedTerseLabel": "Purchase of capped call"
       }
      }
     },
     "localname": "PurchaseOfCappedCall",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_RSURSAandPRSUawardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]",
        "label": "RSU, RSA, and PRSU awards [Member]",
        "terseLabel": "RSAs, RSUs, PSUs and ESPP"
       }
      }
     },
     "localname": "RSURSAandPRSUawardsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ResearchandDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Services [Member]",
        "label": "Research and Development Services [Member]",
        "terseLabel": "Device Licensing and development revenue"
       }
      }
     },
     "localname": "ResearchandDevelopmentServicesMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RocheandBaxaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche and Baxalta [Member]",
        "label": "Roche and Baxalta [Member]",
        "terseLabel": "Roche and Baxalta"
       }
      }
     },
     "localname": "RocheandBaxaltaMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_SaleOfStockPremiumOverLastReportedSalePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock Premium Over Last Reported Sale Price, Percentage",
        "label": "Sale of Stock Premium Over Last Reported Sale Price, Percentage",
        "terseLabel": "Sale of stock premium over last reported sale price, percentage"
       }
      }
     },
     "localname": "SaleOfStockPremiumOverLastReportedSalePricePercentage",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_SalesbasedmilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone [Member]",
        "label": "Sales-based milestone [Member]",
        "terseLabel": "Sales-based milestones"
       }
      }
     },
     "localname": "SalesbasedmilestoneMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsTable",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Employee purchase maximum amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Share purchases, employee payroll deduction percent minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards",
        "terseLabel": "Shares subject to outstanding awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price",
        "terseLabel": "Options, exercise price, percent of share price (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Abstract]",
        "terseLabel": "Shares Underlying Stock\u00a0Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term",
        "terseLabel": "Options, outstanding, initial contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_ShareBasedCompensationAwardUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Unvested",
        "label": "Share-based Compensation Award, Unvested [Member]",
        "terseLabel": "Equity Compensation Award, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardUnvestedMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ShareBasedCompensationAwardsVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Vested",
        "label": "Share-based Compensation Awards, Vested [Member]",
        "terseLabel": "Equity Compensation Awards, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardsVestedMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units [Member]",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options And Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TLANDOProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TLANDO, Product Rights",
        "label": "TLANDO, Product Rights [Member]",
        "terseLabel": "TLANDO product rights"
       }
      }
     },
     "localname": "TLANDOProductRightsMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TreasuryStockAcquiredFeeCostPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Acquired, Fee Cost Per Share",
        "label": "Treasury Stock Acquired, Fee Cost Per Share",
        "terseLabel": "Treasury Stock Acquired, Fee Cost Per Share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredFeeCostPerShare",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_UpfrontfeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees [Member]",
        "label": "Upfront fees [Member]",
        "terseLabel": "Upfront license and target nomination fees"
       }
      }
     },
     "localname": "UpfrontfeesMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component",
        "label": "Variable Rate Component [Axis]",
        "terseLabel": "Variable Rate Component [Axis]"
       }
      }
     },
     "localname": "VariableRateComponentAxis",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_VariableRateComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "terseLabel": "Variable Rate Component [Domain]"
       }
      }
     },
     "localname": "VariableRateComponentDomain",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "terseLabel": "Variable Rate Component One"
       }
      }
     },
     "localname": "VariableRateComponentOneMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "terseLabel": "Variable Rate Component Two"
       }
      }
     },
     "localname": "VariableRateComponentTwoMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_XYOSTEDProprietaryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XYOSTED Proprietary Product",
        "label": "XYOSTED Proprietary Product [Member]",
        "terseLabel": "XYOSTED proprietary product"
       }
      }
     },
     "localname": "XYOSTEDProprietaryProductMember",
     "nsuri": "http://www.halozyme.com/20221231",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r464",
      "r495",
      "r702",
      "r707",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r303",
      "r347",
      "r352",
      "r358",
      "r423",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r576",
      "r577",
      "r578",
      "r579",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r303",
      "r347",
      "r352",
      "r358",
      "r423",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r576",
      "r577",
      "r578",
      "r579",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r303",
      "r347",
      "r352",
      "r358",
      "r423",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r576",
      "r577",
      "r578",
      "r579",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r407",
      "r726",
      "r782",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r525",
      "r645",
      "r664",
      "r688",
      "r689",
      "r723",
      "r736",
      "r741",
      "r778",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Period after expiration"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r525",
      "r645",
      "r664",
      "r688",
      "r689",
      "r723",
      "r736",
      "r741",
      "r778",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Period prior to expiration"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r407",
      "r726",
      "r782",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r404",
      "r647",
      "r724",
      "r739",
      "r782",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r404",
      "r647",
      "r724",
      "r739",
      "r782",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r518",
      "r525",
      "r621",
      "r645",
      "r664",
      "r688",
      "r689",
      "r723",
      "r736",
      "r741",
      "r778",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r518",
      "r525",
      "r621",
      "r645",
      "r664",
      "r688",
      "r689",
      "r723",
      "r736",
      "r741",
      "r778",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r687",
      "r692",
      "r703",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of property.",
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r687",
      "r692",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.",
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r464",
      "r495",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r526",
      "r765",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r358",
      "r526",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r343",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r405",
      "r406",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r690",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r725",
      "r740",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r672",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r690",
      "r691",
      "r725",
      "r740",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r358",
      "r526",
      "r751",
      "r752",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MINNESOTA",
        "terseLabel": "MINNESOTA"
       }
      }
     },
     "localname": "MN",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r305",
      "r408",
      "r409",
      "r706"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable",
        "verboseLabel": "Accounts receivable, net and other contract assets"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (accretion of discounts) premiums on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Total accrued expenses, current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r146"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r306",
      "r659",
      "r669",
      "r670"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r64",
      "r245",
      "r665",
      "r666",
      "r705",
      "r753",
      "r754",
      "r755",
      "r762",
      "r763",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r762",
      "r763",
      "r764",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r212",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r178",
      "r206",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r307",
      "r412",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r71",
      "r87",
      "r259",
      "r483"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Total amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r87",
      "r132",
      "r139"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r731",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r266",
      "r286",
      "r332",
      "r389",
      "r398",
      "r402",
      "r422",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r571",
      "r573",
      "r585",
      "r738",
      "r776",
      "r777",
      "r804"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r56",
      "r332",
      "r422",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r571",
      "r573",
      "r585",
      "r738",
      "r776",
      "r777",
      "r804"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r415",
      "r430"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r115",
      "r417",
      "r657"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one but within five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r115",
      "r416",
      "r656"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r112",
      "r414",
      "r430",
      "r651"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Available-for-sale marketable securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r111",
      "r430"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r179",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r229",
      "r230",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information (unaudited)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r237",
      "r238",
      "r241"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase consideration",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Cash consideration for Antares shares outstanding as of May 24, 2022"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r565"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Consideration related to Antares closing indebtedness settled by Halozyme",
        "verboseLabel": "Consideration related toacquiree closing indebtedness settled"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.",
        "label": "Business Combination, Consideration Transferred, Other",
        "terseLabel": "Consideration for seller transaction costs paid by Halozyme"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r567",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Change in contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r236",
      "r239",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "negatedLabel": "Proforma earnings loss of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Pro forma revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Provisional Information [Abstract]",
        "terseLabel": "Measurement period adjustment"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangibles, net",
        "verboseLabel": "TLANDO product rights"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired, excluding goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r35",
      "r89"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r90",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r89",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r258"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r150",
      "r272",
      "r293"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r151",
      "r450",
      "r451",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r762",
      "r763",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Savings Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EmployeeSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r311",
      "r313",
      "r320",
      "r653",
      "r661"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r255",
      "r256",
      "r407",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r255",
      "r256",
      "r407",
      "r671",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r255",
      "r256",
      "r407",
      "r674",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r282",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, Sources of Supply and Significant Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r103",
      "r104",
      "r255",
      "r256",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r100",
      "r103",
      "r104",
      "r105",
      "r255",
      "r257",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r255",
      "r256",
      "r407",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r509",
      "r511",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsreceivableDetails",
      "http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r509",
      "r510",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueContractwithCustomerAssetandLiabilityDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r509",
      "r510",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r509",
      "r510",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.",
        "label": "Contract with Customer, Refund Liability",
        "terseLabel": "Contract with Customer, Refund Liability"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r155",
      "r461",
      "r462",
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r17",
      "r270",
      "r288",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Total carrying amount"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r731",
      "r733",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r647"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "verboseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r224",
      "r759",
      "r791"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current - federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r224",
      "r759",
      "r791"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current - state"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r101",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Amount paid for conversion of debt instrument"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Stock issued for conversion of debt instrument (shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r330",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r484",
      "r485",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt, Net"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r267",
      "r270",
      "r284",
      "r338",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r600",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r270",
      "r284",
      "r488"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtFairValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Gross balance of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r159",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt, convertible, conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r45",
      "r162",
      "r163",
      "r165",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate (shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization per period of debt discount (in years):"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r260",
      "r262",
      "r461",
      "r600",
      "r719",
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Total Principal Amount",
        "verboseLabel": "Aggregate principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r475",
      "r584",
      "r719",
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Total fair value of outstanding notes"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Lender Ffee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r44",
      "r260",
      "r491",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rates:"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r338",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r600",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to interest.",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Total Coupon Interest"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r162",
      "r164",
      "r165",
      "r166",
      "r259",
      "r260",
      "r262",
      "r280",
      "r338",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r486",
      "r600",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r259",
      "r262",
      "r779"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtFairValue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less unamortized debt discount",
        "terseLabel": "Total unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r261",
      "r473",
      "r489",
      "r719",
      "r720"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r421",
      "r433",
      "r717"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Securities in continuous unrealized loss position, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r421",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Securities in continuous unrealized loss position, less than 12 months, accumulated loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r769"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "negatedTerseLabel": "Realized loss on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r420",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Deferred Credits and Other Liabilities"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "terseLabel": "Deferred Credits and Other Liabilities, Current"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r224",
      "r759",
      "r792"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r535",
      "r536"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r269",
      "r283",
      "r545"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r224",
      "r759",
      "r792"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - state"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory related reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r789"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r789"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r220",
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development and orphan drug credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance for deferred tax assets",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails",
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r222",
      "r790"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EmployeeSavingsPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization [Abstract]",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r87",
      "r387"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails",
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r515",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r321",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r373",
      "r579",
      "r580",
      "r654",
      "r662",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share - basic (USD per share)",
        "verboseLabel": "Basic (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r321",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r361",
      "r367",
      "r368",
      "r369",
      "r373",
      "r579",
      "r580",
      "r654",
      "r662",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share - diluted (USD per share)",
        "verboseLabel": "Diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r334",
      "r538",
      "r556"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax expense (benefit) at 21%"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r788",
      "r793"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "(Decrease) increase in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r788",
      "r793"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign income subject to tax at other than federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r788",
      "r793"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Non-deductible expenses and other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r788",
      "r793"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedTerseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r788",
      "r793"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax expense (benefit), net of federal income tax impact"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesScheduleofIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and payroll taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r161",
      "r303",
      "r315",
      "r316",
      "r317",
      "r344",
      "r345",
      "r346",
      "r349",
      "r355",
      "r357",
      "r376",
      "r423",
      "r508",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r578",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r665",
      "r666",
      "r667",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r247",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r247",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r475",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r582",
      "r618",
      "r619",
      "r620",
      "r719",
      "r720",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r475",
      "r519",
      "r524",
      "r582",
      "r618",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r475",
      "r519",
      "r524",
      "r582",
      "r619",
      "r719",
      "r720",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r475",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r582",
      "r620",
      "r719",
      "r720",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r475",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r618",
      "r619",
      "r620",
      "r719",
      "r720",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r604",
      "r608",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "ROU amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentNetTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r418",
      "r419",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r434",
      "r435",
      "r486",
      "r506",
      "r575",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r717",
      "r771",
      "r772",
      "r773",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r441",
      "r444",
      "r445",
      "r447",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r138",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r138",
      "r648"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Carrying Value -finite",
        "totalLabel": "Net Carrying Value -finite"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r786",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. Government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss (gain) on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business Tax Credit Carryforward"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r102",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r125",
      "r126",
      "r650",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r128",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "ATRS-1902 (IPR&amp;D)"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r333",
      "r555"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r263",
      "r273",
      "r295",
      "r389",
      "r397",
      "r401",
      "r403",
      "r655",
      "r716"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r333",
      "r555"
     ],
     "calculation": {
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r334",
      "r539",
      "r543",
      "r549",
      "r553",
      "r557",
      "r559",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r335",
      "r356",
      "r357",
      "r388",
      "r537",
      "r554",
      "r558",
      "r663"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r533",
      "r534",
      "r543",
      "r544",
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid (received), net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes (including benefit from valuation allowance release)"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferral of unearned revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r443",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "ATRS-1902 (IPR&amp;D)- Indefinite"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r135",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived intangible assets acquired"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.",
        "label": "Induced Conversion of Convertible Debt Expense",
        "negatedTerseLabel": "Induced conversion expense related to convertible notes",
        "terseLabel": "Induced conversion expense related to convertible notes"
       }
      }
     },
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r131",
      "r136"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r261",
      "r275",
      "r318",
      "r386",
      "r599"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r71",
      "r481",
      "r492",
      "r721",
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r325",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r124"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r54",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r55",
      "r375",
      "r436",
      "r437",
      "r438",
      "r646",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r124"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r124"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date [Table Text Block]"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, Level 3"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r271",
      "r291",
      "r738",
      "r758",
      "r774",
      "r799"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r332",
      "r422",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r572",
      "r573",
      "r574",
      "r585",
      "r738",
      "r776",
      "r804",
      "r805"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r270",
      "r289",
      "r474",
      "r490",
      "r719",
      "r720"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "totalLabel": "Present value of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r153",
      "r338",
      "r780"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 6.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r153",
      "r338",
      "r479"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 1.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r153",
      "r338",
      "r479"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 5.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r153",
      "r338",
      "r479"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 4.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r153",
      "r338",
      "r479"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 3.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r153",
      "r338",
      "r479"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails": {
       "order": 2.0,
       "parentTag": "halo_LongTermDebtIncludingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, less current portion and unamortized debt discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/LongtermDebtNetCarryingValueofDebtComponentsofInterestExpenseandFutureMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r377",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r67",
      "r88",
      "r274",
      "r294",
      "r304",
      "r310",
      "r312",
      "r317",
      "r332",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356",
      "r357",
      "r366",
      "r389",
      "r397",
      "r401",
      "r403",
      "r422",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r580",
      "r585",
      "r716",
      "r776"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r389",
      "r397",
      "r401",
      "r403",
      "r716"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r609",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r801"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r800"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Loss on impairment of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
      "http://www.halozyme.com/role/CommitmentsandContingenciesAnnualFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r605",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r601"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r612",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingenciesOperatingLeasetextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss Ccarryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r42"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r14",
      "r265",
      "r285"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r586",
      "r587",
      "r589"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized gain (loss) on foreign currency"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r123",
      "r319",
      "r590",
      "r595",
      "r597",
      "r652",
      "r660",
      "r753",
      "r754"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r58",
      "r62",
      "r588",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedTerseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Investment and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r775"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance cost",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Payments for tax withholding for restricted stock units vested, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r110",
      "r322"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Total purchase consideration, net of $46,548 cash acquired",
        "verboseLabel": "Acquisitions of business, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r179",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expense and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Total prepaid expense and other assets, current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r265",
      "r285"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "negatedTerseLabel": "Less long-term portion",
        "verboseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails",
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidexpensesandotherassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of 2027 Convertible Notes, net"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of 2028 Convertible Notes"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r79",
      "r209"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facilities"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r110",
      "r322"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r79",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from options exercised",
        "verboseLabel": "Net proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r145"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r147",
      "r292",
      "r658",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r147",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful lives (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Repayments of convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Repayment of revolving credit facilities"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r215",
      "r298",
      "r812"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r89",
      "r95",
      "r673"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments, Current [Abstract]",
        "terseLabel": "Restricted Cash and Investments, Current [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r167",
      "r290",
      "r530",
      "r668",
      "r670",
      "r738"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (Accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r303",
      "r344",
      "r345",
      "r346",
      "r349",
      "r355",
      "r357",
      "r423",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r578",
      "r665",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r384",
      "r385",
      "r396",
      "r399",
      "r400",
      "r404",
      "r405",
      "r407",
      "r514",
      "r515",
      "r647"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r611",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.",
        "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Total Purchase Price Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Values and Fair Values of Convertible Notes"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Share-based Compensation Expense By Type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r47",
      "r162",
      "r164",
      "r165",
      "r166",
      "r259",
      "r260",
      "r262",
      "r280",
      "r719",
      "r721",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Components of Interest Expense and the Effective Interest Rates"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r97",
      "r99",
      "r361",
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Provision for Income taxes to Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r178",
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r178",
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Compensation Expense Related To Share-based Payment Awards Excluding Acceleration of Antares Equity Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r133",
      "r137",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "verboseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets Accumulated Amortization and Weighted Average Useful Lives"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes Summarized By Region"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Future Maturities Interest Payments of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongtermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of PSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r179",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r184",
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Activity under Approved Share Repurchase Programs"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Total Unrecognized Estimated Compensation Cost By Type"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r100",
      "r103",
      "r104",
      "r105",
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, Ending (in shares)",
        "periodStartLabel": "Outstanding, Beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Ending (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term\u00a0(yrs)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vested in period, fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Share purchases, employee payroll deduction maximum percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercised, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, granted weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, End of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r186",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending (in shares)",
        "periodStartLabel": "Outstanding, Beginning (in shares)",
        "terseLabel": "Options, outstanding in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average\u00a0Exercise Price\u00a0per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable, End of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable, End of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Ending weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, End of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, End of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, Ending weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedExpenseDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r179",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationPerformanceStockUnitsDetails",
      "http://www.halozyme.com/role/SharebasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r202",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, End of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, End of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, End of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares outstanding (in shares)",
        "periodStartLabel": "Beginning Balance, shares outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "verboseLabel": "Number of RSUs surrendered to pay for minimum withholding taxes"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r52",
      "r161",
      "r303",
      "r315",
      "r316",
      "r317",
      "r344",
      "r345",
      "r346",
      "r349",
      "r355",
      "r357",
      "r376",
      "r423",
      "r508",
      "r527",
      "r528",
      "r529",
      "r551",
      "r552",
      "r578",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r665",
      "r666",
      "r667",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentDetails",
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r376",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued for induced conversion related to convertible notes"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r161",
      "r162",
      "r167",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock awards, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "verboseLabel": "Stock option exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationOptionsDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r161",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r161",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r20",
      "r21",
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Total Number of Shares Purchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r109",
      "r738",
      "r758",
      "r774",
      "r799"
     ],
     "calculation": {
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/ConsolidatedStatementsofStockholdersEquityDeficitStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit) (textual)",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedBalanceSheets",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r331",
      "r494",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r598",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r598",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r598",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Summary of Change in Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r16",
      "r268",
      "r287"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "Taxes Payable"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r410",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r418",
      "r419",
      "r486",
      "r506",
      "r575",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r771",
      "r772",
      "r773",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Weighted Average Price Paid Per Share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r21",
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Stock repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r161",
      "r167",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "verboseLabel": "Value of stock repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r714",
      "r731",
      "r733",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementSummarybyMajorSecurityofFairValueMeasuredonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r281",
      "r296",
      "r531",
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Undistributed foreign earnings"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r532",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, end of period",
        "periodStartLabel": "Unrecognized Tax Benefits, beginning of period",
        "terseLabel": "Unrecognized tax Bbenefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesNarrativeDetails",
      "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases in tax positions for prior years and lapse in statue of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Increases in tax positions related to business acquisition"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases in tax positions for current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases in tax positions for prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r378",
      "r379",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r339",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Accounts receivable allowance, ending balance",
        "periodStartLabel": "Accounts receivable allowance, beginning balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": {
     "auth_ref": [
      "r761"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired",
        "terseLabel": "Acquired"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r360",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average stock outstanding - diluted (USD per share)",
        "verboseLabel": "Diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r359",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average stock outstanding - basic (USD per share)",
        "verboseLabel": "Basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations",
      "http://www.halozyme.com/role/NetIncomepershareBasicandDilutedIncomePerCommonShareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Shares used in computing net income per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28200-109314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Footnote": "5",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule III",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r743": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r744": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r745": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r746": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r747": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r748": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r749": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001159036-23-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001159036-23-000012-xbrl.zip
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MRN9F3V),\^UWI^%WW:\KC3B?E]"9.0<R?7?)EA[A>BS;E47C=/@O4$L#!!0
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M!N3Q+@&YVMH$<F[*VL!S?K++#6M8"C,>(*U3+6.*K$XU(!VK2K@XH2I8P@D
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M9K76SN,0F(1B^0C??9$&H!-PLQ; ,F".*[$@"80=$8M(%F(%R0P-^L'0@/K
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MG?ZXX_DIT?#B\[\]^.)EW[?7^[LWPLE\1\_D3)G%)RWP?69QK06^HV]_IEI
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MTJ169$Z;/M<B\C5&_$1$-M$D3ARS5+E TC&2+#)1+IQI *>/L\^(%8JC-6Z
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M2WF;TO& 8?YFI=E926)CC#J*3!Y<8GALB,$6\@Q.REG2#$^WNC$\3_J#H_Z
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M+I12*2;;J'R^F$:OKVQ6_YHV^\U'J"6&MD<,0;WS=J(>,@ 73S ^=/G.T_Z
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M6:CL #R9 !KKRC"M;-VOL &RM?&^<%;"HC+90#0LCHL% 3J.>ST*668'E=2
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MEG<^ C63:$P(-"=8#DV?"G'21 ,DB@XCU$]3_D/_ )2_'!Z]'J6H3# \ BB
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M@#--X4E_ L]>^3'<;Q@S&M@//#]3-$3:QX?XFOO>%-8*-P:6"3-I !,)1M[
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MT-%B9FEHLQ*\!H)NN'D>#>\.,=[&[4'>563WN="KY-LXV4 F/,K.OGG7ENO
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MJPT;HA9*H0DA:&B]4)?@W%[B4@6E6(GL1R<J]LZZWBP; (P&7C1%JR%4C-Z
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M -L\B"F4-<*\YA1S]] C]5<1#ET(L+%I7RB]T5P^ CN0)C')/Q,.&O@ZOW7
M\60'T.<R ?.#+VX+X3IRH&S!*K]A_LQ=48N@09P8W(+6CBRT.>+E&BZ@<@3I
MV.""(-""BXLJ[FA5_TS(31LYW$&XR9;2Q6B^2>I+O\AY7W0JL1F,MVO\QI',
M#NUO.K_:&>F&C@NU*3MEBW(T4C[=K9M[69::6+9['*\I=22HO@&8C.(BH072
MZ Q>K%,&BFP(CY#@2_&&,W<NJ*D0A^090"&_:4]UY#V?@&7$=.@;F1%2 M>@
M=B:_BRP@=-,D=4HHB:: )_.Q%!,:A8!W;[Q=H /@[J;F3N$CI)+2Z4994(PY
MN8&/GY"&,L(P0WONU@G/;QW&5> O%DPX8^ OT@B)<L<%?8+3@?&0XI1#+F,8
MJ?Z$]'8BEQU/N(MJ2%NAP7*4;?,DNVSOW\ E;UJ?35:]I<)\<=,O$" Y"HQE
M9=YGRMQQV&VYD>_].*4&)7-*.&)8C6'B<QKL]=R/B[SAZK-:"2Z,@9GAJ_&M
M^G78*C;S)Q30RT6EH6#7E#("D,X0/HD3=:(P\C-@VF:N]/M&13&2#[G%[=P7
M)D^,1V]61B>=L/K8Z0>O]ZYNP-X[O"4UNTDX4'.+QKUDA"CX ^50&E,!1NCT
MWSUWKWC)DO76S$#,)S6CW%V_$Z&V.V5*?22W57UTY;1W=N$=K?QX9D-VOHD?
M;W.Y_'ASWOJN\>QIUWSW,1J!U],P:RFM[^R:7\C<ZR95<=9OM38Z+J;O'>79
M$^WGQRMLQJBN7XC4O?$ZWR3?J,=1/THYF<7M+@0ZZ500STGBLEXC%CD*A"2]
MXDHF28@E+.4KJB0MI&)>YT2C0Y*<.6-Z/AG^SW^UMUF>8]42:HEH%X/$T[FH
MQK>%0E>T_9:W#*?QL9+OH'NQ";XS-32D5EJ(V.H'Z#G0V/6@&00%*-$*5=HU
M$>_G^R+;U[%N MM9D:>%6VLA,A/EOY."&A=1F)/R[P*\.6>.KEM-"R:QB<]?
MH-X<OQ$%L766I'%)B7&')9HE_+A5;[_[DPI[R<RI.@>E#U\VUU" N7$U.5B&
MXJ@MS;U@G9_S?6)6\I'@FS+.XY5TRW@V5\#1\)Y*0BY@S3-JC+FZ' ^X')F2
M2G"0'OH^R'[J^] P3M\J7+Z^%_,5/C>4I1L'G^'5%M&2XF)V0HR(.)KY<9&E
M"8R!,';$Z5L&R5]Z$OH,=P52,5.A@![^0&1ZQ^-N2*ITFEU2W(.,".HVA_Y4
MO=$P+T,*/8<*=/(.:A.4UD/YO1AO'LU"Z0WC3UD;&OM_,3(N]^[2CA[@=YF/
M(!4%AL7&_C2+OI@P\KX'>Q+ V5+L'+U'("*SB#Q30$F*3[KOPXO9:J8@" ED
M^._TVH.II=<2XQ(U23I&$/  )V7":UP1/X+M@>5CL(/^>06*UUB)Y*=L-1#F
ME,*9-TQ8:YPF:1!SFTE0L/IIJ+W%'(6@#IG4,T T17@B5D%!D!N.\S,?PY3M
M=U4%H^1G</I94LM V\FBHN"XJ^/IF.H]'AO?+%>YI,?@PS4=,O$-K,*Z$7"6
MDC<J.D@,6K4Q!8$R&:['DM+$/MR+061[D?#FXT*O(E_31I864ZG7<INJMT %
M7Y ^:V0U@ISX5RIQ-;ZCSU;CHQF)NA7:A-JZKJO QWPNI>PKE4A1SY0<3A09
MEJYK3J-3I$4S4BJD;#3V*=Q :M>.43;0 TH=5"DTEC+,4I&9HX?-*.\!3]FV
M_X43D#JZH\]SVZ5_ALY5Q?F8@^B+"IMX">AVI)*X;X=AIM)DUBW?3V<3//#8
M5.5QQ=/<&QN,>\-EIO(L>8*O9'-X^TTTSH]A2\*9&84RF%VE/9[-&3=T\6DP
MSK+/2-J0 C]@C ==;X#I;-)CKV8CB$T,8O6%$"+LV:32,T??_Q%"M%3. +O(
M5O @!ASS1[,M*\W7M=D(N"=30[RS+=;#/O@YQ;+J>B5J8FWBG2QX4:7C=X@S
M\TFDEBH8.3< TQ?D7 S%2B59-#"M#K0$[ZM9*@<HOP)#,V(.([\S\X/SQRDN
MA58\WT2DOL4VT2-S44H]L T_Z&3>MKSWZ6" !<_-#SY,+!B!M/DP#=DS7O,=
M>14TIZ+/K!CV+OQ+%?KBL=9\-X=GX*HD&F%$W-MO_"] D+[WZ1S'-$/R$';,
MTP'L2E9^+7]F?_,OV,@<J.H-USQ6)BG?VI_W^OW/474I_*']T6$<>1^B6&ZT
M1"7,K^D;^^,W&<;HX^8QU?:< \_I]^>>>7-\[LP!;S)<31,M<'?HHXT1?4HH
MY*F<*?B) <59%+9 ZN_A]?\3A$  !_)A?]TLE-_L*$^@$"1?O#>?W_3,7/DS
M^YOW:1;] ]-U/4S>)';V3WYA'_D<19^]]Y;IK)&C*$[[L$ ,>6&Q)9AS[^%6
MZJ619D:9)+0>8%OO8O]+>@X;,/H5[\"Z>1V.;J0DG="H&/I1A?1@9*)F\QC_
M2C]( EJS(): B*F&%Z68@+@GGJ.OSD#I<BY7 %=S[Z2: -GI5*K#-% ;1TLI
M^0<!SD1D 6]00#L)\J^9!'UUHU(;KJ=6EW"HI4YAE""8SG39-O[6J46DEY2;
M859RF&Y@U:1\609CL.;*;YN.@)L(IT7$S,I>V&3(RG-F:K1LX>1FK<)$2J,U
MY%T6E5[_FEA0-=T)M=VZH36C*/W<='&WBE'Y &[@K*4#,KUS[7*K+>+,_*F*
MG[$)=">%2AJ5S7U"&!62ZMB+6VMS?#]L=')J*II=F'\E^?(: $"  19WRKZS
MN;RH:MKYT5((VHM11LE'W$ XH"M<!@BM394SW):_M&SQ6AHFUQW6_*XV="I<
MKJCK C94,$5UAD!0JVG>@)[G%;G.-?/#*Y\ ^/UBFC;9FJGD*;9 ..5I5=NG
MAVL7WC M@G05-)#G((VCM&KL."@K%&W.O7__\?'\XO!@Y1][@,/DY6W:]_9Z
MW7R1/_1.#CZ^O$U[>DI#MO3\]JW=ZK:?+;&=?-P_^'1VTGM^V_;\R8UT3S)I
M2Z*P*K(<50J1.M4555 O=/E99?1"755-5(UQ31E99/T:<Q1^;(7W/I8L>>]
M(YAXYRV_E;5B^U/ZLF23?,1L[JHU#"_XL&\>HI]8>T2OW/48:O1.9PFEG9 =
M. KAG]&\\5U:CORH-$NVIN^GK#T'S8P#[; IT82R#P8$A"'-?)2?87-;=C]'
M$M^)TX!3_:=>N[.YMP%&OK</4TM2S#^-&]XYK.(@4D.P&O=[WEZGO;G1(@ST
MJ8K59(0V15*,^X@-EWMKNUN[Z^P5V]GK-G=W=_=,.$HU0=>.T;:DAHKPZ^<5
M\(F20?K_C<1X:,$M>=H+CUM\K?K K]3SW;/KZ^N6NV6M)Y4P1PE5_0C>5T%F
M)!7K,68+>XG9=F$%7>\O["M!(W%)3CH0P!?^%"$/,XQM,>;1-&W4U56XU:)\
M>)C;DX91H!&!,\:/QU];..Y!%&LW P5.#O?9JZY!FC32EJ&$Z3.G@*>-EP[$
M^8+M+A!;#7T#:4IA&G04I!@WF&F((-I?3L6_%AFC,(\?@]<<*N'3H3""+ABA
MLR*B&A29P$'#R8T]I@LZ0M?-PR!!"=>D\-F[I-+P_BZH,P=78U6__ZTQ1SGZ
MV]WFKU*E.N.Z7<%Y3TU-+?W^UEK]S7;KATGRW?T!$*(?"OSS0P_SZ*FVP!4N
M3)QZ&7R"V@$OK2,H_0'52O28E5/Z3)(M@6<'R)<5@\MR6V]B:L!1LHD!M::T
MB(79G8U2L)8B]A0EK<3J6\@W/?7%QWX6)O>4,.LH_JH34+F7_-0-=%-SF;[)
MU6 ]0.<H<(UPBK%XDPG!A<XF?0#E@BC)G!#@_#!1*I1@O-,'D&)*,S!^1C"S
MFBP/S-J1+2X'VUD(F7 (&H.HXNN@'77WBJ3XDM0.WYM&>5Z@ (P'31U/CKGG
M.1SFYH8'O*Y WS4K]N][J(50A38.[)%>@GE@"9#D%'](U4,)JF+HSX?W36<&
M#N,Z]4+@IMR7%)=);7EXUDJ*QVRZC X#@.$2(9*K8 "[^4>>DWPT6XYTZ3O[
MUQO59&9RHQM/LH9<;/HY078O]'#/,(E+W>/WG#5&MYA0;3.2ZGC<Y>Q=3HQF
M* ?23:B_NM-8G<OAQW3GQZGD-FC4<H;%X[P+]'L0CD/+.R0<9IPCFOU4[Z@X
M1H2;G,N8"-0[OT'2-D-@!!B:@!<MB5-R6W$=$F7BS'Y"5"H( 5O'WNB,*-!U
M&27R5M*)<C,$<P8A5P(8A@L(W"2@A#J^>*Z' R>M&&H[S1FD];9#$6AW@:XF
M,]$/BJD$3D:DS)H=16;C),9E(U6 8IMBLY0,5@3T)=$M8+^1#^]K8+*.@IL3
MV%R<!D*(93XFNV-9,0%.P89@R!;S?] C$"IN9AW,= T_AO)U Q:VC[1BJ^6!
MK6S&_?I\].;PWRM7X<,\TZL=_*H=_*V(@LOS43I=[=Y#"C@,\[J9=R%398PZ
MP4SY3%DHW=W.+Q46I[L/Z%%5XLT-P3REX@1.">L!%-!4(6P%J NHBH *-#3)
MJQNM+6_\ ;EGI]7!?Y(HY/9HAA^C<@:L7[*3'9$T0-</PTZ@@$JIG!]_C<G)
MH')=(4 ZUN*C+#!]6>P;&*<[^H?S.M&I@#D0G-3,G!@Y-GP7JV0X'7$K Z6F
MM9C#Q-QI%,)3D-0)MPF#ZY@@A7.L,*DIF%'C$"=E^6OR%)[0I#K'[$ZU' ;5
M[YPUY</1(PP$HZJ398*G=_39)KI[;'P8K8LA=]QDT6H>+QLA9. TG$0(MXRH
M";^3XOAY\X,O6XU90OKG2)"DRDG5E43^2B[]/-:QA'O8AHQ!-6RB^D&KT+G^
M;@X_6TPFD5V#G%*F.M]TRO+/J'C@)_FW5 \X4^,D+Y/4)'C-L:"G5")I^/9R
M3XE2W>!(Q1/V#=ZY8M#=2^T4CK(%E6PXU2DN9,IK:VB87@(3H_1]0DM!=!89
MO\F9T^6RBOGSHL0I^K:$7:W1:::1DU/&MCG:7]C32F^Y 4BW&3E:Z92]=ZH&
M-+MS4\BI^B,V:<\VD5T3L:"RLX4=UF3F(Z*I3;5$//J\E-S8<'*PQ04 E@A:
ML9EN5"-YYM-1.8<(+=#KM%0PXM254+LDG&JL["(K(#IS]0\(<>:D'G)3PYH.
M'EP!H@0*GSMN$\^+@@83#U)FHY3-AN(I%H =B^N$5DL<Y]R0;,(QC'*6W?]%
M@YRC%;8U"$ZTDMYOO2)6PLWG8D^O,5VKMBQE@,1E?UZ?<.?VY9G/O:OT1[,\
MK8YY_:YA^ZA8(LTN;0*91:QS&@2H+Q,=Q*Q,GXTNVA2^B=KZY,UR/ZN9M(5G
MPGY@!EY'X'"JF^4DJM,2*%V2&*ZVL'D%]LS(*&<3E.FK.G=X/16SVZW5O0E,
M4J_+>MP]7!81B_NGZ7\!F[=,'8M&2).5=@[S%[DA2(8(V0<_:BPPUHF@R]^@
MAEB7J#A_XQ6JKTIE-'[EHMO,2<*KXBL^M4NL[56!6'N56^$4 66$,HM)TV7E
MVL8HT6DJQCRKK->E3%WJJTAEBV6>YY=*^$JC-Z2U:D;2Q9F,]:*:"PJ'@EXE
M? $5!)DO!M*&R<RM-/_ODHE[KW#$W9[Y <-T>\L?IGLJV"<10I3C)/_>-P+I
M+G2[^<QY^@4!,NK*8BX)SHLQK(!\PXQM*:TN:_.P;Y3552SJ\G#S;;/N/-A<
M!OO/#V!/?&F_$7>J0!GM.I]DO-^[=W][- 9AE 7 S?PX;78V.IUV9[/]GV&G
M]==D^ JD\'315V4NN-O9G7SY128J'*[&'T9SX*_EOF]WMB9?D#<\(K?_ 3EW
M>V/Y6??W4PA>Y,B/P28V%[.)S7HVL?7H;.)1\UI^1-;2_B%9RQ.@UBY4'8VR
M=.KJ-P_3(^^PF^W-)X+MK=\  03RSEP,IC+:$2,@&:??^I(X200*ACP;Z,+4
M.^&"/S&*M$D+T4Y,%_H&?=X6_":O 4:A<MM@%"FJ-V>8(G*>ZCPQ\9T^)%F,
MLCG@E065CDQ&,ZH/%M@A+(]PQLC\,$HG_M^%\H"?D,.M;LV1"W+O>B<29=NG
MAUX_\\F!7:*5NWG0]E[<+9'J56^ME ^B<+_@_-6Z=Z1OQY)>#G$+?FJ=M^8<
MJ-H4U)MD8R 2(:O<!W0(N]N8*4+-)XM14@1M5=;9A2EAPA!$B$7*8RK!'W"S
M 7;R(IY4G@:1Q3?PW70=O(']7'< 5$F8#AF)J321-5C2F$ U,B#K23I,$[@R
M^7B]Y=G%\64EA/ZW![VF<>O#.NN)PX(38($W3 $V7UUB$,B?-@G$!W9XT*QL
MDI1JF.'9#2HV.9T&%@6$:8[^TQQ;D& DO>%M;7CC8</;V8+_H8= ^L,_6]ZY
M/U"Z<PE64/D!12SMH<FVVAS)]JXW4SXF',0A1SNX5[9*L*64WX^I3N!.'L>7
M=^-U7:>W%JI\G'+K)$SRP[[W<.'/"UA_,L0HU@6Z8Z;?2C]X;C??;(3# AI6
M,%*K$(+K9"P.[FFBMX8\55-"L>&"/.V]=F"M!D!6Y-J'&\O]H_EOBHFE\8R^
MT?S@Y'2.'1#HON=?^Y<8'Z5X!\R&0IFT-2!4O80"Y]B:.L-(A#* ;69U 4R9
MXB)3K(>!BW1R2GW<D8DD'*ZG09HX* UC+C9>5_4E4(I+8V!/N6N3!+XZ7;CE
MP#*KS[2<K44%8V[;&N4+CSG&<]>=\>TBX'V$&O$WYGC!$3@QN!2&M&U5KC%G
M4?IB2G@X'R'N(B9BZ"W(IT4HT7Y)]::EFY4;K+$$V ."$B$9^?' 6T.<,,XC
MDE.1  ]S*SM*W\=,TW2,J401*"+K+@2@V18*U[U5A/%()_8QF*:HBJ"A3  ;
M.;DLD2\A(@;,5WYM*M$P2(YA2)JTY(V8\?4+30A2)$?BYJSKAV'%E <5E::Q
MN:3LCS$4*OH.4E7@)RDQP(^8&/W6*L7+P/YDU70=I]=(4J&/T)]IQND^K@%0
MVID*@[M-NWD:32;%QL914%5M9-'([#18'R@VMB\>3/:8:JSQUM$U_%<!KS!W
MT$_@_80T(QDE&AW&MKI[KH@<MR%+/&WA[P*-[;ENYK/&A%FIMY56>Q=GYU[3
M:^]M=):!<>M:$^KA-TRE.2>":;A97OX<B*FW&$O+J*K(8P-0*CA_D54R1NLJ
MJ3J2D>RF'5'"#'%^+!*9A5D:(#IO#ARZH=NA2CDAGD<33X-KEFI003"9.2==
M![XJ+:2"EN(4(NIT1Q]4G;\1H3J?ZIQL5Y25I[848&Z.E&JSIECTQ]&4DO43
M[^CDH 1E;9 *4/#I<]<I/KQ'!+<"NF*[K"8S *<^/';UA:"=8X)5!KHM5NCG
M0:'X6*OO-35M F [A5/@O&)RN$:4MEIY']5R$BHR/\597=C)3V'*)O4I90A)
M-#J86FX\;P\H) <%XCR-B^8^ @X.7IYP>?H*$<<F]A/*G(6+,(C]\9CSV(9Q
M$?"F!U29QOX=-Y,+NRJ&/AN.@32 Y<I!F]Z*E,AU< Z5+0D (]U9T+;YSNKK
MR&65BK-2\ +AKM@;1\G,A..:<^DU75I.*:R_L7P5Z[]KV.H83!<$];<P+7M(
M&T/W>@Q*O-,'N'(#+;K[Z:_&5T$,Y!X\N$'JN%X,V?_GN MC,3O;O CF"-=4
MCAYD:9XWTRM*P<$UT JT(D-+./W590]V#]?81[A>@EMWV('Y@91AZ]Z$S9C+
MGTQ9Z69'DM-GXII9CHQ:)$P_*5#6+K!ZF&E=V6Z[!BYV@=1 PKG&$@9C<J'3
MZB+S@TLY/N-DD8L@Q<S5%UF06"HI9]!/M^>Q/>8ZI0)3O;U)=)5.S=1J771E
MIA,E>3$P)JE-2__L1S7Z"4M *G#[>N7D*PCJV2C?IR:E3H><EV!1NB1AOY2/
MOYQ!<X:B+JUT2?C<@0JTD-G8%D87"O0VY<D(6ICG5\LX3/<!UY_*?FA6C'B0
MM(^XU*B&8XU*'%Z#'62;OSBVVF+8:6NKY6XDGCJG3P@JBHMR^(522V8*S!B>
MON8$UUO>)W&;HPZGU]#0JX\Y].[#&Z9<;:@XJL#E, WRT,.GTGD:L>&ET<5-
M7.M'S'GJ_) Y3\_JGKO:9'M3TSA[;(G(S_>K@O@]7$5X"EM&3S/05HI_BK'?
M7_?6S!<KL_$!P +G^Q3*/"RP%K)>^;)^)O13O#\\ZS2-'H@W)*<T_  .DVL$
MN&. '":7;EJG5 !<D/!OI<69>\K%-(I-04%=(;0D);@EK1*:1)P9JM!E5*5&
MR9;8I!9A>P9SR3I<C,U[])EF0O&%$G'NSJG;_E3(59I5A#9606HWMR+!S#T_
MI+PMAW29K+]BBVF";U4_$W.@O7?O^9E$FK=IRHZ  W1%]LH)(-J*!-7?F)%S
M:[%Q7DK'\A)_K)Q?8'I7,/4U_H1[;SD&[.9N-=-9?LF=4GJ@N\>R.%[*V ]K
M!G:JY=P$H;E(+8]1Q2O>'X$8KQA29J=*# ?^GW]\A[.CD#0H=!AVIJ09,$+@
M+_2-W72L2Z*_::?GAN- T2E$G*IANJQ5:K]/5?87;-6*AS^ AZ]A%;N6A]1.
MRY"NI,#9G+BU4^#)PU3NY+KP7+2@:QCN-^!5CD:OJ8)E#>S3/BC8$;6'LWV(
M;1-JJB(VU,/3OO,-O,_=\QS/G^$6UF&/KSL29_@QA5]PMWJ.']V GA^7>>62
M4OR31E(?0.OK*/WWN6X??T/B[I"=J^[Q[1\<NME=Q/);7E4C0!)9U .LI4']
M?>]8Z9IJ:^\1GO]Z1>00H?$E(#<M%GJ?'%"^V[]\W&!&,'*[4U8(R>Z(1J,T
M4G8M1XF\H%4KJ69"A>6M7*_TZ")-K10YRFT/8VH'RIH%*&)S65PN!$V-@U(:
MM;&?<A-4FP.@BWU?G(&EA*Y;V<UR"=%V=\XN.O;[U!B/90X3^SU4=T+3(H)B
M7(PD39KOTW"(2(OQ;#P9P?2]M9/W']:?2),G;O\E0F1# @JW"GU)GS>:FOEI
MN[6%7W0]2G4$95XW/27F?NR3JKRM][.B+9=DTC&".L*IY%Z/0;R,9'*8NY%*
M<""45$7IURGO?773!2V2-SB8H32*57&IQDY>Z?Z'#Z5>@9H$=FKTJ'<*NTG#
M7@K41.Z='5U\^G?OQ'O_Q_[AAU4KF =%3_TJ5\VB:8'TU9< 0PT5K]6GQUNK
M2-]7) ^VD AP3.X-7(YI'@DT)UDNU%^2[,9U3O$ NF">CB;N;,*-_N""-NB"
M1HQX:JXN0_H-!H@[Q^VWWS2QT;CYA=P&SJ9#T[9LJ]KE+-X,@H<2E^>MZW>L
M0J'1%7$^T$=33OA!Q@*T0>=Y B<PKAJ[%?7UF/-**NP*%!ZKZ"R)\"PY;W;(
M.5(.'"35?&OQT]_D^\<TE9H.TL:[OXA#<-"TW.+5]%^EIMM]51*UU+I5&K;J
M-JUXEJC1XA1-'V3B^US59\*MU.R6,KJ<4.L<F%%M3]@JB!OO"8%AP32</J-8
MPP"*P,!I^6AN>R4BDU7[:BT+B5GGDG@'[T1@6C_+="W(P\F-.Y1(1W8"HJ+H
M$$D)YSD-E"8H\0-4C3CE=$6O=Z)7RTMS]7>AI$,QU@8)7Z6SS!U;'PN1JL>U
M-':)X\I!PN?-L4E")D6Q_U-GD?F&%@>#E+)>4@ 9FMA!YET<[A^>7)P=_;92
M$Q[B!H1C^"<%TF7GR.)+/N^66W26FP\XR+63\_T/HK&8 [UY-KUBB,U 7 6F
MQD8K3VF,A7W<6UQ7FZ@DG*0103)C51F^$.<)MB!V#<L(\"\F%?J"&D!DT=^>
MCAST8XR&K%6SZ=8)ZU7##]0T!C%V*?=&M)8G9:3)ED389B&5\IMF O9[9W,/
M:*FRJ:9G,LS5\5W2?M)V7H,2CZT()<\:3..Q*>K!@KJ!C[VU)#F/RS><C#OI
MF.#:Z9B[ASU&T ;7XHKV&WX.:S';=!=%T_?>&/#D#R(ZZKRD;SY80UJ,>;)O
M4:BY#M9B.DJSZ!]^N&Z@X][<0(>BZ,Z'C^V)5ZZ)Z^D""85IC(CL:HTA*:[2
M^1YSV^+DYFTVRCFC."58KA$0-TW+Q"2IP20ZFT\//KWM><,4.X!03NG T6[;
M6PTN %P*Z5)B C;L5R-<Y/9+;BP2RL?]L\//G\Y7(N,A(B,-$-:^[BJX?6D2
MK=,)HP(*GD83! $,8@4W)LI+<5O+'19+E/D#_*K7+\,E*)L6YA(D*54 TQYB
M<  4V @6GJ)"/&<: !_L*_&]AS<+79>=MV^_<88_N>]W#!(=+%BEFCFI9IL_
M2JK9(]V?^Y:1^Y<J])<R4];U<VWLF%196?%7YLK**'7)L@V'YWR3O%GB*^]Z
MQ\>]=[VS ^_#T6^?C@Z\M?=__/;Y:!7+> !QK'.*<1WMK[<\WE<,OMV"BJ*-
M*K9=' @ X/YI%B(6>!4I 'Y$0EI,*GI222^A99'0$DO<E%26?5-!(_L]-@:,
M7S)@,+H)5H6),WY*2FDOGXPE(XD#YPSGIH\&0SJ8D\:GMV8:Z(FQ U^O<S_F
M>;0'+@I%N(>RM:D/F*%V$ "BYK@YO,M+,V%H34.)X_4Z_"2!+=+7))VFO6FP
M7G0[!0K@"C3#HGCRDI!**131;>AMHWHY;5S: BL^ZE+1TPV'-G<KW01(>\?M
M^6"N -]'S+@H8LRC/GJW[KS1S,DAF$5OJ_@M=!N93 UA#Q,I1F<X(@;H,6X1
MJ9% (#*"1AK#3HZ\-26M+1&GAWI&4GMV=9FO"["3T_:%FZ-.")!0!D5\A32W
MF]4H5W@-"KAZ;F<9RJ1!8_[=LA";S7&0VUIQH E-V)S@A9S*I.8<LM/)AZT.
M@<MGL&_6%Z+KC:^I^9 P!IN-8I,A'"X3@-#$5J4W<YMJOM7&HB5IAX\3M@91
MIV(@,=,R3I;=SU(?CHDZC& ,()?D7/^2/ZK#$;.HFJ&Y/:FY/#?AZF 7I3"-
M51[0'>&>H5&,U8L6XHG:WU!/)ND$<M.N>&OG1P?KRT*K3G9VVQQNK>5)#9\H
M[ZVA_V"#KH$-?9(FG7>#^4;3S\86I !T$X9:4?,ET^(:A3VOLD0XYS7"FUU'
M[]K_L8UJ2[Z)M8O>K\W=W?8ZXKUAIUP$0#*\*-.]DTJUR,:%L2R'Z&3,SEU/
MDZ ':\&'RVE_NMY7.X0(\LYU"/&EY0R8L4_]<ZC/5DDZZKRJ$LI!J,8S5,1Y
M'(3O0]39H(A!@"!C\O$\UO:/#D[7&ZZ]!#</;O\861CIK]2S36*KY. N126=
MEHY&[@+U(I]@K8W\(65-#\L(< .B'),C,0SK EI5MQ)=]B&!\CD0+K>XU_,W
M'WHV[]CVG3.<IJQ#4D))#6/G+Q8(_GMZFY^G5^!T (]G2^D5<$.T'>,4D 7?
MWRG0*'D%9!C=V?!A];.Y. )TS;YV ZCDG]E8.D/*B]PB?MN7$T.10IV$4D(,
M'3,)@-G*1T[$IN7.6M?0#JS#-#<&B@WL8ZX=?[D4Y/XO&"U7R=+3>]?0NU[Q
MUQ*\'N?[4[Q^4SW)AU'&A(O9+!-3ZVB(]$)(61)T<DWGM$K'7]?W*5+C+DO_
M=/]@<U=WT60]6%S[=QC#:FXY==2+2Z&>"*LQ^8..*0H@KN2$%R+.;#WHG?W9
M^[!JL/ZP6![8#OZT&%,LKV&)!G14/-W&XCSFN>P.?SR+TPB->DRE&*=Q2(T1
M/52N=**Q"<+)A\L1B)ZOKA5*-TEL)1@;1E)I8$X^['JC3@4N:[ES]2_['S]\
M.G[3FX^*@BFBKP-GC6.>"8+0X/T_^ESZLGQZ2+B3G--(,C7 YL6HMLX?F!GB
M?']UXQYRXVXJGEPGU\@ 03\D*EO*18*/S/;#:<K!#;$6G7,3Y[.:D$-^) 8;
M>V<JGZ0H@<[0TX'W\=C_$L'=]RZRM!ABK4]"F27^M%P%@^Z4^8)QS<Z->^C3
M>1F%EZ2E=O-4@'8Q0]/EWM[;WOGIV0N$B'T&)*7S=,63FNN,)!+X;B82>CPK
M%]KQ?MJBNT1=8S?IR!\F&+%O8'E@DF-W6F2XL/!AA/7SAH,X';47\!']TY;7
MH\8TMC31R6UJ5*D!4^'P$I1*O@@NSCI]2P ."$(6(>PPI=TR;BYBMQ-X;NGJ
MD*XF^*<Y[PI#WFN73%Z"C;[;!3#F^R(WZ;UN!(9HYGB%N X./[6PG8.D&$LF
M6VZQ"/+&_.RTHE5J,NTZ*/A)<>6;W[@$1-B!?)0@K"9R;D18G\X;,*N&U)]2
M49+4PKX!LDQ(DS7I(/CCJ)0%UZZ9<(F94!%NA3Q8Q)F:(QJ^C\AR_Z3CJ$^=
M!F+02,84@N9VX%_\L8*/<PX.5"E]\?7@U@ (D*2IG[:IF"+?1E<>QBLYK]5>
MEFJJ7]TB,>\/78W36LP-'>.Y[\J#60#ZQBC-)R,?EU^S^K6#YN?]<+T^D%L7
M1JKN5>^#J_-Y:PA%34V98)!P882X-&1E"-QCPD0^^>-]S]N/?;B_1T=';Y"9
MR%^?T5J'.0084L9&5!Z5*,U2=*,-E?Q<:N30XP?L,P,;#N93:9>Q7G*C?3/Z
MFP#5:**KV?55II.3Z=3]43*='@G^\&80A(/F:5A7$SC'\VB;Q:*'7]M2%BW=
MO\_-P?E]N^E5,A6_S11_G<$#<91++?T:\*)!%!//7:^Y[/.+N:.993FAF2^.
M1V(>%1].YX^IY)R3]#&6:#H$H1R.JFCBMRDO=PWMNOJ) &EAAJFC)C06'"^(
MFSJ96R=K*H+!5$'7D8SI3/) B_9(@V:X74,<DK$;5Y;/]) Q\8\9"&O&*% 8
MQ&MX'_P^JI0X^]]5/$#U8>WX_8??UV]([C?;NW:98),CT*GQH]\^G7U<+^-[
MS,G6ZM(:>M_$BFN;);&0QB55%5#]ADJ)3:WFXN!>Z2G2Q#AY*PJJIU@:F\&Q
MHFI@M^HYJ=[*ND08'NK$%X65T!C0H:A=J564LI/CT]X"O4?;SS$57 8CS#PH
M.;;N1=G&ZED2+Y?K.;=>+N,//GSW]HQ=VL>'%QXA?/<C*=@,-(H,(B",HROX
MRZ?Z@9M<Q@X^?5\A9](YZI@/ GP86%DQ3K-\CN%OV,DM3DY'-=?.I)2/7H??
MLWC 33M@[/^#CH(DXO'<\4O9 '/^-S4!?3$#U=$;9NDU?# @?D6W;8+_6,/=
M76^."TXN65#V=5.)W6GOP\?C7G-SO:XP:_'J.O7;55V.83[&"S'O(:Z?LWN2
MCA/BOCMRAZ5WL"OF,MS%!?J7OHA3BR'\'BRF# U_##RA81IDT62*YQI'XTCB
M0[AU21'$*B6SJ?[W43**^M%47S>W&+1]\W4K&UY.9"N+XDET%5&3P=+ULZ(W
M]#Y'T6>!)I[ [FI0*#!W\DCR<Y T$P\(,/.;<8H:3$"*S)7T)H;O]WMO#D\^
M?>Z5 QKW8\S/,U3;Z_<_1\N)[*T1C;9,E%86^[5!6AGF^\=HY45W#=$F>!,>
M&J+5>V-^I6X1KA<G;ST_GHS\AA0*DZR=TK9@N9;)OG;#5X3EX^(9"&#!$MRD
M#U$,+'49+Y*KN-G+Q.O]VKO$HWS_J\3OJ;U)+?G2]H#7TS' *8)V(F#['#UX
MX#VS"S;RUF;_U#]D\M&="PGO&4?-N=&7X!Z].3Y?REM4 Q.%YXK+?<@EXNO3
M5P%"G=GNO5%)-\?WN+<-7S;RP^]\U_ MYN=N4@C?'X6@&,D#+Q!J_ZAPSE$^
M+RTWO83<< SGE#;3).#L$WW;K+D@W8'&)*Y\6$,;U/Z#9GO=).O5H1]MUF$?
M]6<EZZA;00='TQ?G>J-E27[[.)($#^ZM]J'W#E\H=G"]+R&)KM*XN E!T(W+
MMQ?-9).@.F\=J]H3\@8K#:P#/V/32KJXX3\#'\@K(0C0_9$*+H]A%LWMG8OU
M!@&G9/X07TQHK^R+R@7]"!UHLFD_=4 [[VSL-7=__?<BZ)@Y:]_IYXL[<%.]
MNT94JF+&+-HYME(J/0NI\Z;%@K%;6X8"<0/59=07[XJB5W[9%T4+Q<R""%B:
M\7@#[=">,FH6[B!.)5932HK70,7.AK\[7.?[@V''<E.YZKK@C0QVC4 @S##&
M:4(3<E8*ME::%[#VNB6S"JCI>Q%:==E!D%.G6IO),B)_*[SUBEM!WV5?)F"8
M1KR96/6GF$58$H5QBX0WB/#]S3ZNG1U^Z%T<?3ZZ^*/9[NR\F)J8^UJ"L?J"
MFU<K>Y_$3?%"]OD^ZK.5^WJ[O]H8E7$>P1KE-QGG.G;A QX3I>SZ7BCO*;NH
M"AMBL^ QA2%GV#R&<#;7GM[JZMQS@RSI5<3%)5_*-W%9;D-=)QD@%E[Q8EC+
M>V)95BF%:^>IS@XD/.AK6-WT-K#NX+?!F2DP-4V*>5;_%WNH^R'5]TU!U1ZB
M:!E&8P1OZYV]^W>SW=Z4VJY[0&3>04'#_9&-<344KMJ\"7YGE2;BI(ELK=)$
M'F^WZXP$7^X=:Z%\FSD8L]^9 _20ON",WP)7*J*Z:KEF.W,A/>$"[ 7E\F]*
M5%247">UMI+K13&E8[0)!RG&$XY3G,.)4Z5Y?'RR7FWFM'%W'H6V+54^UF"]
M\A4#57D436S;125!7YLD0 ,PF*.\;\B .-2!0"(6]")A</@T2] %C0^8<Z+X
MK.%"7&UO^CNRL,VC+Y9-F9F"\,\YP0,!UFG:ILZSM-:E*<O0D"*6#8=L$IJ*
M)8T[C'%^;(M=%[!R"BS<KMIS3;3=SMKA+($U!60Y+10X=T5;=>:?*=,Z&6Y*
M73\5O'XE;P0;WD#R#)@"-FV"'_KQC*( /HE;3J%V\#)*IBPC;70874.[>3@"
M%ZLZ;%B9[8VQ<KT1BVN,YIT3P@_@-H"RBXTQL*(?>V(<77!UMF<Y!@$.X<$R
MQ[& K6&JV!P-8OBO),4@<SRK2=;]-JM 6U:-)Z-H"';N51$/L22'3@5U;VP%
ME'MKIY]Q^E[FUS(^/NW +Y '3GS,48^]/K4RS\CE3'2)+5FXRBI DWH,!Y+Y
MA'M=:0#X[=8V?T)W++&?*ZT7,OW:G1[/_!PV VEBF/E7F)=\_(XIH[RM3!V"
M<#LN<JSWSR]!X:.NXC-.Y\8-IS2CH^$[>MZV0JH+@LN>EGLUE1(-Y[C!YS\^
MO^N=77P7*WVKM?MUA2_M&RM?+HZ?%K&L-H$+#@"+'!"*O886]"-'GROH0WQ%
M3/9?I_8LX0I:/LO?6U-:J+5WT#N]:)[OU];FE8\>=,Z-\;#T81--]@>M;&T(
M9*[!\D-1PLJU8$3LI"<@-0-;+P*;X*F/U:-% I, D6,]@YQ[!?^;<]<RMRI-
MU!DA9&^MM$@_'OC-08")7M(M5:<ZPEV%*3N%066G;@U[HAUM>&]Z'S[T#AKN
MUAZZKZPF)O6+.$9V*#PXC<+:]*[:NUOMLX:XS((:+<5N@J566O3BB@KAD;#P
MNARLVBDP+C1!F0BSPDFX?=7JIB"[*TA;$WU.Z$"%Z\>PV:>9XNP>'(3ZVWV"
MN^B]146S!RJ1QIDC2&D#-:=1I?5=T8C2<Z#6M:N1"5!1%J9R@J[(Q2(.IAEL
ML!!"PSBI?72$FU_DQ8#!1:92WI7*P"VOQV\EMQ3V@G2AQA=693F;J3'!%[;V
M>NB!&Q G%"'HUL8YU=1?P:T+(HU/1GHJ6 7PY-^PM5.66+3A+T1#OZ??[#V>
MRB(7]C-?ZFW&2"5!56Q2O>**%UE:'-X%A)4$TQ#$=FX',\XSZYM=H+W-9Z"/
M#<FS"8D7YNC=VV;[K&5>0&A'H;1*L?Y>UZM7!UQ_>'KXYY\K@-8'U8U/%3 (
M@6IH3K/^]7KC-CA6T*XSD'>>FAE+HD'N1T(?:W#,',B#" 5HZXH83Q-]#3 H
MIVC6&R0-BQ4%%G8^0IN4?D_1PTHP#WET@Q4._ E#G!'HS@2K,N@\T$6!K)P2
M908#AHYPW!T##%TX<&Q!FES!&[&(H62$E+K5H4ZN*59'4$.M^9'%7VD04,HP
M74B_W"N#?0-4C^!1WG'#A9XS(U>\!/HQUTT=&EV&7[/@IE9O5*NJLNJEED6N
M+-SH,'IB/!%--[(T?(5D4BRIA*%TXO>6!)=1TI0+OQXN64AEP0UCBM<_8%E#
M&UDG:&[P8E(@T52$<+8^U\1CX\EQ&BLPPU7)MUEF:N1BRZB#F!#T^R.>7>[$
M)0G.:ZJ BDMYZXU;,]M+2?%W3XCWUD[.+H[8A7'K8_17G.JFR.5!+HZP>U#@
M3V  ]SL<F?!(@=LFJIBB(4A<K+Y-\UK_I-?'D=A+&"6F!>YP E3B[1]TZ5.R
MZV#!=<X,.E]K?ZD$RZB-<EOAG.C/9AX&# ?(BC;_*LINS(@I]XNNN*@Z7S$#
MZZ4M^62-HQ;[H6Y_.$=96-W4?]@_KE.T[CK]JO/6L63ON@J2'0PRK!#OD>EC
M?G'5U33<I99@2[$>*4V&3:F&>-"YE!;V0MCC/26"-&9?9<U\<W1IJYI\O1B2
M4SIEZB=$;GA\/VTUO _3L.752"AYY"9CB-15P?R>S2E<26T>H0SKF$"L-ZH*
MAJI I^I7L0HG#]-[37343>F$S3(O6)1?6N5U\RRA&H9J5#",>2TXM*[*O#.C
M?B'4>4\F<'+TWML_ZQWT7LCR[EHZM5>I_<?F'ND$\6;P0IR!VD2W%*GCP*GR
MZ9G+9[K-X^88+Z")])NJZZ,$-F%:L'.P%X,8&K)(.DHHLQU=L <2QA>ON?<9
M+B3ZG,TT]HE)>&N?S_9!><$,4)+5M>^0-N1K<'+PVU7"C),PL[U*F'F\W5:)
MWX^USP (UX2$*OS?$2Z.FZQLTI-JBH-L[#2W.IL?SND&H:YZHZ+**G^"*C^(
M33^":T*%O]3, /[7V$_ECGML'EYCKDV23KFKLFF2P.D1&NP+W1R<.D$WGV9$
M:>"291HE.&MO>V//B"K\>=/19&MDE\ZD<+76QHTJ^\TI$T[23Z>ASZ,T*6E+
M1[UEQ!^TI )MOW=Z=G2^+.*LVMQC7I\L*Y)&/J%$R6PC]=[1P3D"@W"I$%*5
MD3W8R2$M,$MZD(%NZ:W)#E)>!@8\J2ON5&?0-&ZEY(6$K-/IYFWW&;VUL[7]
MN?/AG.!>X/HV$S5D<4WQ OC X,1>IV.JN2_-O#[_[2'7W,ZE>MEE;[R-=N?-
MPAO_M1?>?7V<"D9 7=&4RS!O9!#E])Z:77GPAMPXI[ML'FU6J_38C;X)FAJU
M>HAL^!1TH9^0Y7'.GT_50D3<-;=#9E%U5UP[F%.#"&F3CY$3S]@GMW@!VC<O
M?FUT]]WPZKLPI[U'EO7W9+.@-(/-2<O^B#!<'$@7Z*&R3R%_(;SXOOTRX7;K
MYB*-DA&!FW*.%#JS]L1+V80[9I9N;-?(HF2^W65C#D,AYXVI>#EH,\7WH";P
MXLF(T5&*:=J4[$QJM<+TQ:4#G-? L$BFGQLAL/J)'X(\."VRO/ -3JQ;B$0O
MQ*)<T&&'OKB^)P7P#+S5Z)_'CD=8%:2=)"%3O&#GTIER"E&1M[S?'>Z![I,)
M?)-@YF(^ IXZ,ZOW/3@6E4^1J^O/BPGP!TSOT*O3*1$T+&5SR-A4Y#E,Q3MB
M9@MZK40#E1^,]$3!: L;)8CB= :6(W4/2&C]1F.O@*%I;#T](8Z"N">&%;""
MDH$EB5$L>=:3*#/1//PD]G.=7!YE!)QL O>8E4:->Q)L<3A54AO9[G"7NUS@
M#MTL0MH/0@<T]=$\8LY#TE=]!9J![C,IXJ'<<.B49T$=C3(_5$A&WD?,K%'&
MZO]T?GKQT5C]G(4J ,PP<=F7AJP1!B5[79J\X>[(@H$P.QN;FW;B)/)C/^$R
M6]E!@G,VBRFW3**WLI5E7\R$(8XW>^=$*IKL3B8$TWQ.V9H#KG\NT0"EV46!
M=^C<OB.3%0W[80KEJN%W((J,<X1*07A=S4 ND0@+EOQ HR;KXO7I*-5)OKB<
M.!I0CK.)PJ_!19Z,9K'_)<K7;<LXSVV09_LRV5AX:66U*VHX&-,HK7GO846?
MC]ZL>FH\$(Y=4XM;0[.H@R?E#VBB([>P9G\Z8:SWQN,4S(8W5G["](*<8RK=
M.G6'2LK%0+8,/,*B@GN8!([*F"GP!$(X5=\GQ+'L9TLH9;1]WK^RE[J#WE-N
MH11790I8)C9HE/H;+%I"L01BY)H^94\OU?&+J2HFXHRXOJA/EKVS'!-M)N-.
M%P:G7>,:-*@$=-R/Q3CW@TM"J,#.-SGPSGYAPE!N16I)E@\P3#*R]\D%S[JN
MZ"F+50VP<EG'>"GNIWO4R$MK^8J#YB&:L%LF[\IM>HX4#/TP'B#<":*7"?E$
M1%6FX[].73YI..'/H#0H--H%JAWF&TVP(1)\X);XN: ]]0JNJ]NZZS-:KD3@
M",<0U)UIS)IV+:$@;6@AP'HHR LF;90I688Y(?C;:[Q'Y=KIL.5]=!,IMAJZ
M220^;SP=16YD" HF&'2LJW-8E]+;(LE@%O,#UVU.*F2M#7OH!I<,MV\TZ*M(
M'#R2+J=?@4X S/PV@$<:E&63I[H4%^).>BEW':&,#R#9>OV4"I"BI%Y'=>G5
M43N,=GR4Z%[(>/BF\<B%^YBC"5)^D SM0&<>QA%CGIGW5S0*[VV:Y5.5OE1Y
M^*0:Q0"4_"+3ZG>9)-!$FF)XB&5,#5:W[ND2I(B(0_S#]KXPO@#F9"6_A,.D
M&C;EXD9NS)'D3-5*5]B( FO">2G.0+6T?@^R-LZ 6\0[[0BQ7U>25PUXN9?H
MPX<5&].-58B<? 7(T.A%)&/4MV#9S/XTVUX*!E>N9VC7IO@8B:]IJGHZ-SB_
MR.$UY^]"5X'/&#=Y,49K%TNC%J#A1R"X(BY_O8EP+.6:F39JM+]%I"5J)49F
M_#@EK)W;7U1S01PMMEY'7:1_UA(U^6GRJ?1E%KH<11.-<F (G/YAUJ7R$GR#
MZT_D)QSEUL5*H3OD;D[&,&\P0$I><9?\42SIS/Z&OCF#2!)W<]#R,4WR[X+,
MV;Z:7J,GRVRNGK35*O3&6&K2'J6<^&-"G;/%2>GP4):'1NSZN=,SHXU^7;*_
M@0['C"X&5X!:<&? IJZQ45:1<(<QT6PP;RJE2@:X^RJB=6,*"]4E^T&09B&5
M\9G8)#Z8S\U^:=,L4ZQ37;I 0 D4M%O'!JOVSJ($1]R?1A48R=@WY_L5GB@U
MZGCU,-.$QCCV+T%Q;U#)9SI4B/;!/J6UT2S,TB\S^5AEZ'@/?/@3Z';=<622
M@(/+KP2K*;]D;#!%-ZT?82DB0BI0X!D^'B:^7@ .V??[S+:P@0VR0)M$* $$
M0:8V(^(#PF<F?CY=;'91J%8[M%U=IF$1TQHBE6?-/MQ49)I&!IE;9R&!B[[Y
M%MW0XD?%O,X8<9^  1'<L,(KS S-;9*([5F:H_2Z89SO9$)J3SKP.:;X!=+
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M*KZW:J!NSC=<USP(.4 4FM?7Y"+ P_^]U=K '(08KPWEUZHO*K!)+C2$G[A
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M?RHB9UT0OW+>HC-N&!6(D:;,C$K;;X,+Y).'9Y"P3"\S1PJ@SL4)5V%A^MR
MCICEIF#8G9Z<(##]2S69EB= O2[2J>?@HZ=E.PTO&CZ&9<JZY4<094$QSJF?
M'2N4- .?WV_(@T\U181.4T87(=64RH)J]@AG0TA1,H9UC! J(:<O"_J.LR\Z
M+,C"78=R=?$/S=.6!\GL+8'R(1K-@M2LDM^[-OV3^^C2C\70=?S6SO6TITLP
MDTDB]BQ[X@L$[W:NWX'*)Y'D;!;F5,N411<!5TJ9TWF5M=460#48M(5C([HL
MK$AT(SV"E""=7N@!(V6('&?)U,0%Q@3\,N^:PNVPGO0^ZD^6DALX-FDLG$'G
M;)"T(T9IA=:+<I-HZ;0;@D-I](67H@?<"C&!]AL9.*;L;,ZJT2=+2;S^F(/C
M<Q)L7CTT',D=#[<:+STI>M)W<6BC7JS8TVD$(P0\2X;ZNI7\-Y)N3*X:.DPS
M^[*_QD>[M,^ &6&$'A6N[M4VK0_:LL02256^Z[D^D>-\,=H^.J]( GTKPNRV
M=I[6@Y&Y:W7Y'Y@7&/(B?IQ'&&LV1B[AQ^1(D7F>!@SN:&*YFD)+]@H6B6OE
MQ-'P@!@NM=X1EBI#<"2-#6S!-<R<YEYL(]B8M5P*U**N8L[-Q-ZQ%$5[Y8U\
MX!='V5RM9SGEQ!8?N68:L%^<):>X]!7<JX&YPD9#,K7_^AJRW#0+PRDM/!)X
M0XYR)6YHB)I<9H=(',!D&AY,DJ,1<D!H>@,?GY;BZFB[!9$P^]^)!V!;+ZX5
MO(T<3%""+6D"(IA)*R]08S-$-CI%_Y!V/)32V/$%TZPPJ0CI323H'!L5%5L*
M'*1!(<E$-2G?IX?O$,+YF7.98Y>F'HZP7.(G[7:K\YPL7KG"2R+&PY2$*JF"
ME'QPG50X@[E^AK4XV3PN)]"=56X1[J1-L>8]<>*,DD]44@^LYQ"D.=5OEI7\
M2G94OX@O#=:YXP];?&E^Q##BW@\91GQ6EXY)6CMRJ_E_8M-IN[TJJ+.AGXCH
MR[T>&)'>FRC%D#O[\(^2H.6MX>?K@L,]9436([B ?N)['S[L>VOZTW51TZD"
MU0A@D#?N7=+JN'/70+%P*ITK5X^=NR0XX;WOTC3T2H(!9"F*002]6@O>'9^N
M,\*8!J6H9-L6Z#RURY!A,=K*[\[++]>8)-B_0MSA/*";]U-G<M!6WF/TVA$U
M#+EX!TGQ<IB<I%YPZE@EL1/M3G\:C% !(L ><2H;""7M8-<!,8+@C<:H]F$
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MQ>665#WFIB1+$?_17JZ"\/%O4#PI9:Y4].ZX"&]5AUTH_DHD6"?+4P@^8=W
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M\%%#GV.897[HQL&D_>V#..-<V?0\EZN6*]O*2UTUO&)RSYFVWE+Z;@2:TZ]
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M3U\L.!RF'?,ABZ@4YY!Y<$./'U?ZG(PT+%!^ ]PGF ^>#%&(5;SU;T]1^R\
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M/#S.X^,3QWG\]AS6KZGMJU,C\(*W]*_GGG]8<5:PM!2O$-T/927^BNJC@D4
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M$;$948=H\PB7+^J.1\Q6;3&VU[)<'/@&W8\37'CLR,%' 109(59=A?7HGM;
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MS@$P<J9] D:06>LHW2>V+^R9K0J,43/C$\3#5:EN%.!B]UAXZ?KB<=6F<"A
MFRJ (;5UCBBN'_D:HV8\3AO,HTJR^SP=@4[L\:PU_!ADA%#1/,XEYRSB<-G
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M[2@@39HXSPW*[WF:"=KB?.^-)1^\D7:9.CJ+B9VD:5^)_L!IY#<W2F8M/7F
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M#03]2Q2!@@?[@A+.+3[P]$MK^@O.:4$-CN%I0NP25E%1(=4!X@SF0;9V/NY
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M(LKG1<*KA%39Q>*G+:7[M(TY7S=[]"O[RUC#FT>IR/AKOC--=:9H:EJ#KJG
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MN]A9DP6$E_][I'.!'_VN"?O<+<5^YXGIY(L1IM@QG'3_D9S(\,C]YO>FNK\
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M%&)OT)>&T@!2=^;N):7?W ZP"+M)/]9EW,^SN40FVI WZ+NT*B,^!$_R;NW
M-DG!*Y#[9#NOXBN^R5LU:HH2IPUW_*IJ?&VNM[/Y %=K%@Z_%9:=/L#8SW#,
M&RQ4BQ0.BK+K5.(1S:>28:OYQ/T[)8DYY<FV_+2<;4X/AK\:F&GPYG(2SQYV
MMT#91M^!#"BA!")3']$8Z 9QY3_&AWSZAC@E)XY)_6S82-H%<+Z+?R!01?X3
M81BO,KT/DBYR^I9K& @=!$1M$ 2L';BRX4=TRJ(*%7?<-P:OL46J!X+%>CPT
M@?<B+SKF[A$OQ]EI%A;E7X?_]G^ZAUR-<IUGZ252\Q.9'ZBQ$;7A3>(!_ZR
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M@;V:">T'I>B-4.HTM_D FU(Y]4#5_$RA5_1:S0HPBKM"&2J:$%LL@S^?4*+
M-CW3!U37;TOZ28ZF$]O77B.15MC>#.B-%5R093#7+9VVEM]BQB!6!@%&71\L
MQP3Y:4PL1,!B2PF8NNXV^]BZF1,-@GTQ:G#"(5XUFR6Z52@W)"A,YGT,FDM)
MXR&G-L\XN?*8VY3##$T-L%I0#E,)=VBCM<;II ?!VXH;I80/E1QXV])3,_S(
MW-D)U2Z>< IH@?G+O;],KX6 ,1WBW[.4>#T?J8V5S-<IN*-84$OZ=H3<=LA
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MZR0Y'OR[[\)7*+U:NB?]?>:3Q)9Q6*@AA23N%Z5I[&S)P(EA<YJQUSA "XR
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M%\1Q#*4@PA#MQBRDLB $?XH],N,"%#C1GY#DV2[E(,,JGYB.BG[/=[>WNBZ
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MJ=^@@@;A\!NX)&4:[<EPAT.E1J-E2X"1W<=9@)M-2EJ!"^VL#<KDFR[S744
M;II\]>S<]+O5)*H3/(=%?55=P'N:O#OI'-^W5K,^[K4ZQP(E?9@%P(]NN1!;
M$=Z*\"U$N-,Z.>QN17@KPL]6A+NM;J^_[A+<NUF"?T 2UW!3UFQ#GF(-_O9C
MMO6(_K_G:5N[4#:=,+B3C5U9A(7^Z;+SU;"0S^04'?5:Q_LGMSQ*S7+SH'?P
MR]ZE7K_5.[SM#;3=I4?>I?V3UL'QX7KLTF:N<*_[-(?@&=[MSSEN)GB*.CK]
M(8)HMS&@G^&1Z1^V.B='=[.5U\C)WO!=(B!$[_5VF]9[F];I,&WF"L/_/LGR
M/L,;?HEITSL@L-%:W_9?J8!_6D-?/803?]/O)"@DN*H^K&*4E8C2HL#0RPS@
MWN?2K/<Y[)YT6YW^;?7./:[/$[OE#S3%[0&YU>JL^1GI[+=ZO=MFHN]WB3;S
MF&S/R$9<(L>'K>/.'8-_ZW*'K! T?# A7\,=O6.L\8EV<TT\F)^I4N%^2:<?
MO29DD6_B,&L.YL&KXT.'CK"ID(VYRYC**$Z8B%4*L/PJ,JR&JI)S+(R"8FD*
MDR'<4%KFUH$1D4.Q+'O*#9RI( SF(HP?<RHBA1=>J^ ZR[]1\S-J&J29()ER
M3UC9OG[Y*G^OO=M;S2HZ\H8)T\A&"?PW-5VSPYMBLX6H"+@AM9!$I$0E(85L
M\K1;L),\KVJR+US75T@+\C/;._T*9,*0LSQIB964>05FK$SB./3&:HED;JJ_
M6FDGMP58VP*L;0'6M@!K6X!U&_]ZO4M+'K$&ZSFNS6.583V[M;FW2JQG-_,?
M*L9:,E-M&#_*5$]N)F&ER?XQ!5\JG05@."/O&A&QM;Q_F0ZHU+!&\W=9VG9N
MK00_0D,5[#CR*J2=DO,HMU>C87L+)T@E]Z]0/S92(Y6C%U/*L/!+&1+H>D/Z
MY0D.[1/<+^OYRML_YYYP6!P!Z[5[ZYZE=1M</F+-S";'Q)NFN-YAOGZGU7DB
M7,96Z%ZJT/4.MD*W%;I'GML:R=QFXOMZ6WC?C\/[5C0<'R >MN+4S\;E91AO
MR_$>Y]+;%GH]"[3^=IM>\&':S!6^/5I_6X_W#*]S(A7>UM[= 5B^/N[$=I>>
M@<^WW:2%1VE_?79I,U>X=[QUS5^ :RY-#[:^^>U5T!JY$]M=6GB;W\7FVN[2
M(^_2SC[=Y[M/O4,;NKI'!X^]LL_P%G_.'OG7\)N*PJU+?H>(U?KX$=M=VM+A
M/.MM6J?#M*DKO'7*7X!3_F<<_[GUR+=YV,W<IOUMX.09[-(.;]/6)7^8U>T^
M_M*N_26N2ZS3+%7+#^OVF_XWMPN[7=CG]<WMPFX7]GE]\SX#ROW.^I?Z792#
M&?(>;3L5;GMDW7[6)S^ =5L/EM2M"+]P$>[V?P!DMI7AK0ROP:QW^K>,XFS[
M%#[TCO0.UV<WUCXDM&HL;*U5SULFLF2:%QBT9K=4239%*ID@9R+$IT[Y_!AU
M^_I)VDGKL'O;MJ"W78IGE(38M.WMMKIW;:_W8]N[5,%L=_>>Z+9;^[V#9W!X
M7^#6''5_K#G*@VS,,S1EE@0(GT_'IGPU$N<GC"(V,^^_+"]VQ358[^/6[1S?
MP:*[RT(\C[C,5K W1;#[!W>P9;>"O17L-1?LG=YAZ^ VU4=/)=.K1R%_0#;7
M<7_N'!I^L+U9$T-^$QH728,5[BGD$5]'RFU<U#]H=ZJ-BUJUSD7UQD5(G3V+
M)QC2S$;X %7,LA0?GX/UG^*SI=].$ [!(8AGL2K:@3>LTF?I+GZ$IGLI(7>=
M:YO^W$3M'5QA(R0:'G<4PLG*?YG60MA-Z-WOOYW^_C_O7*\'/I&YSOV>1ZI0
MUEF2KD]QR@NY4B\CMWT10=V/7@?A($[@3?B,B5(S''B<E44P!&' PT53S-5E
MF82S#.;D[%$!7X>%G8WQG44Y'+LM=VC!X'W.\[/!#)8U2$$T%SEYF]I4Z2PK
MJ*_6!?:J6HO627I$W#T+1*F("]@V>T+ALSR\AI,P@S>%"1R.V3C.HST4(!"#
M,"U'(*9ECF=W" ^#+XRPJQ9N_ ADIQB;/^<T OU//%DYGCKZ=\"=O]RG9:#8
MQRJ,@K HLF$, XB"ZQC$#$^PM/"2,WS+-F?PJ=LD['$VHM9(@3;"2OI3B('>
M?;^'&K7)>M7MG[3[2[O0O3KNMO<KW^BV@Z]C9?K9X<-?'1RU3]RO#9O?&A:D
M;^VM$*;V.:A:Z&MQ6MWMUH)6=N'-C>P:&RS$*6IR5'+%3$WWRFE- *=E/ASC
MJ,+A$ R;&4JKOEJ:VN5MIC([K:W;+$POX\&ZJ+8EXZ/+%&]O%+I7^_UVU\@G
M[B-*.LMQ73;JSX@+UXQQI0M^H,4!Q/9C.!>#"/YQ/8[AHKR6[Z/HVD>CO($9
MPNT-L0FBC )O;]")^)HX#\I"C<H$[) K,(462I@L31_%:YKQN'[)54(W[FO=
ML8NZ>3F_$IN\8W\2#HHL*6>+?U)K5_-$INI!UU\+]W_'N1[--+Q4>P-0+=_V
MPA$,]I<PN0[GQ4\_^\<3SJ8\?)^;Q2R:_0\<Y/_PVWDYP]T41?$%+-8P1[LP
MQ49F!J[PI%KB*2]]T5!/.G]O4UP,B:@U8PRB%@/9<FRU%E[%8!V*XS-0J1K%
M8E>%29(-C;H$8P[-_MCSG(Q=9]Y$^HAMBEP/R[,%L=>M6N2*6(_0?=!"K\KZ
M).ZLI_!#4/V3]@H+P_;1X6'[<+EY!-[PT0KF4;_CFD=%W3N&L:4IW1"@ZF?L
M5\'C].QHV7U3"8<!8^5]T/>4LSAX467I9<9&^V00X^,3]'YSZL8+*S%4*]I0
M&VK=7"C8$)2\7T&\<Y&ZTVB"+LV,'=:M_GK"^9O]N73V)_3V)]BY^/7?PLGT
M]>EN7:MY'JZGS_0Y8;\4[<&IRHL,CF""9TM]5\,2'P]JD,?0].I1F0Y%VZ#"
M0(<83W8V4D7!P283D$K4I1Z^<2=:X* 6,.FB<%40A=(F*@=?) DR&)4HM**<
M3L%"Y+$V=> 6S1Q3( O6'JP?4FFVW39.PWT,ZD=?;;8#O9I53=@% _I@N2H\
MZ-1\R295>-)O]_376F2<UY1AACV309*,*OH\#O-)Z-G=-J+P$'IQ0Q7>.1KM
M<+\$[WA=7KIV>]+ C-D,SU'M'OJ!E/HY.ZH=Q,9CYH1MZH>L<F;BZE JYX4&
M 5^9!$D&,V[1'W-UE257=(Q@:/%,6X(<FI.?'0=G64K9&W1Z?\]FRQS99WZV
M8)=4\#7\_N"QD84C:Q;V=3AI3ZII9&MFX?=*4.BP?;STK,7VA^(!T=GJ'NS;
M.VS!&:1357NM'T<"?R?+(\F(X6T\BG,XA'-L"4Z!J/KO4_KAL,QSO-OIF]?@
M<,$K]6=PT.%NIT]T/@J_0#,.TZ8I>2-*M ;!?UZ%22EI*O#YKM&T6/7T/L&Y
M;!; ,]K/N&!O%=NM%PW]UCEIB8H+_J/S3#344JE_#U(0Q<6P)&/4U>A#ZN9,
M C.*,?$9D]>?1C9>SK* 7F%!LFGM4#0<1_!8^ G)&*V;>V8J'W9:\* 11C2S
MX',(EN?Y>; 7G,_4)#AJ!Q^-G2I)RB)X:\=,[AC8T7.PYG$8[\UHS[S1?K$C
M_61'"I*>E!'YU#0?$H1T;EYTFJ8E/.J+(H,8'@4K-@FZG;W_-(%^=R[*DQF&
M7VG!:>E8+YRQ49RX2:R+=V?T;#7(2[#7^7<8(*8 ]),?IJ5'YT,,]G:D;_2S
M<(J'#E<;=-70WG+/^91\HCP3B$H\A:G)Q%"0$CMW4)ZHG-5W</W(W F+<8O^
M-U#P)5"2)@T>7H5Q@EB0/1"A/<QFB>^%?P-?$A2WX!I.Z2V-X@3"<:V"<1@M
M>U/C8SG6=-BSUQK!"@8JB<'#Y&0#>7UR?]SZ^=>8]AW G\K1*![&^ P\\J5$
MVRIZ MZ&UPD!&H(4MCR8@9L, YG OHP+#_+0_!1VT^!9UV$NA\K;!E12O&<M
M&/4LQFU$+6>P$X3+\'>O'BBD)]'B7.-^S8,\C M<KCPK+\<:8P%N/[B50W&4
M_W*_*0_@KX..00]6WZ&C#*].F@:K+_BO*P7J(E'%+\%.O,M[OPPJ\1J^IK\'
MZP7#H*'#"L,\8_X'+&#3%*_$EL?OC.,I/TH_"P3_"G$D9F#T\95\RI%<E LX
M!'B9J,',_^K5+NZDFL7_H@@)9;1>XXK^#%_?N=*O(:ND',!U#6L"5X$8/,YI
MV 1-P@+1TK<-"TTKB!!9(8 <LT'X:UP"=IQ:O"PDB@6%D2Q<B9>_Q8OO'$3\
M+IP)$,D9[;U-5Z<<[4*,COU^*U Q;2>L5'P51W#Q);2I,-HRC?D96I99S9L_
MX+F4\VS'A9$2/H3T[9;Y&9NJ\#V8/681QJ@^<Z7'A^?41G%(ABD418/383ZP
MBJ<HO2@V\%\%ZDM4U!J@HH\^955UK)PN^\J)0]A4C@D&";Y)<@)$\5("7K>2
MO/5T/#]DZ>4>.><H))MPE'"O$V]6%K6$I\:)**044> \_B4HS$N2&G.AAQ,,
MMFKWJO9#],=>=5L'_6,;4VGQ-?.JZP8\APEHMW@4*T0J@5"CQ8B#:P?O^7(P
M$10#"ZP"2IH'0*Q)X(D>VZB/'H +S8&GTE6,G\"1[?;T%;H)\HL>Y^V,R740
MTK_01(/KE1UF4L67HHPJ*<H,;24E>0=)/%:RID.0"@1,AN4LT]5Q:9;N#='E
M)H-26T5X>]""K61"FO&)6+JZCXS%_2.+YM6"=^1$1399\+XN!#DZJ[0)^E2+
MJKX.K7_:M  JMR!J3!=Q^LP%4S+\\V>!?L*'O\%TP+ZG@!9F5$+,8_%ENS!7
M50?TM8,_2/ 9_FS-7Y)E-B,$1^4://KH_+-$!X!.E KAA)'3'O%^$O8<U'6A
MC7(7AGSF& GN\:!,FS9;\(>7&4*LX:^P#8@[M5:' X8V@"Z54B:)3@_.EU*
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M=;';"2Z/+9 KU"3>"XE[(9G3N8&-05(.AR4AZ!Z 8#'_ Q])^@.R5)K2CI"
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M:(A$JAC"MRQ)D@EF3M0$'IE&Y<1$*ILU (QP?Q>/VS4=T82G8+<"K@XU(=W
M)NO.P2[?W7../&$,JB;WCB' JC5 SM2$5PU+![U*&UD<'3E"V%R))$SNFKNB
M/5 P,.:*\%3Z364N2R+K^FYU*OPWX#;X8TI,JS;"?ZV8 @@M.LZ)Z4)A-9LE
M2B/)G<.)]HA\!Y34)"XGI)O!=@?/$R_H^D,1VHPM#_)%84L,&PEWJZ$AI]&$
M.G!8^TTK$.HCW19*9Q;9;J^>Q.4BCU9>]ZA]?- ]6C1$1U/%::.R6F3T62(F
MLG[J-T\VJGH^!X?M3F^Y'N+I5J<9(Z_PX!]"P!1&*'ZTA]B*!<MO1)]@!0AM
M$8KX0,DW%6\MGN1P.,Q++DLN4ZD\8WO_>>4[FZ,?G7;O8$GTXV@3W+=S;%Z"
MS!0F++\@^''<.;AU\*.^@$W!CZ-J\*,A;K%B\..AXQW-@[MK?*/7:7=7B&]@
MCO+>XAN=]OXVOG&'^$93+&WE^ :?L&[!K.P7:CICMZ4K+3B6!S?H%!D_M6D@
MJP4W2),_>H2C\;S8H3Q"F$.3%SY^J,,N^V#-HAU-4K0HVB'22];PT4:<Z:71
MCL8#M@[1CK^7*<83-/7L-M*Q(-(QBIGSZ%;!CMJ/%L8[5OCF-N3Q_$,>#6K@
M04(>CC5 )_MPI9#'#\0Z\ 9@K:9O)B=XT1($!HF)8;*%OV4U!==:,+<M1,-
M-/:W$(W'6^V'/U/V#KIK"'&1\?Y (<0G-;*V0<3F_<8@8J]]<G!T^$-!Q$:_
MZ@Y!Q*.C=O?H/H.(ST5X;PV%6AH,W'\FL[XEE'EQ/'#_L./7 -V$@UHE%+@?
M[-@P8$,X[W81N^9GK!:MJX.1>AY?63U.M[]_9 N9&D)T];B<%Y9S?KJ-R*T2
MD6N*]JX<D2-?6@?D#(R@&H]K@74,JY*Z#CA?Z9W6(B"2&ZMK&N(ZQ^H:3\LV
M5O<0L3KR0%>/US5)TJ)XG15G$M7]C3CT2T-VC>?LCB$[MMSO,VY'\5//(>C<
M,GJWX<$[;\FW$;SG'<'CS5R;,%Z#:J PGG!=WB:6QS^Y,:"'5@)_5?3O0P?T
M5HH\+#)%W-8D&I?K=ST)S1VE;[?Y)EPHX.O\/4P);&:@#[#]/.V9%+4%4G>G
M3TN<8_=;"CV88 "QL5$$0Y<!RUFW-1'-A=0V['!3D(/( Y=%-9H]].7'P!@[
M^]WV2:]S_$/1B$;+\0[1B%Z_?7QPK]&(Q?'HYR6L"U$Z82#]W&#]4G4)(BR6
M?K50G]S8/A:E^S">IBU=(C:.A]ZE/[D%W1JG(Y+G?O5<!G1F!F2]^?.%<)NF
MW]$"$-JL(CW]HTZ[5\,H<5B0KVDA-RXJ44:-8].^HRAU*:KV7G+2[AS[K[#G
MIG:A&MIV&V: .RXMXJ%X)X;!6ZY80SI?E6^Y9-@<P'):?JEN[HM+9.@%[&_I
M<@BEI:NSKPM7E5L3*V2)Z/KAG09Y,DV5>6G]UJO<>D#:#N_(5XWK@XU<\0\T
M %LN?&&+A#.OJ:M695XCR66]67LZ1KMPU ZE/MF<89S[+J.WDR(+I1_4QHFB
M/6Z39;4?T5U1Z@8W<#!B4#K89\_M2]-\U#;"<5M:7GD[W75T5 &O_8#JZJVN
MNGIW5%U-OUNHNF!NAP^LN;KM@^ZSUUP+%]717.VCVDK>5GME2[671W%0>#J+
M?[)5/FNC?!PCOT^"HL\&6?M#:R5;CV^934M10K=]\23\)HV 3:^]4:6+)!)#
M,TEMY3VQ8];UM]P6%CAQ\"*!$^N<_OP"?F]RA9?!&34OIH- [!<?,AC?>]O7
M<N=C2*>MM[LA&D3/I[6H*@"C.K'MEM= O4F*ATX47]7D#<LZ^JV7WF"B!4N,
M)S#>8=@*?F^?MBGR=1IAYZ=B)NV]3R^I%<\%A;$_8&/I#XH4O;!\?OCY+#A'
M59>W3 Q/DA3T/4Y;V&\5 7? PZ\H&.!.U0B2?3_5X]T%!Q^Y[202KN<C'4[G
M]0>(C,Q-\)120<*0QR;^3KR+[%A]AQTK-X*W[ 4U\:R]C()X,3^_YSR?>@TG
M*,.-#R81KSZ,KW>?FPZ)['KVL;K_-SYJX>#,QG@C\E[)71*)^!(V!5L H='L
MMT5L%+A<,?>2^5CGB4V"CC+#W))SCMECE@C#*KM V)V7F.Q473C((@QCRF8&
MIG<]O"7D]NAL=(68ABE@=BTW>&.#Q"D7M104 3/4@#2*I6 #8ROJ56Q9(D8R
M%9%;D2<(GDALFZ21J93,8^JWJ9FKAMF52JGA.LP /98L(,(J-(%CMSE#S30T
MJ6A\1 [754#^K!M3MU]&-$.BO._9-R-C(;QT-M9A[\95=S;$R@]&^2AB3#%[
M@^\0(#E"XRBC((WBE\NKF$J^A%*V><:^.),@8D04P^F4D5S0BZYY IMP97RM
MK9"TZ"ITU@N3RB;@#ZY I>N;44ET"'4:CQ-C.;IX7/&,L?TXCR2"7*)PS G?
M8-.;%&J1VRDV8 7=;8WR^;A9L%J=O[6" V11:05'^"]Z:K=#[$4ZHZ>A)PM.
MG!TV:A]L;,L)?)9*9U(8V"5LC'/H8=5!6C+J%FP7Q'!P&EWK))$HI4_)+5]_
MH"_+^ 2B#!2J>>\I=,EEHXT0MS=9GM-N%XZGY^N  =:6.1$"1C-R8IR!+.RJ
M&X% 8(O)/P2\&,$T*3%%'NZR!K:?D[!?""[C$VBPE%;?T@5_P8?O7'QZ_V4W
MV*F$,\( _^X6(5/)6[?SMUWJ&+@SP"M[0 RU^)A(H23!*A"G+MQRBK.+ @$9
MPZL5PWBP_H8.#3A<B+;A_GD&6<*/PTG!ZTC^L8X$?U"QP8A5FK_>HAH%HP)I
MY";50N$,4?B2K\7(2BKA2GY5%V?&%AD6$SC$1;+*3M+&V4%JAP%B;J(N'+!Q
MK@_"DC5<(BT^1%R*"XO$0#RY189"RVN75TYH*ORW7?VS7M//*HM OZ6(F"Y'
MI8[=X9S5CRR-3@P[))U6HU@)ME>W"_%E ]'V$B74&[$,D[[1JJA,RQG\^E_*
MZW'+Q[XT5C*9@T,0.SB$H'@2-9M)QR:Q-+5-!(N9#ME&TMDG=P %;X]>Z"ZO
M6*?=A_^8TKO2<K)DZ^J;MA&*J2'RZ[E <+S2B-;P]ZP==/4)KIF2KCEN?F/L
M>KR$]$V'#-SIG'/>O\)5"Z83$N_N$&Y@1#I#)+C)F<%[UOI#=9)<WT%JW=)5
M0SP86T7#< JR/9M[&).FGWB^2T$7.JZR.' W/+#F&.JGL?*AV<J#*O,2VQQ7
MNFC>$19;;C!+WO$^YUR\K:K^RL[FI@WC?S?[N_A);6IZ\ZP#C%]S?%L^M49X
M6C*&3$Q>O#Q;QL'@2:.D:W6RV <E(4%_U8\X(S7QP=%!I=)>FT'%S<^EW#>.
M[CI&LN.4^^9&;0Q)"AS#)3^ ?^9S/E4S?Z+.,I.E&4?Z!]3!QU'"#8XP4SMS
MN@*[93O?YGO"JNO%4['?J;LKFZ#F5L#?+%X<!'3! N7A-<A'L*V=LR'@PPT/
M 7?W'T%B%_2HPHXEV!CO=$A5 2B8[Z2I^$90\J.BQ9*'LBALWZ,PF6.X1I*=
M;GA'PDRB[C#AR%^S\ -4QXOMMR:2<WV-$DA[H%3*?BT;/[6 R!_MB[:N"DB(
M5@DK&"F[JS=(;.1$&JG3+WX]/?VL8Y'X<%/0MM(0;5BB+$PF2S>79\/W'V5T
MZ33A"]TLEH!+=3 ATQUO6BX*OJ6[0U6"B[S4W' $=RK)BE)CG6F^:&8(9I_:
MHMI'4FD-/#4&6:&B/#-BVD+X7RY6IN@<?7F@NR1X7QV#;9'E= YP6'E,;F3(
MW=.O0O#?8%FD'2%8$9RRL]T(!RJ)U149AP,<3UAD:27=6BF7YF4SXL7R07V[
M\1,.)J+W!_N X[=K'P[@YA7'*\_)FZ)<L;/H]44ZY6R\?B'BYJ,8L;(FJ%*X
MN\VCYF_(VILI<V)>8K'M 'O9%W#NXQ$L'G[5$5(0N&$LT%(8=*)M;@);](R)
M[XKF>R.:#OK'S<63-XC+U.WL_2=OJ%[[L8OE;QH'[\Y0*SQYO[.T*)1V$0K[
MQKN<J)7<M@-?>9I;5AI*Z9L[A_W8HU:9TT+]HO_C-1R6:1+.?XE34GOTH]?R
M=+GN\064MH89RTOH??RQW'TG)^WC@SY>?[,<_E^D7RPW8YMNQI]G4?VS_@$X
MMH<+/P;_]XZ?'?1[=_KELL'VCMM'A\?/9+#];KO;7>VQ/].N\<Z!;*#4_?M/
M_9^L743=/'_I3;\'75_>L,%G53Q8,N[[LCZ^R1CI2&*9N@=^4</L,B4=8TZ1
MK,*2"79P>C^MRU=OV!4YU&3]3;'X#71)H!=XR9:QBGCD35L='T#;^%'-QEF$
M#5_G][M]F[QH?Y=[B*ZA/U));'AM];9K>,,:OF.;-!YIB^>+6#QOV=IYC];.
MJ;5FO)65 UOULFD]?V I[U?5/(M7WN^%!"]^?->1Q.D]&;M.@W(+T"FX:UG.
MT;-9PI ,Z1?(A6Q[["2:_*63E>1\OWDP@I?#? 8>W_]%X,88[5F=_<)4!M<A
M.<VQQ66Z+!-.D\+<P7#-4N,0T?7Y+V7:\5Z/P>F,J1@\P@E@<CX;D)%)/@Q[
M /8QIAY(1A-I%Y8;S@TXDZ\S6R;1'Z,5S2?/UOJ!^S&3.&-D*NK9923S7&HL
M"8NQI]"9P?R1I&@'4F5&WDUE93#<;8<L8.=1D"J$P8;YO"6)1,_=,_765^1?
M>TV4J1"I_3 6Q]H+N[:]XL+*3\2"<^UD6D6*C/B$=@MJ0H/AB)A:4L.&,*=T
MX8=.IEB;ZGC<% !A]ZKA=!0M:;<;(/@<T\J,6*(/*0]7IK"6#$=ZH=MX:LX\
M_M^\@*.HMT5"/,:K)2UEM(+)I'-TQS]KSBXC?$I=84 $&]+ZRJ1E&<+I_(L
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M!I+'J.\A$GG1M8OD,-+='EXK>S:7282%[H0M:==1_-UM66EZMPL9>N-  \S
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M:T[2X+P+TN4\S6Y&;A7?OS2L%K8U[X].V; B#K9*6W;8JW*@CINJ7&N!Q#H
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M6K=(OXW3F.%A<'L#<=M[1WRCQF\6;IM$TXW [:$(+//>:;SNNU1B>%*>P\G
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M1R+D@@K/]VCH$1;9#UU$(\,"R'HC<DNHNDE2=3O+TMYYLZBOJLMP>$9 ;:"
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M$2T#D6L!D>N/%XM$B^K[D_GV=Z_6 ,D#0#(3CDRJ6@HL9L$8XED_ZL?UW3H
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M!NC'G7?3=CO)<[T=YRK:K KBZ0!Q+D#KOG_/)X]OZ #T!XOX<O=&+3%*]6M
M5BHAN?BB'@'D%.Q8.;:Z='Y>1-,!H0L"@(7)/%=^SB+<':4=>?>:@834-/2'
MU1:J&_!JD_3#>QD@O]H$H#/Y+H>=:2L&*;( >ZU(S1)&+FB_9JE1@4E4)""^
M41,K4Z;C)&NK/S6WJ(?,L%LJIQ!(H]PK]2?\FV26)L*"ZOKD*=6K@[^ \-KB
MIF0$6!E,4DU87^$?VA*8Z9\DZ_9DL1UI?'>"T!JAUD.9%C.F5(RSGDZK""2
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MS(JKX=\6Y72!9<O.QP675O99L:K*2+/DM>)4M3 @F5[G_WI 7G&BUEE*M:)
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M:3^M4]#][]F.-_<N0M2KV]Q9D\DR4N?.,UH>$?NI^2<OD7XSK;G*UO:>!(X
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ME5D6I6&OW0\> W>I>:9Z/J7Y,<2[.M@WHY'3MVRJ*&#?J+EO9I,[,L:<%6R
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MQ(!XQ/%K[I34MZ<%PV=FDS5RS;QBUI]7E,FP_F)9?US9H9)Z 0U<)(@?(>[
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M-@[RF$J)F0R8D)R*4$B0@+;-'<^+8Y=ZQKI9+QS\,5EU4SC4B3R.!,<Q4I>
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MLJR0X9,\B@_ZYZ@\CMW<P-S\8.[WD"5R"O,Y^!5Y 8E(1$%EB1CB(**0SZA
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M& #G;@;US_9 '^V7-#<8.$\,O)FPA&)NVR0.8J3.#,PA@A$80#'"D<21AT6
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MQ&UYO?PKN,E1[W0\>C\HL7S_J3?J8NRG'N,:QVBU$8+N] />C' '[R88FTU
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MKM,*NQ0<LLJ)Y)(&DZ(%H7P$2PS+8E*@XEHSM*J#2VR-_]1/KBK^<\NM%_?
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MG@F,%&D-'H.F!LE3+GN4GJ\:G2+<?90XO/PJ*!7+3J/H6@X2LX%_N*C.=,=
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M;EX(T,*8'WB!4P2)P[/(+XI N)GC<6^'?^\?5WF_AG^31,!A%9[-O8#; ?9
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MN^HWO.J<.4',\MAUO"1PG8#Y</RYYT3,<9/<83O][Z%=]77]S_-9R@*;!0'
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M*V42!??IIG\/CI3]V<RJEU/1X 6 /_P]_65GG[DAKPO=P D"$64L#H/83=+
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M,33@KS/! <:4LW)Y">RH?]_@6A<,?V1M7<&/E_!NN\+>ED/&/X8[7Q>4O*Q
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M<")G-BM@NC^QV06[;)_\:WA;X*KH34QI$^_/^C?S@-_8K/X"^-HZ ;46N!R
M:P[T][+B>S?A":.XB&^ZE*-Z*?M#/ZLK,G70W7L!EZSB)9O)=H34ZMI2S>:M
M'YYI4?#CVFJW&QHZ<X-YD:3$#9S,]0NW<*("@*:;IGZ8NG'(62PRQTO86/@
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M&QZ%T>(="4!4OLD@H/7.P<&#WGJ)X;A*EQ]MW0P%<1=,BJM4VBV.US_;@O;
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MCV-^#,?X3NG;Q6I64+SET&ISE2V(SO:FUIH!_E1%5EI=7?I+%]<U[S-X>L/
M",)LN&ZDD)LQ%=2V3-&!(E#BC:LK5W/]*K +%B40R^2\@8\$]7^X$%+EKG(V
M0XXY;+(.2]-][-Z\>:7[V V0QT A4=H&R961R*%5-KU  S5P3O-38D>Z3"B:
M']$'+!>^N =8'Q,$E*!$7KNBLHK Q="!B.R:=(]!-#ZB1 V!:OV]#8?P&.[#
MR5HXO!3%>I7C>E Z><)(CB"OYK:<",E-=)ZV9#QF<@;9517O [I8FTTGW[ID
M/25O#>L :".RN18Y%5<RC%BFR\/G,RE2%;=LA [E0^1L:K-XY(TJZ#X(Z)<Q
M>/H3E\JH7<_(=;=/C+FSJ&XS!&)2P$;DH9V)5XC/B=3?"!#0*Q<JU1RM6]+&
M?:VF;.S6=5E]N\"DM<"D<!>8M M,NJ/ I&L#C48!0VX6^SQ.&7>=*(AXF,"+
M>1J[2>:RT"O8U@Z(UP4:K?4A"6,1"R_T0RQY&6#PE,.9!_]DW ^]AQ&89#+T
MH5BHBTVN S0_#MPD<_0EZM@70R<<1(H2=.K\)D8LMM&%HY,\,JR:M&HS!AS-
MEZ0+D.62YI KF[49M#-CBF2-=W75:%GM%V5K[Q0=(DPRD(*"CRKK* Q?RA-S
M6?T70!W>.]V;@/"57G',#I>I*0L8MZM=HEVUF.^##EO3X\1)N\\&1::Z+>F2
M'"AL2VI$JJ)#A9E^H\Z_-<@R,A9= %AKAZURM5:/,R!4K#!BW1LVKAV Z07T
M-9#(.PK<8"7UY+[P))K,J83,0L/NL1]8%K'NT^II[.[,0(#G&>-GH[CG<>*)
MX953#6G(&V 6LRRLET<'%/[TUZJ$M9*_L43PW:);#Z=)'?TVE8QJ5J?F,^@>
M7*[R2\!#.J1^T\IPW\JEWC7$0#*6JJ_5?-JPN9F*T(&VZO)ZX*:1T!H&E#=H
M"Z#3B)10G50"R&E-%'H=OM.17%3Y GC!THQYD^E:HS+BRE1J=]2E5IZ991Q&
MGM?QU:]RE<XC^RSVF:S25C,,(E/UPLTH.DWTN@+5VHX]"LU$VM@D+.Y4"J4+
M(O><BAFE= P=ZCU%H'((=R];+;NR'.U@ *4QJDQ$HXS?N)?T^OY:OVVH_:?#
M]:CWBVS4T&7F&SY(63[=J$BRV4%BFF*D$53MA8RPK49[ E^@=$MEJ<NU&:G;
MB[4LHS4=I]'MY[N19<H?&8&H^JL>^S&0UU-U(I3!T2M+=#H4NW*YH(NVY71^
MT-:6'PV?;E^ JKN6BA 4KZ* &[C$U/*]STSK/!L3G:NN#=9KO%!U3-?V#NW*
MZ>C1>+_L6G#D\I [0R$9N3"3K=9]%^ ,RWQE>!A&2J.Z-@9Q]*XH34A&(64=
M"=>*;D#@P49_,DF&RI ^G',%$E+Y,+2UC57C?3%4;<7_.\R@=5&T_Q@&6+GJ
M]95*<=75'M"*.[XL8P*I5C8ZMQ02[#J<2'2%0D*6TI'&\Q;4/V+9"!H-#X@N
MV:.-@61NU4"S"T1N!$@BE%QR'AB'3D!*H06]8=>(TKZQR+:LP\G-&)V$1)J-
MXC-S+>U5P U?W])^Q^7-Z.J4# 4A<I6NL(A<T*-@+-K"W$EK18>WM[Y.AD70
M"/'\+7/I'-F-08S29"K[TG?Q3Z,I3DR9U7EU25E9RBRXSD381W!*Y#VR9AMU
MP2@ 5WK\<%<&.%\QSRW#2@)0/7Y:%)VZ49 1W##([.PW3AW ]=;N;CY,IO':
MV0JV$%,4R+)&N2E[%I8IE%DJJG("&H:5VTXF?%^@J,!1914QZ<K;8IZ3$:E(
M, H8@ 9(P!_S9J:TZM/.,=IH;7#3HA_#Y7D[8.IM5[J%$)P9AK)%9 W;S:Q!
M'".49$,_+;63LNR#=!4(:J6#P=5E,1YA%*,VPJA4R+G[\ BL;0-6F.&P01\W
M2C&1 ?AZ,'=#(-M?<FJ?A"@%P4F'4F>H(UX.]XKB@J7F8OCIC?U[%(3XTK#
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MEUZRL?1]UE=.'93&E9=YSSI<SW3JTK<D]SO%M1"Z(O-E%Z2%>Z$:QE"8G%3
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M,*F*W=M ED:,C+9F]J4-#!]P)2/@LTLK \)7AR2/1A:%PT^4S: PRKNN&.0
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M:< 1RK8K)JXB)\E"@)%]NN5Z+V_1C53B2#(2DQ N3@?TK$HU@06*9!0IH#=
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M\.RVJ-TP^62A\1YF<>H&68+#[W[0G2S"H%J$WMGX6,Q>K,:X(%,5K-BO^L+
MXM5G4762;&[@.^EQ5#ON\G79HW$61^/K7]T%8^M93$1PSCM'E=9S,HROQK_\
M&KK#DYX]>]4]KE:ENNG7YNF-W%Y0EZ!Z7_WUA0A;Q;48&PW@WS!^<_/U:O75
M?T9AP7=ZE7%^Y==XE?S@=X)=_=+OW?F]P5*^BKE\(H,%7&&*/9'!,K4JN;K1
M8_]3D5A-9D#)F4?^_Q6V,D/L#?F2D^P@!'G?&N/(2<Z+.-Y_14^^M<@B[IDK
MPU$]Z;ZQ:39*; Z,*W;ZN\&2"10TB[-@WN-YX3RKE>]>^JR6:.,"F,LJ7;E*
M;U)JSH0V0-$M"W7-0HU/[2X,A$K5G[(2^H-6W91B^N2J4Y7@'5Y:W@:N9LQH
M5BWJ=]<SB_>K%_,&^W+[+2ROG'G.-;+F.Y3=BVE><>J?K$R9CX^HYQ)1YS]N
M^5$_EP4""Y'4U0[?KO_]VUB)7?_[8_4-PKK=^FWL17Y=]Z9J&N%N]T_ ,M58
M_/O5M F0SP!?C\/&UR_.5R>?_3%UAEQELUY4#;A<V7O&G+Z7C7]:^[1=':Q^
MO8B$FY2%S\Y 7_T^:(JQ-+5=*I=@<XH_6V^I.3RH/[L4,N";L_6JC>'DU,!?
M[/>BB+V: "265=!^=3Q[8',L<7<_W]4<9TQV=];%^ +W\W=[?)J=P\!QP%WL
M"F?28X_JES<V'^O;L66?*YCE@ J08&$ZLO[B@LH9727.=8\:Z_56GK$7N/6Y
M1>_%,E^&V*QCK)\,NKV&,&A3FFV\W@&$4W8)-$7NQCF0DUZUD]3]1674+L**
MQF[W.L>A.5=(4X<&BSATL=(BOZ.T/(S$?O*75@OYG\JQ<E7@R7=/7:[RGR]B
ML)=^6'-1\W_^L"8/N')F*T:C())H9S6/1#DN#3$X">\)TU[N$4I6RA%/.>*Y
M[HAG\8(0^M.*;[/5U@.?'XU-@BF+8*,[]+U^UCN7YM0HOZ<^-3K8_-0YVSSJ
MP/>[!YM'[W'G?/-HY^@#V7SW@78./WS;/=R!^WX_W'P]>VKTANR<OZ<[Y_\<
M[AZ]H?"N\P[=[>YN?,2[&SMGFQMOCS8/W\ \.OB_YQV^N;%_MK6]SCH;'\7F
M1F>/8$=<C %9RSGBRC#DO%=(6IXTYDH3JF9#L90)A#!&I7>2!QP=U29982W\
ME(!8LP=.B^RS[\=B+3R4O/ZULWWM "L3T\G:R*TBCF"CF/$"*Y<3SIYLK:6M
MXU;'GK4HKY6Q.D)K;"%5L:6GH^IHIXI_'N<- =S%IH9#$]K5%$BN,;2QGJIS
MI>G6(HU-5N>Y3"I K$]ZBU1G;SF/"K[IQ,%^+JG:5(*HWU7KC;0>:^N7?'<3
M&5Q??O&LBVK,XP%VJR"126>\F3+S.38Y!T&GOC]M"I".BW$TD>PWB0J:K5T_
MJ4F53[NB/SB&7=V?U*< S6F027G<)2Z'%=>%@JOR0K5-.19/.8+9-G4,Q_LS
MGEH5_Y(C=\:123F[:A3WJ[K\\=M)%>&=KPF#T_V+-BWC.5?96N-D^XL%&@?T
M/(?0QJKO2G^4]V2<L'>Y(.D4)7^%I?K7E1&$I\,P$SUH 3I$<HHDZGE@U"4J
MK(O!6I&T-*$1,;ELQ?B7Z>A!)&X@<%Y/#W;[H@0QN11/F&,)4>B/4//T24"A
M?''2Z2/>VO9D<WO_K'.X?M;9WTO:8XH]0X3GT$+K-7)">X1)5#($!KC.5M9(
M&W.QJN;""^L@N*/<]RZG8;[)2255DMLTX61(R/5^J\30\0EYSE*8@M"O=6GP
M;*]7+JAQ].&X?ONXTO!W"?#/.*AR'^^7$.F8#@] .[X-$;ZIQ,+[L51X7\T\
M9ZS#+]D$?&V'!W_:;A[V>@U=L1G^LL2[_ESRQ)O[>Y@P(HA(B'DO$"=.(>M!
M@6)*<$(E[%X4*VMB5>+YT-?<%PR6N')4 JU-Y'.[U:O#J,^F6Z3GJP[ZO= D
MW\2+[)I&AE[:YBDY>JFP7G=QR_NIVN'M.O5JS!R-[E#GXE:YQ0NXHQ;STPI)
M$[Y:Z0GUDRHK1OTZ?N"E]-*<A#V\,8\MFN]J<[YUT1*FDNN+A<98:%:K?P(4
MGA/.LF'0:#[#.,K=ER9+,$YF"]%5HOJI2)FI4XSW3;V:(G=NP-AT\^N>A&TC
M(6AD=#"(&TZ1Y2HBRF,P*C*!398[YCJA4Q<EB+U>YH:I"OUU);>*^%SNJ)7U
M51<!PM.T:'I"Q%;Q7]%K;D)?(@L.*138KP1YR20(CFB1-5$@XVRD/O!$O%M9
M ^7;7*?4W$3/9T] SU^<>U1)A5PJJ<ZJK2 []SZHLU_AL_Y@4(5"#J=$3CZ/
M;/K]7G3 K(3=;_:XZG^W7KD<P.[=7%U?G4C2W_II4:)JKRJVU%A_DUC+?(C\
M2Q>NNQ6+AJ@C=DY&EP!/$M,B.NVT94+(@(G9>[^0,^4L9_X!:[B57E>3?%N7
M5#OKV&_=H].CW\9+\MJ>P#>CL\*4US/EF[/-]3WI [&,$)2(B<"4%K0Y9A+2
M6!JA. TRT)4UP/YK,'\P29,>=YUN=NB2[^.OR57U-K;&^WB)!',NSRUI3#CA
MDV*!T)"X9\Y% G 20XJ4<TIPH;&?1&.D\V$/X\1(8!X9GJMBXD20=<Z@2%SB
M!C-'&%@,]%H:JUI+]?J U0N):SM_/4-0[7$?*="B>V<7VO^5A%@'W31/K-3Z
M>1(=-L'FK@[-R.<:+7VYF4]8H/G<4K,!UB,&S*E(M ,:5EH"FSH+YI=-6#I]
M3:KGC32;]0L!]%>=T)?KX X+95]/V>\KE3E:9E7TR',"*@U+!KG(%0)MV8M$
MP"1.!"B;7*?2C%,/1E]C[TLN_W \.@ KK%(!-L &S"FZ]0UL.A9A&,?ED0?C
M?BTU23;=K=KCYEI-O?FC7'%YU&153E4O_5Z@PL)N ZWM.>IN+,QVRX%=G\>3
M0R-ZW:-NG27:KHH>UXV;6PY4DNPQM^%+=]@?G&7S?S^W$K]00'+[+*#5RHJO
M"LY?[=R]C99WQ;'\LN3V_#FVWB^9'(]9U_EO?Q##:0^$X!@NIC!B^-O9U%_E
M0'%\H/AQ+XFHM5<"C&4J$$\R(@WV)Z)2!V=B(E&&[V6D+;NE\MT3B=J+=70R
MZ%;E<U+3Q6.<L/5+!6[]4QA#&/[[1EE3MSVDN9*M'S?-RJA5C=6/9%EIM2J8
M>8A<H!LF[=QFL&95D)MEA%V7"F3]Y_U!'ZQ8U!"S]S&F]+V,A$5!A ^3CW ]
M>U110_G,8(8ALIT\-N:;ZIS?]QW?(-_CVK6:C8"[S1KCUE-8Z7_-+M.MIC@]
MM<K!OE1S>T27)[N#R_.Z [2;60[LB6H,.Y]^'^YN]\76N[\..T?PW(U_#CK;
M'_$.?4.V-G[K[M#WYYN?-C]O'NZ I;![V!G?\]_?#]Q1Z&T=?N:[[SIG.S"'
MS4]OOFUN_W6XL_V1=][]?KASF,?P@6X>?A PGJ__/5\?=;KXVQ_;;T9;&Q_$
MUO;'/4,QMSP&E#NT@98A-#(^,.2)29CGN" /AK01LJVUO,+BN L/Y:2<6_+2
MCXF!5/WOA\7 SP@GKV7!E6)@T1E@=<(X?)@*<=<V.:C&^XO]]XUS *[=I2M#
ML.GM=GJA,"J(?4_Q#AFEZX^G:[2O5Z18T/O^T/O-''JG) RAU""B-4= !QQ9
MJ0R28#FFI)@AUJVL<='65-\5O!<#Z.. ]U/4X>=P^]KSZW%@_D.H[C="SINJ
M\04Y'^%XOV#B33#Q_1PF:NFD%H(A+GE$7 6+M \:,4N=CD9++K,#G;8-?LD*
M[<_'Q*EZCY,@TB9\+#OD''Q7)3O4@61W1\BB6SX!A/SA:+L"ES>!R\X<7(8@
M:,+Y< $#4G(J%-(QT%SX3FL2?3 BY1"]MM3L!:N0/\_^G_<%3P%G%<GE^L>G
MP['I?Z4R>7MCO*B4RVZ,_Y9W?FQH%R"\!1!^F -":4SRG"C$/':(Z\20D5P@
M&3$F(B2B)5M98U*\8*7Q$5!P<8FN[>\<%C^<N_&Z^RY706,GN>OV:3X=S@OR
MZY6EIY;ZG&SQ^M_\G.P^EV99!,3B-7DB&G5Q-]RCV/@X+S:<<S9ACEQNR,XM
M\<AXP1$FGF)'!&'8-ZF5;2GGO; /W,SGNRK.CZGO]\':=Q)XEVOKW+],NOZ@
M2]4'7:T?.IRKA-</1.\FI4%UD(08'C@+TEANG!>18  ,D]B-\Y*6XLCGA8?Z
MYNPE[3'( 4J1<ADZ@LI9V9(@8RQ.P2?AJD0)NDJO"?6M;+ZJ)1OL#QB&T^FF
M58&$KS&W?[E=9G_ 1!MO,'?,<8N9)C;*$"R76KE ="&WIT-N\+X/>]9+;2)U
MB"63P,")!FD*NT>"34Y:'(C4(*G8ZE5N\3ERRT&9)X.(ILM'5FW:ZN2ST^.%
M]-CTLAKD9#4?>U43JZI$Q[B(1W[L;$F3NE#>?,_E*]YA1Z-!UYW6L9I-"O1)
M?SBZ/-1)7^7;\,4=^V7=*(DB$_]^S1@EB>*6I$XZ7_<< ]4Z1(FP(H"L">!5
MF^!1[MQ&K2<."[NRIJ]-.^Y.DA#"5$[#]S,9JL2+FR==7-NA<MFS# C-E?@R
M8_XS9LRF&/#ZI)32<;A4#!B^APF&YU);YXJ<VP.;V_[&XW&CD*9MZD4OXNG[
MZM;#58OZBPK+"TKQKO_].E=BOJ)6<[N^:%+A;S2(8W"M7SAY]+BF\+A1W+C>
M<#LW((;OF^:RN7UKU=3$CNHG-/6%IW?V4GWA>F?K'JP7/=)'39_B:?P^GEN#
MS%.KK:ETD$MKD5/D3F*UY:W3DQP\ 8:"A26:]*$=3B7[#$>G85)KJBJGFMNL
MC/IUZ:JJ56V5$;1?%:'*S6<S,^_'W#47)-.H^ID;V)VFU/55A:KN10/,:B-M
M[OW;/:Z[VC:5F"]$%3S;YT?G*T%"=8_JOFRC2U*LAHT\I6[J5K*J"\1SO-_-
MOT[7<FZFNNB[\9)/;\.D>G0E(H<54UZT6#Z>-%*>4.))W=$N-YRKGG=RL9[-
MX+^7+O7$^+76"ESL];]F]658X7>CR^3TLN.JIV$S[3"[73=E@2L(_*(C] S=
M3K6ZOECRUML+CIE\>KFQM)VTELY+4H]QO-=PJ<M%<=+I*)<)SVT7&ZK)K9LJ
MFIIT$A_D;-:#:+\T==^F7C>FLIHJ:OJ^>$55,NY2=^X\[T7KEY\"5%%?7A7(
M\3WXZ!:KVIZV9JI[6KF>&T"4!UH:UTO./9J:BLFG5U5 KFK)#7(B3^X9G6LG
M][KG$W[H]?I^4ANM(HVQZQFXI&I7G0$">+O^=7J.4^LV-=LYOFZW]OO]4#6L
M;OJX7YSKV6_-^"=E J>HZ#)"=T'_R*"=9W+J#G,?BPQR!_"R6*W1I'#1)?RJ
MVJQ7A8!" XI 04TO6:##WMFXZ>0%\N1.Y4!%QS7Y-0N6FX8_6OK@7Q.)\KZ!
MS!AJ56.L::P?3P<0-&K&=F;WDEDXSBS<W_-""8L%1X8SCSC'%NE(%0K6",,<
MB2ZZN1J@RB5AN!:<&:Z4T4I(+9+A@CN<PEPFXE1;Y/:5V#H$CCVK=84O5:)?
MJ%NYYNNG!&ICJ(WSDT,W)6 ^ +#L2SOMA3&YY]LN&8<+A&E#*.U)QP)X7W[%
M&&O.II"F8<MI=ISIFSL-[G5=S#R<[U=O7PA'U=WS!=Q7OU_=]2;-6PEF+ZH@
M."G=6TMI[WOJWGIMX>,9D.1,4,^B=MPIKG@TEEL3-:>>2.%X&)^@+W[9=0C[
MZ*G'=%6:'VKP*/"J,O0!4H_YP_1,A(6^]\&25<%$&:RZ&1G<L.G6?73O(.(F
MC666KTO=^E%VA0QG:A\LZCOW<WJ@/*E%G'9.U=759\WT7W*KJ^S<J<S)<26<
M?]\@\ORYKEUG3B,'ZS([>/(G+WA=;D=3]9+!-;=BW><1SZRNB>1KMX[CH]<&
MGHNMRA'78X?"VT'_:&H;7T(H%=RSL?]U:WO];.=PA^^^>X\W-][CK8W=SYWM
M]6\P/KJS[;_MG.^+N5"JHS=PW;KH;/S>W3P\^ SCP_ .OGGTX5MGX\VWK6T8
MP_G;PZV-SW4VZ^LZE&KSW.>*1U_"NW]X^-_?>[NT]\4=GL"\=[[!^UGGTWMX
MWWN\L_W7YYVCCV>=C<^TD]?LTP[;W?[,.O]HLKGQF6WFL*WMCH!UVI,Q&$RQ
M1#$2BKCQ%#F#.?(TQ&0$ Y5>K*QQV19\/B:K#JL?^PH>+H+^NON>9@3I/55:
M>6(QHLN31##&L3_M664?;_<;-!L?&<;A9AQMI6F<*\!VK\ VB1']^+6SL;YG
M@V!!^XB,5#DEE5*DJ9,(QQ@8HYP3V,LU8TR;T*LJECX,^_QH'&8!P * -PPQ
MKGQSA88+#3]9&KZ%$)<A*"%$"M(2[K1S0DKOJ;:"4F(BG1'B<\&!18@OB1!_
M/]H<"_'MC^=;V^_W?"!8QL@0;%I"G/B$0#LC2,L<4RA3P#X\+2&^T.=@GFK)
MB2N<,]6Y[ZL'+1CQU)_Q$LHQ_7W0'XQ05>[_HFKXL%1:>DAAZ'"D 4?K<Q\W
M&XR.F*; A0A!V!C4%1TTKLV&GX\#RD><-X@$>IWKB1R/ZBLKBL@-'MY?T$,1
MDK<2DIT92_?]GG%4A]RS@!('EJZ4!CG#/6)1FJ X5I2 I<O-G:O1W6,2?>'[
M!S?DRC8M(3Q+YZ+0'FP5[GCBP7D54N3P'&.)I*Z&YZM-E +/2P[/'^9LF"0B
M!5$<$0AFCSCL/#))"22P2XP8([AQRP;/+Z$PWGJ=YS(.RL[\4IV%ECIWRZR?
M?B>!\WXP\*\)-;R(.LJ/AXMS:BM1L/,>@% R4%MS.3S+L$"6Q"2P5M91NK*F
M:9LL:$']\XK@%41X.,VU;-/R O==-=<"W$\3N#_.*;24N,"(CTA+FA!/T2'-
M+48R4,NEX%HIMX3 _1(\KMEN.Q[U<TKJC^NRQ9A_PKKLF )NV-:X8.#-,'!.
M>67)X\@9LB ,$><YND@HAY1D05!A?(IV98WQ-E-7]8PM_KQEA8!?'C?X(">L
MPV\W0(4_!_TOW;J9[ON+Q/+W=<;$^J1NQ_OC<6[Y^B17H.#" ^#"SFCS]40W
MPCGJ4%"=-+:PV2$;M=%$Y)1.R#M% "6\-9&LK,DV(V0.%N;R7 HB+ LB/'$[
MJ3#_PS#_;+22!!U0*8H<)@9Q*PTR!H#?4*QH8MG9+U?6J&[C!35IB[/_(1GX
MST&L*BC&;[F299RN6E57J2A>_Y=F*5UR'C7T\:8F#[B^ZAI6?U= \SY!<]:2
M"AASB75$3$2,X-> #% '2E)J(:,7 *@K:Z)-^;S&5-S+RXT0Y13@26S3$]=N
M"Y#_!"#W<]HOB8I:+T33 U+'A"SS%DF)18A8\(C9\@'Y2S@5^'.0BY[E,FO'
M=<WND^P1*@<$+U+M'1/#GST+F'E<5?ZOZ*&@XWVBX]R!@4\@,A5%6"J".*$"
M.1$D<E9RFJ)R+-:^ 2GO#(_%/?@D]-RR3<N+W,NHYQ;D?@3DWI_3:X4S2A,>
MD.*:(8X]0SH8CI2U7!,A.#9D"9'[)7AUWT]J#=\AW*78_D]8F[V@@/KBRMK?
M/K#'[YI"[P4;[Q,;9[5:88)+V@M$$U>(BY"0D\DBG<D#Q*3&GJZL&:W: B]3
M+&#!AI<;!S,1&04:[@\:/L]%PB2M@U!, C18!VI3H+G'(OS@DL3@J,8.U"9F
M5%LM@(:;Q\(45%A>C6$9K:BB,3PN+,Q84\$Q"5JDSK%Q\$,P@RQW HE(="2"
M$^?MRIK0IJV72F.X==V>I3XG6%RW9XI9?JQXSTW=2\ORC.?IYOKIWLB7X'J8
M9(__:<^RY"FNAY?F>FC"#J:_:&BB(8FB2-QC?=^O?VR_'W7^SLK$/@'[ N\)
M QH"V!5(B>3!P# 6.:,LDA$T2V(,PQ(,#-4FYJJ.P\7&6%9H*(%C3V*;GK@I
M6!#\,1$<D'NG0?#/I'/^^6PO$*^8C!X120CBEDNDHU=(,V,(P+N++"X?@K^$
MB#'@@\%IO$B7*&%BRZS=WGM1N,N(F"FAB:<M/O-[1L09G5:RA&U,$>$D7:YW
M;9 A)"''(E:!1&J#7UECK*VP6*)8@X((RUK2_BIHN,,)6D&$AT.$LS^V/TQT
MI,V-]:][@3LG<<"(4YW]Y5(@+65"T3/,$]"""RGK2(:7.A//&1"6K6YL41$>
M"Q!FC*:4N#;*!*2)2(C[$)'#%HPF8 +&G 0&R>5D25L*OD2(\!+.!#9 <QL
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M-F,I]7.?,$'FHFUTE$1HGI!0GB#. D.:1(8\M4IC&:4S:F5-:T )6G+6GPY
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MSA'\O@W/_[3;V]K^YV#W:/?SYK;GG?/U;UNSO04.WQYN;L!SW_U^!/>=[6[
M>P[S/6 %?7I[M)O?>[Y_WMEXP^>R9+8[>]1)"_M$D7;92K+*(\.B1TF(2$PP
MB7*_LJ8(;4M]5?W,!V.<I]%TI0#@RP% SQ-)@?N8(N6,8(NQUL(+3RWE#M<
M2,8 2 H +AT 7HHPWOZXQYVDSO*(K"4:\2@3TM(G!+MKE<#)>QE7UB15;6KH
M4P' EQ#QO!E'3>W^APASOG-H\]*MUZT[@#]/!']4%19H]'U%HOE(I^#X_>%X
M9TZ1C5SCE*M+,"(=XEH$9#" >70FD$B\Y8JNK%&BVXK>69%=OL#M@E?/%*\>
M5>,L>/5@>#6K=UK+M17)@KFM N)$,N0$$XA(%4D$L&+& 5X9T9:,+Q%>78YR
MF]1;GLZ]>[J'J#<_.LUQ3;;7FS0QF"Y?7<5(U<7Y7<-LS5EHT_QGTGJX!=9
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M>MW/L7>&1D!@*'\(OXSR$[_"].$-,+3_.^W"D*Y^J*L\#M7\!M'GI/>S9KZ
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M\D%Z0=2"J/>/J(1:[(.6@8$2:ZE1E#''6#!*$W>+7D(%41\'46=.@Z*FS,6
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M[XWN"!53^^*^001M; \=+=%VX_; %Z)6$-;"U6(,O_[-.I(P2&"#$2!!3?0
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M#GKMK6341\48M]P8&K0-R6$="%Q,EGV[5</!V51$IVS$$D@O]P2<7 [,5^M
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M<FH3]^ ;9P-'*M]( 2(RL0AWN"!B0<351D1&B8["1"N\X-8"&N+H TN4J<#
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M$Z^J!0(./#GO-PEG7_K:Y+0@_O85ZP:]]FAX\U?FCCD]$9:]153.3-"EGWG
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M8)6QJ:JX87KOS=RE.8Y>D+4@Z[(BZV/P]8*L#X"LLV2=6D-U"A%1DMNSA&2
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M[U.)VMVV1:[W=+6AD7N"I;1 ZKTUN0"*,%I08;&]C:>[\ !7-EXKZ@M/-DK
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M:&.\HPK<':,19SXA0R)!FCI+0LS'J-C"X@FW5:CO<83;E@M;:8X@!4O&".%
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MSI70)%'AB%_;4!2OWW0T'V2N75F$;LT>'O;C(>!,[:3? G9T,CYP!>N1!:1
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M03@\IBDHXY'SWB!PBRRRA@"B>A4U#CH(+,&V8OHCZ5BO?8HU6*@>@(@?]?O
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M9IG+*A#;=4!+[4@>'?I-:^+U(I^/#^ZV5SSP6)G?>J=X??$@?^>I*9Z!X99
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M_K#)D#<Z=+!-F >C_?+23.@UJAY'M>\]=@][-VU:-SG,CB98RS! S\68-UE
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MN#0WZFY!_1BO?M+UQIM!MS5L[W&6N[;7*'E56=&3H?[F1QK;'(?/-%%%?AQ
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M(A@,P.' TO',*H*-<4HY%ZSGI)BP*P]?LVT_%+8.D L#:$6#..<4.9\PDCS
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M[G'MVIC*L5?M7YM+^:)=ZE^]KH\Q]#_ PSZ )_,-"N$97 <@'M%@2S 2EFC
M>?"3)5(A0HDF4CBP=3GI(V84TJR(/ZP$X $"\/U ALPQ3P.R(@+0=RHA0T *
M:*"P1,E34%,0 'D+('I^9U;)P+UE 'X^B(1&3HE$@2;P1"%391#P1"DZC*EP
M),:TMB%E?4:&:;8GFF=Z\$O(]HX=9NTD%P;D /6J/[U,[;; A_Y[""'MH%NX
M5=_N]G/4>O&UXH_=X^-N9WR&SO0\]C(VOLPBYP^B]8?7ITSG:\%2'1>#UF>=
MIC;LCR/FW]O6?T=_^\-N._91(_8&W8L1[OG>\G''W1#;M5_^ZS\T.-[?KGVC
M_*SXA/SVKWIMO"=3^]%M UYLYUG7<#O%_FV^E<,6/%PO;W]=/6(T,/OJXY=/
M>ME)&7O'LS+F5\]M.[9]UB\SZU>N$X]/VMVS&(MSM#H%BJWE(?3]PBQ- I_R
MPKU6_SM*O9AGT</W<A-G_LJUZ^7E^U+_&[[0B[8_[)W5SEJQ74[TMCF[ 9@W
MF[4^W O(:NVT-3@LOC3U5/F/H_MHP:VD!!_G(LS\=WB/%_)Q109 8UJ@ 6%T
M3=OO#X]'9YBXQ?)JY6/#>3K=6AIF5KG+4YR4X!T>_;&W^_UA#,-VW$ZS(X>K
MECG'!V7$<?%H_=V\8[0+=_1[&PY\<[9X[V=.]QMF17(0$#BK&>)*2>0(#RA"
M:*FLP9H*5KK35F<8PV9V:0DSC2VAFDG)B4T:@#1.4=(@J8</UL!@>'L"KVK0
M@ZBLL&R7(M4'>Y%UK3-M,4:VH=A[NC:<_H8]_7EFQ5\KAKEF['E=E=8>SCYZ
MP%*N"T&X\R&?8>P\H^0^8^>%K LYWPSOQ3X34C[*)'=^OSGFU<W>?;,K-\J=
MB/N/B09%?YX9T7O1]FKOKV4Q:HRL%S.B%VGX6 EZ\<E'GEW<,[MN^V'"\1)&
MJ\XG$-?:61[XP&]MX4BU</=;./P<O66/8'/G[BF;B@97I+IS87&ZJVEO?.')
M<L]EK[QY6+]89]1O=2VR2YHY)7UD)D2NE7(4)_A_A[UC(GA\1\J=+VWGZ**P
MXDK,-U&$\<^%)'V&>/PB,8?H"XT&RYK.DZ/F>8-L?VP>[A^%[\VM3=S\^OYT
M^^N7T\;6YL^]XW_:\/VSO?-_CIJ3-9W'#;C/+WR/YIK/?*T=LK>[*?9W-^&[
M'UK[7_^!:/+/H^;7!IXQ6_1'^/@/#__S9WN?MG^XH^Y9X_C/[_M'OQ_N;WW^
MWMCZE,]WNOUQ3^P=?1';7_=H$YYG;[=]V/B@\0$6W!O./)()R[S/Z9!+PJ&
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MM6$AEBUPYQ$^*(?LS&!)K0U/X,<?F>VU\VW,$IIA2TD2"F?NUTY;[7;M6^R
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M,V0BNYE)ES3HUD[L6>%SCEN=UO'PN$CBC5Y3;6!_QGXY ZRHL%^=$2&CPA5
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M[I>(X2][E@_>[/5LYUOQO2H-OT3?[:<)GKDG1D:"K%!Y;*-2R#&F$;:182;
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MNSGH7XSW>3O@[6F8F]N'(>NGTT;5"-O.C[ GMA?Z^4G].!BT1@D?5QH;>:@
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M7.G,Y+OWH]IF[RY-ZEHGO(V=F("N5O/^-D_[Y0O>=5_'0>3'@L7=&<[#?-#
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MYPEHOY$PT'ZS>\T%PU*$;8O&I56%9S,P_UY,5R]!6A?&6HJTSD%:IUB*,#'
M/&'$ A 4;@Q%5FF"F!2!:D&C27II55P3(/XDTCK/LS[$U)E]7%.DKO*=Y>*P
MWV>9R5-4%BL:Z:O32!?&Q+9B"8N?)]*?S? R[XW#"7L4=' YY:(!I*<<49<<
MULI3[VRVO9%E,[>8LF)[*TA7IX[7@<46I)L[TDUS6DV9B3(!B>4"<0RZJ+6
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M1!.GE,+V7+.20T^/U 5VZJM^SA=V"KS<#5YFZJ0'&7Q*%BFF!.+.*J25C\
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M2<G(Z-#H > TOU<:L6VUNB<9GON+T?1E=>SD5VV[YDA0GEW$5JY1MYWMQ_R
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ME;*)EJR=T<A9,Q>K5,9>!O6Z-(?,XJ;/$XTUCLKVE6VY>536^5%^ZE(F@!D
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MQ.D4_(WUW*P?FY[.AM']AI@XU.>[DW7F^VV Z\>FH[)A9&EL-)>*<$,#_N;
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MSVT3TF_^!!%O+PW=.5Z@]S_\/U!+ P04    " !H@U56HDGI:R(Q  #Z"0(
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M2,6*TI;<"68%_6.0Z$ 'W&!)E0R)?31)^SN6&I2;35??^U]A<HHCS26)Y!1
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MZ]@G:+@/M4.(VPP.?/MP\A$QMXIMVB@P%(>@9<AD6C!!YR,4H+>*MU*:X/E
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MK[A37O#2IDWNXSI ;\N6;91PH -TQ57A:'4UQP33A=/01:1O!<\I!Y'XDSM
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MZPS9[H$0:QV8\AH*32WI99O+]$T1?DM4ZT1+3<L@K$<\/T$T/#O(,VV#JKD
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M1W&M;.:!.1<X^5H\,^#*LLR-]MFC1MLFAO.40J9.DE$=*>UH33!H:#;;F%G
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M,.H&GNMP:[S*GMX U#;WCMOH_RZ<PUX6=J.INVKO2,R'XX JDM=.Z 8]@>,
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M$-[8@IHNITH=5Y&%7,,$P427=)!.M.FQZ1,*&TS6OI"PBZP;(&"IG/[NG?+
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M9%0N*8)F)@3#-/+,H,A U"55?, 8>7NKZ8@E23V91/L)?$78L].XY^OKR83
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M)#R9%=A%(^<23]V&IY>LP!Y9@9W TD=@=1]-GPN*I?'%)B493Y'3&0^.^>"
M*9=,%H);DX^TZN]DT+M35N#DP+N+@GO-"G@0$DS(S"I+KXLP=>I(J"V"WH#S
M40O?9J?!I6<%=M+XUEF!7=35( [P]+21Q(O35GHZ==P1<46S$,G?,C)$ )*
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M-C*JTE7:K&1;24[_IF@WVEH.HQXLZB8;^F[26[_2?WGUOZ\GPVD>IGOMG)&
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MEIS^:^,[4M>XE:R[O@C6$B?10JRC^$O$P'3F=01ZE"PD80!"'0BTU>"F4P3
M$Z7I?>I_%Q%WJ??9U\G@]:N!U$4+49")Q8IG8BTH,FJY1#)QT;LG]Q5,,?WM
MT_C;W^N/N]%P_=U<NS=ZO?E,OX7C'0E[O+^DNBZQ?#_[C),Y*F_M!F643D%F
M9HJLO8B1@)@(EV0U.G00E8;EC.*:DO_E'WW.NNI 6%V?L7^^&R07E(]8[SLA
MF88L6+3.DN4O<VWUC0J>ND6W.F/_?'?.>MM'4@UB:[>V^;TJV9O12:!=S$2'
M $'X22(SGT&S$IQV63E1@MWF&=S9+5I#T(58QEV*O4%!V2JR;A96W\U"VX+
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M/5K;LTE&:R&UYFU;_'7])1+P_]=_^_]02P,$%     @ :(-55D.,4[ST(
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MVSPU3ZYG[Y-CC1DYUG_3G)T?K_8^=G!!;H9#7['?)*_U8*R@1_J&[HMUI=%
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M+390VZ,*.SHKN)V-DQQ*K]O.'?/@"DE@<MPTB6_$9X9"0-'$T"Q!C,]I]P@
M)VH[ \]L4T, +A_BE8CTW^:U!A"@6?%A+:7M,=_0B&[2\)P\=*JU330[8C&$
M.-_&3C.@N-W7>&Q^$J8P_JT0OLD95>I!SF\Z&7$%Q\I)9^CYI9I-#6*D 4",
MC*PF!0HR1\ZE\@MUMXU2IR@P^B&<NT/A]?A>S&:!D"(%/!X^"PCB.RT) '@/
M7H%-U]<U^6H1''A=B\O>@:[= YYX!\%8-S18\L6;O] Z-D?P0OTC[-TTE&V
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M@\)KQN!3]NGK3Q;\$BP_/V\:'<]JU@?GS"E.CD$(KZ8@>,TAS3\PZ._N(J!
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M!<BF'X ?ITT@1I0N_"CAK\;N>]AKD[:X*G+4*X1(OIB-6*5<\-GQ[&Q)'Q+
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M,9T^^WU1Z3\!_A--_]--X?>]I_%NZ2;YG^HZ]NL2=AP=^\="6M=[R?X$P)5
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MKRV6IJET=*(G5A4_#I:("P$Y_*'VMG:49^(LSE8JMW<!N!3;[C/.3/[GP>#
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M97]#2"BFWVJ;_MZ%<Y#A>*=Z[Q6DMI(MMG#)#@RC^U8!M=X7S0F8_M@'RB+
M:@C]3@!; NGHZLS/7W11,.OCRNFZDI*([1U,B.YGK>!/V]3$30"I3*-T(%2T
MGIS<N'KEB"D3JH 0[:.]Q@K/2X;]GW@SNCK']UGA\Z5EC[4>-.5+'&%Z$5.K
M4HU6/BM<<+VUV%YRUST=5L]*#5&[4<6,._EYN+Z_;%8PYMDMW9P8,A<.F85
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MV"_T>KWX8[461+&9GI][Z?'+RG9^ L]XJ_22^(<L,G_T\3"].=/ZV:0^"OI
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MC,YAKYO#='L;<&A8<8PIM&RUEU\R;;>$? APC(98^J59/OYC1'XI)<D@#MS
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MK[ARM(PT)+LNVLLY*7DXX8UO&JX<18\:VHI:+,A>M(GH3,F5U<D4(V:5)K@
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MI0':'Y7KH&F*SO;X2C6?B,S76$S!^-C![K!('KAUTTNI5_"T-5MJ,+[:5![
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M+O/4YZ*^A>.KZV6&_UME!=E$_@8P$\OX2J"2MEW.>![&[--4+E*7!&$9!"!
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MU?84,JP2/RZOZH+]&V US?ZNCJ"X 2_TX%I_#ZQ*#CAB6/[A*V#BKLSUVMC
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MG3MOOB=(&@ID%_HNMXP3R?EZL-+$9$/?:#0@].A(&$."P_M"7#-X:Q[A3]#
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M#KZ?K2PSD7/ XI>L35^(U4^Q[CZL&L7_,*1N9S45!S^<"@*8%NP91$L G+3
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MO%UOGDFA0<Z>)T%[,1;M[ OYW8*M0/) $94(J)/DE3&.)F:471P"XM3#T^_
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MS>,;]!^ ,4+]'X!VL[8UJ7\R?W]82N*?P=9%&ZZOLC[),EXI1W@;1-XE_-8
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M7&XJX JWCE0E],I-5XZ2R4.J@;60$.LD>B%DX(]\51;=,:NJM\>4R+;8[^+
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M"7CXX#H#@E)6NB^1AF%IY_VV<)*LP\%Y>A)0 P1:IUD^,)3H%>#=(0"@Q@
MTJ%9%>G=JI\'.W/C$%4VA,L,-,$S+ \%TP(Q-1W/J.3"G#?@J/$&UM6/2.?@
MI>BK=*9%T]0ICR"-J+D-I_*\7*+:]6$[326*OCLV5&&/IZ>%9_OZ#>S=RK<Q
M7;%BX416F1I81C3$ *Q]P"KCD1LAD)CWJO!J#V1OX,6,C,8N'V?F)1?Z[!9!
MX]#(=[24FISKD'O@HMM90#83E4F2XAW+.55217H98*JI+.9 .SD+,QDMGQ7
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M\:2A5<:TF/W7Y :?Q Y4^4K&].]"KRLE*KJR&)(ZS9&<Y>S;B5B);O;A124
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M,$F*V>./L$?-92#;IG^LTIM;[.2HO6&3RN>,^NKDR$XIS&OF$O#S<(YO\,Z
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MFK39(/U95E2_S1]_A">O.]MZWCY=0--=\PQ1F:';1-FB%]\7+>G<^SYY\M>
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MF3ESOF_O??:U]X_W3U_]>+W/6W77755T!*3(@;O:(D>)5?H_1K>#E&HHQ23
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MIY<GBHYR[=E-X+.)B^<-V "=TN0463((N^TK/]>C?DH9GGKVI.\BVC0Q.CI
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M$3'0"\3"(HX@"Y!?/G=&!YT&L K]&%:'";A(ERSL)1KHZNLK%4KCTI#*1WU
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M/4-3Z!/:\RP??7[>(Q((:XS5:KH!P4YEYQV?7F%M*4YQ7$6@\=2<P[:8R \
MXM34IJJ3U6;B&,)$#5L4[B5NUC#-VCT/N(TN@G51!Z[#,?C4RGPU( QT^"XY
M.CCSND+\EX66&WI1V8!U)_@6(I0Z-C8VHYBP151S4^0_VD8C.\%[)"E.D'J6
M#^81R>Z2X.Y'+JG$L;^P9%MMFKWP>X$EVHH(%.^6;*U(TH&2S:"(:@0,.N/*
M(P/=3)>D_4MW]SU<7(K?81PV:*O9VQ&_G Q])'[Z<8<5\L4=J5\7<,$S5 8U
M0B_A:]AN&=V:[;.KXG28NKIYLPR<-FD8D5U2(<>+:Q>(Z;UR=.;N8SD.Y5?!
M-_B1 IXI&M-U:("OA0<\<C<BF^&TI3YL<CD"B'8.]01(L3A*BC/C%@RAH2:C
M%(M%KN7#9G9.>[<J*I97LFQ<WH^+-9Y6FFK4P>#(/''/;<_$,<K]#Y7M@*V9
M[#7ZL$63ME;+MF82NNF8 TT!L4-#]SA! NZY ''%3V=]87@,)1LE_;[^(JNK
MLV[2A;O]>C-'M@>,5N=^=O@</X!#FN:Q 5I>R]7V<'&OB@J=<8%:6 3[UG<'
M8_//NR1?;!X A4\57@3CQ*8UBIQ*TL1+T:M#A9 35*S/F]TRK.R.,BD1\[,R
M[0@#[;MT+_<0,)A<&E:Y&N",N"+\GJ@N4I"9YE.T\M7@79=+4?>YLA-%3/G9
MASB<4@"JPK57+\ ;($Q.%<DZ=G'H? 17EDG6;JMOA[7)VY575,RN<QU))9Y1
M;9(,#B"FJ9P'&F()&V'>5<(Z^$?!NJ5U&+FJ]V^1M@"\X0.B"/>CS ":6!FO
MB]'QB/IV6I+Y>:TK00K;MX/L/< KSFV&@2%\H6Y>@27!Y6_>)+L>(O<%XDEM
MJ1G]"[I'K\8?._#*UJ M&*SK5][S$'F0'TO2?(#4TID:#7VA"XZSLAFKQQI<
MKY\^=&.]6:;/:V@@T81"C4"=/041JF$96Q^+^R:0-H0KLWH\4@LS0+R[$8S=
M2\\:\%GL\8<6SC;%NX/CEJME  ZJ\JH*?]FX^1DQ!?1HS8$5 6!3)'..8_]X
ML.57^D?L^5GI1RL (-F!C8Q'A9Q%/H[TVXYVZ,\YN<S9BAGJ$4IR&L/'S&1
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M24X1Y5/U4VQ@I(QF\_X2L2SONG^UV(EE;V2G+Y[&5U5 P2"TY2C"(0),FJ4
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MWY. HDKAESM6).!TFB@)H.HC 6TNWP^L5P8EC=[Z$\^ =+/H29-!.H1+"D?
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M>D8F1F(*5DY6!@Y:!D:&'T3@D%%0T%#1<-'1<1E("4D9_I<!^@W 1H&O@4>
MAZ,$[F'#P6/#05L!<@" 0X3[!7Z_(,#=@T= 1$)&045#AW6HP +NP<'#WT.
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MQNJ_//I8,A1RS5_)D.,#CC\B=:RYI!7Y8+]M:9%79F-=:G>DF!6I&[L)T\C
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MWVY[VYW1=ML"J-^/4$>%>30H@@+BE2\)OBB*XR'"Q'E*.M%*)G\B>2BWMY_
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M-;]@29*)M(!X$>]E97X64DV=W09/'5K8"?<OI\+;]0HB;2I\Y<\OV791VB;
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MH'WKE[X&1]QI.7]5=<=F7NTTHLUY)]<'THFTK8-=9K7,;6TEZ!+=0@S:MG9
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M(GOAVS(M'%4"X(D3U+=-^)B^G2QL-?:?5F-^<,%.B2-3N3E>D2W Q"AFS$)
M+(.Z[L4)8_5S.@71,R06N#,XI9RZ'*PH-%(5XVKL*N# ,.&B%6U4?J\;-K3%
M'6"*H/)OS^NN64UE'&U)W(RDU'U?^PTFR@9Q59X6YORG4UM%^64,7%??KAM[
MDI_\[_/TWTB/__395V)[=W<T'S_]O2^4/T%\U]] ?*6_C.L_%L,?*'">^1^X
M,!#[\_)/()C.["<F[ /Z*RK&2/CDB!2:>:VR_7NHU1^K*C?K_L$6F[@'Z/\8
MN3]P?$>FOXWKWVO],Y4[,D@/E8"]+2RC'V;3+@P9]D%I;N_W6=<#[4G_58SJ
M3^EWPQ-9ODX$U95A7$(6?E%#4L)D!$-LX;H1M'"/;LB+Q"T$<YNT C*I5'05
M8%WE</KI:Z-C^3_IAK%=XA,462RPJ-2.4%4$@2Q<(@6J(*&(1S8MAY),I^L.
MJ TD.8V&33E%,A86@E5?M4HRHEQ7K9F$^B)[ZGW9]#_[O(JZ7G<J\'HT6<+L
M,:?W]L?IYDF<S9.NH$P#1>BK_*2-]V3O0WSXGB(HQK5K9T66X3UY*[<*;Q%X
MV:$UL;F\A9X5LN+L9N<*XEL(&=EY39&<"<OO$^71W)4?1!J>QJ5I,=NV*UID
M*%.S8#W?SNC[3#S *-056=X&%*Z^E5:PL[J=/2XW[S1#:A;TZ 4UP4=QFP5!
M4$XE\.ZUB[-Z8[1BXG -VH;\E)#:&ADV)*3G&R(1\[S)^[$<:U2]W@(JEF?3
M%YKVY*)NRQ4$/NL!"Z'S:SS#G-\:C/- AH)=H?"FL4KZ_57'99KZ A@1QEU3
M:SFD;EF-)S&#60S.M\EP,]*V7 TF!RZ?(6]ZGW$O&W6YP$>FF&)IS[V<MB0O
M2^&NK8FG")#IF3VC-E-K,D A,C$3\EE^%PN&TVB&@B?[]<0IYP8N(E#&,NB"
MHTF<JI  EOR0R$&MN YM/XE@6S#QY[UG27,4B8,8.../^\KH624%.?8M#,7K
M4S8J"0[U7:L;HZ@L,>K]#7C.T<+;?'CW]"@[+%8_U-8E2$C4G#TUMHX0#_^N
M>2:,3GFYH-I@:+.3I]]"5>.^DQEBM@H:1PI,>8RUCD^UOO'"C;BF1#3#AT=]
MQ/'+6BP'_&G%)Z&>X]>N,F:4<I36MC56\.PD<"2/NPN*.(FU&79PP8=DR95(
M7Z$NC0/4")%?2CZ#\A"_+B(-[9_H=>+ =.CNO":; #-%Z;B2N_.\#3RJ57\B
M58P48^.)[VNS]/Q5A6&:>>RXJ,NI_/3;[\^/ZM^)6F_X&^#SNZV?#[D6UP4!
MZY7$_-I\MP>#(2J<DKV1]HX0H6XQ0]%Z.')-XCY>81>_3IUD&M7:R7'%QG$6
M9J:EX<%"C7ZB2 2V?41T&.B'96X$]VEK<<"VZH=$!<Z(M_D+^]R>/$Q?S9(!
M"W!X VF$3O4 ;K S;-2EU%0EL="6; JA1W;8N>N@'??\=6)#-@%_P'/4PQ:"
M-:Z941$BKCN_@@]1( N+6N,!V+%5)I&NV)/\-"/CA2@[HG/P7"UE1?;Q8CVN
M[SWP;F&0>/]XJ%JYWV&XUT81T($+\=$@&'0Z5T1$ V=:?#(7&L>=J!);Y]C9
MLZ&,'']#B+99#0KDE_7C.1@9XKP',.=F^I$E!9HM*D\I[P$9^)E4MKZXMW;?
M)!6U[.R2K[AFE$0(7A.7-U<T3-S-1@4:)7JP<$)GKGG7;&'<#/T% ]=HG/[\
M'*-;/YY7^&JAP<'5/T]XE 6IF".0[6U\ 8O#UE>V\B7,S:';5=?SZ%,EF$6S
M)FR'Z; H]@)DNEI5Y<US':1II^OK I=&/ 2D(>/3K6*Y$H1#S:R]OK6]\WM3
MB7</< ^FAR'-5=P6S0SCHCIYT=>.O8NWXM*DJ2PW- T0A>YTA 88N/(J-E,^
M:=WBJG<\092HT/3O3HIF=8I%_%8"2-!WOG^3A.FBU['F8Z[9 '[CR%BFJ:W_
MFD_6(.0%9L=^)J-B+) +C]WQOH=P& <FWM6B4&M1&LQ8U]D5$;TU4!7MV/Z.
MBW*3E+L%6D/D%S:)_6*55X &9K)HO4[J4%TB0!7#J:^:EQ#EE#0"_9&Y^%H]
MR'=U6GZ2QE0I*UEY&@%7BX1=$YMWX8E')J-(#T*:D/!XT5/QQEA>S4'R0)V(
MFO=2H&_U@-L]@"Z]C\$)$Y\WM\<AYY[GXM2V)E=58XJ]RD$89N9KO4"1G]QR
M]G0K@%R>!S:S>EQ SKM<3EZGE]R?G%6'/5=#V)27&?0LWA!87S[GF6<H&VMX
M85RXJ-OZ9I-O[H.0TVA9.^V;,/N1L#23*AN+Q.:3L$+F#C=++*$5AU&)*A5=
MSB;9#-8/Z1WN84?Q-42*L.:*5PW?Y&-/7V4,O:Q&+XJK_^BT]?G1EM-"\+>M
M@6XEQ;E[H.W%!;]*@;<%5P3[/AY948ME25PS59FN=9=G-7I,UB+9U$IEXZ1Q
M6"<$RA\7I&,00JVJ/JLI75. -6TUFA*/ T5SUL 7=Z0T9M2?_=K.?=Q@+"+6
M&J97+@,F^#&"$/?AH-CRAB:GU1/4:1/Y]F6TU;*=V\&:L#S#V]^G'-SPEA!%
M9=V4CFS4[BR/^,&Z:57ZW3C]Y]-QQIP-2INVY:1C"?J]YY\2-:O'$;(=(J3I
M&ZK[34@VU ,D:&O%TA!56\DBD[#M$_:WT]#1Y]1/!"M#_3?.= >8R8)6#]F,
M$&=\$K@<U=06HD(Z_&*OI74=\I[> QUN,9T+G<F3D]F?G<YT=6C+%,=Q[2A5
M&J4!'Y>6MX]YB:$/#?.KG!90>1Y,&>3BD4OBH%^!X^D+ZQ/7\^%FAJ8PS<B@
MQ.WHOV-C*%Q=Q=W!*4]Y3(_I+/9]>N-HPYKC(<KVHY0S=7;L'ABAN ?NKA]L
MX>#\#<L4A]"G#/Q0;?T?\$OWP!+=/= Y>EM$<PM;<@\<?;@'5O-.V>P[?J&-
MUI &-C%/<GJC9^XX.>.5<#;IS"L\C?"#/^DE%/I>='RFUWR"_^%MXR2.ZZI$
M^  *Y!7BB>'Y#8.DF'E<I3NA)!:2VH6,N^[N@V;8LHW\A_V0G=N\L7\/U-Z:
MPFK_[(0$-/0\.\NZ9ND58/FG;K(3\9?W^G>5Z&_M).-/Y_7OCO _F(43E7\0
M$+9_K_3/E.F:8:8=VJ:0:U;EK$(V6ZX 6T\[9(-$",?E%@1\K9-(*%>@V+E(
M/Y3B*/6WIT.DM.T6^#%1]FVVTY5I7GTD>Z %Z9UFBS-<&M/$:DZ&#YVVF?I4
M@')!0R]523SP[&5H[83MI8Q]N+92YH[O#K-$LCDSMC"=,2;SAJRA*<\06Q?]
M!@X,3"F$M@=L0#\:J.51YNO'HW\IH4#,FTOZ<BRKWCV/L_]YC7<SATZ>TQI1
MDDD.[D.S<ARS=?0:&'M+.[:O16!L/L0HVUZ*\G87"75U\1-L:,[,]W,,'*X;
M51!=G"]C&- /_FOD434D!QFZ$KF)R++/0]%;KM#M;-6U;3G]#!]6JP90UH+L
M.&X*H9&S&0EA4!SZ7+ST>2_-' TN8PK>> (0<9LQ,^5<(YT6'_O2&?K-^L7.
M6)5I&KH\"Z#YPIU?W-X=%U+Z.$C2F<QDH+P'.L=KT*6?NY5B?M#M>_[I.HP7
MG&B/?7&*PV-I[+VP;#M7:3TJ0EBEC9L<D,-TCF#(&,DH(LW U^57[C=BDA L
M/9(Y;N(Z__&SP"JU;H@D8Y,9O#-_N/9TA@\;QH?]I]^WHG2ZPV3"(94%NL^C
MC(;V]X^&>792)AGK<+PMJ]V=D+ 7*_=W[63#%'.[TWH1CW&+_I^=I_*?\&A?
MWRV""I#2:P-X,XQYI7'84ULF2MN)&^APL J5TMHR:&$DTV"C_F;8\M=KJFO4
M/!0,^!^@V>(H:<UV52($$R?.=U,&U_<4/>F'^QA9Y6LG20*!R10W*@D6$#@=
M?FI19R$-KA]6<HH/-H.I1CWQE; ?IX@5QKGRTC2(9;*7=SDT9A79<_H@0[8;
M9-_OCFX*IQ[4YXVSC34SK]=4F\-46=@D>P;*0GIR#SB&V6"494=W_$!EUY%D
MKLS)7,CGJJL<@V-]*Q9#>/V>;(W85N3IY__!4W(D?K[5$=68W^PK\?\CR3;)
M)Q@!S)6W&O(QWYW\Y"'Q-%&]!LK&D4CT+^/[H-^'^#7$=<,:J:/O 20M.2_H
M?BF:H#;F-!A=9P#<:=/.%-J4DPT8L+0NG;LR&4_C'OB'3+&2C8]J44:.-CFA
M0=NX#6D(AZWLW2Y7[(;SN19B\XBCN--8/+)*);[!=G'3T81_-TS"&J:W0>->
MZWS:E)C18\7"=,#,5-A1*NYM.<AT#\"'P2"2/8('I*C6T>G77U-,(4M2I[OG
M[$Q=/AG*LV>JMPR4F%,CB ,J[.PC>%H0WL>K>)";%6V2SG720%T:JHS*5<,H
M*S\74)0N1&Q%J)I$(/*6T;3)T(POSEAC:4&N"J<4*DSZC9._FN$S2LWK$ P3
M[)I9-KPHZ.7;PW\BN9Y(D* 9BZBJ=)$13O:HG#5>('Q#XU! LN"U[GQ5*%?J
MM]4PU\SD=#/X_J=?82-:,+6^&+G9BA#'X/9TKNI ^;\(5ZY7RF@)Q!NG]M.6
M,@9>*4M3!JB!POC.<=45L/=..^V=S2[$J]]31G&Z.U,[1JV^5$F>1PL*32)I
M.G]\2%LLY.FM7%GO#MK;8^ *< []3E?4$]HCE:S(?(- H<QKY43DN/:TOS,A
M^O;KJ9[8$,K'RB#3HF>^"N<YH*Z>5@-1'B) )T4<<)/#^1:?@N,L%M*').:U
M<YZC^,^N]?^8<+?.YEW>,QG'\KZUX)J^\!](<56 O(<0K1&7C>/ ;.-H).[<
M/3]!VW^.'#$;'!7TBB\="H+D)Q(KJQNVDS9@;K@Y=L5/>TB^HXEZ _9B.ERO
MP!2U[#F+Q(K4).XF6K'U2WT] 3,[^MHP[RI.8X+ID-'AUJEMSS%C'A3,H(%F
M39;R['1X>+L[)("XI4A0LF/63U=?NVBR.K'.!3V12);Y30@#.*GJ, EA:/Z-
M#Z*@"'\=PP?(B7Q6-9O8L^H$!WN,"^'8)3.'QU*)KE8?82JJ"7B&S&D%#/-!
M-;[Z.]/;C(NGNR!W$XVJ;Z-'@<E;F\B#K3#EC;1P([2%M]@_P JR.CLQZOP!
M9DP3=/ O%7KDW2.'UX)&?D%.UKG8BN1660XL9 2G$BP>CVH[2T8*;Y1A[9.?
MLN)']ME.0028W$DO1*L<:J6+9M4CC:LB>=C9")[9S+N]\WF^78R6VA$KYUF8
M'=L]\2:"(BN4HZ-5NGH!KP4?>%.JP#1<N7\5-'OH"!;;W>1W!8N]FV+;0B)@
MK"7GH^TE:"7MD$I#KPM:,6F:YH)#Z8238XYW,*"K0!'8(ZJUDWPI3+;/WN%$
M@#:4YS;5^F@JF\A>IZ_KM+N7=; ^1C_&2]=YRTKH9!!P5M5(:;RH9IK,'F#)
MU5UH-V-0()IUZJB*V$?%/-#[!BJMM3P@^C$7K3ZEI%3$[(A2(.I((&TT?B''
M2KDI)E *("(^4Q$(;2<D(V[$[7;1]I184JHJ3:#+J(22OX&=W0_#FW>+:I1W
M:2>Y!VBAD]_^ YGC?TWNN,7[_?/W@^G_2&K'OYMTSW_<98R]EONZ8ZO[[5N]
M)&.X?;DTH= ]$%LOQ;/N,5!+=FN17BA3@BII:VOS9L*ZB.D(Y#A9B/Z>FLH@
M*8:Q%BXYVWXZ;Q# 6V0=M3KLA.#+Z\8H=RV*/BT369'U=PJ@%VWES9%<':20
M,;."'V=4RC4XLJ!'$N719V& #D0!<TGKAD54*;CC69"HR0^^2,RQVUV/46+4
M%).%#G%L?TR\:'M?>#<H5)8G&[D/97,.Y^Y$5_O\ 138LG%IY#@D!Z"M$;/*
M82WVPU$%2,0^#Y-:T,(A_Q3GM,F.BFITXF-';WTEPYE*3H4]C^\J*S:O_<ID
M'G@K4%3?!8.8(X;A5D#CN[]U>S!YL#^=&)Q8981MW8=K^0B9^]K"!X%OG2BA
MQ'LE<<\IZ$RZ+F%-Y8PPNS[!(4A"74VO>3>>>P4_-+D<W3X"C=_ZB6E=3/"P
MM>-F:RV%9<?:L[FW(5C1L3TW:(Q"^&/I,OZ8 ZNK3^"NIY5[7IKDT[WCQY^Q
MX7-3EP]=OK:T.H\O>8;-%8)-*!51G<A1:R O2?Z\UV]Z2P!YSQ0&5RQ7#0!8
M@0.97[RMP]5!AE7-$],_:>ER K"GG"%CR\N(IVVWX]&^2-OV066(09!/A_ H
M GG4JR'455%L()AZBUA%G,@>1/@P<8VX]BK\Z4L%YDQ;-F75-F-UJ-"F]&,B
M*R!&)8 *9AR7?YO/*H=H_).V"PNS^O%G&Z6>3X8 ULTS5>]0@.U&*P?R:LI_
MXUT4+@JC-=YZE+@"FPSM?*:3';O@=>Y2E[9FO2]G9,,GRBCUFJCGH=QDB':Q
MNCR\7:HIBY5Z#G+$4[CU4Z^/:?V9/HQWGGX][O$S!543G$1'.2610*J%T,<7
M)]].<H%J]S,"Y]H?=40&KJJWP/&+OGVLB/+D:M.'1HAVE)$)]PT+:E1?+W&%
MM@P(\@&?5RXQP!7<89AWH*SI4B'7P-IV9EECXRM2UC,J24GFF6*F6-NZQD,S
MECY^@YMC=LI85A^/^^50*B.0N$<%7B*(!_YB3R&\O4[_PC(6:YXSLM4F6@HU
MZ%4=Q8H.W'L('64Q&J!==D(=E[LH:6'!&:!ER-Y!LO@2.ZU+2^LS E&8Z)'J
M=&<@^'LUE-(UP:B(R/9C;^U^EFV7/L,2P:#J\6&P5UU,]NW"6+^)A?FH-KWN
MIYB8BV5?RM>LF?"Q-(*>#JGM/SR>JT^S#U,0%%-%($0\BEE_*U9-M!*FZO9^
MRH?89-63>TNJNCG6\;TQ,@&K,"5!QQ<:8MBDK:^\7Y\'%6J1FSZ/.*,03@6U
M*!%@4[7G]MWDI"2[YI=><8^\?E7A]RQP?*J3PF3HQ+=PL 4X://E?Q<UW>(F
MU\ "LHHT8JC'[,1310 IQ 9'.!-%#S<"ND+,H_[U Y?8&<4#B)4QVB);R$JO
M-EH%8-/"/F\+:&3.LZ$X]. (;28@AJKF+"D/I"$04.6MNZG:NKS&8E1>6%I\
M+0T3WFL6S_$T$P'E-'=(BI"&:ME>(;'M A\3HA*?\CS%;,9YC8F,/$!D2,@P
M[!Q&*'45C5^EP4)&BQH?!?-+-U=#Y/-8>3BT77:D(VVUZ)QMX;>3(,54Y8:F
MI!:FUAHZ?Y&Y&N2"(??O7$7_^3%Y5C2U 2MW_6872>_K+]]SWSF2SCD*_X G
MO4'23G"'\H,^0L'S>-"6N<V>)\[C7*07=^%_T0J*L)VNO#EXN;R#EFR6JG:]
MSQ\+7V%#/*M5[H$TT7N@)2;'VWK['CC'_>GU_OSSS,SJ<^\?R-_N@>57WJ'\
MPALWO75WWCU![@M2<TT.40CC]P +G0+4*N<>$/&[!]XS2 LU_A,!X9;TGP@(
M]T#$?__1>-[]U_[39W<OO.;R[H$1LI]7)[S!$TUC"A?20\/7UPK:B5!OR;\H
M$Q/><[.2LY_N)LN[AJ^O%/2+_JJ@Z>\*1B\6%.[>(]X#L.K)M\V9#Y?5NQ]^
MJ-R8WBV-W@/;##_Y!71_L0Z&K]%^Z:E6$\4)0EZFB]OIK</;+H)38:]"1)Y>
MN"34]:F<7X>\L.2)RYS4*"=A\=CJXNW5R^H X[?K/]8$U-J8>IEE;M=5/ZN"
MMJKG[>\!U!OG?)>,'[O]*KX4I1U4TBMB:78(X]?KGFAN3+;":#<:AJL,,KE@
MAQJ'F8,^2&1+&H-?TG/ OM-IXH2.OLCN]!KE\5Q&8MSS+TH_XT[^72OR__UD
M>VHZ&V4^&W)QL?]$O>[42OX[Z URNM&-7S'?35O:6.'W PZ%CZ]T="*RY@HY
M)"FN;2BDS_R&)!0=@"V>(O$3SKR\/>Y+3.I^"=B!8GL.L%R?YV5=>/I%]FB#
M:EP"O+/S:$R-^ ==1IG3CQ'^UW;V(2GGJ%M%#8)Y.[O,-Y\R'2 5&@/7JJ<#
MG<>U+2U&Z^A;Q'),R2EEN:87*:I\T4A,RU$[)<4?@CE]I;YP&MIV 7:V$$.B
M)V,'.2%'A]2A5DR4091H627,@WUW9I_9<Y<B[PH-(F<J4NC/FUCU][>_^BG4
M0LRFZ)B:O@7A:<Z^5"=CP'Z,C@Y"G"L"U(X7JC^13YT5]'-0SPB-#61U4YIL
MS,1K L(SXFM%Y*-<SR9*9OGMR*>8%_FK%C.-9'Q*KM*,UU*_>#UUDPSE3+96
MPG-2-I[G>-DE-9R <RI6@*>O_X79'/=$8,^YZ 53W;LIN5@=.X$S_T<*31=P
M81UNBI0TLE738,.JD:)L4Q(&JIIG63W^D:\8/;Q1V L,TV%V^8DY.LJ[\ARW
MFN.X("',HF0]Y;!#2/%7 )$/CAORS+B'O@5UL+5K'GG QAB+H!+/IN!&-^\W
MP*OA)J?$Q?#DP/_<-EGP,V\"<9L6I4?'(4YSSY89X?8WRIHT8ZK2$_B+ AQ)
M]<K(J&>-41;9;T]=1P]=F@PAEF?V/IGPM@FEL_+-EN\\^3;W!ZKM.L$7B9E4
M%C#^0;'PR=_B2#F,ZQU6(50G,87<;:Z%7/!:2E15",^8[ JW?=+0NMEIT"#+
MY^D>QN\*-P^'3H=XLER^QAK)E4D%&M$ZE5'M$_9MN)L(*%(TO4?(2"%#/]XM
MG?$,*<RXVW[UU+._+W1 DG#'_QRV+J&O=#KV4AF/W>RRRJX!806M[>NTB,AN
MH8W7F];6[[@%_W4 UKEV;)Z"M6!G^S5^^>PRZK7I1^?;\Z^9=T.-/X^!GK[]
M\?&/R/W>G+),<1-OD]<_3W':N[M]<0]T*-TFN_\\T+@$^AWC'L!2B'&^Z1R
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MXX:MRRF'1G3OD#NI840YUT'#XAJ#G.VBP<"<^#)>V4X'>Q48,A^Q%0KR-PD
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M),%904>QQ+'E2FBGW3 4SR%X^XB?T)W@*]C4*?@]=SUG8H:BE&9I-^Q N"D
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M0LS=0R@AR?P)P-Y@NWO]!#QZ3Q-?W3(]TH8?(CX!MU":7LL[+=>%7I=;T4^
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MMS3*U7E]_JC8_,[K?$CH.%*FX7F_2'DM_$(8TK/UA3^ZY3V<49\9/ &I9D^
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M8)H,#FN6';T&C'[>CC\!_Q^6\O9/?;O.81.D_B)Z3;5J=TE*$L(PE02/>\
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M 9SC(%A^J>:@9Q0:F+/_T6N:-O[O\YFYW+\^/;S&$FPS>0($([R6RR5FZ)^
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MQ5=M:7;F#J@W$3[>7,S&EA=]H%2W8V4;?H:,/902MYQYZ6IHO;=Z;[\M0J/
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M' V:DHU10M3<_07TMJIAMGPN&X90G\#=29UVK:/BERXT'/UT&J_W,'/U;3_
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M3$C853"@>'9?W3B]S?);>DIP!1 &3Y^.+@2(W)M"7F!&\;_/_-ZOWE$P-^!
M\H);V6CA!E=GN+9$>;3)(,\"N[M/5<21-$".9D.9O->_W3?;5_C#2.2N,/Y/
M1><KYL77%#6Q1B%14!F]Y 3$$V@*?V(E7Q ';WZ7@9;(7DC2& C.)P6_#X]G
M+?WX!%36J0@XK#7>."71W:&F=E-3!6Q-_.IQM$& ="2&E/[QB"AVTC50N7:D
MRF3"^G!IC=LP!&Y=7K62-YV$:*7&/"RK9)?%W'87G9A\:6[ GC&+MN@E.:.+
ML_&2K6<H8#*PCE\4)+2FSGZ='L7#R'#$9$P;W?Z9">=(@TH ,I:;9ZW2M>+X
MPT1Z=0A#AIEN%+2:[+;R^T@J:,R%&;JVE8^G&6O(%AU+1.-C4[<_< ^KKO'$
M@O7+_ 84Y^H$X%%8WFC3CH9_:1Z@J,(Z[X^6HQAH,KBRC2C<]#FN6R$2AN5.
M1_%Z<VJ=9V&D1_'0Z8(N9V4XC<J>9UY4M!DKO!CEO''&^A%"8XEIXIB!\;Y1
M.M#'H-PMK"-T:*O3[PQI^6L)5)&KOA8'T]RZG(4JA9*4I *Z&#$U40C$>C.R
MA%?1M1%C"0?^@\(8_WPOF4F",_^; GU/'Y%A?63 84J0HJEB0NPQZ^-QKHCE
MOGVQ.&;JFA[^[?:5",OC=+7ZR5%.$:$SGY7"FA0YEXJ=-.Y=(8(8*^HUG&=F
MM?6]:.[<M?43H'P')0-3M?4"S*XPCAEO.L=+4&GH:=HP617LA676&(Q;6D(9
M2X4$S9*+&<S5"+-R"W),1P&#6QM.2P-ALK'1=,0<"*8CU?Q>^54OK)B<;.\J
MZW3Q(AEO2!7-YLUB5&WFRH. E2A/"!)B46&\"66!Z:"?\]+?.6DH*!FDI'Q7
MQ0W6K;FXK.:]87-M^<!BI\I1Z0\5>WR<=V]J=J+K8 :MY<LN>_>/A?'9E6@N
M4CBG9H\8;4K6 KA,ER0B8)3EI2$]A:'3,@I/7;-$4RU,]29+B*33D1 J_+9,
M2 SV_<*U)R"*Q(SF7)/>-->Y6EYH2&6'2E=DMZZ@Y)T<[RK:\+NM[FM@U0<K
MU-;#DTOV(7F7H4N^Y!1@=4@S$";$Q S26SO$N^?&'A%EM]X[E:(]TJK .?,B
M^*1?93QAI5?;%-/_[9*"@;>@[QWC ;&H+^H:->0D9J#>6I+TXNNC'ZHYU5%C
M4W0)2'7=TUJ=D*A*T"8/JTH_Y?!F]UV<XW:M["ROG$/MFVT!QEE<)!/8X_MB
MNQW4', Q1H4CUW5?>J(:Y^!R"$J&OOSU6?[,07@M+B&B(29L_M7:-S-!4C^5
M!E>R ,D$ U;(#8_6MZ=$J:?;.^W>'#O_#-!D"!S/,B[@6P350@RR'/5,)3Q4
M".T0YWNM\!25_XK\+8L5F$=K!9FKC":TS(,>?6X#'Z$2A6HD'J N4.]A.7+$
M^'K*2ABW9+K+D(NS[H3D-U'O&]/>1M\9>HT(R3\!K0Y2:P+:TZ]'&+\=SWS)
M>J<G+OVJ%6HAL6!5#GOWD:D\;EU.C<Q4D[[\[8O-8=$>'*&Q$I$ZA[,=XZV8
MAZ2XG.'#R&>-]8LQ&V*(^,_'CV5FGAZ8F;FP>?TIQ];NJ?7)]?Q!VNQH,&P=
MUITJ&O--S=%^R':-$-Y%8:<.PH[7261SR4,"[+P/"F7;W<+]S&Z:AW%-ED*(
MS3!^\D7!=.SWY)+2W,5G9=>CJB!T6W.K,/;K4QY*]R_,,'Y_9X;Y[4\$M:SO
M"5UIW/Z%RO\/_%2A^N^XV]^;YBARA-)P))&:V($8*KG-(J5>*!$<]I+X)-L+
ML"Q]&Q4FZ%R"&=^L>P+4J&:Y$MZA=(MNQ= U\:&+W&5_Q+PJXB(B;HQ,E>2
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M11#N"9V.;G1,-3ZL>$,<@.38S9D!V!;!"@.L17]X'WBYZ\N'(21AMY(PFF-
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M%^TVSD*5U+V!"@L$SZ5PJ*6WP]!<[+5$(P&N7[1Q0*MSUY1:C? 7M"QXC2;
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MLL@9K:I6TE43!QX:-GUS JY-E2F=2+:?T)^^F!SJ5&55')N;':#-Y( /(-"
MB \+'OLR8_A_$GS6%:AD7K0;HFMADSNQ\L->)/QKCM^QJQ9Z ^5"\=MKSY6!
M2*PSY?'<1FAU(X23898][(#S56(-54>,<]R('D#\A$Z^+F';&FNH;KO+GB*]
M9ER^ETZ&O1>/#JY;MI>$?%HES]JM<3@.7 0Z-*MKC%# (V"6S_B$$FM0>>VZ
M,A=*KZ]0LLW^+BDQ8>HBX>T"*8NTCG-M_/,8SR-#Z>@\?2LOWO)DTQ_[E[&H
M.8MSJ58[<8L![&I2TM6=T]CPO?E6DX8QE&_) V3/A536K>#EF8.'&_)FYTJO
M](*;U82J6'B"-LV![T0<I+'S# (]RM_)E:W+F<38R4@CZ7@%,L*=O^6[<KNR
M/K#A<49=MTK+0:B=6/ER%P1+NHU,<QLWD'/%[;#K,H^I;\>9P)OYB93"7)N?
M8^Z7-6LH"33#Q6;K\,F-P1ZGCFZ=3 $PEK:M*N'O$D[1:57SN\O2!V*+N/<7
M9*NEQ6IO- 2BT4:!(/S)=6]*6XEL\3[L.J#]8H279R()++(  LSB8*F8H_-B
M<>*T??AA)!18D@@_@\2PO^;<O3$&W8DF?7<;>C#R S=T.^ZDJ-3.W4/W_5S\
M0:>_EA@<%JJ!"]&*)RE/RXN9MS[XD!(Q5G&TT%+,4]4Y4.8[]H88KIIBAD=9
MV7K&JE08XT134QJ26A_]K49;;^_Z/V!^9H9[D"Y_MO+,? /C5(=G'9V]7[FD
M)2([[6R=/^P*;.:F=GI)U<1V>?HCE8[1UH>XH^XU95&?O^X.X-DNS;R6=Z&B
ME^?UYB:3-<5\J8Z!:>9'0G(^I%UYXI?J7'!?=_CF6T 5*]B1R^<N1Q?8)I+D
M>GO>EO5LE^5%LT*^U(L>F%U.(*,N@84[F?GBA^[QI2!U@^MHJ6J=E#W-FE"+
MZ,'(#'.XN+O66^^?R/$$1FP2P^_10G89SF83V,JQ3AOF4<HYG,]+_N?R %K!
MWNS8(*;UYT[/ &SX&F\^#_>7YL4= 3RI] "N^%%[Y+:G'&_5$IYFWVN,Q%1+
M;#BKUR$@LZ7;XV(U@.*O>9%.?-Y'([LAX\"EJ8.++/OP+KIU?* PAN9]<Z#$
M%@29RU_MYB?\J&Q4%?OV#-=Z1-&(\C->AC YLR@!M?7/'VA+X%5C8V/GP@"^
M^!I&;Z(I38L/A:25N7P9X28T3&-?1IJ%3HZ&:'Y9Q]D'3?Q[Y0T7O[&;_TQ&
M_$&0_P?@5>TO7OS?Z.K_K(B 3P+15@X <%("T/^9<MPEDS--&>,+>1/K]J&!
M&&<<EO__1J%S)^&8(<C/@*_"Y<WG+I,D*=KE+1];CWDL5,0 QZF:[2PLY#W9
M$Y=IPK&:<JK]$V9/1*1 ,>5+AY=2 FM ;0HQA*;#&B40;9-QM='()FOWH*YQ
MN"-B&7UDR\/[&$D:*F]B.OL*=RF (XZ'MT8M$6X-OS-;UR"7H232CBZ#&GP1
MK*O50 XBO=%+X8606C+@G =+N@@/_[8YI?*M-:4@GAY3M\X>W#'TC@\[<9 Z
MJ&U8)?>GF(@4P!/FX=V9.:NF;/?*/$6W8UYLFG5P]'. :LY0!#L9?61KQLV.
M(5%(S8+R\,KFI)R[-]!TL9-POH()YF?:BY4C(' A8O/U:P PDO:9Q+1*]83+
M'HTW4Y6-.ISAL7P5)P-F/RJKPQ*'*//%_IR"B!^LVSU()=FL.6SC60UW,5ON
MR$O-[R9<S5M.Z[>_%U S[I!V.@&_!][>/AN[80+YKU<)Q'YV$YJF+I]W<@PZ
M/5,BQ2J.+DP=$'B5W5 /H@D1JOP?[5UI,-S9%O^C;;$D:!);$"(1>B9#M*T3
M)-;!A(Q]C8H4;0LZV@C10C"Q:Q7+$+O$OM.:B"6B:5OL=-MBC5@;L:1U]TC>
M&TQJOKT/[WUX'\Z'4W7KWM\]]YZJ>^J<W[EGT:_<;QMAHV6+?-F!?6WYKTUD
ME39VJKTYNB<ZK7,W1T'54E[BD"L=XE+Q]J>L&.6&O PLPWX>FC*?0 A/(VMC
MN[UWIL9UW<=:7<ZYA@)Y/7U!K../SM>% S-5JF$U-84YDS:ZWAQ#.5S/($_)
MLXZ&2A)S:6H?/9L*_U@+*72Q++2V&B>.Y68Q5FYERJ+W.1U BF/M;.TPAF4;
M S!=1W$)UB=%K] J*0O]22\L954/@W?J$=NW0MZ"*KO-BFX7[?FK%EDL[=3$
MO7UD*ZTC7HT6I)03=+(79:7\:WNOBXA'<E+FP71=RP1H9IXSJ<.U'\>F";[3
M":+^.JW/WR0Z=Q_17[:VXAV?-[5DZ3:8F65#TG)G1PLB+@C71X2"J!OL%:GL
M#IS:F49J0M=KGI=<+&*X$TI=&W*(I41/KG<DRYZUARP*XZ\>^(8)AEE[0MJ>
MY+,1"T?%L%T;EA)]N:2MBQI3"Q?*19GF QXDPC9E#9 /#9E9" ;;-QZOY>V^
MAR.'$R&\19AW^'B,<T>H2H_"-'>3.\.E\)5K>;G!6A6ABY2'2%)1^CHC0*UV
M/_85'+9O72OS>D]\/B2ICJ%7&\,=U437H"1H!7#Z<#(+(W[>;4D\R^K-^"9_
MGFC;(82AM_*4B/QXQN&&&C\+MAVV>.Y;[^C5 VEH^@.G.M.,6#W&\FJ?A$&=
M"C&W,;9:^PK='AVEN?-7A%6;T4ML['^XORQ$</_>&D]DOI-F;!17=;69@D\-
M4HX+DBXX?!='H)BA+ZZ9"=AFB-<^9=1*&]>I]R^+/!74@ QN/K<T$-XY!),K
ML"38P D78.6?^-YH;-5I&*/M()U2ZHDP1L_HP/,-$V"ZX!PG+XOED1%TPJ9'
MO@N_: @^_SGNY0(;CBRQN_CHN_I:N59(P$.X?=^  D8$&W[K15G"=/OH2O:E
MY2>3V-]DO!MX] 3,XB2@7..L;' EGV@F4[SDA]1GP"7@12GN%Y7#YV=L MFD
MHOK9=)AY;:B+4M93O5-5G=#UB<HGNU[*/ ,B4 Z'"7C Q?(4D[I*O^R+73OI
M<(_6A*B[;Y-:@A"-P#1/Y$P#7S@P2Q@Q&Z3R3UDX>W;(=\]Y6154G%FXI,(T
M[8&H2M-A%M9R+B+<R/<N@ ?I.$9#^-;;@^Z+RVJ1=%X:;9M%.NR>;I.N._1]
M\W7O9<J/JUX-A&;>EK$>F9M5)7%K%I+JO9/Q# RQ!9X=K^26[1RJR7XNMVY3
MUG#5D8*5^'U;)P;Q^0GB )(#V?=.Z*??/VA&G<W*:Q()40Y4%#FC.\/%\0&C
M/#-!25:M-.U7Q"=LMJVK\!N2MU)C?XK"RHL%6V-") =+/N>[+=9CY2!94@F\
MW%ST!7D3\ZL@M*RN=-I79+ 1O;(1F95["7I6>WSZCTO,,V-6 RQJZ[R8)E_]
MR"6&".PR=A@N#14=RB%QVSBSYLE7P7V%7V,^9:D+"MX)G!UQ3>J%"6W9%(/I
M%C>6WH@%]>^OSC=BR#+<!G"7,X:5^B,*'+V@U-)$G+Z\LC"/37"KF=>HM6TS
M>$0A4=,BL3.YI57,5,)!3&4/Y%%;\B4<V!I-;PUP03G6U-* CP8[<7Y"=UEW
M<>G2HO1$_ZY[4OW%UO 1@=R2Y!WDR'GIQY;\N@UT(G>9/9OI:F)VP@;"URYG
MG(:51[3RU2!-9Z[?)"PH0H9[!)V,W-0(L.8?F,"+2'7<.6*W*[R&,/^FV!&!
M0/AY)"KX2"' ]?ZU]H)=&H B.4]N<&VAKNX?0F?29 .1$K[ HL;@D< @&9#D
M_4ZA?5CUHY@C#0@TH $XY_%_\XYR)9]YZO=NRL=\8;&@'5XE%(D B[I'#>)#
M[8&F#I!5E[.3:8".=<075SPVV(PL@QV4(94M\ADLT0 ;9SMQ<QJ0$9).I5.@
M <*%/D?,-H3J$O,%:HK<P8FI8OXVN/C4Y054/Z<F!>JX+X"C@&1HP 9KX]ZJ
M1JPS#7"*ITKR^;;0@,YX/QHP8#ETG)P0ZOVBWM[X$I^F54X#U-E4#^@?4%6T
MXXI0[V_VT@ @A09$#X> _VG],IA;]F\1)ALO)HJ?K[Y&7P6] S-)QC*@ZR/2
MJ0W>VU_3G*$EO$(..76^/,I&J=8VG[<<4_TE-A8PF6]1DL4\!&(O!H]!]'Q(
MK5%Y9);SZXGR+TWGDJ+Q*2/#;(%K0XK;7WMA0__7?D7[SUAJH&&/7\CSD7+W
M^#O O2O$V_NSAYL7(66P&9O8K73^I6:390>HAR:9Q1TXT5L=!:L%#SME6:X&
MG38Z=)0HD;&:]"W<X;Y59]7X\@H:CU7M';=7!X=A*BYF[SUCP5&)F-W)$??3
M$'.1-. UJBT08F2"JG1378RAPE!M,7_#]"UC;46&'H&A=E?1@#35O</9!8"T
MO[B3GXWA"<$YXM0OWZ]]I?18[:.DP&D #$6:I5ZCDS[B69:>@!+SO4&(QP8Y
MQD _=.*XL_Z%R.X;HHH"+EY#>^.[WW%V_B__?6&FC?T)4$L#!!0    ( &B#
M558=+J"TCX@  )/4   4    :&%L;RTR,#(R,3(S,5]G-"YJ<&?LNP5<5.^W
M+[R1;E#I#@6EI+M$2D1"I;MK&)H!:03IE) N">EN$&E0NAQZZ!B8(4?RY?<_
M]=[_.??><]]SSEO7Q6?-7GOO[SSK6>N)_5W#S.W<[0I \E)!60% 0T,#XN[^
M@-M5D@MYB*T5 *BJ D\! , !,-#$@7MW%LG=R<N/M@#&G8UV9^ME9/YU!!CO
M;DWLT@+8=]<([LZE[A2@W?W;>__('_DC?^2/_)$_\K^I*%JZF;I:>C+J6KI:
M6INZ 0!F'/K?&,7#.^90'(?QSW9;0OS?;'0!/@!(2/@7^U_8!4[&7RW^81=_
MY(_\D3_R1_[(_]["]XR/7^P9K]@S?D9>83$!83%!H7_SVAT/ 2P!-\ 4<+T[
M>@*,@.[=\2_;^N[:'2L!;E?QF6W<W)S$>'@<7;E-+<!FEMSF8! /Q-2)AY?[
M&0\@(0UQ,C6WMW1C-+.TMG649#ML[61CM+609-,65'VFZB1G:6.KY.UB^<;[
M]5MS;WMS40LV:2E"/ F(& 3D!+IC08P0D(.CJQA$DOEOK8O=V7]=YF&6DG"Q
ML!+3?*'PCXB[,\E_ZHNGIR>W)S\WV,6:AU=45)3G&1\/'Q_7'8++U<O1S13"
MY>C*\H\-O+!T-7>Q=7*S!3LR_G5N:@9V=Y-D=G>WM1"S,K42-+.P$.0R,^6W
MX.+EM3#E,K7@Y^6RX.>W$!;D%>&SXC5C_D?W%N;_[-W)W<7A;[XMS'DL'2Q!
MEHYNKG?9X.5AYOG/]7F7(LG_8?KO8KS#B,FY6)JZ6;ZX4ZF_AIGK&2_7,_ZW
M_S3,W )\O!(\?X>3X/F[COX_D"TI"0MS,?._^@1V^0?W;RR=_V.C[6 K]7?4
M^A\"O;O^#\:=A[OIAXN+*\'S?W;^K[/!\X^S[\[ZY[EZ]T[&_QODCY,_3OXX
M^>/DCY,_3OXX^7^7DW_ANY:.=R37\X[-WLX#<@ V)B86)@8V%B86#C8V#AXI
M_AW'P",C)B$@I22CIJ(DHZ2@H6=CHJ%[1$=!R<S-_(C]"0<G!S4C#S_/4SZV
MIQQ/_VH$#1L'!P\7[R$^_L.GM)2T3_^7Y?8;0(ISC_0>$AV-&;A'BH9.BG;;
M S   !HFVM_DGPH$M'OH&)A8V#BX>/AW@'H2X!X:.OH]#'1,3 R,N[N^=_<!
M#%+,^TR\LE@/-$RQF9T?\@7&Y^*P/*_N(M,<1[#RF[D$X>*14U!243]ZS,;^
MY*F H)"PB*B8W MY!44EY9=OWK[3TM;1U3.WL+2RMK&U<W5S]_"$>'D'?P@)
M_1@6'I&0^"DI.27U<UI>?L&7PJ+BDJ\UM77U#8U-S2W?NWMZ^_H'!H<F)J>F
M9V;G?D%786OK&YM;VSN[R*/CD].S<]3OB[_B0@/0T?Y)_LVX2._BNH>!@8Z!
M_5=<:/<\_P*08F R\6+=E]7 -G5^P,P7B//P>7QN=1<N"[\F@LS,91R/G%5@
M]1'RK]#^%MF_+["@_TN1_7-@_Q(7%"! 1[L;/'120!JX4(A@S[GW_VOE8.GU
M8ZE#Q(8($KY7UX)PFO+Q/=D8E=<X4$9'YA!Z<PS!?=XAK:@$VM]H(@IC/0MV
M^?/J0[,YLT%U,6HM$_S9G'#*P15O^"Z7W8T(TK%^K5RQFX&P[OK12#0UG:+Z
MC)$:J])5F5+UU:]^T76G;G0@COAE7EO,%FRIN0C%UML);7F7F1TIP<U\##^:
MT!NIX=M/$B6L"X*,*%))K&B"H[V;4(P^+SDY.U=9#=4N.7_MNQ)G,3SR.%B\
M*<UPW!M]S8X.M:F\7X\J6<OT(,;0AWC/=@^60!(F-KU43US#S'GYG5IIJS"U
M.[Q.RD>)KE1G0((,Y#O&)%QU!6V(Q9R.]]&/%9\-4JG./_MM<BUV.OJ:3T92
M(>*8^$/G?<%E2B/CG2R>JMKJ*;/ZQLX&\K#=FOD?@<&FGV,4%/R:X+K4TM$W
M3R%YL_I3;C@^=/397Y87]$ =%$\XO RV-LS:<;98,DYRB*WRVO)?H9J+[86D
MB7FX'+AR8GO.^>>76'-3^\P>*4<%B56QQ4'.ORZQH/)AAZC7I]<472V.T2X=
M]#%L:7VG&\+0T(VE6\#JQ5Y@X("D[);30[3]A]H9J$38X_JS:^SN):)Q&/B^
MO9:]W[C=?'ZLVL?FS]J$&:$&!"2*?B$M;#%7:D6H&C6\*]G)NCE!\4AE'H'Y
M1:Z%>8.OW'J2E<=8!KQL43'=0=_HX^4A14$WHDNH]-6/X8+ZK?J4$G)YT$&W
MY-T8IC1&HEF@ 29\KPS=@S9JQ3LVU+UQV@>WP!Z:DH2_N%.U9.!E\N$Y$MOA
MGC)@<2Z 5B_O19ZYUAGNQS/)+:&\4H[]G)[AODAMXY1E"CRE^$/0T-L/FG.,
M6-NRZS$J[FJ1:3.5^2CNM6\>+78&J&2O\O5(;5TJT'H4X= K"WJB R>79T[L
MZ+/;%=;?C1&9OQOO7FZ![^(;<.-:?W.OWZ/BC;_;6\SI3\-A_E2HM+6^_N_2
MQ&[70B"%F47'PT-W:V>P8W1<-3QVDWN!]@2]>O IVK: =N+N+4#J UH]#)%B
MF6F371T6I[-_T1R#LRZ>-8(2&.BPL&^26JQ<.#W,'&K'CKVR+T9I*R)^+F43
MEB7807O+/\#<S,A%WT62=1,(#_%FQ)K+T/62K:=)]Y8;;:WU;@6=THBS3KRH
MF8<N],4\XBLPDZ&*)-OP],<9[!/3HD]!CO90%X7YV&)H4=OM7$@E^1;;)J06
M+(J$JH<9'':].;8&7,3&L%O'C>QA:F'0CE@$UFP_^<R9:LE/:UMQ>6;1#P)E
M@0%HP>:;(K_;Q68:8M?HY-11U:40,QM0\M"P:M"!**F.DB$R[O6^>98(@QX
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ML9#?Y)E:+?P6Z#@_Z&_@&!6X!<*7'QRT496A"O7!.-'BB@DPW'R= Y_-!-Z
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MA>))A0)L4G[B5 *^ALE=8F^56"*;%%<C%??\G>-!GTBZ^4&[J%F\)FB%TN^
M;]]$^]C1MQ8=AWNH/:^8DJ7OMZE*%:U(JNW_?O]>"23?UN6I^+#@R2,1*O%
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M+51)R6Z#F&#DDEVCL]Y\+C#(87+?&VU7S414LC1LVN\9! SO?X4X:\Y=, S
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MX)ZTZ;P 49$;:I0'S0-+TAG-J9(W]_;.NW!$!^:WS+'9I/7>(B3T6&UN<%M
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MM$N9!UN0]XA-#',@1ZO_#'F%GZO/>9ZKSQE"GP!1A8\X$R$B>TK/\;I7ZT^
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M2D= +9YC?DY,%!Z'^#?&DLRNX3@QG4BT]"L1#MT68?ZS[*(<HZ$HMX\IC8'
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MO#*IWWKP3+FJX9CX^6"\NB)L>Q%-!YMYY_F<5S=^/H+HI4^ ;?Z**H/KY-M
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MMAL#1?+(SU"5O+=0?0::@EVO&+SS0CR;FEJG'2@7M;Z*T[#L+(=T<R"-IOY
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M8LU']7?'!?=AWQ?+M?K1O@5]+_-7O5S57-JRR*1'7W=Q]<=Z27_W=SLWU"2
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MP7MG^J#7^+QC[?YQ0O#.L.8URNY<.]TF:%O!#?5,<&M=[H-<3C$/A8II#*,
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M#$DIF$S<@C!MFQY?_.27U>,C*Y[K>/<:NK,[;$V\G<?;!YE]+V8WD+=I?)Z
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MZ6$QEQ]65:!@E*4)H3&'F K]'Z0D9 EE4/)$I/HSD 1;Q38<>_C8I+7"!RJ
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MY_=5I9^GF5S*&_%?JW)9[UI_U?]=:&"QGL<C3#)(F7;P<<(B2 57D$5(D"Q
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M2W=2SYK<FE+O>S>+D^;G]1\:(R>[14?,^D!KZ&3G..=!G4%_VMUG7W@5]UZ
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M\_AX;]OV8MI7[])V'@:;IFP7[NQ@'IN1/JWH\@/E59>WZE T(U)&)$20J81
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M#&0E<AGFM2HKZY>%-ASC/%K!MJ/:H2#T3)>UF.#] 6Y51X*;=MPZ=$2Y#LC
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M-$XC&(4D@RBD":18_U40(4.5\B3#S"T _L),4Z.*.N;;//K'XH)*7M>8^$L
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M$#,<J92[)=(Z3#XUJKB5ZXV&']1R@U)P4!92<O1XN:R I4_*$ZZ^O48'8K_
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M61H%C$'%3;%CK#>V%-,(QJF02HHH4L3)975^FJD1:"FE?H:-F$ 9.=T\5Q?
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M-4VF]GT\*-8K#XKU_JB*]1Z6=YY$26>+1\7.J/]3/ ">/\VC%7T^0&4&=KB
M'3!5+/?DZT#;+^Z?H3"TA3;_'2I%VR_:2*6C'01R3RNL@U$_Y 6GB_^4=*TI
M_)V>8!X&'%%."0PE#B R=5(QU3]EF*<T2PEEV&IGV#;)U+YMM9R@$A082<M/
MVCOKWGZMD+9_:(8"RO,WH!-&3NF'UT#HG(1X<>#14A&OJ7:8D'CUVB$Z?OZV
MK(M52?%.3[3:+C=W:_F8;Q_+Q&5]:5%LJ=;K=E5LBL]R,Z=8"J02!3F5&42A
M,+F'G)FD8\0CK$B4QMT;@3K+,S4*.5  "-/>,J\%UEODPC% O.]2V1FV(RZ
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MR1Q793JIQ#-3N_J#"E>'>V3)0TKI>'[] 7B19%T!"J"9\Z$[MBQRK?6 ?+
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M][F2S[1LJZHT5>M,3%X;L=M:,C36^O0 6'*'7UA#,TFGK8%T%[TNQCF,1^(
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M65A<$:*V<_-DLRB*XKB(89)$3/L(F$&J5 [3@N0%DD)@@OQ5=IXBB5C5(!Y
M)Q;@V]&*7T@#TXL'-#W7<PY&.!9B)U3+^1P!.5PYT'NYOM7KQW(A[U?RJ9ZA
M2&59G@C(42P@0D)!1HH(QBIE:91+$BNK=F,AE)L:N9ULZ5P#;1W8-^]5D^==
M \$?QD30V.CJ5OD<>TM'[(U&-+3KYJ$_M\TPNGMZ ?#VZQOZ5'!<;S( M ?^
M9P@9 [>V35L4MM\694?H;R_;KW1]?)I>*9^:":O^>]L]92%,\4NN?WQ8FH\^
MK5?UBC;E:/XA3;*Y_LYWO4)_E%^D"271GYN\#K,WOZ;S!UD]Q3,1\R)+.(9"
MF4 0_79"EJ%"3S.9]HUCI6+A%@,R&=.F-DFUEC4D)CO;S*&>Z833%!$R 19M
M]2+'[?S)(&Y[@C 9A2<TZ^UV[MJ%Y=6$QU[ T0Y?;2NO#IX;L/.DO=]YTO[>
M/&D[,-V 'BC0(04V4($=K( !R^/)R>3&W^]AS73,&_=\:#IVGSJ2FIZ& _V'
MU9+_\XM\UN3S3>OZN5H^5O3I=KWZMJQ,IF;;NR^>\0@G&:,(IBHI3(G>"!*$
M$B@3KN(TYFE.$J?)W4[NU&;>K8*@VB@/Z( >EK; 6TZ$_N$,/4L9C<%69=#I
M? -V,/;=.=(1)K]D;BE[7*9U ^2 !ATO#U=UZG;UH2V#]+6O@O3JR[,BHA&/
MI(2F!BM$J6#:\T$84DYQFF!"%?=>=.J"3E/CMD[9310H_=&L+A;ZW?R%R854
MY>I74WHJB?^'_^)2E\;/C@9''I7 %&E?6DJ/2C]Z&ZOV+WJCTE*6<(]>6>J2
M7I,K+&4)Y)"Z4K:WOC9OZ*%J^A.^--/&;R]W<UK7VU07DB08\83!HB ,(FH2
M!F4BH<B%8@F+"Y+EPW*(SLJ=&@WO9LETD; O8+T0II_*LPG'UWY1L[8XXCP-
M[E1S?F0L?5#_>(<^'S"*&9Q[A4'KE8Z3DV2%4J#\I/.RWRA7R0J0TWE+=I</
M/8]=Z'7XRI2Q,&>_70<XG"J*,J9@G*8<(A(C2%&.H) B$C%C12'= LF.29D:
M/^TH"8R6KH>;QX"T/:6\$I[@QXVOD0G02N\L!)Y/ (])&ODH[XRQAV=RY[X\
M[*W_;5V7"UG7=\LG5BX:5^E^L9*/;=6C+[(I4F9B5>M9PCB*.(\@DTA"% N]
MM$R57F1*HI($J4(HIU02>]%3XX?=8P6^>_S0+2;=^,)A".Q() RP@9FE5QKL
M:'T#=O0&G>)-F+K'8H[N:'DE(0?QHS*3.RS[=#7@#@-;[]&R:OJ=[?2&KS<?
M_I]2+_OT&N*E*S5"N, R27.H<*YIC&C?AM$D@E**%.E%6$)3I\;D3M*GQF1&
MSZY7W$;3YBCT]]N_.Q9X&38:=HP6#./ I'8=O.[MY8; Y+?;G),&XS:?&P+.
M02^Z03<91FNO\HEG,2)9JOTL&,LX,XF\VO'"<01SSC!A@DF6$)?>EJ_N[D1+
M([6R;/?HW;CG-611%.6Q5 JF69)#5*0I9!%+S"J6QBR-4X6E"],/AVRD%JL>
M(,MQ$F<80:3BU+3W0Y (J5_SC$>IGBMSE0NWFB.#01NG6(@?V.QFL<%0!)ZE
M#LMGW*Y65<G6JV:/<+4$GVGE]53E*!)>)Z+7$D:=:(X:MS^1'/]2@$YV,Q8I
MD60D@T6LO5QD E=)I!+]/Z$*%L=%'CDMV\]*FQHK6K0J\]@[SD='N GQPC7@
M^>W6%H0BSDN<3F>U4Q1B=]'0+%$EJTJ*!_JC[;2\%:;YJNDRKI:5B?8S/@.*
M:<HQC! VK>TQ@2PN"DC30B(1<Y5QIY(2#K*G1C=F)MV6$&NZU?!=?5VS1>T'
MP8YY D$;F(=ZK9LXC[XO^PXY&9COK& >D$;J#)CG?%)[^2,GECH#<YAAZGZ+
M@=%U3\_SY8N4W9YC7]2_E/7=NC*>[2Q**!$Y59 DK(!(DQ@D&4=0)"2*>2XP
M<G.2+DJ<&G/=<EZM]X\SS$[5,WW12LQ-K)QM-7A[V.U8RRN8@;FJUQ56W6G%
MCK8WH-/78WB:+31^@\\N2ATWM,P6A(/ ,>L+!_3R:/)MF[8A=1<"$!<1$R)#
MD$4B@8@2"G&L_Y<4*2$%35!46,52'+_]U!BES3=N-73H(G$(VWF2N!Z,T*NH
M'1PNATO8 .+01>,J8$9JFF'UH+BUQCAI]ME.&(=7C=?XXJ3&K_I<G/[6,,>H
MW8+:]#;Z:% UP;)M";%<9'F:PB1O#AQ$#HDL,%0D405'*(ISIV:F9V1-C;JZ
MS=!MJ[!>V4%%?\Z!;.< >8(N,-$-1LW9Z[' PZN_<T[>J)Z.A>'[/H[-)0/#
M+LI%N9(?R^^FLO%*/PDF,*U=R>TTN+Q]6E:K\M_M7%5PJ1C*"<PB@B'*$88L
M41(6>28CF:LHHTXG<NXJ3(UJ=IO4[NKI&'/A/A1VS!,6X,"$U"H/&^W!5OW-
M%I(S]NX!&8/A\QN5X:[&N*$9@V$ZB,\8?B?WQF!?3"9\YY,7(DJ1HD*O[:1>
MVR%&(8MQ"CF-I.1)K#)EW0ILY[Y3HRLSCY3UJN1T#G9"8 ;T ML%[SP770%)
M8((9C(93^Z\CME_=\&OWGJ.U^#IBR&Y3KV-_OC8=[Z]TU?7L_J0^+A>/IIZ$
MB9UOLI^VV5]41#QEIN(I*AA$7,201#&""<\CP:F@A#I5/'558&JO^8>UUEJ"
MK?)-(+:6L.K+Z#0Y9<8@J#]_&I EXSQ&=@Y+2.1#L\E.5N0.\@<XCY2[YX9?
MH"0^2R7>*)O/#:+3:7V.]QE(BO*QK>3Z;)R?Q>/GY;SD+^W_MV]9REF<9&FN
M%V>R@(A%$60926%!E<C3+,M4Y+1"LY(Z-?KKE-:DIY;5TX#UF!W6EHSF&\'0
M--:!MU'X!K3*@C^Z?\,0EPM,?MG*2O*X%.4"Q@$O.5WL1D9"EK/WBU6Y:LHO
M5,_+-AFHV9ZZ,X5TJI>[I9 S(JC"L2:?C EL@I'-<DJD,,]PI(HLSQ6UJL5E
M*6]J!-2J#%[I?-/NK&J80:<Y,*K;$9,M[N<I*0":@<G(!Y#65.0(SQ$2JB7_
MC\?E]__4=VKXYU_(_ C;'QO2L94Q"MTX&MP3C>MEP_R=S]622RGJ#UK=K]2X
M6?J39UFM7C[K1V1E"A/^:UT^&ZJ;)9ADA'$*LXQ*B)+(U/5E&4RC+,$YS57A
M5M?70?;4J*=7'9AA!C5MUR.TV4)S<X)<!L#.%0H$:V .>HWHUP[17G/M'1G=
M;]H"M+WZ_ORB 9AY]8Y<Y(_J(PT 9M]3&G*+863V17Z7B[4T@OKJJ/\H5]_N
MUO5J^22K39_@(A:*X8Q )?,8HHQ%D&11!N.$2%HD.<F9T_+-4N[42*Q3NWWC
M>L7!GUIST*MNT^_WJJ&PH[0   >F,T_8.A.9(U)>2<Q6]J@$Y@C(/GFY7CZ,
MN&Z%*(US1^>?:2GN%W?TN5S1^=WRZ<EX?&8;!/&$D#1AD$J40T12!%F..>04
MF3S=!$M2N/:YOR34Y7T:JVM]KS-XUDK#<@%XJ[9K^_F+@-LQDU\0 Y/2#GI&
M6Z#1Z_0U;4V-QFW=.Y^MW6WA\=RH_:+8D=NNV\)PV$3=^LHK^L;\=KF _6_[
M!>PW]1QNZWK==CVK^R+V[TK3T'TAFHJ]/"TRCJ)<#Q8WF6^(04P2#B-)HC@O
M:!0AIU(RP36>FI^V:;@A.B7!2RGG0UJZ!!UGRXWZ*8U>Z$W^ZQNP[-3&V;'[
M9MN$I3>]*>WLN:'*&,/DOT]*4*W';W\RQB <[6HRBN"A$?G-ID)=?Y&U-+6$
M;A?BG?;4Y\MF&Z'/)(IYCJA)5\0%-J48.:2$29BE1/$"15&!G5*NK:1.;?*X
M??CR%<8D2L O]Y^__$_Z]/R_W_WJ&IIO@[8=_7O',#"%WR] IS#H-6[V('=T
M#E#=U0DEST'\-I)'#N=W .,PL-_EXJ$UH7<X4O.;7)5MB..[LN;SI0EXW.QW
MY8QPG&<)E+E)H18<0\I$ N.(4<-(:9(X<9*#[*DQTU97\%O;5:0>O-WH,@1V
M1!4(V.#;CH,P'5!^VAD=ST6I[>6/7*K:&9C# M;NMQ@:7_*AG,O?U\W\G161
M4!'.((NPV6 4#-(DSB!6-(L4(7$NA%LPR?;F4Z.>+N#!* A:#5T#1': LXT&
M&0;'.*$?-D@,B/ X-/G*<(Z=&XX<NW%HRF&@QI'O##T/^.]UO6HBR!^6)[8
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M5"&*"[?XU:#Z3B\<MC<7F >L20LT!IM,0+Y\>M*KJ+K)%UP;RYO]$\VH98\
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M1!EAV@/+<D@YCB$FF6"(,!8SIQ[CUI*GYC(UB@_H[F:%LMUZ, AV@1V/MD;
M-GM@J[4F;ZTW,(J#C>:>^[RY@.6_UYN5]/'[O;F <K3GF],-!JPX^]7) _WQ
MF@_[1-G?ERLY2_-$I#%#,*81ADAFR+2"2V'!"BP%B2/)L]G"U!73=[)<(EI)
MMGJ[2/MV'<@/&O6S2>U>:#4=W&P[P"T66_[P&ZEX8+\.-MW#]QW+#9J_AT#3
M87GA'=61%@(>T'5STYV .NM0V]UI/-?7R;)73JK;E0/K*^ZXLPOQ=;7D__RV
MG.OKZ[9XRHRB&"/*"102I^84(85,?P8+5.2I*!A&;C7^+PET<AY'B,A\,#+
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MV6Y@_G^4WV0(CS9 =JNT4+ '=C9ZM4VML$X]L-6\#3W6F#=+M]M+6+N'O@T
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M"4\QC%7*4<:B(G=SO,[(FAIWM$H.:0=R'$H[FO $4&":Z-M\M'J&C>2T0"1
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MG<8C92?+7K&RVY4#:/G.J+]8M4&S7\KZG_K>Y@/Z*(U<NEB],XW#2"PCJ92
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M>X+7'<C8]Z%]J[0NN92B-('@U=9PT[*C[< A9C2F6 4I@6&(,TVY7*_S(I)
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MG:)<,G+O(.7BQ?WF]F^RE/JF'[<+\5X^R_FR2J-O=FEGE!'.,8HA"T.F9_J
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M'HH(8Z>^5QY0'6.:V&1W;?#4TX(8$FB[*< #? .3_08YK6)-[S>@T=(?IU^
MP2M[GY,U*D]?,/B0D2]=WC>V^*G.W"GOE-GXN9?%XV?3E.I.U2N,F4BB)(L)
M@80PS<+25$Q#*8$<<4&3B,<\<ZIP>%'BU'ACH[!Q;@KYO)P_&Y>R.890E.?S
M'J>DEX&W8P^O< [,(UM=]_<9*WW-GVJ-?8;:6H+C.8;VDM21@V,M03B.>K6]
ML6]%1B%5OLA7<IX_FV-4[5,^F.:@=:'6J@^>EC.+,^V>(.VJ$/V&:09*30$
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MHY_#3MM(@VRQ^3F]H1N855N#P8[%IF+CIM+[KM&'D1A5]9\=,T%C^<WN'V]
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M7Y(63>Q1F$F9<(9A@F2B.3%*(2,I@E3))"212)A,K"N>7)(V-0)L] 6-PC>
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M?[X!'TR M@)/=8I&_WI 8[T4EAO7$QSJ$?>R=XW>W= &[ 6<W/.NBPPUQM^
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M((H3#EEH"@\+DHI$29E2JWIECG*GQH^;LKBRUE0[@:VJ#COC#KA;'#D,@^;
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MJQ4)]Y)7JX6VD44(P1*O.3AP1DE(7'/M$CJ##]7%'\_K33K&<0R;H>)B3QA
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MM*@X0HF&"U9,$**1H_4 5>-$WPT!-I0&NC!KK^=?B>[%\CLQ,0E<!$T&F58
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MV#2NJTN^^DQK\^8WKOWF_B&9E^OUU3?:[>:?\GO:>5Z5DNLLI1",5;J 5E*
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MT]6]&%KV'0#HV@V*G2V5)CAD.H((CFQI= A.,@M21"WKC.S2*.2[0\JXP!E
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M6J81Y^MG,2[.Y[67TSN2=*QGWT=8MP.?/(BQ.X:+@6S?W==<34P1EJ#A-:3
ML5[R*Q1N95O'A JCHW04X[>ZNG0/32<[40_)]R.)]/FLCN2*6A=::Y$V^TUW
MV<+ IUQ[PD;ML_=>-!HG>AA]XUJS@1!SQ^<:7C7]FJT+=^;%XBR0R=\<"AYA
MH_8]9A"#]$/Z!K(^>]Y#>^*F%^.SN"WRO=[U6<6 6BD&QIH(*E"LC\84@INR
M))><LFRS+A]'YZE6:L_;KOH/7BT%:YEAG@DPNC8<-D@A26$.9,DED5S0- K_
M#J-O7"O5$%FW+5<#=?7:YO$7G"XWIU=_R5BY.[:!X][G#&*Y?DSA0*;K\D57
MNK[:")4RGM=+@SXYTK45M:>>C!"=8JSF"K1O$_H\1-6I9FG?LZ_@K;/*W-;2
M-15H[T<3(!11H 02ABG*6]VFB\*#9(UKA ;#R&V3,YPJ>K4T[_/7/#_/QQB7
MBS\=Q)[LI6,@$[)[=AV0^F(QWZ#BK]/UYQ?GJ_7B+"\OD>(20^$8J3+5/GBH
M/?BJ3T3C4$F,3AS4.?#12^M  D_OY3.C[RZ6F\YISY;+VGB[VNU]NVCAAA4F
M,XB0:N.C(,!':R#&K!D:C22>)K)X!)'C&IT6J+K;$:B-QGJU1B_RLG:!>(ZS
M.L7XP^><U]O&!4>8IWN?-4QKZH,H'2I\N_:6]WG3<F7O3I>BDDQ*<$69>G9B
MP$6CP%"L[HT@N+$VG28.HV_(\7/7W[AW;RXL.NYSA.R"!N59! H\B'*!*!5+
MS-LV4\(>0^7(H=OPJ'IH)-V@*NO5@/WK8I%^GY+1GJ?7]+CYIUJ[M8F&C[)A
M#SUN$#-V,+T#6;*+]SV[^[X]HQ^$Q&R84\!$K5['4BHB%)#C[;1UD0?1)C/^
M*#)/M6L'O>QJF03A3&(V@+.AEO1CA'IG!*11W'I6O)1MJE<>1^>XMJT=SFZ;
MN(;:Z]7(O5G,/]$KSFI-:IUD>(1AN_V(08S9@W0-9,#JL_<AJ @6?*!E$W1U
MOKD 5-G7(37.<>=L+FTRYOOI.=4DW7SJ%7JSXP4CN0&D2 O*B 3!!0>\L(0)
MB]:N3:WN/02-:V0&P,)M:S*$X'LU&_N;S!Q5,[#_2</4"!Q Y5"VY%+1M=3_
M>M^=C3/^8K%:KZ[(>8??;Q:J<!:"SIRVJ<C),4\E0@C&@A 9BV61E=0FW#N-
M[I-MTZ%O?W[][5=+20;O!/<%F*HUJ5$%"+6:.7GT/BBKDFOC/YU(^,BV[NFP
M>L<F/J'"N[6==RN!C[&;]]03GVPS?T#=0/;RUD MX;%PD1)PR0,H25NLYR6#
M](Q+EY@,LLWAW] 3U6X+[]?%.N]U K*.)6H&'&DE*:8L.*XE%+2"UP0)-KK.
M=S")/73D/PH?/ZY,'T(I_19*7=[P^4(,5UMZC'FY^Y!!K,L/:!O*N.SZ3K_+
MR\UF<NW\V#G%M858.WY2E*XA".-!RF)8V5;#M3$S]U!T\DR86\^]CN7:74S7
MN:A!UA43P3.A@'!8G*4%$WF;VH)[21K9H R!B3MC8081?Z^.2IUA,MW><\9Y
MJ@>CQ&N>'UL=_M#C!AHQ>R"] YF9:^][=NM]>U()T2@>HF2$ T:(\)(#VJ(!
MO7&<?%IN&\[:.9C,(68,_?!EU\Z)O&:L9 ?%%[G+K^@0P=2FB"*ZH!L9Y,?1
M.:[I:H>S?5.+&FFO7W]IZY!\Q&_'F;7K?SZ(&;N7GH',UN7S]X#'\MI&*@J0
M&!R!1T@(&F5M\&.C=":&1GFH!X@ZU23M>?05A 4:6Z2F2,)E!LHX UBBA:(2
M8RI'^M F@_005>.:FZ'P<=NX#*:'7OVE5V0N%M]S_H!?-T[A#(_*B.][S""&
MY8?T#><772;V+KLYW2QUN[JAJ4(.%'43E@K6CD[URCDI/Y'OG+3E7H5F#L"A
M1 [@$UU_U84:GN=Y+M-U5<.U#*=7!0VOE[4<SQ2.. HA5(RTS&1!)U/DUCV%
M0!ZD<G1_J F^]GA#;?36JP'[$#_G=#[+KU_70OF+/@+_WSG.IN4[F8S=)</C
M[@8?^NQALMA'<7*B_:OCK"]?]VS?ZZ[.4!(OP05+.,0Z9\-YP! YV!*X5<9H
MS0\J:3QHUOAA-)TR:_U"W&_+P^_:M_.C""89BAJRPCK/6R-@]K5T!V4.A3%W
MV"R^@T1Q J'C36!O@*GK$]B?2GG=6KV#.@FT[XLP1G^$L?HD!*[K]4V$&!/%
M$9D+<,(&H.""=NSDLM2-NEDVZY/PVXI6T*O5>GJ&Z[R:^&*(C:1!9EU/R9,"
M[R.Y(-E3C*19]J;-B>9-.KKM>_ 8!-QVS$X0=0=-[%[@ZG/-KM&'>ASY%6<U
MW[81T/=KN34I9& >:Z\:LJS&,W!&!I#>&:>M25FTN:E^$'GC#@EL!*OA%=,!
MVOZ"R[_E-=Z8YK)E:8*:? +'=+WNFD!9"I <6@DQ&U44MUR:-A6@]],T[K2^
M1K@:2 4=@&G_"KF:S_;0"II(JVIM?JVEK7>"L$CPG(1I(HLBDJM8?)M4ZRE4
MCSME[TD-70,U=@#9RVO_USK%O9X3I^=GUY@2UD0=2H147!WB@@*"=0DDXSHZ
M]-K:-IV&#R)OW+%YC4 XO&(&/&(\)=D[C[E>(=^4M4Y7?WM!5$S7];-)8,@3
M&@;%B$#,E +.F0 V!V>B-[FD5LGN>XD:=\9=*P,WD!(ZL%\?EY@R&>--N_>+
M5,S['#.99?(H=LO$9O(]A12U:2\9Y3H6*+"8P#")3F64VK5!UD'DC3NMKA'&
MAE=,!VA[/?]*$ETLO]^.>E@L@A=I*>H)9GNA.ZBH:=5PQZUA:'V;R4SW433N
MU+E&F!I$_%UL@V_R:I7SFXRK?">"9B4&SP51+R)98.LT>)<MA. 9$UB8Q397
MP1\@:MSY<HW@-)02.C!,[Y:++WFY_EY/7=?U,);BDB_54;S-5_0DL&@RV%@'
M@Z)0X.I$<&^#J4UZN YM\JZ'4CCR^+A&4&NBGPYP]_KL"\4IE9&WRY?3U9?%
M"F=O2[V=_F;Z-6^;8]Y96Q27!/3,  ;!0 7AP7':]',(S',3N+>-BLJ.H';D
M:7*M=M+6>NL FWN&/VTYNLT79QE=TA9T(I]!\<C >9M!."%C,-J;V.8NR*$4
MCCP?KED4VD _'>!N3_/>BW2-9YK)S.KTXUI\;DL$3#*"<9P+CDS8W*9Z[7Z:
M1I[ZU@A; ^E@[('4%QUW;K7;N0BK]]KKVZLG*T4^;#$@?:RC:(4ACX(5B*QH
MBI0,2G_[&&O_;.H!B!EY5MS 8!M%11T8N%T[T/<Y+C[--TW/;S.DG)1<60VY
MRE#IH$F:1=4"4_JN+=ZJ-E'&#TD;>0Q=(W,WK$:ZR)#47A=ORP><[8G-HPG(
M<@2F5!W:J1%"204X/25K\D,E:U3[<2]-(P^K:^:A#:*#+O#TGE1")-2#VY>T
M6F:+3?C]ZELM8;_,1A>NT%GR!:STH J%X2$'!XP9IYU4F$H;]^P X@Y#V!_M
ME&!HK70!M:L./=>O2+S]LBL=?KTY?".?8'-%8L>D<LIQH^KE^MHUB"(=0-2F
MSB7&K'U0O!'TCB#V,"C^T0X76FNM"VA>7C*\;<_KD2]7W@!*8;>=HWQ(Y"0X
M*8+SDLG0^&;K43OJ'^W(81#Y=Q "?,B?JJ%^G[\LEI="NAO7>,X+T[0\-.E>
M:>-)2#Y!*CQCECE$UJB+TR'D'5:D^T<[:1A>,QW [=?\^S5Q+1=S^C3F:X50
MM_GS1E!$'14X%JI[2@LK).N@9G@BER8GUJ9@[;&4'@;"/]KQ0E-]]=LJX[!+
M11]K_4O#BU*[YS_A-:E]'+6_).4P8\!LJHQT!2C9,!$)I2YCC-+RZ%F3-=YP
MF.SNKN&JMO^\5J/WMM3:O.??Z[^_T'L6RVNG<HE[#)9!%IG$4,C]=-)0.,Z]
MPV2-0]\H<G@\L=U>MWH,EN[LN(V5UNO%T#UG+,>;MOL?UFKZ;$.C]<A)H3)P
MI7QB0'M?!&6#K+E96G*>_D4N,M-M!O@\[0S:JXO4%^^]]I+5\^_7OKK6T=@&
MW"2J:362%V*BI#7B%%AAC;8R4J34)M=[#+5_J/FTCT'=?2:OF2H[B#FN>-P=
MJ_P]I]>IYH#*].(X;\,GD49R?C/%,)UM+J_1S\[/<MH8F&L1ODT2DT(P+-5^
M*RC \\ @N"10>6Y1MD;R((R,>[=U%) _/0"ZPO\%D[],Y]-UWIQFWY[_\_S[
M7_!_+Y8O9KBZ/C66\6R0([!L8VUZ8<$57VJ09WF2T;'8UC4]GO9Q;]J.@O(G
M47.7P'Y-/E]Y+-?6U>XN6H/TGE47OBYG7L 7G4@%.F%J$WX.0_^X-W='!7AS
M=7< \CU^V;OEXI?%\@Q?STO]<-,YPUBJD%/EQX"2S$$(R$$)Y5(0UN9&]P(>
M2>BX=WV?$+8M%=AK1N'RSO-?,M9&6C5A?'Q*X8&G#9)3.)3:@9(*EZ_;-[G6
MZ"13UJ1SKNH $$&&R4@)DD5TQ1IF0YO@XB&JAAC-=]42Y-E7G,ZJ>&D-U)*D
M6]YU))#FDB)HQ5.] IC U3NE&9U1S)*I;G3%]S%4CIL@& Q!^T;Y-5%4!QMI
MO7.ZVO9\WW@$F^#O^??:_+W*[1QG?\%UY?S[2US?YC6@M58FA.)KK;FN&X!F
M&0IS-A3ALF\T*_,4JL<-\)N!],D4V0%H+X6X]6AW&U1Z.W]?5^ER.O_T'%?3
MZX/CE B%%X2LR(50/#C 0O]HB<B9,$H:;+M_'$CIN'%Y,W V55BO[MZN:OUX
M#^_F P9QZAZ@:2 _;O>&7PA<%[;GK]/UYQ?GJ_7B+"\OX92LB<6) )9;3R;'
MREIAS<&J8 A+.7'?9N\XD, !AIOBIT_+_.GBL/2:Y*_=6ZC' CY9R$G5^] J
M0\!BJQW.TB$+.;6YFWD0>>/Z<RV0M&<BZ<!:ZF![W"NMW:VMBS3^]ULL,N&"
MS(8\ ,T8*&4"A%R'7DLO!'FR*B3=!(A'$#NN!_<4L&RMP5ZWS!=YN<;I_#G.
M<![SA\\YKU^O\]D)-64_>.(PD^<>0?50)1C7WK6;GKS/9^/*6!U, :%S)@QB
M!!=1072$0:F48+9-UN P^H8\ZMAVX*JS75=O%CBO$\QVC07GGZ[Z<ETK$2YH
M*:RQH)W9E"AE<$)[D#9FQY/&+!L5;Q]/],@%&,-C[J'#C)8*[6"3OF+ULNW7
M"PJ%+I*LU_G*/.=$4C2VYKNC! P4=V7./0NU@._.!?>A@?HPA2-73#PE*@=4
M51?WI:XXV_8QW$3GMYBR41MAF2*7HGH3&'CMUF3K9Z7P;!R6-KW_#B!NY#*&
MIX3>, KJP/#=VROL6L5%J=/6DP.?ZU!FU!)<818"15KH@B[&M#GN^3%M(]<5
MM$?<P.KI ' WG(KE>;Y>RG9K*9F8M8V2Q!5XK6&C&,J3L,"$9)SV(<0GJ.AZ
MF,:1*P2>V <<3EV]AKP7#79P?J=2Y_BH]\</'23P?23M \6^%V]]=O>M>T9
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M38H$/]$YY,)MJ+-C9=V>&7P6&DSB.3C->8EM9K\-H:Z[!X@]L?!@D&U$Q70
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MTD&T.=1]$V6@TSN$@>;WP!6GS;UO?#.VD'H_%9R/">]$<4[[@FL@^NW%R+7
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ML>TV$E(>>#P942-=V&R_T8&S^(ETOJV#3/=9.XG.,&GHM.<NUHHS+L '7V^
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M>?P0&_7+)6YZ'9$CZ%,R'H*M^=-U5%C@ 2%6^Y]E;6-I\Q[W)&G3XFP4  P
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M$2UXJQ5$DTT4LC!6VN2D#:&N)SOZ<$3L!+@]U-,]Y-[/-_,<E'4R6$&>0<U
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M;I*KU<J_B4P\H%<(N4@**+D+$*PCO01NDRQ68[Y?0#OPT7"7H'%G+)[D.7"
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M "4BG3;(%!F6L)!"XJA4YE:W>?@_9)OA:6UW/02%0ZBM W_XV(ID:2(CIXZ
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M9027%/D'EI@LH@ELGR6K\[ZDYJB9MU)A!W@<H*]2<.U+G5,5L1:7&NX@B)
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M=;2_YN4RYY4&?L[+N)BN"E[6M^_&!.%BS!2+U,5^M8BAAC7@5#)6&(G&M)'
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MJ$"&X"5%+JJXWH/+P2^JN\#?/@HZSDWBYA_J'P&7^?_[?_XO4$L! A0#%
M  @ :(-55K@K#FBC P  \1<  !D              ( !     &5X,C$Q<W5B
M<VED:6%R:65S,C R,BYH=&U02P$"% ,4    " !H@U56[R!MQ2H$  "3%0
M&P              @ ': P  97@R,S%A=61I=&]R8V]N<V5N=#(P,C(N:'1M
M4$L! A0#%     @ :(-55C_M9L.J"   CC(  !               ( !/0@
M &5X,S$Q,3!K,C R,BYH=&U02P$"% ,4    " !H@U56D3?Y39D(  !2,@
M$               @ $5$0  97@S,3(Q,&LR,#(R+FAT;5!+ 0(4 Q0    (
M &B#558M.U]L_ 4  /DU   /              "  =P9  !E>#,R,3!K,C R
M,BYH=&U02P$"% ,4    " !H@U56$G'IP+,D! !;+"D $0
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M              "  2D_!0!H86QO+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0
M   ( &B#558:PR?&#!$! %YK 0 4              "  1O<!@!H86QO+3(P
M,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( &B#558=+J"TCX@  )/4   4
M          "  5GM!P!H86QO+3(P,C(Q,C,Q7V<T+FIP9U!+ 0(4 Q0    (
M &B#55:F2H&#878! %&X#P 5              "  1IV" !H86QO+3(P,C(Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " !H@U56^^0I$%OA  !@B0H %0
M        @ &N[ D :&%L;RTR,#(R,3(S,5]P<F4N>&UL4$L%!@     /  \
*VP,  #S."@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
